

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>7</sup> :  C07K 14/00, C12N 15/11, 15/63, 15/64, 1/21		A1	(11) International Publication Number: <b>WO 00/58350</b>  (43) International Publication Date: 5 October 2000 (05.10.00)
(21) International Application Number: PCT/US00/07483		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 22 March 2000 (22.03.00)			
(30) Priority Data: 60/126,596 26 March 1999 (26.03.99) US 60/171,552 22 December 1999 (22.12.99) US			
(71) Applicant ( <i>for all designated States except US</i> ): HUMAN GENOME SCIENCES, INC. [US/US]; 9410 Key West Avenue, Rockville, MD 20850 (US).			
(72) Inventors; and		Published	
(75) Inventors/Applicants ( <i>for US only</i> ): ROSEN, Craig, A. [US/US]; 22400 Rolling Hill Road, Laytonville, MD 20882 (US). RUBEN, Steven, M. [US/US]; 18528 Heritage Hills Drive, Laytonsville, MD 20882 (US). KOMATSOU利, George [US/US]; 9518 Garwood Street, Silver Spring, MD 20901 (US).		With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	
(74) Agents: HOOVER, Kenley, K. et al.; Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, MD 20850 (US).			

(54) Title: 49 HUMAN SECRETED PROTEINS

## (57) Abstract

The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## 49 Human Secreted Proteins

### *Field of the Invention*

This invention relates to newly identified polynucleotides and the polypeptides encoded by these polynucleotides, uses of such polynucleotides and 5 polypeptides, and their production.

### *Background of the Invention*

Unlike bacterium, which exist as a single compartment surrounded by a membrane, human cells and other eucaryotes are subdivided by membranes into many functionally distinct compartments. Each membrane-bounded compartment, or 10 organelle, contains different proteins essential for the function of the organelle. The cell uses "sorting signals," which are amino acid motifs located within the protein, to target proteins to particular cellular organelles.

One type of sorting signal, called a signal sequence, a signal peptide, or a leader sequence, directs a class of proteins to an organelle called the endoplasmic 15 reticulum (ER). The ER separates the membrane-bounded proteins from all other types of proteins. Once localized to the ER, both groups of proteins can be further directed to another organelle called the Golgi apparatus. Here, the Golgi distributes the proteins to vesicles, including secretory vesicles, the cell membrane, lysosomes, and the other organelles.

20 Proteins targeted to the ER by a signal sequence can be released into the extracellular space as a secreted protein. For example, vesicles containing secreted proteins can fuse with the cell membrane and release their contents into the extracellular space - a process called exocytosis. Exocytosis can occur constitutively or after receipt of a triggering signal. In the latter case, the proteins are stored in 25 secretory vesicles (or secretory granules) until exocytosis is triggered. Similarly, proteins residing on the cell membrane can also be secreted into the extracellular space by proteolytic cleavage of a "linker" holding the protein to the membrane.

Despite the great progress made in recent years, only a small number of genes 30 encoding human secreted proteins have been identified. These secreted proteins include the commercially valuable human insulin, interferon, Factor VIII, human

growth hormone, tissue plasminogen activator, and erythropoietin. Thus, in light of the pervasive role of secreted proteins in human physiology, a need exists for identifying and characterizing novel human secreted proteins and the genes that encode them. This knowledge will allow one to detect, to treat, and to prevent medical diseases, disorders, and/or conditions by using secreted proteins or the genes that encode them.

5      medical diseases, disorders, and/or conditions by using secreted proteins or the genes  
that encode them.

***Summary of the Invention***

The present invention relates to novel polynucleotides and the encoded 10 polypeptides. Moreover, the present invention relates to vectors, host cells, antibodies, and recombinant and synthetic methods for producing the polypeptides and polynucleotides. Also provided are diagnostic methods for detecting diseases, disorders, and/or conditions related to the polypeptides and polynucleotides, and therapeutic methods for treating such diseases, disorders, and/or conditions. The 15 invention further relates to screening methods for identifying binding partners of the polypeptides.

***Detailed Description***

**Definitions**

20      The following definitions are provided to facilitate understanding of certain terms used throughout this specification.

In the present invention, "isolated" refers to material removed from its original environment (e.g., the natural environment if it is naturally occurring), and thus is altered "by the hand of man" from its natural state. For example, an isolated 25 polynucleotide could be part of a vector or a composition of matter, or could be contained within a cell, and still be "isolated" because that vector, composition of matter, or particular cell is not the original environment of the polynucleotide. The term "isolated" does not refer to genomic or cDNA libraries, whole cell total or mRNA preparations, genomic DNA preparations (including those separated by 30 electrophoresis and transferred onto blots), sheared whole cell genomic DNA

preparations or other compositions where the art demonstrates no distinguishing features of the polynucleotide/sequences of the present invention.

- In the present invention, a "secreted" protein refers to those proteins capable of being directed to the ER, secretory vesicles, or the extracellular space as a result of
- 5 a signal sequence, as well as those proteins released into the extracellular space without necessarily containing a signal sequence. If the secreted protein is released into the extracellular space, the secreted protein can undergo extracellular processing to produce a "mature" protein. Release into the extracellular space can occur by many mechanisms, including exocytosis and proteolytic cleavage.
- 10 In specific embodiments, the polynucleotides of the invention are at least 15, at least 30, at least 50, at least 100, at least 125, at least 500, or at least 1000 continuous nucleotides but are less than or equal to 300 kb, 200 kb, 100 kb, 50 kb, 15 kb, 10 kb, 7.5 kb, 5 kb, 2.5 kb, 2.0 kb, or 1 kb, in length. In a further embodiment, polynucleotides of the invention comprise a portion of the coding sequences, as
- 15 disclosed herein, but do not comprise all or a portion of any intron. In another embodiment, the polynucleotides comprising coding sequences do not contain coding sequences of a genomic flanking gene (i.e., 5' or 3' to the gene of interest in the genome). In other embodiments, the polynucleotides of the invention do not contain the coding sequence of more than 1000, 500, 250, 100, 50, 25, 20, 15, 10, 5, 4, 3, 2, or
- 20 1 genomic flanking gene(s).

- As used herein, a "polynucleotide" refers to a molecule having a nucleic acid sequence contained in SEQ ID NO:X or the cDNA contained within the clone deposited with the ATCC. For example, the polynucleotide can contain the nucleotide sequence of the full length cDNA sequence, including the 5' and 3'
- 25 untranslated sequences, the coding region, with or without the signal sequence, the secreted protein coding region, as well as fragments, epitopes, domains, and variants of the nucleic acid sequence. Moreover, as used herein, a "polypeptide" refers to a molecule having the translated amino acid sequence generated from the polynucleotide as broadly defined.
- 30 In the present invention, the full length sequence identified as SEQ ID NO:X was often generated by overlapping sequences contained in multiple clones (contig

analysis). A representative clone containing all or most of the sequence for SEQ ID NO:X was deposited with the American Type Culture Collection ("ATCC"). As shown in Table 1, each clone is identified by a cDNA Clone ID (Identifier) and the ATCC Deposit Number. The ATCC is located at 10801 University Boulevard,  
5 Manassas, Virginia 20110-2209, USA. The ATCC deposit was made pursuant to the terms of the Budapest Treaty on the international recognition of the deposit of microorganisms for purposes of patent procedure.

A "polynucleotide" of the present invention also includes those polynucleotides capable of hybridizing, under stringent hybridization conditions, to  
10 sequences contained in SEQ ID NO:X, the complement thereof, or the cDNA within the clone deposited with the ATCC. "Stringent hybridization conditions" refers to an overnight incubation at 42 degree C in a solution comprising 50% formamide, 5x SSC (750 mM NaCl, 75 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 µg/ml denatured, sheared salmon  
15 sperm DNA, followed by washing the filters in 0.1x SSC at about 65 degree C.

Also contemplated are nucleic acid molecules that hybridize to the polynucleotides of the present invention at lower stringency hybridization conditions. Changes in the stringency of hybridization and signal detection are primarily accomplished through the manipulation of formamide concentration (lower  
20 percentages of formamide result in lowered stringency); salt conditions, or temperature. For example, lower stringency conditions include an overnight incubation at 37 degree C in a solution comprising 6X SSPE (20X SSPE = 3M NaCl; 0.2M NaH<sub>2</sub>PO<sub>4</sub>; 0.02M EDTA, pH 7.4), 0.5% SDS, 30% formamide, 100 µg/ml salmon sperm blocking DNA; followed by washes at 50 degree C with 1XSSPE,  
25 0.1% SDS. In addition, to achieve even lower stringency, washes performed following stringent hybridization can be done at higher salt concentrations (e.g. 5X SSC).

Note that variations in the above conditions may be accomplished through the inclusion and/or substitution of alternate blocking reagents used to suppress  
30 background in hybridization experiments. Typical blocking reagents include Denhardt's reagent, BLOTO, heparin, denatured salmon sperm DNA, and

commercially available proprietary formulations. The inclusion of specific blocking reagents may require modification of the hybridization conditions described above, due to problems with compatibility.

Of course, a polynucleotide which hybridizes only to polyA+ sequences (such 5 as any 3' terminal polyA+ tract of a cDNA shown in the sequence listing), or to a complementary stretch of T (or U) residues, would not be included in the definition of "polynucleotide," since such a polynucleotide would hybridize to any nucleic acid molecule containing a poly (A) stretch or the complement thereof (e.g., practically any double-stranded cDNA clone generated using oligo dT as a primer).

10 The polynucleotide of the present invention can be composed of any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. For example, polynucleotides can be composed of single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of 15 single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, the polynucleotide can be composed of triple-stranded regions comprising RNA or DNA or both RNA and DNA. A polynucleotide may also contain one or more modified bases or DNA or RNA backbones modified for stability or for other reasons. "Modified" bases include, for 20 example, tritylated bases and unusual bases such as inosine. A variety of modifications can be made to DNA and RNA; thus, "polynucleotide" embraces chemically, enzymatically, or metabolically modified forms.

The polypeptide of the present invention can be composed of amino acids 25 joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres, and may contain amino acids other than the 20 gene-encoded amino acids. The polypeptides may be modified by either natural processes, such as posttranslational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more 30 detailed monographs, as well as in a voluminous research literature. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid

- side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched, for example, as a result of
- 5      ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched, and branched cyclic polypeptides may result from posttranslational natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent
- 10     attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristylation, oxidation, pegylation, proteolytic processing,
- 15     phosphorylation, prenylation, racemization, selenylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination. (See, for instance, PROTEINS - STRUCTURE AND MOLECULAR PROPERTIES, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York (1993); POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS, B. C.
- 20     Johnson, Ed., Academic Press, New York, pgs. 1-12 (1983); Seifert et al., Meth Enzymol 182:626-646 (1990); Rattan et al., Ann NY Acad Sci 663:48-62 (1992).)
- "SEQ ID NO:X" refers to a polynucleotide sequence while "SEQ ID NO:Y" refers to a polypeptide sequence, both sequences identified by an integer specified in Table 1.
- 25     "A polypeptide having biological activity" refers to polypeptides exhibiting activity similar, but not necessarily identical to, an activity of a polypeptide of the present invention, including mature forms, as measured in a particular biological assay, with or without dose dependency. In the case where dose dependency does exist, it need not be identical to that of the polypeptide, but rather substantially similar
- 30     to the dose-dependence in a given activity as compared to the polypeptide of the present invention (i.e.; the candidate polypeptide will exhibit greater activity or not

more than about 25-fold less and, preferably, not more than about tenfold less activity, and most preferably, not more than about three-fold less activity relative to the polypeptide of the present invention.)

Many proteins (and translated DNA sequences) contain regions where the 5 amino acid composition is highly biased toward a small subset of the available residues. For example, membrane spanning domains and signal peptides (which are also membrane spanning) typically contain long stretches where Leucine (L), Valine (V), Alanine (A), and Isoleucine (I) predominate. Poly-Adenosine tracts (polyA) at the end of cDNAs appear in forward translations as poly-Lysine (poly-K) and poly-10 Phenylalanine (poly-F) when the reverse complement is translated. These regions are often referred to as "low complexity" regions.

Such regions can cause database similarity search programs such as BLAST to find high-scoring sequence matches that do not imply true homology. The problem is exacerbated by the fact that most weight matrices (used to score the alignments 15 generated by BLAST) give a match between any of a group of hydrophobic amino acids (L, V and I) that are commonly found in certain low complexity regions almost as high a score as for exact matches.

In order to compensate for this, BLASTX.2 (versión 2.0a5MP-WashU) employs two filters ("seg" and "xnu") which "mask" the low complexity regions in a 20 particular sequence. These filters parse the sequence for such regions, and create a new sequence in which the amino acids in the low complexity region have been replaced with the character "X". This is then used as the input sequence (sometimes referred to herein as "Query" and/or "Q") to the BLASTX program. While this 25 regime helps to ensure that high-scoring matches represent true homology, there is a negative consequence in that the BLASTX program uses the query sequence that has been masked by the filters to draw alignments.

Thus, a stretch of "X"s in an alignment shown in the following application does not necessarily indicate that either the underlying DNA sequence or the 30 translated protein sequence is unknown or uncertain. Nor is the presence of such stretches meant to indicate that the sequence is identical or not identical to the sequence disclosed in the alignment of the present invention. Such stretches may

simply indicate that the BLASTX program masked amino acids in that region due to the detection of a low complexity region, as defined above. In all cases, the reference sequence(s) (sometimes referred to herein as "Subject", "Sbjct", and/or "S") indicated in the specification, sequence table (Table 1), and/or the deposited clone is (are) the  
5 definitive embodiment(s) of the present invention, and should not be construed as limiting the present invention to the partial sequence shown in an alignment, unless specifically noted otherwise herein.

### Polynucleotides and Polypeptides of the Invention

10

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 1

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no.  
15 gil3135669 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "prenylcysteine carboxyl methyltransferase [Homo sapiens]." A partial alignment demonstrating the observed homology is shown immediately below.

20 >gi|3135669 (AF064084) prenylcysteine carboxyl methyltransferase [Homo sapiens]  
>sp|060725|060725 PRENYLCYSTEINE CARBOXYL METHYLTRANSFERASE.  
Length = 284

25 Plus Strand HSPs:

Score = 1039 (365.7 bits), Expect = 3.8e-130, Sum P(2) = 3.8e-130  
Identities = 196/223 (87%), Positives = 196/223 (87%), Frame = +1

30 Q: 121 SEARLSLATXXXXXXXXXXXXXTRAGLQGRTGXXXXXXXXXXXXRPPRYQIAIRAC 300  
SEARLSLATF TRAGLQGRTG YRPPRYQIAIRAC  
S: 12 SEARLSLATFLLGASVLALPLLTRAGLQGRTGLALYVAGLNALLLLYRPPRYQIAIRAC 71

35 Q: 301 FLGFVFGCGTLLSFQSWSHFGWYMCSSLFHYSEYLVTAVNNPKSLSDLFLLNHSLE 480  
FLGFVFGCGTLLSFQSWSHFGWYMCSSLFHYSEYLVTAVNNPKSLSDLFLLNHSLE  
S: 72 FLGFVFGCGTLLSFQSWSHFGWYMCSSLFHYSEYLVTAVNNPKSLSDLFLLNHSLE 131

40 Q: 481 YTVAALSSWLEFTLENIFWPELKQITWLSTVTGLMMVFGECLRKAAAMFTAGSNFNHVVQN 660  
YTVAALSSWLEFTLENIFWPELKQITWLSTVTGLMMVFGECLRKAAAMFTAGSNFNHVVQN  
S: 132 YTVAALSSWLEFTLENIFWPELKQITWLSTVTGLMMVFGECLRKAAAMFTAGSNFNHVVQN 191

Q: 661 EKSDTHTLVTSGVYAWFRHPSYVGWFYWSIGTQVMLCNPICGV 789  
EKSDTHTLVTSGVYAWFRHPSYVGWFYWSIGTQVMLCNPICGV  
S: 192 EKSDTHTLVTSGVYAWFRHPSYVGWFYWSIGTQVMLCNPICGV 234

Score = 265 (93.3 bits), Expect = 3.8e-130, Sum P(2) = 3.8e-130  
Identities = 54/67 (80%), Positives = 55/67 (82%), Frame = +3

5       Q: 747 YWNSGDAV\*---PHLRRHYALTWRFFRDRTEEEEISLIHFFGEEYLEYKKRVPTGLPFI 917  
          YW+ G V P YALTWRFFRDRTEEEEISLIHFFGEEYLEYKKRVPTGLPFI  
      S: 218 YWSIGTQVMLCNPICGVSYALTWRFFRDRTEEEEISLIHFFGEEYLEYKKRVPTGLPFI 277

10      Q: 918 KGVKVDL 938  
          KGVKVDL  
      S: 278 KGVKVDL 284

The segments of gi|3135669 that are shown as "S" above are set out in the sequence listing as SEQ ID NO. 109 and SEQ ID NO. 111. Based on the structural similarity these homologous polypeptides are expected to share at least some biological activities. Such activities are known in the art, some of which are described elsewhere herein. Assays for determining such activities are also known in the art, some of which have been described elsewhere herein.

Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 110 and/or SEQ ID NO. 112 which correspond to the Q sequences in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares fetal liver spleen 1NFLS and to a lesser extent in Soares placenta Nb2HP; Soares infant brain 1NIB; Human Testes Tumor; Human Fetal Heart; Stratagene pancreas (#937208); Activated T-cells; Soares melanocyte 2NbHM; Soares\_fetal\_heart\_NbHH19W; Soares\_senescent\_fibroblasts\_NbHSF; Lung Carcinoma A549 TNFalpha activated; Tongue Normal; Human Adult Pulmonary; Human Umbilical Vein Endothelial Cells, fract. A; Human Pineal Gland; Synovial hypoxia-RSF subtracted; Myeloid Progenitor Cell Line; Prostate BPH; Breast Cancer Cell line, angiogenic; Human Jurkat Membrane Bound Polysomes; Human Heart; Liver, Hepatoma; Bone Marrow Stromal Cell, untreated; Human T-Cell Lymphoma; Smooth muscle, serum treated; Early Stage Human Brain; Dendritic cells, pooled; Human Microvascular Endothelial Cells, fract. A; Monocyte activated; Activated T-cell(12h)/Thiouridine-re-excision; Keratinocyte; Human 8 Week Whole

Embryo; Human Cerebellum; Soares\_placenta\_8to9weeks\_2NbHP8to9W and Primary Dendritic Cells, lib 1.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 60 as residues: Ser-33 to Tyr-39.

- 5 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:11 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence
- 10 would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2542 of SEQ ID NO:11, b is an integer of 15 to 2556, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:11, and where b is greater than or equal to a
- 15 + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 2

- It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: H. Normalized Fetal Liver, II; and Bone Marrow Stromal  
20 Cell, untreated.

- Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:12 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1135 of SEQ ID NO:12, b is an integer of 15 to 1149, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:12, and where b is greater than or equal to a + 14.

**FEATURES OF PROTEIN ENCODED BY GENE NO: 3**

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares retina N2b4HR; Colon Tumor II and to a lesser extent  
5 in Soares retina N2b5HR; HEL cell line; pBMC stimulated w/ poly I/C; Bone Marrow Stromal Cell, untreated; NCI\_CGAP\_GC4; Hepatocellular Tumor, re-excision; NCI\_CGAP\_Pr2; Bone Marrow Cell Line (RS4,11) and Soares placenta Nb2HP.

Many polynucleotide sequences, such as EST sequences, are publicly  
10 available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:13 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention  
15 are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1267 of SEQ ID NO:13, b is an integer of 15 to 1281, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:13, and where b is greater than or equal to a + 14.

20

**FEATURES OF PROTEIN ENCODED BY GENE NO: 4**

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no.  
25 gnl|PID|e1318055 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "putative protein [Arabidopsis thaliana]." A partial alignment demonstrating the observed homology is shown immediately below.

30 >gnl|PID|e1318055 (AL031394) putative protein [Arabidopsis thaliana]  
>sp|081881|081881\_HYPOTHETICAL 18.3 KD PROTEIN.  
Length = 161

## Plus Strand HSPs:

Score = 291 (102.4 bits), Expect = 5.4e-25, P = 5.4e-25  
 Identities = 56/83 (67%), Positives = 65/83 (78%), Frame = +3

5           Q: 114 RREAAMNVDHEVNLLVEEIHLGSKNADGKLSVKFGVLFRDDCANLFEALVGTLLAAKR 293  
              +E MNVD E+ L EEEIHLGS+ DG V FGVLF DD+CAN+FEALVGTLLAAKR+  
              S: 62 KEEERMNVDEEIQKLEEEIHLGSRQTDGSYKVTGVLFNDDRCANIFEALVGTLLRAAKK 121

10          Q: 294 RKIVTYPGEPLLQQGVHDDVDIIL 362  
              RKIV + GELLLQQGVHD V+I L  
              S: 122 RKIVAFEGEPLLQQGVHDKVEITL 144

The segment of gnl|PIDle1318055 that is shown as "S" above is set out in the  
 15 sequence listing as SEQ ID NO. 113.

Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 114 which corresponds to the Q sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

20          It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Bone Marrow Cell Line (RS4,11) and to a lesser extent in Colon Normal III; Macrophage-oxLDL; T-Cell PHA 24 hrs; Mo7e Cell Line GM-CSF treated (1ng/ml); Macrophage-oxLDL, re-excision; T cell helper II; Human Macrophage; Colon Tumor; prostate-edited; Human Colon Cancer,re-excision;  
 25          Synovial hypoxia; Synovial Fibroblasts (IL1/TNF), subt; Prostate BPH; Soares\_total\_fetus\_Nb2HF8\_9w; Human Thymus; L428; Human Jurkat Membrane Bound Polysomes; Human Ovarian Cancer Reexcision; Human umbilical vein endothelial cells, IL-4 induced; Human Fetal Brain; Pancreas Islet Cell Tumor; PC3 Prostate cell line; Human T-Cell Lymphoma; Human Testes Tumor; Dendritic cells,  
 30          pooled; Colon Tumor II; Human fetal heart, Lambda ZAP Express; Normal colon; Soares melanocyte 2NbHM; Bone marrow; Endothelial cells-control; NCI\_CGAP\_Alv1; NCI\_CGAP\_GCB1; Human Osteoclastoma; Smooth muscle,control; Activated T-cell(12h)/Thiouridine-re-excision and Keratinocyte.

Many polynucleotide sequences, such as EST sequences, are publicly  
 35 available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:14 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically

excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 698 of SEQ ID NO:14, b 5 is an integer of 15 to 712, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:14, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 5

10 It has been discovered that this gene is expressed primarily in Bone Marrow Cell Line (RS4,11).

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 64 as residues: Arg-19 to Gln-24, Cys-33 to Lys-38.

Many polynucleotide sequences, such as EST sequences, are publicly 15 available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:15 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention 20 are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 472 of SEQ ID NO:15, b is an integer of 15 to 486, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:15, and where b is greater than or equal to a + 14.

25

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 6

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Morton Fetal Cochlea; Synovial Fibroblasts (IL1/TNF), subt and to a lesser extent in Soares\_pregnant\_uterus\_NbHPU; Healing Abdomen 30 wound,70&90 min post incision; Human Testes Tumor; Early Stage Human Brain;

CD34 depleted Buffy Coat (Cord Blood), re-excision; Bone Marrow Cell Line (RS4,11) and Human Endometrial Tumor.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 65 as residues: Gln-15 to Glu-20.

5 Many polynucleotide sequences, such as EST sequences, are publicly  
available and accessible through sequence databases. Some of these sequences are  
related to SEQ ID NO:16 and may have been publicly available prior to conception of  
the present invention. Preferably, such related polynucleotides are specifically  
excluded from the scope of the present invention. To list every related sequence  
10 would be cumbersome. Accordingly, preferably excluded from the present invention  
are one or more polynucleotides comprising a nucleotide sequence described by the  
general formula of a-b, where a is any integer between 1 to 640 of SEQ ID NO:16, b  
is an integer of 15 to 654, where both a and b correspond to the positions of  
nucleotide residues shown in SEQ ID NO:16, and where b is greater than or equal to a  
15 + 14.

## **FEATURES OF PROTEIN ENCODED BY GENE NO: 7**

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. gil288145 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "put. ORF [Homo sapiens]." A partial alignment demonstrating the observed homology is shown immediately below.

25

>gi|288145 put. ORF [Homo sapiens] >pir|I38022|I38022 hypothetical protein

human  
Length = 196

30 Plus Strand HSPs:

```
Score = 188 (66.2 bits), Expect = 2.7e-17, Sum P(2) = 2.7e-17
Identities = 40/60 (66%), Positives = 45/60 (75%), Frame = +1

Q: 739 LRSQVRDQPGQPSETPPLLKIQKLAGLGCVRL*SQLLGKLRQENHNLNGSGGCSEPRFRL 918
     LRSGV+D PGQ + P LLXIO+LAG GG L SOLL +LROENHNL G GCSEP+ L
```

S: 4 LRSGVQDYPGQHGKIPSLKIQELAGHGGRCIQLSQLLRLRQENHLNSGGRGCSEPKSHL 63

Score = 46 (16.2 bits), Expect = 2.7e-17, Sum P(2) = 2.7e-17  
Identities = 9/14 (64%), Positives = 11/14 (78%), Frame = +2

5

Q: 917 CILAWATK\*DSVSE 958  
CI AW T+ DSVS+  
S: 64 CIPAWVTEGDSVSK 77

10 The segments of gil288145 that are shown as "S" above are set out in the sequence listing as SEQ ID NO. 115 and SEQ ID NO. 117.

Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 116 and/or SEQ ID NO. 118 which correspond to the Q sequences in the alignment shown above  
15 (gaps introduced in a sequence by the computer are, of course, removed).

When tested against sensory neuron cells, supernatants removed from cells containing this gene activated the EGR1 assay. Thus, it is likely that this gene activates sensory neuron cells through a signal transduction pathway. Early growth response 1 (EGR1) is a promoter associated with certain genes that induces various  
20 tissues and cell types upon activation, leading the cells to undergo differentiation and proliferation.

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Human Testes and to a lesser extent in Adrenal Gland,normal; Human Umbilical Vein Endothelial Cells, fract. A; Human Stomach,re-excision; H.  
25 Meningima, M1; Spleen metastatic melanoma; PC3 Prostate cell line; Activated T-cell(12h)/Thiouridine-re-excision and Bone Marrow Cell Line (RS4,11).

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 66 as residues: Leu-52 to Cys-59.

Many polynucleotide sequences, such as EST sequences, are publicly  
30 available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:17 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention.  
35 are one or more polynucleotides comprising a nucleotide sequence described by the

general formula of a-b, where a is any integer between 1 to 960 of SEQ ID NO:17, b is an integer of 15 to 974, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:17, and where b is greater than or equal to a + 14.

5

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 8

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Human Whole Six Week Old Embryo; and Bone Marrow Cell Line (RS4,11).

- 10 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:18 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence  
15 would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 458 of SEQ ID NO:18, b is an integer of 15 to 472, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:18, and where b is greater than or equal to a  
20 + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 9

- The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting  
25 example, the sequence accessible through the following database accession no. gnll|PID|e353155 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "hypothetical protein [Arabidopsis thaliana]." A partial alignment demonstrating the observed homology is shown immediately below.  
30

```
>gnl|PID|e353155 hypothetical protein [Arabidopsis thaliana]
>sp|023175|023175
```

HYPOTHETICAL 50.3 KD PROTEIN.  
Length = 446

5 Plus Strand HSPs:

Score = 225 (79.2 bits), Expect = 1.1e-14, P = 1.1e-14  
Identities = 47/102 (46%), Positives = 57/102 (55%), Frame = +2

10 Q: 896 CSNSREKIQYNRSLGSTCHQCR-----QKTIDTKTNCRNPDCWGVRGQFCGP 1033  
C + ++IY+ G CHQCR QKT+ T C + VRGQFCG  
S: 167 CDKNGKRIYDPVRGKCCCHQCRIEANVFNGYCGFYRQKTLGYHTQCSQCN-HSVRGQFCGD 225

Q: 1034 CLRNRYGEEVVRDALLDPNWHCPPCRGICNCSCFQRDGRCATG 1162  
CL RYGE V +AL +P+W CP CR ICNCSFCR + G TG  
15 S: 226 CLYMRYGEHVLEALENPDWICPVCRDICNCSCFCKKGWLPTG 268

The segment of gnl|PIDle353155 that is shown as "S" above is set out in the sequence listing as SEQ ID NO. 119.

Preferred polypeptides of the invention comprise a polypeptide having the 20 amino acid sequence set out in the sequence listing as SEQ ID NO. 120 which corresponds to the Q sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Colon Carcinoma; Bone Marrow Cell Line (RS4,11) and to a 25 lesser extent in Jurkat T-Cell, S phase; Colon Normal II; T cell helper II; Human 8 Week Whole Embryo; Soares fetal liver spleen 1NFLS; Smooth Muscle- HASTE normalized; Stratagene endothelial cell 937223; Mo7e Cell Line GM-CSF treated (1ng/ml); Human Thymus; Human Testes Tumor; Soares\_fetal\_lung\_NbHL19W; Soares\_multiple\_sclerosis\_2NbHMSP; Keratinocyte; Colorectal Tumor; HL-60, 30 PMA 4H; Human T-cell lymphoma,re-excision; Human Skin Tumor; Jurkat T-cell G1 phase; Myeloid Progenitor Cell Line; 12 Week Old Early Stage Human, II; Human Pancreas Tumor; NTERA2, control; Human T-Cell Lymphoma; Human fetal brain (TFujiiwara); NCI\_CGAP\_GCB1; Normal colon; Human Synovial Sarcoma; Endothelial-induced; Human Endometrial Tumor and Stratagene lung carcinoma 35 937218.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:19 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically

excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2582 of SEQ ID NO:19, b 5 is an integer of 15 to 2596, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:19, and where b is greater than or equal to a + 14.

#### 10 FEATURES OF PROTEIN ENCODED BY GENE NO: 10

It has been discovered that this gene is expressed primarily in Bone Marrow Cell Line (RS4,11).

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are 15 related to SEQ ID NO:20 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the 20 general formula of a-b, where a is any integer between 1 to 910 of SEQ ID NO:20, b is an integer of 15 to 924, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:20, and where b is greater than or equal to a + 14.

#### 25 FEATURES OF PROTEIN ENCODED BY GENE NO: 11

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. gil34754 (all information available through the recited accession number is 30 incorporated herein by reference) which is described therein as "put. ribosomal

protein L3 [Homo sapiens]." A partial alignment demonstrating the observed homology is shown immediately below.

```

5      >gi|34754 put. ribosomal protein L3 (AA 1 - 348) [Homo sapiens]
      >pir|A27294|R5HUL3 ribosomal protein L3 precursor, mitochondrial
      human
      Length = 348

10     Plus Strand HSPs:

      Score = 344 (121.1 bits), Expect = 3.0e-63, Sum P(2) = 3.0e-63
      Identities = 62/62 (100%), Positives = 62/62 (100%), Frame = +2

15     Q: 14 GQYVDVTAKTIGKGFQGVMKRWGFKQPATHGQTKTHRRPGAVATGDIGRVWPGTKMPGK 193
           GQYVDVTAKTIGKGFQGVMKRWGFKQPATHGQTKTHRRPGAVATGDIGRVWPGTKMPGK
      S: 201 GQYVDVTAKTIGKGFQGVMKRWGFKQPATHGQTKTHRRPGAVATGDIGRVWPGTKMPGK 260

20     Q: 194 MG 199
           MG
      S: 261 MG 262

      Score = 326 (114.8 bits), Expect = 3.0e-63, Sum P(2) = 3.0e-63
      Identities = 62/77 (80%), Positives = 62/77 (80%), Frame = +1

25     Q: 199 KVWRINTKHNI IYVNGSVPGHKNCLVKVKDSKL PAYKDLGKNLPPFTYFXXXXXXXXXXXX 378
           KVWRINTKHNI IYVNGSVPGHKNCLVKVKDSKL PAYKDLGKNLPPFTYF
      S: 272 KVWRINTKHNI IYVNGSVPGHKNCLVKVKDSKL PAYKDLGKNLPPFTYFPDGDEEELPED 331

30     Q: 379 XXXXNVCQPGAPSITFA 429
           NVCQPGAPSITFA
      S: 332 LYDENVCQPGAPSITFA 348

```

The segments of gil34754 that are shown as "S" above are set out in the  
 35 sequence listing as SEQ ID NO. 121 and SEQ ID NO. 123.

Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 122 and/or SEQ ID NO. 124 which correspond to the Q sequences in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

40 It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares fetal liver spleen 1NFLS and to a lesser extent in Human Prostate Cancer, Stage C fraction; Human Fetal Heart; Bone Marrow Cell Line (RS4,11); Stromal cell TF274; Human T-Cell Lymphoma; Activated T-Cell (12hs)/Thiouridine labelledEco; Human Testes; Keratinocyte; Human Umbilical Vein  
 45 Endothelial Cells, uninduced; Human Fetal Lung III; Human Testes, Reexcision; Soares\_fetal\_heart\_NbHH19W; Nine Week Old Early Stage Human; Soares infant

- brain 1NIB; Human Colon Cancer,re-excision; Glioblastoma; LNCAP prostate cell line; KMH2; Human Infant Brain; Fetal Liver, subtraction II; Human Fetal Kidney; Human Heart; Human umbilical vein endothelial cells, IL-4 induced; Stratagene ovarian cancer (#937219); Synovial Fibroblasts (control); NCI\_CGAP\_GCB1;
- 5 NTERA2, control; Colon Carcinoma; Adipocytes; Colon Tumor II; NCI\_CGAP\_GC4; Osteoblasts; Human 8 Week Whole Embryo; Soares\_fetal\_lung\_NbHL19W; Primary Dendritic Cells, lib 1; Human Pineal Gland; Human Osteoarthritic Cartilage Fraction IV; Pericardium; Human Osteoarthritic Cartilage Fraction III; LNCAP + 30nM R1881; Human Adult Liver, subtracted;
- 10 Smooth muscle-ILb induced; H. Epididymus, caput & corpus; Human Liver; Human Soleus; Human Pineal Gland; CHME Cell Line,untreated; Hepatocellular Tumor; pBMC stimulated w/ poly I/C; human corpus colosum; NTERA2 + retinoic acid, 14 days; Human Stomach,re-excision; Prostate BPH; H. Lymph node breast Cancer; Human Thymus; human ovarian cancer; Human Jurkat Membrane Bound Polysomes;
- 15 NCI\_CGAP\_GC2; NCI\_CGAP\_SS1; Human Pancreas Tumor; Human Ovarian Cancer Reexcision; Stratagene neuroepithelium NT2RAMI 937234; Human Adipose; Spinal cord; Human Adrenal Gland Tumor; Rejected Kidney, lib 4; NCI\_CGAP\_Br2; Stratagene neuroepithelium (#937231); Pancreas Islet Cell Tumor; Human Gall Bladder; PC3 Prostate cell line; 12 Week Old Early Stage Human; Smooth muscle,
- 20 serum treated; Human Placenta; Human Synovial Sarcoma; human tonsils; Endothelial-induced; Colon Normal III; Human Osteoclastoma; Human B Cell Lymphoma; Human Bone Marrow, treated; Spleen, Chronic lymphocytic leukemia; Human Endometrial Tumor; Human fetal heart, Lambda ZAP Express; NCI\_CGAP\_Lu5; NCI\_CGAP\_Kid5; NCI\_CGAP\_Pr12; NCI\_CGAP\_Pr25;
- 25 NCI\_CGAP\_Brn23; Stratagene neuroepithelium (#937231); T cell helper II; Human Cerebellum; Soares placenta Nb2HP and Soares\_multiple\_sclerosis\_2NbHMSP.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:21 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence

would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 793 of SEQ ID NO:21, b is an integer of 15 to 807, where both a and b correspond to the positions of  
 5 nucleotide residues shown in SEQ ID NO:21, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 12

The computer algorithm BLASTX has been used to determine that the  
 10 translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. gnl|PID|d1013934 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "similar to Mouse yolk sac permease-like molecule 1 (U25739) [Homo sapiens]." A partial alignment  
 15 demonstrating the observed homology is shown immediately below.

```

>gnl|PID|d1013934 similar to Mouse yolk sac permease-like molecule 1
(U25739)
 20 [Homo sapiens]
Length = 330

Plus Strand HSPs:

 25 Score = 374 (131.7 bits), Expect = 5.4e-75, Sum P(4) = 5.4e-75
  Identities = 70/87 (80%), Positives = 80/87 (91%), Frame = +2

  Q: 986 QVGSRVQYGAIMLVLGTTGKFTALFASLPDPILGGMFCTLFGMITAVGLSNLQFVDM 1165
      +VGSRRV+Q GAA+ML LG IGKF+ALFASLPDP+LG +FCTLFGMITAVGLSNLQF+D+
  S: 132 KVGSRVVIQCGAALM ALGMIGKFSALFASLPDPVGLGALFCTLFGMITAVGLSNLQFIDL 191

 30 Q: 1166 NSSRNLFVLGFSMFFGTLTPNYLESNP 1246
      NSSRNLFVLGFS+FFGL LP+YL NP
  S: 192 NSSRNLFVLGFSIFFGLVLPQLPSYLRQNP 218

 35 Q: 208 (73.2 bits), Expect = 5.4e-75, Sum P(4) = 5.4e-75
  Identities = 33/54 (61%), Positives = 42/54 (77%), Frame = +3

  Q: 576 WLLCYVLTLTDVLPTDPKAYGFQARTDARGDIMAIAPWIRIYPYCQWGLPTVTA 737
      WLLC++ T+TDV P D YGF ARTDAR ++ +APW ++PYP QWGLPTV+A
  40 S: 4 WLLCFIFTVTVDVFPFDSTKYGFYARTDARQGVLLVAPWFKVVPYPPQWGLPTVSA 57

Score = 133 (46.8 bits), Expect = 5.4e-75, Sum P(4) = 5.4e-75
  Identities = 22/56 (39%), Positives = 34/56 (60%), Frame = +2

 45 Q: 1262 GSPEERGLIQWKAGAHANSMDSSSLKSYDFPIGMGIVKRITFLKYIPICPVFKGFS 1429
      G+PEERG+ +WK G + ++SY+ P GM I+K+ Y+PI P F G++
  S: 254 GTPEERGIRKWKKGVGKGNSLDGMESYNLPFGMNIKKYRCFSYLPISPTFVGYT 309

```

Score = 100 (35.2 bits), Expect = 5.4e-75, Sum P(4) = 5.4e-75  
Identities = 19/22 (86%), Positives = 20/22 (90%), Frame = +1

5 Q: 769 AGIIESIGDYACARLAGAPPP 834  
A IIIESIGDYACARL+ APPP  
S: 69 ASIIIESIGDYACARLSCAPPP 90

Score = 40 (14.1 bits), Expect = 7.1e-05, Sum P(2) = 7.1e-05  
Identities = 9/27 (33%), Positives = 15/27 (55%), Frame = +2

10 Q: 1010 QYGAAIMLVLGTTIGKFTALFASLPDPI 1090  
Q+G + G IG +A+ AS+ + I  
S: 49 QWGLPTVSAAGVIGMLS A VASIIIESI 75

15 The segments of gnl|PID|d1013934 that are shown as "S" above are set out in the sequence listing as SEQ ID NO. 125,SEQ ID NO. 127,SEQ ID NO. 129,SEQ ID NO. 131 and SEQ ID NO. 133.

Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 126,SEQ ID NO. 20 128,SEQ ID NO. 130,SEQ ID NO. 132 and/or SEQ ID NO. 134 which correspond to the Q sequences in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Spleen/normal; Colon, tumour; Fetal Liver, subtraction II; 25 NTERA2, control; and Bone Marrow Cell Line (RS4,11).

The tissue distribution in bone marrow indicates the polynucleotides and polypeptides corresponding to this gene would be useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections below, in Example 11, 30 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. Involvement in the regulation of cytokine production, antigen presentation, or other processes suggests a usefulness for treatment of cancer (e.g. by boosting immune responses). Expression in cells of 35 lymphoid origin, indicates the natural gene product would be involved in immune functions. Therefore it would also be useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis,

acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus

5       erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages,

10      and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or

15      immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:22 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically

20      excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2023 of SEQ ID NO:22, b is an integer of 15 to 2037, where both a and b correspond to the positions of

25      nucleotide residues shown in SEQ ID NO:22, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 13

It has been discovered that this gene is expressed primarily in the following

30      tissues/cDNA libraries: NCI\_CGAP\_GCB1 and to a lesser extent in Larynx carcinoma III; T cell helper II; SoaresNFL\_T\_GBC\_S1;

Soares\_total\_fetus\_Nb2HF8\_9w; Healing groin wound, 6.5 hours post incision;  
Dendritic cells, pooled; Bone Marrow Cell Line (RS4,11); Soares\_NhHMPu\_S1 and  
Soares fetal liver spleen 1NFLS.

- Many polynucleotide sequences, such as EST sequences, are publicly
- 5 available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:23 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention
- 10 are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1403 of SEQ ID NO:23, b is an integer of 15 to 1417, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:23, and where b is greater than or equal to a + 14.

15

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 14

- The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no.
- 20 gil2981435 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "SLOB [Drosophila melanogaster]." A partial alignment demonstrating the observed homology is shown immediately below.

25 >gi|2981435 (AF051162) SLOB [Drosophila melanogaster] >sp|061564|061564  
SLOB  
(FRAGMENT).  
Length = 515

30 Plus Strand HSPs:

Score = 332 (116.9 bits), Expect = 5.4e-27, P = 5.4e-27  
Identities = 75/157 (47%), Positives = 100/157 (63%), Frame = +2

35 Q: 1034 QCLIKLLPSCLHPYIYRVT-FATANESS---ALLIRMFNEKGTLKDLIYKAKPKDPFLKK 1201  
+ L++LL S HPYIY V SS A L+ FN +G+LKDLIYKA+ +P+ +K  
S: 229 EILMELLGSLHHPYIYPVLDLGFLRNSSSYACLVTPFNSRGSLKDLIYKAQWNEPWARK 288  
Q: 1202 YCNPKKIQGLELQQIKTYGRQILEVLKFLHDKGFP-YGHLHASNVMLDGDTCRLLDLENS 1378

S: 289 Y +K GL + Q++ GRQILE L FL ++GFP +GHLH+ NV+L RL LEN  
YT--RKPNGLPVSVQRQLGRQILEALLFLKERGFPLHGHLHSQNVILQNGAARLSGLENG 346

5 Q: 1379 LLGLPSFYRSYFSQFRKINTLESVDVHCFGHLLYEMTYGR 1498  
LLGL S + R + +E+VD+ CFGHLLYEM G+  
S: 347 LLGLSSRINAVMWS-RSVTEIENVDIVCFGHLLYEMCTQQ 385

The segment of gil2981435 that is shown as "S" above is set out in the sequence listing as SEQ ID NO. 135. Based on the structural similarity these 10 homologous polypeptides are expected to share at least some biological activities. Such activities are known in the art, some of which are described elsewhere herein. Assays for determining such activities are also known in the art, some of which have been described elsewhere herein.

Preferred polypeptides of the invention comprise a polypeptide having the 15 amino acid sequence set out in the sequence listing as SEQ ID NO. 136 which corresponds to the Q sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares fetal liver spleen 1NFLS and to a lesser extent in 20 Soares\_NhHMPu\_S1; Corpus Callosum; Soares\_multiple\_sclerosis\_2NbHMSP; Soares\_fetal\_liver\_spleen\_1NFLS\_S1; H. Kidney Medulla, re-excision; Soares breast 2NbHBst; Human T-Cell Lymphoma; Dendritic cells, pooled; Human Placenta; Bone marrow; Bone Marrow Cell Line (RS4,11) and Nine Week Old Early Stage Human.

Many polynucleotide sequences, such as EST sequences, are publicly 25 available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:24 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention 30 are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1823 of SEQ ID NO:24, b is an integer of 15 to 1837, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:24, and where b is greater than or equal to a + 14.

**FEATURES OF PROTEIN ENCODED BY GENE NO: 15**

It has been discovered that this gene is expressed primarily in Bone Marrow Cell Line (RS4,11).

- 5        Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:25 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence  
10      would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 479 of SEQ ID NO:25, b is an integer of 15 to 493, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:25, and where b is greater than or equal to a  
15      + 14.

**FEATURES OF PROTEIN ENCODED BY GENE NO: 16**

- The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. gil414185 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "NAD+-isocitrate dehydrogenase, gamma subunit [Rattus norvegicus]." A partial alignment demonstrating the observed homology is shown immediately below.

25

```
>gi|414185 NAD+-isocitrate dehydrogenase, gamma subunit [Rattus
norvegicus]
Length = 388
```

30

Minus Strand HSPs:

```
Score = 162 (57.0 bits), Expect = 1.3e-12, Sum P(2) = 1.3e-12
Identities = 32/32 (100%), Positives = 32/32 (100%), Frame = -1
```

35

```
Q: 169 ATRNTGKSIANKNIANPTATLLASCMMMDHLK 74
      ATRNTGKSIANKNIANPTATLLASCMMMDHLK
S: 304 ATRNTGKSIANKNIANPTATLLASCMMMDHLK 335
```

Score = 38 (13.4 bits), Expect = 1.3e-12, Sum P(2) = 1.3e-12  
Identities = 11/33 (33%), Positives = 18/33 (54%), Frame = -2

5       Q:     399 PGLYCRHHQVIPEHFFHPTRKACPHKLSVPTPS 301  
            P L CR +V+ H P R++ + ++P PS  
      S:     14 PALLCRPWEVLAAH-EAP-RRSIQQQTIP-PS 43

The segments of gil414185 that are shown as "S" above are set out in the  
10 sequence listing as SEQ ID NO. 137 and SEQ ID NO. 139. Based on the structural  
similarity these homologous polypeptides are expected to share at least some  
biological activities. Such activities are known in the art, some of which are described  
elsewhere herein. Assays for determining such activities are also known in the art,  
some of which have been described elsewhere herein.

15       Preferred polypeptides of the invention comprise a polypeptide having the  
amino acid sequence set out in the sequence listing as SEQ ID NO. 138 and/or SEQ  
ID NO. 140 which correspond to the Q sequences in the alignment shown above  
(gaps introduced in a sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in Bone Marrow  
20 Cell Line (RS4,11).

Preferred epitopes include those comprising a sequence shown in SEQ ID NO.  
75 as residues: Gly-17 to Trp-24.

Many polynucleotide sequences, such as EST sequences, are publicly  
available and accessible through sequence databases. Some of these sequences are  
25 related to SEQ ID NO:26 and may have been publicly available prior to conception of  
the present invention. Preferably, such related polynucleotides are specifically  
excluded from the scope of the present invention. To list every related sequence  
would be cumbersome. Accordingly, preferably excluded from the present invention  
are one or more polynucleotides comprising a nucleotide sequence described by the  
30 general formula of a-b, where a is any integer between 1 to 446 of SEQ ID NO:26, b  
is an integer of 15 to 460, where both a and b correspond to the positions of  
nucleotide residues shown in SEQ ID NO:26, and where b is greater than or equal to a  
+ 14.

**FEATURES OF PROTEIN ENCODED BY GENE NO: 17**

It has been discovered that this gene is expressed primarily in Bone Marrow Cell Line (RS4,11).

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:27 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1355 of SEQ ID NO:27, b is an integer of 15 to 1369, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:27, and where b is greater than or equal to a + 14.

15

**FEATURES OF PROTEIN ENCODED BY GENE NO: 18**

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. gi|473407 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "NST-1 [Mus musculus]." A partial alignment demonstrating the observed homology is shown immediately below.

25 >gi|473407 NST-1 [Mus musculus] >sp|Q60637|Q60637 HEAT SHOCK PROTEIN HSP70  
NST-1.  
Length = 511

30 Plus Strand HSPs:

Score = 732 (257.7 bits), Expect = 3.4e-187, Sum P(3) = 3.4e-187  
Identities = 142/156 (91%), Positives = 153/156 (98%), Frame = +3

35 Q: 105 MAAIGVHLGCTSACVAVYKDGRAGVVANDAGDRVTPAVVAYSENEEIVGLAAKQSRIRNI 284  
MAAIGVHLGCTSACVAVYKDGRA VVANDAGDRVTPA+VAYSE E++VGLAAKQSRIR++  
S: 1 MAAIGVHLGCTSACVAVYKDGRADVVANDAGDRVTPAIVAYSEREQVVGAAKQSRIRHV 60  
Q: 285 SNTVMVKVQILGRSSDPQAQKYIAESKCLVIEKNGKLRYEIDTGEETKFVNPEDVARLI 464  
S+TV+KVKQILGRSS+DPQAQKYI+ESKCLVIEKNGKLRYEIDTGEETK VNPEDVARLI

```

S: 61 SSTVVVKQILGRSSADPQAQKYISESKCLVIEKNGKLRYEIDTGEETKLVNPEDVARLI 120
Q: 465 FSKMKETAHSVLGSDANDVVITVPDFGEKQKNALG 572
FSKMKETAHSVLGSDANDVV+TVPDFGEKQK+ALG
5 S: 121 FSKMKETAHSVLGSDANDVVVTVPDFGEKQKSALG 156

Score = 657 (231.3 bits), Expect = 3.4e-187, Sum P(3) = 3.4e-187
Identities = 134/165 (81%), Positives = 140/165 (84%), Frame = +3

10 Q: 576 FKHDVRGNARAMMKLNSAEVAKHSLSTLGSANCFLDSLYEGQDFDCNVSRARFELLCSP 755
FKHDVRGNARAMMKL NSAEVAKHSLSTLGSANCF+DSLYEGQDFDCNVSRARFELLCSP
S: 247 FKHDVRGNARAMMKLNSAEVAKHSLSTLGSANCFVDSLYEGQDFDCNVSRARFELLCSP 306

15 Q: 756 LFNKCIEAIRGLLDQNGFTADDINKVVL--GGSSRIPKLQQLIKDLFPAVELLNSIPPD 929
LFNKC EAIR LL Q GFTADDINKVVL GGSSRIPKLQQLIKDLFPAV+LLNSIPPD
S: 307 LFNKCTEAIRELLRQTGFTADDINKVVLWHEGGSSRIPKLQQLIKDLFPAVDLLNSIPPD 366

Q: 930 EVXXXXXXXXXXXXXXKENLLVEDSLMIECSARDILVKGVDESGA 1064
EV KE+ +DS+MIECSA+DILVKGVDESGA
20 S: 367 EVIPIGAAIEAGILVCESTSGDDSVMIECSAKDILVKGVDESGA 411

```

The segments of gil473407 that are shown as "S" above are set out in the sequence listing as SEQ ID NO. 141 and SEQ ID NO. 143. Based on the structural similarity these homologous polypeptides are expected to share at least some biological activities. Such activities are known in the art, some of which are described elsewhere herein. Assays for determining such activities are also known in the art, some of which have been described elsewhere herein.

Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 142 and/or SEQ 30 ID NO. 144 which correspond to the Q sequences in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: NCI\_CGAP\_GCB1 and to a lesser extent in Soares\_multiple\_sclerosis\_2NbHMSP; Stratagene ovarian cancer (#937219); Soares 35 fetal liver spleen 1NFLS; Liver Normal Met5No; Human Placenta, subtracted; Human Tongue, frac 2; Human Stomach; Human adult small intestine,re-excision; Jurkat T-Cell, S phase; L428; Human Jurkat Membrane Bound Polysomes; Human Pancreas Tumor; Human umbilical vein endothelial cells, IL-4 induced; Human adult (K.Okubo); Smooth muscle, serum induced,re-exc; Primary Dendritic cells,frac 2; T 40 Cell helper I; Human Testes; Bone Marrow Cell Line (RS4,11); Keratinocyte and Soares\_fetal\_liver\_spleen\_1NFLS\_S1.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 77 as residues: Asp-21 to Glu-28.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are 5 related to SEQ ID NO:28 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the 10 general formula of a-b, where a is any integer between 1 to 1542 of SEQ ID NO:28, b is an integer of 15 to 1556, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:28, and where b is greater than or equal to a + 14.

#### 15 FEATURES OF PROTEIN ENCODED BY GENE NO: 19

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Bone Marrow Cell Line (RS4,11).

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are 20 related to SEQ ID NO:29 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the 25 general formula of a-b, where a is any integer between 1 to 1245 of SEQ ID NO:29, b is an integer of 15 to 1259, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:29, and where b is greater than or equal to a + 14.

#### 30 FEATURES OF PROTEIN ENCODED BY GENE NO: 20

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. gnl|PID|d1026368 (all information available through the recited accession number is 5 incorporated herein by reference) which is described therein as "KIAA0512 protein [Homo sapiens]." A partial alignment demonstrating the observed homology is shown immediately below.

```

10      >gnl|PID|d1026368 (AB011084) KIAA0512 protein [Homo sapiens]
      >sp|O60267|O60267
                           KIAA0512 PROTEIN.
                           Length = 632

15      Plus Strand HSPs:
      Score = 629 (221.4 bits), Expect = 5.5e-72, Sum P(2) = 5.5e-72
      Identities = 126/264 (47%), Positives = 174/264 (65%), Frame = +2

20      Q: 398 VQKRASPNSDDTVLSPQELQKVLCILVEMSEKPYILEAAIALGNNAAYAFNRDIIRDLGG 577
             +QKR P D +L ++L+KVL L++ S+ P+I + AL+ L NNA Y+ N++ IR LGG
      S: 370 MQKRPFPYEIDEITLGVRDLRKVLALLQKSDDPFIQVQVALTLSNNANYSCNQETIRKLGG 429

25      Q: 578 LPIVAKILNTRDPIVKEKALIVLNNSVNAENQRRLKVMVNQVCDDDTITSRLNSSVQLAG 757
             LPI+A ++N DP +KEKAL+ +NNLS N ENQ RL+VVMN+V DD + S LNS+VQ+ G
      S: 430 LPIIANMINKTDPIKEKALMAMNNLSENYENQRLQVYMNKVMDDIMASNLNSAVQVVG 489

30      Q: 758 LRLLTNMTVTNEYQHMLANSISDFRFLSACNEETKXXXXXXXXXAENPAMTRELLRAQ 937
             L+ LTNMT+TN+YQH+L NSI++FRL S G + K          AENP M ++LL Q
      S: 490 LKFLTNMTITNDYQHLLVNSIANFFRLLSQGGGKIKVEILKILSNFAENPDMLKKLLSTQ 549

35      Q: 938 VP$SLGSFLFNKKENKEVILKLLVIFENINDFKWEENEPTQNQPGEGLFFFKEFQVCA 1117
             VP+S SL+N E+++ L +FE I DN + E          +F +GSLF+ VC
      S: 550 VPASFSSLYNSYVESEILINALTLEIIYDNLRAEVFN--YREFNKGSFLYLCFTSGVCV 607

      Q: 1118 DKVLGIESHHDFLVVKVKGVKFMAK 1189
             K+ + +HHD LVVKV K + K
      S: 608 KKIRALANHHDLLVKVKVIKLVNK 631

```

The segment of gnl|PID|d1026368 that is shown as "S" above is set out in the 40 sequence listing as SEQ ID NO. 145.

Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 146 which corresponds to the Q sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

45 It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Human 8 Week Whole Embryo; Soares placenta Nb2HP;

Soares infant brain INIB and to a lesser extent in Synovial Fibroblasts (IL1/TNF),  
subt; Soares fetal liver spleen INFSL; 12 Week Old Early Stage Human, II; Rejected  
Kidney, lib 4; NCI\_CGAP\_GCB1; Larynx Tumour;  
Soares\_parathyroid\_tumor\_NbHPA; Soares\_NhHMPu\_S1; Stratagene fetal spleen  
5 (#937205); Stratagene hNT neuron (#937233); Human Adipose; Human Thymus  
Stromal Cells; 12 Week Old Early Stage Human; Human Placenta; Nine Week Old  
Early Stage Human; Hypothalamus; Prostate; Soares\_pregnant\_uterus\_NbHPU;  
Soares\_fetal\_liver\_spleen\_INFSL\_S1; Frontal Lobe, Dementia; Human Adult  
Spleen; Human Adult Retina; Smooth Muscle Serum Treated, Norm; Human adult  
10 small intestine,re-excision; Stratagene ovary (#937217); HEL cell line; Stromal-  
Osteoclastoma; Human endometrial stromal cells-treated with estradiol; Stratagene  
hNT neuron (#937233); Synovial IL-1/TNF stimulated; Human Umbilical Vein,  
Endo. remake; H Female Bladder, Adult; Human Stomach,re-excision;  
Soares\_total\_fetus\_Nb2HF8\_9w; Human Manic Depression Tissue; Brain Frontal  
15 Cortex, re-excision; Human Chronic Synovitis; Human Prostate; Apoptotic T-cell; T-  
Cell PHA 24 hrs; Human Chondrosarcoma; Stratagene NT2 neuronal precursor  
937230; Hepatocellular Tumor, re-excision; Colon Carcinoma; Brain frontal cortex;  
Soares melanocyte 2NbHM; human tonsils; Human Adult Pulmonary,re-excision;  
Human Amygdala; Bone Marrow Cell Line (RS4,11); Human Endometrial Tumor;  
20 Hodgkin's Lymphoma II and Soares\_fetal\_lung\_NbHL19W.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:30 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1589 of SEQ ID NO:30, b is an integer of 15 to 1603, where both a and b correspond to the positions of 25 nucleotide residues shown in SEQ ID NO:30, and where b is greater than or equal to a  
30 + 14.

**FEATURES OF PROTEIN ENCODED BY GENE NO: 21**

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Human Primary Breast Cancer; Stratagene pancreas

5 (#937208) and to a lesser extent in Human Normal Breast; HL-60, PMA 4H, re-excision; Myeloid Progenitor Cell Line; Spinal Cord, re-excision; T-Cell PHA 24 hrs and Bone Marrow Cell Line (RS4,11).

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 80 as residues: Thr-96 to Ser-104, Arg-117 to Arg-122, Pro-169 to Gly-177.

10 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:31 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence  
15 would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1345 of SEQ ID NO:31, b is an integer of 15 to 1359, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:31, and where b is greater than or equal to a  
20 + 14.

**FEATURES OF PROTEIN ENCODED BY GENE NO: 22**

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. gil407483 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "unknown [Saccharomyces cerevisiae]." A partial alignment demonstrating the observed homology is shown immediately below.

protein [Saccharomyces cerevisiae] >pir|S37786|S37786 hypothetical  
 YKL165c - yeast (Saccharomyces cerevisiae)  
 Length = 919

5 Plus Strand HSPs:

Score = 197 (69.3 bits), Expect = 4.4e-13, Sum P(2) = 4.4e-13  
 Identities = 35/94 (37%), Positives = 63/94 (67%), Frame = +2

10 Q: 620 LTVFSPMMGALMMWKLIPFVLMCAFEAVQLTQLSSKSLFLIVLVISDIMALHFFFL 799  
 L +F PF+MGAL+M K++IP+ L+ + L ++ +++ +SDI++L+FF+L  
 S: 809 LPIDDPFLMGALLMLKLIIPYGLLSTCLGILNLKLNFKDYTISSLIISMSDILSLNFFYL 868

15 Q: 800 VKDYGSWLDIGTSISHYVIVMSMTIFLVFLNGLG 901  
 ++ GSWLDIG +IS+Y + + ++F++ L LG  
 S: 869 LRTEGSWLDIGITISNYCLAILSSLFMLILEVLG 902

Score = 59 (20.8 bits), Expect = 4.4e-13, Sum P(2) = 4.4e-13  
 Identities = 20/95 (21%), Positives = 36/95 (37%), Frame = +1

20 Q: 40 WFFFSLLLAVFPLMPVVGRKPDIXXXXXXXXXXXXXXXXXXXXXMKRKSFIKEELLVHL 219  
 W S+LL+ F L V + D+ R +S+ + +  
 S: 603 WIITSVLLSTFTLFDAV-KIEDLNQIHLAGLLIILSAFYALYKIHSRINSYTRA---IFA 658

25 Q: 220 LQVLSTVLSMYVVYSTQSSLLRKQQLPLMNQIISW 324  
 +Q+ + V + + SL +QGLP +Q+ W  
 S: 659 IQISLVAAMLAVENTHRSVISLQLRQGLPPRESQVAGW 693

30 The segments of gil407483 that are shown as "S" above are set out in the sequence listing as SEQ ID NO. 147 and SEQ ID NO. 149.

Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 148 and/or SEQ ID NO. 150 which correspond to the Q sequences in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Human Infant Brain and to a lesser extent in Stratagene HeLa cell s3 937216; Human Osteoclastoma, excised; Human Pineal Gland; Mo7e Cell Line GM-CSF treated (1ng/ml); Human Thymus; Human Adrenal Gland Tumor; Neutrophils IL-1 and LPS induced; Soares\_fetal\_liver\_spleen\_INFSL\_S1 and Bone Marrow Cell Line (RS4,11).

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:32 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence

- would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1476 of SEQ ID NO:32, b is an integer of 15 to 1490, where both a and b correspond to the positions of
- 5 nucleotide residues shown in SEQ ID NO:32, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 23**

- It has been discovered that this gene is expressed primarily in Bone Marrow
- 10 Cell Line (RS4,11).

- Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:33 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically
- 15 excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 508 of SEQ ID NO:33, b is an integer of 15 to 522, where both a and b correspond to the positions of
- 20 nucleotide residues shown in SEQ ID NO:33, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 24**

- It has been discovered that this gene is expressed primarily in Bone Marrow
- 25 Cell Line (RS4,11).

- Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:34 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically
- 30 excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention

are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 916 of SEQ ID NO:34, b is an integer of 15 to 930, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:34, and where b is greater than or equal to a  
5 + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 25

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting 10 example, the sequence accessible through the following database accession no. gil288145 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "put. ORF [Homo sapiens]." A partial alignment demonstrating the observed homology is shown immediately below.

15

```
>gi|288145 put. ORF [Homo sapiens] >pir|I38022|I38022 hypothetical protein
human >sp|Q29976|Q29976 MAHLAVU HEPATOCELLULAR CARCINOMA HHC(M)
DNA. Length = 196

Minus Strand HSPs:

Score = 197 (69.3 bits), Expect = 4.6e-18, Sum P(2) = 4.6e-18
25 Identities = 41/55 (74%), Positives = 44/55 (80%), Frame = -1
Q: 227 LRSGVQVQPGQHQGETPSLLKIKKKLARHGGMRLXSQPLERLRQENCLNLGGRGCSE 63
    LRSQVQ PGQHG+ PSLLKI++LA HGG L SQ L RLRQEN LN GGRGCSE
S: 4 LRSGVQDYPGQHGKIPSSLKIQEELAGHGGRCLQSQQLRRLRQENHLNSGGRGCSE 58
30 Score = 56 (19.7 bits), Expect = 4.6e-18, Sum P(2) = 4.6e-18
    Identities = 10/15 (66%), Positives = 11/15 (73%), Frame = -3
Q: 48 CTPVWVTE*DSTSCK 4
    C P WVTE DS SK+
S: 64 CIPAWVTEGDSVSKQ 78
```

The segments of gil288145 that are shown as "S" above are set out in the sequence listing as SEQ ID NO. 151 and SEQ ID NO. 153.

40 Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 152 and/or SEQ

ID NO. 154 which correspond to the Q sequences in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in Bone Marrow Cell Line (RS4,11).

5 Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 84 as residues: Leu-3 to Ser-10.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:35 and may have been publicly available prior to conception of 10 the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1434 of SEQ ID NO:35, b 15 is an integer of 15 to 1448, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:35, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 26

20 The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. gnl|PID|e1345052 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "Similarity in 3' 25 end to Human KIAA0173 protein (TR:Q14679)." A partial alignment demonstrating the observed homology is shown immediately below.

>gnl|PID|e1345052 predicted using Genefinder; Similarity in 3' end to  
30 Human KIAA0173 protein (TR:Q14679); cDNA EST EMBL:D33319 comes from  
this gene; cDNA EST EMBL:D34000 comes from this gene; cDNA EST  
EMBL:D36110 comes from this gene; cDNA EST EMBL:D36987 comes>  
35 >sp|O17720|O17720 C55A6.2 PROTEIN.  
Length = 1203

## Plus Strand HSPs:

5           Score = 169 (59.5 bits), Expect = 5.6e-08, P = 5.6e-08  
          Identities = 30/69 (43%), Positives = 47/69 (68%), Frame = +1

Q: 247 VAFHLCVDDHVKGNI TARDPAIMGLRNILKVCCTHDITTISIPLLLVHD MSEEMTIPWC 426  
      + +HL VD+ ++S I +R P + G+RNI++ ++ +TI IPLL+ E TI WC  
S: 413 IVYHLVVDETLQSLEINSRHPCLAGVRNIIRTAARYNTSTIHIPLLLIDRPDESTTIAWC 472

10          Q: 427 LRRAE LVFK 453  
          L+RAE++FK  
S: 473 LKRAEMLFK 481

15          The segment of gnl|PIDle1345052 that is shown as "S" above is set out in the sequence listing as SEQ ID NO. 155.

Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 156 which corresponds to the Q sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares infant brain 1NIB and to a lesser extent in Soares breast 3NbHBst; Soares fetal liver spleen 1NFLS; Soares breast 2NbHBst; Soares\_fetal\_heart\_NbHH19W; Bone Marrow Cell Line (RS4,11); Human Placenta; NCI\_CGAP\_GCB1; Soares\_NhHMPu\_S1; Soares retina N2b4HR; Stratagene neuroepithelium NT2RAMI 937234; Stromal-Osteoclastoma; Synovial Fibroblasts (II1/TNF), subt; Human Manic Depression Tissue; Stromal cell TF274; Merkel Cells; Rejected Kidney, lib 4; Soares melanocyte 2NbHM; Soares\_placenta\_8to9weeks\_2NbHP8to9W; T Cell helper I; Activated T-cell(12h)/Thiouridine-re-excision and Soares placenta Nb2HP.

When tested against Jurkat E cell lines, supernatants removed from cells containing this gene activated the GAS assay. Thus, it is likely that this gene activates T-cells cells through the Jak-STAT signal transduction pathway. The gamma activating sequence (GAS) is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS

element, can be used to indicate proteins involved in the proliferation and differentiation of cells.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are 5 related to SEQ ID NO:36 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the 10 general formula of a-b, where a is any integer between 1 to 2177 of SEQ ID NO:36, b is an integer of 15 to 2191, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:36, and where b is greater than or equal to a + 14.

## 15 FEATURES OF PROTEIN ENCODED BY GENE NO: 27

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. gi|1710216 (all information available through the recited accession number is 20 incorporated herein by reference) which is described therein as "unknown [Homo sapiens]." A partial alignment demonstrating the observed homology is shown immediately below.

25 >gi|1710216 unknown [Homo sapiens] >sp|Q99770|Q99770 HYPOTHETICAL 15.4 KD  
PROTEIN.  
Length = 139

Minus Strand HSPs:

30 Score = 133 (46.8 bits), Expect = 8.1e-10, Sum P(2) = 8.1e-10  
Identities = 31/75 (41%), Positives = 46/75 (61%), Frame = -2

35 Q: 274 FFFSRERPTLLPRLECSGANMAYCSLRLPSSTDPPAASRVGGTTDMDYHTKL-FLFLVQ 98  
FFF + + RLECSG A+C+L LP S++ PA+ASRV GT +L F+FL +  
S: 50 FFFFETQSHSVTRLECSGTISAHCNLCLPGSSNSPASASRVAGTAGTCRRAQLIFVFLAE 109

Q: 97 VGSQFVAQE-LETSL 56  
+G V ++ L+ +L  
S: 110 MGFHHVGRDGLDLNL 124

The segment of gil1710216 that is shown as "S" above is set out in the sequence listing as SEQ ID NO. 157.

Preferred polypeptides of the invention comprise a polypeptide having the 5 amino acid sequence set out in the sequence listing as SEQ ID NO. 158 which corresponds to the Q sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Bone Marrow Cell Line (RS4,11).

10 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:37 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence  
15 would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1575 of SEQ ID NO:37, b is an integer of 15 to 1589, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:37, and where b is greater than or equal to a  
20 + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 28

It has been discovered that this gene is expressed primarily in Bone Marrow Cell Line (RS4,11).

25 Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 87 as residues: Lys-50 to Tyr-57.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:38 and may have been publicly available prior to conception of 30 the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence

would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 817 of SEQ ID NO:38, b is an integer of 15 to 831, where both a and b correspond to the positions of  
5 nucleotide residues shown in SEQ ID NO:38, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 29

It has been discovered that this gene is expressed primarily in Bone Marrow  
10 Cell Line (RS4,11).

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:39 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically  
15 excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 770 of SEQ ID NO:39, b is an integer of 15 to 784, where both a and b correspond to the positions of  
20 nucleotide residues shown in SEQ ID NO:39, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 30

The computer algorithm BLASTX has been used to determine that the  
25 translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. gnl|PID|d1012150 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "KIAA0167 protein [Homo sapiens]." A partial alignment demonstrating the observed homology is shown  
30 immediately below.

>gnl|PID|d1012150 KIAA0167 protein [Homo sapiens] >sp|Q99490|Q99490  
 KIAA0167  
 PROTEIN.  
 Length = 836

5 Minus Strand HSPs:

Score = 341 (120.0 bits), Expect = 3.2e-31, Sum P(2) = 3.2e-31  
 Identities = 91/231 (39%), Positives = 130/231 (56%), Frame = -2

10 Q: 1042 RKCIFLKGNCNLKSLGPCKPLPNF\*SHSSFCSTQVSTVHITKXXXXXXXXXXXXXX 863  
 +K + L+ +L + CK LP+ SHS+ ST V+ +  
 S: 228 QKVVTLRKQQQL-LAACKSLPSSPSHSA-ASTPVAG---QASNGGHTSDYSSSLPSSPN 281

15 Q: 862 XXXQE-DPQFSVPPTANTPTPVCKRSMRWSNLFTSEKGSDPDKERAKAPENHADTIGSGRA 686  
 +E + + +TP + + + R ++LF + +GSD E+++ ++ +T GSRA  
 S: 282 VGHRELRAAAAVAGLSTPGSLHRAAKRRTSLFANRRGSD--SEKRSLDSRGETTGSGRA 339

20 Q: 685 IPIKQGMLLKRSGKWL-KTWKKKYVTLCNSGVLYYSSLGDYMKNIHKKEIDLRTSTIKV 509  
 IPIKQ LLKRSG L K WKKKYVTL SNG L Y+ S+ DY+ + H KE+DL +T+KV  
 S: 340 IPIKQSFLLKRSGNLSNKEWKKKYVTLSSNGFLYHPSINDYIHSTHGKEMDLLRTTVKV 399

Q: 508 PGKWPPLATSACAPISSKSNSGLSKDMDT-GLGDSI-CFPSISSTTSPK-LNPPP 350  
 PGK P A SA P S+ NGL KDM T +G+ + +P S + SP L PPP  
 S: 400 PGKRPRAISAFGP--SASINGLVKDMSTVQMGEGLEATTPMPSPSPSSLQPPP 453

The segment of gnl|PID|d1012150 that is shown as "S" above is set out in the sequence listing as SEQ ID NO. 159.

Preferred polypeptides of the invention comprise a polypeptide having the  
 30 amino acid sequence set out in the sequence listing as SEQ ID NO. 160 which  
 corresponds to the Q sequence in the alignment shown above (gaps introduced in a  
 sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares\_pregnant\_uterus\_NbHPU; Soares infant brain 1NIB  
 35 and to a lesser extent in Synovial hypoxia-RSF subtracted; Stratagene fetal spleen (#937205); Soares breast 2NbHBst; NCI\_CGAP\_GCB1; Soares fetal liver spleen 1NFLS; Stratagene hNT neuron (#937233); Stratagene endothelial cell 937223;  
 Primary Dendritic Cells, lib 1; Stomach Normal; LNCAP untreated; H. Epididymus,  
 caput & corpus; Soares\_fetal\_liver\_spleen\_1NFLS\_S1; Apoptotic T-cell, re-excision;  
 40 NTERA2 + retinoic acid, 14 days; Glioblastoma; T-Cell PHA 16 hrs; Human  
 umbilical vein endothelial cells, IL-4 induced; Human Thymus Stromal Cells; Human  
 Whole Six Week Old Embryo; NTERA2, control; Human Gall Bladder; Soares breast  
 3NbHBst; Bone marrow; Spleen, Chronic lymphocytic leukemia; Human Testes;

Soares\_fetal\_lung\_NbHL19W; Bone Marrow Cell Line (RS4,11); Hodgkin's Lymphoma II; T cell helper II and Human 8 Week Whole Embryo.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:40 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1164 of SEQ ID NO:40, b is an integer of 15 to 1178, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:40, and where b is greater than or equal to a + 14.

## 15 FEATURES OF PROTEIN ENCODED BY GENE NO: 31

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. gi|3411185 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "putative ferredoxin reductase MocF [Rhizobium leguminosarum bv. viciae]." A partial alignment demonstrating the observed homology is shown immediately below.

>gi|3411185 (AF076240) putative ferredoxin reductase MocF [Rhizobium leguminosarum bv. viciae] >sp|085778|085778 PUTATIVE FERREDOXIN REDUCTASE MOCF.  
Length = 421

30 Minus Strand HSPs:

Score = 222 (78.1 bits), Expect = 1.6e-24, Sum P(3) = 1.6e-24  
Identities = 65/205 (31%), Positives = 101/205 (49%), Frame = -1

35 Q: 1156 KSITIIGGGFLGSELACALGRKARALGTEVIQLFPEKGNGKILPEYLSNWTMEKVRREG 977  
KS+ ++GGGF+G E+A AR LG EV+ + + +P ++ E+ R+EG  
S: 155 KSLAVVGGFIGLEIAAT---ARKLGAEVLLIESSPRVLSRGVPAEIAKVVTERHRQEG 210

40 Q: 976 VKVMPNAIVQSVGVSSGKLLIKLKDGKRKVETDHIVAAVGLEPNVELAKTGGLEIDSDFGG 797  
V ++ + S+ + K+ I +G D +V +G+ PNVELA+ GL ID+ G

S: 211 VNILCGEQITSIATENDKVQILFANGTTRLADIVVVGIGVIPNVELAEAAGLLIDN---G 267  
Q: 796 FRVNAELQARS-NIWVAGDAACFYDIKLGRRRV--EHHDHAVVSGRLAGENMTGAAKPYW 626  
5 S: 268 IAVDATLRTSDPDIFAAGDCCSFPPLSHYRERRVRLEAWRNAQDQGMLVAANLLGRGLAIA 327  
Q: 625 HQSMFWSDLGPDVGYEAIGLVDSLPTV 542  
FWSD ++ + GL D + TV  
S: 328 SVPWFWSQY-ELTLQIAGLSDGAATT 354

10

The segment of gil3411185 that is shown as "S" above is set out in the sequence listing as SEQ ID NO. 161.

Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 162 which  
15 corresponds to the Q sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares ovary tumor NbHOT; Primary Dendritic Cells, lib 1 and to a lesser extent in NCI\_CGAP\_Kid3; Human Testes;  
20 Soares\_parathyroid\_tumor\_NbHPA; Human adult small intestine,re-excision; Human Adult Small Intestine; Human heart cDNA (YNakamura); T cell helper II; Soares fetal liver spleen 1NFLS; Stratagene colon (#937204); H. Kidney Medulla, re-excision; Soares\_fetal\_liver\_spleen\_1NFLS\_S1; Human Liver, normal; Human Osteoclastoma; Stratagene muscle 937209; T Cell helper I; Nine Week Old Early  
25 Stage Human; Soares placenta Nb2HP; Soares infant brain 1NIB; Gessler Wilms tumor; Soares\_testis\_NHT; Soares\_NFL\_T\_GBC\_S1; Stratagene HeLa cell s3 937216; Human B Cell 8866; H. Striatum Depression, subtracted; Human Adult Spleen; Human Thyroid; NCI\_CGAP\_AA1; NCI\_CGAP\_Br2; NCI\_CGAP\_Sch1; Raji Cells, cyclohexamide treated; HEL cell line; Glioblastoma; LNCAP prostate cell  
30 line; Myeloid Progenitor Cell Line; Fetal Liver, subtraction II; L428; Human Fetal Kidney; Human Uterine Cancer; Human Heart; Epithelial-TNF $\alpha$  and INF induced; Human T-Cell Lymphoma; NCI\_CGAP\_GCB1; Normal colon; Human Synovial Sarcoma; Endothelial-induced; Soares\_NhHMPu\_S1; Human Microvascular Endothelial Cells, fract. A; Smooth muscle,control; Monocyte activated; Human B

Cell Lymphoma; Activated T-cell(12h)/Thiouridine-re-excision; Bone Marrow Cell Line (RS4,11) and Human Endometrial Tumor.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 90 as residues: Lys-22 to Ser-35, Gln-42 to Gln-51, Leu-65 to Thr-72, Ser-77 to Trp-  
5 86.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:41 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically  
10 excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1565 of SEQ ID NO:41, b is an integer of 15 to 1579, where both a and b correspond to the positions of  
15 nucleotide residues shown in SEQ ID NO:41, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 32

The computer algorithm BLASTX has been used to determine that the  
20 translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. gnl|PID|d1022517 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "HYA22 [Homo sapiens]." A partial alignment demonstrating the observed homology is shown  
25 immediately below.

```
>gnl|PID|d1022517 HYA22 [Homo sapiens]
Length = 340
30 Plus Strand HSPs:
Score = 807 (284.1 bits), Expect = 6.6e-88, Sum P(2) = 6.6e-88
Identities = 148/182 (81%), Positives = 166/182 (91%), Frame = +1
35 Q: 160 PVQYLLPEAKAQDSKICVVVIDLDETLVHSSFKPVNNADFIIPVEIDGVVHQVYVLKRPH 339
      P +YLLPE D K CVVIDLDETLVHSSFKP++NADFI+PVEIDG +HQVYVLKRPH
```

S: 155 PAKYLLPEVTVLVDYGKKCVVIDLDETLVHSSFKPISNADEFIVPVEIDGTIHQVYVLKRPH 214  
 Q: 340 VDEFQLQRMGELFECVLFASLAKYADPVADLLDKWGAFRARLFRESCVFHRGNVVKDSR 519  
 5 S: 215 VDEFQLQRMGQLFECVLFASLAKYADPVADLLD+WG FRARLFRESCVFHRGNVVKDSR 274  
 Q: 520 LGRDLRRVLILIDNSPASYVFHPDNAPVASWFDNMSDTELHDLLPFFEQLSRVDDVYSVL 699  
 LGR+L +V+I+DNSPASY+FHP+NAVPA SWFD+M+DTEL DL+PFFE LSR DDVYS+L  
 10 S: 275 LGRELSKVIIVDNSPASYIFHPENAVPVQSWFDDMTDELLDIPFFEGLSREDDVYSML 334  
 Q: 700 RQ 705  
 +  
 S: 335 HR 336  
 15 Score = 96 (33.8 bits), Expect = 6.6e-88, Sum P(2) = 6.6e-88  
 Identities = 27/61 (44%), Positives = 34/61 (55%), Frame = +3  
 Q: 3 KGDQKSAASQKPRSRGILHSLFCCVCRD-DGEALPAHSGA--PLLVEENGAIPTDPSPPIP 173  
 K Q + + +K RSR IL S FCC RD + EA P S + P LVEENG + P+  
 20 S: 101 KASQCNVSLKKQRSRSILSSFFCCF-RDYNVEAPPSSPSVPLPVEENGLQKPPAKYL 159  
 Q: 174 AP 179  
 P  
 S: 160 LP 161  
 25

The segments of gnl|PID|d1022517 that are shown as "S" above are set out in the sequence listing as SEQ ID NO. 163 and SEQ ID NO. 165. Based on the structural similarity these homologous polypeptides are expected to share at least some biological activities. Such activities are known in the art, some of which are 30 described elsewhere herein. Assays for determining such activities are also known in the art, some of which have been described elsewhere herein.

Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 164 and/or SEQ ID NO. 166 which correspond to the Q sequences in the alignment shown above 35 (gaps introduced in a sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: breast lymph node cDNA library and to a lesser extent in Human B Cell Lymphoma; Soares placenta Nb2HP; Human Synovial Sarcoma; Smooth Muscle Serum Treated, Norm; Breast Lymph node cDNA library; Soares 40 retina N2b4HR; Amniotic Cells - Primary Culture; wilm's tumor; Prostate BPH; Epithelial-TNF $\alpha$  and INF induced; Rejected Kidney, lib 4; Pancreas Islet Cell Tumor; Smooth muscle, serum treated; Stratagene colon HT29 (#937221); Human Adult Pulmonary,re-excision; CD34 depleted Buffy Coat (Cord Blood), re-excision; CD34

positive cells (Cord Blood); Osteoblasts; Human Cerebellum; Human Fetal Brain, normalized CO; Human Fetal Brain, normalized C500H; Duodenum; Larynx carcinoma III; Human Aortic Endothelium; Human Pancreatic Carcinoma; Human Liver; Raji Cells, cyclohexamide treated; Healing groin wound - zero hr post-incision  
5 (control); Human Epididymus; Hepatocellular Tumor; Human Fetal Epithelium (Skin); Synovial hypoxia-RSF subtracted; H. Kidney Cortex, subtracted; Human Osteosarcoma; Synovial hypoxia; KMH2; Human Neutrophil; T-Cell PHA 16 hrs; Mo7e Cell Line GM-CSF treated (1ng/ml); L428; human ovarian cancer; Human Jurkat Membrane Bound Polysomes; Human Uterine Cancer; Human Pancreas  
10 Tumor; Liver, Hepatoma; Human Adipose; Spinal cord; Human Rhabdomyosarcoma; Human Thymus Stromal Cells; Human Thymus; Bone Marrow Stromal Cell, untreated; Soares breast 2NbHBst; Macrophage (GM-CSF treated); 12 Week Old Early Stage Human; Human T-Cell Lymphoma; Human Fetal Heart; human tonsils; Human Neutrophil, Activated; T Cell helper I; Human Bone Marrow, treated; Spleen,  
15 Chronic lymphocytic leukemia; Soares\_fetal\_lung\_NbHL19W; Bone Marrow Cell Line (RS4,11); Keratinocyte and Primary Dendritic Cells, lib 1.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:42 and may have been publicly available prior to conception of  
20 the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2274 of SEQ ID NO:42, b  
25 is an integer of 15 to 2288, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:42, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 33

30 It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Larynx carcinoma III; Synovial hypoxia; Prostate BPH;

Temporal cortex-Alzheizmer, subtracted; L428; CD34 depleted Buffy Coat (Cord Blood), re-excision; Human Amygdala; and Bone Marrow Cell Line (RS4,11).

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:43 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 940 of SEQ ID NO:43, b is an integer of 15 to 954, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:43, and where b is greater than or equal to a + 14.

## 15 FEATURES OF PROTEIN ENCODED BY GENE NO: 34

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: LNCAP prostate cell line; Stratagene NT2 neuronal precursor 937230; Synovial hypoxia; Soares\_pregnant\_uterus\_NbHPU; Human Adrenal Gland Tumor; Stratagene ovarian cancer (#937219); Resting T-Cell Library,II; Soares\_fetal\_heart\_NbHH19W; Soares\_fetal\_liver\_spleen\_1NFLS\_S1; Soares\_fetal\_lung\_NbHL19W; Soares fetal liver spleen 1NFLS and to a lesser extent in Human Whole 6 Week Old Embryo (II), subt; Human Pituitary, re-excision; wilm's tumor; Human Fetal Kidney; Human Uterine Cancer; Human umbilical vein endothelial cells, IL-4 induced; Ulcerative Colitis; Human Whole Six Week Old Embryo; Human Liver, normal; Pancreas Islet Cell Tumor; Stratagene endothelial cell 937223; 12 Week Old Early Stage Human; Stratagene fibroblast (#937212); H. Frontal cortex,epileptic,re-excision; Colon Tumor II; Soares melanocyte 2NbHM; Human Synovial Sarcoma; Human Placenta; Human B Cell Lymphoma; Spleen, Chronic lymphocytic leukemia; Bone Marrow Cell Line (RS4,11); Osteoblasts; Stratagene muscle 937209; T cell helper II; Keratinocyte; Primary Dendritic Cells, lib 1 and Soares infant brain 1NIB.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 93 as residues: Met-1 to Asp-6.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are 5 related to SEQ ID NO:44 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the 10 general formula of a-b, where a is any integer between 1 to 1549 of SEQ ID NO:44, b is an integer of 15 to 1563, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:44, and where b is greater than or equal to a + 14.

## 15 FEATURES OF PROTEIN ENCODED BY GENE NO: 35

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Human Tongue, frac 1; and Macrophage (GM-CSF treated).

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are 20 related to SEQ ID NO:45 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the 25 general formula of a-b, where a is any integer between 1 to 1833 of SEQ ID NO:45, b is an integer of 15 to 1847, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:45, and where b is greater than or equal to a + 14.

## 30 FEATURES OF PROTEIN ENCODED BY GENE NO: 36

It has been discovered that this gene is expressed primarily in Human Tongue, frac 1.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are 5 related to SEQ ID NO:46 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the 10 general formula of a-b, where a is any integer between 1 to 1377 of SEQ ID NO:46, b is an integer of 15 to 1391, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:46, and where b is greater than or equal to a + 14.

## 15 FEATURES OF PROTEIN ENCODED BY GENE NO: 37

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. gil1203969 (all information available through the recited accession number is 20 incorporated herein by reference) which is described therein as "filamin [Homo sapiens]." A partial alignment demonstrating the observed homology is shown immediately below.

25 >gi|1203969 filamin [Homo sapiens] >gnl|PID|e68033 filamin [Homo sapiens]  
(SUB  
1586-1656)  
Length = 2647

30 Plus Strand HSPs:  
Score = 1441 (507.3 bits), Expect = 4.6e-155, Sum P(2) = 4.6e-155  
Identities = 266/364 (73%), Positives = 315/364 (86%), Frame = +1

35 Q: 79 AKRQIAFEDRKDGSCGVSYVVQEPEGDYEVSIKFNDEHIPDSPFVVPVASLSDDARRLT 258  
+K +I+FEDRKDGSCGV+YVVQEPEGDYEV+S+KFN+EHI+PDSPFVVPVAS S DARRLT+  
S: 2279 SKAEISFEDRKDGSCGVAYVVQEPEGDYEVSVKFNEEHIPDSPFVVPASPCDARRLT 2338

Q: 259 SLQETGLKVNPQFASFAVQLNGARGVIDARVHTPSGAVEECCYVSELDSDKHTIRFIPHENG 438  
SLQE+GLKVNPQFASFAV LNGA+G IDA+VH+PSGA+ECCYV+E+D DK+ +RFIP ENG  
40 S: 2339 SLQESGLKVNPQFASFAVSLNGAKGAIDAKVHSPSGALEECYVTEIDQDKYAVRFIPRENG 2398

5           Q:    439 VHSIDVKFNGAHI PGSPFKIRVGEQS QAGDPGLVSAYGPGLEGXTTGVSSEFIVNTLNAG 618  
               V+ IDVKFNG HIPGSPFKIRVGE GDPGLVSAYG GLEG TG +EF+VNT NAG  
       S: 2399 VYLDVKFNGTHIPGSPFKIRVGE PGHGGDPGLVSAYGAGLEGGVTGNPAEFVVNTSNAG 2458

10          Q:    619 SGALSVTIDGPSKVQLDCRECPEGHVVTYTPMA PGNYLIAIKYGGPQHIVGSPFKAKVTG 798  
               +GALSVTIDGPSKV++DC+ECPEG+ VTYTPMAPG+YLI+IKYGGP HI GSPFKAKVTG  
       S: 2459 AGALSVTIDGPSKVKMDCQECPEGYRVTVTPMAPGSYLSIKYGGPYHIGGSPFKAKVTG 2518

15          Q:    799 PRLSGGHSLHETSTVLVETVTKXXXXXXXXXIPKFSSDASKVVTRGPGLSQAFVGQKN 978  
               PRL HSLHETS+V V+++TK P +DASKVV +G GLS+A+VGQK+  
       S: 2519 PRLVSNHSLHETSSVFVDSLTKATCAPQHGAPG-PG-PADASKVVAKG LGLSKAYVGQKS 2576

20          Q:    979 SFTVDCSKAGTNMMMVGVHGPKTPCEEVVKHMGNR VNVTVTKEKGDYI LIVKGDES 1158  
               SFTVDCSKAG NM++VGVHGP+TPCEE+ VKH+G+R+Y+V+Y +K+KG+Y L+VKWGDE  
       S: 2577 SFTVDCSKAGNNMLLVGVHGPRTPCCEEILVKHVGSRLYSVSYLLDKGEYTLVVKGDEH 2636

             Q: 1159 VPGS 1170  
              +PGS  
       S: 2637 IPGS 2640

The segment of gil1203969 that is shown as "S" above is set out in the sequence listing as SEQ ID NO. 167. Based on the structural similarity these homologous polypeptides are expected to share at least some biological activities.

25 Such activities are known in the art, some of which are described elsewhere herein. Assays for determining such activities are also known in the art, some of which have been described elsewhere herein.

Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 168 which

30 corresponds to the Q sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Human Quadriceps; Human Adult Heart, re-excision and to a lesser extent in Human Gastrocnemius; Stratagene muscle 937209; Human

35 Hippocampus, prescreened; Human Adult Heart, subtracted; HSC172 cells; Human Soleus; Soares\_fetal\_heart\_NbHH19W; H Female Bladder, Adult; Human Colon, re-excision; Soares\_fetal\_liver\_spleen\_1NFLS\_S1; Smooth muscle, serum treated; Human Amygdala; Human Tongue, frac 2; Human Adult Heart; Smooth Muscle-HASTE normalized; Human Normal Breast; Pancreas Tumor PCA4 Tu; Smooth

40 muscle, IL1b induced; Soares\_fetal\_lung\_NbHL19W; Human Pituitary, subt IX; Human Prostate; CHME Cell Line, treated 5 hrs; Human umbilical vein endothelial

cells, IL-4 induced; Ulcerative Colitis; Human Thymus Stromal Cells; Human Whole Six Week Old Embryo; Smooth muscle,control; Human 8 Week Whole Embryo and Nine Week Old Early Stage Human.

- Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 5 96 as residues: Ala-28 to Arg-35.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:47 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically 10 excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1994 of SEQ ID NO:47, b is an integer of 15 to 2008, where both a and b correspond to the positions of 15 nucleotide residues shown in SEQ ID NO:47, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 38

It has been discovered that this gene is expressed primarily in the following 20 tissues/cDNA libraries: neutrophils control; and Human Neutrophil.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:48 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically 25 excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 808 of SEQ ID NO:48, b is an integer of 15 to 822, where both a and b correspond to the positions of 30 nucleotide residues shown in SEQ ID NO:48, and where b is greater than or equal to a + 14.

**FEATURES OF PROTEIN ENCODED BY GENE NO: 39**

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Neutrophils IL-1 and LPS induced; neutrophils control; and  
5 Human Neutrophil.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 98 as residues: Thr-39 to Thr-44.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are  
10 related to SEQ ID NO:49 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the  
15 general formula of a-b, where a is any integer between 1 to 1369 of SEQ ID NO:49, b is an integer of 15 to 1383, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:49, and where b is greater than or equal to a + 14.

**20 FEATURES OF PROTEIN ENCODED BY GENE NO: 40**

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: eosinophil-IL5 induced; Human Neutrophil; Pancreas Islet Cell Tumor; and neutrophils control.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are  
25 related to SEQ ID NO:50 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the  
30 general formula of a-b, where a is any integer between 1 to 734 of SEQ ID NO:50, b

is an integer of 15 to 748, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:50, and where b is greater than or equal to a + 14.

## 5 FEATURES OF PROTEIN ENCODED BY GENE NO: 41

It has been discovered that this gene is expressed primarily in Human Neutrophil.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:51 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1210 of SEQ ID NO:51, b is an integer of 15 to 1224, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:51, and where b is greater than or equal to a + 14.

## 20 FEATURES OF PROTEIN ENCODED BY GENE NO: 42

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Human Neutrophil; and Human Fetal Dura Mater.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 101 as residues: Ser-19 to Lys-24.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:52 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the

general formula of a-b, where a is any integer between 1 to 1251 of SEQ ID NO:52, b is an integer of 15 to 1265, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:52, and where b is greater than or equal to a + 14.

5

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 43

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no.

10 gil1518458 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "mitochondrial solute carrier [Onchocerca volvulus]." A partial alignment demonstrating the observed homology is shown immediately below.

```

15 >gi|1518458 mitochondrial solute carrier [Onchocerca volvulus]
      Length = 303

      Plus Strand HSPs:

20 Score = 507 (178.5 bits), Expect = 2.4e-47, P = 2.4e-47
      Identities = 96/194 (49%), Positives = 134/194 (69%), Frame = +1

      Q: 1738 SGVCFAGIAGSMATLLHDAVMNPAEVVKORLQMYNSQHRSAlSciRTVWRTEGLAFYRS 1917
          + V +A I+G++AT++HDAVMNPAEVVKQR+QM S + +++ CIR ++ EGL AFYRS
25      S: 109 NSVSYA-ISGALATVIHDAVMNPAEVVKQRMQMIFSPYGNSELRCIYIREGLRAFYRS 167

      Q: 1918 YTTQLTMNIPFQSIHFITYEFLQEQQVNPHRTYNPQSHIISXXXXXXXXXXTPLDVCKT 2097
          Y TQLT+N+P+Q HF+ YE++Q +NPH YNP SH++S TTPLD KT
      S: 168 YITQLTLNVPYQCTHFMIVYEMQNLLNPYHDYNPSSHLVSGGIAGGIAAAITTPLDCVKT 227

      Q: 2098 LLNTQE----NVALSLANISGRRLS---GMANAFRTVYQLNGLAGYFKGIQARVIYQMPST 2256
          +LNTQ+ N L S + G+A+ +T+Y L G G+F+G+QAR+I+Q+PST
      S: 228 VLNTQQTQPRFNTTYRLLTQSEHTAYYKGLADGIKTIYLRGTGGFFRGLQARIIFQIPST 287

30      Q: 2257 AISWSVYEFFKYFLT 2301
          A+SWS YE KY L+
      S: 288 ALSWSAYELCKYMLS 302

```

The segment of gil1518458 that is shown as "S" above is set out in the 40 sequence listing as SEQ ID NO. 169. Based on the structural similarity these homologous polypeptides are expected to share at least some biological activities. Such activities are known in the art, some of which are described elsewhere herein.

Assays for determining such activities are also known in the art, some of which have been described elsewhere herein.

Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 170 which 5 corresponds to the Q sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares fetal liver spleen 1NFLS and to a lesser extent in Soares placenta Nb2HP; Human Neutrophil; Soares breast 3NbHBst; Bone marrow; 10 Human Neutrophil, Activated; Human Placenta; Nine Week Old Early Stage Human; Soares breast 2NbHBst; Soares ovary tumor NbHOT; Soares retina N2b4HR; Soares\_NhHMPu\_S1; Human Fetal Heart; Stratagene placenta (#937225); Human Bone Marrow, re-excision; Neutrophils control, re-excision; CD34 positive cells (Cord Blood); NCI\_CGAP\_Co9; NCI\_CGAP\_GCB1;

15 Soares\_fetal\_liver\_spleen\_1NFLS\_S1; Soares\_NFL\_T\_GBC\_S1; Human T-cell lymphoma,re-excision; Resting T-Cell Library,II; Endothelial cells-control; Smooth muscle,control; Bone Marrow Cell Line (RS4,11); neutrophils control; Human 8 Week Whole Embryo; Soares\_parathyroid\_tumor\_NbHPA; H. Epididymus, caput & corpus; Stratagene neuroepithelium (#937231); Human adult small intestine,re-excision; Soares\_pregnant\_uterus\_NbHPU; pBMC stimulated w/ poly I/C; HL-60, PMA 4H, re-excision; Fetal Liver, subtraction II; Human Prostate; Stratagene fetal spleen (#937205); Human Activated T-Cells; Human Pancreas Tumor; Human Thymus; Human Whole Six Week Old Embryo; Stratagene lung (#937210); NCI\_CGAP\_Lu5; NCI\_CGAP\_Kid3; Human Eosinophils; Colon Normal II; Human 20 Placenta; Human Fetal Lung III; Human Adult Pulmonary,re-excision; Endothelial-induced; CD34 depleted Buffy Coat (Cord Blood), re-excision; Human Microvascular Endothelial Cells, fract. A; Human Bone Marrow, treated; Keratinocyte; Human Cerebellum; Early Stage Human Liver; Bone Cancer, re-excision; Human Activated T-Cells (II); Human Eosinophils; human caudate nucleus; Human Macrophage, 25 subtracted; Soares\_testis\_NHT; Soares\_fetal\_heart\_NbHH19W; Osteoclastoma-normalized A; Human Placenta, subtracted; Human epithelioid sarcoma; Morton Fetal 30

- Cochlea; Frontal Lobe, Dementia; A-14 cell line; Human colon carcinoma (HCC) cell line, remake; Hodgkin's Lymphoma I; Human Fetal Spleen; Human Placenta; Human Neutrophils, Activated, re-excision; H. cerebellum, Enzyme subtracted; Human Lung; Human Tonsils, Lib 2; B Cell lymphoma; HEL cell line; Stromal-Osteoclastoma;
- 5 Human Umbilical Vein, Endo. remake; Human Fetal Epithelium (Skin); Salivary Gland, Lib 2; Jurkat T-cell G1 phase; Myeloid Progenitor Cell Line; H. Meningima, M1; Prostate BPH; H. Kidney Medulla, re-excision; Monocyte activated, re-excision; 12 Week Old Early Stage Human, II; Human Adult Testes, Large Inserts, Reexcision; Stromal cell TF274; Human Chondrosarcoma; Soares adult brain N2b5HB55Y;
- 10 Ulcerative Colitis; Human Adrenal Gland Tumor; Soares\_fetal\_lung\_NbHL19W; NTERA2, control; Human retina cDNA randomly primed sublibrary; NCI\_CGAP\_Co10; Fetal Heart; Colon Carcinoma; breast lymph node CDNA library; Human Testes Tumor; Primary Dendritic cells, frac 2; human tonsils; Anergic T-cell; Soares\_fetal\_liver\_spleen\_1NFLS\_S1; T cell helper II; NCI\_CGAP\_Pr22; and
- 15 Primary Dendritic Cells, lib 1.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:53 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2696 of SEQ ID NO:53, b is an integer of 15 to 2710, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:53, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 44

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no.

gil1458285 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "No definition line found [Caenorhabditis elegans]." A partial alignment demonstrating the observed homology is shown immediately below.

5

```
>gi|1458285 No definition line found [Caenorhabditis elegans]
Length = 484

Plus Strand HSPs:

Score = 539 (189.7 bits), Expect = 6.9e-77, Sum P(2) = 6.9e-77
Identities = 96/206 (46%), Positives = 131/206 (63%), Frame = +3

Q:   630 WREISVCGNVFSLRETRSAQQRGKVMVEIETNQLQDGSLIDLGGATLLWRTAEGLSHTPTV 809
      WRE+S+ G+V+ R TRS+ +G V TN LDG+LIDLGGAT+LWRTA+GL +P +
S:   234 WREVSINGDVYEPRVTRSSSAKGVFVPEWTNMLQDGTLIDLGGATILWRTADGLERSPKM 293

Q:   810 KHLEALRQEINAARPQCPVGFTNLAFPSMKRKDVVDEKQPWVYLNCGHVGHYHNWGNKEE 989
      + LE +NA RPQCPV NTL P + ++ +QP+VYL CGHV G H WG +E
S:   294 RELEMALDRLNAGRQPCPVNLNTLVIPKKRNQRQINRRQPYVYLLQCGHVQGRHEWGVQEN 353

Q:   990 RDGKDRECPCMRSVGP-YVPLWLGCCEAGFYVDAGPPTHAFSPCGHVCSEKTTAYWSQIPL 1166
      + +CP+C V L +G E F++D+G H F+PGH+ S++T YWS+IPL
S:   354 SGQRSGKCPICLVESERIVQLSMGMEPSFHLDGVLDDHTFNPGHMASKQTVLYWSRIPL 413

Q:   1167 PHGTHTFHAAACPFCAHQLAGEQGYIR 1244
      P GT + CPFC LA E+ + +
S:   414 PQGTCRYDPVCPFCYQLLATERPFYK 439
```

30 The segment of gil1458285 that is shown as "S" above is set out in the sequence listing as SEQ ID NO. 171.

Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 172 which corresponds to the Q sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

35 It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares placenta Nb2HP and to a lesser extent in Human Neutrophil; Soares breast 3NbHBst; Human T-cell lymphoma,re-excision; pBMC stimulated w/ poly I/C; Stratagene lung (#937210); Human Eosinophils; Human Placenta; Human Fetal Heart; Human Adult Pulmonary,re-excision; NCI\_CGAP\_GCB1; Human Bone Marrow, treated; Human 8 Week Whole Embryo; Soares fetal liver spleen 1NFLS; Human Eosinophils; Morton Fetal Cochlea; Frontal Lobe, Dementia; A-14 cell line; Hodgkin's Lymphoma I; Human adult small

- intestine,re-excision; Human Tonsils, Lib 2; B Cell lymphoma; Jurkat T-cell G1 phase; Myeloid Progenitor Cell Line; Human Bone Marrow, re-excision; 12 Week Old Early Stage Human, II; Stromal cell TF274;
- Soares\_fetal\_liver\_spleen\_1NFLS\_S1; Ulcerative Colitis; Resting T-Cell Library,II;
- 5 Colon Carcinoma; Primary Dendritic cells,frac 2; Bone marrow; Human Neutrophil, Activated; Bone Marrow Cell Line (RS4,11); T cell helper II; Nine Week Old Early Stage Human and Human Cerebellum.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:54 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 3318 of SEQ ID NO:54, b is an integer of 15 to 3332, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:54, and where b is greater than or equal to a + 14.

## 20 FEATURES OF PROTEIN ENCODED BY GENE NO: 45

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Human Neutrophil; and CD34 depleted Buffy Coat (Cord Blood), re-excision.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 25 104 as residues: Cys-21 to Trp-26, Val-37 to Ser-53.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:55 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention

are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 475 of SEQ ID NO:55, b is an integer of 15 to 489, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:55, and where b is greater than or equal to a  
 5 + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 46

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting 10 example, the sequence accessible through the following database accession no. gnl|PID|e1350143 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "similar to RNA recognition motif. (aka RRM, RBD, or RNP domain)." A partial alignment demonstrating the observed homology is shown immediately below.

15

```
>gnl|PID|e1350143 predicted using Genefinder; similar to RNA recognition
motif.
(aka RRM, RBD, or RNP domain); cDNA EST EMBL:T01682 comes from
this
20 gene; cDNA EST EMBL:M75823 comes from this gene; cDNA EST
EMBL:D27559 comes from this gene; cDNA EST EMBL:T00202 >
>sp|O18181|O18181 W09D10.1 PROTEIN.
Length = 495
```

25

Minus Strand HSPs:

```
Score = 344 (121.1 bits), Expect = 1.3e-30, P = 1.3e-30
Identities = 67/118 (56%), Positives = 82/118 (69%), Frame = -3
```

30

```
Q: 1231 PRWASWNIGVFIGICIRCAGIHRNLGVHISRVKSVNLDQWTQEIQIQCQMQUEGNGKANRLYEA 1052
PRWA+WN+GVFICIRCAGIHRNLGVHIS+V+SVNLD WT EQ+Q M+ MGN KA ++YE
S: 40 PRWAAWNLGVFIGICIRCAGIHRNLGVHISKVRSVNLD SWTPEQVQTMRVMGNEKARQVYEH 99
```

35

```
Q: 1051 YLPETFRRPQIDPAVEGFIRDKYEKKKYMDRS----LDINAFRKEKDDKWKGSEPV 893
LP FRRP D +E FIR KYE-K+Y+ R +D + K K+ PV
S: 100 DLPAQFRRPTNDQQMEQFIRSKYEQKRYILRDFVYPRVDASQLPKSLSQAQKKVGTPV 157
```

The segment of gnl|PID|e1350143 that is shown as "S" above is set out in the sequence listing as SEQ ID NO. 173.

40

Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 174 which

corresponds to the Q sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Activated T-Cell (12hs)/Thiouridine labelledEco and to a  
5 lesser extent in Human Primary Breast Cancer,re-excision; Resting T-Cell, re-excision; Human Tonsils, Lib 2; Soares\_testis\_NHT; KMH2; Human Neutrophil; T-Cell PHA 16 hrs; Human Thymus; NCI\_CGAP\_GCB1; NCI\_CGAP\_Kid3; Human Adult Testes, Large Inserts, Reexcision; Human Eosinophils; Human Placenta; Soares\_fetal\_heart\_NbHH19W; Brain frontal cortex and Human Synovial Sarcoma.

10 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:56 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence  
15 would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1300 of SEQ ID NO:56, b is an integer of 15 to 1314, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:56, and where b is greater than or equal to a  
20 + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 47

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares\_fetal\_liver\_spleen\_1NFLS\_S1; Spleen metastatic  
25 melanoma; Human Neutrophil; Human Neutrophil, Activated; and Spleen, Chronic lymphocytic leukemia.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 106 as residues: Pro-27 to Ser-37, Gln-40 to Pro-49.

Many polynucleotide sequences, such as EST sequences, are publicly  
30 available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:57 and may have been publicly available prior to conception of

the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the 5 general formula of a-b, where a is any integer between 1 to 1550 of SEQ ID NO:57, b is an integer of 15 to 1564, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:57, and where b is greater than or equal to a + 14.

#### 10    FEATURES OF PROTEIN ENCODED BY GENE NO: 48

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Human Neutrophil; and Smooth muscle,control.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 107 as residues: Lys-22 to Gly-27.

15    Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:58 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence 20 would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2059 of SEQ ID NO:58, b is an integer of 15 to 2073, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:58, and where b is greater than or equal to a 25 + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 49

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting 30 example, the sequence accessible through the following database accession no. gi|288145 (all information available through the recited accession number is

incorporated herein by reference) which is described therein as "put. ORF [Homo sapiens]." A partial alignment demonstrating the observed homology is shown immediately below.

5 >gi|288145 put. ORF [Homo sapiens] >pir|I38022|I38022 hypothetical protein  
- human >sp|Q29976|Q29976 MAHLAVU HEPATOCELLULAR CARCINOMA HHC(M)  
DNA.  
Length = 196  
10 Plus Strand HSPs:  
  
Score = 143 (50.3 bits), Expect = 1.6e-08, P = 1.6e-08  
Identities = 30/49 (61%), Positives = 34/49 (69%), Frame = +3  
15 Q: 744 MARHGGSHL\*SQHFRRRLRQENCLNLGGGGCSELRRWHHCTPAWRTK\*DSI 890  
+ A HGG L SQ RRLRQEN LN GG GCSE + H C PAW T+ DS+  
S: 27 LAGHGGRCLOSQLLRLRQENHLNSGGRGCEPKSHLCIPAWVTEGDSV 75

20 The segment of gil288145 that is shown as "S" above is set out in the sequence listing as SEQ ID NO. 175.

Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 176 which corresponds to the Q sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in Human Neutrophil.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 108 as residues: Glu-13 to Asp-18.

30 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:59 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence  
35 would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 900 of SEQ ID NO:59, b is an integer of 15 to 914, where both a and b correspond to the positions of

nucleotide residues shown in SEQ ID NO:59, and where b is greater than or equal to a + 14.

Table 1

			ATCC Deposit NO:Z and Date	NT SEQ ID NO: X	5' NT of Clone Seq.	5' NT of Clone Seq.	AA SEQ	First AA of ID	Last AA of ID	First AA of Signal Pep	First AA of Sig Pep	First AA of Secreted Portion	Last AA of Signal Pep	Last AA of Sig Pep	Last AA of ORF	
Gene No.	cDNA Clone ID	Vector		Total NT Seq.	Start Codon	Signal Pep	NO: Y									
1	HMVBC31	203957 4/26/99	pSport1	11 2556	1327	2546	1437	1437	60	1	32	33	40			
2	HMVBC84	203957 4/26/99	pSport1	12 1149	1	1149	69	69	61	1	18	19	40			
3	HMVBD68	203957 4/26/99	pSport1	13 1281	1	1281	467	467	62	1	18	19	40			
4	HMWAO65	203957 4/26/99	Uni-Zap XR	14 712	1	712	340	340	63	1			22			
5	HMWAO82	203957 4/26/99	Uni-Zap XR	15 486	1	486	72	72	64	1	17	18	40			
6	HMWBD74	203957 4/26/99	Uni-Zap XR	16 654	181	653	410	410	65	1	17	18	20			
7	HMWBK35	203957 4/26/99	Uni-Zap XR	17 974	1	974	194	194	66	1	20	21	63			
8	HMWBK86	203957 4/26/99	Uni-Zap XR	18 472	1	472			268	67	1		6			
9	HMWBL03	203957 4/26/99	Uni-Zap XR	19 2596	80	2596	240	240	68	1	18	19	39			

Gene No.	cDNA Clone ID	ATCC Deposit NO:Z and Date	NT SEQ ID NO: X	NT Total Seq. X	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of AA SEQ First ID of Signal NO:	5' NT of AA SEQ First ID of Signal NO:	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of Secreted Portion	First AA of AA Portion	Last AA of AA Portion
10	HMWBL38	203957 4/26/99	Uni-Zap XR Vector	20 924	1 924	31 807	31 807	31 1857	69 116	1 71	18 1	19 12	19 13	33 13
11	HMWBM48	203957 4/26/99	Uni-Zap XR	21	807	1	1	116	70 116	1	18 71	19 1	19 13	33 13
12	HMWCP85	203957 4/26/99	Uni-Zap XR	22	2037	1								14
13	HMWDG30	203957 4/26/99	Uni-Zap XR	23	1417	1	1417	187	187 72	1	20 1	21 1		
14	HMWDU20	203957 4/26/99	Uni-Zap XR	24	1837	1	1837	92	92 73	1	27 1	28 1	28 33	28 33
15	HMwdx57	203957 4/26/99	Uni-Zap XR	25	493	1	493	127	127 74	1				8
16	HMWDZ63	203957 4/26/99	Uni-Zap XR	26	460	1	460	129	129 75	1	16 1	17 16	17 16	36 29
17	HMWEA77	203957 4/26/99	Uni-Zap XR	27	1369	1	1369	213	213 190	1	16 77	17 1	17 18	28 19
18	HMWE03	203957 4/26/99	Uni-Zap XR	28	1556	1	1555	190	190 77	1	18 1	19 1	19 18	28 19
19	HMWEF46	203957 4/26/99	Uni-Zap XR	29	1259	1	1259	71	71 78	1	18 1	19 1	19 18	61

Gene No.	cDNA Clone ID	ATCC Deposit NO:Z and Date	NT SEQ ID NO: X	NT Total NT Seq.	3' NT of Clone Seq.	5' NT of Clone Seq.	First AA of Start Signal Codon	SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
20	HMWEU96	203957 4/26/99	Uni-Zap XR	30	1603	1	1603	219	79	1	16	17
21	HMWEX02	203957 4/26/99	Uni-Zap XR	31	1359	1	1359	48	80	1	25	26
22	HMWFB65	203957 4/26/99	Uni-Zap XR	32	1490	1	1490	29	81	1		16
23	HMWF77	203957 4/26/99	Uni-Zap XR	33	522	1	522	17	17	82	1	32
24	HMWFO25	203957 4/26/99	Uni-Zap XR	34	930	1	930		185	83	1	10
25	HMWGO95	203957 4/26/99	Uni-Zap XR	35	1448	1	1448	175	175	84	1	29
26	HKGCK41	203957 4/26/99	pSport1	36	2191	1	1040	316	316	85	1	50
27	HMWGZ42	203957 4/26/99	Uni-Zap XR	37	1589	1	1589	224	224	86	1	21
28	HMWHR36	203957 4/26/99	Uni-Zap XR	38	831	1	831	164	164	87	1	28
29	HMWIM55	203957 4/26/99	Uni-Zap XR	39	784	1	784	53	53	88	1	25

Gene No.	cDNA Clone ID	ATCC Deposit NO:Z and Date	NT SEQ ID NO: X	NT Total NT Seq. X	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of AA of Start Signal Seq. Y	NT SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of Secreted Portion ORF
30	HMWIQ26	203957 4/26/99	Uni-Zap XR	40	1178	1	1178	135	89	1	22	23
31	HMWIU49	203957 4/26/99	Uni-Zap XR	41	1579	920	1579	989	90	1	20	21
32	HMWJF53	203957 4/26/99	Uni-Zap XR	42	2288	927	2101	1015	91	1	32	33
33	HMWJJ62	203957 4/26/99	Uni-Zap XR	43	954	1	954	115	115	92	1	19
34	HMWJJ64	203957 4/26/99	Uni-Zap XR	44	1563	1	1563	187	187	93	1	38
35	HNAAD76	203957 4/26/99	pSport1	45	1847	1	1847	116	116	94	1	38
36	HNAAE24	203957 4/26/99	pSport1	46	1391	1	1391	107	107	95	1	39
37	HNALE44	203957 4/26/99	pSport1	47	2008	1	1980	179	179	96	1	27
38	HNEAA04	203957 4/26/99	Uni-ZAP XR	48	822	1	822	112	112	97	1	26
39	HNEAK38	203957 4/26/99	Uni-ZAP XR	49	1383	105	1383	247	98	1	28	29

		ATCC Deposit NO:Z and Date	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of AA SEQ First ID of AA of Signal NO:	5' NT of AA SEQ First ID of AA of Signal NO:	First AA of Sig Pep	Last AA of Sig Pep	First AA of AA Secreted Portion	Last AA of AA Secreted Portion
Gene No.	cDNA Clone ID	Vector										
40	HNEAK65	203957 Uni-ZAP XR	50	748	1	748	66	66	99	1	20	21
41	HNEAK81	203957 Uni-ZAP XR	51	1224	1	1224	288	288	100	1		31
42	HNECD52	203957 Uni-ZAP XR	52	1265	1	1265	262	262	101	1	20	21
43	HNECL22	203957 Uni-ZAP XR	53	2710	225	2710	472	472	102	1	24	25
44	HNECL75	203957 Uni-ZAP XR	54	3332	1077	3135	1120	1120	103	1	32	33
45	HNECW49	203957 Uni-ZAP XR	55	489	1	463	316	316	104	1	21	22
46	HNECX90	203957 Uni-ZAP XR	56	1314	1	1314	71	71	105	1	18	19
47	HNEDA05	203957 Uni-ZAP XR	57	1564	575	1564	649	649	106	1	17	18
48	HNEDH88	203957 Uni-ZAP XR	58	2073	1	2073	70	70	107	1	19	20
49	HNEDP75	203957 Uni-ZAP XR	59	914	1	914	211	211	108	1		24

Table 1 summarizes the information corresponding to each "Gene No." described above. The nucleotide sequence identified as "NT SEQ ID NO:X" was assembled from partially homologous ("overlapping") sequences obtained from the "cDNA clone ID" identified in Table 1 and, in some cases, from additional related DNA 5 clones. The overlapping sequences were assembled into a single contiguous sequence of high redundancy (usually three to five overlapping sequences at each nucleotide position), resulting in a final sequence identified as SEQ ID NO:X.

The cDNA Clone ID was deposited on the date and given the corresponding deposit number listed in "ATCC Deposit No:Z and Date." Some of the deposits 10 contain multiple different clones corresponding to the same gene. "Vector" refers to the type of vector contained in the cDNA Clone ID.

"Total NT Seq." refers to the total number of nucleotides in the contig identified by "Gene No." The deposited clone may contain all or most of these sequences, reflected by the nucleotide position indicated as "5' NT of Clone Seq." 15 and the "3' NT of Clone Seq." of SEQ ID NO:X. The nucleotide position of SEQ ID NO:X of the putative start codon (methionine) is identified as "5' NT of Start Codon." Similarly , the nucleotide position of SEQ ID NO:X of the predicted signal sequence is identified as "5' NT of First AA of Signal Pep."

The translated amino acid sequence, beginning with the methionine, is 20 identified as "AA SEQ ID NO:Y," although other reading frames can also be easily translated using known molecular biology techniques. The polypeptides produced by these alternative open reading frames are specifically contemplated by the present invention.

The first and last amino acid position of SEQ ID NO:Y of the predicted signal 25 peptide is identified as "First AA of Sig Pep" and "Last AA of Sig Pep." The predicted first amino acid position of SEQ ID NO:Y of the secreted portion is identified as "Predicted First AA of Secreted Portion." Finally, the amino acid position of SEQ ID NO:Y of the last amino acid in the open reading frame is identified as "Last AA of ORF."

30 SEQ ID NO:X (where X may be any of the polynucleotide sequences disclosed in the sequence listing) and the translated SEQ ID NO:Y (where Y may be

- any of the polypeptide sequences disclosed in the sequence listing) are sufficiently accurate and otherwise suitable for a variety of uses well known in the art and described further below. For instance, SEQ ID NO:X is useful for designing nucleic acid hybridization probes that will detect nucleic acid sequences contained in SEQ ID
- 5 NO:X or the cDNA contained in the deposited clone. These probes will also hybridize to nucleic acid molecules in biological samples, thereby enabling a variety of forensic and diagnostic methods of the invention. Similarly, polypeptides identified from SEQ ID NO:Y may be used, for example, to generate antibodies which bind specifically to proteins containing the polypeptides and the secreted
- 10 proteins encoded by the cDNA clones identified in Table 1.

Nevertheless, DNA sequences generated by sequencing reactions can contain sequencing errors. The errors exist as misidentified nucleotides, or as insertions or deletions of nucleotides in the generated DNA sequence. The erroneously inserted or deleted nucleotides cause frame shifts in the reading frames of the predicted amino acid sequence. In these cases, the predicted amino acid sequence diverges from the actual amino acid sequence, even though the generated DNA sequence may be greater than 99.9% identical to the actual DNA sequence (for example, one base insertion or deletion in an open reading frame of over 1000 bases).

Accordingly, for those applications requiring precision in the nucleotide sequence or the amino acid sequence, the present invention provides not only the generated nucleotide sequence identified as SEQ ID NO:X and the predicted translated amino acid sequence identified as SEQ ID NO:Y, but also a sample of plasmid DNA containing a human cDNA of the invention deposited with the ATCC, as set forth in Table 1. The nucleotide sequence of each deposited clone can readily be determined by sequencing the deposited clone in accordance with known methods. The predicted amino acid sequence can then be verified from such deposits. Moreover, the amino acid sequence of the protein encoded by a particular clone can also be directly determined by peptide sequencing or by expressing the protein in a suitable host cell containing the deposited human cDNA, collecting the protein, and determining its sequence.

- The present invention also relates to the genes corresponding to SEQ ID NO:X, SEQ ID NO:Y, or the deposited clone. The corresponding gene can be isolated in accordance with known methods using the sequence information disclosed herein. Such methods include preparing probes or primers from the disclosed
- 5 sequence and identifying or amplifying the corresponding gene from appropriate sources of genomic material.

Also provided in the present invention are allelic variants, orthologs, and/or species homologs. Procedures known in the art can be used to obtain full-length genes, allelic variants, splice variants, full-length coding portions, orthologs, and/or

10 species homologs of genes corresponding to SEQ ID NO:X, SEQ ID NO:Y, or a deposited clone, using information from the sequences disclosed herein or the clones deposited with the ATCC. For example, allelic variants and/or species homologs may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source for allelic variants and/or

15 the desired homologue.

The polypeptides of the invention can be prepared in any suitable manner. Such polypeptides include isolated naturally occurring polypeptides, recombinantly produced polypeptides, synthetically produced polypeptides, or polypeptides produced by a combination of these methods. Means for preparing such polypeptides

20 are well understood in the art.

The polypeptides may be in the form of the secreted protein, including the mature form, or may be a part of a larger protein, such as a fusion protein (see below). It is often advantageous to include an additional amino acid sequence which contains secretory or leader sequences, pro-sequences, sequences which aid in purification ,

25 such as multiple histidine residues, or an additional sequence for stability during recombinant production.

The polypeptides of the present invention are preferably provided in an isolated form, and preferably are substantially purified. A recombinantly produced version of a polypeptide, including the secreted polypeptide, can be substantially

30 purified using techniques described herein or otherwise known in the art, such as, for example, by the one-step method described in Smith and Johnson, Gene 67:31-40

(1988). Polypeptides of the invention also can be purified from natural, synthetic or recombinant sources using techniques described herein or otherwise known in the art, such as, for example, antibodies of the invention raised against the secreted protein.

The present invention provides a polynucleotide comprising, or alternatively  
5 consisting of, the nucleic acid sequence of SEQ ID NO:X, and/or a cDNA contained  
in ATCC deposit Z. The present invention also provides a polypeptide comprising, or  
alternatively, consisting of, the polypeptide sequence of SEQ ID NO:Y and/or a  
polypeptide encoded by the cDNA contained in ATCC deposit Z. Polynucleotides  
encoding a polypeptide comprising, or alternatively consisting of the polypeptide  
10 sequence of SEQ ID NO:Y and/or a polypeptide sequence encoded by the cDNA  
contained in ATCC deposit Z are also encompassed by the invention.

#### Signal Sequences

The present invention also encompasses mature forms of the polypeptide  
having the polypeptide sequence of SEQ ID NO:Y and/or the polypeptide sequence  
15 encoded by the cDNA in a deposited clone. Polynucleotides encoding the mature  
forms (such as, for example, the polynucleotide sequence in SEQ ID NO:X and/or the  
polynucleotide sequence contained in the cDNA of a deposited clone) are also  
encompassed by the invention. According to the signal hypothesis, proteins secreted  
by mammalian cells have a signal or secretary leader sequence which is cleaved from  
20 the mature protein once export of the growing protein chain across the rough  
endoplasmic reticulum has been initiated. Most mammalian cells and even insect  
cells cleave secreted proteins with the same specificity. However, in some cases,  
cleavage of a secreted protein is not entirely uniform, which results in two or more  
mature species of the protein. Further, it has long been known that cleavage  
25 specificity of a secreted protein is ultimately determined by the primary structure of  
the complete protein, that is, it is inherent in the amino acid sequence of the  
polypeptide.

Methods for predicting whether a protein has a signal sequence, as well as the  
cleavage point for that sequence, are available. For instance, the method of  
30 McGeoch, Virus Res. 3:271-286 (1985), uses the information from a short N-terminal  
charged region and a subsequent uncharged region of the complete (uncleaved)

protein. The method of von Heinje, Nucleic Acids Res. 14:4683-4690 (1986) uses the information from the residues surrounding the cleavage site, typically residues -13 to +2, where +1 indicates the amino terminus of the secreted protein. The accuracy of predicting the cleavage points of known mammalian secretory proteins for each of 5 these methods is in the range of 75-80%. (von Heinje, *supra*.) However, the two methods do not always produce the same predicted cleavage point(s) for a given protein.

In the present case, the deduced amino acid sequence of the secreted polypeptide was analyzed by a computer program called SignalP (Henrik Nielsen et 10 al., Protein Engineering 10:1-6 (1997)), which predicts the cellular location of a protein based on the amino acid sequence. As part of this computational prediction of localization, the methods of McGeoch and von Heinje are incorporated. The analysis of the amino acid sequences of the secreted proteins described herein by this program provided the results shown in Table 1.

15 As one of ordinary skill would appreciate, however, cleavage sites sometimes vary from organism to organism and cannot be predicted with absolute certainty. Accordingly, the present invention provides secreted polypeptides having a sequence shown in SEQ ID NO:Y which have an N-terminus beginning within 5 residues (i.e., + or - 5 residues) of the predicted cleavage point. Similarly, it is also recognized that 20 in some cases, cleavage of the signal sequence from a secreted protein is not entirely uniform, resulting in more than one secreted species. These polypeptides, and the polynucleotides encoding such polypeptides, are contemplated by the present invention.

Moreover, the signal sequence identified by the above analysis may not 25 necessarily predict the naturally occurring signal sequence. For example, the naturally occurring signal sequence may be further upstream from the predicted signal sequence. However, it is likely that the predicted signal sequence will be capable of directing the secreted protein to the ER. Nonetheless, the present invention provides the mature protein produced by expression of the polynucleotide sequence of SEQ ID 30 NO:X and/or the polynucleotide sequence contained in the cDNA of a deposited clone, in a mammalian cell (e.g., COS cells, as described below). These polypeptides,

and the polynucleotides encoding such polypeptides, are contemplated by the present invention.

#### Polynucleotide and Polypeptide Variants

5 The present invention is directed to variants of the polynucleotide sequence disclosed in SEQ ID NO:X, the complementary strand thereto, and/or the cDNA sequence contained in a deposited clone.

The present invention also encompasses variants of the polypeptide sequence disclosed in SEQ ID NO:Y and/or encoded by a deposited clone.

10 "Variant" refers to a polynucleotide or polypeptide differing from the polynucleotide or polypeptide of the present invention, but retaining essential properties thereof. Generally, variants are overall closely similar, and, in many regions, identical to the polynucleotide or polypeptide of the present invention.

15 The present invention is also directed to nucleic acid molecules which comprise, or alternatively consist of, a nucleotide sequence which is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to, for example, the nucleotide coding sequence in SEQ ID NO:X or the complementary strand thereto, the nucleotide coding sequence contained in a deposited cDNA clone or the complementary strand thereto, a nucleotide sequence encoding the polypeptide of  
20 SEQ ID NO:Y, a nucleotide sequence encoding the polypeptide encoded by the cDNA contained in a deposited clone, and/or polynucleotide fragments of any of these nucleic acid molecules (e.g., those fragments described herein).  
25 Polynucleotides which hybridize to these nucleic acid molecules under stringent hybridization conditions or lower stringency conditions are also encompassed by the invention, as are polypeptides encoded by these polynucleotides.

The present invention is also directed to polypeptides which comprise, or alternatively consist of, an amino acid sequence which is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to, for example, the polypeptide sequence shown in SEQ ID NO:Y, the polypeptide sequence encoded by the cDNA contained  
30 in a deposited clone, and/or polypeptide fragments of any of these polypeptides (e.g., those fragments described herein).

By a nucleic acid having a nucleotide sequence at least, for example, 95% "identical" to a reference nucleotide sequence of the present invention, it is intended that the nucleotide sequence of the nucleic acid is identical to the reference sequence except that the nucleotide sequence may include up to five point mutations per each 5 100 nucleotides of the reference nucleotide sequence encoding the polypeptide. In other words, to obtain a nucleic acid having a nucleotide sequence at least 95% identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may 10 be inserted into the reference sequence. The query sequence may be an entire sequence shown in Table 1, the ORF (open reading frame), or any fragment specified as described herein.

As a practical matter, whether any particular nucleic acid molecule or polypeptide is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to a 15 nucleotide sequence of the present invention can be determined conventionally using known computer programs. A preferred method for determining the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp. 20 App. Biosci. 6:237-245(1990)). In a sequence alignment the query and subject sequences are both DNA sequences. An RNA sequence can be compared by converting U's to T's. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB alignment of DNA sequences to calculate percent identity are: Matrix=Unitary, k-tuple=4, Mismatch Penalty=1, 25 Joining Penalty=30, Randomization Group Length=0, Cutoff Score=1, Gap Penalty=5, Gap Size Penalty 0.05, Window Size=500 or the length of the subject nucleotide sequence, whichever is shorter.

If the subject sequence is shorter than the query sequence because of 5' or 3' deletions, not because of internal deletions, a manual correction must be made to the 30 results. This is because the FASTDB program does not account for 5' and 3' truncations of the subject sequence when calculating percent identity. For subject

sequences truncated at the 5' or 3' ends, relative to the query sequence, the percent identity is corrected by calculating the number of bases of the query sequence that are 5' and 3' of the subject sequence, which are not matched/aligned, as a percent of the total bases of the query sequence. Whether a nucleotide is matched/aligned is

5 determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This corrected score is what is used for the purposes of the present invention. Only bases outside the 5' and 3' bases of the subject sequence, as displayed by the FASTDB alignment,

10 which are not matched/aligned with the query sequence, are calculated for the purposes of manually adjusting the percent identity score.

For example, a 90 base subject sequence is aligned to a 100 base query sequence to determine percent identity. The deletions occur at the 5' end of the subject sequence and therefore, the FASTDB alignment does not show a

15 matched/alignment of the first 10 bases at 5' end. The 10 unpaired bases represent 10% of the sequence (number of bases at the 5' and 3' ends not matched/total number of bases in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 bases were perfectly matched the final percent identity would be 90%. In another example, a 90 base

20 subject sequence is compared with a 100 base query sequence. This time the deletions are internal deletions so that there are no bases on the 5' or 3' of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only bases 5' and 3' of the subject sequence which are not matched/aligned with the query sequence

25 are manually corrected for. No other manual corrections are to be made for the purposes of the present invention.

By a polypeptide having an amino acid sequence at least, for example, 95% "identical" to a query amino acid sequence of the present invention, it is intended that the amino acid sequence of the subject polypeptide is identical to the query sequence

30 except that the subject polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the query amino acid sequence. In other

words, to obtain a polypeptide having an amino acid sequence at least 95% identical to a query amino acid sequence, up to 5% of the amino acid residues in the subject sequence may be inserted, deleted, (indels) or substituted with another amino acid. These alterations of the reference sequence may occur at the amino or carboxy

5 terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence.

As a practical matter, whether any particular polypeptide is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to, for instance, an amino acid

10 sequences shown in Table 1 (SEQ ID NO:Y) or to the amino acid sequence encoded by cDNA contained in a deposited clone can be determined conventionally using known computer programs. A preferred method for determining the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using

15 the FASTDB computer program based on the algorithm of Brutlag et al. (Comp. App. Biosci. 6:237-245(1990)). In a sequence alignment the query and subject sequences are either both nucleotide sequences or both amino acid sequences. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB amino acid alignment are: Matrix=PAM 0, k-tuple=2, Mismatch

20 Penalty=1, Joining Penalty=20, Randomization Group Length=0, Cutoff Score=1, Window Size=sequence length, Gap Penalty=5, Gap Size Penalty=0.05, Window Size=500 or the length of the subject amino acid sequence, whichever is shorter.

If the subject sequence is shorter than the query sequence due to N- or C-terminal deletions, not because of internal deletions, a manual correction must be

25 made to the results. This is because the FASTDB program does not account for N- and C-terminal truncations of the subject sequence when calculating global percent identity. For subject sequences truncated at the N- and C-termini, relative to the query sequence, the percent identity is corrected by calculating the number of residues of the query sequence that are N- and C-terminal of the subject sequence, which are

30 not matched/aligned with a corresponding subject residue, as a percent of the total bases of the query sequence. Whether a residue is matched/aligned is determined by

results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This final percent identity score is what is used for the purposes of the present invention. Only residues to the N- and 5 C-termini of the subject sequence, which are not matched/aligned with the query sequence, are considered for the purposes of manually adjusting the percent identity score. That is, only query residue positions outside the farthest N- and C-terminal residues of the subject sequence.

For example, a 90 amino acid residue subject sequence is aligned with a 100 10 residue query sequence to determine percent identity. The deletion occurs at the N- terminus of the subject sequence and therefore, the FASTDB alignment does not show a matching/alignment of the first 10 residues at the N-terminus. The 10 unpaired residues represent 10% of the sequence (number of residues at the N- and C- termini not matched/total number of residues in the query sequence) so 10% is 15 subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 residues were perfectly matched the final percent identity would be 90%. In another example, a 90 residue subject sequence is compared with a 100 residue query sequence. This time the deletions are internal deletions so there are no residues at the N- or C-termini of the subject sequence which are not matched/aligned 20 with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only residue positions outside the N- and C-terminal ends of the subject sequence, as displayed in the FASTDB alignment, which are not matched/aligned with the query sequence are manually corrected for. No other manual corrections are made for the purposes of the present invention.

25 The variants may contain alterations in the coding regions, non-coding regions, or both. Especially preferred are polynucleotide variants containing alterations which produce silent substitutions, additions, or deletions, but do not alter the properties or activities of the encoded polypeptide. Nucleotide variants produced by silent substitutions due to the degeneracy of the genetic code are preferred.  
30 Moreover, variants in which 5-10, 1-5, or 1-2 amino acids are substituted, deleted, or added in any combination are also preferred. Polynucleotide variants can be produced

for a variety of reasons, e.g., to optimize codon expression for a particular host (change codons in the human mRNA to those preferred by a bacterial host such as *E. coli*).

Naturally occurring variants are called "allelic variants," and refer to one of 5 several alternate forms of a gene occupying a given locus on a chromosome of an organism. (Genes II, Lewin, B., ed., John Wiley & Sons, New York (1985).) These allelic variants can vary at either the polynucleotide and/or polypeptide level and are included in the present invention. Alternatively, non-naturally occurring variants may be produced by mutagenesis techniques or by direct synthesis.

10 Using known methods of protein engineering and recombinant DNA technology, variants may be generated to improve or alter the characteristics of the polypeptides of the present invention. For instance, one or more amino acids can be deleted from the N-terminus or C-terminus of the secreted protein without substantial loss of biological function. The authors of Ron et al., *J. Biol. Chem.* 268: 2984-2988 15 (1993), reported variant KGF proteins having heparin binding activity even after deleting 3, 8, or 27 amino-terminal amino acid residues. Similarly, Interferon gamma exhibited up to ten times higher activity after deleting 8-10 amino acid residues from the carboxy terminus of this protein. (Dobeli et al., *J. Biotechnology* 7:199-216 (1988).)

20 Moreover, ample evidence demonstrates that variants often retain a biological activity similar to that of the naturally occurring protein. For example, Gayle and coworkers (*J. Biol. Chem.* 268:22105-22111 (1993)) conducted extensive mutational analysis of human cytokine IL-1 $\alpha$ . They used random mutagenesis to generate over 3,500 individual IL-1 $\alpha$  mutants that averaged 2.5 amino acid changes per variant over 25 the entire length of the molecule. Multiple mutations were examined at every possible amino acid position. The investigators found that "[m]ost of the molecule could be altered with little effect on either [binding or biological activity]." (See, Abstract.) In fact, only 23 unique amino acid sequences, out of more than 3,500 nucleotide sequences examined, produced a protein that significantly differed in 30 activity from wild-type.

- Furthermore, even if deleting one or more amino acids from the N-terminus or C-terminus of a polypeptide results in modification or loss of one or more biological functions, other biological activities may still be retained. For example, the ability of a deletion variant to induce and/or to bind antibodies which recognize the secreted
- 5 form will likely be retained when less than the majority of the residues of the secreted form are removed from the N-terminus or C-terminus. Whether a particular polypeptide lacking N- or C-terminal residues of a protein retains such immunogenic activities can readily be determined by routine methods described herein and otherwise known in the art.
- 10 Thus, the invention further includes polypeptide variants which show substantial biological activity. Such variants include deletions, insertions, inversions, repeats, and substitutions selected according to general rules known in the art so as have little effect on activity. For example, guidance concerning how to make phenotypically silent amino acid substitutions is provided in Bowie et al., *Science*
- 15 247:1306-1310 (1990), wherein the authors indicate that there are two main strategies for studying the tolerance of an amino acid sequence to change.
- The first strategy exploits the tolerance of amino acid substitutions by natural selection during the process of evolution. By comparing amino acid sequences in different species, conserved amino acids can be identified. These conserved amino
- 20 acids are likely important for protein function. In contrast, the amino acid positions where substitutions have been tolerated by natural selection indicates that these positions are not critical for protein function. Thus, positions tolerating amino acid substitution could be modified while still maintaining biological activity of the protein.
- 25 The second strategy uses genetic engineering to introduce amino acid changes at specific positions of a cloned gene to identify regions critical for protein function. For example, site directed mutagenesis or alanine-scanning mutagenesis (introduction of single alanine mutations at every residue in the molecule) can be used. (Cunningham and Wells, *Science* 244:1081-1085 (1989).) The resulting mutant
- 30 molecules can then be tested for biological activity.

As the authors state, these two strategies have revealed that proteins are surprisingly tolerant of amino acid substitutions. The authors further indicate which amino acid changes are likely to be permissive at certain amino acid positions in the protein. For example, most buried (within the tertiary structure of the protein) amino acid residues require nonpolar side chains, whereas few features of surface side chains are generally conserved. Moreover, tolerated conservative amino acid substitutions involve replacement of the aliphatic or hydrophobic amino acids Ala, Val, Leu and Ile; replacement of the hydroxyl residues Ser and Thr; replacement of the acidic residues Asp and Glu; replacement of the amide residues Asn and Gln, replacement of the basic residues Lys, Arg, and His; replacement of the aromatic residues Phe, Tyr, and Trp, and replacement of the small-sized amino acids Ala, Ser, Thr, Met, and Gly.

Besides conservative amino acid substitution, variants of the present invention include (i) substitutions with one or more of the non-conserved amino acid residues, where the substituted amino acid residues may or may not be one encoded by the genetic code, or (ii) substitution with one or more of amino acid residues having a substituent group, or (iii) fusion of the mature polypeptide with another compound, such as a compound to increase the stability and/or solubility of the polypeptide (for example, polyethylene glycol), or (iv) fusion of the polypeptide with additional amino acids, such as, for example, an IgG Fc fusion region peptide, or leader or secretory sequence, or a sequence facilitating purification. Such variant polypeptides are deemed to be within the scope of those skilled in the art from the teachings herein.

For example, polypeptide variants containing amino acid substitutions of charged amino acids with other charged or neutral amino acids may produce proteins with improved characteristics, such as less aggregation. Aggregation of pharmaceutical formulations both reduces activity and increases clearance due to the aggregate's immunogenic activity. (Pinckard et al., Clin. Exp. Immunol. 2:331-340 (1967); Robbins et al., Diabetes 36: 838-845 (1987); Cleland et al., Crit. Rev. Therapeutic Drug Carrier Systems 10:307-377 (1993).)

A further embodiment of the invention relates to a polypeptide which comprises the amino acid sequence of the present invention having an amino acid sequence which contains at least one amino acid substitution, but not more than 50

- amino acid substitutions, even more preferably, not more than 40 amino acid substitutions, still more preferably, not more than 30 amino acid substitutions, and still even more preferably, not more than 20 amino acid substitutions. Of course, in order of ever-increasing preference, it is highly preferable for a peptide or polypeptide
- 5 to have an amino acid sequence which comprises the amino acid sequence of the present invention, which contains at least one, but not more than 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 amino acid substitutions. In specific embodiments, the number of additions, substitutions, and/or deletions in the amino acid sequence of the present invention or fragments thereof (e.g., the mature form and/or other fragments described herein), is
- 10 1-5, 5-10, 5-25, 5-50, 10-50 or 50-150, conservative amino acid substitutions are preferable.

#### Polynucleotide and Polypeptide Fragments

The present invention is also directed to polynucleotide fragments of the  
15 polynucleotides of the invention.

- In the present invention, a "polynucleotide fragment" refers to a short polynucleotide having a nucleic acid sequence which: is a portion of that contained in a deposited clone, or encoding the polypeptide encoded by the cDNA in a deposited clone; is a portion of that shown in SEQ ID NO:X or the complementary strand  
20 thereto, or is a portion of a polynucleotide sequence encoding the polypeptide of SEQ ID NO:Y. The nucleotide fragments of the invention are preferably at least about 15 nt, and more preferably at least about 20 nt, still more preferably at least about 30 nt, and even more preferably, at least about 40 nt, at least about 50 nt, at least about 75 nt, or at least about 150 nt in length. A fragment "at least 20 nt in length," for  
25 example, is intended to include 20 or more contiguous bases from the cDNA sequence contained in a deposited clone or the nucleotide sequence shown in SEQ ID NO:X. In this context "about" includes the particularly recited value, a value larger or smaller by several (5, 4, 3, 2, or 1) nucleotides, at either terminus or at both termini. These nucleotide fragments have uses that include, but are not limited to, as  
30 diagnostic probes and primers as discussed herein. Of course, larger fragments (e.g., 50, 150, 500, 600, 2000 nucleotides) are preferred.

Moreover, representative examples of polynucleotide fragments of the invention, include, for example, fragments comprising, or alternatively consisting of, a sequence from about nucleotide number 1-50, 51-100, 101-150, 151-200, 201-250, 251-300, 301-350, 351-400, 401-450, 451-500, 501-550, 551-600, 651-700, 701-750, 5 751-800, 800-850, 851-900, 901-950, 951-1000, 1001-1050, 1051-1100, 1101-1150, 1151-1200, 1201-1250, 1251-1300, 1301-1350, 1351-1400, 1401-1450, 1451-1500, 1501-1550, 1551-1600, 1601-1650, 1651-1700, 1701-1750, 1751-1800, 1801-1850, 1851-1900, 1901-1950, 1951-2000, or 2001 to the end of SEQ ID NO:X, or the complementary strand thereto, or the cDNA contained in a deposited clone. In this 10 context "about" includes the particularly recited ranges, and ranges larger or smaller by several (5, 4, 3, 2, or 1) nucleotides, at either terminus or at both termini. Preferably, these fragments encode a polypeptide which has biological activity. More preferably, these polynucleotides can be used as probes or primers as discussed herein. Polynucleotides which hybridize to these nucleic acid molecules under 15 stringent hybridization conditions or lower stringency conditions are also encompassed by the invention, as are polypeptides encoded by these polynucleotides.

In the present invention, a "polypeptide fragment" refers to an amino acid sequence which is a portion of that contained in SEQ ID NO:Y or encoded by the cDNA contained in a deposited clone. Protein (polypeptide) fragments may be "free-standing," or comprised within a larger polypeptide of which the fragment forms a part or region, most preferably as a single continuous region. Representative examples of polypeptide fragments of the invention, include, for example, fragments comprising, or alternatively consisting of, from about amino acid number 1-20, 21-40, 20 41-60, 61-80, 81-100, 102-120, 121-140, 141-160, or 161 to the end of the coding region. Moreover, polypeptide fragments can be about 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, or 150 amino acids in length. In this context "about" includes the particularly recited ranges or values, and ranges or values larger or smaller by several (5, 4, 3, 2, or 1) amino acids, at either extreme or at both extremes. Polynucleotides encoding these polypeptides are also encompassed by the invention. 25

30 Preferred polypeptide fragments include the secreted protein as well as the mature form. Further preferred polypeptide fragments include the secreted protein or

- the mature form having a continuous series of deleted residues from the amino or the carboxy terminus, or both. For example, any number of amino acids, ranging from 1-60, can be deleted from the amino terminus of either the secreted polypeptide or the mature form. Similarly, any number of amino acids, ranging from 1-30, can be
- 5 deleted from the carboxy terminus of the secreted protein or mature form.
- Furthermore, any combination of the above amino and carboxy terminus deletions are preferred. Similarly, polynucleotides encoding these polypeptide fragments are also preferred.
- Also preferred are polypeptide and polynucleotide fragments characterized by
- 10 structural or functional domains, such as fragments that comprise alpha-helix and alpha-helix forming regions, beta-sheet and beta-sheet-forming regions, turn and turn-forming regions, coil and coil-forming regions, hydrophilic regions, hydrophobic regions, alpha amphipathic regions, beta amphipathic regions, flexible regions, surface-forming regions, substrate binding region, and high antigenic index regions.
- 15 Polypeptide fragments of SEQ ID NO:Y falling within conserved domains are specifically contemplated by the present invention. Moreover, polynucleotides encoding these domains are also contemplated.

Other preferred polypeptide fragments are biologically active fragments. Biologically active fragments are those exhibiting activity similar, but not necessarily

20 identical, to an activity of the polypeptide of the present invention. The biological activity of the fragments may include an improved desired activity, or a decreased undesirable activity. Polynucleotides encoding these polypeptide fragments are also encompassed by the invention.

Preferably, the polynucleotide fragments of the invention encode a

25 polypeptide which demonstrates a functional activity. By a polypeptide demonstrating a "functional activity" is meant, a polypeptide capable of displaying one or more known functional activities associated with a full-length (complete) polypeptide of invention protein. Such functional activities include, but are not limited to, biological activity, antigenicity [ability to bind (or compete with a

30 polypeptide of the invention for binding) to an antibody to the polypeptide of the invention], immunogenicity (ability to generate antibody which binds to a polypeptide

of the invention), ability to form multimers with polypeptides of the invention, and ability to bind to a receptor or ligand for a polypeptide of the invention.

The functional activity of polypeptides of the invention, and fragments, variants derivatives, and analogs thereof, can be assayed by various methods.

5       For example, in one embodiment where one is assaying for the ability to bind or compete with full-length polypeptide of the invention for binding to an antibody of the polypeptide of the invention, various immunoassays known in the art can be used, including but not limited to, competitive and non-competitive assay systems using techniques such as radioimmunoassays, ELISA (enzyme linked immunosorbent assay), "sandwich" immunoassays, immunoradiometric assays, gel diffusion precipitation reactions, immunodiffusion assays, *in situ* immunoassays (using colloidal gold, enzyme or radioisotope labels, for example), western blots, precipitation reactions, agglutination assays (e.g., gel agglutination assays, hemagglutination assays), complement fixation assays, immunofluorescence assays, 10 protein A assays, and immunoelectrophoresis assays, etc. In one embodiment, antibody binding is detected by detecting a label on the primary antibody. In another embodiment, the primary antibody is detected by detecting binding of a secondary antibody or reagent to the primary antibody. In a further embodiment, the secondary antibody is labeled. Many means are known in the art for detecting binding in an 15 immunoassay and are within the scope of the present invention.

20

In another embodiment, where a ligand for a polypeptide of the invention identified, or the ability of a polypeptide fragment, variant or derivative of the invention to multimerize is being evaluated, binding can be assayed, e.g., by means well-known in the art, such as, for example, reducing and non-reducing gel 25 chromatography, protein affinity chromatography, and affinity blotting. See generally, Phizicky, E., et al., 1995, *Microbiol. Rev.* 59:94-123. In another embodiment, physiological correlates of binding of a polypeptide of the invention to its substrates (signal transduction) can be assayed.

30       In addition, assays described herein (see Examples) and otherwise known in the art may routinely be applied to measure the ability of polypeptides of the invention and fragments, variants derivatives and analogs thereof to elicit related

biological activity related to that of the polypeptide of the invention (either *in vitro* or *in vivo*). Other methods will be known to the skilled artisan and are within the scope of the invention.

5

### Epitopes and Antibodies

The present invention encompasses polypeptides comprising, or alternatively consisting of, an epitope of the polypeptide having an amino acid sequence of SEQ ID NO:Y, or an epitope of the polypeptide sequence encoded by a polynucleotide sequence contained in ATCC deposit No. Z or encoded by a polynucleotide that hybridizes to the complement of the sequence of SEQ ID NO:X or contained in ATCC deposit No. Z under stringent hybridization conditions or lower stringency hybridization conditions as defined *supra*. The present invention further encompasses polynucleotide sequences encoding an epitope of a polypeptide sequence of the invention (such as, for example, the sequence disclosed in SEQ ID NO:X),

10      polynucleotide sequences of the complementary strand of a polynucleotide sequence encoding an epitope of the invention, and polynucleotide sequences which hybridize to the complementary strand under stringent hybridization conditions or lower stringency hybridization conditions defined *supra*.

15      polynucleotide sequences of the complementary strand of a polynucleotide sequence encoding an epitope of the invention, and polynucleotide sequences which hybridize to the complementary strand under stringent hybridization conditions or lower stringency hybridization conditions defined *supra*.

The term "epitopes," as used herein, refers to portions of a polypeptide having antigenic or immunogenic activity in an animal, preferably a mammal, and most preferably in a human. In a preferred embodiment, the present invention encompasses a polypeptide comprising an epitope, as well as the polynucleotide encoding this polypeptide. An "immunogenic epitope," as used herein, is defined as a portion of a protein that elicits an antibody response in an animal, as determined by any method known in the art, for example, by the methods for generating antibodies described *infra*. (See, for example, Geysen et al., Proc. Natl. Acad. Sci. USA 81:3998- 4002 (1983)). The term "antigenic epitope," as used herein, is defined as a portion of a protein to which an antibody can immunospecifically bind its antigen as determined by any method well known in the art, for example, by the immunoassays described herein. Immunospecific binding excludes non-specific binding but does not

20

25

30

necessarily exclude cross-reactivity with other antigens. Antigenic epitopes need not necessarily be immunogenic.

Fragments which function as epitopes may be produced by any conventional means. (See, e.g., Houghten, Proc. Natl. Acad. Sci. USA 82:5131-5135 (1985),  
5 further described in U.S. Patent No. 4,631,211).

In the present invention, antigenic epitopes preferably contain a sequence of at least 4, at least 5, at least 6, at least 7, more preferably at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 20, at least 25, at least 30, at least 40, at least 50, and, most preferably, between about 15 to about 30  
10 amino acids. Preferred polypeptides comprising immunogenic or antigenic epitopes are at least 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 amino acid residues in length. Additional non-exclusive preferred antigenic epitopes include the antigenic epitopes disclosed herein, as well as portions thereof. Antigenic epitopes are useful, for example, to raise antibodies, including monoclonal antibodies,  
15 that specifically bind the epitope. Preferred antigenic epitopes include the antigenic epitopes disclosed herein, as well as any combination of two, three, four, five or more of these antigenic epitopes. Antigenic epitopes can be used as the target molecules in immunoassays. (See, for instance, Wilson et al., Cell 37:767-778 (1984); Sutcliffe et al., Science 219:660-666 (1983)).

20 Similarly, immunogenic epitopes can be used, for example, to induce antibodies according to methods well known in the art. (See, for instance, Sutcliffe et al., supra; Wilson et al., supra; Chow et al., Proc. Natl. Acad. Sci. USA 82:910-914; and Bittle et al., J. Gen. Virol. 66:2347-2354 (1985). Preferred immunogenic epitopes include the immunogenic epitopes disclosed herein, as well as any  
25 combination of two, three, four, five or more of these immunogenic epitopes. The polypeptides comprising one or more immunogenic epitopes may be presented for eliciting an antibody response together with a carrier protein, such as an albumin, to an animal system (such as rabbit or mouse), or, if the polypeptide is of sufficient length (at least about 25 amino acids), the polypeptide may be presented without a  
30 carrier. However, immunogenic epitopes comprising as few as 8 to 10 amino acids

have been shown to be sufficient to raise antibodies capable of binding to, at the very least, linear epitopes in a denatured polypeptide (e.g., in Western blotting).

Epitope-bearing polypeptides of the present invention may be used to induce antibodies according to methods well known in the art including, but not limited to, 5 in vivo immunization, in vitro immunization, and phage display methods. See, e.g., Sutcliffe et al., *supra*; Wilson et al., *supra*, and Bittle et al., *J. Gen. Virol.*, 66:2347-2354 (1985). If in vivo immunization is used, animals may be immunized with free peptide; however, anti-peptide antibody titer may be boosted by coupling the peptide to a macromolecular carrier, such as keyhole limpet hemacyanin (KLH) or tetanus 10 toxoid. For instance, peptides containing cysteine residues may be coupled to a carrier using a linker such as maleimidobenzoyl- N-hydroxysuccinimide ester (MBS), while other peptides may be coupled to carriers using a more general linking agent such as glutaraldehyde. Animals such as rabbits, rats and mice are immunized with either free or carrier- coupled peptides, for instance, by intraperitoneal and/or 15 intradermal injection of emulsions containing about 100 µg of peptide or carrier protein and Freund's adjuvant or any other adjuvant known for stimulating an immune response. Several booster injections may be needed, for instance, at intervals of about two weeks, to provide a useful titer of anti-peptide antibody which can be detected, for example, by ELISA assay using free peptide adsorbed to a solid 20 surface. The titer of anti-peptide antibodies in serum from an immunized animal may be increased by selection of anti-peptide antibodies, for instance, by adsorption to the peptide on a solid support and elution of the selected antibodies according to methods well known in the art.

As one of skill in the art will appreciate, and as discussed above, the 25 polypeptides of the present invention comprising an immunogenic or antigenic epitope can be fused to other polypeptide sequences. For example, the polypeptides of the present invention may be fused with the constant domain of immunoglobulins (IgA, IgE, IgG, IgM), or portions thereof (CH1, CH2, CH3, or any combination thereof and portions thereof) resulting in chimeric polypeptides. Such fusion proteins 30 may facilitate purification and may increase half-life in vivo. This has been shown for chimeric proteins consisting of the first two domains of the human CD4-

polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. See, e.g., EP 394,827; Traunecker et al., *Nature*, 331:84-86 (1988). Enhanced delivery of an antigen across the epithelial barrier to the immune system has been demonstrated for antigens (e.g., insulin) conjugated to an

5 FcRn binding partner such as IgG or Fc fragments (see, e.g., PCT Publications WO 96/22024 and WO 99/04813). IgG Fusion proteins that have a disulfide-linked dimeric structure due to the IgG portion desulfide bonds have also been found to be more efficient in binding and neutralizing other molecules than monomeric polypeptides or fragments thereof alone. See, e.g., Fountoulakis et al., *J. Biochem.*,

10 270:3958-3964 (1995). Nucleic acids encoding the above epitopes can also be recombined with a gene of interest as an epitope tag (e.g., the hemagglutinin ("HA") tag or flag tag) to aid in detection and purification of the expressed polypeptide. For example, a system described by Janknecht et al. allows for the ready purification of non-denatured fusion proteins expressed in human cell lines (Janknecht et al., 1991,

15 Proc. Natl. Acad. Sci. USA 88:8972- 897). In this system, the gene of interest is subcloned into a vaccinia recombination plasmid such that the open reading frame of the gene is translationally fused to an amino-terminal tag consisting of six histidine residues. The tag serves as a matrix binding domain for the fusion protein. Extracts from cells infected with the recombinant vaccinia virus are loaded onto Ni<sup>2+</sup>

20 nitriloacetic acid-agarose column and histidine-tagged proteins can be selectively eluted with imidazole-containing buffers.

Additional fusion proteins of the invention may be generated through the techniques of gene-shuffling, motif-shuffling, exon-shuffling, and/or codon-shuffling (collectively referred to as "DNA shuffling"). DNA shuffling may be employed to modulate the activities of polypeptides of the invention, such methods can be used to generate polypeptides with altered activity, as well as agonists and antagonists of the polypeptides. See, generally, U.S. Patent Nos. 5,605,793; 5,811,238; 5,830,721; 5,834,252; and 5,837,458, and Patten et al., *Curr. Opinion Biotechnol.* 8:724-33 (1997); Harayama, *Trends Biotechnol.* 16(2):76-82 (1998); Hansson, et al., *J. Mol. Biol.* 287:265-76 (1999); and Lorenzo and Blasco, *Biotechniques* 24(2):308- 13 (1998) (each of these patents and publications are hereby incorporated by reference in

its entirety). In one embodiment, alteration of polynucleotides corresponding to SEQ ID NO:X and the polypeptides encoded by these polynucleotides may be achieved by DNA shuffling. DNA shuffling involves the assembly of two or more DNA segments by homologous or site-specific recombination to generate variation in the 5 polynucleotide sequence. In another embodiment, polynucleotides of the invention, or the encoded polypeptides, may be altered by being subjected to random mutagenesis by error-prone PCR, random nucleotide insertion or other methods prior to recombination. In another embodiment, one or more components, motifs, sections, parts, domains, fragments, etc., of a polynucleotide encoding a polypeptide of the 10 invention may be recombined with one or more components, motifs, sections, parts, domains, fragments, etc. of one or more heterologous molecules.

#### Antibodies

Further polypeptides of the invention relate to antibodies and T-cell antigen 15 receptors (TCR) which immunospecifically bind a polypeptide, polypeptide fragment, or variant of SEQ ID NO:Y, and/or an epitope, of the present invention (as determined by immunoassays well known in the art for assaying specific antibody-antigen binding). Antibodies of the invention include, but are not limited to, polyclonal, monoclonal, multispecific, human, humanized or chimeric antibodies, 20 single chain antibodies, Fab fragments, F(ab') fragments, fragments produced by a Fab expression library, anti-idiotypic (anti-Id) antibodies (including, e.g., anti-Id antibodies to antibodies of the invention), and epitope-binding fragments of any of the above. The term "antibody," as used herein, refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules 25 that contain an antigen binding site that immunospecifically binds an antigen. The immunoglobulin molecules of the invention can be of any type (e.g., IgG, IgE, IgM, IgD, IgA and IgY), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2) or subclass of immunoglobulin molecule.

Most preferably the antibodies are human antigen-binding antibody fragments 30 of the present invention and include, but are not limited to, Fab, Fab' and F(ab')2, Fd, single-chain Fvs (scFv), single-chain antibodies, disulfide-linked Fvs (sdFv) and

fragments comprising either a VL or VH domain. Antigen-binding antibody fragments, including single-chain antibodies, may comprise the variable region(s) alone or in combination with the entirety or a portion of the following: hinge region, CH1, CH2, and CH3 domains. Also included in the invention are antigen-binding  
5 fragments also comprising any combination of variable region(s) with a hinge region, CH1, CH2, and CH3 domains. The antibodies of the invention may be from any animal origin including birds and mammals. Preferably, the antibodies are human, murine (e.g., mouse and rat), donkey, sheep rabbit, goat, guinea pig, camel, horse, or chicken. As used herein, "human" antibodies include antibodies having the amino  
10 acid sequence of a human immunoglobulin and include antibodies isolated from human immunoglobulin libraries or from animals transgenic for one or more human immunoglobulin and that do not express endogenous immunoglobulins, as described infra and, for example in, U.S. Patent No. 5,939,598 by Kucherlapati et al.

The antibodies of the present invention may be monospecific, bispecific,  
15 trispecific or of greater multispecificity. Multispecific antibodies may be specific for different epitopes of a polypeptide of the present invention or may be specific for both a polypeptide of the present invention as well as for a heterologous epitope, such as a heterologous polypeptide or solid support material. See, e.g., PCT publications WO 93/17715; WO 92/08802; WO 91/00360; WO 92/05793; Tutt, et al., J. Immunol.  
20 147:60-69 (1991); U.S. Patent Nos. 4,474,893; 4,714,681; 4,925,648; 5,573,920;  
5,601,819; Kostelny et al., J. Immunol. 148:1547-1553 (1992).

Antibodies of the present invention may be described or specified in terms of the epitope(s) or portion(s) of a polypeptide of the present invention which they recognize or specifically bind. The epitope(s) or polypeptide portion(s) may be  
25 specified as described herein, e.g., by N-terminal and C-terminal positions, by size in contiguous amino acid residues, or listed in the Tables and Figures. Antibodies which specifically bind any epitope or polypeptide of the present invention may also be excluded. Therefore, the present invention includes antibodies that specifically bind polypeptides of the present invention, and allows for the exclusion of the same.

30 Antibodies of the present invention may also be described or specified in terms of their cross-reactivity. Antibodies that do not bind any other analog,

ortholog, or homolog of a polypeptide of the present invention are included.

Antibodies that bind polypeptides with at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 65%, at least 60%, at least 55%, and at least 50% identity (as calculated using methods known in the art and described

5 herein) to a polypeptide of the present invention are also included in the present invention. In specific embodiments, antibodies of the present invention cross-react with murine, rat and/or rabbit homologs of human proteins and the corresponding epitopes thereof. Antibodies that do not bind polypeptides with less than 95%, less than 90%, less than 85%, less than 80%, less than 75%, less than 70%, less than 65%,

10 less than 60%, less than 55%, and less than 50% identity (as calculated using methods known in the art and described herein) to a polypeptide of the present invention are also included in the present invention. In a specific embodiment, the above-described cross-reactivity is with respect to any single specific antigenic or immunogenic polypeptide, or combination(s) of 2, 3, 4, 5, or more of the specific

15 antigenic and/or immunogenic polypeptides disclosed herein. Further included in the present invention are antibodies which bind polypeptides encoded by polynucleotides which hybridize to a polynucleotide of the present invention under stringent hybridization conditions (as described herein). Antibodies of the present invention may also be described or specified in terms of their binding affinity to a polypeptide

20 of the invention. Preferred binding affinities include those with a dissociation constant or Kd less than  $5 \times 10^{-2}$  M,  $10^{-2}$  M,  $5 \times 10^{-3}$  M,  $10^{-3}$  M,  $5 \times 10^{-4}$  M,  $10^{-4}$  M,  $5 \times 10^{-5}$  M,  $10^{-5}$  M,  $5 \times 10^{-6}$  M,  $10^{-6}$  M,  $5 \times 10^{-7}$  M,  $10^{-7}$  M,  $5 \times 10^{-8}$  M,  $10^{-8}$  M,  $5 \times 10^{-9}$  M,  $10^{-9}$  M,  $5 \times 10^{-10}$  M,  $10^{-10}$  M,  $5 \times 10^{-11}$  M,  $10^{-11}$  M,  $5 \times 10^{-12}$  M,  $10^{-12}$  M,  $5 \times 10^{-13}$  M,  $10^{-13}$  M,  $5 \times 10^{-14}$  M,  $10^{-14}$  M,  $5 \times 10^{-15}$  M, or  $10^{-15}$  M.

25 The invention also provides antibodies that competitively inhibit binding of an antibody to an epitope of the invention as determined by any method known in the art for determining competitive binding, for example, the immunoassays described herein. In preferred embodiments, the antibody competitively inhibits binding to the epitope by at least 95%, at least 90%, at least 85 %, at least 80%, at least 75%, at least 70%, at least 60%, or at least 50%.

Antibodies of the present invention may act as agonists or antagonists of the polypeptides of the present invention. For example, the present invention includes antibodies which disrupt the receptor/ligand interactions with the polypeptides of the invention either partially or fully. Preferably, antibodies of the present invention bind an antigenic epitope disclosed herein, or a portion thereof. The invention features both receptor-specific antibodies and ligand-specific antibodies. The invention also features receptor-specific antibodies which do not prevent ligand binding but prevent receptor activation. Receptor activation (i.e., signaling) may be determined by techniques described herein or otherwise known in the art. For example, receptor activation can be determined by detecting the phosphorylation (e.g., tyrosine or serine/threonine) of the receptor or its substrate by immunoprecipitation followed by western blot analysis (for example, as described supra). In specific embodiments, antibodies are provided that inhibit ligand activity or receptor activity by at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 60%, or at least 50% of the activity in absence of the antibody.

The invention also features receptor-specific antibodies which both prevent ligand binding and receptor activation as well as antibodies that recognize the receptor-ligand complex, and, preferably, do not specifically recognize the unbound receptor or the unbound ligand. Likewise, included in the invention are neutralizing antibodies which bind the ligand and prevent binding of the ligand to the receptor, as well as antibodies which bind the ligand, thereby preventing receptor activation, but do not prevent the ligand from binding the receptor. Further included in the invention are antibodies which activate the receptor. These antibodies may act as receptor agonists, i.e., potentiate or activate either all or a subset of the biological activities of the ligand-mediated receptor activation, for example, by inducing dimerization of the receptor. The antibodies may be specified as agonists, antagonists or inverse agonists for biological activities comprising the specific biological activities of the peptides of the invention disclosed herein. The above antibody agonists can be made using methods known in the art. See, e.g., PCT publication WO 96/40281; U.S. Patent No. 5,811,097; Deng et al., Blood 92(6):1981-1988 (1998); Chen et al., Cancer Res.

58(16):3668-3678 (1998); Harrop et al., J. Immunol. 161(4):1786-1794 (1998); Zhu et al., Cancer Res. 58(15):3209-3214 (1998); Yoon et al., J. Immunol. 160(7):3170-3179 (1998); Prat et al., J. Cell. Sci. 111(Pt2):237-247 (1998); Pitard et al., J. Immunol. Methods 205(2):177-190 (1997); Liautard et al., Cytokine 9(4):233-241  
5 (1997); Carlson et al., J. Biol. Chem. 272(17):11295-11301 (1997); Taryman et al., Neuron 14(4):755-762 (1995); Muller et al., Structure 6(9):1153-1167 (1998); Bartunek et al., Cytokine 8(1):14-20 (1996) (which are all incorporated by reference herein in their entireties).

10 Antibodies of the present invention may be used, for example, but not limited to, to purify, detect, and target the polypeptides of the present invention, including both in vitro and in vivo diagnostic and therapeutic methods. For example, the antibodies have use in immunoassays for qualitatively and quantitatively measuring levels of the polypeptides of the present invention in biological samples. See, e.g., Harlow et al., Antibodies: A Laboratory Manual, (Cold Spring Harbor Laboratory  
15 Press, 2nd ed. 1988) (incorporated by reference herein in its entirety).

As discussed in more detail below, the antibodies of the present invention may be used either alone or in combination with other compositions. The antibodies may further be recombinantly fused to a heterologous polypeptide at the N- or C-terminus or chemically conjugated (including covalently and non-covalently conjugations) to  
20 polypeptides or other compositions. For example, antibodies of the present invention may be recombinantly fused or conjugated to molecules useful as labels in detection assays and effector molecules such as heterologous polypeptides, drugs, radionuclides, or toxins. See, e.g., PCT publications WO 92/08495; WO 91/14438; WO 89/12624; U.S. Patent No. 5,314,995; and EP 396,387.

25 The antibodies of the invention include derivatives that are modified, i.e., by the covalent attachment of any type of molecule to the antibody such that covalent attachment does not prevent the antibody from generating an anti-idiotypic response. For example, but not by way of limitation, the antibody derivatives include antibodies that have been modified, e.g., by glycosylation, acetylation, pegylation,  
30 phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to a cellular ligand or other protein, etc. Any of

numerous chemical modifications may be carried out by known techniques, including, but not limited to specific chemical cleavage, acetylation, formylation, metabolic synthesis of tunicamycin, etc. Additionally, the derivative may contain one or more non-classical amino acids.

5       The antibodies of the present invention may be generated by any suitable method known in the art. Polyclonal antibodies to an antigen-of-interest can be produced by various procedures well known in the art. For example, a polypeptide of the invention can be administered to various host animals including, but not limited to, rabbits, mice, rats, etc. to induce the production of sera containing polyclonal 10 antibodies specific for the antigen. Various adjuvants may be used to increase the immunological response, depending on the host species, and include but are not limited to, Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and 15 potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and corynebacterium parvum. Such adjuvants are also well known in the art.

Monoclonal antibodies can be prepared using a wide variety of techniques known in the art including the use of hybridoma, recombinant, and phage display technologies, or a combination thereof. For example, monoclonal antibodies can be 20 produced using hybridoma techniques including those known in the art and taught, for example, in Harlow et al., *Antibodies: A Laboratory Manual*, (Cold Spring Harbor Laboratory Press, 2nd ed. 1988); Hammerling, et al., in: *Monoclonal Antibodies and T-Cell Hybridomas* 563-681 (Elsevier, N.Y., 1981) (said references incorporated by reference in their entireties). The term "monoclonal antibody" as used herein is not 25 limited to antibodies produced through hybridoma technology. The term "monoclonal antibody" refers to an antibody that is derived from a single clone, including any eukaryotic, prokaryotic, or phage clone, and not the method by which it is produced.

Methods for producing and screening for specific antibodies using hybridoma 30 technology are routine and well known in the art and are discussed in detail in the Examples (e.g., Example 16). In a non-limiting example, mice can be immunized

- with a polypeptide of the invention or a cell expressing such peptide. Once an immune response is detected, e.g., antibodies specific for the antigen are detected in the mouse serum, the mouse spleen is harvested and splenocytes isolated. The splenocytes are then fused by well known techniques to any suitable myeloma cells,
- 5 for example cells from cell line SP20 available from the ATCC. Hybridomas are selected and cloned by limited dilution. The hybridoma clones are then assayed by methods known in the art for cells that secrete antibodies capable of binding a polypeptide of the invention. Ascites fluid, which generally contains high levels of antibodies, can be generated by immunizing mice with positive hybridoma clones.
- 10 Accordingly, the present invention provides methods of generating monoclonal antibodies as well as antibodies produced by the method comprising culturing a hybridoma cell secreting an antibody of the invention wherein, preferably, the hybridoma is generated by fusing splenocytes isolated from a mouse immunized with an antigen of the invention with myeloma cells and then screening the
- 15 hybridomas resulting from the fusion for hybridoma clones that secrete an antibody able to bind a polypeptide of the invention.

Antibody fragments which recognize specific epitopes may be generated by known techniques. For example, Fab and F(ab')2 fragments of the invention may be produced by proteolytic cleavage of immunoglobulin molecules, using enzymes such 20 as papain (to produce Fab fragments) or pepsin (to produce F(ab')2 fragments). F(ab')2 fragments contain the variable region, the light chain constant region and the CH1 domain of the heavy chain.

For example, the antibodies of the present invention can also be generated using various phage display methods known in the art. In phage display methods, 25 functional antibody domains are displayed on the surface of phage particles which carry the polynucleotide sequences encoding them. In a particular embodiment, such phage can be utilized to display antigen binding domains expressed from a repertoire or combinatorial antibody library (e.g., human or murine). Phage expressing an antigen binding domain that binds the antigen of interest can be selected or identified 30 with antigen, e.g., using labeled antigen or antigen bound or captured to a solid surface or bead. Phage used in these methods are typically filamentous phage

including fd and M13 binding domains expressed from phage with Fab, Fv or disulfide stabilized Fv antibody domains recombinantly fused to either the phage gene III or gene VIII protein. Examples of phage display methods that can be used to make the antibodies of the present invention include those disclosed in Brinkman et al., J. Immunol. Methods 182:41-50 (1995); Ames et al., J. Immunol. Methods 184:177-186 (1995); Kettleborough et al., Eur. J. Immunol. 24:952-958 (1994); Persic et al., Gene 187 9-18 (1997); Burton et al., Advances in Immunology 57:191-280 (1994); PCT application No. PCT/GB91/01134; PCT publications WO 90/02809; WO 91/10737; WO 92/01047; WO 92/18619; WO 93/11236; WO 95/15982; WO 10 95/20401; and U.S. Patent Nos. 5,698,426; 5,223,409; 5,403,484; 5,580,717; 5,427,908; 5,750,753; 5,821,047; 5,571,698; 5,427,908; 5,516,637; 5,780,225; 5,658,727; 5,733,743 and 5,969,108; each of which is incorporated herein by reference in its entirety.

As described in the above references, after phage selection, the antibody coding regions from the phage can be isolated and used to generate whole antibodies, including human antibodies, or any other desired antigen binding fragment, and expressed in any desired host, including mammalian cells, insect cells, plant cells, yeast, and bacteria, e.g., as described in detail below. For example, techniques to recombinantly produce Fab, Fab' and F(ab')<sup>2</sup> fragments can also be employed using methods known in the art such as those disclosed in PCT publication WO 92/22324; Mullinax et al., BioTechniques 12(6):864-869 (1992); and Sawai et al., AJRI 34:26-34 (1995); and Better et al., Science 240:1041-1043 (1988) (said references incorporated by reference in their entireties).

Examples of techniques which can be used to produce single-chain Fvs and antibodies include those described in U.S. Patents 4,946,778 and 5,258,498; Huston et al., Methods in Enzymology 203:46-88 (1991); Shu et al., PNAS 90:7995-7999 (1993); and Skerra et al., Science 240:1038-1040 (1988). For some uses, including in vivo use of antibodies in humans and in vitro detection assays, it may be preferable to use chimeric, humanized, or human antibodies. A chimeric antibody is a molecule in which different portions of the antibody are derived from different animal species, such as antibodies having a variable region derived from a murine monoclonal

antibody and a human immunoglobulin constant region. Methods for producing chimeric antibodies are known in the art. See e.g., Morrison, Science 229:1202 (1985); Oi et al., BioTechniques 4:214 (1986); Gillies et al., (1989) J. Immunol. Methods 125:191-202; U.S. Patent Nos. 5,807,715; 4,816,567; and 4,816397, which  
5 are incorporated herein by reference in their entirety. Humanized antibodies are antibody molecules from non-human species antibody that binds the desired antigen having one or more complementarity determining regions (CDRs) from the non-human species and a framework regions from a human immunoglobulin molecule. Often, framework residues in the human framework regions will be substituted with  
10 the corresponding residue from the CDR donor antibody to alter, preferably improve, antigen binding. These framework substitutions are identified by methods well known in the art, e.g., by modeling of the interactions of the CDR and framework residues to identify framework residues important for antigen binding and sequence comparison to identify unusual framework residues at particular positions. (See, e.g.,  
15 Queen et al., U.S. Patent No. 5,585,089; Riechmann et al., Nature 332:323 (1988), which are incorporated herein by reference in their entireties.) Antibodies can be humanized using a variety of techniques known in the art including, for example, CDR-grafting (EP 239,400; PCT publication WO 91/09967; U.S. Patent Nos.  
5,225,539; 5,530,101; and 5,585,089), veneering or resurfacing (EP 592,106; EP  
20 519,596; Padlan, Molecular Immunology 28(4/5):489-498 (1991); Studnicka et al., Protein Engineering 7(6):805-814 (1994); Roguska. et al., PNAS 91:969-973 (1994)), and chain shuffling (U.S. Patent No. 5,565,332).

Completely human antibodies are particularly desirable for therapeutic treatment of human patients. Human antibodies can be made by a variety of methods  
25 known in the art including phage display methods described above using antibody libraries derived from human immunoglobulin sequences. See also, U.S. Patent Nos. 4,444,887 and 4,716,111; and PCT publications WO 98/46645, WO 98/50433, WO 98/24893, WO 98/16654, WO 96/34096, WO 96/33735, and WO 91/10741; each of which is incorporated herein by reference in its entirety.

30 Human antibodies can also be produced using transgenic mice which are incapable of expressing functional endogenous immunoglobulins, but which can

express human immunoglobulin genes. For example, the human heavy and light chain immunoglobulin gene complexes may be introduced randomly or by homologous recombination into mouse embryonic stem cells. Alternatively, the human variable region, constant region, and diversity region may be introduced into 5 mouse embryonic stem cells in addition to the human heavy and light chain genes. The mouse heavy and light chain immunoglobulin genes may be rendered non-functional separately or simultaneously with the introduction of human immunoglobulin loci by homologous recombination. In particular, homozygous deletion of the JH region prevents endogenous antibody production. The modified 10 embryonic stem cells are expanded and microinjected into blastocysts to produce chimeric mice. The chimeric mice are then bred to produce homozygous offspring which express human antibodies. The transgenic mice are immunized in the normal fashion with a selected antigen, e.g., all or a portion of a polypeptide of the invention. Monoclonal antibodies directed against the antigen can be obtained from the 15 immunized, transgenic mice using conventional hybridoma technology. The human immunoglobulin transgenes harbored by the transgenic mice rearrange during B cell differentiation, and subsequently undergo class switching and somatic mutation. Thus, using such a technique, it is possible to produce therapeutically useful IgG, IgA, IgM and IgE antibodies. For an overview of this technology for producing human 20 antibodies, see Lonberg and Huszar, Int. Rev. Immunol. 13:65-93 (1995). For a detailed discussion of this technology for producing human antibodies and human monoclonal antibodies and protocols for producing such antibodies, see, e.g., PCT publications WO 98/24893; WO 92/01047; WO 96/34096; WO 96/33735; European Patent No. 0 598 877; U.S. Patent Nos. 5,413,923; 5,625,126; 5,633,425; 5,569,825; 25 5,661,016; 5,545,806; 5,814,318; 5,885,793; 5,916,771; and 5,939,598, which are incorporated by reference herein in their entirety. In addition, companies such as Abgenix, Inc. (Freemont, CA) and Genpharm (San Jose, CA) can be engaged to provide human antibodies directed against a selected antigen using technology similar to that described above.

30 Completely human antibodies which recognize a selected epitope can be generated using a technique referred to as "guided selection." In this approach a

selected non-human monoclonal antibody, e.g., a mouse antibody, is used to guide the selection of a completely human antibody recognizing the same epitope. (Jespers et al., Bio/technology 12:899-903 (1988)).

Further, antibodies to the polypeptides of the invention can, in turn, be utilized  
5 to generate anti-idiotype antibodies that "mimic" polypeptides of the invention using techniques well known to those skilled in the art. (See, e.g., Greenspan & Bona, FASEB J. 7(5):437-444; (1989) and Nissinoff, J. Immunol. 147(8):2429-2438 (1991)). For example, antibodies which bind to and competitively inhibit polypeptide multimerization and/or binding of a polypeptide of the invention to a ligand can be  
10 used to generate anti-idiotypes that "mimic" the polypeptide multimerization and/or binding domain and, as a consequence, bind to and neutralize polypeptide and/or its ligand. Such neutralizing anti-idiotypes or Fab fragments of such anti-idiotypes can be used in therapeutic regimens to neutralize polypeptide ligand. For example, such anti-idiotypic antibodies can be used to bind a polypeptide of the invention and/or to  
15 bind its ligands/receptors, and thereby block its biological activity.

#### Polynucleotides Encoding Antibodies

The invention further provides polynucleotides comprising a nucleotide sequence encoding an antibody of the invention and fragments thereof. The  
20 invention also encompasses polynucleotides that hybridize under stringent or lower stringency hybridization conditions, e.g., as defined supra, to polynucleotides that encode an antibody, preferably, that specifically binds to a polypeptide of the invention, preferably, an antibody that binds to a polypeptide having the amino acid sequence of SEQ ID NO:Y.

25 The polynucleotides may be obtained, and the nucleotide sequence of the polynucleotides determined, by any method known in the art. For example, if the nucleotide sequence of the antibody is known, a polynucleotide encoding the antibody may be assembled from chemically synthesized oligonucleotides (e.g., as described in Kutmeier et al., BioTechniques 17:242 (1994)), which, briefly, involves the  
30 synthesis of overlapping oligonucleotides containing portions of the sequence

encoding the antibody, annealing and ligating of those oligonucleotides, and then amplification of the ligated oligonucleotides by PCR.

Alternatively, a polynucleotide encoding an antibody may be generated from nucleic acid from a suitable source. If a clone containing a nucleic acid encoding a particular antibody is not available, but the sequence of the antibody molecule is known, a nucleic acid encoding the immunoglobulin may be chemically synthesized or obtained from a suitable source (e.g., an antibody cDNA library, or a cDNA library generated from, or nucleic acid, preferably poly A+ RNA, isolated from, any tissue or cells expressing the antibody, such as hybridoma cells selected to express an antibody of the invention) by PCR amplification using synthetic primers hybridizable to the 3' and 5' ends of the sequence or by cloning using an oligonucleotide probe specific for the particular gene sequence to identify, e.g., a cDNA clone from a cDNA library that encodes the antibody. Amplified nucleic acids generated by PCR may then be cloned into replicable cloning vectors using any method well known in the art.

Once the nucleotide sequence and corresponding amino acid sequence of the antibody is determined, the nucleotide sequence of the antibody may be manipulated using methods well known in the art for the manipulation of nucleotide sequences, e.g., recombinant DNA techniques, site directed mutagenesis, PCR, etc. (see, for example, the techniques described in Sambrook et al., 1990, Molecular Cloning, A Laboratory Manual, 2d Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY and Ausubel et al., eds., 1998, Current Protocols in Molecular Biology, John Wiley & Sons, NY, which are both incorporated by reference herein in their entireties ), to generate antibodies having a different amino acid sequence, for example to create amino acid substitutions, deletions, and/or insertions.

In a specific embodiment, the amino acid sequence of the heavy and/or light chain variable domains may be inspected to identify the sequences of the complementarity determining regions (CDRs) by methods that are well known in the art, e.g., by comparison to known amino acid sequences of other heavy and light chain variable regions to determine the regions of sequence hypervariability. Using routine recombinant DNA techniques, one or more of the CDRs may be inserted

- within framework regions, e.g., into human framework regions to humanize a non-human antibody, as described supra. The framework regions may be naturally occurring or consensus framework regions, and preferably human framework regions (see, e.g., Chothia et al., J. Mol. Biol. 278: 457-479 (1998) for a listing of human framework regions). Preferably, the polynucleotide generated by the combination of the framework regions and CDRs encodes an antibody that specifically binds a polypeptide of the invention. Preferably, as discussed supra, one or more amino acid substitutions may be made within the framework regions, and, preferably, the amino acid substitutions improve binding of the antibody to its antigen. Additionally, such methods may be used to make amino acid substitutions or deletions of one or more variable region cysteine residues participating in an intrachain disulfide bond to generate antibody molecules lacking one or more intrachain disulfide bonds. Other alterations to the polynucleotide are encompassed by the present invention and within the skill of the art.
- In addition, techniques developed for the production of "chimeric antibodies" (Morrison et al., Proc. Natl. Acad. Sci. 81:851-855 (1984); Neuberger et al., Nature 312:604-608 (1984); Takeda et al., Nature 314:452-454 (1985)) by splicing genes from a mouse antibody molecule of appropriate antigen specificity together with genes from a human antibody molecule of appropriate biological activity can be used.
- As described supra, a chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable region derived from a murine mAb and a human immunoglobulin constant region, e.g., humanized antibodies.
- Alternatively, techniques described for the production of single chain antibodies (U.S. Patent No. 4,946,778; Bird, Science 242:423- 42 (1988); Huston et al., Proc. Natl. Acad. Sci. USA 85:5879-5883 (1988); and Ward et al., Nature 334:544-54 (1989)) can be adapted to produce single chain antibodies. Single chain antibodies are formed by linking the heavy and light chain fragments of the Fv region via an amino acid bridge, resulting in a single chain polypeptide. Techniques for the assembly of functional Fv fragments in E. coli may also be used (Skerra et al., Science 242:1038- 1041 (1988)).

### Methods of Producing Antibodies

The antibodies of the invention can be produced by any method known in the art for the synthesis of antibodies, in particular, by chemical synthesis or preferably,  
5 by recombinant expression techniques.

Recombinant expression of an antibody of the invention, or fragment, derivative or analog thereof, (e.g., a heavy or light chain of an antibody of the invention or a single chain antibody of the invention), requires construction of an expression vector containing a polynucleotide that encodes the antibody. Once a  
10 polynucleotide encoding an antibody molecule or a heavy or light chain of an antibody, or portion thereof (preferably containing the heavy or light chain variable domain), of the invention has been obtained, the vector for the production of the antibody molecule may be produced by recombinant DNA technology using techniques well known in the art. Thus, methods for preparing a protein by  
15 expressing a polynucleotide containing an antibody encoding nucleotide sequence are described herein. Methods which are well known to those skilled in the art can be used to construct expression vectors containing antibody coding sequences and appropriate transcriptional and translational control signals. These methods include, for example, in vitro recombinant DNA techniques, synthetic techniques, and in vivo  
20 genetic recombination. The invention, thus, provides replicable vectors comprising a nucleotide sequence encoding an antibody molecule of the invention, or a heavy or light chain thereof, or a heavy or light chain variable domain, operably linked to a promoter. Such vectors may include the nucleotide sequence encoding the constant region of the antibody molecule (see, e.g., PCT Publication WO 86/05807; PCT  
25 Publication WO 89/01036; and U.S. Patent No. 5,122,464) and the variable domain of the antibody may be cloned into such a vector for expression of the entire heavy or light chain.

The expression vector is transferred to a host cell by conventional techniques and the transfected cells are then cultured by conventional techniques to produce an  
30 antibody of the invention. Thus, the invention includes host cells containing a polynucleotide encoding an antibody of the invention, or a heavy or light chain

thereof, or a single chain antibody of the invention, operably linked to a heterologous promoter. In preferred embodiments for the expression of double-chained antibodies, vectors encoding both the heavy and light chains may be co-expressed in the host cell for expression of the entire immunoglobulin molecule, as detailed below.

- 5        A variety of host-expression vector systems may be utilized to express the antibody molecules of the invention. Such host-expression systems represent vehicles by which the coding sequences of interest may be produced and subsequently purified, but also represent cells which may, when transformed or transfected with the appropriate nucleotide coding sequences, express an antibody molecule of the
- 10      invention in situ. These include but are not limited to microorganisms such as bacteria (e.g., *E. coli*, *B. subtilis*) transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing antibody coding sequences; yeast (e.g., *Saccharomyces*, *Pichia*) transformed with recombinant yeast expression vectors containing antibody coding sequences; insect cell systems
- 15      infected with recombinant virus expression vectors (e.g., baculovirus) containing antibody coding sequences; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing antibody coding sequences; or mammalian cell systems (e.g., COS, CHO,
- 20      BHK, 293, 3T3 cells) harboring recombinant expression constructs containing promoters derived from the genome of mammalian cells (e.g., metallothionein promoter) or from mammalian viruses (e.g., the adenovirus late promoter; the vaccinia virus 7.5K promoter). Preferably, bacterial cells such as *Escherichia coli*, and more preferably, eukaryotic cells, especially for the expression of whole
- 25      recombinant antibody molecule, are used for the expression of a recombinant antibody molecule. For example, mammalian cells such as Chinese hamster ovary cells (CHO), in conjunction with a vector such as the major intermediate early gene promoter element from human cytomegalovirus is an effective expression system for antibodies (Foecking et al., Gene 45:101 (1986); Cockett et al., Bio/Technology 8:2
- 30      (1990)).

In bacterial systems, a number of expression vectors may be advantageously selected depending upon the use intended for the antibody molecule being expressed. For example, when a large quantity of such a protein is to be produced, for the generation of pharmaceutical compositions of an antibody molecule, vectors which 5 direct the expression of high levels of fusion protein products that are readily purified may be desirable. Such vectors include, but are not limited, to the *E. coli* expression vector pUR278 (Ruther et al., EMBO J. 2:1791 (1983)), in which the antibody coding sequence may be ligated individually into the vector in frame with the lac Z coding region so that a fusion protein is produced; pIN vectors (Inouye & Inouye, Nucleic 10 Acids Res. 13:3101-3109 (1985); Van Heeke & Schuster, J. Biol. Chem. 24:5503-5509 (1989)); and the like. pGEX vectors may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption and binding to matrix glutathione-agarose beads followed by elution in the presence 15 of free glutathione. The pGEX vectors are designed to include thrombin or factor Xa protease cleavage sites so that the cloned target gene product can be released from the GST moiety.

In an insect system, *Autographa californica* nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes. The virus grows in 20 *Spodoptera frugiperda* cells. The antibody coding sequence may be cloned individually into non-essential regions (for example the polyhedrin gene) of the virus and placed under control of an AcNPV promoter (for example the polyhedrin promoter).

In mammalian host cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, the antibody coding sequence of interest may be ligated to an adenovirus transcription/translation control complex, e.g., the late promoter and tripartite leader sequence. This chimeric gene may then be inserted in the adenovirus genome by in vitro or in vivo recombination. Insertion in a non- essential region of the viral genome (e.g., region 25 E1 or E3) will result in a recombinant virus that is viable and capable of expressing the antibody molecule in infected hosts. (e.g., see Logan & Shenk, Proc. Natl. Acad. 30

- Sci. USA 81:355-359 (1984)). Specific initiation signals may also be required for efficient translation of inserted antibody coding sequences. These signals include the ATG initiation codon and adjacent sequences. Furthermore, the initiation codon must be in phase with the reading frame of the desired coding sequence to ensure 5 translation of the entire insert. These exogenous translational control signals and initiation codons can be of a variety of origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of appropriate transcription enhancer elements, transcription terminators, etc. (see Bittner et al., Methods in Enzymol. 153:51-544 (1987)).
- 10 In addition, a host cell strain may be chosen which modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Such modifications (e.g., glycosylation) and processing (e.g., cleavage) of protein products may be important for the function of the protein. Different host cells have characteristic and specific mechanisms for the post- 15 translational processing and modification of proteins and gene products. Appropriate cell lines or host systems can be chosen to ensure the correct modification and processing of the foreign protein expressed. To this end, eukaryotic host cells which possess the cellular machinery for proper processing of the primary transcript, glycosylation, and phosphorylation of the gene product may be used. Such 20 mammalian host cells include but are not limited to CHO, VERY, BHK, Hela, COS, MDCK, 293, 3T3, WI38, and in particular, breast cancer cell lines such as, for example, BT483, Hs578T, HTB2, BT20 and T47D, and normal mammary gland cell line such as, for example, CRL7030 and Hs578Bst.
- For long-term, high-yield production of recombinant proteins, stable 25 expression is preferred. For example, cell lines which stably express the antibody molecule may be engineered. Rather than using expression vectors which contain viral origins of replication, host cells can be transformed with DNA controlled by appropriate expression control elements (e.g., promoter, enhancer, sequences, transcription terminators, polyadenylation sites, etc.), and a selectable marker.
- 30 Following the introduction of the foreign DNA, engineered cells may be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media.

- The selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci which in turn can be cloned and expanded into cell lines. This method may advantageously be used to engineer cell lines which express the antibody molecule.
- 5 Such engineered cell lines may be particularly useful in screening and evaluation of compounds that interact directly or indirectly with the antibody molecule.
- A number of selection systems may be used, including but not limited to the herpes simplex virus thymidine kinase (Wigler et al., Cell 11:223 (1977)), hypoxanthine-guanine phosphoribosyltransferase (Szybalska & Szybalski, Proc. Natl. Acad. Sci. USA 48:202 (1992)), and adenine phosphoribosyltransferase (Lowy et al., Cell 22:817 (1980)) genes can be employed in tk-, hgprt- or aprt- cells, respectively. Also, antimetabolite resistance can be used as the basis of selection for the following genes: dhfr, which confers resistance to methotrexate (Wigler et al., Natl. Acad. Sci. USA 77:357 (1980); O'Hare et al., Proc. Natl. Acad. Sci. USA 78:1527 (1981)); gpt, which confers resistance to mycophenolic acid (Mulligan & Berg, Proc. Natl. Acad. Sci. USA 78:2072 (1981)); neo, which confers resistance to the aminoglycoside G-418 Clinical Pharmacy 12:488-505; Wu and Wu, Biotherapy 3:87-95 (1991); Tolstoshev, Ann. Rev. Pharmacol. Toxicol. 32:573-596 (1993); Mulligan, Science 260:926-932 (1993); and Morgan and Anderson, Ann. Rev. Biochem. 62:191-217 (1993); May, 1993, TIB TECH 11(5):155-215); and hygro, which confers resistance to hygromycin (Santerre et al., Gene 30:147 (1984)). Methods commonly known in the art of recombinant DNA technology may be routinely applied to select the desired recombinant clone, and such methods are described, for example, in Ausubel et al. (eds.), Current Protocols in Molecular Biology, John Wiley & Sons, NY (1993); Kriegler, Gene Transfer and Expression, A Laboratory Manual, Stockton Press, NY (1990); and in Chapters 12 and 13, Dracopoli et al. (eds), Current Protocols in Human Genetics, John Wiley & Sons, NY (1994); Colberre-Garapin et al., J. Mol. Biol. 150:1 (1981), which are incorporated by reference herein in their entireties.
- The expression levels of an antibody molecule can be increased by vector amplification (for a review, see Bebbington and Hentschel, The use of vectors based on gene amplification for the expression of cloned genes in mammalian cells in DNA

cloning, Vol.3. (Academic Press, New York, 1987)). When a marker in the vector system expressing antibody is amplifiable, increase in the level of inhibitor present in culture of host cell will increase the number of copies of the marker gene. Since the amplified region is associated with the antibody gene, production of the antibody will  
5 also increase (Crouse et al., Mol. Cell. Biol. 3:257 (1983)).

The host cell may be co-transfected with two expression vectors of the invention, the first vector encoding a heavy chain derived polypeptide and the second vector encoding a light chain derived polypeptide. The two vectors may contain identical selectable markers which enable equal expression of heavy and light chain  
10 polypeptides. Alternatively, a single vector may be used which encodes, and is capable of expressing, both heavy and light chain polypeptides. In such situations, the light chain should be placed before the heavy chain to avoid an excess of toxic free heavy chain (Proudfoot, Nature 322:52 (1986); Kohler, Proc. Natl. Acad. Sci. USA 77:2197 (1980)). The coding sequences for the heavy and light chains may  
15 comprise cDNA or genomic DNA.

Once an antibody molecule of the invention has been produced by an animal, chemically synthesized, or recombinantly expressed, it may be purified by any method known in the art for purification of an immunoglobulin molecule, for example, by chromatography (e.g., ion exchange, affinity, particularly by affinity for  
20 the specific antigen after Protein A, and sizing column chromatography), centrifugation, differential solubility, or by any other standard technique for the purification of proteins. In addition, the antibodies of the present invention or fragments thereof can be fused to heterologous polypeptide sequences described herein or otherwise known in the art, to facilitate purification.

25 The present invention encompasses antibodies recombinantly fused or chemically conjugated (including both covalently and non-covalently conjugations) to a polypeptide (or portion thereof, preferably at least 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 amino acids of the polypeptide) of the present invention to generate fusion proteins. The fusion does not necessarily need to be direct, but may occur through  
30 linker sequences. The antibodies may be specific for antigens other than polypeptides (or portion thereof, preferably at least 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 amino

acids of the polypeptide) of the present invention. For example, antibodies may be used to target the polypeptides of the present invention to particular cell types, either in vitro or in vivo, by fusing or conjugating the polypeptides of the present invention to antibodies specific for particular cell surface receptors. Antibodies fused or 5 conjugated to the polypeptides of the present invention may also be used in in vitro immunoassays and purification methods using methods known in the art. See e.g., Harbor et al., *supra*, and PCT publication WO 93/21232; EP 439,095; Naramura et al., *Immunol. Lett.* 39:91-99 (1994); U.S. Patent 5,474,981; Gillies et al., *PNAS* 89:1428-1432 (1992); Fell et al., *J. Immunol.* 146:2446-2452(1991), which are 10 incorporated by reference in their entireties.

The present invention further includes compositions comprising the polypeptides of the present invention fused or conjugated to antibody domains other than the variable regions. For example, the polypeptides of the present invention may be fused or conjugated to an antibody Fc region, or portion thereof. The antibody 15 portion fused to a polypeptide of the present invention may comprise the constant region, hinge region, CH1 domain, CH2 domain, and CH3 domain or any combination of whole domains or portions thereof. The polypeptides may also be fused or conjugated to the above antibody portions to form multimers. For example, Fc portions fused to the polypeptides of the present invention can form dimers 20 through disulfide bonding between the Fc portions. Higher multimeric forms can be made by fusing the polypeptides to portions of IgA and IgM. Methods for fusing or conjugating the polypeptides of the present invention to antibody portions are known in the art. See, e.g., U.S. Patent Nos. 5,336,603; 5,622,929; 5,359,046; 5,349,053; 5,447,851; 5,112,946; EP 307,434; EP 367,166; PCT publications WO 96/04388; WO 25 91/06570; Ashkenazi et al., *Proc. Natl. Acad. Sci. USA* 88:10535-10539 (1991); Zheng et al., *J. Immunol.* 154:5590-5600 (1995); and Vil et al., *Proc. Natl. Acad. Sci. USA* 89:11337- 11341(1992) (said references incorporated by reference in their entireties).

As discussed, *supra*, the polypeptides corresponding to a polypeptide, 30 polypeptide fragment, or a variant of SEQ ID NO:Y may be fused or conjugated to the above antibody portions to increase the in vivo half life of the polypeptides or for

- use in immunoassays using methods known in the art. Further, the polypeptides corresponding to SEQ ID NO:Y may be fused or conjugated to the above antibody portions to facilitate purification. One reported example describes chimeric proteins consisting of the first two domains of the human CD4-polypeptide and various 5 domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. (EP 394,827; Traunecker et al., Nature 331:84-86 (1988). The polypeptides of the present invention fused or conjugated to an antibody having disulfide-linked dimeric structures (due to the IgG) may also be more efficient in binding and neutralizing other molecules, than the monomeric secreted protein or 10 protein fragment alone. (Fountoulakis et al., J. Biochem. 270:3958-3964 (1995)). In many cases, the Fc part in a fusion protein is beneficial in therapy and diagnosis, and thus can result in, for example, improved pharmacokinetic properties. (EP A 232,262). Alternatively, deleting the Fc part after the fusion protein has been expressed, detected, and purified, would be desired. For example, the Fc portion may 15 hinder therapy and diagnosis if the fusion protein is used as an antigen for immunizations. In drug discovery, for example, human proteins, such as hIL-5, have been fused with Fc portions for the purpose of high-throughput screening assays to identify antagonists of hIL-5. (See, Bennett et al., J. Molecular Recognition 8:52-58 (1995); Johanson et al., J. Biol. Chem. 270:9459-9471 (1995)).
- 20 Moreover, the antibodies or fragments thereof of the present invention can be fused to marker sequences, such as a peptide to facilitate purification. In preferred embodiments, the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA, 91311), among others, many of which are commercially available. As described in 25 Gentz et al., Proc. Natl. Acad. Sci. USA 86:821-824 (1989), for instance, hexa-histidine provides for convenient purification of the fusion protein. Other peptide tags useful for purification include, but are not limited to, the "HA" tag, which corresponds to an epitope derived from the influenza hemagglutinin protein (Wilson et al., Cell 37:767 (1984)) and the "flag" tag.
- 30 The present invention further encompasses antibodies or fragments thereof conjugated to a diagnostic or therapeutic agent. The antibodies can be used

diagnostically to, for example, monitor the development or progression of a tumor as part of a clinical testing procedure to, e.g., determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling the antibody to a detectable substance. Examples of detectable substances include various enzymes, 5 prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, radioactive materials, positron emitting metals using various positron emission tomographies, and nonradioactive paramagnetic metal ions. The detectable substance may be coupled or conjugated either directly to the antibody (or fragment thereof) or indirectly, through an intermediate (such as, for example, a linker known 10 in the art) using techniques known in the art. See, for example, U.S. Patent No. 4,741,900 for metal ions which can be conjugated to antibodies for use as diagnostics according to the present invention. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, beta-galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and 15 avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin; and examples of suitable radioactive material include 125I, 131I, 111In 20 or 99Tc.

Further, an antibody or fragment thereof may be conjugated to a therapeutic moiety such as a cytotoxin, e.g., a cytostatic or cytoidal agent, a therapeutic agent or a radioactive metal ion, e.g., alpha-emitters such as, for example, 213Bi. A cytotoxin or cytotoxic agent includes any agent that is detrimental to cells. Examples include 25 paclitaxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and puromycin and analogs or homologs thereof. Therapeutic agents include, but are not 30 limited to, antimetabolites (e.g., methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarbazine), alkylating agents (e.g., mechlorethamine,

thioepa, chlorambucil, melphalan, carmustine (BSNU) and lomustine (CCNU), cyclothosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis-dichlorodiamine platinum (II) (DDP) cisplatin), anthracyclines (e.g., daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (e.g., dactinomycin (formerly 5 actinomycin), bleomycin, mithramycin, and anthramycin (AMC)), and anti-mitotic agents (e.g., vincristine and vinblastine).

The conjugates of the invention can be used for modifying a given biological response, the therapeutic agent or drug moiety is not to be construed as limited to classical chemical therapeutic agents. For example, the drug moiety may be a protein 10 or polypeptide possessing a desired biological activity. Such proteins may include, for example, a toxin such as abrin, ricin A, pseudomonas exotoxin, or diphtheria toxin; a protein such as tumor necrosis factor,  $\alpha$ -interferon,  $\beta$ -interferon, nerve growth factor, platelet derived growth factor, tissue plasminogen activator, an apoptotic agent, e.g., TNF-alpha, TNF-beta, AIM I (See, International Publication No. WO 15 97/33899), AIM II (See, International Publication No. WO 97/34911), Fas Ligand (Takahashi *et al.*, *Int. Immunol.*, 6:1567-1574 (1994)), VEGI (See, International Publication No. WO 99/23105), a thrombotic agent or an anti-angiogenic agent, e.g., angiostatin or endostatin; or, biological response modifiers such as, for example, lymphokines, interleukin-1 ("IL-1"), interleukin-2 ("IL-2"), interleukin-6 ("IL-6"), 20 granulocyte macrophage colony stimulating factor ("GM-CSF"), granulocyte colony stimulating factor ("G-CSF"), or other growth factors.

Antibodies may also be attached to solid supports, which are particularly useful for immunoassays or purification of the target antigen. Such solid supports include, but are not limited to, glass, cellulose, polyacrylamide, nylon, polystyrene, 25 polyvinyl chloride or polypropylene.

Techniques for conjugating such therapeutic moiety to antibodies are well known, see, e.g., Arnon *et al.*, "Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy", in *Monoclonal Antibodies And Cancer Therapy*, Reisfeld et al. (eds.), pp. 243-56 (Alan R. Liss, Inc. 1985); Hellstrom *et al.*, "Antibodies For 30 Drug Delivery", in *Controlled Drug Delivery* (2nd Ed.), Robinson *et al.* (eds.), pp. 623-53 (Marcel Dekker, Inc. 1987); Thorpe, "Antibody Carriers Of Cytotoxic Agents

- In Cancer Therapy: A Review", in Monoclonal Antibodies '84: Biological And Clinical Applications, Pinchera et al. (eds.), pp. 475-506 (1985); "Analysis, Results, And Future Prospective Of The Therapeutic Use Of Radiolabeled Antibody In Cancer Therapy", in Monoclonal Antibodies For Cancer Detection And Therapy,  
5 Baldwin et al. (eds.), pp. 303-16 (Academic Press 1985), and Thorpe et al., "The Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates", Immunol. Rev. 62:119-58 (1982).

Alternatively, an antibody can be conjugated to a second antibody to form an antibody heteroconjugate as described by Segal in U.S. Patent No. 4,676,980, which  
10 is incorporated herein by reference in its entirety.

An antibody, with or without a therapeutic moiety conjugated to it, administered alone or in combination with cytotoxic factor(s) and/or cytokine(s) can be used as a therapeutic.

15 Immunophenotyping

The antibodies of the invention may be utilized for immunophenotyping of cell lines and biological samples. The translation product of the gene of the present invention may be useful as a cell specific marker, or more specifically as a cellular marker that is differentially expressed at various stages of differentiation and/or  
20 maturation of particular cell types. Monoclonal antibodies directed against a specific epitope, or combination of epitopes, will allow for the screening of cellular populations expressing the marker. Various techniques can be utilized using monoclonal antibodies to screen for cellular populations expressing the marker(s), and include magnetic separation using antibody-coated magnetic beads, "panning" with  
25 antibody attached to a solid matrix (i.e., plate), and flow cytometry (See, e.g., U.S. Patent 5,985,660; and Morrison et al., *Cell*, 96:737-49 (1999)).

These techniques allow for the screening of particular populations of cells, such as might be found with hematological malignancies (i.e. minimal residual disease (MRD) in acute leukemic patients) and "non-self" cells in transplantations to  
30 prevent Graft-versus-Host Disease (GVHD). Alternatively, these techniques allow for

the screening of hematopoietic stem and progenitor cells capable of undergoing proliferation and/or differentiation, as might be found in human umbilical cord blood.

#### Assays For Antibody Binding

5       The antibodies of the invention may be assayed for immunospecific binding by any method known in the art. The immunoassays which can be used include but are not limited to competitive and non-competitive assay systems using techniques such as western blots, radioimmunoassays, ELISA (enzyme linked immunosorbent assay), "sandwich" immunoassays, immunoprecipitation assays, precipitin reactions, 10 gel diffusion precipitin reactions, immunodiffusion assays, agglutination assays, complement-fixation assays, immunoradiometric assays, fluorescent immunoassays, protein A immunoassays, to name but a few. Such assays are routine and well known in the art (see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York, which is incorporated by 15 reference herein in its entirety). Exemplary immunoassays are described briefly below (but are not intended by way of limitation).

Immunoprecipitation protocols generally comprise lysing a population of cells in a lysis buffer such as RIPA buffer (1% NP-40 or Triton X- 100, 1% sodium deoxycholate, 0.1% SDS, 0.15 M NaCl, 0.01 M sodium phosphate at pH 7.2, 1% 20 Trasylol) supplemented with protein phosphatase and/or protease inhibitors (e.g., EDTA, PMSF, aprotinin, sodium vanadate), adding the antibody of interest to the cell lysate, incubating for a period of time (e.g., 1-4 hours) at 4° C, adding protein A and/or protein G sepharose beads to the cell lysate, incubating for about an hour or more at 4° C, washing the beads in lysis buffer and resuspending the beads in 25 SDS/sample buffer. The ability of the antibody of interest to immunoprecipitate a particular antigen can be assessed by, e.g., western blot analysis. One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the binding of the antibody to an antigen and decrease the background (e.g., pre-clearing the cell lysate with sepharose beads). For further discussion regarding 30 immunoprecipitation protocols see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York at 10.16.1.

Western blot analysis generally comprises preparing protein samples, electrophoresis of the protein samples in a polyacrylamide gel (e.g., 8%- 20% SDS-PAGE depending on the molecular weight of the antigen), transferring the protein sample from the polyacrylamide gel to a membrane such as nitrocellulose, PVDF or 5 nylon, blocking the membrane in blocking solution (e.g., PBS with 3% BSA or non-fat milk), washing the membrane in washing buffer (e.g., PBS-Tween 20), blocking the membrane with primary antibody (the antibody of interest) diluted in blocking buffer, washing the membrane in washing buffer, blocking the membrane with a secondary antibody (which recognizes the primary antibody, e.g., an anti-human 10 antibody) conjugated to an enzymatic substrate (e.g., horseradish peroxidase or alkaline phosphatase) or radioactive molecule (e.g., <sup>32</sup>P or <sup>125</sup>I) diluted in blocking buffer, washing the membrane in wash buffer, and detecting the presence of the antigen. One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the signal detected and to reduce the background noise. For 15 further discussion regarding western blot protocols see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York at 10.8.1.

ELISAs comprise preparing antigen, coating the well of a 96 well microtiter plate with the antigen, adding the antibody of interest conjugated to a detectable 20 compound such as an enzymatic substrate (e.g., horseradish peroxidase or alkaline phosphatase) to the well and incubating for a period of time, and detecting the presence of the antigen. In ELISAs the antibody of interest does not have to be conjugated to a detectable compound; instead, a second antibody (which recognizes the antibody of interest) conjugated to a detectable compound may be added to the 25 well. Further, instead of coating the well with the antigen, the antibody may be coated to the well. In this case, a second antibody conjugated to a detectable compound may be added following the addition of the antigen of interest to the coated well. One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the signal detected as well as other variations of ELISAs 30 known in the art. For further discussion regarding ELISAs see, e.g., Ausubel et al,

eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York at 11.2.1.

The binding affinity of an antibody to an antigen and the off-rate of an antibody-antigen interaction can be determined by competitive binding assays. One example of a competitive binding assay is a radioimmunoassay comprising the incubation of labeled antigen (e.g., <sup>3</sup>H or <sup>125</sup>I) with the antibody of interest in the presence of increasing amounts of unlabeled antigen, and the detection of the antibody bound to the labeled antigen. The affinity of the antibody of interest for a particular antigen and the binding off-rates can be determined from the data by scatchard plot analysis. Competition with a second antibody can also be determined using radioimmunoassays. In this case, the antigen is incubated with antibody of interest conjugated to a labeled compound (e.g., <sup>3</sup>H or <sup>125</sup>I) in the presence of increasing amounts of an unlabeled second antibody.

15        Therapeutic Uses

The present invention is further directed to antibody-based therapies which involve administering antibodies of the invention to an animal, preferably a mammal, and most preferably a human, patient for treating one or more of the disclosed diseases, disorders, or conditions. Therapeutic compounds of the invention include, but are not limited to, antibodies of the invention (including fragments, analogs and derivatives thereof as described herein) and nucleic acids encoding antibodies of the invention (including fragments, analogs and derivatives thereof and anti-idiotypic antibodies as described herein). The antibodies of the invention can be used to treat, inhibit or prevent diseases, disorders or conditions associated with aberrant expression and/or activity of a polypeptide of the invention, including, but not limited to, any one or more of the diseases, disorders, or conditions described herein. The treatment and/or prevention of diseases, disorders, or conditions associated with aberrant expression and/or activity of a polypeptide of the invention includes, but is not limited to, alleviating symptoms associated with those diseases, disorders or conditions. Antibodies of the invention may be provided in pharmaceutically acceptable compositions as known in the art or as described herein.

A summary of the ways in which the antibodies of the present invention may be used therapeutically includes binding polynucleotides or polypeptides of the present invention locally or systemically in the body or by direct cytotoxicity of the antibody, e.g. as mediated by complement (CDC) or by effector cells (ADCC).

- 5 Some of these approaches are described in more detail below. Armed with the teachings provided herein, one of ordinary skill in the art will know how to use the antibodies of the present invention for diagnostic, monitoring or therapeutic purposes without undue experimentation.

- The antibodies of this invention may be advantageously utilized in  
10 combination with other monoclonal or chimeric antibodies, or with lymphokines or hematopoietic growth factors (such as, e.g., IL-2, IL-3 and IL-7), for example, which serve to increase the number or activity of effector cells which interact with the antibodies.

- The antibodies of the invention may be administered alone or in combination  
15 with other types of treatments (e.g., radiation therapy, chemotherapy, hormonal therapy, immunotherapy and anti-tumor agents). Generally, administration of products of a species origin or species reactivity (in the case of antibodies) that is the same species as that of the patient is preferred. Thus, in a preferred embodiment, human antibodies, fragments derivatives, analogs, or nucleic acids, are administered  
20 to a human patient for therapy or prophylaxis.

- It is preferred to use high affinity and/or potent in vivo inhibiting and/or neutralizing antibodies against polypeptides or polynucleotides of the present invention, fragments or regions thereof, for both immunoassays directed to and therapy of disorders related to polynucleotides or polypeptides, including fragments  
25 thereof, of the present invention. Such antibodies, fragments, or regions, will preferably have an affinity for polynucleotides or polypeptides of the invention, including fragments thereof. Preferred binding affinities include those with a dissociation constant or Kd less than  $5 \times 10^{-2}$  M,  $10^{-2}$  M,  $5 \times 10^{-3}$  M,  $10^{-3}$  M,  $5 \times 10^{-4}$  M,  $10^{-4}$  M,  $5 \times 10^{-5}$  M,  $10^{-5}$  M,  $5 \times 10^{-6}$  M,  $10^{-6}$  M,  $5 \times 10^{-7}$  M,  $10^{-7}$  M,  $5 \times 10^{-8}$  M,  
30  $10^{-8}$  M,  $5 \times 10^{-9}$  M,  $10^{-9}$  M,  $5 \times 10^{-10}$  M,  $10^{-10}$  M,  $5 \times 10^{-11}$  M,  $10^{-11}$  M,  $5 \times 10^{-12}$  M,  $10^{-12}$  M,  $5 \times 10^{-13}$  M,  $10^{-13}$  M,  $5 \times 10^{-14}$  M,  $10^{-14}$  M,  $5 \times 10^{-15}$  M, and  $10^{-15}$  M.

Gene Therapy

- In a specific embodiment, nucleic acids comprising sequences encoding antibodies or functional derivatives thereof, are administered to treat, inhibit or prevent a disease or disorder associated with aberrant expression and/or activity of a polypeptide of the invention, by way of gene therapy. Gene therapy refers to therapy performed by the administration to a subject of an expressed or expressible nucleic acid. In this embodiment of the invention, the nucleic acids produce their encoded protein that mediates a therapeutic effect.
- Any of the methods for gene therapy available in the art can be used according to the present invention. Exemplary methods are described below.
- For general reviews of the methods of gene therapy, see Goldspiel et al., Clinical Pharmacy 12:488-505 (1993); Wu and Wu, Biotherapy 3:87-95 (1991); Tolstoshev, Ann. Rev. Pharmacol. Toxicol. 32:573-596 (1993); Mulligan, Science 260:926-932 (1993); and Morgan and Anderson, Ann. Rev. Biochem. 62:191-217 (1993); May, TIBTECH 11(5):155-215 (1993). Methods commonly known in the art of recombinant DNA technology which can be used are described in Ausubel et al. (eds.), Current Protocols in Molecular Biology, John Wiley & Sons, NY (1993); and Kriegler, Gene Transfer and Expression, A Laboratory Manual, Stockton Press, NY (1990).

In a preferred aspect, the compound comprises nucleic acid sequences encoding an antibody, said nucleic acid sequences being part of expression vectors that express the antibody or fragments or chimeric proteins or heavy or light chains thereof in a suitable host. In particular, such nucleic acid sequences have promoters operably linked to the antibody coding region, said promoter being inducible or constitutive, and, optionally, tissue-specific. In another particular embodiment, nucleic acid molecules are used in which the antibody coding sequences and any other desired sequences are flanked by regions that promote homologous recombination at a desired site in the genome, thus providing for intrachromosomal expression of the antibody encoding nucleic acids (Koller and Smithies, Proc. Natl. Acad. Sci. USA 86:8932-8935 (1989); Zijlstra et al., Nature 342:435-438 (1989). In specific

embodiments, the expressed antibody molecule is a single chain antibody; alternatively, the nucleic acid sequences include sequences encoding both the heavy and light chains, or fragments thereof, of the antibody.

Delivery of the nucleic acids into a patient may be either direct, in which case 5 the patient is directly exposed to the nucleic acid or nucleic acid- carrying vectors, or indirect, in which case, cells are first transformed with the nucleic acids in vitro, then transplanted into the patient. These two approaches are known, respectively, as in vivo or ex vivo gene therapy.

In a specific embodiment, the nucleic acid sequences are directly administered 10 in vivo, where it is expressed to produce the encoded product. This can be accomplished by any of numerous methods known in the art, e.g., by constructing them as part of an appropriate nucleic acid expression vector and administering it so that they become intracellular, e.g., by infection using defective or attenuated retrovirals or other viral vectors (see U.S. Patent No. 4,980,286), or by direct 15 injection of naked DNA, or by use of microparticle bombardment (e.g., a gene gun; Biolistic, Dupont), or coating with lipids or cell-surface receptors or transfecting agents, encapsulation in liposomes, microparticles, or microcapsules, or by administering them in linkage to a peptide which is known to enter the nucleus, by administering it in linkage to a ligand subject to receptor-mediated endocytosis (see, 20 e.g., Wu and Wu, J. Biol. Chem. 262:4429-4432 (1987)) (which can be used to target cell types specifically expressing the receptors), etc. In another embodiment, nucleic acid-ligand complexes can be formed in which the ligand comprises a fusogenic viral peptide to disrupt endosomes, allowing the nucleic acid to avoid lysosomal degradation. In yet another embodiment, the nucleic acid can be targeted in vivo for 25 cell specific uptake and expression, by targeting a specific receptor (see, e.g., PCT Publications WO 92/06180; WO 92/22635; WO92/20316; WO93/14188, WO 93/20221). Alternatively, the nucleic acid can be introduced intracellularly and incorporated within host cell DNA for expression, by homologous recombination (Koller and Smithies, Proc. Natl. Acad. Sci. USA 86:8932-8935 (1989); Zijlstra et al., 30 Nature 342:435-438 (1989)).

- In a specific embodiment, viral vectors that contains nucleic acid sequences encoding an antibody of the invention are used. For example, a retroviral vector can be used (see Miller et al., Meth. Enzymol. 217:581-599 (1993)). These retroviral vectors contain the components necessary for the correct packaging of the viral genome and integration into the host cell DNA. The nucleic acid sequences encoding the antibody to be used in gene therapy are cloned into one or more vectors, which facilitates delivery of the gene into a patient. More detail about retroviral vectors can be found in Boesen et al., Biotherapy 6:291-302 (1994), which describes the use of a retroviral vector to deliver the mdr1 gene to hematopoietic stem cells in order to make the stem cells more resistant to chemotherapy. Other references illustrating the use of retroviral vectors in gene therapy are: Clowes et al., J. Clin. Invest. 93:644-651 (1994); Kiem et al., Blood 83:1467-1473 (1994); Salmons and Gunzberg, Human Gene Therapy 4:129-141 (1993); and Grossman and Wilson, Curr. Opin. in Genetics and Devel. 3:110-114 (1993).
- 15 Adenoviruses are other viral vectors that can be used in gene therapy. Adenoviruses are especially attractive vehicles for delivering genes to respiratory epithelia. Adenoviruses naturally infect respiratory epithelia where they cause a mild disease. Other targets for adenovirus-based delivery systems are liver, the central nervous system, endothelial cells, and muscle. Adenoviruses have the advantage of being capable of infecting non-dividing cells. Kozarsky and Wilson, Current Opinion in Genetics and Development 3:499-503 (1993) present a review of adenovirus-based gene therapy. Bout et al., Human Gene Therapy 5:3-10 (1994) demonstrated the use of adenovirus vectors to transfer genes to the respiratory epithelia of rhesus monkeys. Other instances of the use of adenoviruses in gene therapy can be found in Rosenfeld et al., Science 252:431-434 (1991); Rosenfeld et al., Cell 68:143- 155 (1992); Mastrangeli et al., J. Clin. Invest. 91:225-234 (1993); PCT Publication WO94/12649; and Wang, et al., Gene Therapy 2:775-783 (1995). In a preferred embodiment, adenovirus vectors are used.
- 30 Adeno-associated virus (AAV) has also been proposed for use in gene therapy (Walsh et al., Proc. Soc. Exp. Biol. Med. 204:289-300 (1993); U.S. Patent No. 5,436,146).

Another approach to gene therapy involves transferring a gene to cells in tissue culture by such methods as electroporation, lipofection, calcium phosphate mediated transfection, or viral infection. Usually, the method of transfer includes the transfer of a selectable marker to the cells. The cells are then placed under selection 5 to isolate those cells that have taken up and are expressing the transferred gene. Those cells are then delivered to a patient.

In this embodiment, the nucleic acid is introduced into a cell prior to administration in vivo of the resulting recombinant cell. Such introduction can be carried out by any method known in the art, including but not limited to transfection, 10 electroporation, microinjection, infection with a viral or bacteriophage vector containing the nucleic acid sequences, cell fusion, chromosome-mediated gene transfer, microcell-mediated gene transfer, spheroplast fusion, etc. Numerous techniques are known in the art for the introduction of foreign genes into cells (see, e.g., Loeffler and Behr, Meth. Enzymol. 217:599-618 (1993); Cohen et al., Meth. 15 Enzymol. 217:618-644 (1993); Cline, Pharmac. Ther. 29:69-92m (1985) and may be used in accordance with the present invention, provided that the necessary developmental and physiological functions of the recipient cells are not disrupted. The technique should provide for the stable transfer of the nucleic acid to the cell, so 20 that the nucleic acid is expressible by the cell and preferably heritable and expressible by its cell progeny.

The resulting recombinant cells can be delivered to a patient by various methods known in the art. Recombinant blood cells (e.g., hematopoietic stem or progenitor cells) are preferably administered intravenously. The amount of cells envisioned for use depends on the desired effect, patient state, etc., and can be 25 determined by one skilled in the art.

Cells into which a nucleic acid can be introduced for purposes of gene therapy encompass any desired, available cell type, and include but are not limited to epithelial cells, endothelial cells, keratinocytes, fibroblasts, muscle cells, hepatocytes; blood cells such as Tlymphocytes, Blymphocytes, monocytes, macrophages, 30 neutrophils, eosinophils, megakaryocytes, granulocytes; various stem or progenitor

cells, in particular hematopoietic stem or progenitor cells, e.g., as obtained from bone marrow, umbilical cord blood, peripheral blood, fetal liver, etc.

In a preferred embodiment, the cell used for gene therapy is autologous to the patient.

5        In an embodiment in which recombinant cells are used in gene therapy, nucleic acid sequences encoding an antibody are introduced into the cells such that they are expressible by the cells or their progeny, and the recombinant cells are then administered in vivo for therapeutic effect. In a specific embodiment, stem or progenitor cells are used. Any stem and/or progenitor cells which can be isolated and  
10      maintained in vitro can potentially be used in accordance with this embodiment of the present invention (see e.g. PCT Publication WO 94/08598; Stemple and Anderson, Cell 71:973-985 (1992); Rheinwald, Meth. Cell Bio. 21A:229 (1980); and Pittelkow and Scott, Mayo Clinic Proc. 61:771 (1986)).

15      In a specific embodiment, the nucleic acid to be introduced for purposes of gene therapy comprises an inducible promoter operably linked to the coding region, such that expression of the nucleic acid is controllable by controlling the presence or absence of the appropriate inducer of transcription. Demonstration of Therapeutic or Prophylactic Activity

The compounds or pharmaceutical compositions of the invention are  
20      preferably tested in vitro, and then in vivo for the desired therapeutic or prophylactic activity, prior to use in humans. For example, in vitro assays to demonstrate the therapeutic or prophylactic utility of a compound or pharmaceutical composition include, the effect of a compound on a cell line or a patient tissue sample. The effect of the compound or composition on the cell line and/or tissue sample can be  
25      determined utilizing techniques known to those of skill in the art including, but not limited to, rosette formation assays and cell lysis assays. In accordance with the invention, in vitro assays which can be used to determine whether administration of a specific compound is indicated, include in vitro cell culture assays in which a patient tissue sample is grown in culture, and exposed to or otherwise administered a  
30      compound, and the effect of such compound upon the tissue sample is observed.

### Therapeutic/Prophylactic Administration and Composition

The invention provides methods of treatment, inhibition and prophylaxis by administration to a subject of an effective amount of a compound or pharmaceutical composition of the invention, preferably an antibody of the invention. In a preferred aspect, the compound is substantially purified (e.g., substantially free from substances that limit its effect or produce undesired side-effects). The subject is preferably an animal, including but not limited to animals such as cows, pigs, horses, chickens, cats, dogs, etc., and is preferably a mammal, and most preferably human.

Formulations and methods of administration that can be employed when the compound comprises a nucleic acid or an immunoglobulin are described above; additional appropriate formulations and routes of administration can be selected from among those described herein below.

Various delivery systems are known and can be used to administer a compound of the invention, e.g., encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing the compound, receptor-mediated endocytosis (see, e.g., Wu and Wu, J. Biol. Chem. 262:4429-4432 (1987)), construction of a nucleic acid as part of a retroviral or other vector, etc. Methods of introduction include but are not limited to intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes. The compounds or compositions may be administered by any convenient route, for example by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.) and may be administered together with other biologically active agents. Administration can be systemic or local. In addition, it may be desirable to introduce the pharmaceutical compounds or compositions of the invention into the central nervous system by any suitable route, including intraventricular and intrathecal injection; intraventricular injection may be facilitated by an intraventricular catheter, for example, attached to a reservoir, such as an Ommaya reservoir. Pulmonary administration can also be employed, e.g., by use of an inhaler or nebulizer, and formulation with an aerosolizing agent.

In a specific embodiment, it may be desirable to administer the pharmaceutical compounds or compositions of the invention locally to the area in need of treatment;

this may be achieved by, for example, and not by way of limitation, local infusion during surgery, topical application, e.g., in conjunction with a wound dressing after surgery, by injection, by means of a catheter, by means of a suppository, or by means of an implant, said implant being of a porous, non-porous, or gelatinous material,  
5 including membranes, such as sialastic membranes, or fibers. Preferably, when administering a protein, including an antibody, of the invention, care must be taken to use materials to which the protein does not absorb.

In another embodiment, the compound or composition can be delivered in a vesicle, in particular a liposome (see Langer, Science 249:1527-1533 (1990); Treat et  
10 al., in Liposomes in the Therapy of Infectious Disease and Cancer, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 353- 365 (1989); Lopez-Berestein, ibid., pp. 317-327; see generally *ibid.*)

In yet another embodiment, the compound or composition can be delivered in a controlled release system. In one embodiment, a pump may be used (see Langer,  
15 supra; Sefton, CRC Crit. Ref. Biomed. Eng. 14:201 (1987); Buchwald et al., Surgery 88:507 (1980); Saudek et al., N. Engl. J. Med. 321:574 (1989)). In another embodiment, polymeric materials can be used (see Medical Applications of Controlled Release, Langer and Wise (eds.), CRC Pres., Boca Raton, Florida (1974); Controlled Drug Bioavailability, Drug Product Design and Performance, Smolen and  
20 Ball (eds.), Wiley, New York (1984); Ranger and Peppas, J., Macromol. Sci. Rev. Macromol. Chem. 23:61 (1983); see also Levy et al., Science 228:190 (1985); During et al., Ann. Neurol. 25:351 (1989); Howard et al., J.Neurosurg. 71:105 (1989)). In yet another embodiment, a controlled release system can be placed in proximity of the therapeutic target, i.e., the brain, thus requiring only a fraction of the systemic dose  
25 (see, e.g., Goodson, in Medical Applications of Controlled Release, *supra*, vol. 2, pp. 115-138 (1984)).

Other controlled release systems are discussed in the review by Langer (Science 249:1527-1533 (1990)).

In a specific embodiment where the compound of the invention is a nucleic  
30 acid encoding a protein, the nucleic acid can be administered *in vivo* to promote expression of its encoded protein, by constructing it as part of an appropriate nucleic

acid expression vector and administering it so that it becomes intracellular, e.g., by use of a retroviral vector (see U.S. Patent No. 4,980,286), or by direct injection, or by use of microparticle bombardment (e.g., a gene gun; Biostatic, Dupont), or coating with lipids or cell-surface receptors or transfecting agents, or by administering it in linkage to a homeobox- like peptide which is known to enter the nucleus (see e.g., Joliot et al., Proc. Natl. Acad. Sci. USA 88:1864-1868 (1991)), etc. Alternatively, a nucleic acid can be introduced intracellularly and incorporated within host cell DNA for expression, by homologous recombination.

The present invention also provides pharmaceutical compositions. Such compositions comprise a therapeutically effective amount of a compound, and a pharmaceutically acceptable carrier. In a specific embodiment, the term "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. The term "carrier" refers to a diluent, adjuvant, excipient, or vehicle with which the therapeutic is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a preferred carrier when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. The composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. These compositions can take the form of solutions, suspensions, emulsion, tablets, pills, capsules, powders, sustained-release formulations and the like. The composition can be formulated as a suppository, with traditional binders and carriers such as triglycerides. Oral formulation can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. Examples of suitable

pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by E.W. Martin. Such compositions will contain a therapeutically effective amount of the compound, preferably in purified form, together with a suitable amount of carrier so as to provide the form for proper administration to the patient. The formulation 5 should suit the mode of administration.

In a preferred embodiment, the composition is formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous administration to human beings. Typically, compositions for intravenous administration are solutions in sterile isotonic aqueous buffer. Where necessary, the 10 composition may also include a solubilizing agent and a local anesthetic such as lignocaine to ease pain at the site of the injection. Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent. Where the 15 composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the composition is administered by injection, an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.

- The compounds of the invention can be formulated as neutral or salt forms. 20 Pharmaceutically acceptable salts include those formed with anions such as those derived from hydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc., and those formed with cations such as those derived from sodium, potassium, ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2-ethylamino ethanol, histidine, procaine, etc.
- 25 The amount of the compound of the invention which will be effective in the treatment, inhibition and prevention of a disease or disorder associated with aberrant expression and/or activity of a polypeptide of the invention can be determined by standard clinical techniques. In addition, in vitro assays may optionally be employed to help identify optimal dosage ranges. The precise dose to be employed in the 30 formulation will also depend on the route of administration, and the seriousness of the disease or disorder, and should be decided according to the judgment of the

practitioner and each patient's circumstances. Effective doses may be extrapolated from dose-response curves derived from in vitro or animal model test systems..

For antibodies, the dosage administered to a patient is typically 0.1 mg/kg to 100 mg/kg of the patient's body weight. Preferably, the dosage administered to a 5 patient is between 0.1 mg/kg and 20 mg/kg of the patient's body weight, more preferably 1 mg/kg to 10 mg/kg of the patient's body weight. Generally, human antibodies have a longer half-life within the human body than antibodies from other species due to the immune response to the foreign polypeptides. Thus, lower dosages of human antibodies and less frequent administration is often possible. Further, the 10 dosage and frequency of administration of antibodies of the invention may be reduced by enhancing uptake and tissue penetration (e.g., into the brain) of the antibodies by modifications such as, for example, lipidation.

The invention also provides a pharmaceutical pack or kit comprising one or 15 more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. Diagnosis and Imaging

20 Labeled antibodies, and derivatives and analogs thereof, which specifically bind to a polypeptide of interest can be used for diagnostic purposes to detect, diagnose, or monitor diseases, disorders, and/or conditions associated with the aberrant expression and/or activity of a polypeptide of the invention. The invention provides for the detection of aberrant expression of a polypeptide of interest, 25 comprising (a) assaying the expression of the polypeptide of interest in cells or body fluid of an individual using one or more antibodies specific to the polypeptide interest and (b) comparing the level of gene expression with a standard gene expression level, whereby an increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is indicative of aberrant expression.

30 The invention provides a diagnostic assay for diagnosing a disorder, comprising (a) assaying the expression of the polypeptide of interest in cells or body

fluid of an individual using one or more antibodies specific to the polypeptide interest and (b) comparing the level of gene expression with a standard gene expression level, whereby an increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is indicative of a particular disorder. With 5 respect to cancer, the presence of a relatively high amount of transcript in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier 10 thereby preventing the development or further progression of the cancer.

Antibodies of the invention can be used to assay protein levels in a biological sample using classical immunohistological methods known to those of skill in the art (e.g., see Jalkanen, et al., *J. Cell. Biol.* 101:976-985 (1985); Jalkanen, et al., *J. Cell. Biol.* 105:3087-3096 (1987)). Other antibody-based methods useful for detecting 15 protein gene expression include immunoassays, such as the enzyme linked immunosorbent assay (ELISA) and the radioimmunoassay (RIA). Suitable antibody assay labels are known in the art and include enzyme labels, such as, glucose oxidase; radioisotopes, such as iodine (125I, 121I), carbon (14C), sulfur (35S), tritium (3H), indium (112In), and technetium (99Tc); luminescent labels, such as luminol; and 20 fluorescent labels, such as fluorescein and rhodamine, and biotin.

One aspect of the invention is the detection and diagnosis of a disease or disorder associated with aberrant expression of a polypeptide of interest in an animal, preferably a mammal and most preferably a human. In one embodiment, diagnosis comprises: a) administering (for example, parenterally, subcutaneously, or 25 intraperitoneally) to a subject an effective amount of a labeled molecule which specifically binds to the polypeptide of interest; b) waiting for a time interval following the administering for permitting the labeled molecule to preferentially concentrate at sites in the subject where the polypeptide is expressed (and for unbound labeled molecule to be cleared to background level); c) determining 30 background level; and d) detecting the labeled molecule in the subject, such that detection of labeled molecule above the background level indicates that the subject

has a particular disease or disorder associated with aberrant expression of the polypeptide of interest. Background level can be determined by various methods including, comparing the amount of labeled molecule detected to a standard value previously determined for a particular system.

- 5        It will be understood in the art that the size of the subject and the imaging system used will determine the quantity of imaging moiety needed to produce diagnostic images. In the case of a radioisotope moiety, for a human subject, the quantity of radioactivity injected will normally range from about 5 to 20 millicuries of  $^{99m}\text{Tc}$ . The labeled antibody or antibody fragment will then preferentially  
10      accumulate at the location of cells which contain the specific protein. In vivo tumor imaging is described in S.W. Burchiel et al., "Immunopharmacokinetics of Radiolabeled Antibodies and Their Fragments." (Chapter 13 in Tumor Imaging: The Radiochemical Detection of Cancer, S.W. Burchiel and B. A. Rhodes, eds., Masson Publishing Inc. (1982).  
15      Depending on several variables, including the type of label used and the mode of administration, the time interval following the administration for permitting the labeled molecule to preferentially concentrate at sites in the subject and for unbound labeled molecule to be cleared to background level is 6 to 48 hours or 6 to 24 hours or 6 to 12 hours. In another embodiment the time interval following administration is 5  
20      to 20 days or 5 to 10 days.

In an embodiment, monitoring of the disease or disorder is carried out by repeating the method for diagnosing the disease or disease, for example, one month after initial diagnosis, six months after initial diagnosis, one year after initial diagnosis, etc.

- 25      Presence of the labeled molecule can be detected in the patient using methods known in the art for in vivo scanning. These methods depend upon the type of label used. Skilled artisans will be able to determine the appropriate method for detecting a particular label. Methods and devices that may be used in the diagnostic methods of the invention include, but are not limited to, computed tomography (CT), whole body  
30      scan such as position emission tomography (PET), magnetic resonance imaging (MRI), and sonography.

In a specific embodiment, the molecule is labeled with a radioisotope and is detected in the patient using a radiation responsive surgical instrument (Thurston et al., U.S. Patent No. 5,441,050). In another embodiment, the molecule is labeled with a fluorescent compound and is detected in the patient using a fluorescence responsive scanning instrument. In another embodiment, the molecule is labeled with a positron emitting metal and is detected in the patient using positron emission-tomography. In yet another embodiment, the molecule is labeled with a paramagnetic label and is detected in a patient using magnetic resonance imaging (MRI). Kits

The present invention provides kits that can be used in the above methods. In one embodiment, a kit comprises an antibody of the invention, preferably a purified antibody, in one or more containers. In a specific embodiment, the kits of the present invention contain a substantially isolated polypeptide comprising an epitope which is specifically immunoreactive with an antibody included in the kit. Preferably, the kits of the present invention further comprise a control antibody which does not react with the polypeptide of interest. In another specific embodiment, the kits of the present invention contain a means for detecting the binding of an antibody to a polypeptide of interest (e.g., the antibody may be conjugated to a detectable substrate such as a fluorescent compound, an enzymatic substrate, a radioactive compound or a luminescent compound, or a second antibody which recognizes the first antibody may be conjugated to a detectable substrate).

In another specific embodiment of the present invention, the kit is a diagnostic kit for use in screening serum containing antibodies specific against proliferative and/or cancerous polynucleotides and polypeptides. Such a kit may include a control antibody that does not react with the polypeptide of interest. Such a kit may include a substantially isolated polypeptide antigen comprising an epitope which is specifically immunoreactive with at least one anti-polypeptide antigen antibody. Further, such a kit includes means for detecting the binding of said antibody to the antigen (e.g., the antibody may be conjugated to a fluorescent compound such as fluorescein or rhodamine which can be detected by flow cytometry). In specific embodiments, the kit may include a recombinantly produced or chemically synthesized polypeptide antigen. The polypeptide antigen of the kit may also be attached to a solid support.

In a more specific embodiment the detecting means of the above-described kit includes a solid support to which said polypeptide antigen is attached. Such a kit may also include a non-attached reporter-labeled anti-human antibody. In this embodiment, binding of the antibody to the polypeptide antigen can be detected by 5 binding of the said reporter-labeled antibody.

In an additional embodiment, the invention includes a diagnostic kit for use in screening serum containing antigens of the polypeptide of the invention. The diagnostic kit includes a substantially isolated antibody specifically immunoreactive with polypeptide or polynucleotide antigens, and means for detecting the binding of 10 the polynucleotide or polypeptide antigen to the antibody. In one embodiment, the antibody is attached to a solid support. In a specific embodiment, the antibody may be a monoclonal antibody. The detecting means of the kit may include a second, labeled monoclonal antibody. Alternatively, or in addition, the detecting means may include a labeled, competing antigen.

15       In one diagnostic configuration, test serum is reacted with a solid phase reagent having a surface-bound antigen obtained by the methods of the present invention. After binding with specific antigen antibody to the reagent and removing unbound serum components by washing, the reagent is reacted with reporter-labeled anti-human antibody to bind reporter to the reagent in proportion to the amount of 20 bound anti-antigen antibody on the solid support. The reagent is again washed to remove unbound labeled antibody, and the amount of reporter associated with the reagent is determined. Typically, the reporter is an enzyme which is detected by incubating the solid phase in the presence of a suitable fluorometric, luminescent or colorimetric substrate (Sigma, St. Louis, MO).

25       The solid surface reagent in the above assay is prepared by known techniques for attaching protein material to solid support material, such as polymeric beads, dip sticks, 96-well plate or filter material. These attachment methods generally include non-specific adsorption of the protein to the support or covalent attachment of the protein, typically through a free amine group, to a chemically reactive group on the 30 solid support, such as an activated carboxyl, hydroxyl, or aldehyde group.

Alternatively, streptavidin coated plates can be used in conjunction with biotinylated antigen(s).

Thus, the invention provides an assay system or kit for carrying out this diagnostic method. The kit generally includes a support with surface- bound

- 5 recombinant antigens, and a reporter-labeled anti-human antibody for detecting surface-bound anti-antigen antibody.

### Fusion Proteins

- 10 Any polypeptide of the present invention can be used to generate fusion proteins. For example, the polypeptide of the present invention, when fused to a second protein, can be used as an antigenic tag. Antibodies raised against the polypeptide of the present invention can be used to indirectly detect the second protein by binding to the polypeptide. Moreover, because secreted proteins target 15 cellular locations based on trafficking signals, the polypeptides of the present invention can be used as targeting molecules once fused to other proteins.

Examples of domains that can be fused to polypeptides of the present invention include not only heterologous signal sequences, but also other heterologous functional regions. The fusion does not necessarily need to be direct, but may occur 20 through linker sequences.

Moreover, fusion proteins may also be engineered to improve characteristics of the polypeptide of the present invention. For instance, a region of additional amino acids, particularly charged amino acids, may be added to the N-terminus of the polypeptide to improve stability and persistence during purification from the host cell 25 or subsequent handling and storage. Also, peptide moieties may be added to the polypeptide to facilitate purification. Such regions may be removed prior to final preparation of the polypeptide. The addition of peptide moieties to facilitate handling of polypeptides are familiar and routine techniques in the art.

Moreover, polypeptides of the present invention, including fragments, and 30 specifically epitopes, can be combined with parts of the constant domain of immunoglobulins (IgA, IgE, IgG, IgM) or portions thereof (CH1, CH2, CH3, and any

combination thereof, including both entire domains and portions thereof), resulting in chimeric polypeptides. These fusion proteins facilitate purification and show an increased half-life in vivo. One reported example describes chimeric proteins consisting of the first two domains of the human CD4-polypeptide and various 5 domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. (EP A 394,827; Traunecker et al., Nature 331:84-86 (1988).) Fusion proteins having disulfide-linked dimeric structures (due to the IgG) can also be more efficient in binding and neutralizing other molecules, than the monomeric secreted protein or protein fragment alone. (Fountoulakis et al., J. Biochem. 10 270:3958-3964 (1995).)

Similarly, EP-A-O 464 533 (Canadian counterpart 2045869) discloses fusion proteins comprising various portions of constant region of immunoglobulin molecules together with another human protein or part thereof. In many cases, the Fc part in a fusion protein is beneficial in therapy and diagnosis, and thus can result in, for 15 example, improved pharmacokinetic properties. (EP-A 0232 262.) Alternatively, deleting the Fc part after the fusion protein has been expressed, detected, and purified, would be desired. For example, the Fc portion may hinder therapy and diagnosis if the fusion protein is used as an antigen for immunizations. In drug discovery, for example, human proteins, such as hIL-5, have been fused with Fc portions for the 20 purpose of high-throughput screening assays to identify antagonists of hIL-5. (See, D. Bennett et al., J. Molecular Recognition 8:52-58 (1995); K. Johanson et al., J. Biol. Chem. 270:9459-9471 (1995).)

Moreover, the polypeptides of the present invention can be fused to marker sequences, such as a peptide which facilitates purification of the fused polypeptide. 25 In preferred embodiments, the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA, 91311), among others, many of which are commercially available. As described in Gentz et al., Proc. Natl. Acad. Sci. USA 86:821-824 (1989), for instance, hexa-histidine provides for convenient purification of the fusion protein. 30 Another peptide tag useful for purification, the "HA" tag, corresponds to an epitope

derived from the influenza hemagglutinin protein. (Wilson et al., Cell 37:767 (1984).)

Thus, any of these above fusions can be engineered using the polynucleotides or the polypeptides of the present invention.

5

### Vectors, Host Cells, and Protein Production

The present invention also relates to vectors containing the polynucleotide of the present invention, host cells, and the production of polypeptides by recombinant techniques. The vector may be, for example, a phage, plasmid, viral, or retroviral 10 vector. Retroviral vectors may be replication competent or replication defective. In the latter case, viral propagation generally will occur only in complementing host cells.

The polynucleotides may be joined to a vector containing a selectable marker for propagation in a host. Generally, a plasmid vector is introduced in a precipitate, 15 such as a calcium phosphate precipitate, or in a complex with a charged lipid. If the vector is a virus, it may be packaged in vitro using an appropriate packaging cell line and then transduced into host cells.

The polynucleotide insert should be operatively linked to an appropriate promoter, such as the phage lambda PL promoter, the E. coli lac, trp, phoA and tac 20 promoters, the SV40 early and late promoters and promoters of retroviral LTRs, to name a few. Other suitable promoters will be known to the skilled artisan. The expression constructs will further contain sites for transcription initiation, termination, and, in the transcribed region, a ribosome binding site for translation. The coding portion of the transcripts expressed by the constructs will preferably include a 25 translation initiating codon at the beginning and a termination codon (UAA, UGA or UAG) appropriately positioned at the end of the polypeptide to be translated.

As indicated, the expression vectors will preferably include at least one selectable marker. Such markers include dihydrofolate reductase, G418 or neomycin resistance for eukaryotic cell culture and tetracycline, kanamycin or ampicillin 30 resistance genes for culturing in E. coli and other bacteria. Representative examples of appropriate hosts include, but are not limited to, bacterial cells, such as E. coli,

Streptomyces and Salmonella typhimurium cells; fungal cells, such as yeast cells (e.g., Saccharomyces cerevisiae or Pichia pastoris (ATCC Accession No. 201178)); insect cells such as Drosophila S2 and Spodoptera Sf9 cells; animal cells such as CHO, COS, 293, and Bowes melanoma cells; and plant cells. Appropriate culture  
5 media and conditions for the above-described host cells are known in the art.

Among vectors preferred for use in bacteria include pQE70, pQE60 and pQE-9, available from QIAGEN, Inc.; pBluescript vectors, Phagescript vectors, pNH8A, pNH16a, pNH18A, pNH46A, available from Stratagene Cloning Systems, Inc.; and ptrc99a, pKK223-3, pKK233-3, pDR540; pRIT5 available from Pharmacia Biotech,  
10 Inc. Among preferred eukaryotic vectors are pWLNEO, pSV2CAT, pOG44, pXT1 and pSG available from Stratagene; and pSVK3, pBPV, pMSG and pSVL available from Pharmacia. Preferred expression vectors for use in yeast systems include, but are not limited to pYES2, pYD1, pTEF1/Zeo, pYES2/GS,pPICZ,pGAPZ, pGAPZalph,  
15 pPIC9, pPIC3.5, pHIL-D2, pHIL-S1, pPIC3.5K, pPIC9K, and PAO815 (all available from Invitrogen, Carlsbad, CA). Other suitable vectors will be readily apparent to the skilled artisan.

Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-dextran mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection, or other methods. Such methods  
20 are described in many standard laboratory manuals, such as Davis et al., Basic Methods In Molecular Biology (1986). It is specifically contemplated that the polypeptides of the present invention may in fact be expressed by a host cell lacking a recombinant vector.

A polypeptide of this invention can be recovered and purified from  
25 recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography ("HPLC") is employed for  
30 purification.

Polypeptides of the present invention, and preferably the secreted form, can also be recovered from: products purified from natural sources, including bodily fluids, tissues and cells, whether directly isolated or cultured; products of chemical synthetic procedures; and products produced by recombinant techniques from a 5 prokaryotic or eukaryotic host, including, for example, bacterial, yeast, higher plant, insect, and mammalian cells. Depending upon the host employed in a recombinant production procedure, the polypeptides of the present invention may be glycosylated or may be non-glycosylated. In addition, polypeptides of the invention may also include an initial modified methionine residue, in some cases as a result of host- 10 mediated processes. Thus, it is well known in the art that the N-terminal methionine encoded by the translation initiation codon generally is removed with high efficiency from any protein after translation in all eukaryotic cells. While the N-terminal methionine on most proteins also is efficiently removed in most prokaryotes, for some 15 proteins, this prokaryotic removal process is inefficient, depending on the nature of the amino acid to which the N-terminal methionine is covalently linked.

In one embodiment, the yeast *Pichia pastoris* is used to express the polypeptide of the present invention in a eukaryotic system. *Pichia pastoris* is a methylotrophic yeast which can metabolize methanol as its sole carbon source. A main step in the methanol metabolism pathway is the oxidation of methanol to 20 formaldehyde using O<sub>2</sub>. This reaction is catalyzed by the enzyme alcohol oxidase. In order to metabolize methanol as its sole carbon source, *Pichia pastoris* must generate high levels of alcohol oxidase due, in part, to the relatively low affinity of alcohol 25 oxidase for O<sub>2</sub>. Consequently, in a growth medium depending on methanol as a main carbon source, the promoter region of one of the two alcohol oxidase genes (*AOX1*) is highly active. In the presence of methanol, alcohol oxidase produced from the *AOX1* gene comprises up to approximately 30% of the total soluble protein in *Pichia pastoris*. See, Ellis, S.B., et al., *Mol. Cell. Biol.* 5:1111-21 (1985); Koutz, P.J., et al., *Yeast* 5:167-77 (1989); Tschopp, J.F., et al., *Nucl. Acids Res.* 15:3859-76 (1987). Thus, a heterologous coding sequence, such as, for example, a polynucleotide of the 30 present invention, under the transcriptional regulation of all or part of the *AOX1*

regulatory sequence is expressed at exceptionally high levels in *Pichia* yeast grown in the presence of methanol.

In one example, the plasmid vector pPIC9K is used to express DNA encoding a polypeptide of the invention, as set forth herein, in a *Pichia* yeast system essentially as described in "Pichia Protocols: Methods in Molecular Biology," D.R. Higgins and J. Cregg, eds. The Humana Press, Totowa, NJ, 1998. This expression vector allows expression and secretion of a protein of the invention by virtue of the strong *AOX1* promoter linked to the *Pichia pastoris* alkaline phosphatase (PHO) secretory signal peptide (i.e., leader) located upstream of a multiple cloning site.

Many other yeast vectors could be used in place of pPIC9K, such as, pYES2, pYD1, pTEF1/Zeo, pYES2/GS, pPICZ, pGAPZ, pGAPZalpha, pPIC9, pPIC3.5, pHIL-D2, pHIL-S1, pPIC3.5K, and PAO815, as one skilled in the art would readily appreciate, as long as the proposed expression construct provides appropriately located signals for transcription, translation, secretion (if desired), and the like, including an in-frame AUG as required.

In another embodiment, high-level expression of a heterologous coding sequence, such as, for example, a polynucleotide of the present invention, may be achieved by cloning the heterologous polynucleotide of the invention into an expression vector such as, for example, pGAPZ or pGAPZalpha, and growing the yeast culture in the absence of methanol.

In addition to encompassing host cells containing the vector constructs discussed herein, the invention also encompasses primary, secondary, and immortalized host cells of vertebrate origin, particularly mammalian origin, that have been engineered to delete or replace endogenous genetic material (e.g., coding sequence), and/or to include genetic material (e.g., heterologous polynucleotide sequences) that is operably associated with the polynucleotides of the invention, and which activates, alters, and/or amplifies endogenous polynucleotides. For example, techniques known in the art may be used to operably associate heterologous control regions (e.g., promoter and/or enhancer) and endogenous polynucleotide sequences via homologous recombination, resulting in the formation of a new transcription unit

(see, e.g., U.S. Patent No. 5,641,670, issued June 24, 1997; U.S. Patent No. 5,733,761, issued March 31, 1998; International Publication No. WO 96/29411, published September 26, 1996; International Publication No. WO 94/12650, published August 4, 1994; Koller et al., Proc. Natl. Acad. Sci. USA 86:8932-8935 5 (1989); and Zijlstra et al., Nature 342:435-438 (1989), the disclosures of each of which are incorporated by reference in their entireties).

In addition, polypeptides of the invention can be chemically synthesized using techniques known in the art (e.g., see Creighton, 1983, Proteins: Structures and Molecular Principles, W.H. Freeman & Co., N.Y., and Hunkapiller et al., *Nature*, 10 310:105-111 (1984)). For example, a polypeptide corresponding to a fragment of a polypeptide sequence of the invention can be synthesized by use of a peptide synthesizer. Furthermore, if desired, nonclassical amino acids or chemical amino acid analogs can be introduced as a substitution or addition into the polypeptide sequence. Non-classical amino acids include, but are not limited to, to the D-isomers of the 15 common amino acids, 2,4-diaminobutyric acid,  $\alpha$ -amino isobutyric acid, 4-aminobutyric acid, Abu, 2-amino butyric acid, g-Abu, e-Ahx, 6-amino hexanoic acid, Aib, 2-amino isobutyric acid, 3-amino propionic acid, ornithine, norleucine, norvaline, hydroxyproline, sarcosine, citrulline, homocitrulline, cysteic acid, t-butylglycine, t-butylalanine, phenylglycine, cyclohexylalanine,  $\beta$ -alanine, fluoro-20 amino acids, designer amino acids such as  $\beta$ -methyl amino acids, Ca-methyl amino acids, Na-methyl amino acids, and amino acid analogs in general. Furthermore, the amino acid can be D (dextrorotary) or L (levorotary).

The invention encompasses polypeptides which are differentially modified during or after translation, e.g., by glycosylation, acetylation, phosphorylation, 25 amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to an antibody molecule or other cellular ligand, etc. Any of numerous chemical modifications may be carried out by known techniques, including but not limited, to specific chemical cleavage by cyanogen bromide, trypsin, chymotrypsin, papain, V8 protease, NaBH<sub>4</sub>; acetylation, formylation, oxidation, reduction; metabolic 30 synthesis in the presence of tunicamycin; etc.

Additional post-translational modifications encompassed by the invention include, for example, e.g., N-linked or O-linked carbohydrate chains, processing of N-terminal or C-terminal ends), attachment of chemical moieties to the amino acid backbone, chemical modifications of N-linked or O-linked carbohydrate chains, and 5 addition or deletion of an N-terminal methionine residue as a result of prokaryotic host cell expression. The polypeptides may also be modified with a detectable label, such as an enzymatic, fluorescent, isotopic or affinity label to allow for detection and isolation of the protein.

Also provided by the invention are chemically modified derivatives of the 10 polypeptides of the invention which may provide additional advantages such as increased solubility, stability and circulating time of the polypeptide, or decreased immunogenicity (see U.S. Patent NO: 4,179,337). The chemical moieties for derivitization may be selected from water soluble polymers such as polyethylene glycol, ethylene glycol/propylene glycol copolymers, carboxymethylcellulose, 15 dextran, polyvinyl alcohol and the like. The polypeptides may be modified at random positions within the molecule, or at predetermined positions within the molecule and may include one, two, three or more attached chemical moieties.

The polymer may be of any molecular weight, and may be branched or unbranched. For polyethylene glycol, the preferred molecular weight is between 20 about 1 kDa and about 100 kDa (the term "about" indicating that in preparations of polyethylene glycol, some molecules will weigh more, some less, than the stated molecular weight) for ease in handling and manufacturing. Other sizes may be used, depending on the desired therapeutic profile (e.g., the duration of sustained release desired, the effects, if any on biological activity, the ease in handling, the degree or 25 lack of antigenicity and other known effects of the polyethylene glycol to a therapeutic protein or analog).

The polyethylene glycol molecules (or other chemical moieties) should be attached to the protein with consideration of effects on functional or antigenic domains of the protein. There are a number of attachment methods available to those 30 skilled in the art, e.g., EP 0 401 384, herein incorporated by reference (coupling PEG to G-CSF), see also Malik et al., Exp. Hematol. 20:1028-1035 (1992) (reporting

pegylation of GM-CSF using tresyl chloride). For example, polyethylene glycol may be covalently bound through amino acid residues via a reactive group, such as, a free amino or carboxyl group. Reactive groups are those to which an activated polyethylene glycol molecule may be bound. The amino acid residues having a free 5 amino group may include lysine residues and the N-terminal amino acid residues; those having a free carboxyl group may include aspartic acid residues glutamic acid residues and the C-terminal amino acid residue. Sulfhydryl groups may also be used as a reactive group for attaching the polyethylene glycol molecules. Preferred for therapeutic purposes is attachment at an amino group, such as attachment at the 10 N-terminus or lysine group.

One may specifically desire proteins chemically modified at the N-terminus. Using polyethylene glycol as an illustration of the present composition, one may select from a variety of polyethylene glycol molecules (by molecular weight, branching, etc.), the proportion of polyethylene glycol molecules to protein 15 (polypeptide) molecules in the reaction mix, the type of pegylation reaction to be performed, and the method of obtaining the selected N-terminally pegylated protein. The method of obtaining the N-terminally pegylated preparation (i.e., separating this moiety from other monopegylated moieties if necessary) may be by purification of the N-terminally pegylated material from a population of pegylated protein molecules. 20 Selective proteins chemically modified at the N-terminus modification may be accomplished by reductive alkylation which exploits differential reactivity of different types of primary amino groups (lysine versus the N-terminal) available for derivatization in a particular protein. Under the appropriate reaction conditions, substantially selective derivatization of the protein at the N-terminus with a carbonyl 25 group containing polymer is achieved.

The polypeptides of the invention may be in monomers or multimers (i.e., dimers, trimers, tetramers and higher multimers). Accordingly, the present invention relates to monomers and multimers of the polypeptides of the invention, their preparation, and compositions (preferably, *Therapeutics*) containing them. In specific 30 embodiments, the polypeptides of the invention are monomers, dimers, trimers or

tetramers. In additional embodiments, the multimers of the invention are at least dimers, at least trimers, or at least tetramers.

Multimers encompassed by the invention may be homomers or heteromers.

As used herein, the term homomer, refers to a multimer containing only polypeptides corresponding to the amino acid sequence of SEQ ID NO:Y or encoded by the cDNA contained in a deposited clone (including fragments, variants, splice variants, and fusion proteins, corresponding to these polypeptides as described herein). These homomers may contain polypeptides having identical or different amino acid sequences. In a specific embodiment, a homomer of the invention is a multimer containing only polypeptides having an identical amino acid sequence. In another specific embodiment, a homomer of the invention is a multimer containing polypeptides having different amino acid sequences. In specific embodiments, the multimer of the invention is a homodimer (*e.g.*, containing polypeptides having identical or different amino acid sequences) or a homotrimer (*e.g.*, containing polypeptides having identical and/or different amino acid sequences). In additional embodiments, the homomeric multimer of the invention is at least a homodimer, at least a homotrimer, or at least a homotetramer.

As used herein, the term heteromer refers to a multimer containing one or more heterologous polypeptides (*i.e.*, polypeptides of different proteins) in addition to the polypeptides of the invention. In a specific embodiment, the multimer of the invention is a heterodimer, a heterotrimer, or a heterotetramer. In additional embodiments, the heteromeric multimer of the invention is at least a heterodimer, at least a heterotrimer, or at least a heterotetramer.

Multimers of the invention may be the result of hydrophobic, hydrophilic, ionic and/or covalent associations and/or may be indirectly linked, by for example, liposome formation. Thus, in one embodiment, multimers of the invention, such as, for example, homodimers or homotrimers, are formed when polypeptides of the invention contact one another in solution. In another embodiment, heteromultimers of the invention, such as, for example, heterotrimers or heterotetramers, are formed when polypeptides of the invention contact antibodies to the polypeptides of the invention (including antibodies to the heterologous polypeptide sequence in a fusion

protein of the invention) in solution. In other embodiments, multimers of the invention are formed by covalent associations with and/or between the polypeptides of the invention. Such covalent associations may involve one or more amino acid residues contained in the polypeptide sequence (e.g., that recited in the sequence listing, or contained in the polypeptide encoded by a deposited clone). In one instance, the covalent associations are cross-linking between cysteine residues located within the polypeptide sequences which interact in the native (i.e., naturally occurring) polypeptide. In another instance, the covalent associations are the consequence of chemical or recombinant manipulation. Alternatively, such covalent associations may involve one or more amino acid residues contained in the heterologous polypeptide sequence in a fusion protein of the invention.

In one example, covalent associations are between the heterologous sequence contained in a fusion protein of the invention (see, e.g., US Patent Number 5,478,925). In a specific example, the covalent associations are between the heterologous sequence contained in an Fc fusion protein of the invention (as described herein). In another specific example, covalent associations of fusion proteins of the invention are between heterologous polypeptide sequence from another protein that is capable of forming covalently associated multimers, such as for example, oseteoprotegerin (see, e.g., International Publication NO: WO 98/49305, the contents of which are herein incorporated by reference in its entirety). In another embodiment, two or more polypeptides of the invention are joined through peptide linkers. Examples include those peptide linkers described in U.S. Pat. No. 5,073,627 (hereby incorporated by reference). Proteins comprising multiple polypeptides of the invention separated by peptide linkers may be produced using conventional recombinant DNA technology.

Another method for preparing multimer polypeptides of the invention involves use of polypeptides of the invention fused to a leucine zipper or isoleucine zipper polypeptide sequence. Leucine zipper and isoleucine zipper domains are polypeptides that promote multimerization of the proteins in which they are found. Leucine zippers were originally identified in several DNA-binding proteins (Landschulz et al., Science 240:1759, (1988)), and have since been found in a variety of different

proteins. Among the known leucine zippers are naturally occurring peptides and derivatives thereof that dimerize or trimerize. Examples of leucine zipper domains suitable for producing soluble multimeric proteins of the invention are those described in PCT application WO 94/10308, hereby incorporated by reference. Recombinant 5 fusion proteins comprising a polypeptide of the invention fused to a polypeptide sequence that dimerizes or trimerizes in solution are expressed in suitable host cells, and the resulting soluble multimeric fusion protein is recovered from the culture supernatant using techniques known in the art.

Trimeric polypeptides of the invention may offer the advantage of enhanced 10 biological activity. Preferred leucine zipper moieties and isoleucine moieties are those that preferentially form trimers. One example is a leucine zipper derived from lung surfactant protein D (SPD), as described in Hoppe et al. (FEBS Letters 344:191, (1994)) and in U.S. patent application Ser. No. 08/446,922, hereby incorporated by reference. Other peptides derived from naturally occurring trimeric proteins may be 15 employed in preparing trimeric polypeptides of the invention.

In another example, proteins of the invention are associated by interactions between Flag® polypeptide sequence contained in fusion proteins of the invention containing Flag® polypeptide sequence. In a further embodiment, associations 20 proteins of the invention are associated by interactions between heterologous polypeptide sequence contained in Flag® fusion proteins of the invention and anti-Flag® antibody.

The multimers of the invention may be generated using chemical techniques 25 known in the art. For example, polypeptides desired to be contained in the multimers of the invention may be chemically cross-linked using linker molecules and linker molecule length optimization techniques known in the art (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety).

Additionally, multimers of the invention may be generated using techniques known in the art to form one or more inter-molecule cross-links between the cysteine residues located within the sequence of the polypeptides desired to be contained in the 30 multimer (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). Further, polypeptides of the invention may be routinely

modified by the addition of cysteine or biotin to the C terminus or N-terminus of the polypeptide and techniques known in the art may be applied to generate multimers containing one or more of these modified polypeptides (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). Additionally,

5    techniques known in the art may be applied to generate liposomes containing the polypeptide components desired to be contained in the multimer of the invention (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety).

Alternatively, multimers of the invention may be generated using genetic engineering techniques known in the art. In one embodiment, polypeptides contained in multimers of the invention are produced recombinantly using fusion protein technology described herein or otherwise known in the art (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). In a specific embodiment, polynucleotides coding for a homodimer of the invention are

10    generated by ligating a polynucleotide sequence encoding a polypeptide of the invention to a sequence encoding a linker polypeptide and then further to a synthetic polynucleotide encoding the translated product of the polypeptide in the reverse orientation from the original C-terminus to the N-terminus (lacking the leader sequence) (see, e.g., US Patent Number 5,478,925, which is herein incorporated by

15    reference in its entirety). In another embodiment, recombinant techniques described herein or otherwise known in the art are applied to generate recombinant polypeptides of the invention which contain a transmembrane domain (or hydrophobic or signal peptide) and which can be incorporated by membrane reconstitution techniques into liposomes (see, e.g., US Patent Number 5,478,925, which is herein incorporated by

20    reference in its entirety).

25   

#### Uses of the Polynucleotides

Each of the polynucleotides identified herein can be used in numerous ways as reagents. The following description should be considered exemplary and utilizes

30    known techniques.

The polynucleotides of the present invention are useful for chromosome identification. There exists an ongoing need to identify new chromosome markers, since few chromosome marking reagents, based on actual sequence data (repeat polymorphisms), are presently available. Each polynucleotide of the present 5 invention can be used as a chromosome marker.

Briefly, sequences can be mapped to chromosomes by preparing PCR primers (preferably 15-25 bp) from the sequences shown in SEQ ID NO:X. Primers can be selected using computer analysis so that primers do not span more than one predicted exon in the genomic DNA. These primers are then used for PCR screening of 10 somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to the SEQ ID NO:X will yield an amplified fragment.

Similarly, somatic hybrids provide a rapid method of PCR mapping the polynucleotides to particular chromosomes. Three or more clones can be assigned per 15 day using a single thermal cycler. Moreover, sublocalization of the polynucleotides can be achieved with panels of specific chromosome fragments. Other gene mapping strategies that can be used include *in situ* hybridization, prescreening with labeled flow-sorted chromosomes, and preselection by hybridization to construct chromosome specific-cDNA libraries.

20 Precise chromosomal location of the polynucleotides can also be achieved using fluorescence *in situ* hybridization (FISH) of a metaphase chromosomal spread. This technique uses polynucleotides as short as 500 or 600 bases; however, polynucleotides 2,000-4,000 bp are preferred. For a review of this technique, see 15 Verma et al., "Human Chromosomes: a Manual of Basic Techniques," Pergamon Press, New York (1988).

For chromosome mapping, the polynucleotides can be used individually (to 25 mark a single chromosome or a single site on that chromosome) or in panels (for marking multiple sites and/or multiple chromosomes). Preferred polynucleotides correspond to the noncoding regions of the cDNAs because the coding sequences are 30 more likely conserved within gene families, thus increasing the chance of cross hybridization during chromosomal mapping.

Once a polynucleotide has been mapped to a precise chromosomal location, the physical position of the polynucleotide can be used in linkage analysis. Linkage analysis establishes coinheritance between a chromosomal location and presentation of a particular disease. (Disease mapping data are found, for example, in V.

- 5 McKusick, Mendelian Inheritance in Man (available on line through Johns Hopkins University Welch Medical Library). Assuming 1 megabase mapping resolution and one gene per 20 kb, a cDNA precisely localized to a chromosomal region associated with the disease could be one of 50-500 potential causative genes.

Thus, once coinheritance is established, differences in the polynucleotide and  
10 the corresponding gene between affected and unaffected individuals can be examined. First, visible structural alterations in the chromosomes, such as deletions or translocations, are examined in chromosome spreads or by PCR. If no structural alterations exist, the presence of point mutations are ascertained. Mutations observed in some or all affected individuals, but not in normal individuals, indicates that the  
15 mutation may cause the disease. However, complete sequencing of the polypeptide and the corresponding gene from several normal individuals is required to distinguish the mutation from a polymorphism. If a new polymorphism is identified, this polymorphic polypeptide can be used for further linkage analysis.

Furthermore, increased or decreased expression of the gene in affected  
20 individuals as compared to unaffected individuals can be assessed using polynucleotides of the present invention. Any of these alterations (altered expression, chromosomal rearrangement, or mutation) can be used as a diagnostic or prognostic marker.

Thus, the invention also provides a diagnostic method useful during diagnosis  
25 of a disorder, involving measuring the expression level of polynucleotides of the present invention in cells or body fluid from an individual and comparing the measured gene expression level with a standard level of polynucleotide expression level, whereby an increase or decrease in the gene expression level compared to the standard is indicative of a disorder.

30 In still another embodiment, the invention includes a kit for analyzing samples for the presence of proliferative and/or cancerous polynucleotides derived from a test

subject. In a general embodiment, the kit includes at least one polynucleotide probe containing a nucleotide sequence that will specifically hybridize with a polynucleotide of the present invention and a suitable container. In a specific embodiment, the kit includes two polynucleotide probes defining an internal region of 5 the polynucleotide of the present invention, where each probe has one strand containing a 31'mer-end internal to the region. In a further embodiment, the probes may be useful as primers for polymerase chain reaction amplification.

Where a diagnosis of a disorder, has already been made according to conventional methods, the present invention is useful as a prognostic indicator, 10 whereby patients exhibiting enhanced or depressed polynucleotide of the present invention expression will experience a worse clinical outcome relative to patients expressing the gene at a level nearer the standard level.

By "measuring the expression level of polynucleotide of the present invention" is intended qualitatively or quantitatively measuring or estimating the level 15 of the polypeptide of the present invention or the level of the mRNA encoding the polypeptide in a first biological sample either directly (e.g., by determining or estimating absolute protein level or mRNA level) or relatively (e.g., by comparing to the polypeptide level or mRNA level in a second biological sample). Preferably, the polypeptide level or mRNA level in the first biological sample is measured or 20 estimated and compared to a standard polypeptide level or mRNA level, the standard being taken from a second biological sample obtained from an individual not having the disorder or being determined by averaging levels from a population of individuals not having a disorder. As will be appreciated in the art, once a standard polypeptide level or mRNA level is known, it can be used repeatedly as a standard for 25 comparison.

By "biological sample" is intended any biological sample obtained from an individual, body fluid, cell line, tissue culture, or other source which contains the polypeptide of the present invention or mRNA. As indicated, biological samples include body fluids (such as semen, lymph, sera, plasma, urine, synovial fluid and 30 spinal fluid) which contain the polypeptide of the present invention, and other tissue sources found to express the polypeptide of the present invention. Methods for

obtaining tissue biopsies and body fluids from mammals are well known in the art. Where the biological sample is to include mRNA, a tissue biopsy is the preferred source.

- The method(s) provided above may preferably be applied in a diagnostic
- 5 method and/or kits in which polynucleotides and/or polypeptides are attached to a solid support. In one exemplary method, the support may be a "gene chip" or a "biological chip" as described in US Patents 5,837,832, 5,874,219, and 5,856,174. Further, such a gene chip with polynucleotides of the present invention attached may be used to identify polymorphisms between the polynucleotide sequences, with
- 10 polynucleotides isolated from a test subject. The knowledge of such polymorphisms (i.e. their location, as well as, their existence) would be beneficial in identifying disease loci for many disorders, including cancerous diseases and conditions. Such a method is described in US Patents 5,858,659 and 5,856,104. The US Patents referenced supra are hereby incorporated by reference in their entirety herein.
- 15 The present invention encompasses polynucleotides of the present invention that are chemically synthesized, or reproduced as peptide nucleic acids (PNA), or according to other methods known in the art. The use of PNAs would serve as the preferred form if the polynucleotides are incorporated onto a solid support, or gene chip. For the purposes of the present invention, a peptide nucleic acid (PNA) is a
- 20 polyamide type of DNA analog and the monomeric units for adenine, guanine, thymine and cytosine are available commercially (Perceptive Biosystems). Certain components of DNA, such as phosphorus, phosphorus oxides, or deoxyribose derivatives, are not present in PNAs. As disclosed by P. E. Nielsen, M. Egholm, R. H. Berg and O. Buchardt, Science 254, 1497 (1991); and M. Egholm, O. Buchardt,
- 25 L. Christensen, C. Behrens, S. M. Freier, D. A. Driver, R. H. Berg, S. K. Kim, B. Norden, and P. E. Nielsen, Nature 365, 666 (1993), PNAs bind specifically and tightly to complementary DNA strands and are not degraded by nucleases. In fact, PNA binds more strongly to DNA than DNA itself does. This is probably because there is no electrostatic repulsion between the two strands, and also the polyamide
- 30 backbone is more flexible. Because of this, PNA/DNA duplexes bind under a wider range of stringency conditions than DNA/DNA duplexes, making it easier to perform

multiplex hybridization. Smaller probes can be used than with DNA due to the strong binding. In addition, it is more likely that single base mismatches can be determined with PNA/DNA hybridization because a single mismatch in a PNA/DNA 15-mer lowers the melting point ( $T_{\text{sub.m}}$ ) by  $8^{\circ}\text{-}20^{\circ}$  C, vs.  $4^{\circ}\text{-}16^{\circ}$  C for the DNA/DNA 15-  
5 mer duplex. Also, the absence of charge groups in PNA means that hybridization can be done at low ionic strengths and reduce possible interference by salt during the analysis.

The present invention is useful for detecting cancer in mammals. In particular the invention is useful during diagnosis of pathological cell proliferative neoplasias  
10 which include, but are not limited to: acute myelogenous leukemias including acute monocytic leukemia, acute myeloblastic leukemia, acute promyelocytic leukemia, acute myelomonocytic leukemia, acute erythroleukemia, acute megakaryocytic leukemia, and acute undifferentiated leukemia, etc.; and chronic myelogenous leukemias including chronic myelomonocytic leukemia, chronic granulocytic  
15 leukemia, etc. Preferred mammals include monkeys, apes, cats, dogs, cows, pigs, horses, rabbits and humans. Particularly preferred are humans.

Pathological cell proliferative diseases, disorders, and/or conditions are often associated with inappropriate activation of proto-oncogenes. (Gelmann, E. P. et al., "The Etiology of Acute Leukemia: Molecular Genetics and Viral Oncology," in  
20 Neoplastic Diseases of the Blood, Vol 1., Wiernik, P. H. et al. eds., 161-182 (1985)). Neoplasias are now believed to result from the qualitative alteration of a normal cellular gene product, or from the quantitative modification of gene expression by insertion into the chromosome of a viral sequence, by chromosomal translocation of a gene to a more actively transcribed region, or by some other mechanism. (Gelmann  
25 et al., *supra*) It is likely that mutated or altered expression of specific genes is involved in the pathogenesis of some leukemias, among other tissues and cell types. (Gelmann et al., *supra*) Indeed, the human counterparts of the oncogenes involved in some animal neoplasias have been amplified or translocated in some cases of human leukemia and carcinoma. (Gelmann et al., *supra*)  
30 For example, c-myc expression is highly amplified in the non-lymphocytic leukemia cell line HL-60. When HL-60 cells are chemically induced to stop proliferation, the

level of c-myc is found to be downregulated. (International Publication Number WO 91/15580) However, it has been shown that exposure of HL-60 cells to a DNA construct that is complementary to the 5' end of c-myc or c-myb blocks translation of the corresponding mRNAs which downregulates expression of the c-myc or c-myb proteins and causes arrest of cell proliferation and differentiation of the treated cells. (International Publication Number WO 91/15580; Wickstrom et al., Proc. Natl. Acad. Sci. 85:1028 (1988); Anfossi et al., Proc. Natl. Acad. Sci. 86:3379 (1989)). However, the skilled artisan would appreciate the present invention's usefulness would not be limited to treatment of proliferative diseases, disorders, and/or conditions of hematopoietic cells and tissues, in light of the numerous cells and cell types of varying origins which are known to exhibit proliferative phenotypes.

In addition to the foregoing, a polynucleotide can be used to control gene expression through triple helix formation or antisense DNA or RNA. Antisense techniques are discussed, for example, in Okano, J. Neurochem. 56: 560 (1991); "Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988). Triple helix formation is discussed in, for instance Lee et al., Nucleic Acids Research 6: 3073 (1979); Cooney et al., Science 241: 456 (1988); and Dervan et al., Science 251: 1360 (1991). Both methods rely on binding of the polynucleotide to a complementary DNA or RNA. For these techniques, preferred polynucleotides are usually oligonucleotides 20 to 40 bases in length and complementary to either the region of the gene involved in transcription (triple helix - see Lee et al., Nucl. Acids Res. 6:3073 (1979); Cooney et al., Science 241:456 (1988); and Dervan et al., Science 251:1360 (1991) ) or to the mRNA itself (antisense - Okano, J. Neurochem. 56:560 (1991); Oligodeoxy-nucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988).) Triple helix formation optimally results in a shut-off of RNA transcription from DNA, while antisense RNA hybridization blocks translation of an mRNA molecule into polypeptide. Both techniques are effective in model systems, and the information disclosed herein can be used to design antisense or triple helix polynucleotides in an effort to treat or prevent disease.

Polynucleotides of the present invention are also useful in gene therapy. One goal of gene therapy is to insert a normal gene into an organism having a defective gene, in an effort to correct the genetic defect. The polynucleotides disclosed in the present invention offer a means of targeting such genetic defects in a highly accurate 5 manner. Another goal is to insert a new gene that was not present in the host genome, thereby producing a new trait in the host cell.

- The polynucleotides are also useful for identifying individuals from minute biological samples. The United States military, for example, is considering the use of restriction fragment length polymorphism (RFLP) for identification of its personnel.
- 10 In this technique, an individual's genomic DNA is digested with one or more restriction enzymes, and probed on a Southern blot to yield unique bands for identifying personnel. This method does not suffer from the current limitations of "Dog Tags" which can be lost, switched, or stolen, making positive identification difficult. The polynucleotides of the present invention can be used as additional DNA 15 markers for RFLP.

The polynucleotides of the present invention can also be used as an alternative to RFLP, by determining the actual base-by-base DNA sequence of selected portions of an individual's genome. These sequences can be used to prepare PCR primers for amplifying and isolating such selected DNA, which can then be sequenced. Using 20 this technique, individuals can be identified because each individual will have a unique set of DNA sequences. Once an unique ID database is established for an individual, positive identification of that individual, living or dead, can be made from extremely small tissue samples.

Forensic biology also benefits from using DNA-based identification 25 techniques as disclosed herein. DNA sequences taken from very small biological samples such as tissues, e.g., hair or skin, or body fluids, e.g., blood, saliva, semen, synovial fluid, amniotic fluid, breast milk, lymph, pulmonary sputum or surfactant, urine, fecal matter, etc., can be amplified using PCR. In one prior art technique, gene sequences amplified from polymorphic loci, such as DQa class II 30 HLA gene, are used in forensic biology to identify individuals. (Erlich, H., PCR Technology, Freeman and Co. (1992).) Once these specific polymorphic loci are

amplified, they are digested with one or more restriction enzymes, yielding an identifying set of bands on a Southern blot probed with DNA corresponding to the DQ<sub>a</sub> class II HLA gene. Similarly, polynucleotides of the present invention can be used as polymorphic markers for forensic purposes.

5 There is also a need for reagents capable of identifying the source of a particular tissue. Such need arises, for example, in forensics when presented with tissue of unknown origin. Appropriate reagents can comprise, for example, DNA probes or primers specific to particular tissue prepared from the sequences of the present invention. Panels of such reagents can identify tissue by species and/or by  
10 organ type. In a similar fashion, these reagents can be used to screen tissue cultures for contamination.

In the very least, the polynucleotides of the present invention can be used as molecular weight markers on Southern gels, as diagnostic probes for the presence of a specific mRNA in a particular cell type, as a probe to "subtract-out" known sequences  
15 in the process of discovering novel polynucleotides, for selecting and making oligomers for attachment to a "gene chip" or other support, to raise anti-DNA antibodies using DNA immunization techniques, and as an antigen to elicit an immune response.

20 **Uses of the Polypeptides**

Each of the polypeptides identified herein can be used in numerous ways. The following description should be considered exemplary and utilizes known techniques.

A polypeptide of the present invention can be used to assay protein levels in a biological sample using antibody-based techniques. For example, protein expression  
25 in tissues can be studied with classical immunohistological methods. (Jalkanen, M., et al., J. Cell. Biol. 101:976-985 (1985); Jalkanen, M., et al., J. Cell. Biol. 105:3087-3096 (1987).) Other antibody-based methods useful for detecting protein gene expression include immunoassays, such as the enzyme linked immunosorbent assay (ELISA) and the radioimmunoassay (RIA). Suitable antibody assay labels are known  
30 in the art and include enzyme labels, such as, glucose oxidase, and radioisotopes, such as iodine (125I, 121I), carbon (14C), sulfur (35S), tritium (3H), indium (112In), and

technetium (99mTc), and fluorescent labels, such as fluorescein and rhodamine, and biotin.

In addition to assaying secreted protein levels in a biological sample, proteins can also be detected in vivo by imaging. Antibody labels or markers for in vivo 5 imaging of protein include those detectable by X-radiography, NMR or ESR. For X-radiography, suitable labels include radioisotopes such as barium or cesium, which emit detectable radiation but are not overtly harmful to the subject. Suitable markers for NMR and ESR include those with a detectable characteristic spin, such as deuterium, which may be incorporated into the antibody by labeling of nutrients for 10 the relevant hybridoma.

A protein-specific antibody or antibody fragment which has been labeled with an appropriate detectable imaging moiety, such as a radioisotope (for example, 131I, 112In, 99mTc), a radio-opaque substance, or a material detectable by nuclear magnetic resonance, is introduced (for example, parenterally, subcutaneously, or 15 intraperitoneally) into the mammal. It will be understood in the art that the size of the subject and the imaging system used will determine the quantity of imaging moiety needed to produce diagnostic images. In the case of a radioisotope moiety, for a human subject, the quantity of radioactivity injected will normally range from about 5 to 20 millicuries of 99mTc. The labeled antibody or antibody fragment will then 20 preferentially accumulate at the location of cells which contain the specific protein. In vivo tumor imaging is described in S.W. Burchiel et al., "Immunopharmacokinetics of Radiolabeled Antibodies and Their Fragments." (Chapter 13 in Tumor Imaging: The Radiochemical Detection of Cancer, S.W. Burchiel and B. A. Rhodes, eds., Masson Publishing Inc. (1982).)

25 Thus, the invention provides a diagnostic method of a disorder, which involves (a) assaying the expression of a polypeptide of the present invention in cells or body fluid of an individual; (b) comparing the level of gene expression with a standard gene expression level, whereby an increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is 30 indicative of a disorder. With respect to cancer, the presence of a relatively high amount of transcript in biopsied tissue from an individual may indicate a

predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the 5 development or further progression of the cancer.

Moreover, polypeptides of the present invention can be used to treat, prevent, and/or diagnose disease. For example, patients can be administered a polypeptide of the present invention in an effort to replace absent or decreased levels of the polypeptide (e.g., insulin), to supplement absent or decreased levels of a different 10 polypeptide (e.g., hemoglobin S for hemoglobin B, SOD, catalase, DNA repair proteins), to inhibit the activity of a polypeptide (e.g., an oncogene or tumor suppressor), to activate the activity of a polypeptide (e.g., by binding to a receptor), to reduce the activity of a membrane bound receptor by competing with it for free ligand (e.g., soluble TNF receptors used in reducing inflammation), or to bring about a 15 desired response (e.g., blood vessel growth inhibition, enhancement of the immune response to proliferative cells or tissues).

Similarly, antibodies directed to a polypeptide of the present invention can also be used to treat, prevent, and/or diagnose disease. For example, administration of an antibody directed to a polypeptide of the present invention can bind and reduce 20 overproduction of the polypeptide. Similarly, administration of an antibody can activate the polypeptide, such as by binding to a polypeptide bound to a membrane (receptor).

At the very least, the polypeptides of the present invention can be used as molecular weight markers on SDS-PAGE gels or on molecular sieve gel filtration 25 columns using methods well known to those of skill in the art. Polypeptides can also be used to raise antibodies, which in turn are used to measure protein expression from a recombinant cell, as a way of assessing transformation of the host cell. Moreover, the polypeptides of the present invention can be used to test the following biological activities.

Gene Therapy Methods

Another aspect of the present invention is to gene therapy methods for treating or preventing disorders, diseases and conditions. The gene therapy methods relate to the introduction of nucleic acid (DNA, RNA and antisense DNA or RNA) sequences into an animal to achieve expression of a polypeptide of the present invention. This method requires a polynucleotide which codes for a polypeptide of the invention that is operatively linked to a promoter and any other genetic elements necessary for the expression of the polypeptide by the target tissue. Such gene therapy and delivery techniques are known in the art, see, for example, WO90/11092, which is herein incorporated by reference.

Thus, for example, cells from a patient may be engineered with a polynucleotide (DNA or RNA) comprising a promoter operably linked to a polynucleotide of the invention *ex vivo*, with the engineered cells then being provided to a patient to be treated with the polypeptide. Such methods are well-known in the art. For example, see Belldegrun et al., J. Natl. Cancer Inst., 85:207-216 (1993); Ferrantini et al., Cancer Research, 53:107-1112 (1993); Ferrantini et al., J. Immunology 153: 4604-4615 (1994); Kaido, T., et al., Int. J. Cancer 60: 221-229 (1995); Ogura et al., Cancer Research 50: 5102-5106 (1990); Santodonato, et al., Human Gene Therapy 7:1-10 (1996); Santodonato, et al., Gene Therapy 4:1246-1255 (1997); and Zhang, et al., Cancer Gene Therapy 3: 31-38 (1996)), which are herein incorporated by reference. In one embodiment, the cells which are engineered are arterial cells. The arterial cells may be reintroduced into the patient through direct injection to the artery, the tissues surrounding the artery, or through catheter injection.

As discussed in more detail below, the polynucleotide constructs can be delivered by any method that delivers injectable materials to the cells of an animal, such as, injection into the interstitial space of tissues (heart, muscle, skin, lung, liver, and the like). The polynucleotide constructs may be delivered in a pharmaceutically acceptable liquid or aqueous carrier.

In one embodiment, the polynucleotide of the invention is delivered as a naked polynucleotide. The term "naked" polynucleotide, DNA or RNA refers to sequences that are free from any delivery vehicle that acts to assist, promote or facilitate entry

into the cell, including viral sequences, viral particles, liposome formulations, lipofectin or precipitating agents and the like. However, the polynucleotides of the invention can also be delivered in liposome formulations and lipofectin formulations and the like can be prepared by methods well known to those skilled in the art. Such 5 methods are described, for example, in U.S. Patent Nos. 5,593,972, 5,589,466, and 5,580,859, which are herein incorporated by reference.

The polynucleotide vector constructs of the invention used in the gene therapy method are preferably constructs that will not integrate into the host genome nor will they contain sequences that allow for replication. Appropriate vectors 10 include pWLNEO, pSV2CAT, pOG44, pXT1 and pSG available from Stratagene; pSVK3, pBPV, pMSG and pSVL available from Pharmacia; and pEF1/V5, pcDNA3.1, and pRc/CMV2 available from Invitrogen. Other suitable vectors will be readily apparent to the skilled artisan.

Any strong promoter known to those skilled in the art can be used for driving 15 the expression of polynucleotide sequence of the invention. Suitable promoters include adenoviral promoters, such as the adenoviral major late promoter; or heterologous promoters, such as the cytomegalovirus (CMV) promoter; the respiratory syncytial virus (RSV) promoter; inducible promoters, such as the MMT promoter, the metallothionein promoter; heat shock promoters; the albumin promoter; 20 the ApoAI promoter; human globin promoters; viral thymidine kinase promoters, such as the Herpes Simplex thymidine kinase promoter; retroviral LTRs; the b-actin promoter; and human growth hormone promoters. The promoter also may be the native promoter for the polynucleotides of the invention.

Unlike other gene therapy techniques, one major advantage of introducing 25 naked nucleic acid sequences into target cells is the transitory nature of the polynucleotide synthesis in the cells. Studies have shown that non-replicating DNA sequences can be introduced into cells to provide production of the desired polypeptide for periods of up to six months.

The polynucleotide construct of the invention can be delivered to the interstitial 30 space of tissues within the an animal, including of muscle, skin, brain, lung, liver, spleen, bone marrow, thymus, heart, lymph, blood, bone, cartilage, pancreas, kidney,

gall bladder, stomach, intestine, testis, ovary, uterus, rectum, nervous system, eye, gland, and connective tissue. Interstitial space of the tissues comprises the intercellular, fluid, mucopolysaccharide matrix among the reticular fibers of organ tissues, elastic fibers in the walls of vessels or chambers, collagen fibers of fibrous tissues, or that 5 same matrix within connective tissue ensheathing muscle cells or in the lacunae of bone. It is similarly the space occupied by the plasma of the circulation and the lymph fluid of the lymphatic channels. Delivery to the interstitial space of muscle tissue is preferred for the reasons discussed below. They may be conveniently delivered by injection into the tissues comprising these cells. They are preferably delivered to and 10 expressed in persistent, non-dividing cells which are differentiated, although delivery and expression may be achieved in non-differentiated or less completely differentiated cells, such as, for example, stem cells of blood or skin fibroblasts. *In vivo* muscle cells are particularly competent in their ability to take up and express polynucleotides.

For the naked nucleic acid sequence injection, an effective dosage amount of 15 DNA or RNA will be in the range of from about 0.05 mg/kg body weight to about 50 mg/kg body weight. Preferably the dosage will be from about 0.005 mg/kg to about 20 mg/kg and more preferably from about 0.05 mg/kg to about 5 mg/kg. Of course, as the artisan of ordinary skill will appreciate, this dosage will vary according to the tissue site of injection. The appropriate and effective dosage of nucleic acid sequence 20 can readily be determined by those of ordinary skill in the art and may depend on the condition being treated and the route of administration.

The preferred route of administration is by the parenteral route of injection into the interstitial space of tissues. However, other parenteral routes may also be used, such as, inhalation of an aerosol formulation particularly for delivery to lungs or 25 bronchial tissues, throat or mucous membranes of the nose. In addition, naked DNA constructs can be delivered to arteries during angioplasty by the catheter used in the procedure.

The naked polynucleotides are delivered by any method known in the art, including, but not limited to, direct needle injection at the delivery site, intravenous 30 injection, topical administration, catheter infusion, and so-called "gene guns". These delivery methods are known in the art.

The constructs may also be delivered with delivery vehicles such as viral sequences, viral particles, liposome formulations, lipofectin, precipitating agents, etc. Such methods of delivery are known in the art.

In certain embodiments, the polynucleotide constructs of the invention are complexed in a liposome preparation. Liposomal preparations for use in the instant invention include cationic (positively charged), anionic (negatively charged) and neutral preparations. However, cationic liposomes are particularly preferred because a tight charge complex can be formed between the cationic liposome and the polyanionic nucleic acid. Cationic liposomes have been shown to mediate intracellular delivery of plasmid DNA (Felgner et al., Proc. Natl. Acad. Sci. USA , 84:7413-7416 (1987), which is herein incorporated by reference); mRNA (Malone et al., Proc. Natl. Acad. Sci. USA , 86:6077-6081 (1989), which is herein incorporated by reference); and purified transcription factors (Debs et al., J. Biol. Chem., 265:10189-10192 (1990), which is herein incorporated by reference), in functional form.

Cationic liposomes are readily available. For example, N[1-2,3-dioleyloxy]propyl]-N,N,N-triethylammonium (DOTMA) liposomes are particularly useful and are available under the trademark Lipofectin, from GIBCO BRL, Grand Island, N.Y. (See, also, Felgner et al., Proc. Natl Acad. Sci. USA , 84:7413-7416 (1987), which is herein incorporated by reference). Other commercially available liposomes include transfectace (DDAB/DOPE) and DOTAP/DOPE (Boehringer).

Other cationic liposomes can be prepared from readily available materials using techniques well known in the art. See, e.g. PCT Publication NO: WO 90/11092 (which is herein incorporated by reference) for a description of the synthesis of DOTAP (1,2-bis(oleoyloxy)-3-(trimethylammonio)propane) liposomes. Preparation of DOTMA liposomes is explained in the literature, see, e.g., Felgner et al., Proc. Natl. Acad. Sci. USA, 84:7413-7417, which is herein incorporated by reference. Similar methods can be used to prepare liposomes from other cationic lipid materials.

Similarly, anionic and neutral liposomes are readily available, such as from Avanti Polar Lipids (Birmingham, Ala.), or can be easily prepared using readily

available materials. Such materials include phosphatidyl choline, cholesterol, phosphatidyl ethanolamine, dioleoylphosphatidyl choline (DOPC), dioleoylphosphatidyl glycerol (DOPG), dioleoylphosphatidyl ethanolamine (DOPE), among others. These materials can also be mixed with the DOTMA and DOTAP starting materials in appropriate ratios. Methods for making liposomes using these materials are well known in the art.

For example, commercially dioleoylphosphatidyl choline (DOPC), dioleoylphosphatidyl glycerol (DOPG), and dioleoylphosphatidyl ethanolamine (DOPE) can be used in various combinations to make conventional liposomes, with or without the addition of cholesterol. Thus, for example, DOPG/DOPC vesicles can be prepared by drying 50 mg each of DOPG and DOPC under a stream of nitrogen gas into a sonication vial. The sample is placed under a vacuum pump overnight and is hydrated the following day with deionized water. The sample is then sonicated for 2 hours in a capped vial, using a Heat Systems model 350 sonicator equipped with an inverted cup (bath type) probe at the maximum setting while the bath is circulated at 15EC. Alternatively, negatively charged vesicles can be prepared without sonication to produce multilamellar vesicles or by extrusion through nucleopore membranes to produce unilamellar vesicles of discrete size. Other methods are known and available to those of skill in the art.

The liposomes can comprise multilamellar vesicles (MLVs), small unilamellar vesicles (SUVs), or large unilamellar vesicles (LUVs), with SUVs being preferred. The various liposome-nucleic acid complexes are prepared using methods well known in the art. See, e.g., Straubinger et al., *Methods of Immunology*, 101:512-527 (1983), which is herein incorporated by reference. For example, MLVs containing nucleic acid can be prepared by depositing a thin film of phospholipid on the walls of a glass tube and subsequently hydrating with a solution of the material to be encapsulated. SUVs are prepared by extended sonication of MLVs to produce a homogeneous population of unilamellar liposomes. The material to be entrapped is added to a suspension of preformed MLVs and then sonicated. When using liposomes containing cationic lipids, the dried lipid film is resuspended in an appropriate solution such as sterile water or an isotonic buffer solution such as 10 mM Tris/NaCl, sonicated, and

then the preformed liposomes are mixed directly with the DNA. The liposome and DNA form a very stable complex due to binding of the positively charged liposomes to the cationic DNA. SUVs find use with small nucleic acid fragments. LUVs are prepared by a number of methods, well known in the art. Commonly used methods  
5 include Ca<sup>2+</sup>-EDTA chelation (Papahadjopoulos et al., Biochim. Biophys. Acta, 394:483 (1975); Wilson et al., Cell, 17:77 (1979)); ether injection (Deamer et al., Biochim. Biophys. Acta, 443:629 (1976); Ostro et al., Biochem. Biophys. Res. Commun., 76:836 (1977); Fraley et al., Proc. Natl. Acad. Sci. USA, 76:3348 (1979));  
detergent dialysis (Enoch et al., Proc. Natl. Acad. Sci. USA, 76:145 (1979)); and  
10 reverse-phase evaporation (REV) (Fraley et al., J. Biol. Chem., 255:10431 (1980); Szoka et al., Proc. Natl. Acad. Sci. USA, 75:145 (1978); Schaefer-Ridder et al., Science, 215:166 (1982)), which are herein incorporated by reference.

Generally, the ratio of DNA to liposomes will be from about 10:1 to about 1:10. Preferably, the ration will be from about 5:1 to about 1:5. More preferably, the  
15 ration will be about 3:1 to about 1:3. Still more preferably, the ratio will be about 1:1.  
U.S. Patent NO: 5,676,954 (which is herein incorporated by reference) reports on the injection of genetic material, complexed with cationic liposomes carriers, into mice. U.S. Patent Nos. 4,897,355, 4,946,787, 5,049,386, 5,459,127, 5,589,466,  
5,693,622, 5,580,859, 5,703,055, and international publication NO: WO 94/9469  
20 (which are herein incorporated by reference) provide cationic lipids for use in transfecting DNA into cells and mammals. U.S. Patent Nos. 5,589,466, 5,693,622,  
5,580,859, 5,703,055, and international publication NO: WO 94/9469 (which are herein incorporated by reference) provide methods for delivering DNA-cationic lipid complexes to mammals.

25 In certain embodiments, cells are engineered, *ex vivo* or *in vivo*, using a retroviral particle containing RNA which comprises a sequence encoding polypeptides of the invention. Retroviruses from which the retroviral plasmid vectors may be derived include, but are not limited to, Moloney Murine Leukemia Virus, spleen necrosis virus, Rous sarcoma Virus, Harvey Sarcoma Virus, avian leukosis  
30 virus, gibbon ape leukemia virus, human immunodeficiency virus, Myeloproliferative Sarcoma Virus, and mammary tumor virus.

The retroviral plasmid vector is employed to transduce packaging cell lines to form producer cell lines. Examples of packaging cells which may be transfected include, but are not limited to, the PE501, PA317, R-2, R-AM, PA12, T19-14X, VT-19-17-H2, RCRE, RCRIP, GP+E-86, GP+envAm12, and DAN cell lines as described

5 in Miller, Human Gene Therapy , 1:5-14 (1990), which is incorporated herein by reference in its entirety. The vector may transduce the packaging cells through any means known in the art. Such means include, but are not limited to, electroporation, the use of liposomes, and CaPO<sub>4</sub> precipitation. In one alternative, the retroviral plasmid vector may be encapsulated into a liposome, or coupled to a lipid, and then

10 administered to a host.

The producer cell line generates infectious retroviral vector particles which include polynucleotide encoding polypeptides of the invention. Such retroviral vector particles then may be employed, to transduce eukaryotic cells, either *in vitro* or *in vivo*. The transduced eukaryotic cells will express polypeptides of the invention.

15 In certain other embodiments, cells are engineered, *ex vivo* or *in vivo*, with polynucleotides of the invention contained in an adenovirus vector. Adenovirus can be manipulated such that it encodes and expresses polypeptides of the invention, and at the same time is inactivated in terms of its ability to replicate in a normal lytic viral life cycle. Adenovirus expression is achieved without integration of the viral DNA

20 into the host cell chromosome, thereby alleviating concerns about insertional mutagenesis. Furthermore, adenoviruses have been used as live enteric vaccines for many years with an excellent safety profile (Schwartz et al., Am. Rev. Respir. Dis., 109:233-238 (1974)). Finally, adenovirus mediated gene transfer has been demonstrated in a number of instances including transfer of alpha-1-antitrypsin and

25 CFTR to the lungs of cotton rats (Rosenfeld et al., Science , 252:431-434 (1991); Rosenfeld et al., Cell , 68:143-155 (1992)). Furthermore, extensive studies to attempt to establish adenovirus as a causative agent in human cancer were uniformly negative (Green et al. Proc. Natl. Acad. Sci. USA , 76:6606 (1979)).

Suitable adenoviral vectors useful in the present invention are described, for

30 example, in Kozarsky and Wilson, Curr. Opin. Genet. Devel., 3:499-503 (1993); Rosenfeld et al., Cell , 68:143-155 (1992); Engelhardt et al., Human Genet. Ther.,

4:759-769 (1993); Yang et al., Nature Genet., 7:362-369 (1994); Wilson et al., Nature, 365:691-692 (1993); and U.S. Patent NO: 5,652,224, which are herein incorporated by reference. For example, the adenovirus vector Ad2 is useful and can be grown in human 293 cells. These cells contain the E1 region of adenovirus and

5 constitutively express Ela and Elb, which complement the defective adenoviruses by providing the products of the genes deleted from the vector. In addition to Ad2, other varieties of adenovirus (e.g., Ad3, Ad5, and Ad7) are also useful in the present invention.

Preferably, the adenoviruses used in the present invention are replication deficient. Replication deficient adenoviruses require the aid of a helper virus and/or packaging cell line to form infectious particles. The resulting virus is capable of infecting cells and can express a polynucleotide of interest which is operably linked to a promoter, but cannot replicate in most cells. Replication deficient adenoviruses may be deleted in one or more of all or a portion of the following genes: E1a, E1b,

10 E3, E4, E2a, or L1 through L5.

In certain other embodiments, the cells are engineered, *ex vivo* or *in vivo*, using an adeno-associated virus (AAV). AAVs are naturally occurring defective viruses that require helper viruses to produce infectious particles (Muzyczka, Curr. Topics in Microbiol. Immunol., 158:97 (1992)). It is also one of the few viruses that

20 may integrate its DNA into non-dividing cells. Vectors containing as little as 300 base pairs of AAV can be packaged and can integrate, but space for exogenous DNA is limited to about 4.5 kb. Methods for producing and using such AAVs are known in the art. See, for example, U.S. Patent Nos. 5,139,941, 5,173,414, 5,354,678, 5,436,146, 5,474,935, 5,478,745, and 5,589,377.

25 For example, an appropriate AAV vector for use in the present invention will include all the sequences necessary for DNA replication, encapsidation, and host-cell integration. The polynucleotide construct containing polynucleotides of the invention is inserted into the AAV vector using standard cloning methods, such as those found in Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor

30 Press (1989). The recombinant AAV vector is then transfected into packaging cells which are infected with a helper virus, using any standard technique, including

lipofection, electroporation, calcium phosphate precipitation, etc. Appropriate helper viruses include adenoviruses, cytomegaloviruses, vaccinia viruses, or herpes viruses. Once the packaging cells are transfected and infected, they will produce infectious AAV viral particles which contain the polynucleotide construct of the invention.

- 5 These viral particles are then used to transduce eukaryotic cells, either *ex vivo* or *in vivo*. The transduced cells will contain the polynucleotide construct integrated into its genome, and will express the desired gene product.

Another method of gene therapy involves operably associating heterologous control regions and endogenous polynucleotide sequences (e.g. encoding the

- 10 polypeptide sequence of interest) via homologous recombination (see, e.g., U.S. Patent NO: 5,641,670, issued June 24, 1997; International Publication NO: WO 96/29411, published September 26, 1996; International Publication NO: WO 94/12650, published August 4, 1994; Koller et al., Proc. Natl. Acad. Sci. USA, 86:8932-8935 (1989); and Zijlstra et al., Nature, 342:435-438 (1989). This method
- 15 involves the activation of a gene which is present in the target cells, but which is not normally expressed in the cells, or is expressed at a lower level than desired.

Polynucleotide constructs are made, using standard techniques known in the art, which contain the promoter with targeting sequences flanking the promoter.

- Suitable promoters are described herein. The targeting sequence is sufficiently  
20 complementary to an endogenous sequence to permit homologous recombination of the promoter-targeting sequence with the endogenous sequence. The targeting sequence will be sufficiently near the 5' end of the desired endogenous polynucleotide sequence so the promoter will be operably linked to the endogenous sequence upon homologous recombination.

- 25 The promoter and the targeting sequences can be amplified using PCR. Preferably, the amplified promoter contains distinct restriction enzyme sites on the 5' and 3' ends. Preferably, the 3' end of the first targeting sequence contains the same restriction enzyme site as the 5' end of the amplified promoter and the 5' end of the second targeting sequence contains the same restriction site as the 3' end of the  
30 amplified promoter. The amplified promoter and targeting sequences are digested and ligated together.

The promoter-targeting sequence construct is delivered to the cells, either as naked polynucleotide, or in conjunction with transfection-facilitating agents, such as liposomes, viral sequences, viral particles, whole viruses, lipofection, precipitating agents, etc., described in more detail above. The P promoter-targeting sequence can 5 be delivered by any method, included direct needle injection, intravenous injection, topical administration, catheter infusion, particle accelerators, etc. The methods are described in more detail below.

The promoter-targeting sequence construct is taken up by cells. Homologous recombination between the construct and the endogenous sequence takes place, such 10 that an endogenous sequence is placed under the control of the promoter. The promoter then drives the expression of the endogenous sequence.

The polynucleotides encoding polypeptides of the present invention may be administered along with other polynucleotides encoding other angiogenic proteins. Angiogenic proteins include, but are not limited to, acidic and basic fibroblast growth 15 factors, VEGF-1, VEGF-2 (VEGF-C), VEGF-3 (VEGF-B), epidermal growth factor alpha and beta, platelet-derived endothelial cell growth factor, platelet-derived growth factor, tumor necrosis factor alpha, hepatocyte growth factor, insulin like growth factor, colony stimulating factor, macrophage colony stimulating factor, granulocyte/macrophage colony stimulating factor, and nitric oxide synthase.

20 Preferably, the polynucleotide encoding a polypeptide of the invention contains a secretory signal sequence that facilitates secretion of the protein. Typically, the signal sequence is positioned in the coding region of the polynucleotide to be expressed towards or at the 5' end of the coding region. The signal sequence 25 may be homologous or heterologous to the polynucleotide of interest and may be homologous or heterologous to the cells to be transfected. Additionally, the signal sequence may be chemically synthesized using methods known in the art.

Any mode of administration of any of the above-described polynucleotides constructs can be used so long as the mode results in the expression of one or more molecules in an amount sufficient to provide a therapeutic effect. This includes direct 30 needle injection, systemic injection, catheter infusion, biostatic injectors, particle accelerators (i.e., "gene guns"), gelfoam sponge depots, other commercially available

depot materials, osmotic pumps (e.g., Alza minipumps), oral or suppositorial solid (tablet or pill) pharmaceutical formulations, and decanting or topical applications during surgery. For example, direct injection of naked calcium phosphate-precipitated plasmid into rat liver and rat spleen or a protein-coated

- 5 plasmid into the portal vein has resulted in gene expression of the foreign gene in the rat livers. (Kaneda et al., Science, 243:375 (1989)).

A preferred method of local administration is by direct injection. Preferably, a recombinant molecule of the present invention complexed with a delivery vehicle is administered by direct injection into or locally within the area of arteries.

- 10 Administration of a composition locally within the area of arteries refers to injecting the composition centimeters and preferably, millimeters within arteries.

Another method of local administration is to contact a polynucleotide construct of the present invention in or around a surgical wound. For example, a patient can undergo surgery and the polynucleotide construct can be coated on the

- 15 surface of tissue inside the wound or the construct can be injected into areas of tissue inside the wound.

Therapeutic compositions useful in systemic administration, include recombinant molecules of the present invention complexed to a targeted delivery vehicle of the present invention. Suitable delivery vehicles for use with systemic

- 20 administration comprise liposomes comprising ligands for targeting the vehicle to a particular site.

Preferred methods of systemic administration, include intravenous injection, aerosol, oral and percutaneous (topical) delivery. Intravenous injections can be performed using methods standard in the art. Aerosol delivery can also be performed

- 25 using methods standard in the art (see, for example, Stribling et al., Proc. Natl. Acad. Sci. USA , 89:11277-11281 (1992), which is incorporated herein by reference). Oral delivery can be performed by complexing a polynucleotide construct of the present invention to a carrier capable of withstanding degradation by digestive enzymes in the gut of an animal. Examples of such carriers, include plastic capsules or tablets, such
- 30 as those known in the art. Topical delivery can be performed by mixing a

polynucleotide construct of the present invention with a lipophilic reagent (e.g., DMSO) that is capable of passing into the skin.

- Determining an effective amount of substance to be delivered can depend upon a number of factors including, for example, the chemical structure and
- 5 biological activity of the substance, the age and weight of the animal, the precise condition requiring treatment and its severity, and the route of administration. The frequency of treatments depends upon a number of factors, such as the amount of polynucleotide constructs administered per dose, as well as the health and history of the subject. The precise amount, number of doses, and timing of doses will be
- 10 determined by the attending physician or veterinarian. Therapeutic compositions of the present invention can be administered to any animal, preferably to mammals and birds. Preferred mammals include humans, dogs, cats, mice, rats, rabbits sheep, cattle, horses and pigs, with humans being particularly

15 **Biological Activities**

- The polynucleotides or polypeptides, or agonists or antagonists of the present invention can be used in assays to test for one or more biological activities. If these polynucleotides and polypeptides do exhibit activity in a particular assay, it is likely that these molecules may be involved in the diseases associated with the biological
- 20 activity. Thus, the polynucleotides or polypeptides, or agonists or antagonists could be used to treat the associated disease.

**Immune Activity**

- The polynucleotides or polypeptides, or agonists or antagonists of the present invention may be useful in treating, preventing, and/or diagnosing diseases, disorders, and/or conditions of the immune system, by activating or inhibiting the proliferation, differentiation, or mobilization (chemotaxis) of immune cells. Immune cells develop through a process called hematopoiesis, producing myeloid (platelets, red blood cells, neutrophils, and macrophages) and lymphoid (B and T lymphocytes) cells from
- 25 pluripotent stem cells. The etiology of these immune diseases, disorders, and/or conditions may be genetic, somatic, such as cancer or some autoimmune diseases,

disorders, and/or conditions, acquired (e.g., by chemotherapy or toxins), or infectious. Moreover, a polynucleotides or polypeptides, or agonists or antagonists of the present invention can be used as a marker or detector of a particular immune system disease or disorder.

- 5        A polynucleotides or polypeptides, or agonists or antagonists of the present invention may be useful in treating, preventing, and/or diagnosing diseases, disorders, and/or conditions of hematopoietic cells. A polynucleotides or polypeptides, or agonists or antagonists of the present invention could be used to increase differentiation and proliferation of hematopoietic cells, including the pluripotent stem  
10      10 cells, in an effort to treat or prevent those diseases, disorders, and/or conditions associated with a decrease in certain (or many) types hematopoietic cells. Examples of immunologic deficiency syndromes include, but are not limited to: blood protein diseases, disorders, and/or conditions (e.g. agammaglobulinemia, dysgammaglobulinemia), ataxia telangiectasia, common variable immunodeficiency,  
15      15 Digeorge Syndrome, HIV infection, HTLV-BLV infection, leukocyte adhesion deficiency syndrome, lymphopenia, phagocyte bactericidal dysfunction, severe combined immunodeficiency (SCIDs), Wiskott-Aldrich Disorder, anemia, thrombocytopenia, or hemoglobinuria.

- Moreover, a polynucleotides or polypeptides, or agonists or antagonists of the  
20      20 present invention could also be used to modulate hemostatic (the stopping of bleeding) or thrombolytic activity (clot formation). For example, by increasing hemostatic or thrombolytic activity, a polynucleotides or polypeptides, or agonists or antagonists of the present invention could be used to treat or prevent blood coagulation diseases, disorders, and/or conditions (e.g., afibrinogenemia, factor  
25      25 deficiencies), blood platelet diseases, disorders, and/or conditions (e.g. thrombocytopenia), or wounds resulting from trauma, surgery, or other causes. Alternatively, a polynucleotides or polypeptides, or agonists or antagonists of the present invention that can decrease hemostatic or thrombolytic activity could be used to inhibit or dissolve clotting. These molecules could be important in the treatment or  
30      30 prevention of heart attacks (infarction), strokes, or scarring.

A polynucleotides or polypeptides, or agonists or antagonists of the present invention may also be useful in treating, preventing, and/or diagnosing autoimmune diseases, disorders, and/or conditions. Many autoimmune diseases, disorders, and/or conditions result from inappropriate recognition of self as foreign material by immune cells. This inappropriate recognition results in an immune response leading to the destruction of the host tissue. Therefore, the administration of a polynucleotides or polypeptides, or agonists or antagonists of the present invention that inhibits an immune response, particularly the proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing autoimmune diseases, disorders, and/or conditions.

Examples of autoimmune diseases, disorders, and/or conditions that can be treated, prevented, and/or diagnosed or detected by the present invention include, but are not limited to: Addison's Disease, hemolytic anemia, antiphospholipid syndrome, rheumatoid arthritis, dermatitis, allergic encephalomyelitis, glomerulonephritis, Goodpasture's Syndrome, Graves' Disease, Multiple Sclerosis, Myasthenia Gravis, Neuritis, Ophthalmia, Bullous Pemphigoid, Pemphigus, Polyendocrinopathies, Purpura, Reiter's Disease, Stiff-Man Syndrome, Autoimmune Thyroiditis, Systemic Lupus Erythematosus, Autoimmune Pulmonary Inflammation, Guillain-Barre Syndrome, insulin dependent diabetes mellitis, and autoimmune inflammatory eye disease.

Similarly, allergic reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory problems, may also be treated, prevented, and/or diagnosed by polynucleotides or polypeptides, or agonists or antagonists of the present invention. Moreover, these molecules can be used to treat anaphylaxis, hypersensitivity to an antigenic molecule, or blood group incompatibility.

A polynucleotides or polypeptides, or agonists or antagonists of the present invention may also be used to treat, prevent, and/or diagnose organ rejection or graft-versus-host disease (GVHD). Organ rejection occurs by host immune cell destruction of the transplanted tissue through an immune response. Similarly, an immune response is also involved in GVHD, but, in this case, the foreign transplanted immune cells destroy the host tissues. The administration of a polynucleotides or

polypeptides, or agonists or antagonists of the present invention that inhibits an immune response, particularly the proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing organ rejection or GVHD.

Similarly, a polynucleotides or

- 5 polypeptides, or agonists or antagonists of the present invention may also be used to modulate inflammation. For example, the polypeptide or polynucleotide or agonists or antagonist may inhibit the proliferation and differentiation of cells involved in an inflammatory response. These molecules can be used to treat, prevent, and/or diagnose inflammatory conditions, both chronic and acute conditions, including
- 10 chronic prostatitis, granulomatous prostatitis and malacoplakia, inflammation associated with infection (e.g., septic shock, sepsis, or systemic inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine induced lung injury, inflammatory bowel disease, Crohn's disease, or resulting from over
- 15 production of cytokines (e.g., TNF or IL-1.)

#### Hyperproliferative Disorders

- A polynucleotides or polypeptides, or agonists or antagonists of the invention can be used to treat, prevent, and/or diagnose hyperproliferative diseases, disorders, including neoplasms. A polynucleotides or polypeptides, or agonists or antagonists of the present invention may inhibit the proliferation of the disorder through direct or indirect interactions. Alternatively, a polynucleotides or polypeptides, or agonists or antagonists of the present invention may proliferate other cells which can inhibit the hyperproliferative disorder.
- 25 For example, by increasing an immune response, particularly increasing antigenic qualities of the hyperproliferative disorder or by proliferating, differentiating, or mobilizing T-cells, hyperproliferative diseases, disorders, and/or conditions can be treated, prevented, and/or diagnosed. This immune response may be increased by either enhancing an existing immune response, or by initiating a new
- 30 immune response. Alternatively, decreasing an immune response may also be a

method of treating, preventing, and/or diagnosing hyperproliferative diseases, disorders, and/or conditions, such as a chemotherapeutic agent.

Examples of hyperproliferative diseases, disorders, and/or conditions that can be treated, prevented, and/or diagnosed by polynucleotides or polypeptides, or

5      agonists or antagonists of the present invention include, but are not limited to neoplasms located in the colon, abdomen, bone, breast, digestive system, liver, pancreas, peritoneum, endocrine glands (adrenal, parathyroid, pituitary, testicles, ovary, thymus, thyroid), eye, head and neck, nervous (central and peripheral), lymphatic system, pelvic, skin, soft tissue, spleen, thoracic, and urogenital.

10     Similarly, other hyperproliferative diseases, disorders, and/or conditions can also be treated, prevented, and/or diagnosed by a polynucleotides or polypeptides, or agonists or antagonists of the present invention. Examples of such hyperproliferative diseases, disorders, and/or conditions include, but are not limited to:

hypergammaglobulinemia, lymphoproliferative diseases, disorders, and/or conditions, 15    paraproteinemias, purpura, sarcoidosis, Sezary Syndrome, Waldenström's Macroglobulinemia, Gaucher's Disease, histiocytosis, and any other hyperproliferative disease, besides neoplasia, located in an organ system listed above.

One preferred embodiment utilizes polynucleotides of the present invention to inhibit aberrant cellular division, by gene therapy using the present invention, and/or 20   protein fusions or fragments thereof.

Thus, the present invention provides a method for treating or preventing cell proliferative diseases, disorders, and/or conditions by inserting into an abnormally proliferating cell a polynucleotide of the present invention, wherein said polynucleotide represses said expression.

25     Another embodiment of the present invention provides a method of treating or preventing cell-proliferative diseases, disorders, and/or conditions in individuals comprising administration of one or more active gene copies of the present invention to an abnormally proliferating cell or cells. In a preferred embodiment, polynucleotides of the present invention is a DNA construct comprising a recombinant expression vector effective in expressing a DNA sequence encoding said 30   polynucleotides. In another preferred embodiment of the present invention, the DNA

construct encoding the polynucleotides of the present invention is inserted into cells to be treated utilizing a retrovirus, or more preferably an adenoviral vector (See G J. Nabel, et. al., PNAS 1999 96: 324-326, which is hereby incorporated by reference). In a most preferred embodiment, the viral vector is defective and will not transform 5 non-proliferating cells, only proliferating cells. Moreover, in a preferred embodiment, the polynucleotides of the present invention inserted into proliferating cells either alone, or in combination with or fused to other polynucleotides, can then be modulated via an external stimulus (i.e. magnetic, specific small molecule, chemical, or drug administration, etc.), which acts upon the promoter upstream of said 10 polynucleotides to induce expression of the encoded protein product. As such the beneficial therapeutic affect of the present invention may be expressly modulated (i.e. to increase, decrease, or inhibit expression of the present invention) based upon said external stimulus.

Polynucleotides of the present invention may be useful in repressing 15 expression of oncogenic genes or antigens. By "repressing expression of the oncogenic genes" is intended the suppression of the transcription of the gene, the degradation of the gene transcript (pre-message RNA), the inhibition of splicing, the destruction of the messenger RNA, the prevention of the post-translational modifications of the protein, the destruction of the protein, or the inhibition of the 20 normal function of the protein.

For local administration to abnormally proliferating cells, polynucleotides of the present invention may be administered by any method known to those of skill in the art including, but not limited to transfection, electroporation, microinjection of cells, or in vehicles such as liposomes, lipofectin, or as naked polynucleotides, or any 25 other method described throughout the specification. The polynucleotide of the present invention may be delivered by known gene delivery systems such as, but not limited to, retroviral vectors (Gilboa, J. Virology 44:845 (1982); Hocke, Nature 320:275 (1986); Wilson, et al., Proc. Natl. Acad. Sci. U.S.A. 85:3014), vaccinia virus system (Chakrabarty et al., Mol. Cell Biol. 5:3403 (1985) or other efficient DNA 30 delivery systems (Yates et al., Nature 313:812 (1985)) known to those skilled in the art. These references are exemplary only and are hereby incorporated by reference.

In order to specifically deliver or transfect cells which are abnormally proliferating and spare non-dividing cells, it is preferable to utilize a retrovirus, or adenoviral (as described in the art and elsewhere herein) delivery system known to those of skill in the art. Since host DNA replication is required for retroviral DNA to integrate and

5 the retrovirus will be unable to self replicate due to the lack of the retrovirus genes needed for its life cycle. Utilizing such a retroviral delivery system for polynucleotides of the present invention will target said gene and constructs to abnormally proliferating cells and will spare the non-dividing normal cells.

The polynucleotides of the present invention may be delivered directly to cell  
10 proliferative disorder/disease sites in internal organs, body cavities and the like by use of imaging devices used to guide an injecting needle directly to the disease site. The polynucleotides of the present invention may also be administered to disease sites at the time of surgical intervention.

By "cell proliferative disease" is meant any human or animal disease or  
15 disorder, affecting any one or any combination of organs, cavities, or body parts, which is characterized by single or multiple local abnormal proliferations of cells, groups of cells, or tissues, whether benign or malignant.

Any amount of the polynucleotides of the present invention may be administered as long as it has a biologically inhibiting effect on the proliferation of  
20 the treated cells. Moreover, it is possible to administer more than one of the polynucleotide of the present invention simultaneously to the same site. By "biologically inhibiting" is meant partial or total growth inhibition as well as decreases in the rate of proliferation or growth of the cells. The biologically inhibitory dose may be determined by assessing the effects of the polynucleotides of  
25 the present invention on target malignant or abnormally proliferating cell growth in tissue culture, tumor growth in animals and cell cultures, or any other method known to one of ordinary skill in the art.

The present invention is further directed to antibody-based therapies which involve administering of anti-polypeptides and anti-polynucleotide antibodies to a  
30 mammalian, preferably human, patient for treating, preventing, and/or diagnosing one or more of the described diseases, disorders, and/or conditions. Methods for

producing anti-polypeptides and anti-poly nucleotide antibodies polyclonal and monoclonal antibodies are described in detail elsewhere herein. Such antibodies may be provided in pharmaceutically acceptable compositions as known in the art or as described herein.

5 A summary of the ways in which the antibodies of the present invention may be used therapeutically includes binding polynucleotides or polypeptides of the present invention locally or systemically in the body or by direct cytotoxicity of the antibody, e.g. as mediated by complement (CDC) or by effector cells (ADCC). Some of these approaches are described in more detail below. Armed with the teachings  
10 provided herein, one of ordinary skill in the art will know how to use the antibodies of the present invention for diagnostic, monitoring or therapeutic purposes without undue experimentation.

In particular, the antibodies, fragments and derivatives of the present invention are useful for treating, preventing, and/or diagnosing a subject having or developing  
15 cell proliferative and/or differentiation diseases, disorders, and/or conditions as described herein. Such treatment comprises administering a single or multiple doses of the antibody, or a fragment, derivative, or a conjugate thereof.

The antibodies of this invention may be advantageously utilized in combination with other monoclonal or chimeric antibodies, or with lymphokines or  
20 hematopoietic growth factors, for example, which serve to increase the number or activity of effector cells which interact with the antibodies.

It is preferred to use high affinity and/or potent in vivo inhibiting and/or neutralizing antibodies against polypeptides or polynucleotides of the present invention, fragments or regions thereof, for both immunoassays directed to and  
25 therapy of diseases, disorders, and/or conditions related to polynucleotides or polypeptides, including fragments thereof, of the present invention. Such antibodies, fragments, or regions, will preferably have an affinity for polynucleotides or polypeptides, including fragments thereof. Preferred binding affinities include those with a dissociation constant or Kd less than  $5 \times 10^{-6}$ M,  $10^{-6}$ M,  $5 \times 10^{-7}$ M,  $10^{-7}$ M,  $5 \times 10^{-8}$ M,  $10^{-8}$ M,  $5 \times 10^{-9}$ M,  $10^{-9}$ M,  $5 \times 10^{-10}$ M,  $10^{-10}$ M,  $5 \times 10^{-11}$ M,  $10^{-11}$ M,  $5 \times 10^{-12}$ M,  $10^{-12}$ M,  
30  $5 \times 10^{-13}$ M,  $10^{-13}$ M,  $5 \times 10^{-14}$ M,  $10^{-14}$ M,  $5 \times 10^{-15}$ M, and  $10^{-15}$ M.

Moreover, polypeptides of the present invention are useful in inhibiting the angiogenesis of proliferative cells or tissues, either alone, as a protein fusion, or in combination with other polypeptides directly or indirectly, as described elsewhere herein. In a most preferred embodiment, said anti-angiogenesis effect may be

5 achieved indirectly, for example, through the inhibition of hematopoietic, tumor-specific cells, such as tumor-associated macrophages (See Joseph IB, et al. J Natl Cancer Inst, 90(21):1648-53 (1998), which is hereby incorporated by reference). Antibodies directed to polypeptides or polynucleotides of the present invention may also result in inhibition of angiogenesis directly, or indirectly (See Witte L, et al.,

10 Cancer Metastasis Rev. 17(2):155-61 (1998), which is hereby incorporated by reference)).

Polypeptides, including protein fusions, of the present invention, or fragments thereof may be useful in inhibiting proliferative cells or tissues through the induction of apoptosis. Said polypeptides may act either directly, or indirectly to induce

15 apoptosis of proliferative cells and tissues, for example in the activation of a death-domain receptor, such as tumor necrosis factor (TNF) receptor-1, CD95 (Fas/APO-1), TNF-receptor-related apoptosis-mediated protein (TRAMP) and TNF-related apoptosis-inducing ligand (TRAIL) receptor-1 and -2 (See Schulze-Osthoff K, et.al., Eur J Biochem 254(3):439-59 (1998), which is hereby incorporated by reference).

20 Moreover, in another preferred embodiment of the present invention, said polypeptides may induce apoptosis through other mechanisms, such as in the activation of other proteins which will activate apoptosis, or through stimulating the expression of said proteins, either alone or in combination with small molecule drugs or adjuvants, such as apoptonin, galectins, thioredoxins, antiinflammatory proteins

25 (See for example, Mutat Res 400(1-2):447-55 (1998), Med Hypotheses.50(5):423-33 (1998), Chem Biol Interact. Apr 24;111-112:23-34 (1998), J Mol Med.76(6):402-12 (1998), Int J Tissue React;20(1):3-15 (1998), which are all hereby incorporated by reference).

30 Polypeptides, including protein fusions to, or fragments thereof, of the present invention are useful in inhibiting the metastasis of proliferative cells or tissues. Inhibition may occur as a direct result of administering polypeptides, or antibodies

directed to said polypeptides as described elsewhere herein, or indirectly, such as activating the expression of proteins known to inhibit metastasis, for example alpha 4 integrins, (See, e.g., Curr Top Microbiol Immunol 1998;231:125-41, which is hereby incorporated by reference). Such therapeutic affects of the present invention may be  
5 achieved either alone, or in combination with small molecule drugs or adjuvants.

In another embodiment, the invention provides a method of delivering compositions containing the polypeptides of the invention (e.g., compositions containing polypeptides or polypeptide antibodies associated with heterologous polypeptides, heterologous nucleic acids, toxins, or prodrugs) to targeted cells  
10 expressing the polypeptide of the present invention. Polypeptides or polypeptide antibodies of the invention may be associated with heterologous polypeptides, heterologous nucleic acids, toxins, or prodrugs via hydrophobic, hydrophilic, ionic and/or covalent interactions.

Polypeptides, protein fusions to, or fragments thereof, of the present invention are  
15 useful in enhancing the immunogenicity and/or antigenicity of proliferating cells or tissues, either directly, such as would occur if the polypeptides of the present invention 'vaccinated' the immune response to respond to proliferative antigens and immunogens, or indirectly, such as in activating the expression of proteins known to enhance the immune response (e.g. chemokines), to said antigens and immunogens.

20

#### Cardiovascular Disorders

Polynucleotides or polypeptides, or agonists or antagonists of the invention may be used to treat, prevent, and/or diagnose cardiovascular diseases, disorders, and/or conditions, including peripheral artery disease, such as limb ischemia.

25 Cardiovascular diseases, disorders, and/or conditions include cardiovascular abnormalities, such as arterio-arterial fistula, arteriovenous fistula, cerebral arteriovenous malformations, congenital heart defects, pulmonary atresia, and Scimitar Syndrome. Congenital heart defects include aortic coarctation, cor triatriatum, coronary vessel anomalies, crisscross heart, dextrocardia, patent ductus  
30 arteriosus, Ebstein's anomaly, Eisenmenger complex, hypoplastic left heart syndrome, levocardia, tetralogy of fallot, transposition of great vessels, double outlet right

ventricle, tricuspid atresia, persistent truncus arteriosus, and heart septal defects, such as aortopulmonary septal defect, endocardial cushion defects, Lutembacher's Syndrome, trilogy of Fallot, ventricular heart septal defects.

- Cardiovascular diseases, disorders, and/or conditions also include heart disease, such as arrhythmias, carcinoid heart disease, high cardiac output, low cardiac output, cardiac tamponade, endocarditis (including bacterial), heart aneurysm, cardiac arrest, congestive heart failure, congestive cardiomyopathy, paroxysmal dyspnea, cardiac edema, heart hypertrophy, congestive cardiomyopathy, left ventricular hypertrophy, right ventricular hypertrophy, post-infarction heart rupture, ventricular septal rupture, heart valve diseases, myocardial diseases, myocardial ischemia, pericardial effusion, pericarditis (including constrictive and tuberculous), pneumopericardium, postpericardiotomy syndrome, pulmonary heart disease, rheumatic heart disease, ventricular dysfunction, hyperemia, cardiovascular pregnancy complications, Scimitar Syndrome, cardiovascular syphilis, and cardiovascular tuberculosis.

- Arrhythmias include sinus arrhythmia, atrial fibrillation, atrial flutter, bradycardia, extrasystole, Adams-Stokes Syndrome, bundle-branch block, sinoatrial block, long QT syndrome, parasystole, Lown-Ganong-Levine Syndrome, Mahaim-type pre-excitation syndrome, Wolff-Parkinson-White syndrome, sick sinus syndrome, tachycardias, and ventricular fibrillation. Tachycardias include paroxysmal tachycardia, supraventricular tachycardia, accelerated idioventricular rhythm, atrioventricular nodal reentry tachycardia, ectopic atrial tachycardia, ectopic junctional tachycardia, sinoatrial nodal reentry tachycardia, sinus tachycardia, Torsades de Pointes, and ventricular tachycardia.

- Heart valve disease include aortic valve insufficiency, aortic valve stenosis, hear murmurs, aortic valve prolapse, mitral valve prolapse, tricuspid valve prolapse, mitral valve insufficiency, mitral valve stenosis, pulmonary atresia, pulmonary valve insufficiency, pulmonary valve stenosis, tricuspid atresia, tricuspid valve insufficiency, and tricuspid valve stenosis.

- Myocardial diseases include alcoholic cardiomyopathy, congestive cardiomyopathy, hypertrophic cardiomyopathy, aortic subvalvular stenosis,

pulmonary subvalvular stenosis, restrictive cardiomyopathy, Chagas cardiomyopathy, endocardial fibroelastosis, endomyocardial fibrosis, Kearns Syndrome, myocardial reperfusion injury, and myocarditis.

- Myocardial ischemias include coronary disease, such as angina pectoris,  
5 coronary aneurysm, coronary arteriosclerosis, coronary thrombosis, coronary vasospasm, myocardial infarction and myocardial stunning.

Cardiovascular diseases also include vascular diseases such as aneurysms, angiodyplasia, angiomas, bacillary angiomas, Hippel-Lindau Disease, Klippel-Trenaunay-Weber Syndrome, Sturge-Weber Syndrome, angioneurotic edema,  
10 aortic diseases, Takayasu's Arteritis, aortitis, Leriche's Syndrome, arterial occlusive diseases, arteritis, enarteritis, polyarteritis nodosa, cerebrovascular diseases, disorders, and/or conditions, diabetic angiopathies, diabetic retinopathy, embolisms, thrombosis, erythromelalgia, hemorrhoids, hepatic veno-occlusive disease, hypertension, hypotension, ischemia, peripheral vascular diseases, phlebitis, pulmonary veno-  
15 occlusive disease, Raynaud's disease, CREST syndrome, retinal vein occlusion, Scimitar syndrome, superior vena cava syndrome, telangiectasia, ataxia telangiectasia, hereditary hemorrhagic telangiectasia, varicocele, varicose veins, varicose ulcer, vasculitis, and venous insufficiency.

- Aneurysms include dissecting aneurysms, false aneurysms, infected  
20 aneurysms, ruptured aneurysms, aortic aneurysms, cerebral aneurysms, coronary aneurysms, heart aneurysms, and iliac aneurysms.

Arterial occlusive diseases include arteriosclerosis, intermittent claudication, carotid stenosis, fibromuscular dysplasias, mesenteric vascular occlusion, Moyamoya disease, renal artery obstruction, retinal artery occlusion, and thromboangiitis  
25 obliterans.

- Cerebrovascular diseases, disorders, and/or conditions include carotid artery diseases, cerebral amyloid angiopathy, cerebral aneurysm, cerebral anoxia, cerebral arteriosclerosis, cerebral arteriovenous malformation, cerebral artery diseases, cerebral embolism and thrombosis, carotid artery thrombosis, sinus thrombosis,  
30 Wallenberg's syndrome, cerebral hemorrhage, epidural hematoma, subdural hematoma, subarachnoid hemorrhage, cerebral infarction, cerebral ischemia

(including transient), subclavian steal syndrome, periventricular leukomalacia, vascular headache, cluster headache, migraine, and vertebrobasilar insufficiency.

Embolisms include air embolisms, amniotic fluid embolisms, cholesterol embolisms, blue toe syndrome, fat embolisms, pulmonary embolisms, and 5 thromboembolisms. Thrombosis include coronary thrombosis, hepatic vein thrombosis, retinal vein occlusion, carotid artery thrombosis, sinus thrombosis, Wallenberg's syndrome, and thrombophlebitis.

Ischemia includes cerebral ischemia, ischemic colitis, compartment syndromes, anterior compartment syndrome, myocardial ischemia, reperfusion 10 injuries, and peripheral limb ischemia. Vasculitis includes aortitis, arteritis, Behcet's Syndrome, Churg-Strauss Syndrome, mucocutaneous lymph node syndrome, thromboangiitis obliterans, hypersensitivity vasculitis, Schoenlein-Henoch purpura, allergic cutaneous vasculitis, and Wegener's granulomatosis.

Polynucleotides or polypeptides, or agonists or antagonists of the invention, 15 are especially effective for the treatment of critical limb ischemia and coronary disease.

Polypeptides may be administered using any method known in the art, including, but not limited to, direct needle injection at the delivery site, intravenous injection, topical administration, catheter infusion, biostatic injectors, particle 20 accelerators, gelfoam sponge depots, other commercially available depot materials, osmotic pumps, oral or suppositorial solid pharmaceutical formulations, decanting or topical applications during surgery, aerosol delivery. Such methods are known in the art. Polypeptides of the invention may be administered as part of a *Therapeutic*, described in more detail below. Methods of delivering polynucleotides of the 25 invention are described in more detail herein.

#### Anti-Angiogenesis Activity

The naturally occurring balance between endogenous stimulators and inhibitors of angiogenesis is one in which inhibitory influences predominate.

30 Rastinejad *et al.*, *Cell* 56:345-355 (1989). In those rare instances in which neovascularization occurs under normal physiological conditions, such as wound

healing, organ regeneration, embryonic development, and female reproductive processes, angiogenesis is stringently regulated and spatially and temporally delimited. Under conditions of pathological angiogenesis such as that characterizing solid tumor growth, these regulatory controls fail. Unregulated angiogenesis becomes 5 pathologic and sustains progression of many neoplastic and non-neoplastic diseases. A number of serious diseases are dominated by abnormal neovascularization including solid tumor growth and metastases, arthritis, some types of eye diseases, disorders, and/or conditions, and psoriasis. See, e.g., reviews by Moses *et al.*, *Biotech.* 9:630-634 (1991); Folkman *et al.*, *N. Engl. J. Med.*, 333:1757-1763 (1995); 10 Auerbach *et al.*, *J. Microvasc. Res.* 29:401-411 (1985); Folkman, *Advances in Cancer Research*, eds. Klein and Weinhouse, Academic Press, New York, pp. 175-203 (1985); Patz, *Am. J. Ophthalmol.* 94:715-743 (1982); and Folkman *et al.*, *Science* 221:719-725 (1983). In a number of pathological conditions, the process of angiogenesis contributes to the disease state. For example, significant data have 15 accumulated which suggest that the growth of solid tumors is dependent on angiogenesis. Folkman and Klagsbrun, *Science* 235:442-447 (1987).

The present invention provides for treatment of diseases, disorders, and/or conditions associated with neovascularization by administration of the polynucleotides and/or polypeptides of the invention, as well as agonists or 20 antagonists of the present invention. Malignant and metastatic conditions which can be treated with the polynucleotides and polypeptides, or agonists or antagonists of the invention include, but are not limited to, malignancies, solid tumors, and cancers described herein and otherwise known in the art (for a review of such disorders, see Fishman *et al.*, *Medicine*, 2d Ed., J. B. Lippincott Co., Philadelphia (1985)). Thus, the 25 present invention provides a method of treating, preventing, and/or diagnosing an angiogenesis-related disease and/or disorder, comprising administering to an individual in need thereof a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist of the invention. For example, polynucleotides, polypeptides, antagonists and/or agonists may be utilized in a variety 30 of additional methods in order to therapeutically treat or prevent a cancer or tumor. Cancers which may be treated, prevented, and/or diagnosed with polynucleotides,

- polypeptides, antagonists and/or agonists include, but are not limited to solid tumors, including prostate, lung, breast, ovarian, stomach, pancreas, larynx, esophagus, testes, liver, parotid, biliary tract, colon, rectum, cervix, uterus, endometrium, kidney, bladder, thyroid cancer; primary tumors and metastases; melanomas; glioblastoma;
- 5 Kaposi's sarcoma; leiomyosarcoma; non- small cell lung cancer; colorectal cancer; advanced malignancies; and blood born tumors such as leukemias. For example, polynucleotides, polypeptides, antagonists and/or agonists may be delivered topically, in order to treat or prevent cancers such as skin cancer, head and neck tumors, breast tumors, and Kaposi's sarcoma.
- 10 Within yet other aspects, polynucleotides, polypeptides, antagonists and/or agonists may be utilized to treat superficial forms of bladder cancer by, for example, intravesical administration. Polynucleotides, polypeptides, antagonists and/or agonists may be delivered directly into the tumor, or near the tumor site, via injection or a catheter. Of course, as the artisan of ordinary skill will appreciate, the appropriate mode of administration will vary according to the cancer to be treated. Other modes of delivery are discussed herein.
- 15 Polynucleotides, polypeptides, antagonists and/or agonists may be useful in treating, preventing, and/or diagnosing other diseases, disorders, and/or conditions, besides cancers, which involve angiogenesis. These diseases, disorders, and/or
- 20 conditions include, but are not limited to: benign tumors, for example hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas; arteriosclerotic plaques; ocular angiogenic diseases, for example, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrobulbar fibroplasia, rubeosis, retinoblastoma, uveitis and Pterygia
- 25 (abnormal blood vessel growth) of the eye; rheumatoid arthritis; psoriasis; delayed wound healing; endometriosis; vasculogenesis; granulations; hypertrophic scars (keloids); nonunion fractures; scleroderma; trachoma; vascular adhesions; myocardial angiogenesis; coronary collaterals; cerebral collaterals; arteriovenous malformations; ischemic limb angiogenesis; Osler-Webber Syndrome; plaque neovascularization;
- 30 telangiectasia; hemophiliac joints; angiofibroma; fibromuscular dysplasia; wound granulation; Crohn's disease; and atherosclerosis.

For example, within one aspect of the present invention methods are provided for treating, preventing, and/or diagnosing hypertrophic scars and keloids, comprising the step of administering a polynucleotide, polypeptide, antagonist and/or agonist of the invention to a hypertrophic scar or keloid.

- 5 Within one embodiment of the present invention polynucleotides, polypeptides, antagonists and/or agonists are directly injected into a hypertrophic scar or keloid, in order to prevent the progression of these lesions. This therapy is of particular value in the prophylactic treatment of conditions which are known to result in the development of hypertrophic scars and keloids (e.g., burns), and is preferably
- 10 initiated after the proliferative phase has had time to progress (approximately 14 days after the initial injury), but before hypertrophic scar or keloid development. As noted above, the present invention also provides methods for treating, preventing, and/or diagnosing neovascular diseases of the eye, including for example, corneal neovascularization, neovascular glaucoma, proliferative diabetic retinopathy,
- 15 retrobulbar fibroplasia and macular degeneration.

Moreover, Ocular diseases, disorders, and/or conditions associated with neovascularization which can be treated, prevented, and/or diagnosed with the polynucleotides and polypeptides of the present invention (including agonists and/or antagonists) include, but are not limited to: neovascular glaucoma, diabetic

- 20 retinopathy, retinoblastoma, retrobulbar fibroplasia, uveitis, retinopathy of prematurity macular degeneration, corneal graft neovascularization, as well as other eye inflammatory diseases, ocular tumors and diseases associated with choroidal or iris neovascularization. See, e.g., reviews by Waltman *et al.*, *Am. J. Ophthal.* 85:704-710 (1978) and Gartner *et al.*, *Surv. Ophthal.* 22:291-312 (1978).

- 25 Thus, within one aspect of the present invention methods are provided for treating or preventing neovascular diseases of the eye such as corneal neovascularization (including corneal graft neovascularization), comprising the step of administering to a patient a therapeutically effective amount of a compound (as described above) to the cornea, such that the formation of blood vessels is inhibited.
- 30 Briefly, the cornea is a tissue which normally lacks blood vessels. In certain pathological conditions however, capillaries may extend into the cornea from the

pericorneal vascular plexus of the limbus. When the cornea becomes vascularized, it also becomes clouded, resulting in a decline in the patient's visual acuity. Visual loss may become complete if the cornea completely opacifies. A wide variety of diseases, disorders, and/or conditions can result in corneal neovascularization,

- 5 including for example, corneal infections (e.g., trachoma, herpes simplex keratitis, leishmaniasis and onchocerciasis), immunological processes (e.g., graft rejection and Stevens-Johnson's syndrome), alkali burns, trauma, inflammation (of any cause), toxic and nutritional deficiency states, and as a complication of wearing contact lenses.

10 Within particularly preferred embodiments of the invention, may be prepared for topical administration in saline (combined with any of the preservatives and antimicrobial agents commonly used in ocular preparations), and administered in eyedrop form. The solution or suspension may be prepared in its pure form and administered several times daily. Alternatively, anti-angiogenic compositions,

- 15 prepared as described above, may also be administered directly to the cornea. Within preferred embodiments, the anti-angiogenic composition is prepared with a muco-adhesive polymer which binds to cornea. Within further embodiments, the anti-angiogenic factors or anti-angiogenic compositions may be utilized as an adjunct to conventional steroid therapy. Topical therapy may also be useful prophylactically in  
20 corneal lesions which are known to have a high probability of inducing an angiogenic response (such as chemical burns). In these instances the treatment, likely in combination with steroids, may be instituted immediately to help prevent subsequent complications.

Within other embodiments, the compounds described above may be injected  
25 directly into the corneal stroma by an ophthalmologist under microscopic guidance. The preferred site of injection may vary with the morphology of the individual lesion, but the goal of the administration would be to place the composition at the advancing front of the vasculature (i.e., interspersed between the blood vessels and the normal cornea). In most cases this would involve perilimetic corneal injection to "protect" the  
30 cornea from the advancing blood vessels. This method may also be utilized shortly after a corneal insult in order to prophylactically prevent corneal neovascularization.

In this situation the material could be injected in the perilimbal cornea interspersed between the corneal lesion and its undesired potential limbic blood supply. Such methods may also be utilized in a similar fashion to prevent capillary invasion of transplanted corneas. In a sustained-release form injections might only be required 2-5 3 times per year. A steroid could also be added to the injection solution to reduce inflammation resulting from the injection itself.

Within another aspect of the present invention, methods are provided for treating or preventing neovascular glaucoma, comprising the step of administering to a patient a therapeutically effective amount of a polynucleotide, polypeptide, 10 antagonist and/or agonist to the eye, such that the formation of blood vessels is inhibited. In one embodiment, the compound may be administered topically to the eye in order to treat or prevent early forms of neovascular glaucoma. Within other embodiments, the compound may be implanted by injection into the region of the anterior chamber angle. Within other embodiments, the compound may also be 15 placed in any location such that the compound is continuously released into the aqueous humor. Within another aspect of the present invention, methods are provided for treating or preventing proliferative diabetic retinopathy, comprising the step of administering to a patient a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist to the eyes, such that the formation of blood 20 vessels is inhibited.

Within particularly preferred embodiments of the invention, proliferative diabetic retinopathy may be treated by injection into the aqueous humor or the vitreous, in order to increase the local concentration of the polynucleotide, polypeptide, antagonist and/or agonist in the retina. Preferably, this treatment should 25 be initiated prior to the acquisition of severe disease requiring photocoagulation.

Within another aspect of the present invention, methods are provided for treating or preventing retrobulbar fibroplasia, comprising the step of administering to a patient a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist to the eye, such that the formation of blood vessels is inhibited. The 30 compound may be administered topically, via intravitreous injection and/or via intraocular implants.

Additionally, diseases, disorders, and/or conditions which can be treated, prevented, and/or diagnosed with the polynucleotides, polypeptides, agonists and/or agonists include, but are not limited to, hemangioma, arthritis, psoriasis, angiofibroma, atherosclerotic plaques, delayed wound healing, granulations,

- 5 hemophilic joints, hypertrophic scars, nonunion fractures, Osler-Weber syndrome, pyogenic granuloma, scleroderma, trachoma, and vascular adhesions.

Moreover, diseases, disorders, and/or conditions and/or states, which can be treated, prevented, and/or diagnosed with the the polynucleotides, polypeptides, agonists and/or agonists include, but are not limited to, solid tumors, blood born

- 10 tumors such as leukemias, tumor metastasis, Kaposi's sarcoma, benign tumors, for example hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas, rheumatoid arthritis, psoriasis, ocular angiogenic diseases, for example, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retroental fibroplasia, rubeosis, retinoblastoma, and

- 15 uvietis, delayed wound healing, endometriosis, vascluogenesis, granulations, hypertrophic scars (keloids), nonunion fractures, scleroderma, trachoma, vascular adhesions, myocardial angiogenesis, coronary collaterals, cerebral collaterals, arteriovenous malformations, ischemic limb angiogenesis, Osler-Webber Syndrome, plaque neovascularization, telangiectasia, hemophiliac joints, angiofibroma

- 20 fibromuscular dysplasia, wound granulation, Crohn's disease, atherosclerosis, birth control agent by preventing vascularization required for embryo implantation controlling menstruation, diseases that have angiogenesis as a pathologic consequence such as cat scratch disease (*Rochelle minalia quintosa*), ulcers (*Helicobacter pylori*), Bartonellosis and bacillary angiomatosis.

- 25 In one aspect of the birth control method, an amount of the compound sufficient to block embryo implantation is administered before or after intercourse and fertilization have occurred, thus providing an effective method of birth control, possibly a "morning after" method. Polynucleotides, polypeptides, agonists and/or agonists may also be used in controlling menstruation or administered as either a  
30 peritoneal lavage fluid or for peritoneal implantation in the treatment of endometriosis.

Polynucleotides, polypeptides, agonists and/or agonists of the present invention may be incorporated into surgical sutures in order to prevent stitch granulomas.

Polynucleotides, polypeptides, agonists and/or agonists may be utilized in a wide variety of surgical procedures. For example, within one aspect of the present invention a compositions (in the form of, for example, a spray or film) may be utilized to coat or spray an area prior to removal of a tumor, in order to isolate normal surrounding tissues from malignant tissue, and/or to prevent the spread of disease to surrounding tissues. Within other aspects of the present invention, compositions (e.g., in the form of a spray) may be delivered via endoscopic procedures in order to coat tumors, or inhibit angiogenesis in a desired locale. Within yet other aspects of the present invention, surgical meshes which have been coated with anti-angiogenic compositions of the present invention may be utilized in any procedure wherein a surgical mesh might be utilized. For example, within one embodiment of the invention a surgical mesh laden with an anti-angiogenic composition may be utilized during abdominal cancer resection surgery (e.g., subsequent to colon resection) in order to provide support to the structure, and to release an amount of the anti-angiogenic factor.

Within further aspects of the present invention, methods are provided for treating tumor excision sites, comprising administering a polynucleotide, polypeptide, agonist and/or agonist to the resection margins of a tumor subsequent to excision, such that the local recurrence of cancer and the formation of new blood vessels at the site is inhibited. Within one embodiment of the invention, the anti-angiogenic compound is administered directly to the tumor excision site (e.g., applied by swabbing, brushing or otherwise coating the resection margins of the tumor with the anti-angiogenic compound). Alternatively, the anti-angiogenic compounds may be incorporated into known surgical pastes prior to administration. Within particularly preferred embodiments of the invention, the anti-angiogenic compounds are applied after hepatic resections for malignancy, and after neurosurgical operations.

Within one aspect of the present invention, polynucleotides, polypeptides, agonists and/or agonists may be administered to the resection margin of a wide

variety of tumors, including for example, breast, colon, brain and hepatic tumors. For example, within one embodiment of the invention, anti-angiogenic compounds may be administered to the site of a neurological tumor subsequent to excision, such that the formation of new blood vessels at the site are inhibited.

- 5       The polynucleotides, polypeptides, agonists and/or agonists of the present invention may also be administered along with other anti-angiogenic factors. Representative examples of other anti-angiogenic factors include: Anti-Invasive Factor, retinoic acid and derivatives thereof, paclitaxel, Suramin, Tissue Inhibitor of Metalloproteinase-1, Tissue Inhibitor of Metalloproteinase-2, Plasminogen Activator 10 Inhibitor-1, Plasminogen Activator Inhibitor-2, and various forms of the lighter "d group" transition metals.

Lighter "d group" transition metals include, for example, vanadium, molybdenum, tungsten, titanium, niobium, and tantalum species. Such transition metal species may form transition metal complexes. Suitable complexes of the 15 above-mentioned transition metal species include oxo transition metal complexes.

- Representative examples of vanadium complexes include oxo vanadium complexes such as vanadate and vanadyl complexes. Suitable vanadate complexes include metavanadate and orthovanadate complexes such as, for example, ammonium metavanadate, sodium metavanadate, and sodium orthovanadate. Suitable vanadyl 20 complexes include, for example, vanadyl acetylacetone and vanadyl sulfate including vanadyl sulfate hydrates such as vanadyl sulfate mono- and trihydrates.

Representative examples of tungsten and molybdenum complexes also include oxo complexes. Suitable oxo tungsten complexes include tungstate and tungsten oxide complexes. Suitable tungstate complexes include ammonium tungstate, 25 calcium tungstate, sodium tungstate dihydrate, and tungstic acid. Suitable tungsten oxides include tungsten (IV) oxide and tungsten (VI) oxide. Suitable oxo molybdenum complexes include molybdate, molybdenum oxide, and molybdenyl complexes. Suitable molybdate complexes include ammonium molybdate and its hydrates, sodium molybdate and its hydrates, and potassium molybdate and its 30 hydrates. Suitable molybdenum oxides include molybdenum (VI) oxide, molybdenum (VI) oxide, and molybdic acid. Suitable molybdenyl complexes include, for example,

molybdenyl acetylacetone. Other suitable tungsten and molybdenum complexes include hydroxo derivatives derived from, for example, glycerol, tartaric acid, and sugars.

A wide variety of other anti-angiogenic factors may also be utilized within the context of the present invention. Representative examples include platelet factor 4; protamine sulphate; sulphated chitin derivatives (prepared from queen crab shells), (Murata et al., Cancer Res. 51:22-26, 1991); Sulphated Polysaccharide Peptidoglycan Complex (SP- PG) (the function of this compound may be enhanced by the presence of steroids such as estrogen, and tamoxifen citrate); Staurosporine; modulators of matrix metabolism, including for example, proline analogs, cishydroxyproline, d,L-3,4-dehydroproline, Thiaproline, alpha,alpha-dipyridyl, aminopropionitrile fumarate; 4-propyl-5-(4-pyridinyl)-2(3H)-oxazolone; Methotrexate; Mitoxantrone; Heparin; Interferons; 2 Macroglobulin-serum; ChIMP-3 (Pavloff et al., J. Bio. Chem. 267:17321-17326, 1992); Chymostatin (Tomkinson et al., Biochem J. 286:475-480, 1992); Cyclodextrin Tetradecasulfate; Eponemycin; Camptothecin; Fumagillin (Ingber et al., Nature 348:555-557, 1990); Gold Sodium Thiomalate ("GST"; Matsubara and Ziff, J. Clin. Invest. 79:1440-1446, 1987); anticollagenase-serum; alpha2-antiplasmin (Holmes et al., J. Biol. Chem. 262(4):1659-1664, 1987); Bisantrene (National Cancer Institute); Lobenzarit disodium (N-(2)-carboxyphenyl-4-chloroanthronilic acid disodium or "CCA"; Takeuchi et al., Agents Actions 36:312-316, 1992); Thalidomide; Angostatic steroid; AGM-1470; carboxynaminolmidazole; and metalloproteinase inhibitors such as BB94.

#### Diseases at the Cellular Level

25 Diseases associated with increased cell survival or the inhibition of apoptosis that could be treated, prevented, and/or diagnosed by the polynucleotides or polypeptides and/or antagonists or agonists of the invention, include cancers (such as follicular lymphomas, carcinomas with p53 mutations, and hormone-dependent tumors, including, but not limited to colon cancer, cardiac tumors, pancreatic cancer, 30 melanoma, retinoblastoma, glioblastoma, lung cancer, intestinal cancer, testicular cancer, stomach cancer, neuroblastoma, myxoma, myoma, lymphoma, endothelioma,

osteoblastoma, osteoclastoma, osteosarcoma, chondrosarcoma, adenoma, breast cancer, prostate cancer, Kaposi's sarcoma and ovarian cancer); autoimmune diseases, disorders, and/or conditions (such as, multiple sclerosis, Sjogren's syndrome, Hashimoto's thyroiditis, biliary cirrhosis, Behcet's disease, Crohn's disease,

5 polymyositis, systemic lupus erythematosus and immune-related glomerulonephritis and rheumatoid arthritis) and viral infections (such as herpes viruses, pox viruses and adenoviruses), inflammation, graft v. host disease, acute graft rejection, and chronic graft rejection. In preferred embodiments, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention are used to inhibit growth, progression, and/or

10 metastasis of cancers, in particular those listed above.

Additional diseases or conditions associated with increased cell survival that could be treated, prevented or diagnosed by the polynucleotides or polypeptides, or agonists or antagonists of the invention, include, but are not limited to, progression, and/or metastases of malignancies and related disorders such as leukemia (including

15 acute leukemias (e.g., acute lymphocytic leukemia, acute myelocytic leukemia (including myeloblastic, promyelocytic, myelomonocytic, monocytic, and erythroleukemia)) and chronic leukemias (e.g., chronic myelocytic (granulocytic) leukemia and chronic lymphocytic leukemia)), polycythemia vera, lymphomas (e.g., Hodgkin's disease and non-Hodgkin's disease), multiple myeloma, Waldenstrom's

20 macroglobulinemia, heavy chain disease, and solid tumors including, but not limited to, sarcomas and carcinomas such as fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic

25 cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilm's tumor,

30 cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma,

craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendrogioma, menangioma, melanoma, neuroblastoma, and retinoblastoma.

- Diseases associated with increased apoptosis that could be treated, prevented, and/or diagnosed by the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, include AIDS; neurodegenerative diseases, disorders, and/or conditions (such as Alzheimer's disease, Parkinson's disease, Amyotrophic lateral sclerosis, Retinitis pigmentosa, Cerebellar degeneration and brain tumor or prior associated disease); autoimmune diseases, disorders, and/or conditions (such as, multiple sclerosis, Sjogren's syndrome, Hashimoto's thyroiditis, biliary cirrhosis, Behcet's disease, Crohn's disease, polymyositis, systemic lupus erythematosus and immune-related glomerulonephritis and rheumatoid arthritis) myelodysplastic syndromes (such as aplastic anemia), graft v. host disease, ischemic injury (such as that caused by myocardial infarction, stroke and reperfusion injury), liver injury (e.g., hepatitis related liver injury, ischemia/reperfusion injury, cholestosis (bile duct injury) and liver cancer); toxin-induced liver disease (such as that caused by alcohol), septic shock, cachexia and anorexia.

#### Wound Healing and Epithelial Cell Proliferation

- In accordance with yet a further aspect of the present invention, there is provided a process for utilizing the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, for therapeutic purposes, for example, to stimulate epithelial cell proliferation and basal keratinocytes for the purpose of wound healing, and to stimulate hair follicle production and healing of dermal wounds.
- Polynucleotides or polypeptides, as well as agonists or antagonists of the invention, may be clinically useful in stimulating wound healing including surgical wounds, excisional wounds, deep wounds involving damage of the dermis and epidermis, eye tissue wounds, dental tissue wounds, oral cavity wounds, diabetic ulcers, dermal ulcers, cubitus ulcers, arterial ulcers, venous stasis ulcers, burns resulting from heat exposure or chemicals, and other abnormal wound healing conditions such as uremia, malnutrition, vitamin deficiencies and complications associated with systemic treatment with steroids, radiation therapy and antineoplastic drugs and

antimetabolites. Polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to promote dermal reestablishment subsequent to dermal loss

The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to increase the adherence of skin grafts to a wound bed and to stimulate re-epithelialization from the wound bed. The following are a non-exhaustive list of grafts that polynucleotides or polypeptides, agonists or antagonists of the invention, could be used to increase adherence to a wound bed: autografts, artificial skin, allografts, autodermic graft, autoepidermic grafts, avascular grafts, Blair-Brown grafts, bone graft, brepheplastic grafts, cutis graft, delayed graft, dermic graft, epidermic graft, fascia graft, full thickness graft, heterologous graft, xenograft, homologous graft, hyperplastic graft, lamellar graft, mesh graft, mucosal graft, Ollier-Thiersch graft, omenpal graft, patch graft, pedicle graft, penetrating graft, split skin graft, thick split graft. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, can be used to promote skin strength and to improve the appearance of aged skin.

It is believed that the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, will also produce changes in hepatocyte proliferation, and epithelial cell proliferation in the lung, breast, pancreas, stomach, small intestine, and large intestine. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could promote proliferation of epithelial cells such as sebocytes, hair follicles, hepatocytes, type II pneumocytes, mucin-producing goblet cells, and other epithelial cells and their progenitors contained within the skin, lung, liver, and gastrointestinal tract. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, may promote proliferation of endothelial cells, keratinocytes, and basal keratinocytes.

The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could also be used to reduce the side effects of gut toxicity that result from radiation, chemotherapy treatments or viral infections. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, may have a cytoprotective effect on the small intestine mucosa. The polynucleotides or

polypeptides, and/or agonists or antagonists of the invention, may also stimulate healing of mucositis (mouth ulcers) that result from chemotherapy and viral infections.

The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could further be used in full regeneration of skin in full and partial thickness skin defects, including burns, (i.e., repopulation of hair follicles, sweat glands, and sebaceous glands), treatment of other skin defects such as psoriasis. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to treat epidermolysis bullosa, a defect in adherence of the epidermis to the underlying dermis which results in frequent, open and painful blisters by accelerating reepithelialization of these lesions. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could also be used to treat gastric and duodenal ulcers and help heal by scar formation of the mucosal lining and regeneration of glandular mucosa and duodenal mucosal lining more rapidly.

Inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis, are diseases which result in destruction of the mucosal surface of the small or large intestine, respectively. Thus, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to promote the resurfacing of the mucosal surface to aid more rapid healing and to prevent progression of inflammatory bowel disease. Treatment with the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, is expected to have a significant effect on the production of mucus throughout the gastrointestinal tract and could be used to protect the intestinal mucosa from injurious substances that are ingested or following surgery. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to treat diseases associated with the under expression of the polynucleotides of the invention.

Moreover, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to prevent and heal damage to the lungs due to various pathological states. A growth factor such as the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, which could stimulate proliferation and differentiation and promote the repair of alveoli and bronchiolar epithelium to

prevent or treat acute or chronic lung damage. For example, emphysema, which results in the progressive loss of aveoli, and inhalation injuries, i.e., resulting from smoke inhalation and burns, that cause necrosis of the bronchiolar epithelium and alveoli could be effectively treated, prevented, and/or diagnosed using the

5 polynucleotides or polypeptides, and/or agonists or antagonists of the invention. Also, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to stimulate the proliferation of and differentiation of type II pneumocytes, which may help treat or prevent disease such as hyaline membrane diseases, such as infant respiratory distress syndrome and bronchopulmonary

10 displasia, in premature infants.

The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could stimulate the proliferation and differentiation of hepatocytes and, thus, could be used to alleviate or treat liver diseases and pathologies such as fulminant liver failure caused by cirrhosis, liver damage caused by viral hepatitis and

15 toxic substances (i.e., acetaminophen, carbon tetrachloride and other hepatotoxins known in the art).

In addition, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used treat or prevent the onset of diabetes mellitus. In patients with newly diagnosed Types I and II diabetes, where some islet cell function

20 remains, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to maintain the islet function so as to alleviate, delay or prevent permanent manifestation of the disease. Also, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used as an auxiliary in islet cell transplantation to improve or promote islet cell function.

25

### Neurological Diseases

Nervous system diseases, disorders, and/or conditions, which can be treated, prevented, and/or diagnosed with the compositions of the invention (e.g.,

30 polypeptides, polynucleotides, and/or agonists or antagonists), include, but are not limited to, nervous system injuries, and diseases, disorders, and/or conditions which

result in either a disconnection of axons, a diminution or degeneration of neurons, or demyelination. Nervous system lesions which may be treated, prevented, and/or diagnosed in a patient (including human and non-human mammalian patients) according to the invention, include but are not limited to, the following lesions of

5 either the central (including spinal cord, brain) or peripheral nervous systems: (1) ischemic lesions, in which a lack of oxygen in a portion of the nervous system results in neuronal injury or death, including cerebral infarction or ischemia, or spinal cord infarction or ischemia; (2) traumatic lesions, including lesions caused by physical injury or associated with surgery, for example, lesions which sever a portion of the

10 nervous system, or compression injuries; (3) malignant lesions, in which a portion of the nervous system is destroyed or injured by malignant tissue which is either a nervous system associated malignancy or a malignancy derived from non-nervous system tissue; (4) infectious lesions, in which a portion of the nervous system is destroyed or injured as a result of infection, for example, by an abscess or associated

15 with infection by human immunodeficiency virus, herpes zoster, or herpes simplex virus or with Lyme disease, tuberculosis, syphilis; (5) degenerative lesions, in which a portion of the nervous system is destroyed or injured as a result of a degenerative process including but not limited to degeneration associated with Parkinson's disease, Alzheimer's disease, Huntington's chorea, or amyotrophic lateral sclerosis (ALS); (6)

20 lesions associated with nutritional diseases, disorders, and/or conditions, in which a portion of the nervous system is destroyed or injured by a nutritional disorder or disorder of metabolism including but not limited to, vitamin B12 deficiency, folic acid deficiency, Wernicke disease, tobacco-alcohol amblyopia, Marchiafava-Bignami disease (primary degeneration of the corpus callosum), and alcoholic cerebellar

25 degeneration; (7) neurological lesions associated with systemic diseases including, but not limited to, diabetes (diabetic neuropathy, Bell's palsy), systemic lupus erythematosus, carcinoma, or sarcoidosis; (8) lesions caused by toxic substances including alcohol, lead, or particular neurotoxins; and (9) demyelinated lesions in which a portion of the nervous system is destroyed or injured by a demyelinating

30 disease including, but not limited to, multiple sclerosis, human immunodeficiency

virus-associated myelopathy, transverse myelopathy or various etiologies, progressive multifocal leukoencephalopathy, and central pontine myelinolysis.

- In a preferred embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to protect neural cells from the damaging effects of cerebral hypoxia. According to this embodiment, the compositions of the invention are used to treat, prevent, and/or diagnose neural cell injury associated with cerebral hypoxia. In one aspect of this embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose neural cell injury associated with cerebral ischemia. In another 10 aspect of this embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose neural cell injury associated with cerebral infarction. In another aspect of this embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose or prevent neural cell injury associated with a stroke.
- 15 In a further aspect of this embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose neural cell injury associated with a heart attack.

- The compositions of the invention which are useful for treating or preventing a nervous system disorder may be selected by testing for biological activity in 20 promoting the survival or differentiation of neurons. For example, and not by way of limitation, compositions of the invention which elicit any of the following effects may be useful according to the invention: (1) increased survival time of neurons in culture; (2) increased sprouting of neurons in culture or *in vivo*; (3) increased production of a neuron-associated molecule in culture or *in vivo*, e.g., choline acetyltransferase or 25 acetylcholinesterase with respect to motor neurons; or (4) decreased symptoms of neuron dysfunction *in vivo*. Such effects may be measured by any method known in the art. In preferred, non-limiting embodiments, increased survival of neurons may routinely be measured using a method set forth herein or otherwise known in the art, such as, for example, the method set forth in Arakawa et al. (*J. Neurosci.* 30 10:3507-3515 (1990)); increased sprouting of neurons may be detected by methods known in the art, such as, for example, the methods set forth in Pestronk et al. (*Exp.*

- Neurol. 70:65-82 (1980)) or Brown et al. (Ann. Rev. Neurosci. 4:17-42 (1981)); increased production of neuron-associated molecules may be measured by bioassay, enzymatic assay, antibody binding, Northern blot assay, etc., using techniques known in the art and depending on the molecule to be measured; and motor neuron dysfunction may be measured by assessing the physical manifestation of motor neuron disorder, e.g., weakness, motor neuron conduction velocity, or functional disability.

In specific embodiments, motor neuron diseases, disorders, and/or conditions that may be treated, prevented, and/or diagnosed according to the invention include, but are not limited to, diseases, disorders, and/or conditions such as infarction, infection, exposure to toxin, trauma, surgical damage, degenerative disease or malignancy that may affect motor neurons as well as other components of the nervous system, as well as diseases, disorders, and/or conditions that selectively affect neurons such as amyotrophic lateral sclerosis, and including, but not limited to, progressive spinal muscular atrophy, progressive bulbar palsy, primary lateral sclerosis, infantile and juvenile muscular atrophy, progressive bulbar paralysis of childhood (Fazio-Londe syndrome), poliomyelitis and the post polio syndrome, and Hereditary Motorsensory Neuropathy (Charcot-Marie-Tooth Disease).

20 **Infectious Disease**

A polypeptide or polynucleotide and/or agonist or antagonist of the present invention can be used to treat, prevent, and/or diagnose infectious agents. For example, by increasing the immune response, particularly increasing the proliferation and differentiation of B and/or T cells, infectious diseases may be treated, prevented, and/or diagnosed. The immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, polypeptide or polynucleotide and/or agonist or antagonist of the present invention may also directly inhibit the infectious agent, without necessarily eliciting an immune response.

30 Viruses are one example of an infectious agent that can cause disease or symptoms that can be treated, prevented, and/or diagnosed by a polynucleotide or

polypeptide and/or agonist or antagonist of the present invention. Examples of viruses, include, but are not limited to Examples of viruses, include, but are not limited to the following DNA and RNA viruses and viral families: Arbovirus, Adenoviridae, Arenaviridae, Arterivirus, Birnaviridae, Bunyaviridae, Caliciviridae,

5 Circoviridae, Coronaviridae, Dengue, EBV, HIV, Flaviviridae, Hepadnaviridae (Hepatitis), Herpesviridae (such as, Cytomegalovirus, Herpes Simplex, Herpes Zoster), Mononegavirus (e.g., Paramyxoviridae, Morbillivirus, Rhabdoviridae), Orthomyxoviridae (e.g., Influenza A, Influenza B, and parainfluenza), Papiloma virus, Papovaviridae, Parvoviridae, Picornaviridae, Poxviridae (such as Smallpox or

10 Vaccinia), Reoviridae (e.g., Rotavirus), Retroviridae (HTLV-I, HTLV-II, Lentivirus), and Togaviridae (e.g., Rubivirus). Viruses falling within these families can cause a variety of diseases or symptoms, including, but not limited to: arthritis, bronchiolitis, respiratory syncytial virus, encephalitis, eye infections (e.g., conjunctivitis, keratitis), chronic fatigue syndrome, hepatitis (A, B, C, E, Chronic Active, Delta), Japanese B

15 encephalitis, Junin, Chikungunya, Rift Valley fever, yellow fever, meningitis, opportunistic infections (e.g., AIDS), pneumonia, Burkitt's Lymphoma, chickenpox, hemorrhagic fever, Measles, Mumps, Parainfluenza, Rabies, the common cold, Polio, leukemia, Rubella, sexually transmitted diseases, skin diseases (e.g., Kaposi's, warts), and viremia. polynucleotides or polypeptides, or agonists or antagonists of the

20 invention, can be used to treat, prevent, and/or diagnose any of these symptoms or diseases. In specific embodiments, polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose: meningitis, Dengue, EBV, and/or hepatitis (e.g., hepatitis B). In an additional specific embodiment polynucleotides, polypeptides, or agonists or antagonists of the invention

25 are used to treat patients nonresponsive to one or more other commercially available hepatitis vaccines. In a further specific embodiment polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose AIDS.

Similarly, bacterial or fungal agents that can cause disease or symptoms and

30 that can be treated, prevented, and/or diagnosed by a polynucleotide or polypeptide and/or agonist or antagonist of the present invention include, but not limited to,

include, but not limited to, the following Gram-Negative and Gram-positive bacteria and bacterial families and fungi: Actinomycetales (e.g., Corynebacterium, Mycobacterium, Nocardia), Cryptococcus neoformans, Aspergillosis, Bacillaceae (e.g., Anthrax, Clostridium), Bacteroidaceae, Blastomycosis, Bordetella, Borrelia (e.g., Borrelia burgdorferi), Brucellosis, Candidiasis, Campylobacter, Coccidioidomycosis, Cryptococcosis, Dermatocycoses, E. coli (e.g., Enterotoxigenic E. coli and Enterohemorrhagic E. coli), Enterobacteriaceae (Klebsiella, Salmonella (e.g., Salmonella typhi, and Salmonella paratyphi), Serratia, Yersinia), Erysipelothrix, Helicobacter, Legionellosis, Leptospirosis, Listeria, Mycoplasmatales, 5 Mycobacterium leprae, Vibrio cholerae, Neisseriaceae (e.g., Acinetobacter, Gonorrhea, Menigococcal), Meisseria meningitidis, Pasteurellacea Infections (e.g., Actinobacillus, Heamophilus (e.g., Heamophilus influenza type B), Pasteurella), Pseudomonas, Rickettsiaceae, Chlamydiaceae, Syphilis, Shigella spp., Staphylococcal, Meningiococcal, Pneumococcal and Streptococcal (e.g., 10 15 Streptococcus pneumoniae and Group B Streptococcus). These bacterial or fungal families can cause the following diseases or symptoms, including, but not limited to: bacteremia, endocarditis, eye infections (conjunctivitis, tuberculosis, uveitis), gingivitis, opportunistic infections (e.g., AIDS related infections), paronychia, prosthesis-related infections, Reiter's Disease, respiratory tract infections, such as Whooping Cough or Empyema, sepsis, Lyme Disease, Cat-Scratch Disease, 20 Dysentery, Paratyphoid Fever, food poisoning, Typhoid, pneumonia, Gonorrhea, meningitis (e.g., mengitis types A and B), Chlamydia, Syphilis, Diphtheria, Leprosy, Paratuberculosis, Tuberculosis, Lupus, Botulism, gangrene, tetanus, impetigo, Rheumatic Fever, Scarlet Fever, sexually transmitted diseases, skin diseases (e.g., cellulitis, dermatocycoses), toxemia, urinary tract infections, wound infections. 25 Polynucleotides or polypeptides, agonists or antagonists of the invention, can be used to treat, prevent, and/or diagnose any of these symptoms or diseases. In specific embodiments, polynucleotides, polypeptides, agonists or antagonists of the invention are used to treat, prevent, and/or diagnose: tetanus, Diphteria, botulism, and/or meningitis type B.

Moreover, parasitic agents causing disease or symptoms that can be treated, prevented, and/or diagnosed by a polynucleotide or polypeptide and/or agonist or antagonist of the present invention include, but not limited to, the following families or class: Amebiasis, Babesiosis, Coccidiosis, Cryptosporidiosis, Dientamoebiasis, 5 Dourine, Ectoparasitic, Giardiasis, Helminthiasis, Leishmaniasis, Theileriasis, Toxoplasmosis, Trypanosomiasis, and Trichomonas and Sporozoans (e.g., Plasmodium virax, Plasmodium falciparium, Plasmodium malariae and Plasmodium ovale). These parasites can cause a variety of diseases or symptoms, including, but not limited to: Scabies, Trombiculiasis, eye infections, intestinal disease (e.g., 10 dysentery, giardiasis), liver disease, lung disease, opportunistic infections (e.g., AIDS related), malaria, pregnancy complications, and toxoplasmosis. Polynucleotides or polypeptides, or agonists or antagonists of the invention, can be used to treat, prevent, and/or diagnose any of these symptoms or diseases. In specific embodiments, polynucleotides, polypeptides, or agonists or antagonists of the invention are used to 15 treat, prevent, and/or diagnose malaria.

Preferably, treatment or prevention using a polypeptide or polynucleotide and/or agonist or antagonist of the present invention could either be by administering an effective amount of a polypeptide to the patient, or by removing cells from the patient, supplying the cells with a polynucleotide of the present invention, and 20 returning the engineered cells to the patient (ex vivo therapy). Moreover, the polypeptide or polynucleotide of the present invention can be used as an antigen in a vaccine to raise an immune response against infectious disease.

### Regeneration

25 A polynucleotide or polypeptide and/or agonist or antagonist of the present invention can be used to differentiate, proliferate, and attract cells, leading to the regeneration of tissues. (See, Science 276:59-87 (1997).) The regeneration of tissues could be used to repair, replace, or protect tissue damaged by congenital defects, trauma (wounds, burns, incisions, or ulcers), age, disease (e.g. osteoporosis, 30 osteoarthritis, periodontal disease, liver failure), surgery, including cosmetic plastic surgery, fibrosis, reperfusion injury, or systemic cytokine damage.

Tissues that could be regenerated using the present invention include organs (e.g., pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac), vasculature (including vascular and lymphatics), nervous, hematopoietic, and skeletal (bone, cartilage, tendon, and ligament) tissue. Preferably, regeneration occurs without or decreased scarring. Regeneration also may include angiogenesis.

Moreover, a polynucleotide or polypeptide and/or agonist or antagonist of the present invention may increase regeneration of tissues difficult to heal. For example, increased tendon/ligament regeneration would quicken recovery time after damage.

A polynucleotide or polypeptide and/or agonist or antagonist of the present invention could also be used prophylactically in an effort to avoid damage. Specific diseases that could be treated, prevented, and/or diagnosed include of tendinitis, carpal tunnel syndrome, and other tendon or ligament defects. A further example of tissue regeneration of non-healing wounds includes pressure ulcers, ulcers associated with vascular insufficiency, surgical, and traumatic wounds.

Similarly, nerve and brain tissue could also be regenerated by using a polynucleotide or polypeptide and/or agonist or antagonist of the present invention to proliferate and differentiate nerve cells. Diseases that could be treated, prevented, and/or diagnosed using this method include central and peripheral nervous system diseases, neuropathies, or mechanical and traumatic diseases, disorders, and/or conditions (e.g., spinal cord disorders, head trauma, cerebrovascular disease, and stoke). Specifically, diseases associated with peripheral nerve injuries, peripheral neuropathy (e.g., resulting from chemotherapy or other medical therapies), localized neuropathies, and central nervous system diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome), could all be treated, prevented, and/or diagnosed using the polynucleotide or polypeptide and/or agonist or antagonist of the present invention.

### Chemotaxis

A polynucleotide or polypeptide and/or agonist or antagonist of the present invention may have chemotaxis activity. A chemotactic molecule attracts or mobilizes cells (e.g., monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils,

epithelial and/or endothelial cells) to a particular site in the body, such as inflammation, infection, or site of hyperproliferation. The mobilized cells can then fight off and/or heal the particular trauma or abnormality.

A polynucleotide or polypeptide and/or agonist or antagonist of the present invention may increase chemotactic activity of particular cells. These chemotactic molecules can then be used to treat, prevent, and/or diagnose inflammation, infection, hyperproliferative diseases, disorders, and/or conditions, or any immune system disorder by increasing the number of cells targeted to a particular location in the body. For example, chemotactic molecules can be used to treat, prevent, and/or diagnose wounds and other trauma to tissues by attracting immune cells to the injured location. Chemotactic molecules of the present invention can also attract fibroblasts, which can be used to treat, prevent, and/or diagnose wounds.

It is also contemplated that a polynucleotide or polypeptide and/or agonist or antagonist of the present invention may inhibit chemotactic activity. These molecules could also be used to treat, prevent, and/or diagnose diseases, disorders, and/or conditions. Thus, a polynucleotide or polypeptide and/or agonist or antagonist of the present invention could be used as an inhibitor of chemotaxis.

## 20 Binding Activity

A polypeptide of the present invention may be used to screen for molecules that bind to the polypeptide or for molecules to which the polypeptide binds. The binding of the polypeptide and the molecule may activate (agonist), increase, inhibit (antagonist), or decrease activity of the polypeptide or the molecule bound. Examples of such molecules include antibodies, oligonucleotides, proteins (e.g., receptors), or small molecules.

Preferably, the molecule is closely related to the natural ligand of the polypeptide, e.g., a fragment of the ligand, or a natural substrate, a ligand, a structural or functional mimetic. (See, Coligan et al., Current Protocols in Immunology 1(2):Chapter 5 (1991).) Similarly, the molecule can be closely related to the natural receptor to which the polypeptide binds, or at least, a fragment of the receptor capable

of being bound by the polypeptide (e.g., active site). In either case, the molecule can be rationally designed using known techniques.

Preferably, the screening for these molecules involves producing appropriate cells which express the polypeptide, either as a secreted protein or on the cell membrane. Preferred cells include cells from mammals, yeast, *Drosophila*, or *E. coli*. Cells expressing the polypeptide (or cell membrane containing the expressed polypeptide) are then preferably contacted with a test compound potentially containing the molecule to observe binding, stimulation, or inhibition of activity of either the polypeptide or the molecule.

The assay may simply test binding of a candidate compound to the polypeptide, wherein binding is detected by a label, or in an assay involving competition with a labeled competitor. Further, the assay may test whether the candidate compound results in a signal generated by binding to the polypeptide.

Alternatively, the assay can be carried out using cell-free preparations, polypeptide/molecule affixed to a solid support, chemical libraries, or natural product mixtures. The assay may also simply comprise the steps of mixing a candidate compound with a solution containing a polypeptide, measuring polypeptide/molecule activity or binding, and comparing the polypeptide/molecule activity or binding to a standard.

Preferably, an ELISA assay can measure polypeptide level or activity in a sample (e.g., biological sample) using a monoclonal or polyclonal antibody. The antibody can measure polypeptide level or activity by either binding, directly or indirectly, to the polypeptide or by competing with the polypeptide for a substrate.

Additionally, the receptor to which a polypeptide of the invention binds can be identified by numerous methods known to those of skill in the art, for example, ligand panning and FACS sorting (Coligan, et al., Current Protocols in Immun., 1(2), Chapter 5, (1991)). For example, expression cloning is employed wherein polyadenylated RNA is prepared from a cell responsive to the polypeptides, for example, NIH3T3 cells which are known to contain multiple receptors for the FGF family proteins, and SC-3 cells, and a cDNA library created from this RNA is divided into pools and used to transfect COS cells or other cells that are not responsive to the

polypeptides. Transfected cells which are grown on glass slides are exposed to the polypeptide of the present invention, after they have been labelled. The polypeptides can be labeled by a variety of means including iodination or inclusion of a recognition site for a site-specific protein kinase.

5 Following fixation and incubation, the slides are subjected to auto-radiographic analysis. Positive pools are identified and sub-pools are prepared and re-transfected using an iterative sub-pooling and re-screening process, eventually yielding a single clones that encodes the putative receptor.

As an alternative approach for receptor identification, the labeled polypeptides  
10 can be photoaffinity linked with cell membrane or extract preparations that express the receptor molecule. Cross-linked material is resolved by PAGE analysis and exposed to X-ray film. The labeled complex containing the receptors of the polypeptides can be excised, resolved into peptide fragments, and subjected to protein microsequencing. The amino acid sequence obtained from microsequencing would  
15 be used to design a set of degenerate oligonucleotide probes to screen a cDNA library to identify the genes encoding the putative receptors.

Moreover, the techniques of gene-shuffling, motif-shuffling, exon-shuffling, and/or codon-shuffling (collectively referred to as "DNA shuffling") may be employed to modulate the activities of polypeptides of the invention thereby  
20 effectively generating agonists and antagonists of polypeptides of the invention. See generally, U.S. Patent Nos. 5,605,793, 5,811,238, 5,830,721, 5,834,252, and 5,837,458, and Patten, P. A., et al., *Curr. Opinion Biotechnol.* 8:724-33 (1997); Harayama, S. *Trends Biotechnol.* 16(2):76-82 (1998); Hansson, L. O., et al., *J. Mol. Biol.* 287:265-76 (1999); and Lorenzo, M. M. and Blasco, R. *Biotechniques* 25(2):308-13 (1998) (each of these patents and publications are hereby incorporated by reference). In one embodiment, alteration of polynucleotides and corresponding polypeptides of the invention may be achieved by DNA shuffling. DNA shuffling involves the assembly of two or more DNA segments into a desired polynucleotide sequence of the invention molecule by homologous, or site-specific, recombination.  
25 In another embodiment, polynucleotides and corresponding polypeptides of the invention may be altered by being subjected to random mutagenesis by error-prone  
30

PCR, random nucleotide insertion or other methods prior to recombination. In another embodiment, one or more components, motifs, sections, parts, domains, fragments, etc., of the polypeptides of the invention may be recombined with one or more components, motifs, sections, parts, domains, fragments, etc. of one or more heterologous molecules. In preferred embodiments, the heterologous molecules are family members. In further preferred embodiments, the heterologous molecule is a growth factor such as, for example, platelet-derived growth factor (PDGF), insulin-like growth factor (IGF-I), transforming growth factor (TGF)-alpha, epidermal growth factor (EGF), fibroblast growth factor (FGF), TGF-beta, bone morphogenetic protein (BMP)-2, BMP-4, BMP-5, BMP-6, BMP-7, activins A and B, decapentaplegic(dpp), 60A, OP-2, dorsalin, growth differentiation factors (GDFs), nodal, MIS, inhibin-alpha, TGF-beta1, TGF-beta2, TGF-beta3, TGF-beta5, and glial-derived neurotrophic factor (GDNF).

Other preferred fragments are biologically active fragments of the polypeptides of the invention. Biologically active fragments are those exhibiting activity similar, but not necessarily identical, to an activity of the polypeptide. The biological activity of the fragments may include an improved desired activity, or a decreased undesirable activity.

Additionally, this invention provides a method of screening compounds to identify those which modulate the action of the polypeptide of the present invention. An example of such an assay comprises combining a mammalian fibroblast cell, a the polypeptide of the present invention, the compound to be screened and 3[H] thymidine under cell culture conditions where the fibroblast cell would normally proliferate. A control assay may be performed in the absence of the compound to be screened and compared to the amount of fibroblast proliferation in the presence of the compound to determine if the compound stimulates proliferation by determining the uptake of 3[H] thymidine in each case. The amount of fibroblast cell proliferation is measured by liquid scintillation chromatography which measures the incorporation of 3[H] thymidine. Both agonist and antagonist compounds may be identified by this procedure.

In another method, a mammalian cell or membrane preparation expressing a receptor for a polypeptide of the present invention is incubated with a labeled polypeptide of the present invention in the presence of the compound. The ability of the compound to enhance or block this interaction could then be measured.

- 5 Alternatively, the response of a known second messenger system following interaction of a compound to be screened and the receptor is measured and the ability of the compound to bind to the receptor and elicit a second messenger response is measured to determine if the compound is a potential agonist or antagonist. Such second messenger systems include but are not limited to, cAMP guanylate cyclase,
- 10 ion channels or phosphoinositide hydrolysis.

All of these above assays can be used as diagnostic or prognostic markers. The molecules discovered using these assays can be used to treat, prevent, and/or diagnose disease or to bring about a particular result in a patient (e.g., blood vessel growth) by activating or inhibiting the polypeptide/molecule. Moreover, the assays

- 15 can discover agents which may inhibit or enhance the production of the polypeptides of the invention from suitably manipulated cells or tissues. Therefore, the invention includes a method of identifying compounds which bind to the polypeptides of the invention comprising the steps of: (a) incubating a candidate binding compound with the polypeptide; and (b) determining if binding has occurred. Moreover, the
- 20 invention includes a method of identifying agonists/antagonists comprising the steps of: (a) incubating a candidate compound with the polypeptide, (b) assaying a biological activity , and (b) determining if a biological activity of the polypeptide has been altered.

Also, one could identify molecules bind a polypeptide of the invention

- 25 experimentally by using the beta-pleated sheet regions contained in the polypeptide sequence of the protein. Accordingly, specific embodiments of the invention are directed to polynucleotides encoding polypeptides which comprise, or alternatively consist of, the amino acid sequence of each beta pleated sheet regions in a disclosed polypeptide sequence. Additional embodiments of the invention are directed to
- 30 polynucleotides encoding polypeptides which comprise, or alternatively consist of, any combination or all of contained in the polypeptide sequences of the invention.

Additional preferred embodiments of the invention are directed to polypeptides which comprise, or alternatively consist of, the amino acid sequence of each of the beta pleated sheet regions in one of the polypeptide sequences of the invention. Additional embodiments of the invention are directed to polypeptides which comprise, or 5 alternatively consist of, any combination or all of the beta pleated sheet regions in one of the polypeptide sequences of the invention.

### **Targeted Delivery**

In another embodiment, the invention provides a method of delivering 10 compositions to targeted cells expressing a receptor for a polypeptide of the invention, or cells expressing a cell bound form of a polypeptide of the invention.

As discussed herein, polypeptides or antibodies of the invention may be associated with heterologous polypeptides, heterologous nucleic acids, toxins, or prodrugs via hydrophobic, hydrophilic, ionic and/or covalent interactions. In one 15 embodiment, the invention provides a method for the specific delivery of compositions of the invention to cells by administering polypeptides of the invention (including antibodies) that are associated with heterologous polypeptides or nucleic acids. In one example, the invention provides a method for delivering a therapeutic protein into the targeted cell. In another example, the invention provides a method for 20 delivering a single stranded nucleic acid (e.g., antisense or ribozymes) or double stranded nucleic acid (e.g., DNA that can integrate into the cell's genome or replicate episomally and that can be transcribed) into the targeted cell.

In another embodiment, the invention provides a method for the specific destruction of cells (e.g., the destruction of tumor cells) by administering polypeptides 25 of the invention (e.g., polypeptides of the invention or antibodies of the invention) in association with toxins or cytotoxic prodrugs.

By "toxin" is meant compounds that bind and activate endogenous cytotoxic effector systems, radioisotopes, holotoxins, modified toxins, catalytic subunits of toxins, or any molecules or enzymes not normally present in or on the surface of a cell 30 that under defined conditions cause the cell's death. Toxins that may be used according to the methods of the invention include, but are not limited to, radioisotopes

known in the art, compounds such as, for example, antibodies (or complement fixing containing portions thereof) that bind an inherent or induced endogenous cytotoxic effector system, thymidine kinase, endonuclease, RNase, alpha toxin, ricin, abrin, *Pseudomonas* exotoxin A, diphtheria toxin, saporin, momordin, gelonin, pokeweed 5 antiviral protein, alpha-sarcin and cholera toxin. By "cytotoxic prodrug" is meant a non-toxic compound that is converted by an enzyme, normally present in the cell, into a cytotoxic compound. Cytotoxic prodrugs that may be used according to the methods of the invention include, but are not limited to, glutamyl derivatives of benzoic acid mustard alkylating agent, phosphate derivatives of etoposide or 10 mitomycin C, cytosine arabinoside, daunorubisin, and phenoxyacetamide derivatives of doxorubicin.

### Drug Screening

Further contemplated is the use of the polypeptides of the present invention, or 15 the polynucleotides encoding these polypeptides, to screen for molecules which modify the activities of the polypeptides of the present invention. Such a method would include contacting the polypeptide of the present invention with a selected compound(s) suspected of having antagonist or agonist activity, and assaying the activity of these polypeptides following binding.

20 This invention is particularly useful for screening therapeutic compounds by using the polypeptides of the present invention, or binding fragments thereof, in any of a variety of drug screening techniques. The polypeptide or fragment employed in such a test may be affixed to a solid support, expressed on a cell surface, free in solution, or located intracellularly. One method of drug screening utilizes eukaryotic 25 or prokaryotic host cells which are stably transformed with recombinant nucleic acids expressing the polypeptide or fragment. Drugs are screened against such transformed cells in competitive binding assays. One may measure, for example, the formulation of complexes between the agent being tested and a polypeptide of the present invention.

30 Thus, the present invention provides methods of screening for drugs or any other agents which affect activities mediated by the polypeptides of the present

invention. These methods comprise contacting such an agent with a polypeptide of the present invention or a fragment thereof and assaying for the presence of a complex between the agent and the polypeptide or a fragment thereof, by methods well known in the art. In such a competitive binding assay, the agents to screen are typically labeled. Following incubation, free agent is separated from that present in bound form, and the amount of free or uncomplexed label is a measure of the ability of a particular agent to bind to the polypeptides of the present invention.

Another technique for drug screening provides high throughput screening for compounds having suitable binding affinity to the polypeptides of the present invention, and is described in great detail in European Patent Application 84/03564, published on September 13, 1984, which is incorporated herein by reference herein. Briefly stated, large numbers of different small peptide test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The peptide test compounds are reacted with polypeptides of the present invention and washed. Bound polypeptides are then detected by methods well known in the art. Purified polypeptides are coated directly onto plates for use in the aforementioned drug screening techniques. In addition, non-neutralizing antibodies may be used to capture the peptide and immobilize it on the solid support.

This invention also contemplates the use of competitive drug screening assays in which neutralizing antibodies capable of binding polypeptides of the present invention specifically compete with a test compound for binding to the polypeptides or fragments thereof. In this manner, the antibodies are used to detect the presence of any peptide which shares one or more antigenic epitopes with a polypeptide of the invention.

25

#### Antisense And Ribozyme (Antagonists)

In specific embodiments, antagonists according to the present invention are nucleic acids corresponding to the sequences contained in SEQ ID NO:X, or the complementary strand thereof, and/or to nucleotide sequences contained a deposited clone. In one embodiment, antisense sequence is generated internally by the organism, in another embodiment, the antisense sequence is separately administered

(see, for example, O'Connor, Neurochem., 56:560 (1991). Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988).

Antisense technology can be used to control gene expression through antisense DNA or RNA, or through triple-helix formation. Antisense techniques are discussed for

- 5 example, in Okano, Neurochem., 56:560 (1991); Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988). Triple helix formation is discussed in, for instance, Lee et al., Nucleic Acids Research, 6:3073 (1979); Cooney et al., Science, 241:456 (1988); and Dervan et al., Science, 251:1300 (1991). The methods are based on binding of a polynucleotide to a complementary

10 DNA or RNA.

For example, the use of c-myc and c-myb antisense RNA constructs to inhibit the growth of the non-lymphocytic leukemia cell line HL-60 and other cell lines was previously described. (Wickstrom et al. (1988); Anfossi et al. (1989)). These experiments were performed in vitro by incubating cells with the oligoribonucleotide.

- 15 A similar procedure for in vivo use is described in WO 91/15580. Briefly, a pair of oligonucleotides for a given antisense RNA is produced as follows: A sequence complimentary to the first 15 bases of the open reading frame is flanked by an EcoR1 site on the 5' end and a HindIII site on the 3' end. Next, the pair of oligonucleotides is heated at 90°C for one minute and then annealed in 2X ligation buffer (20mM TRIS  
20 HCl pH 7.5, 10mM MgCl<sub>2</sub>, 10MM dithiothreitol (DTT) and 0.2 mM ATP) and then ligated to the EcoR1/Hind III site of the retroviral vector PMV7 (WO 91/15580).

- For example, the 5' coding portion of a polynucleotide that encodes the mature polypeptide of the present invention may be used to design an antisense RNA oligonucleotide of from about 10 to 40 base pairs in length. A DNA oligonucleotide  
25 is designed to be complementary to a region of the gene involved in transcription thereby preventing transcription and the production of the receptor. The antisense RNA oligonucleotide hybridizes to the mRNA in vivo and blocks translation of the mRNA molecule into receptor polypeptide.

- In one embodiment, the antisense nucleic acid of the invention is produced  
30 intracellularly by transcription from an exogenous sequence. For example, a vector or a portion thereof, is transcribed, producing an antisense nucleic acid (RNA) of the

invention. Such a vector would contain a sequence encoding the antisense nucleic acid of the invention. Such a vector can remain episomal or become chromosomally integrated, as long as it can be transcribed to produce the desired antisense RNA. Such vectors can be constructed by recombinant DNA technology methods standard 5 in the art. Vectors can be plasmid, viral, or others known in the art, used for replication and expression in vertebrate cells. Expression of the sequence encoding a polypeptide of the invention, or fragments thereof, can be by any promoter known in the art to act in vertebrate, preferably human cells. Such promoters can be inducible or constitutive. Such promoters include, but are not limited to, the SV40 early 10 promoter region (Bernoist and Chambon, Nature, 29:304-310 (1981), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto et al., Cell, 22:787-797 (1980), the herpes thymidine promoter (Wagner et al., Proc. Natl. Acad. Sci. U.S.A., 78:1441-1445 (1981), the regulatory sequences of the metallothionein gene (Brinster et al., Nature, 296:39-42 (1982)), etc.

15       The antisense nucleic acids of the invention comprise a sequence complementary to at least a portion of an RNA transcript of a gene of interest. However, absolute complementarity, although preferred, is not required. A sequence "complementary to at least a portion of an RNA," referred to herein, means a sequence having sufficient complementarity to be able to hybridize with the RNA, 20 forming a stable duplex; in the case of double stranded antisense nucleic acids of the invention, a single strand of the duplex DNA may thus be tested, or triplex formation may be assayed. The ability to hybridize will depend on both the degree of complementarity and the length of the antisense nucleic acid. Generally, the larger the hybridizing nucleic acid, the more base mismatches with a RNA sequence of the 25 invention it may contain and still form a stable duplex (or triplex as the case may be). One skilled in the art can ascertain a tolerable degree of mismatch by use of standard procedures to determine the melting point of the hybridized complex.

          Oligonucleotides that are complementary to the 5' end of the message, e.g., the 5' untranslated sequence up to and including the AUG initiation codon, should 30 work most efficiently at inhibiting translation. However, sequences complementary to the 3' untranslated sequences of mRNAs have been shown to be effective at

- inhibiting translation of mRNAs as well. See generally, Wagner, R., *Nature*, 372:333-335 (1994). Thus, oligonucleotides complementary to either the 5' - or 3' - non-translated, non-coding regions of a polynucleotide sequence of the invention could be used in an antisense approach to inhibit translation of endogenous mRNA.
- 5 Oligonucleotides complementary to the 5' untranslated region of the mRNA should include the complement of the AUG start codon. Antisense oligonucleotides complementary to mRNA coding regions are less efficient inhibitors of translation but could be used in accordance with the invention. Whether designed to hybridize to the 5' -, 3' - or coding region of mRNA, antisense nucleic acids should be at least six
- 10 nucleotides in length, and are preferably oligonucleotides ranging from 6 to about 50 nucleotides in length. In specific aspects the oligonucleotide is at least 10 nucleotides, at least 17 nucleotides, at least 25 nucleotides or at least 50 nucleotides.

The polynucleotides of the invention can be DNA or RNA or chimeric mixtures or derivatives or modified versions thereof, single-stranded or double-stranded. The oligonucleotide can be modified at the base moiety, sugar moiety, or phosphate backbone, for example, to improve stability of the molecule, hybridization, etc. The oligonucleotide may include other appended groups such as peptides (e.g., for targeting host cell receptors *in vivo*), or agents facilitating transport across the cell membrane (see, e.g., Letsinger et al., Proc. Natl. Acad. Sci. U.S.A. 86:6553-6556 (1989); Lemaitre et al., Proc. Natl. Acad. Sci., 84:648-652 (1987); PCT Publication NO: WO88/09810, published December 15, 1988) or the blood-brain barrier (see, e.g., PCT Publication NO: WO89/10134, published April 25, 1988), hybridization-triggered cleavage agents. (See, e.g., Krol et al., BioTechniques, 6:958-976 (1988)) or intercalating agents. (See, e.g., Zon, Pharm. Res., 5:539-549 (1988)). To this end, 25 the oligonucleotide may be conjugated to another molecule, e.g., a peptide, hybridization triggered cross-linking agent, transport agent, hybridization-triggered cleavage agent, etc.

The antisense oligonucleotide may comprise at least one modified base moiety which is selected from the group including, but not limited to, 5-fluorouracil, 30 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xantine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine,

- 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil,
- 5 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v),
- 10 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine.

The antisense oligonucleotide may also comprise at least one modified sugar moiety selected from the group including, but not limited to, arabinose, 2-fluoroarabinose, xylulose, and hexose.

- 15 In yet another embodiment, the antisense oligonucleotide comprises at least one modified phosphate backbone selected from the group including, but not limited to, a phosphorothioate, a phosphorodithioate, a phosphoramidothioate, a phosphoramidate, a phosphordiamidate, a methylphosphonate, an alkyl phosphotriester, and a formacetal or analog thereof.

- 20 In yet another embodiment, the antisense oligonucleotide is an a-anomeric oligonucleotide. An a-anomeric oligonucleotide forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual b-units, the strands run parallel to each other (Gautier et al., Nucl. Acids Res., 15:6625-6641 (1987)). The oligonucleotide is a 2-O-methylribonucleotide (Inoue et al., Nucl. Acids Res., 25 15:6131-6148 (1987)), or a chimeric RNA-DNA analogue (Inoue et al., FEBS Lett. 215:327-330 (1987)).

- 30 Polynucleotides of the invention may be synthesized by standard methods known in the art, e.g. by use of an automated DNA synthesizer (such as are commercially available from Biosearch, Applied Biosystems, etc.). As examples, phosphorothioate oligonucleotides may be synthesized by the method of Stein et al. (Nucl. Acids Res., 16:3209 (1988)), methylphosphonate oligonucleotides can be

prepared by use of controlled pore glass polymer supports (Sarin et al., Proc. Natl. Acad. Sci. U.S.A., 85:7448-7451 (1988)), etc.

While antisense nucleotides complementary to the coding region sequence of the invention could be used, those complementary to the transcribed untranslated region are most preferred.

Potential antagonists according to the invention also include catalytic RNA, or a ribozyme (See, e.g., PCT International Publication WO 90/11364, published October 4, 1990; Sarver et al, Science, 247:1222-1225 (1990)). While ribozymes that cleave mRNA at site specific recognition sequences can be used to destroy mRNAs corresponding to the polynucleotides of the invention, the use of hammerhead ribozymes is preferred. Hammerhead ribozymes cleave mRNAs at locations dictated by flanking regions that form complementary base pairs with the target mRNA. The sole requirement is that the target mRNA have the following sequence of two bases: 5'-UG-3'. The construction and production of hammerhead ribozymes is well known in the art and is described more fully in Haseloff and Gerlach, Nature, 334:585-591 (1988). There are numerous potential hammerhead ribozyme cleavage sites within each nucleotide sequence disclosed in the sequence listing. Preferably, the ribozyme is engineered so that the cleavage recognition site is located near the 5' end of the mRNA corresponding to the polynucleotides of the invention; i.e., to increase efficiency and minimize the intracellular accumulation of non-functional mRNA transcripts.

As in the antisense approach, the ribozymes of the invention can be composed of modified oligonucleotides (e.g. for improved stability, targeting, etc.) and should be delivered to cells which express the polynucleotides of the invention *in vivo*. DNA constructs encoding the ribozyme may be introduced into the cell in the same manner as described above for the introduction of antisense encoding DNA. A preferred method of delivery involves using a DNA construct "encoding" the ribozyme under the control of a strong constitutive promoter, such as, for example, pol III or pol II promoter, so that transfected cells will produce sufficient quantities of the ribozyme to destroy endogenous messages and inhibit translation. Since

ribozymes unlike antisense molecules, are catalytic, a lower intracellular concentration is required for efficiency.

Antagonist/agonist compounds may be employed to inhibit the cell growth and proliferation effects of the polypeptides of the present invention on neoplastic cells and tissues, i.e. stimulation of angiogenesis of tumors, and, therefore, retard or prevent abnormal cellular growth and proliferation, for example, in tumor formation or growth.

The antagonist/agonist may also be employed to prevent hyper-vascular diseases, and prevent the proliferation of epithelial lens cells after extracapsular cataract surgery. Prevention of the mitogenic activity of the polypeptides of the present invention may also be desirous in cases such as restenosis after balloon angioplasty.

The antagonist/agonist may also be employed to prevent the growth of scar tissue during wound healing.

15 The antagonist/agonist may also be employed to treat, prevent, and/or diagnose the diseases described herein.

Thus, the invention provides a method of treating or preventing diseases, disorders, and/or conditions, including but not limited to the diseases, disorders, and/or conditions listed throughout this application, associated with 20 overexpression of a polynucleotide of the present invention by administering to a patient (a) an antisense molecule directed to the polynucleotide of the present invention, and/or (b) a ribozyme directed to the polynucleotide of the present invention. invention, and/or (b) a ribozyme directed to the polynucleotide of the present 25 invention.

### Other Activities

The polypeptide of the present invention, as a result of the ability to stimulate vascular endothelial cell growth, may be employed in treatment for stimulating re-30 vascularization of ischemic tissues due to various disease conditions such as thrombosis, arteriosclerosis, and other cardiovascular conditions. These polypeptide

may also be employed to stimulate angiogenesis and limb regeneration, as discussed above.

The polypeptide may also be employed for treating wounds due to injuries, burns, post-operative tissue repair, and ulcers since they are mitogenic to various cells 5 of different origins, such as fibroblast cells and skeletal muscle cells, and therefore, facilitate the repair or replacement of damaged or diseased tissue.

The polypeptide of the present invention may also be employed stimulate neuronal growth and to treat, prevent, and/or diagnose neuronal damage which occurs 10 in certain neuronal disorders or neuro-degenerative conditions such as Alzheimer's disease, Parkinson's disease, and AIDS-related complex. The polypeptide of the invention may have the ability to stimulate chondrocyte growth, therefore, they may be employed to enhance bone and periodontal regeneration and aid in tissue transplants or bone grafts.

The polypeptide of the present invention may be also be employed to prevent 15 skin aging due to sunburn by stimulating keratinocyte growth.

The polypeptide of the invention may also be employed for preventing hair loss, since FGF family members activate hair-forming cells and promotes melanocyte growth. Along the same lines, the polypeptides of the present invention may be employed to stimulate growth and differentiation of hematopoietic cells and bone 20 marrow cells when used in combination with other cytokines.

The polypeptide of the invention may also be employed to maintain organs before transplantation or for supporting cell culture of primary tissues.

The polypeptide of the present invention may also be employed for inducing tissue of mesodermal origin to differentiate in early embryos.

25

The polypeptide or polynucleotides and/or agonist or antagonists of the present invention may also increase or decrease the differentiation or proliferation of embryonic stem cells, besides, as discussed above, hematopoietic lineage.

The polypeptide or polynucleotides and/or agonist or antagonists of the 30 present invention may also be used to modulate mammalian characteristics, such as body height, weight, hair color, eye color, skin, percentage of adipose tissue,

pigmentation, size, and shape (e.g., cosmetic surgery). Similarly, polypeptides or polynucleotides and/or agonist or antagonists of the present invention may be used to modulate mammalian metabolism affecting catabolism, anabolism, processing, utilization, and storage of energy.

5 Polypeptide or polynucleotides and/or agonist or antagonists of the present invention may be used to change a mammal's mental state or physical state by influencing biorhythms, cardiac rhythms, depression (including depressive diseases, disorders, and/or conditions), tendency for violence, tolerance for pain, reproductive capabilities (preferably by Activin or Inhibin-like activity), hormonal or endocrine levels, appetite, libido, memory, stress, or other cognitive qualities.

10 Polypeptide or polynucleotides and/or agonist or antagonists of the present invention may also be used as a food additive or preservative, such as to increase or decrease storage capabilities, fat content, lipid, protein, carbohydrate, vitamins, minerals, cofactors or other nutritional components.

15

#### Other Preferred Embodiments

Other preferred embodiments of the claimed invention include an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 50 contiguous nucleotides in the nucleotide 20 sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1.

Also preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the Clone Sequence and ending with the nucleotide at about the position of the 3'  
25 Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Also preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the Start Codon and ending with the nucleotide at about the position of the 3'  
30 Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Similarly preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the First Amino Acid of the Signal Peptide and ending with the 5 nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 150 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X.

10 Further preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 500 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X.

A further preferred embodiment is a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the nucleotide sequence of SEQ 15 ID NO:X beginning with the nucleotide at about the position of the 5' Nucleotide of the First Amino Acid of the Signal Peptide and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

20 A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete nucleotide sequence of SEQ ID NO:X.

Also preferred is an isolated nucleic acid molecule which hybridizes under stringent hybridization conditions to a nucleic acid molecule, wherein said nucleic acid molecule which hybridizes does not hybridize under stringent hybridization 25 conditions to a nucleic acid molecule having a nucleotide sequence consisting of only A residues or of only T residues.

Also preferred is a composition of matter comprising a DNA molecule which comprises a human cDNA clone identified by a cDNA Clone Identifier in Table 1, which DNA molecule is contained in the material deposited with the American Type 30 Culture Collection and given the ATCC Deposit Number shown in Table 1 for said cDNA Clone Identifier.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least 50 contiguous nucleotides in the nucleotide sequence of a human cDNA clone identified by a cDNA Clone Identifier in Table 1, which DNA molecule is contained in the deposit given the

5 ATCC Deposit Number shown in Table 1.

Also preferred is an isolated nucleic acid molecule, wherein said sequence of at least 50 contiguous nucleotides is included in the nucleotide sequence of the complete open reading frame sequence encoded by said human cDNA clone.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to sequence of at least 150 contiguous nucleotides in the nucleotide sequence encoded by said human cDNA clone.

A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to sequence of at least 500 contiguous nucleotides in the nucleotide sequence encoded by said human cDNA clone.

A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete nucleotide sequence encoded by said human cDNA clone.

A further preferred embodiment is a method for detecting in a biological sample a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1; which method comprises a step of comparing a nucleotide sequence of at least one nucleic acid molecule in said sample with a sequence selected from said group and determining whether the sequence of said nucleic acid molecule in said sample is at least 95% identical to said selected sequence.

30 Also preferred is the above method wherein said step of comparing sequences comprises determining the extent of nucleic acid hybridization between nucleic acid

molecules in said sample and a nucleic acid molecule comprising said sequence selected from said group. Similarly, also preferred is the above method wherein said step of comparing sequences is performed by comparing the nucleotide sequence determined from a nucleic acid molecule in said sample with said sequence selected 5 from said group. The nucleic acid molecules can comprise DNA molecules or RNA molecules.

A further preferred embodiment is a method for identifying the species, tissue or cell type of a biological sample which method comprises a step of detecting nucleic acid molecules in said sample, if any, comprising a nucleotide sequence that is at least 10 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 15 1.

The method for identifying the species, tissue or cell type of a biological sample can comprise a step of detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 20 contiguous nucleotides in a sequence selected from said group.

Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a gene encoding a secreted protein identified in Table 1, which method comprises a step of detecting in a biological sample obtained from said subject nucleic acid molecules, if any, 25 comprising a nucleotide sequence that is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit 30 Number shown for said cDNA clone in Table 1.

The method for diagnosing a pathological condition can comprise a step of detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.

Also preferred is a composition of matter comprising isolated nucleic acid molecules wherein the nucleotide sequences of said nucleic acid molecules comprise a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1. The nucleic acid molecules can comprise DNA molecules or RNA molecules.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence of at least about 10 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1.

Also preferred is a polypeptide, wherein said sequence of contiguous amino acids is included in the amino acid sequence of SEQ ID NO:Y in the range of positions beginning with the residue at about the position of the First Amino Acid of the Secreted Portion and ending with the residue at about the Last Amino Acid of the Open Reading Frame as set forth for SEQ ID NO:Y in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to the complete amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence of at least about 10 contiguous amino acids in the complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is a polypeptide wherein said sequence of contiguous amino acids is included in the amino acid sequence of a secreted portion of the secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is an isolated antibody which binds specifically to a polypeptide comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group

consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table  
5 1.

Further preferred is a method for detecting in a biological sample a polypeptide comprising an amino acid sequence which is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as  
10 defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1; which method comprises a step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence selected from said group  
15 and determining whether the sequence of said polypeptide molecule in said sample is at least 90% identical to said sequence of at least 10 contiguous amino acids.

Also preferred is the above method wherein said step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence selected from said group comprises determining the extent of specific binding of  
20 polypeptides in said sample to an antibody which binds specifically to a polypeptide comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA  
25 clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is the above method wherein said step of comparing sequences is performed by comparing the amino acid sequence determined from a polypeptide molecule in said sample with said sequence selected from said group.

30 Also preferred is a method for identifying the species, tissue or cell type of a biological sample which method comprises a step of detecting polypeptide molecules

in said sample, if any, comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is the above method for identifying the species, tissue or cell type of a biological sample, which method comprises a step of detecting polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the above group.

Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a gene encoding a secreted protein identified in Table 1, which method comprises a step of detecting in a biological sample obtained from said subject polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

In any of these methods, the step of detecting said polypeptide molecules includes using an antibody.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a nucleotide sequence encoding a polypeptide wherein said polypeptide comprises an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y

wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

5       Also preferred is an isolated nucleic acid molecule, wherein said nucleotide sequence encoding a polypeptide has been optimized for expression of said polypeptide in a prokaryotic host.

Also preferred is an isolated nucleic acid molecule, wherein said polypeptide comprises an amino acid sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

10      Further preferred is a method of making a recombinant vector comprising inserting any of the above isolated nucleic acid molecule into a vector. Also preferred is the recombinant vector produced by this method. Also preferred is a method of making a recombinant host cell comprising introducing the vector into a host cell, as well as the recombinant host cell produced by this method.

15      Also preferred is a method of making an isolated polypeptide comprising culturing this recombinant host cell under conditions such that said polypeptide is expressed and recovering said polypeptide. Also preferred is this method of making an isolated polypeptide, wherein said recombinant host cell is a eukaryotic cell and said polypeptide is a secreted portion of a human secreted protein comprising an amino acid sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y beginning with the residue at the position of the First Amino Acid of the Secreted Portion of SEQ ID NO:Y wherein Y is an integer set forth in Table 1 and said position of the First Amino Acid of the Secreted Portion of SEQ ID NO:Y is defined in Table 1; and an amino acid sequence of a secreted portion of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1. The isolated polypeptide produced by this method is also preferred.

Also preferred is a method of treatment of an individual in need of an increased level of a secreted protein activity, which method comprises administering to such an individual a pharmaceutical composition comprising an amount of an isolated polypeptide, polynucleotide, or antibody of the claimed invention effective to 5 increase the level of said protein activity in said individual.

The above-recited applications have uses in a wide variety of hosts. Such hosts include, but are not limited to, human, murine, rabbit, goat, guinea pig, camel, horse, mouse, rat, hamster, pig, micro-pig, chicken, goat, cow, sheep, dog, cat, non-human primate, and human. In specific embodiments, the host is a mouse, rabbit, 10 goat, guinea pig, chicken, rat, hamster, pig, sheep, dog or cat. In preferred embodiments, the host is a mammal. In most preferred embodiments, the host is a human.

In specific embodiments of the invention, for each "Contig ID" listed in the fourth column of Table 2, preferably excluded are one or more polynucleotides 15 comprising, or alternatively consisting of, a nucleotide sequence referenced in the fifth column of Table 2 and described by the general formula of a-b, whereas a and b are uniquely determined for the corresponding SEQ ID NO:X referred to in column 3 of Table 2. Further specific embodiments are directed to polynucleotide sequences excluding one, two, three, four, or more of the specific polynucleotide sequences 20 referred to in the fifth column of Table 2. In no way is this listing meant to encompass all of the sequences which may be excluded by the general formula, it is just a representative example. All references available through these accessions are hereby incorporated by reference in their entirety.

TABLE 2

Gene No.	cDNA Clone ID	NT SEQ ID NO: X	Contig ID	Public Accession Numbers
1	HMVBC31	11	825598	T75515, R32790, R32791, R34285, R35487, R41822, R44002, R41822, R44002, H47300, H47299, R94915, R94999, H59434, H60086, N31954, N34605, N36752, N69447, N92092, W03272, W46540, W46177, W78108, W79933.

				AA150396, AA156578, AA158922
3	HMVBD68	13	831130	R66161, H39007, R84843, R85715, H86142, AA013394, AA054285, AA574451, AA862725, AA059178
6	HMWBD74	16	711155	N67924, N67372, AA129966
9	HMWBL03	19	822861	H60046, N51950, N53714, AA146858
13	HMWDG30	23	623758	H63780, AA257113, AA255427
26	HKGCK41	36	795256	R12263, T98404, R14167, R19452, R20056, R27034, R59545, R72453, R72541, H42077, H42211, R86051, H73023, H96527, N57067, W24839, W32552, W92478, AA082756, AA193335, AA215589, AA233113
31	HMWIU49	41	800894	T99761, T99856, R23192, R23191, H17067, H20713, H38876, H52328, AA004615, AA004890, AA086474, AA112729, AA134414, AA134415
32	HMWJF53	42	758158	R25118, R25117, R25133, R50472, R80446, R80649, H85096, H84736, N93597, AA079216, AA079217
37	HNALE44	47	785045	W37193, W74692, W74789, W78908, W84731, AA055362, AA055694, AA180925, AA196586, AA196684, AA196747, AA196947
44	HNECL75	54	782493	T94864, T94909, R21919, R22568, R27358, R27359, R28364, R28569, R77601, R77600, H13043, H13254, H26839, H27013, H27695, H27696, H72755, H72756, N67136, W86504, AA255608, AA255632
46	HNECX90	56	834776	W72766, AA426368, AA811255, AA862521
47	HNEDA05	57	834777	W87625, W87626

Having generally described the invention, the same will be more readily understood by reference to the following examples, which are provided by way of illustration and are not intended as limiting.

5

### Examples

#### Example 1: Isolation of a Selected cDNA Clone From the Deposited Sample

- Each cDNA clone in a cited ATCC deposit is contained in a plasmid vector.
- 10 Table 1 identifies the vectors used to construct the cDNA library from which each clone was isolated. In many cases, the vector used to construct the library is a phage vector from which a plasmid has been excised. The table immediately below correlates the related plasmid for each phage vector used in constructing the cDNA library. For example, where a particular clone is identified in Table 1 as being
- 15 isolated in the vector "Lambda Zap," the corresponding deposited clone is in "pBluescript."

	<u>Vector Used to Construct Library</u>	<u>Corresponding Deposited</u>
	<u>Plasmid</u>	
	Lambda Zap	pBluescript (pBS)
20	Uni-Zap XR	pBluescript (pBS)
	Zap Express	pBK
	lafmid BA	plafmid BA
	pSport1	pSport1
	pCMVSport 2.0	pCMVSport 2.0
25	pCMVSport 3.0	pCMVSport 3.0
	pCR®2.1	pCR®2.1

- Vectors Lambda Zap (U.S. Patent Nos. 5,128,256 and 5,286,636), Uni-Zap XR (U.S. Patent Nos. 5,128,256 and 5,286,636), Zap Express (U.S. Patent Nos. 5,128,256 and 5,286,636), pBluescript (pBS) (Short, J. M. et al., Nucleic Acids Res. 30 16:7583-7600 (1988); Alting-Mees, M. A. and Short, J. M., Nucleic Acids Res. 17:9494 (1989)) and pBK (Alting-Mees, M. A. et al., Strategies 5:58-61 (1992)) are

commercially available from Stratagene Cloning Systems, Inc., 11011 N. Torrey Pines Road, La Jolla, CA, 92037. pBS contains an ampicillin resistance gene and pBK contains a neomycin resistance gene. Both can be transformed into E. coli strain XL-1 Blue, also available from Stratagene. pBS comes in 4 forms SK+, SK-, KS+ and KS. The S and K refers to the orientation of the polylinker to the T7 and T3 primer sequences which flank the polylinker region ("S" is for SacI and "K" is for KpnI which are the first sites on each respective end of the linker). "+" or "-" refer to the orientation of the f1 origin of replication ("ori"), such that in one orientation, single stranded rescue initiated from the f1 ori generates sense strand DNA and in the other, antisense.

Vectors pSport1, pCMVSport 2.0 and pCMVSport 3.0, were obtained from Life Technologies, Inc., P. O. Box 6009, Gaithersburg, MD 20897. All Sport vectors contain an ampicillin resistance gene and may be transformed into E. coli strain DH10B, also available from Life Technologies. (See, for instance, Gruber, C. E., et al., Focus 15:59 (1993).) Vector lafmid BA (Bento Soares, Columbia University, NY) contains an ampicillin resistance gene and can be transformed into E. coli strain XL-1 Blue. Vector pCR®2.1, which is available from Invitrogen, 1600 Faraday Avenue, Carlsbad, CA 92008, contains an ampicillin resistance gene and may be transformed into E. coli strain DH10B, available from Life Technologies. (See, for instance, Clark, J. M., Nuc. Acids Res. 16:9677-9686 (1988) and Mead, D. et al., Bio/Technology 9: (1991).) Preferably, a polynucleotide of the present invention does not comprise the phage vector sequences identified for the particular clone in Table 1, as well as the corresponding plasmid vector sequences designated above.

The deposited material in the sample assigned the ATCC Deposit Number cited in Table 1 for any given cDNA clone also may contain one or more additional plasmids, each comprising a cDNA clone different from that given clone. Thus, deposits sharing the same ATCC Deposit Number contain at least a plasmid for each cDNA clone identified in Table 1. Typically, each ATCC deposit sample cited in Table 1 comprises a mixture of approximately equal amounts (by weight) of about 50 plasmid DNAs, each containing a different cDNA clone; but such a deposit sample

may include plasmids for more or less than 50 cDNA clones, up to about 500 cDNA clones.

- Two approaches can be used to isolate a particular clone from the deposited sample of plasmid DNAs cited for that clone in Table 1. First, a plasmid is directly 5 isolated by screening the clones using a polynucleotide probe corresponding to SEQ ID NO:X.

Particularly, a specific polynucleotide with 30-40 nucleotides is synthesized using an Applied Biosystems DNA synthesizer according to the sequence reported. The oligonucleotide is labeled, for instance, with  $^{32}\text{P}$ - $\gamma$ -ATP using T4 polynucleotide 10 kinase and purified according to routine methods. (E.g., Maniatis et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press, Cold Spring, NY (1982).) The plasmid mixture is transformed into a suitable host, as indicated above (such as XL-1 Blue (Stratagene)) using techniques known to those of skill in the art, such as those provided by the vector supplier or in related publications or patents cited above. 15 The transformants are plated on 1.5% agar plates (containing the appropriate selection agent, e.g., ampicillin) to a density of about 150 transformants (colonies) per plate. These plates are screened using Nylon membranes according to routine methods for bacterial colony screening (e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Edit., (1989), Cold Spring Harbor Laboratory Press, pages 1.93 to 20 1.104), or other techniques known to those of skill in the art.

Alternatively, two primers of 17-20 nucleotides derived from both ends of the SEQ ID NO:X (i.e., within the region of SEQ ID NO:X bounded by the 5' NT and the 3' NT of the clone defined in Table 1) are synthesized and used to amplify the desired cDNA using the deposited cDNA plasmid as a template. The polymerase 25 chain reaction is carried out under routine conditions, for instance, in 25 ul of reaction mixture with 0.5 ug of the above cDNA template. A convenient reaction mixture is 1.5-5 mM MgCl<sub>2</sub>, 0.01% (w/v) gelatin, 20 uM each of dATP, dCTP, dGTP, dTTP, 25 pmol of each primer and 0.25 Unit of Taq polymerase. Thirty five cycles of PCR (denaturation at 94 degree C for 1 min; annealing at 55 degree C for 1 min; elongation 30 at 72 degree C for 1 min) are performed with a Perkin-Elmer Cetus automated thermal cycler. The amplified product is analyzed by agarose gel electrophoresis and

the DNA band with expected molecular weight is excised and purified. The PCR product is verified to be the selected sequence by subcloning and sequencing the DNA product.

Several methods are available for the identification of the 5' or 3' non-coding portions of a gene which may not be present in the deposited clone. These methods include but are not limited to, filter probing, clone enrichment using specific probes, and protocols similar or identical to 5' and 3' "RACE" protocols which are well known in the art. For instance, a method similar to 5' RACE is available for generating the missing 5' end of a desired full-length transcript. (Fromont-Racine et al., Nucleic Acids Res. 21(7):1683-1684 (1993).)

Briefly, a specific RNA oligonucleotide is ligated to the 5' ends of a population of RNA presumably containing full-length gene RNA transcripts. A primer set containing a primer specific to the ligated RNA oligonucleotide and a primer specific to a known sequence of the gene of interest is used to PCR amplify the 5' portion of the desired full-length gene. This amplified product may then be sequenced and used to generate the full length gene.

This above method starts with total RNA isolated from the desired source, although poly-A+ RNA can be used. The RNA preparation can then be treated with phosphatase if necessary to eliminate 5' phosphate groups on degraded or damaged RNA which may interfere with the later RNA ligase step. The phosphatase should then be inactivated and the RNA treated with tobacco acid pyrophosphatase in order to remove the cap structure present at the 5' ends of messenger RNAs. This reaction leaves a 5' phosphate group at the 5' end of the cap cleaved RNA which can then be ligated to an RNA oligonucleotide using T4 RNA ligase.

This modified RNA preparation is used as a template for first strand cDNA synthesis using a gene specific oligonucleotide. The first strand synthesis reaction is used as a template for PCR amplification of the desired 5' end using a primer specific to the ligated RNA oligonucleotide and a primer specific to the known sequence of the gene of interest. The resultant product is then sequenced and analyzed to confirm that the 5' end sequence belongs to the desired gene.

**Example 2: Isolation of Genomic Clones Corresponding to a Polynucleotide**

A human genomic P1 library (Genomic Systems, Inc.) is screened by PCR using primers selected for the cDNA sequence corresponding to SEQ ID NO:X., according to the method described in Example 1. (See also, Sambrook.)

5

**Example 3: Tissue Distribution of Polypeptide**

Tissue distribution of mRNA expression of polynucleotides of the present invention is determined using protocols for Northern blot analysis, described by, among others, Sambrook et al. For example, a cDNA probe produced by the method 10 described in Example 1 is labeled with P<sup>32</sup> using the rediprime™ DNA labeling system (Amersham Life Science), according to manufacturer's instructions. After labeling, the probe is purified using CHROMA SPIN-100™ column (Clontech Laboratories, Inc.), according to manufacturer's protocol number PT1200-1. The purified labeled probe is then used to examine various human tissues for mRNA 15 expression.

Multiple Tissue Northern (MTN) blots containing various human tissues (H) or human immune system tissues (IM) (Clontech) are examined with the labeled probe using ExpressHyb™ hybridization solution (Clontech) according to manufacturer's protocol number PT1190-1. Following hybridization and washing, the 20 blots are mounted and exposed to film at -70 degree C overnight, and the films developed according to standard procedures.

**Example 4: Chromosomal Mapping of the Polynucleotides**

An oligonucleotide primer set is designed according to the sequence at the 5' 25 end of SEQ ID NO:X. This primer preferably spans about 100 nucleotides. This primer set is then used in a polymerase chain reaction under the following set of conditions : 30 seconds, 95 degree C; 1 minute, 56 degree C; 1 minute, 70 degree C. This cycle is repeated 32 times followed by one 5 minute cycle at 70 degree C. Human, mouse, and hamster DNA is used as template in addition to a somatic cell 30 hybrid panel containing individual chromosomes or chromosome fragments (Bios, Inc). The reactions is analyzed on either 8% polyacrylamide gels or 3.5 % agarose

gels. Chromosome mapping is determined by the presence of an approximately 100 bp PCR fragment in the particular somatic cell hybrid.

**Example 5: Bacterial Expression of a Polypeptide**

5 A polynucleotide encoding a polypeptide of the present invention is amplified using PCR oligonucleotide primers corresponding to the 5' and 3' ends of the DNA sequence, as outlined in Example 1, to synthesize insertion fragments. The primers used to amplify the cDNA insert should preferably contain restriction sites, such as BamHI and XbaI, at the 5' end of the primers in order to clone the amplified product  
10 into the expression vector. For example, BamHI and XbaI correspond to the restriction enzyme sites on the bacterial expression vector pQE-9. (Qiagen, Inc., Chatsworth, CA). This plasmid vector encodes antibiotic resistance (Amp<sup>R</sup>), a bacterial origin of replication (ori), an IPTG-regulatable promoter/operator (P/O), a ribosome binding site (RBS), a 6-histidine tag (6-His), and restriction enzyme cloning  
15 sites.

The pQE-9 vector is digested with BamHI and XbaI and the amplified fragment is ligated into the pQE-9 vector maintaining the reading frame initiated at the bacterial RBS. The ligation mixture is then used to transform the E. coli strain M15/rep4 (Qiagen, Inc.) which contains multiple copies of the plasmid pREP4, which  
20 expresses the lacI repressor and also confers kanamycin resistance (Kan<sup>R</sup>). Transformants are identified by their ability to grow on LB plates and ampicillin/kanamycin resistant colonies are selected. Plasmid DNA is isolated and confirmed by restriction analysis.

Clones containing the desired constructs are grown overnight (O/N) in liquid  
25 culture in LB media supplemented with both Amp (100 ug/ml) and Kan (25 ug/ml). The O/N culture is used to inoculate a large culture at a ratio of 1:100 to 1:250. The cells are grown to an optical density 600 (O.D. <sup>600</sup>) of between 0.4 and 0.6. IPTG (Isopropyl-B-D-thiogalacto pyranoside) is then added to a final concentration of 1 mM. IPTG induces by inactivating the lacI repressor; clearing the P/O leading to  
30 increased gene expression.

Cells are grown for an extra 3 to 4 hours. Cells are then harvested by centrifugation (20 mins at 6000Xg). The cell pellet is solubilized in the chaotropic agent 6 Molar Guanidine HCl by stirring for 3-4 hours at 4 degree C. The cell debris is removed by centrifugation, and the supernatant containing the polypeptide is loaded 5 onto a nickel-nitrilo-tri-acetic acid ("Ni-NTA") affinity resin column (available from QIAGEN, Inc., *supra*). Proteins with a 6 x His tag bind to the Ni-NTA resin with high affinity and can be purified in a simple one-step procedure (for details see: The QIAexpressionist (1995) QIAGEN, Inc., *supra*).

Briefly, the supernatant is loaded onto the column in 6 M guanidine-HCl, pH 10 8, the column is first washed with 10 volumes of 6 M guanidine-HCl, pH 8, then washed with 10 volumes of 6 M guanidine-HCl pH 6, and finally the polypeptide is eluted with 6 M guanidine-HCl, pH 5.

The purified protein is then renatured by dialyzing it against phosphate-buffered saline (PBS) or 50 mM Na-acetate, pH 6 buffer plus 200 mM NaCl. 15 Alternatively, the protein can be successfully refolded while immobilized on the Ni-NTA column. The recommended conditions are as follows: renature using a linear 6M-1M urea gradient in 500 mM NaCl, 20% glycerol, 20 mM Tris/HCl pH 7.4, containing protease inhibitors. The renaturation should be performed over a period of 1.5 hours or more. After renaturation the proteins are eluted by the addition of 250 20 mM immidazole. Immidazole is removed by a final dialyzing step against PBS or 50 mM sodium acetate pH 6 buffer plus 200 mM NaCl. The purified protein is stored at 4 degree C or frozen at -80 degree C.

In addition to the above expression vector, the present invention further includes an expression vector comprising phage operator and promoter elements 25 operatively linked to a polynucleotide of the present invention, called pHE4a. (ATCC Accession Number 209645, deposited on February 25, 1998.) This vector contains: 1) a neomycinphosphotransferase gene as a selection marker, 2) an E. coli origin of replication, 3) a T5 phage promoter sequence, 4) two lac operator sequences, 5) a Shine-Delgarno sequence, and 6) the lactose operon repressor gene (*lacIq*). The 30 origin of replication (*oriC*) is derived from pUC19 (LTI, Gaithersburg, MD). The promoter sequence and operator sequences are made synthetically.

- DNA can be inserted into the pHEa by restricting the vector with NdeI and XbaI, BamHI, XhoI, or Asp718, running the restricted product on a gel, and isolating the larger fragment (the stuffer fragment should be about 310 base pairs). The DNA insert is generated according to the PCR protocol described in Example 1, using PCR primers having restriction sites for NdeI (5' primer) and XbaI, BamHI, XhoI, or Asp718 (3' primer). The PCR insert is gel purified and restricted with compatible enzymes. The insert and vector are ligated according to standard protocols.

The engineered vector could easily be substituted in the above protocol to express protein in a bacterial system.

10

**Example 6: Purification of a Polypeptide from an Inclusion Body**

The following alternative method can be used to purify a polypeptide expressed in *E coli* when it is present in the form of inclusion bodies. Unless otherwise specified, all of the following steps are conducted at 4-10 degree C.

- 15       Upon completion of the production phase of the *E. coli* fermentation, the cell culture is cooled to 4-10 degree C and the cells harvested by continuous centrifugation at 15,000 rpm (Heraeus Sepatech). On the basis of the expected yield of protein per unit weight of cell paste and the amount of purified protein required, an appropriate amount of cell paste, by weight, is suspended in a buffer solution  
20       containing 100 mM Tris, 50 mM EDTA, pH 7.4. The cells are dispersed to a homogeneous suspension using a high shear mixer.

The cells are then lysed by passing the solution through a microfluidizer (Microfluidics, Corp. or APV Gaulin, Inc.) twice at 4000-6000 psi. The homogenate is then mixed with NaCl solution to a final concentration of 0.5 M NaCl, followed by 25 centrifugation at 7000 xg for 15 min. The resultant pellet is washed again using 0.5M NaCl, 100 mM Tris, 50 mM EDTA, pH 7.4.

The resulting washed inclusion bodies are solubilized with 1.5 M guanidine hydrochloride (GuHCl) for 2-4 hours. After 7000 xg centrifugation for 15 min., the pellet is discarded and the polypeptide containing supernatant is incubated at 4 degree 30 C overnight to allow further GuHCl extraction.

Following high speed centrifugation (30,000 xg) to remove insoluble particles, the GuHCl solubilized protein is refolded by quickly mixing the GuHCl extract with 20 volumes of buffer containing 50 mM sodium, pH 4.5, 150 mM NaCl, 2 mM EDTA by vigorous stirring. The refolded diluted protein solution is kept at 4 degree C  
5 without mixing for 12 hours prior to further purification steps.

To clarify the refolded polypeptide solution, a previously prepared tangential filtration unit equipped with 0.16 um membrane filter with appropriate surface area (e.g., Filtron), equilibrated with 40 mM sodium acetate, pH 6.0 is employed. The filtered sample is loaded onto a cation exchange resin (e.g., Poros HS-50, Perseptive Biosystems). The column is washed with 40 mM sodium acetate, pH 6.0 and eluted with 250 mM, 500 mM, 1000 mM, and 1500 mM NaCl in the same buffer, in a stepwise manner. The absorbance at 280 nm of the effluent is continuously monitored. Fractions are collected and further analyzed by SDS-PAGE.

Fractions containing the polypeptide are then pooled and mixed with 4  
15 volumes of water. The diluted sample is then loaded onto a previously prepared set of tandem columns of strong anion (Poros HQ-50, Perseptive Biosystems) and weak anion (Poros CM-20, Perseptive Biosystems) exchange resins. The columns are equilibrated with 40 mM sodium acetate, pH 6.0. Both columns are washed with 40 mM sodium acetate, pH 6.0, 200 mM NaCl. The CM-20 column is then eluted using  
20 a 10 column volume linear gradient ranging from 0.2 M NaCl, 50 mM sodium acetate, pH 6.0 to 1.0 M NaCl, 50 mM sodium acetate, pH 6.5. Fractions are collected under constant  $A_{280}$  monitoring of the effluent. Fractions containing the polypeptide (determined, for instance, by 16% SDS-PAGE) are then pooled.

The resultant polypeptide should exhibit greater than 95% purity after the  
25 above refolding and purification steps. No major contaminant bands should be observed from Commassie blue stained 16% SDS-PAGE gel when 5 ug of purified protein is loaded. The purified protein can also be tested for endotoxin/LPS contamination, and typically the LPS content is less than 0.1 ng/ml according to LAL assays.

**Example 7: Cloning and Expression of a Polypeptide in a Baculovirus Expression System**

In this example, the plasmid shuttle vector pA2 is used to insert a polynucleotide into a baculovirus to express a polypeptide. This expression vector 5 contains the strong polyhedrin promoter of the *Autographa californica* nuclear polyhedrosis virus (AcMNPV) followed by convenient restriction sites such as BamHI, Xba I and Asp718. The polyadenylation site of the simian virus 40 ("SV40") is used for efficient polyadenylation. For easy selection of recombinant virus, the plasmid contains the beta-galactosidase gene from *E. coli* under control of a weak 10 Drosophila promoter in the same orientation, followed by the polyadenylation signal of the polyhedrin gene. The inserted genes are flanked on both sides by viral sequences for cell-mediated homologous recombination with wild-type viral DNA to generate a viable virus that express the cloned polynucleotide.

Many other baculovirus vectors can be used in place of the vector above, such 15 as pAc373, pVL941, and pAcIM1, as one skilled in the art would readily appreciate, as long as the construct provides appropriately located signals for transcription, translation, secretion and the like, including a signal peptide and an in-frame AUG as required. Such vectors are described, for instance, in Luckow et al., Virology 170:31-39 (1989).

20 Specifically, the cDNA sequence contained in the deposited clone, including the AUG initiation codon and the naturally associated leader sequence identified in Table 1, is amplified using the PCR protocol described in Example 1. If the naturally occurring signal sequence is used to produce the secreted protein, the pA2 vector does not need a second signal peptide. Alternatively, the vector can be modified (pA2 GP) 25 to include a baculovirus leader sequence, using the standard methods described in Summers et al., "A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures," Texas Agricultural Experimental Station Bulletin No. 1555 (1987).

The amplified fragment is isolated from a 1% agarose gel using a 30 commercially available kit ("Geneclean," BIO 101 Inc., La Jolla, Ca.). The fragment

then is digested with appropriate restriction enzymes and again purified on a 1% agarose gel.

The plasmid is digested with the corresponding restriction enzymes and optionally, can be dephosphorylated using calf intestinal phosphatase, using routine 5 procedures known in the art. The DNA is then isolated from a 1% agarose gel using a commercially available kit ("Geneclean" BIO 101 Inc., La Jolla, Ca.).

The fragment and the dephosphorylated plasmid are ligated together with T4 DNA ligase. *E. coli* HB101 or other suitable *E. coli* hosts such as XL-1 Blue (Stratagene Cloning Systems, La Jolla, CA) cells are transformed with the ligation 10 mixture and spread on culture plates. Bacteria containing the plasmid are identified by digesting DNA from individual colonies and analyzing the digestion product by gel electrophoresis. The sequence of the cloned fragment is confirmed by DNA sequencing.

Five ug of a plasmid containing the polynucleotide is co-transfected with 1.0 15 ug of a commercially available linearized baculovirus DNA ("BaculoGold™ baculovirus DNA", Pharmingen, San Diego, CA), using the lipofection method described by Felgner et al., Proc. Natl. Acad. Sci. USA 84:7413-7417 (1987). One ug of BaculoGold™ virus DNA and 5 ug of the plasmid are mixed in a sterile well of a microtiter plate containing 50 ul of serum-free Grace's medium (Life Technologies 20 Inc., Gaithersburg, MD). Afterwards, 10 ul Lipofectin plus 90 ul Grace's medium are added, mixed and incubated for 15 minutes at room temperature. Then the transfection mixture is added drop-wise to Sf9 insect cells (ATCC CRL 1711) seeded in a 35 mm tissue culture plate with 1 ml Grace's medium without serum. The plate is then incubated for 5 hours at 27 degrees C. The transfection solution is then removed 25 from the plate and 1 ml of Grace's insect medium supplemented with 10% fetal calf serum is added. Cultivation is then continued at 27 degrees C for four days.

After four days the supernatant is collected and a plaque assay is performed, as described by Summers and Smith, *supra*. An agarose gel with "Blue Gal" (Life 30 Technologies Inc., Gaithersburg) is used to allow easy identification and isolation of gal-expressing clones, which produce blue-stained plaques. (A detailed description of a "plaque assay" of this type can also be found in the user's guide for insect cell

culture and baculovirology distributed by Life Technologies Inc., Gaithersburg, page

9-10.) After appropriate incubation, blue stained plaques are picked with the tip of a micropipettor (e.g., Eppendorf). The agar containing the recombinant viruses is then resuspended in a microcentrifuge tube containing 200 ul of Grace's medium and the

- 5 suspension containing the recombinant baculovirus is used to infect Sf9 cells seeded in 35 mm dishes. Four days later the supernatants of these culture dishes are harvested and then they are stored at 4 degree C.

To verify the expression of the polypeptide, Sf9 cells are grown in Grace's medium supplemented with 10% heat-inactivated FBS. The cells are infected with

- 10 the recombinant baculovirus containing the polynucleotide at a multiplicity of infection ("MOI") of about 2. If radiolabeled proteins are desired, 6 hours later the medium is removed and is replaced with SF900 II medium minus methionine and cysteine (available from Life Technologies Inc., Rockville, MD). After 42 hours, 5 uCi of  $^{35}\text{S}$ -methionine and 5 uCi  $^{35}\text{S}$ -cysteine (available from Amersham) are added.
- 15 The cells are further incubated for 16 hours and then are harvested by centrifugation. The proteins in the supernatant as well as the intracellular proteins are analyzed by SDS-PAGE followed by autoradiography (if radiolabeled).

Microsequencing of the amino acid sequence of the amino terminus of purified protein may be used to determine the amino terminal sequence of the

- 20 produced protein.

#### Example 8: Expression of a Polypeptide in Mammalian Cells

The polypeptide of the present invention can be expressed in a mammalian

cell. A typical mammalian expression vector contains a promoter element, which

mediates the initiation of transcription of mRNA, a protein coding sequence, and

- 25 signals required for the termination of transcription and polyadenylation of the transcript. Additional elements include enhancers, Kozak sequences and intervening sequences flanked by donor and acceptor sites for RNA splicing. Highly efficient transcription is achieved with the early and late promoters from SV40, the long terminal repeats (LTRs) from Retroviruses, e.g., RSV, HTLV, HIVI and the early

promoter of the cytomegalovirus (CMV). However, cellular elements can also be used (e.g., the human actin promoter).

Suitable expression vectors for use in practicing the present invention include, for example, vectors such as pSVL and pMSG (Pharmacia, Uppsala, Sweden),

- 5 pRSVcat (ATCC 37152), pSV2dhfr (ATCC 37146), pBC12MI (ATCC 67109), pCMVSport 2.0, and pCMVSport 3.0. Mammalian host cells that could be used include, human Hela, 293, H9 and Jurkat cells, mouse NIH3T3 and C127 cells, Cos 1, Cos 7 and CV1, quail QC1-3 cells, mouse L cells and Chinese hamster ovary (CHO) cells.

- 10 Alternatively, the polypeptide can be expressed in stable cell lines containing the polynucleotide integrated into a chromosome. The co-transfection with a selectable marker such as dhfr, gpt, neomycin, hygromycin allows the identification and isolation of the transfected cells.

- 15 The transfected gene can also be amplified to express large amounts of the encoded protein. The DHFR (dihydrofolate reductase) marker is useful in developing cell lines that carry several hundred or even several thousand copies of the gene of interest. (See, e.g., Alt, F. W., et al., J. Biol. Chem. 253:1357-1370 (1978); Hamlin, J. L. and Ma, C., Biochem. et Biophys. Acta, 1097:107-143 (1990); Page, M. J. and Sydenham, M. A., Biotechnology 9:64-68 (1991).) Another useful selection marker 20 is the enzyme glutamine synthase (GS) (Murphy et al., Biochem J. 227:277-279 (1991); Bebbington et al., Bio/Technology 10:169-175 (1992). Using these markers, the mammalian cells are grown in selective medium and the cells with the highest resistance are selected. These cell lines contain the amplified gene(s) integrated into a chromosome. Chinese hamster ovary (CHO) and NSO cells are often used for the 25 production of proteins.

- Derivatives of the plasmid pSV2-dhfr (ATCC Accession No. 37146), the expression vectors pC4 (ATCC Accession No. 209646) and pC6 (ATCC Accession No. 209647) contain the strong promoter (LTR) of the Rous Sarcoma Virus (Cullen et al., Molecular and Cellular Biology, 438-447 (March, 1985)) plus a fragment of the 30 CMV-enhancer (Boshart et al., Cell 41:521-530 (1985).) Multiple cloning sites, e.g., with the restriction enzyme cleavage sites BamHI, XbaI and Asp718, facilitate the

cloning of the gene of interest. The vectors also contain the 3' intron, the polyadenylation and termination signal of the rat preproinsulin gene, and the mouse DHFR gene under control of the SV40 early promoter.

Specifically, the plasmid pC6, for example, is digested with appropriate 5 restriction enzymes and then dephosphorylated using calf intestinal phosphates by procedures known in the art. The vector is then isolated from a 1% agarose gel.

A polynucleotide of the present invention is amplified according to the protocol outlined in Example 1. If the naturally occurring signal sequence is used to produce the secreted protein, the vector does not need a second signal peptide.

10 Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. (See, e.g., WO 96/34891.)

The amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("Geneclean," BIO 101 Inc., La Jolla, Ca.). The fragment then is digested with appropriate restriction enzymes and again purified on a 1% 15 agarose gel.

The amplified fragment is then digested with the same restriction enzyme and purified on a 1% agarose gel. The isolated fragment and the dephosphorylated vector are then ligated with T4 DNA ligase. *E. coli* HB101 or XL-1 Blue cells are then transformed and bacteria are identified that contain the fragment inserted into plasmid 20 pC6 using, for instance, restriction enzyme analysis.

Chinese hamster ovary cells lacking an active DHFR gene is used for transfection. Five  $\mu$ g of the expression plasmid pC6 a pC4 is cotransfected with 0.5  $\mu$ g of the plasmid pSVneo using lipofectin (Felgner et al., *supra*). The plasmid pSV2-neo contains a dominant selectable marker, the *neo* gene from Tn5 encoding an 25 enzyme that confers resistance to a group of antibiotics including G418. The cells are seeded in alpha minus MEM supplemented with 1 mg/ml G418. After 2 days, the cells are trypsinized and seeded in hybridoma cloning plates (Greiner, Germany) in alpha minus MEM supplemented with 10, 25, or 50 ng/ml of methotrexate plus 1 mg/ml G418. After about 10-14 days single clones are trypsinized and then seeded in 30 6-well petri dishes or 10 ml flasks using different concentrations of methotrexate (50 nM, 100 nM, 200 nM, 400 nM, 800 nM). Clones growing at the highest

concentrations of methotrexate are then transferred to new 6-well plates containing even higher concentrations of methotrexate (1 uM, 2 uM, 5 uM, 10 mM, 20 mM). The same procedure is repeated until clones are obtained which grow at a concentration of 100 - 200 uM. Expression of the desired gene product is analyzed, 5 for instance, by SDS-PAGE and Western blot or by reversed phase HPLC analysis.

#### Example 9: Protein Fusions

The polypeptides of the present invention are preferably fused to other proteins. These fusion proteins can be used for a variety of applications. For 10 example, fusion of the present polypeptides to His-tag, HA-tag, protein A, IgG domains, and maltose binding protein facilitates purification. (See Example 5; see also EP A 394,827; Traunecker, et al., Nature 331:84-86 (1988).) Similarly, fusion to IgG-1, IgG-3, and albumin increases the halflife time in vivo. Nuclear localization signals fused to the polypeptides of the present invention can target the protein to a 15 specific subcellular localization, while covalent heterodimer or homodimers can increase or decrease the activity of a fusion protein. Fusion proteins can also create chimeric molecules having more than one function. Finally, fusion proteins can increase solubility and/or stability of the fused protein compared to the non-fused protein. All of the types of fusion proteins described above can be made by 20 modifying the following protocol, which outlines the fusion of a polypeptide to an IgG molecule, or the protocol described in Example 5.

Briefly, the human Fc portion of the IgG molecule can be PCR amplified, using primers that span the 5' and 3' ends of the sequence described below. These 25 primers also should have convenient restriction enzyme sites that will facilitate cloning into an expression vector, preferably a mammalian expression vector.

For example, if pC4 (Accession No. 209646) is used, the human Fc portion can be ligated into the BamHI cloning site. Note that the 3' BamHI site should be destroyed. Next, the vector containing the human Fc portion is re-restricted with BamHI, linearizing the vector, and a polynucleotide of the present invention, isolated 30 by the PCR protocol described in Example 1, is ligated into this BamHI site. Note

that the polynucleotide is cloned without a stop codon, otherwise a fusion protein will not be produced.

If the naturally occurring signal sequence is used to produce the secreted protein, pC4 does not need a second signal peptide. Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. (See, e.g., WO 96/34891.)

Human IgG Fc region:

GGGATCCGGAGCCAAATCTTCTGACAAAACTCACACATGCCACC GTGC  
10 CCAGCACCTGAATT CGAGGGTGCACCGTCAGTCTTCCCTTTCCCCCAAAA  
CCCAAGGACACCCTCATGATCTCCGGACTCCTGAGGTACATGCGTGGT  
GGTGGACGTAAGCCACGAAGACCC TGAGGTCAAGTTCAACTGGTACGTGG  
ACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGAGGAGCAGTA  
CAACAGCACGTACCGTGTGGTCAGCGTCCCTCACCGTCTGCACCAGGACT  
15 GGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCA  
ACCCCCATCGAGAAAACCATCTCAAAGCCAAGGGCAGCCCCGAGAAC  
CACAGGTGTACACCCTGCCCTGGTCAAAGGTTCTATCCAAGCGACATGCCGT  
GTCAGCCTGACCTGCCTGGTCAAAGGTTCTATCCAAGCGACATGCCGT  
GGAGTGGGAGAGCAATGGG CAGCCGGAGAACAACTACAAGACCACGCC  
20 CCCGTGCTGGACTCCGACGGCTCCTCTTCCCTCTACAGCAAGCTACCGTG  
GACAAGAGCAGGTGGCAGCAGGGAACGTCTTCTCATGCTCCGTGATGCA  
TGAGGCTCTGCACAACCACTACACG CAGAAGAGCCTCTCCGTCTCCGG  
GTAAATGAGTGCGACGCCCGACTCTAGAGGAT (SEQ ID NO:1)

25 **Example 10: Production of an Antibody from a Polypeptide**

The antibodies of the present invention can be prepared by a variety of methods. (See, Current Protocols, Chapter 2.) As one example of such methods, cells expressing a polypeptide of the present invention are administered to an animal to induce the production of sera containing polyclonal antibodies. In a preferred method, a preparation of the secreted protein is prepared and purified to render it

substantially free of natural contaminants. Such a preparation is then introduced into an animal in order to produce polyclonal antisera of greater specific activity.

- In the most preferred method, the antibodies of the present invention are monoclonal antibodies (or protein binding fragments thereof). Such monoclonal 5 antibodies can be prepared using hybridoma technology. (Köhler et al., *Nature* 256:495 (1975); Köhler et al., *Eur. J. Immunol.* 6:511 (1976); Köhler et al., *Eur. J. Immunol.* 6:292 (1976); Hammerling et al., in: *Monoclonal Antibodies and T-Cell Hybridomas*, Elsevier, N.Y., pp. 563-681 (1981).) In general, such procedures involve immunizing an animal (preferably a mouse) with polypeptide or, more 10 preferably, with a secreted polypeptide-expressing cell. Such cells may be cultured in any suitable tissue culture medium; however, it is preferable to culture cells in Earle's modified Eagle's medium supplemented with 10% fetal bovine serum (inactivated at about 56 degrees C), and supplemented with about 10 g/l of nonessential amino acids, about 1,000 U/ml of penicillin, and about 100 ug/ml of streptomycin.
- 15 The splenocytes of such mice are extracted and fused with a suitable myeloma cell line. Any suitable myeloma cell line may be employed in accordance with the present invention; however, it is preferable to employ the parent myeloma cell line (SP2O), available from the ATCC. After fusion, the resulting hybridoma cells are selectively maintained in HAT medium, and then cloned by limiting dilution as 20 described by Wands et al. (*Gastroenterology* 80:225-232 (1981).) The hybridoma cells obtained through such a selection are then assayed to identify clones which secrete antibodies capable of binding the polypeptide.

- Alternatively, additional antibodies capable of binding to the polypeptide can be produced in a two-step procedure using anti-idiotypic antibodies. Such a method 25 makes use of the fact that antibodies are themselves antigens, and therefore, it is possible to obtain an antibody which binds to a second antibody. In accordance with this method, protein specific antibodies are used to immunize an animal, preferably a mouse. The splenocytes of such an animal are then used to produce hybridoma cells, and the hybridoma cells are screened to identify clones which produce an antibody 30 whose ability to bind to the protein-specific antibody can be blocked by the polypeptide. Such antibodies comprise anti-idiotypic antibodies to the protein-

specific antibody and can be used to immunize an animal to induce formation of further protein-specific antibodies.

It will be appreciated that Fab and F(ab')2 and other fragments of the antibodies of the present invention may be used according to the methods disclosed

5 herein. Such fragments are typically produced by proteolytic cleavage, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab')2 fragments). Alternatively, secreted protein-binding fragments can be produced through the application of recombinant DNA technology or through synthetic chemistry.

10 For in vivo use of antibodies in humans, it may be preferable to use "humanized" chimeric monoclonal antibodies. Such antibodies can be produced using genetic constructs derived from hybridoma cells producing the monoclonal antibodies described above. Methods for producing chimeric antibodies are known in the art. (See, for review, Morrison, Science 229:1202 (1985); Oi et al.,  
15 BioTechniques 4:214 (1986); Cabilly et al., U.S. Patent No. 4,816,567; Taniguchi et al., EP 171496; Morrison et al., EP 173494; Neuberger et al., WO 8601533; Robinson et al., WO 8702671; Boulian et al., Nature 312:643 (1984); Neuberger et al., Nature 314:268 (1985).)

20 **Example 11: Production Of Secreted Protein For High-Throughput Screening Assays**

The following protocol produces a supernatant containing a polypeptide to be tested. This supernatant can then be used in the Screening Assays described in Examples 13-20.

- 25 First, dilute Poly-D-Lysine (644 587 Boehringer-Mannheim) stock solution (1mg/ml in PBS) 1:20 in PBS (w/o calcium or magnesium 17-516F Biowhittaker) for a working solution of 50ug/ml. Add 200 ul of this solution to each well (24 well plates) and incubate at RT for 20 minutes. Be sure to distribute the solution over each well (note: a 12-channel pipetter may be used with tips on every other channel).
- 30 Aspirate off the Poly-D-Lysine solution and rinse with 1ml PBS (Phosphate Buffered

Saline). The PBS should remain in the well until just prior to plating the cells and plates may be poly-lysine coated in advance for up to two weeks.

Plate 293T cells (do not carry cells past P+20) at  $2 \times 10^5$  cells/well in .5ml DMEM(Dulbecco's Modified Eagle Medium)(with 4.5 G/L glucose and L-glutamine 5 (12-604F Biowhittaker))/10% heat inactivated FBS(14-503F Biowhittaker)/1x Penstrep(17-602E Biowhittaker). Let the cells grow overnight.

The next day, mix together in a sterile solution basin: 300 ul Lipofectamine (18324-012 Gibco/BRL) and 5ml Optimem I (31985070 Gibco/BRL)/96-well plate. With a small volume multi-channel pipetter, aliquot approximately 2ug of an 10 expression vector containing a polynucleotide insert, produced by the methods described in Examples 8 or 9, into an appropriately labeled 96-well round bottom plate. With a multi-channel pipetter, add 50ul of the Lipofectamine/Optimem I mixture to each well. Pipette up and down gently to mix. Incubate at RT 15-45 minutes. After about 20 minutes, use a multi-channel pipetter to add 150ul Optimem 15 I to each well. As a control, one plate of vector DNA lacking an insert should be transfected with each set of transfections.

Preferably, the transfection should be performed by tag-teaming the following tasks. By tag-teaming, hands on time is cut in half, and the cells do not spend too much time on PBS. First, person A aspirates off the media from four 24-well plates 20 of cells, and then person B rinses each well with .5-1ml PBS. Person A then aspirates off PBS rinse, and person B, using a12-channel pipetter with tips on every other channel, adds the 200ul of DNA/Lipofectamine/Optimem I complex to the odd wells first, then to the even wells, to each row on the 24-well plates. Incubate at 37 degrees C for 6 hours.

25 While cells are incubating, prepare appropriate media, either 1%BSA in DMEM with 1x penstrep, or CHO-5 media (116.6 mg/L of CaCl<sub>2</sub> (anhyd); 0.00130 mg/L CuSO<sub>4</sub>·5H<sub>2</sub>O; 0.050 mg/L of Fe(NO<sub>3</sub>)<sub>3</sub>·9H<sub>2</sub>O; 0.417 mg/L of FeSO<sub>4</sub>·7H<sub>2</sub>O; 311.80 mg/L of Kcl; 28.64 mg/L of MgCl<sub>2</sub>; 48.84 mg/L of MgSO<sub>4</sub>; 6995.50 mg/L of NaCl; 2400.0 mg/L of NaHCO<sub>3</sub>; 62.50 mg/L of Na<sub>2</sub>HPO<sub>4</sub>·H<sub>2</sub>O; 71.02 mg/L of 30 Na<sub>2</sub>HPO<sub>4</sub>; .4320 mg/L of ZnSO<sub>4</sub>·7H<sub>2</sub>O; .002 mg/L of Arachidonic Acid ; 1.022 mg/L of Cholesterol; .070 mg/L of DL-alpha-Tocopherol-Acetate; 0.0520 mg/L of Linoleic

Acid; 0.010 mg/L of Linolenic Acid; 0.010 mg/L of Myristic Acid; 0.010 mg/L of Oleic Acid; 0.010 mg/L of Palmitric Acid; 0.010 mg/L of Palmitic Acid; 100 mg/L of Pluronic F-68; 0.010 mg/L of Stearic Acid; 2.20 mg/L of Tween 80; 4551 mg/L of D-Glucose; 130.85 mg/ml of L- Alanine; 147.50 mg/ml of L-Arginine-HCL; 7.50 mg/ml of L-Asparagine-H<sub>2</sub>O; 6.65 mg/ml of L-Aspartic Acid; 29.56 mg/ml of L-Cystine-2HCL-H<sub>2</sub>O; 31.29 mg/ml of L-Cystine-2HCL; 7.35 mg/ml of L-Glutamic Acid; 365.0 mg/ml of L-Glutamine; 18.75 mg/ml of Glycine; 52.48 mg/ml of L-Histidine-HCL-H<sub>2</sub>O; 106.97 mg/ml of L-Isoleucine; 111.45 mg/ml of L-Leucine; 163.75 mg/ml of L-Lysine HCL; 32.34 mg/ml of L-Methionine; 68.48 mg/ml of L-Phenylalanine; 40.0 mg/ml of L-Proline; 26.25 mg/ml of L-Serine; 101.05 mg/ml of L-Threonine; 19.22 mg/ml of L-Tryptophan; 91.79 mg/ml of L-Tyrosine-2Na-2H<sub>2</sub>O; 99.65 mg/ml of L-Valine; 0.0035 mg/L of Biotin; 3.24 mg/L of D-Ca Pantothenate; 11.78 mg/L of Choline Chloride; 4.65 mg/L of Folic Acid; 15.60 mg/L of i-Inositol; 3.02 mg/L of Niacinamide; 3.00 mg/L of Pyridoxal HCL; 0.031 mg/L of Pyridoxine HCL; 0.319 mg/L of Riboflavin; 3.17 mg/L of Thiamine HCL; 0.365 mg/L of Thymidine; and 0.680 mg/L of Vitamin B<sub>12</sub>; 25 mM of HEPES Buffer; 2.39 mg/L of Na Hypoxanthine; 0.105 mg/L of Lipoic Acid; 0.081 mg/L of Sodium Putrescine-2HCL; 55.0 mg/L of Sodium Pyruvate; 0.0067 mg/L of Sodium Selenite; 20uM of Ethanolamine; 0.122 mg/L of Ferric Citrate; 41.70 mg/L of Methyl-B-Cyclodextrin complexed with Linoleic Acid; 33.33 mg/L of Methyl-B-Cyclodextrin complexed with Oleic Acid; and 10 mg/L of Methyl-B-Cyclodextrin complexed with Retinal) with 2mm glutamine and 1x penstrep. (BSA (81-068-3 Bayer) 100gm dissolved in 1L DMEM for a 10% BSA stock solution). Filter the media and collect 50 ul for endotoxin assay in 15ml polystyrene conical.

The transfection reaction is terminated, preferably by tag-teaming, at the end of the incubation period. Person A aspirates off the transfection media, while person B adds 1.5ml appropriate media to each well. Incubate at 37 degrees C for 45 or 72 hours depending on the media used: 1%BSA for 45 hours or CHO-5 for 72 hours.

On day four, using a 300ul multichannel pipetter, aliquot 600ul in one 1ml deep well plate and the remaining supernatant into a 2ml deep well. The supernatants from each well can then be used in the assays described in Examples 13-20.

It is specifically understood that when activity is obtained in any of the assays described below using a supernatant, the activity originates from either the polypeptide directly (e.g., as a secreted protein) or by the polypeptide inducing expression of other proteins, which are then secreted into the supernatant. Thus, the 5 invention further provides a method of identifying the protein in the supernatant characterized by an activity in a particular assay.

**Example 12: Construction of GAS Reporter Construct**

One signal transduction pathway involved in the differentiation and 10 proliferation of cells is called the Jaks-STATs pathway. Activated proteins in the Jaks-STATs pathway bind to gamma activation site "GAS" elements or interferon-sensitive responsive element ("ISRE"), located in the promoter of many genes. The binding of a protein to these elements alter the expression of the associated gene.

GAS and ISRE elements are recognized by a class of transcription factors 15 called Signal Transducers and Activators of Transcription, or "STATs." There are six members of the STATs family. Stat1 and Stat3 are present in many cell types, as is Stat2 (as response to IFN-alpha is widespread). Stat4 is more restricted and is not in many cell types though it has been found in T helper class I, cells after treatment with IL-12. Stat5 was originally called mammary growth factor, but has been found at 20 higher concentrations in other cells including myeloid cells. It can be activated in tissue culture cells by many cytokines.

The STATs are activated to translocate from the cytoplasm to the nucleus upon tyrosine phosphorylation by a set of kinases known as the Janus Kinase ("Jaks") 25 family. Jaks represent a distinct family of soluble tyrosine kinases and include Tyk2, Jak1, Jak2, and Jak3. These kinases display significant sequence similarity and are generally catalytically inactive in resting cells.

The Jaks are activated by a wide range of receptors summarized in the Table below. (Adapted from review by Schidler and Darnell, Ann. Rev. Biochem. 64:621-51 (1995).) A cytokine receptor family, capable of activating Jaks, is divided into two 30 groups: (a) Class 1 includes receptors for IL-2, IL-3, IL-4, IL-6, IL-7, IL-9, IL-11, IL-12, IL-15, Epo, PRL, GH, G-CSF, GM-CSF, LIF, CNTF, and thrombopoietin; and (b)

Class 2 includes IFN-a, IFN-g, and IL-10. The Class 1 receptors share a conserved cysteine motif (a set of four conserved cysteines and one tryptophan) and a WSXWS motif (a membrane proximal region encoding Trp-Ser-Xxx-Trp-Ser (SEQ ID NO:2)).

Thus, on binding of a ligand to a receptor, Jaks are activated, which in turn  
5 activate STATs, which then translocate and bind to GAS elements. This entire process is encompassed in the Jaks-STATs signal transduction pathway.

Therefore, activation of the Jaks-STATs pathway, reflected by the binding of the GAS or the ISRE element, can be used to indicate proteins involved in the proliferation and differentiation of cells. For example, growth factors and cytokines  
10 are known to activate the Jaks-STATs pathway. (See Table below.) Thus, by using GAS elements linked to reporter molecules, activators of the Jaks-STATs pathway can be identified.

	<u>Ligand</u>	<u>tyk2</u>	<u>JAKs</u>	<u>STATS</u>	<u>GAS(elements) or ISRE</u>		
		<u>Jak1</u>	<u>Jak2</u>	<u>Jak3</u>			
<b><u>IFN family</u></b>							
5	IFN-a/B	+	+	-	-	1,2,3	ISRE
	IFN-g		+	+	-	1	GAS (IRF1>Lys6>IFP)
	Il-10	+	?	?	-	1,3	
<b><u>gp130 family</u></b>							
10	IL-6 (Pleiotrophic)	+	+	+	?	1,3	GAS (IRF1>Lys6>IFP)
	Il-11(Pleiotrophic)	?	+	?	?	1,3	
	OnM(Pleiotrophic)	?	+	+	?	1,3	
	LIF(Pleiotrophic)	?	+	+	?	1,3	
	CNTF(Pleiotrophic)	-/+	+	+	?	1,3	
15	G-CSF(Pleiotrophic)	?	+	?	?	1,3	
	IL-12(Pleiotrophic)	+	-	+	+	1,3	
<b><u>g-C family</u></b>							
	IL-2 (lymphocytes)	-	+	-	+	1,3,5	GAS
20	IL-4 (lymph/myeloid)	-	+	-	+	6	GAS (IRF1 = IFP >>Ly6)(IgH)
	IL-7 (lymphocytes)	-	+	-	+	5	GAS
	IL-9 (lymphocytes)	-	+	-	+	5	GAS
	IL-13 (lymphocyte)	-	+	?	?	6	GAS
	IL-15	?	+	?	+	5	GAS
25	<b><u>gp140 family</u></b>						
	IL-3 (myeloid)	-	-	+	-	5	GAS (IRF1>IFP>>Ly6)
	IL-5 (myeloid)	-	-	+	-	5	GAS
	GM-CSF (myeloid)	-	-	+	-	5	GAS
30	<b><u>Growth hormone family</u></b>						
	GH	?	-	+	-	5	
	PRL	?	+/-	+	-	1,3,5	
	EPO	?	-	+	-	5	GAS(B-CAS>IRF1=IFP>>Ly6)
35	<b><u>Receptor Tyrosine Kinases</u></b>						
	EGF	?	+	+	-	1,3	GAS (IRF1)
	PDGF	?	+	+	-	1,3	
	CSF-1	?	+	+	-	1,3	GAS (not IRF1)
40							

- To construct a synthetic GAS containing promoter element, which is used in the Biological Assays described in Examples 13-14, a PCR based strategy is employed to generate a GAS-SV40 promoter sequence. The 5' primer contains four tandem copies of the GAS binding site found in the IRF1 promoter and previously demonstrated to bind STATs upon induction with a range of cytokines (Rothman et al., *Immunity* 1:457-468 (1994).), although other GAS or ISRE elements can be used instead. The 5' primer also contains 18bp of sequence complementary to the SV40 early promoter sequence and is flanked with an XhoI site. The sequence of the 5' primer is:
- 5 10 15 20 25 30
- 5':GCGCCTCGAGATTCCCCGAAATCTAGATTCCCCGAAATGATTCCCC  
GAAATGATTCCCCGAAATATCTGCCATCTCAATTAG:3' (SEQ ID NO:3)
- The downstream primer is complementary to the SV40 promoter and is flanked with a Hind III site: 5':GCGGCAAGCTTTGCAAAGCCTAGGC:3'  
(SEQ ID NO:4)
- PCR amplification is performed using the SV40 promoter template present in the B-gal:promoter plasmid obtained from Clontech. The resulting PCR fragment is digested with XhoI/Hind III and subcloned into BLSK2-. (Stratagene.) Sequencing with forward and reverse primers confirms that the insert contains the following sequence:
- 5':CTCGAGATTCCCCGAAATCTAGATTCCCCGAAATGATTCCCCGAAA  
TGATTCCCCGAAATATCTGCCATCTCAATTAGTCAGCAACCATAGTCCCG  
CCCCTAACTCCGCCATCCGCCCTAACTCCGCCAGTTCCGCCATTCT  
CCGCCCATGGCTGACTAATTTTTATTATGCAGAGGCCGAGGCC  
TCGGCCTCTGAGCTATTCCAGAAGTAGTAGTGAGGAGGCTTTGGAGGCCT  
AGGCTTTGCAAAAGCTT:3' (SEQ ID NO:5)
- With this GAS promoter element linked to the SV40 promoter, a GAS:SEAP2 reporter construct is next engineered. Here, the reporter molecule is a secreted alkaline phosphatase, or "SEAP." Clearly, however, any reporter molecule can be instead of SEAP, in this or in any of the other Examples. Well known reporter molecules that can be used instead of SEAP include chloramphenicol

acetyltransferase (CAT), luciferase, alkaline phosphatase, B-galactosidase, green fluorescent protein (GFP), or any protein detectable by an antibody.

The above sequence confirmed synthetic GAS-SV40 promoter element is subcloned into the pSEAP-Promoter vector obtained from Clontech using HindIII and 5 XhoI, effectively replacing the SV40 promoter with the amplified GAS:SV40 promoter element, to create the GAS-SEAP vector. However, this vector does not contain a neomycin resistance gene, and therefore, is not preferred for mammalian expression systems.

Thus, in order to generate mammalian stable cell lines expressing the GAS-10 SEAP reporter, the GAS-SEAP cassette is removed from the GAS-SEAP vector using SalI and NotI, and inserted into a backbone vector containing the neomycin resistance gene, such as pGFP-1 (Clontech), using these restriction sites in the multiple cloning site, to create the GAS-SEAP/Neo vector. Once this vector is transfected into mammalian cells, this vector can then be used as a reporter molecule for GAS binding 15 as described in Examples 13-14.

Other constructs can be made using the above description and replacing GAS with a different promoter sequence. For example, construction of reporter molecules containing NFK-B and EGR promoter sequences are described in Examples 15 and 16. However, many other promoters can be substituted using the protocols described 20 in these Examples. For instance, SRE, IL-2, NFAT, or Osteocalcin promoters can be substituted, alone or in combination (e.g., GAS/NF-KB/EGR, GAS/NF-KB, IL-2/NFAT, or NF-KB/GAS). Similarly, other cell lines can be used to test reporter construct activity, such as HELA (epithelial), HUVEC (endothelial), Reh (B-cell), Saos-2 (osteoblast), HUVAC (aortic), or Cardiomyocyte.

25

**Example 13: High-Throughput Screening Assay for T-cell Activity.**

The following protocol is used to assess T-cell activity by identifying factors, and determining whether supernate containing a polypeptide of the invention proliferates and/or differentiates T-cells. T-cell activity is assessed using the 30 GAS/SEAP/Neo construct produced in Example 12. Thus, factors that increase SEAP activity indicate the ability to activate the Jaks-STATs signal transduction pathway.

The T-cell used in this assay is Jurkat T-cells (ATCC Accession No. TIB-152), although Molt-3 cells (ATCC Accession No. CRL-1552) and Molt-4 cells (ATCC Accession No. CRL-1582) cells can also be used.

Jurkat T-cells are lymphoblastic CD4+ Th1 helper cells. In order to generate  
5 stable cell lines, approximately 2 million Jurkat cells are transfected with the GAS-  
SEAP/neo vector using DMRIE-C (Life Technologies)(transfection procedure  
described below). The transfected cells are seeded to a density of approximately  
20,000 cells per well and transfectants resistant to 1 mg/ml genticin selected.  
Resistant colonies are expanded and then tested for their response to increasing  
10 concentrations of interferon gamma. The dose response of a selected clone is  
demonstrated.

Specifically, the following protocol will yield sufficient cells for 75 wells  
containing 200 ul of cells. Thus, it is either scaled up, or performed in multiple to  
generate sufficient cells for multiple 96 well plates. Jurkat cells are maintained in  
15 RPMI + 10% serum with 1%Pen-Strep. Combine 2.5 mls of OPTI-MEM (Life  
Technologies) with 10 ug of plasmid DNA in a T25 flask. Add 2.5 ml OPTI-MEM  
containing 50 ul of DMRIE-C and incubate at room temperature for 15-45 mins.

During the incubation period, count cell concentration, spin down the required  
number of cells ( $10^7$  per transfection), and resuspend in OPTI-MEM to a final  
20 concentration of  $10^7$  cells/ml. Then add 1ml of  $1 \times 10^7$  cells in OPTI-MEM to T25  
flask and incubate at 37 degrees C for 6 hrs. After the incubation, add 10 ml of RPMI  
+ 15% serum.

The Jurkat:GAS-SEAP stable reporter lines are maintained in RPMI + 10%  
serum, 1 mg/ml Genticin, and 1% Pen-Strep. These cells are treated with  
25 supernatants containing polypeptides of the invention and/or induced polypeptides of  
the invention as produced by the protocol described in Example 11.

On the day of treatment with the supernatant, the cells should be washed and  
resuspended in fresh RPMI + 10% serum to a density of 500,000 cells per ml. The  
exact number of cells required will depend on the number of supernatants being  
30 screened. For one 96 well plate, approximately 10 million cells (for 10 plates, 100  
million cells) are required.

Transfer the cells to a triangular reservoir boat, in order to dispense the cells into a 96 well dish, using a 12 channel pipette. Using a 12 channel pipette, transfer 200 ul of cells into each well (therefore adding 100,000 cells per well).

After all the plates have been seeded, 50 ul of the supernatants are transferred  
5 directly from the 96 well plate containing the supernatants into each well using a 12 channel pipette. In addition, a dose of exogenous interferon gamma (0.1, 1.0, 10 ng) is added to wells H9, H10, and H11 to serve as additional positive controls for the assay.

The 96 well dishes containing Jurkat cells treated with supernatants are placed  
10 in an incubator for 48 hrs (note: this time is variable between 48-72 hrs). 35 ul samples from each well are then transferred to an opaque 96 well plate using a 12 channel pipette. The opaque plates should be covered (using sellophene covers) and stored at -20 degrees C until SEAP assays are performed according to Example 17. The plates containing the remaining treated cells are placed at 4 degrees C and serve  
15 as a source of material for repeating the assay on a specific well if desired.

As a positive control, 100 Unit/ml interferon gamma can be used which is known to activate Jurkat T cells. Over 30 fold induction is typically observed in the positive control wells.

The above protocol may be used in the generation of both transient, as well as,  
20 stable transfected cells, which would be apparent to those of skill in the art.

#### Example 14: High-Throughput Screening Assay Identifying Myeloid Activity

The following protocol is used to assess myeloid activity by determining whether polypeptides of the invention proliferates and/or differentiates myeloid cells.  
25 Myeloid cell activity is assessed using the GAS/SEAP/Neo construct produced in Example 12. Thus, factors that increase SEAP activity indicate the ability to activate the Jaks-STATS signal transduction pathway. The myeloid cell used in this assay is U937, a pre-monocyte cell line, although TF-1, HL60, or KG1 can be used.

To transiently transfet U937 cells with the GAS/SEAP/Neo construct  
30 produced in Exampte 12, a DEAE-Dextran method (Kharbanda et. al., 1994, Cell Growth & Differentiation, 5:259-265) is used. First, harvest  $2 \times 10^7$  U937 cells and

wash with PBS. The U937 cells are usually grown in RPMI 1640 medium containing 10% heat-inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 mg/ml streptomycin.

- Next, suspend the cells in 1 ml of 20 mM Tris-HCl (pH 7.4) buffer containing  
5 0.5 mg/ml DEAE-Dextran, 8 ug GAS-SEAP2 plasmid DNA, 140 mM NaCl, 5 mM KCl, 375 uM Na<sub>2</sub>HPO<sub>4</sub>.7H<sub>2</sub>O, 1 mM MgCl<sub>2</sub>, and 675 uM CaCl<sub>2</sub>. Incubate at 37 degrees C for 45 min.

Wash the cells with RPMI 1640 medium containing 10% FBS and then resuspend in 10 ml complete medium and incubate at 37 degrees C for 36 hr.

- 10 The GAS-SEAP/U937 stable cells are obtained by growing the cells in 400 ug/ml G418. The G418-free medium is used for routine growth but every one to two months, the cells should be re-grown in 400 ug/ml G418 for couple of passages.

- These cells are tested by harvesting  $1 \times 10^8$  cells (this is enough for ten 96-well plates assay) and wash with PBS. Suspend the cells in 200 ml above described  
15 growth medium, with a final density of  $5 \times 10^5$  cells/ml. Plate 200 ul cells per well in the 96-well plate (or  $1 \times 10^5$  cells/well).

- Add 50 ul of the supernatant prepared by the protocol described in Example  
11. Incubate at 37 degrees C for 48 to 72 hr. As a positive control, 100 Unit/ml  
interferon gamma can be used which is known to activate U937 cells. Over 30 fold  
20 induction is typically observed in the positive control wells. SEAP assay the supernatant according to the protocol described in Example 17.

**Example 15: High-Throughput Screening Assay Identifying Neuronal Activity.**

- When cells undergo differentiation and proliferation, a group of genes are  
25 activated through many different signal transduction pathways. One of these genes, EGR1 (early growth response gene 1), is induced in various tissues and cell types upon activation. The promoter of EGR1 is responsible for such induction. Using the EGR1 promoter linked to reporter molecules, activation of cells can be assessed.

- Particularly, the following protocol is used to assess neuronal activity in PC12  
30 cell lines. PC12 cells (rat phenochromocytoma cells) are known to proliferate and/or differentiate by activation with a number of mitogens, such as TPA (tetradecanoyl

phorbol acetate), NGF (nerve growth factor), and EGF (epidermal growth factor). The EGR1 gene expression is activated during this treatment. Thus, by stably transfecting PC12 cells with a construct containing an EGR promoter linked to SEAP reporter, activation of PC12 cells can be assessed.

5 The EGR/SEAP reporter construct can be assembled by the following protocol. The EGR-1 promoter sequence (-633 to +1)(Sakamoto K et al., Oncogene 6:867-871 (1991)) can be PCR amplified from human genomic DNA using the following primers:

5' GCGCTCGAGGGATGACAGCGATAGAACCCGG -3' (SEQ ID NO:6)

10 5' GCGAAGCTTCGCGACTCCCCGGATCCGCCTC-3' (SEQ ID NO:7)

Using the GAS:SEAP/Neo vector produced in Example 12, EGR1 amplified product can then be inserted into this vector. Linearize the GAS:SEAP/Neo vector using restriction enzymes Xhol/HindIII, removing the GAS/SV40 stuffer. Restrict the EGR1 amplified product with these same enzymes. Ligate the vector and the EGR1  
15 promoter.

To prepare 96 well-plates for cell culture, two mls of a coating solution (1:30 dilution of collagen type I (Upstate Biotech Inc. Cat#08-115) in 30% ethanol (filter sterilized)) is added per one 10 cm plate or 50 ml per well of the 96-well plate, and allowed to air dry for 2 hr.

20 PC12 cells are routinely grown in RPMI-1640 medium (Bio Whittaker) containing 10% horse serum (JRH BIOSCIENCES, Cat. # 12449-78P), 5% heat-inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 ug/ml streptomycin on a precoated 10 cm tissue culture dish. One to four split is done every three to four days. Cells are removed from the plates by scraping and  
25 resuspended with pipetting up and down for more than 15 times.

Transfect the EGR/SEAP/Neo construct into PC12 using the Lipofectamine protocol described in Example 11. EGR-SEAP/PC12 stable cells are obtained by growing the cells in 300 ug/ml G418. The G418-free medium is used for routine growth but every one to two months, the cells should be re-grown in 300 ug/ml G418  
30 for couple of passages.

To assay for neuronal activity, a 10 cm plate with cells around 70 to 80% confluent is screened by removing the old medium. Wash the cells once with PBS (Phosphate buffered saline). Then starve the cells in low serum medium (RPMI-1640 containing 1% horse serum and 0.5% FBS with antibiotics) overnight.

- 5       The next morning, remove the medium and wash the cells with PBS. Scrape off the cells from the plate, suspend the cells well in 2 ml low serum medium. Count the cell number and add more low serum medium to reach final cell density as  $5 \times 10^5$  cells/ml.

- Add 200 ul of the cell suspension to each well of 96-well plate (equivalent to  
10       $1 \times 10^5$  cells/well). Add 50 ul supernatant produced by Example 11, 37°C for 48 to 72 hr. As a positive control, a growth factor known to activate PC12 cells through EGR can be used, such as 50 ng/ul of Neuronal Growth Factor (NGF). Over fifty-fold induction of SEAP is typically seen in the positive control wells. SEAP assay the supernatant according to Example 17.

15

**Example 16: High-Throughput Screening Assay for T-cell Activity**

- NF-KB (Nuclear Factor KB) is a transcription factor activated by a wide variety of agents including the inflammatory cytokines IL-1 and TNF, CD30 and CD40, lymphotoxin-alpha and lymphotoxin-beta, by exposure to LPS or thrombin,  
20      and by expression of certain viral gene products. As a transcription factor, NF-KB regulates the expression of genes involved in immune cell activation, control of apoptosis (NF- KB appears to shield cells from apoptosis), B and T-cell development, anti-viral and antimicrobial responses, and multiple stress responses.

- In non-stimulated conditions, NF- KB is retained in the cytoplasm with I-KB  
25      (Inhibitor KB). However, upon stimulation, I- KB is phosphorylated and degraded, causing NF- KB to shuttle to the nucleus, thereby activating transcription of target genes. Target genes activated by NF- KB include IL-2, IL-6, GM-CSF, ICAM-1 and class 1 MHC.

- Due to its central role and ability to respond to a range of stimuli, reporter  
30      constructs utilizing the NF-KB promoter element are used to screen the supernatants produced in Example 11. Activators or inhibitors of NF-KB would be useful in

treating diseases. For example, inhibitors of NF-KB could be used to treat those diseases related to the acute or chronic activation of NF-KB, such as rheumatoid arthritis.

To construct a vector containing the NF-KB promoter element, a PCR based  
5 strategy is employed. The upstream primer contains four tandem copies of the NF-  
KB binding site (GGGGACTTCCC) (SEQ ID NO:8), 18 bp of sequence  
complementary to the 5' end of the SV40 early promoter sequence, and is flanked  
with an XhoI site:

5':GCGGCCTCGAGGGACTTCCCAGGGACTTCCGGGACTTCCGGGACTTCCGGAC  
10 TTTCCATCCTGCCATCTCAATTAG:3' (SEQ ID NO:9)

The downstream primer is complementary to the 3' end of the SV40 promoter  
and is flanked with a Hind III site:

5':GCGGCAAGCTTTGCAAAGCCTAGGC:3' (SEQ ID NO:4)

PCR amplification is performed using the SV40 promoter template present in  
15 the pB-gal:promoter plasmid obtained from Clontech. The resulting PCR fragment is  
digested with XhoI and Hind III and subcloned into BLSK2-. (Stratagene)  
Sequencing with the T7 and T3 primers confirms the insert contains the following  
sequence:

20 5' : CTCGAGGGACTTCCCAGGGACTTCCGGGACTTCCGGACTTCCATCTGCCATCTCAATTAA  
GTCAGCAACCATACTCCGCCCTAACTCCGCCATCCGCCCTAACTCCGCCAGTTCCGCCATTC  
TCCGCCCATGGCTGACTAATTCTTTATTCAGAGGGCGAGGCCCTGGCTCTGAGCTATT  
CCAGAAGTAGTGAGGAGGCTTTTGAGGCCTAGGCTTTGCAAAAGCTT:3' (SEQ ID  
NO:10)

25

Next, replace the SV40 minimal promoter element present in the pSEAP2-  
promoter plasmid (Clontech) with this NF-KB/SV40 fragment using XhoI and  
HindIII. However, this vector does not contain a neomycin resistance gene, and  
therefore, is not preferred for mammalian expression systems.

30 In order to generate stable mammalian cell lines, the NF-KB/SV40/SEAP  
cassette is removed from the above NF-KB/SEAP vector using restriction enzymes  
SalI and NotI, and inserted into a vector containing neomycin resistance. Particularly,

the NF-KB/SV40/SEAP cassette was inserted into pGFP-1 (Clontech), replacing the GFP gene, after restricting pGFP-1 with SalI and NotI.

Once NF-KB/SV40/SEAP/Neo vector is created, stable Jurkat T-cells are created and maintained according to the protocol described in Example 13. Similarly, 5 the method for assaying supernatants with these stable Jurkat T-cells is also described in Example 13. As a positive control, exogenous TNF alpha (0.1, 1, 10 ng) is added to wells H9, H10, and H11, with a 5-10 fold activation typically observed.

#### Example 17: Assay for SEAP Activity

10 As a reporter molecule for the assays described in Examples 13-16, SEAP activity is assayed using the Tropix Phospho-light Kit (Cat. BP-400) according to the following general procedure. The Tropix Phospho-light Kit supplies the Dilution, Assay, and Reaction Buffers used below.

15 Prime a dispenser with the 2.5x Dilution Buffer and dispense 15 ul of 2.5x dilution buffer into Optiplates containing 35 ul of a supernatant. Seal the plates with a plastic sealer and incubate at 65 degree C for 30 min. Separate the Optiplates to avoid uneven heating.

20 Cool the samples to room temperature for 15 minutes. Empty the dispenser and prime with the Assay Buffer. Add 50 ml Assay Buffer and incubate at room temperature 5 min. Empty the dispenser and prime with the Reaction Buffer (see the table below). Add 50 ul Reaction Buffer and incubate at room temperature for 20 minutes. Since the intensity of the chemiluminescent signal is time dependent, and it takes about 10 minutes to read 5 plates on luminometer, one should treat 5 plates at each time and start the second set 10 minutes later.

25 Read the relative light unit in the luminometer. Set H12 as blank, and print the results. An increase in chemiluminescence indicates reporter activity.

#### **Reaction Buffer Formulation:**

# of plates	Rxn buffer diluent (ml)	CSPD (ml)
10	60	3
11	65	3.25
12	70	3.5
13	75	3.75

14	80	4
15	85	4.25
16	90	4.5
17	95	4.75
18	100	5
19	105	5.25
20	110	5.5
21	115	5.75
22	120	6
23	125	6.25
24	130	6.5
25	135	6.75
26	140	7
27	145	7.25
28	150	7.5
29	155	7.75
30	160	8
31	165	8.25
32	170	8.5
33	175	8.75
34	180	9
35	185	9.25
36	190	9.5
37	195	9.75
38	200	10
39	205	10.25
40	210	10.5
41	215	10.75
42	220	11
43	225	11.25
44	230	11.5
45	235	11.75
46	240	12
47	245	12.25
48	250	12.5
49	255	12.75
50	260	13

**Example 18: High-Throughput Screening Assay Identifying Changes in Small Molecule Concentration and Membrane Permeability**

Binding of a ligand to a receptor is known to alter intracellular levels of small molecules, such as calcium, potassium, sodium, and pH, as well as alter membrane potential. These alterations can be measured in an assay to identify supernatants which bind to receptors of a particular cell. Although the following protocol describes an assay for calcium, this protocol can easily be modified to detect changes in potassium, sodium, pH, membrane potential, or any other small molecule which is detectable by a fluorescent probe.

The following assay uses Fluorometric Imaging Plate Reader ("FLIPR") to measure changes in fluorescent molecules (Molecular Probes) that bind small molecules. Clearly, any fluorescent molecule detecting a small molecule can be used instead of the calcium fluorescent molecule, fluo-4 (Molecular Probes, Inc.; catalog 5 no. F-14202), used here.

For adherent cells, seed the cells at 10,000 -20,000 cells/well in a Co-star black 96-well plate with clear bottom. The plate is incubated in a CO<sub>2</sub> incubator for 20 hours. The adherent cells are washed two times in Biotek washer with 200 ul of HBSS (Hank's Balanced Salt Solution) leaving 100 ul of buffer after the final wash.

10 A stock solution of 1 mg/ml fluo-4 is made in 10% pluronic acid DMSO. To load the cells with fluo-4 , 50 ul of 12 ug/ml fluo-4 is added to each well. The plate is incubated at 37 degrees C in a CO<sub>2</sub> incubator for 60 min. The plate is washed four times in the Biotek washer with HBSS leaving 100 ul of buffer.

15 For non-adherent cells, the cells are spun down from culture media. Cells are re-suspended to 2-5x10<sup>6</sup> cells/ml with HBSS in a 50-ml conical tube. 4 ul of 1 mg/ml fluo-4 solution in 10% pluronic acid DMSO is added to each ml of cell suspension. The tube is then placed in a 37 degrees C water bath for 30-60 min. The cells are washed twice with HBSS, resuspended to 1x10<sup>6</sup> cells/ml, and dispensed into a microplate, 100 ul/well. The plate is centrifuged at 1000 rpm for 5 min. The plate is 20 then washed once in Denley CellWash with 200 ul, followed by an aspiration step to 100 ul final volume.

For a non-cell based assay, each well contains a fluorescent molecule, such as fluo-4 . The supernatant is added to the well, and a change in fluorescence is detected.

25 To measure the fluorescence of intracellular calcium, the FLIPR is set for the following parameters: (1) System gain is 300-800 mW; (2) Exposure time is 0.4 second; (3) Camera F/stop is F/2; (4) Excitation is 488 nm; (5) Emission is 530 nm; and (6) Sample addition is 50 ul. Increased emission at 530 nm indicates an extracellular signaling event which has resulted in an increase in the intracellular 30 Ca<sup>++</sup> concentration.

**Example 19: High-Throughput Screening Assay Identifying Tyrosine Kinase Activity**

The Protein Tyrosine Kinases (PTK) represent a diverse group of transmembrane and cytoplasmic kinases. Within the Receptor Protein Tyrosine Kinase RPTK) group are receptors for a range of mitogenic and metabolic growth factors including the PDGF, FGF, EGF, NGF, HGF and Insulin receptor subfamilies. In addition there are a large family of RPTKs for which the corresponding ligand is unknown. Ligands for RPTKs include mainly secreted small proteins, but also membrane-bound and extracellular matrix proteins.

Activation of RPTK by ligands involves ligand-mediated receptor dimerization, resulting in transphosphorylation of the receptor subunits and activation of the cytoplasmic tyrosine kinases. The cytoplasmic tyrosine kinases include receptor associated tyrosine kinases of the src-family (e.g., src, yes, lck, lyn, fyn) and non-receptor linked and cytosolic protein tyrosine kinases, such as the Jak family, members of which mediate signal transduction triggered by the cytokine superfamily of receptors (e.g., the Interleukins, Interferons, GM-CSF, and Leptin).

Because of the wide range of known factors capable of stimulating tyrosine kinase activity, the identification of novel human secreted proteins capable of activating tyrosine kinase signal transduction pathways are of interest. Therefore, the following protocol is designed to identify those novel human secreted proteins capable of activating the tyrosine kinase signal transduction pathways.

Seed target cells (e.g., primary keratinocytes) at a density of approximately 25,000 cells per well in a 96 well Loprodyne Silent Screen Plates purchased from Nalge Nunc (Naperville, IL). The plates are sterilized with two 30 minute rinses with 100% ethanol, rinsed with water and dried overnight. Some plates are coated for 2 hr with 100 ml of cell culture grade type I collagen (50 mg/ml), gelatin (2%) or polylysine (50 mg/ml), all of which can be purchased from Sigma Chemicals (St. Louis, MO) or 10% Matrigel purchased from Becton Dickinson (Bedford, MA), or calf serum, rinsed with PBS and stored at 4 degree C. Cell growth on these plates is assayed by seeding 5,000 cells/well in growth medium and indirect quantitation of cell number through use of alamarBlue as described by the manufacturer Alamar

Biosciences, Inc. (Sacramento, CA) after 48 hr. Falcon plate covers #3071 from Becton Dickinson (Bedford, MA) are used to cover the Loprodynne Silent Screen Plates. Falcon Microtest III cell culture plates can also be used in some proliferation experiments.

- 5 To prepare extracts, A431 cells are seeded onto the nylon membranes of Loprodynne plates (20,000/200ml/well) and cultured overnight in complete medium. Cells are quiesced by incubation in serum-free basal medium for 24 hr. After 5-20 minutes treatment with EGF (60ng/ml) or 50 ul of the supernatant produced in Example 11, the medium was removed and 100 ml of extraction buffer ((20 mM HEPES pH 7.5, 0.15 M NaCl, 1% Triton X-100, 0.1% SDS, 2 mM Na<sub>3</sub>VO<sub>4</sub>, 2 mM Na<sub>4</sub>P<sub>2</sub>O<sub>7</sub> and a cocktail of protease inhibitors (# 1836170) obtained from Boehringer Mannheim (Indianapolis, IN) is added to each well and the plate is shaken on a rotating shaker for 5 minutes at 4 degrees C. The plate is then placed in a vacuum transfer manifold and the extract filtered through the 0.45 mm membrane bottoms of each well using house vacuum. Extracts are collected in a 96-well catch/assay plate in the bottom of the vacuum manifold and immediately placed on ice. To obtain extracts clarified by centrifugation, the content of each well, after detergent solubilization for 5 minutes, is removed and centrifuged for 15 minutes at 4 degrees C at 16,000 x g.
- 10 15 20

Test the filtered extracts for levels of tyrosine kinase activity. Although many methods of detecting tyrosine kinase activity are known, one method is described here.

Generally, the tyrosine kinase activity of a supernatant is evaluated by determining its ability to phosphorylate a tyrosine residue on a specific substrate (a biotinylated peptide). Biotinylated peptides that can be used for this purpose include PSK1 (corresponding to amino acids 6-20 of the cell division kinase cdc2-p34) and PSK2 (corresponding to amino acids 1-17 of gastrin). Both peptides are substrates for a range of tyrosine kinases and are available from Boehringer Mannheim.

The tyrosine kinase reaction is set up by adding the following components in order. First, add 10ul of 5uM Biotinylated Peptide, then 10ul ATP/Mg<sub>2+</sub> (5mM ATP/50mM MgCl<sub>2</sub>), then 10ul of 5x Assay Buffer (40mM imidazole hydrochloride,

pH7.3, 40 mM beta-glycerophosphate, 1mM EGTA, 100mM MgCl<sub>2</sub>, 5 mM MnCl<sub>2</sub>, 0.5 mg/ml BSA), then 5ul of Sodium Vanadate(1mM), and then 5ul of water. Mix the components gently and preincubate the reaction mix at 30 degrees C for 2 min. Initial the reaction by adding 10ul of the control enzyme or the filtered supernatant.

- 5        The tyrosine kinase assay reaction is then terminated by adding 10 ul of 120mm EDTA and place the reactions on ice.

Tyrosine kinase activity is determined by transferring 50 ul aliquot of reaction mixture to a microtiter plate (MTP) module and incubating at 37 degrees C for 20 min. This allows the streptavidin coated 96 well plate to associate with the

- 10      biotinylated peptide. Wash the MTP module with 300ul/well of PBS four times. Next add 75 ul of anti-phospotyrosine antibody conjugated to horse radish peroxidase(anti-P-Tyr-POD(0.5u/ml)) to each well and incubate at 37 degrees C for one hour. Wash the well as above.

- 15      Next add 100ul of peroxidase substrate solution (Boehringer Mannheim) and incubate at room temperature for at least 5 mins (up to 30 min). Measure the absorbance of the sample at 405 nm by using ELISA reader. The level of bound peroxidase activity is quantitated using an ELISA reader and reflects the level of tyrosine kinase activity.

20      **Example 20: High-Throughput Screening Assay Identifying Phosphorylation Activity**

- As a potential alternative and/or compliment to the assay of protein tyrosine kinase activity described in Example 19, an assay which detects activation (phosphorylation) of major intracellular signal transduction intermediates can also be used. For example, as described below one particular assay can detect tyrosine phosphorylation of the Erk-1 and Erk-2 kinases. However, phosphorylation of other molecules, such as Raf, JNK, p38 MAP, Map kinase kinase (MEK), MEK kinase, Src, Muscle specific kinase (MuSK), IRAK, Tec, and Janus, as well as any other phosphoserine, phosphotyrosine, or phosphothreonine molecule, can be detected by substituting these molecules for Erk-1 or Erk-2 in the following assay.

Specifically, assay plates are made by coating the wells of a 96-well ELISA plate with 0.1ml of protein G (1ug/ml) for 2 hr at room temp, (RT). The plates are then rinsed with PBS and blocked with 3% BSA/PBS for 1 hr at RT. The protein G plates are then treated with 2 commercial monoclonal antibodies (100ng/well) against Erk-1 and Erk-2 (1 hr at RT) (Santa Cruz Biotechnology). (To detect other molecules, this step can easily be modified by substituting a monoclonal antibody detecting any of the above described molecules.) After 3-5 rinses with PBS, the plates are stored at 4 degrees C until use.

A431 cells are seeded at 20,000/well in a 96-well Loprodyn filterplate and cultured overnight in growth medium. The cells are then starved for 48 hr in basal medium (DMEM) and then treated with EGF (6ng/well) or 50 ul of the supernatants obtained in Example 11 for 5-20 minutes. The cells are then solubilized and extracts filtered directly into the assay plate.

After incubation with the extract for 1 hr at RT, the wells are again rinsed. As a positive control, a commercial preparation of MAP kinase (10ng/well) is used in place of A431 extract. Plates are then treated with a commercial polyclonal (rabbit) antibody (1ug/ml) which specifically recognizes the phosphorylated epitope of the Erk-1 and Erk-2 kinases (1 hr at RT). This antibody is biotinylated by standard procedures. The bound polyclonal antibody is then quantitated by successive incubations with Europium-streptavidin and Europium fluorescence enhancing reagent in the Wallac DELFIA instrument (time-resolved fluorescence). An increased fluorescent signal over background indicates a phosphorylation.

**Example 21: Method of Determining Alterations in a Gene Corresponding to a Polynucleotide**

RNA isolated from entire families or individual patients presenting with a phenotype of interest (such as a disease) is isolated. cDNA is then generated from these RNA samples using protocols known in the art. (See, Sambrook.) The cDNA is then used as a template for PCR, employing primers surrounding regions of interest in SEQ ID NO:X. Suggested PCR conditions consist of 35 cycles at 95 degrees C for

30 seconds; 60-120 seconds at 52-58 degrees C; and 60-120 seconds at 70 degrees C, using buffer solutions described in Sidransky et al., Science 252:706 (1991).

PCR products are then sequenced using primers labeled at their 5' end with T4 polynucleotide kinase, employing SequiT<sup>TM</sup> Polymerase. (Epicentre

- 5 Technologies). The intron-exon borders of selected exons is also determined and genomic PCR products analyzed to confirm the results. PCR products harboring suspected mutations is then cloned and sequenced to validate the results of the direct sequencing.

- PCR products is cloned into T-tailed vectors as described in Holton et al.,  
10 Nucleic Acids Research, 19:1156 (1991) and sequenced with T7 polymerase (United States Biochemical). Affected individuals are identified by mutations not present in unaffected individuals.

- Genomic rearrangements are also observed as a method of determining  
alterations in a gene corresponding to a polynucleotide. Genomic clones isolated  
15 according to Example 2 are nick-translated with digoxigeninideoxy-uridine 5'-triphosphate (Boehringer Manheim), and FISH performed as described in Johnson et al., Methods Cell Biol. 35:73-99 (1991). Hybridization with the labeled probe is carried out using a vast excess of human cot-1 DNA for specific hybridization to the corresponding genomic locus.

- 20 Chromosomes are counterstained with 4,6-diamino-2-phenylidole and propidium iodide, producing a combination of C- and R-bands. Aligned images for precise mapping are obtained using a triple-band filter set (Chroma Technology, Brattleboro, VT) in combination with a cooled charge-coupled device camera (Photometrics, Tucson, AZ) and variable excitation wavelength filters. (Johnson et  
25 al., Genet. Anal. Tech. Appl., 8:75 (1991).) Image collection, analysis and chromosomal fractional length measurements are performed using the ISee Graphical Program System. (Inovision Corporation, Durham, NC.) Chromosome alterations of the genomic region hybridized by the probe are identified as insertions, deletions, and translocations. These alterations are used as a diagnostic marker for an associated  
30 disease.

**Example 22: Method of Detecting Abnormal Levels of a Polypeptide in a Biological Sample**

A polypeptide of the present invention can be detected in a biological sample, and if an increased or decreased level of the polypeptide is detected, this polypeptide 5 is a marker for a particular phenotype. Methods of detection are numerous, and thus, it is understood that one skilled in the art can modify the following assay to fit their particular needs.

For example, antibody-sandwich ELISAs are used to detect polypeptides in a sample, preferably a biological sample. Wells of a microtiter plate are coated with 10 specific antibodies, at a final concentration of 0.2 to 10 ug/ml. The antibodies are either monoclonal or polyclonal and are produced by the method described in Example 10. The wells are blocked so that non-specific binding of the polypeptide to the well is reduced.

The coated wells are then incubated for > 2 hours at RT with a sample 15 containing the polypeptide. Preferably, serial dilutions of the sample should be used to validate results. The plates are then washed three times with deionized or distilled water to remove unbounded polypeptide.

Next, 50 ul of specific antibody-alkaline phosphatase conjugate, at a concentration of 25-400 ng, is added and incubated for 2 hours at room temperature. 20 The plates are again washed three times with deionized or distilled water to remove unbounded conjugate.

Add 75 ul of 4-methylumbelliferyl phosphate (MUP) or p-nitrophenyl 25 phosphate (NPP) substrate solution to each well and incubate 1 hour at room temperature. Measure the reaction by a microtiter plate reader. Prepare a standard curve, using serial dilutions of a control sample, and plot polypeptide concentration on the X-axis (log scale) and fluorescence or absorbance of the Y-axis (linear scale). Interpolate the concentration of the polypeptide in the sample using the standard curve.

**Example 23: Formulation**

The invention also provides methods of treatment and/or prevention diseases, disorders, and/or conditions (such as, for example, any one or more of the diseases or disorders disclosed herein) by administration to a subject of an effective amount of a Therapeutic.

By therapeutic is meant a polynucleotides or polypeptides of the invention (including fragments and variants), agonists or antagonists thereof, and/or antibodies thereto, in combination with a pharmaceutically acceptable carrier type (e.g., a sterile carrier).

The Therapeutic will be formulated and dosed in a fashion consistent with good medical practice, taking into account the clinical condition of the individual patient (especially the side effects of treatment with the Therapeutic alone), the site of delivery, the method of administration, the scheduling of administration, and other factors known to practitioners. The "effective amount" for purposes herein is thus determined by such considerations.

As a general proposition, the total pharmaceutically effective amount of the Therapeutic administered parenterally per dose will be in the range of about 1ug/kg/day to 10 mg/kg/day of patient body weight, although, as noted above, this will be subject to therapeutic discretion. More preferably, this dose is at least 0.01 mg/kg/day, and most preferably for humans between about 0.01 and 1 mg/kg/day for the hormone. If given continuously, the Therapeutic is typically administered at a dose rate of about 1 ug/kg/hour to about 50 ug/kg/hour, either by 1-4 injections per day or by continuous subcutaneous infusions, for example, using a mini-pump. An intravenous bag solution may also be employed. The length of treatment needed to observe changes and the interval following treatment for responses to occur appears to vary depending on the desired effect.

Therapeutics can be administered orally, rectally, parenterally, intracistemally, intravaginally, intraperitoneally, topically (as by powders, ointments, gels, drops or transdermal patch), buccally, or as an oral or nasal spray.

"Pharmaceutically acceptable carrier" refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any. The term "parenteral" as used herein refers to modes of administration which include

intravenous, intramuscular, intraperitoneal; intrasternal, subcutaneous and intraarticular injection and infusion.

- Therapeutics of the invention are also suitably administered by sustained-release systems. Suitable examples of sustained-release Therapeutics are
- 5 administered orally, rectally, parenterally, intracistemally, intravaginally, intraperitoneally, topically (as by powders, ointments, gels, drops or transdermal patch), buccally, or as an oral or nasal spray. "Pharmaceutically acceptable carrier" refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. The term "parenteral" as used herein refers to
- 10 modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

Therapeutics of the invention are also suitably administered by sustained-release systems. Suitable examples of sustained-release Therapeutics include suitable polymeric materials (such as, for example, semi-permeable polymer matrices in the

15 form of shaped articles, e.g., films, or microcapsules), suitable hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, and sparingly soluble derivatives (such as, for example, a sparingly soluble salt).

- Sustained-release matrices include polylactides (U.S. Pat. No. 3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma-ethyl-L-glutamate (Sidman et al.,
- 20 Biopolymers 22:547-556 (1983)), poly (2-hydroxyethyl methacrylate) (Langer et al., J. Biomed. Mater. Res. 15:167-277 (1981), and Langer, Chem. Tech. 12:98-105 (1982)), ethylene vinyl acetate (Langer et al., Id.) or poly-D-(-)-3-hydroxybutyric acid (EP 133,988).

- Sustained-release Therapeutics also include liposomally entrapped
- 25 Therapeutics of the invention (see generally, Langer, *Science* 249:1527-1533 (1990); Treat et al., in *Liposomes in the Therapy of Infectious Disease and Cancer*, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 317 -327 and 353-365 (1989)). Liposomes containing the Therapeutic are prepared by methods known per se: DE 3,218,121; Epstein et al., Proc. Natl. Acad. Sci. (USA) 82:3688-3692 (1985); Hwang
- 30 et al., Proc. Natl. Acad. Sci.(USA) 77:4030-4034 (1980); EP 52,322; EP 36,676; EP 88,046; EP 143,949; EP 142,641; Japanese Pat. Appl. 83-118008; U.S. Pat. Nos.

4,485,045 and 4,544,545; and EP 102,324. Ordinarily, the liposomes are of the small (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol. percent cholesterol, the selected proportion being adjusted for the optimal Therapeutic.

5 In yet an additional embodiment, the Therapeutics of the invention are delivered by way of a pump (*see* Langer, *supra*; Sefton, CRC Crit. Ref. Biomed. Eng. 14:201 (1987); Buchwald et al., Surgery 88:507 (1980); Saudek et al., N. Engl. J. Med. 321:574 (1989)).

Other controlled release systems are discussed in the review by Langer  
10 (*Science* 249:1527-1533 (1990)).

For parenteral administration, in one embodiment, the Therapeutic is formulated generally by mixing it at the desired degree of purity, in a unit dosage injectable form (solution, suspension, or emulsion), with a pharmaceutically acceptable carrier, i.e., one that is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation.  
15 For example, the formulation preferably does not include oxidizing agents and other compounds that are known to be deleterious to the Therapeutic.

Generally, the formulations are prepared by contacting the Therapeutic uniformly and intimately with liquid carriers or finely divided solid carriers or both.  
20 Then, if necessary, the product is shaped into the desired formulation. Preferably the carrier is a parenteral carrier, more preferably a solution that is isotonic with the blood of the recipient. Examples of such carrier vehicles include water, saline, Ringer's solution, and dextrose solution. Non-aqueous vehicles such as fixed oils and ethyl oleate are also useful herein, as well as liposomes.

25 The carrier suitably contains minor amounts of additives such as substances that enhance isotonicity and chemical stability. Such materials are non-toxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, succinate, acetic acid, and other organic acids or their salts; antioxidants such as ascorbic acid; low molecular weight (less than about ten residues) polypeptides, e.g., polyarginine or tripeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as

- polyvinylpyrrolidone; amino acids, such as glycine, glutamic acid, aspartic acid, or arginine; monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, manose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; counterions such as sodium; and/or nonionic surfactants such as polysorbates, poloxamers, or PEG.

5 The Therapeutic is typically formulated in such vehicles at a concentration of about 0.1 mg/ml to 100 mg/ml, preferably 1-10 mg/ml, at a pH of about 3 to 8. It will be understood that the use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of polypeptide salts.

- 10 Any pharmaceutical used for therapeutic administration can be sterile. Sterility is readily accomplished by filtration through sterile filtration membranes (e.g., 0.2 micron membranes). Therapeutics generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.

- 15 Therapeutics ordinarily will be stored in unit or multi-dose containers, for example, sealed ampoules or vials, as an aqueous solution or as a lyophilized formulation for reconstitution. As an example of a lyophilized formulation, 10-ml vials are filled with 5 ml of sterile-filtered 1% (w/v) aqueous Therapeutic solution, and the resulting mixture is lyophilized. The infusion solution is prepared by
- 20 reconstituting the lyophilized Therapeutic using bacteriostatic Water-for-Injection.

- The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the Therapeutics of the invention. Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. In addition, the Therapeutics may be employed in conjunction with other therapeutic compounds.

- 25 The Therapeutics of the invention may be administered alone or in combination with adjuvants. Adjuvants that may be administered with the
- 30 Therapeutics of the invention include, but are not limited to, alum, alum plus deoxycholate (ImmunoAg), MTP-PE (Biocine Corp.), QS21 (Genentech, Inc.), BCG,

and MPL. In a specific embodiment, Therapeutics of the invention are administered in combination with alum. In another specific embodiment, Therapeutics of the invention are administered in combination with QS-21. Further adjuvants that may be administered with the Therapeutics of the invention include, but are not limited to,

- 5 Monophosphoryl lipid immunomodulator, AdjuVax 100a, QS-21, QS-18, CRL1005, Aluminum salts, MF-59, and Virosomal adjuvant technology. Vaccines that may be administered with the Therapeutics of the invention include, but are not limited to, vaccines directed toward protection against MMR (measles, mumps, rubella), polio, varicella, tetanus/diphtheria, hepatitis A, hepatitis B, haemophilus influenzae B,
- 10 whooping cough, pneumonia, influenza, Lyme's Disease, rotavirus, cholera, yellow fever, Japanese encephalitis, poliomylitis, rabies, typhoid fever, and pertussis. Combinations may be administered either concomitantly, e.g., as an admixture, separately but simultaneously or concurrently; or sequentially. This includes presentations in which the combined agents are administered together as a therapeutic mixture, and also procedures in which the combined agents are administered
- 15 separately but simultaneously, e.g., as through separate intravenous lines into the same individual. Administration "in combination" further includes the separate administration of one of the compounds or agents given first, followed by the second.

- The Therapeutics of the invention may be administered alone or in
- 20 combination with other therapeutic agents. Therapeutic agents that may be administered in combination with the Therapeutics of the invention, include but not limited to, other members of the TNF family, chemotherapeutic agents, antibiotics, steroid and non-steroidal anti-inflammatories, conventional immunotherapeutic agents, cytokines and/or growth factors. Combinations may be administered either
  - 25 concomitantly, e.g., as an admixture, separately but simultaneously or concurrently; or sequentially. This includes presentations in which the combined agents are administered together as a therapeutic mixture, and also procedures in which the combined agents are administered separately but simultaneously, e.g., as through separate intravenous lines into the same individual. Administration "in combination"
  - 30 further includes the separate administration of one of the compounds or agents given first, followed by the second.

In one embodiment, the Therapeutics of the invention are administered in combination with members of the TNF family. TNF, TNF-related or TNF-like molecules that may be administered with the Therapeutics of the invention include, but are not limited to, soluble forms of TNF-alpha, lymphotoxin-alpha (LT-alpha, 5 also known as TNF-beta), LT-beta (found in complex heterotrimer LT-alpha2-beta), OPGL, FasL, CD27L, CD30L, CD40L, 4-1BBL, DcR3, OX40L, TNF-gamma (International Publication No. WO 96/14328), AIM-I (International Publication No. WO 97/33899), endokine-alpha (International Publication No. WO 98/07880), TR6 (International Publication No. WO 98/30694), OPG, and neutrokine-alpha 10 (International Publication No. WO 98/18921, OX40, and nerve growth factor (NGF), and soluble forms of Fas, CD30, CD27, CD40 and 4-IBB, TR2 (International Publication No. WO 96/34095), DR3 (International Publication No. WO 97/33904), DR4 (International Publication No. WO 98/32856), TR5 (International Publication No. WO 98/30693), TR6 (International Publication No. WO 98/30694), TR7 15 (International Publication No. WO 98/41629), TRANK, TR9 (International Publication No. WO 98/56892), TR10 (International Publication No. WO 98/54202), 312C2 (International Publication No. WO 98/06842), and TR12, and soluble forms CD154, CD70, and CD153.

In certain embodiments, Therapeutics of the invention are administered in 20 combination with antiretroviral agents, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and/or protease inhibitors. Nucleoside reverse transcriptase inhibitors that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, RETROVIR™ (zidovudine/AZT), VIDEX™ (didanosine/ddI), HIVID™ (zalcitabine/ddC), ZERIT™ 25 (stavudine/d4T), EPIVIR™ (lamivudine/3TC), and COMBIVIR™ (zidovudine/lamivudine). Non-nucleoside reverse transcriptase inhibitors that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, VIRAMUNE™ (nevirapine), REScriptor™ (delavirdine), and SUSTIVA™ (efavirenz). Protease inhibitors that may be administered in 30 combination with the Therapeutics of the invention, include, but are not limited to, CRIXIVAN™ (indinavir), NORVIR™ (ritonavir), INVIRASE™ (saquinavir), and

VIRACEPT™ (nelfinavir). In a specific embodiment, antiretroviral agents, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and/or protease inhibitors may be used in any combination with Therapeutics of the invention to treat AIDS and/or to prevent or treat HIV infection.

- 5       In other embodiments, Therapeutics of the invention may be administered in combination with anti-opportunistic infection agents. Anti-opportunistic agents that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, TRIMETHOPRIM-SULFAMETHOXAZOLE™, DAPSONE™, PENTAMIDINE™, ATOVAQUONE™, ISONIAZID™,
- 10      RIFAMPIN™, PYRAZINAMIDE™, ETHAMBUTOL™, RIFABUTIN™, CLARITHROMYCIN™, AZITHROMYCIN™, GANCICLOVIR™, FOSCARNET™, CIDOFOVIR™, FLUCONAZOLE™, ITRACONAZOLE™, KETOCONAZOLE™, ACYCLOVIR™, FAMCICOLVIR™, PYRIMETHAMINE™, LEUCOVORIN™, NEUPOGEN™ (filgrastim/G-CSF), and LEUKINE™
- 15      (sargramostim/GM-CSF). In a specific embodiment, Therapeutics of the invention are used in any combination with TRIMETHOPRIM-SULFAMETHOXAZOLE™, DAPSONE™, PENTAMIDINE™, and/or ATOVAQUONE™ to prophylactically treat or prevent an opportunistic *Pneumocystis carinii* pneumonia infection. In another specific embodiment, Therapeutics of the invention are used in any
- 20      combination with ISONIAZID™, RIFAMPIN™, PYRAZINAMIDE™, and/or ETHAMBUTOL™ to prophylactically treat or prevent an opportunistic *Mycobacterium avium* complex infection. In another specific embodiment, Therapeutics of the invention are used in any combination with RIFABUTIN™, CLARITHROMYCIN™, and/or AZITHROMYCIN™ to prophylactically treat or
- 25      prevent an opportunistic *Mycobacterium tuberculosis* infection. In another specific embodiment, Therapeutics of the invention are used in any combination with GANCICLOVIR™, FOSCARNET™, and/or CIDOFOVIR™ to prophylactically treat or prevent an opportunistic cytomegalovirus infection. In another specific embodiment, Therapeutics of the invention are used in any combination with
- 30      FLUCONAZOLE™, ITRACONAZOLE™, and/or KETOCONAZOLE™ to

prophylactically treat or prevent an opportunistic fungal infection. In another specific embodiment, Therapeutics of the invention are used in any combination with ACYCLOVIR™ and/or FAMCICOLVIR™ to prophylactically treat or prevent an opportunistic herpes simplex virus type I and/or type II infection. In another specific 5 embodiment, Therapeutics of the invention are used in any combination with PYRIMETHAMINE™ and/or LEUCOVORIN™ to prophylactically treat or prevent an opportunistic *Toxoplasma gondii* infection. In another specific embodiment, Therapeutics of the invention are used in any combination with LEUCOVORIN™ and/or NEUPOGEN™ to prophylactically treat or prevent an opportunistic bacterial 10 infection.

In a further embodiment, the Therapeutics of the invention are administered in combination with an antiviral agent. Antiviral agents that may be administered with the Therapeutics of the invention include, but are not limited to, acyclovir, ribavirin, amantadine, and remantidine.

15 In a further embodiment, the Therapeutics of the invention are administered in combination with an antibiotic agent. Antibiotic agents that may be administered with the Therapeutics of the invention include, but are not limited to, amoxicillin, beta-lactamases, aminoglycosides, beta-lactam (glycopeptide), beta-lactamases, Clindamycin, chloramphenicol, cephalosporins, ciprofloxacin, ciprofloxacin, 20 erythromycin, fluoroquinolones, macrolides, metronidazole, penicillins, quinolones, rifampin, streptomycin, sulfonamide, tetracyclines, trimethoprim, trimethoprim-sulfamthoxazole, and vancomycin.

Conventional nonspecific immunosuppressive agents, that may be administered in combination with the Therapeutics of the invention include, but are 25 not limited to, steroids, cyclosporine, cyclosporine analogs, cyclophosphamide, methylprednisolone, prednisone, azathioprine, FK-506, 15-deoxyspergualin, and other immunosuppressive agents that act by suppressing the function of responding T cells.

In specific embodiments, Therapeutics of the invention are administered in combination with immunosuppressants. Immunosuppressants preparations that may 30 be administered with the Therapeutics of the invention include, but are not limited to, ORTHOCLONE™ (OKT3), SANDIMMUNE™/NEORAL™/SANGDYA™

(cyclosporin), PROGRAF™ (tacrolimus), CELLCEPT™ (mycophenolate), Azathioprine, glucorticosteroids, and RAPAMUNE™ (sirolimus). In a specific embodiment, immunosuppressants may be used to prevent rejection of organ or bone marrow transplantation.

- 5       In an additional embodiment, Therapeutics of the invention are administered alone or in combination with one or more intravenous immune globulin preparations. Intravenous immune globulin preparations that may be administered with the Therapeutics of the invention include, but not limited to, GAMMAR™, IVEEGAM™, SANDOGLOBULIN™, GAMMAGARD S/D™, and GAMIMUNE™.
- 10      In a specific embodiment, Therapeutics of the invention are administered in combination with intravenous immune globulin preparations in transplantation therapy (e.g., bone marrow transplant).

In an additional embodiment, the Therapeutics of the invention are administered alone or in combination with an anti-inflammatory agent. Anti-inflammatories that may be administered with the Therapeutics of the invention include, but are not limited to, glucocorticoids and the nonsteroidal anti-inflammatories, aminoarylcarboxylic acid derivatives, arylacetic acid derivatives, arylbutyric acid derivatives, arylcarboxylic acids, arylpropionic acid derivatives, pyrazoles, pyrazolones, salicylic acid derivatives, thiazinecarboxamides, e-  
15      acetamidocaproic acid, S-adenosylmethionine, 3-amino-4-hydroxybutyric acid, amixetrine, bendazac, benzydamine, bucolome, difenpiramide, ditazol, emorfazole, guaiazulene, nabumetone, nimesulide, orgotein, oxaceprol, paranyline, perisoxal, pifoxime, proquazone, proxazole, and tenidap.

In another embodiment, compositions of the invention are administered in combination with a chemotherapeutic agent. Chemotherapeutic agents that may be administered with the Therapeutics of the invention include, but are not limited to, antibiotic derivatives (e.g., doxorubicin, bleomycin, daunorubicin, and dactinomycin); antiestrogens (e.g., tamoxifen); antimetabolites (e.g., fluorouracil, 5-FU, methotrexate, floxuridine, interferon alpha-2b, glutamic acid, plicamycin, mercaptopurine, and 6-thioguanine); cytotoxic agents (e.g., carmustine, BCNU, lomustine, CCNU, cytosine arabinoside, cyclophosphamide, estramustine,

hydroxyurea, procarbazine, mitomycin, busulfan, cis-platin, and vincristine sulfate); hormones (e.g., medroxyprogesterone, estramustine phosphate sodium, ethinyl estradiol, estradiol, megestrol acetate, methyltestosterone, diethylstilbestrol diphosphate, chlorotrianisene, and testolactone); nitrogen mustard derivatives (e.g., 5 mephalen, chorambucil, mechlorethamine (nitrogen mustard) and thiotepa); steroids and combinations (e.g., bethamethasone sodium phosphate); and others (e.g., dicarbazine, asparaginase, mitotane, vincristine sulfate, vinblastine sulfate, and etoposide).

In a specific embodiment, Therapeutics of the invention are administered in 10 combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or any combination of the components of CHOP. In another embodiment, Therapeutics of the invention are administered in combination with Rituximab. In a further embodiment, Therapeutics of the invention are administered with Rituxmab and CHOP, or Rituxmab and any combination of the components of 15 CHOP.

In an additional embodiment, the Therapeutics of the invention are administered in combination with cytokines. Cytokines that may be administered with the Therapeutics of the invention include, but are not limited to, IL2, IL3, IL4, IL5, IL6, IL7, IL10, IL12, IL13, IL15, anti-CD40, CD40L, IFN-gamma and TNF-alpha. In another embodiment, Therapeutics of the invention may be administered with any interleukin, including, but not limited to, IL-1alpha, IL-1beta, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, and IL-21.

In an additional embodiment, the Therapeutics of the invention are 25 administered in combination with angiogenic proteins. Angiogenic proteins that may be administered with the Therapeutics of the invention include, but are not limited to, Glioma Derived Growth Factor (GDGF), as disclosed in European Patent Number EP-399816; Platelet Derived Growth Factor-A (PDGF-A), as disclosed in European Patent Number EP-682110; Platelet Derived Growth Factor-B (PDGF-B), as 30 disclosed in European Patent Number EP-282317; Placental Growth Factor (PIGF), as disclosed in International Publication Number WO 92/06194; Placental Growth

- Factor-2 (PIGF-2), as disclosed in Hauser et al., Gorwth Factors, 4:259-268 (1993); Vascular Endothelial Growth Factor (VEGF), as disclosed in International Publication Number WO 90/13649; Vascular Endothelial Growth Factor-A (VEGF-A), as disclosed in European Patent Number EP-506477; Vascular Endothelial Growth
- 5 Factor-2 (VEGF-2), as disclosed in International Publication Number WO 96/39515; Vascular Endothelial Growth Factor B (VEGF-3); Vascular Endothelial Growth Factor B-186 (VEGF-B186), as disclosed in International Publication Number WO 96/26736; Vascular Endothelial Growth Factor-D (VEGF-D), as disclosed in International Publication Number WO 98/02543; Vascular Endothelial Growth
- 10 Factor-D (VEGF-D), as disclosed in International Publication Number WO 98/07832; and Vascular Endothelial Growth Factor-E (VEGF-E), as disclosed in German Patent Number DE19639601. The above mentioned references are incorporated herein by reference herein.

In an additional embodiment, the Therapeutics of the invention are

15 administered in combination with hematopoietic growth factors. Hematopoietic growth factors that may be administered with the Therapeutics of the invention include, but are not limited to, LEUKINE™ (SARGRAMOSTIM™) and NEUPOGEN™ (FILGRASTIM™).

In an additional embodiment, the Therapeutics of the invention are

20 administered in combination with Fibroblast Growth Factors. Fibroblast Growth Factors that may be administered with the Therapeutics of the invention include, but are not limited to, FGF-1, FGF-2, FGF-3, FGF-4, FGF-5, FGF-6, FGF-7, FGF-8, FGF-9, FGF-10, FGF-11, FGF-12, FGF-13, FGF-14, and FGF-15.

In additional embodiments, the Therapeutics of the invention are administered in

25 combination with other therapeutic or prophylactic regimens, such as, for example, radiation therapy.

**Example 24: Method of Treating Decreased Levels of the Polypeptide**

The present invention relates to a method for treating an individual in need of

30 an increased level of a polypeptide of the invention in the body comprising administering to such an individual a composition comprising a therapeutically

effective amount of an agonist of the invention (including polypeptides of the invention). Moreover, it will be appreciated that conditions caused by a decrease in the standard or normal expression level of a secreted protein in an individual can be treated by administering the polypeptide of the present invention, preferably in the 5 secreted form. Thus, the invention also provides a method of treatment of an individual in need of an increased level of the polypeptide comprising administering to such an individual a Therapeutic comprising an amount of the polypeptide to increase the activity level of the polypeptide in such an individual.

For example, a patient with decreased levels of a polypeptide receives a daily 10 dose 0.1-100 ug/kg of the polypeptide for six consecutive days. Preferably, the polypeptide is in the secreted form. The exact details of the dosing scheme, based on administration and formulation, are provided in Example 23.

**Example 25: Method of Treating Increased Levels of the Polypeptide**

15 The present invention also relates to a method of treating an individual in need of a decreased level of a polypeptide of the invention in the body comprising administering to such an individual a composition comprising a therapeutically effective amount of an antagonist of the invention (including polypeptides and antibodies of the invention).

20 In one example, antisense technology is used to inhibit production of a polypeptide of the present invention. This technology is one example of a method of decreasing levels of a polypeptide, preferably a secreted form, due to a variety of etiologies, such as cancer. For example, a patient diagnosed with abnormally increased levels of a polypeptide is administered intravenously antisense 25 polynucleotides at 0.5, 1.0, 1.5, 2.0 and 3.0 mg/kg day for 21 days. This treatment is repeated after a 7-day rest period if the treatment was well tolerated. The formulation of the antisense polynucleotide is provided in Example 23.

**Example 26: Method of Treatment Using Gene Therapy-Ex Vivo**

30 One method of gene therapy transplants fibroblasts, which are capable of expressing a polypeptide, onto a patient. Generally, fibroblasts are obtained from a

subject by skin biopsy. The resulting tissue is placed in tissue-culture medium and separated into small pieces. Small chunks of the tissue are placed on a wet surface of a tissue culture flask, approximately ten pieces are placed in each flask. The flask is turned upside down, closed tight and left at room temperature over night. After 24 hours at room temperature, the flask is inverted and the chunks of tissue remain fixed to the bottom of the flask and fresh media (e.g., Ham's F12 media, with 10% FBS, penicillin and streptomycin) is added. The flasks are then incubated at 37 degree C for approximately one week.

At this time, fresh media is added and subsequently changed every several days. After an additional two weeks in culture, a monolayer of fibroblasts emerge. The monolayer is trypsinized and scaled into larger flasks.

pMV-7 (Kirschmeier, P.T. et al., DNA, 7:219-25 (1988)), flanked by the long terminal repeats of the Moloney murine sarcoma virus, is digested with EcoRI and HindIII and subsequently treated with calf intestinal phosphatase. The linear vector is fractionated on agarose gel and purified, using glass beads.

The cDNA encoding a polypeptide of the present invention can be amplified using PCR primers which correspond to the 5' and 3' end sequences respectively as set forth in Example 1 using primers and having appropriate restriction sites and initiation/stop codons, if necessary. Preferably, the 5' primer contains an EcoRI site and the 3' primer includes a HindIII site. Equal quantities of the Moloney murine sarcoma virus linear backbone and the amplified EcoRI and HindIII fragment are added together, in the presence of T4 DNA ligase. The resulting mixture is maintained under conditions appropriate for ligation of the two fragments. The ligation mixture is then used to transform bacteria HB101, which are then plated onto agar containing kanamycin for the purpose of confirming that the vector has the gene of interest properly inserted.

The amphotropic pA317 or GP+am12 packaging cells are grown in tissue culture to confluent density in Dulbecco's Modified Eagles Medium (DMEM) with 10% calf serum (CS), penicillin and streptomycin. The MSV vector containing the gene is then added to the media and the packaging cells transduced with the vector.

The packaging cells now produce infectious viral particles containing the gene (the packaging cells are now referred to as producer cells).

Fresh media is added to the transduced producer cells, and subsequently, the media is harvested from a 10 cm plate of confluent producer cells. The spent media, 5 containing the infectious viral particles, is filtered through a millipore filter to remove detached producer cells and this media is then used to infect fibroblast cells. Media is removed from a sub-confluent plate of fibroblasts and quickly replaced with the media from the producer cells. This media is removed and replaced with fresh media. If the titer of virus is high, then virtually all fibroblasts will be infected and no 10 selection is required. If the titer is very low, then it is necessary to use a retroviral vector that has a selectable marker, such as neo or his. Once the fibroblasts have been efficiently infected, the fibroblasts are analyzed to determine whether protein is produced.

The engineered fibroblasts are then transplanted onto the host, either alone or 15 after having been grown to confluence on cytodex 3 microcarrier beads.

**Example 27: Gene Therapy Using Endogenous Genes Corresponding To Polynucleotides of the Invention**

Another method of gene therapy according to the present invention involves 20 operably associating the endogenous polynucleotide sequence of the invention with a promoter via homologous recombination as described, for example, in U.S. Patent NO: 5,641,670, issued June 24, 1997; International Publication NO: WO 96/29411, published September 26, 1996; International Publication NO: WO 94/12650, published August 4, 1994; Koller et al., *Proc. Natl. Acad. Sci. USA*, 86:8932-8935 25 (1989); and Zijlstra et al., *Nature*, 342:435-438 (1989). This method involves the activation of a gene which is present in the target cells, but which is not expressed in the cells, or is expressed at a lower level than desired.

Polynucleotide constructs are made which contain a promoter and targeting sequences, which are homologous to the 5' non-coding sequence of endogenous 30 polynucleotide sequence, flanking the promoter. The targeting sequence will be sufficiently near the 5' end of the polynucleotide sequence so the promoter will be

operably linked to the endogenous sequence upon homologous recombination. The promoter and the targeting sequences can be amplified using PCR. Preferably, the amplified promoter contains distinct restriction enzyme sites on the 5' and 3' ends. Preferably, the 3' end of the first targeting sequence contains the same restriction 5 enzyme site as the 5' end of the amplified promoter and the 5' end of the second targeting sequence contains the same restriction site as the 3' end of the amplified promoter.

The amplified promoter and the amplified targeting sequences are digested with the appropriate restriction enzymes and subsequently treated with calf intestinal 10 phosphatase. The digested promoter and digested targeting sequences are added together in the presence of T4 DNA ligase. The resulting mixture is maintained under conditions appropriate for ligation of the two fragments. The construct is size fractionated on an agarose gel then purified by phenol extraction and ethanol precipitation.

15 In this Example, the polynucleotide constructs are administered as naked polynucleotides via electroporation. However, the polynucleotide constructs may also be administered with transfection-facilitating agents, such as liposomes, viral sequences, viral particles, precipitating agents, etc. Such methods of delivery are known in the art.

20 Once the cells are transfected, homologous recombination will take place which results in the promoter being operably linked to the endogenous polynucleotide sequence. This results in the expression of polynucleotide corresponding to the polynucleotide in the cell. Expression may be detected by immunological staining, or any other method known in the art.

25 Fibroblasts are obtained from a subject by skin biopsy. The resulting tissue is placed in DMEM + 10% fetal calf serum. Exponentially growing or early stationary phase fibroblasts are trypsinized and rinsed from the plastic surface with nutrient medium. An aliquot of the cell suspension is removed for counting, and the remaining cells are subjected to centrifugation. The supernatant is aspirated and the pellet is 30 resuspended in 5 ml of electroporation buffer (20 mM HEPES pH 7.3, 137 mM NaCl, 5 mM KCl, 0.7 mM Na<sub>2</sub>HPO<sub>4</sub>, 6 mM dextrose). The cells are recentrifuged, the

supernatant aspirated, and the cells resuspended in electroporation buffer containing 1 mg/ml acetylated bovine serum albumin. The final cell suspension contains approximately  $3 \times 10^6$  cells/ml. Electroporation should be performed immediately following resuspension.

- 5        Plasmid DNA is prepared according to standard techniques. For example, to construct a plasmid for targeting to the locus corresponding to the polynucleotide of the invention, plasmid pUC18 (MBI Fermentas, Amherst, NY) is digested with HindIII. The CMV promoter is amplified by PCR with an XbaI site on the 5' end and a BamHI site on the 3'end. Two non-coding sequences are amplified via PCR: one  
10      non-coding sequence (fragment 1) is amplified with a HindIII site at the 5' end and an Xba site at the 3'end; the other non-coding sequence (fragment 2) is amplified with a BamHI site at the 5'end and a HindIII site at the 3'end. The CMV promoter and the fragments (1 and 2) are digested with the appropriate enzymes (CMV promoter - XbaI and BamHI; fragment 1 - XbaI; fragment 2 - BamHI) and ligated together. The  
15      resulting ligation product is digested with HindIII, and ligated with the HindIII-digested pUC18 plasmid.

- Plasmid DNA is added to a sterile cuvette with a 0.4 cm electrode gap (Bio-Rad). The final DNA concentration is generally at least 120  $\mu$ g/ml. 0.5 ml of the cell suspension (containing approximately  $1.5 \times 10^6$  cells) is then added to the cuvette,  
20      and the cell suspension and DNA solutions are gently mixed. Electroporation is performed with a Gene-Pulser apparatus (Bio-Rad). Capacitance and voltage are set at 960  $\mu$ F and 250-300 V, respectively. As voltage increases, cell survival decreases, but the percentage of surviving cells that stably incorporate the introduced DNA into their genome increases dramatically. Given these parameters, a pulse time of  
25      approximately 14-20 mSec should be observed.

- Electroporated cells are maintained at room temperature for approximately 5 min, and the contents of the cuvette are then gently removed with a sterile transfer pipette. The cells are added directly to 10 ml of prewarmed nutrient media (DMEM with 15% calf serum) in a 10 cm dish and incubated at 37 degree C. The following  
30      day, the media is aspirated and replaced with 10 ml of fresh media and incubated for a further 16-24 hours.

The engineered fibroblasts are then injected into the host, either alone or after having been grown to confluence on cytodex 3 microcarrier beads. The fibroblasts now produce the protein product. The fibroblasts can then be introduced into a patient as described above.

5

**Example 28: Method of Treatment Using Gene Therapy - In Vivo**

Another aspect of the present invention is using *in vivo* gene therapy methods to treat disorders, diseases and conditions. The gene therapy method relates to the introduction of naked nucleic acid (DNA, RNA, and antisense DNA or RNA) sequences into an animal to increase or decrease the expression of the polypeptide. The polynucleotide of the present invention may be operatively linked to a promoter or any other genetic elements necessary for the expression of the polypeptide by the target tissue. Such gene therapy and delivery techniques and methods are known in the art, see, for example, WO90/11092, WO98/11779; U.S. Patent NO. 5693622, 10 5705151, 5580859; Tabata et al., Cardiovasc. Res. 35(3):470-479 (1997); Chao et al., Pharmacol. Res. 35(6):517-522 (1997); Wolff, Neuromuscul. Disord. 7(5):314-318 (1997); Schwartz et al., Gene Ther. 3(5):405-411 (1996); Tsurumi et al., Circulation 15 94(12):3281-3290 (1996) (incorporated herein by reference).

The polynucleotide constructs may be delivered by any method that delivers 20 injectable materials to the cells of an animal, such as, injection into the interstitial space of tissues (heart, muscle, skin, lung, liver, intestine and the like). The polynucleotide constructs can be delivered in a pharmaceutically acceptable liquid or aqueous carrier.

The term "naked" polynucleotide, DNA or RNA, refers to sequences that are 25 free from any delivery vehicle that acts to assist, promote, or facilitate entry into the cell, including viral sequences, viral particles, liposome formulations, lipofectin or precipitating agents and the like. However, the polynucleotides of the present invention may also be delivered in liposome formulations (such as those taught in Felgner P.L. et al. (1995) Ann. NY Acad. Sci. 772:126-139 and Abdallah B. et al. 30 (1995) Biol. Cell 85(1):1-7) which can be prepared by methods well known to those skilled in the art.

The polynucleotide vector constructs used in the gene therapy method are preferably constructs that will not integrate into the host genome nor will they contain sequences that allow for replication. Any strong promoter known to those skilled in the art can be used for driving the expression of DNA. Unlike other gene therapies 5 techniques, one major advantage of introducing naked nucleic acid sequences into target cells is the transitory nature of the polynucleotide synthesis in the cells. Studies have shown that non-replicating DNA sequences can be introduced into cells to provide production of the desired polypeptide for periods of up to six months.

The polynucleotide construct can be delivered to the interstitial space of 10 tissues within the an animal, including of muscle, skin, brain, lung, liver, spleen, bone marrow, thymus, heart, lymph, blood, bone, cartilage, pancreas, kidney, gall bladder, stomach, intestine, testis, ovary, uterus, rectum, nervous system, eye, gland, and connective tissue. Interstitial space of the tissues comprises the intercellular fluid, mucopolysaccharide matrix among the reticular fibers of organ tissues, elastic fibers 15 in the walls of vessels or chambers, collagen fibers of fibrous tissues, or that same matrix within connective tissue ensheathing muscle cells or in the lacunae of bone. It is similarly the space occupied by the plasma of the circulation and the lymph fluid of the lymphatic channels. Delivery to the interstitial space of muscle tissue is preferred for the reasons discussed below. They may be conveniently delivered by injection 20 into the tissues comprising these cells. They are preferably delivered to and expressed in persistent, non-dividing cells which are differentiated, although delivery and expression may be achieved in non-differentiated or less completely differentiated cells, such as, for example, stem cells of blood or skin fibroblasts. *In vivo* muscle cells are particularly competent in their ability to take up and express 25 polynucleotides.

For the naked polynucleotide injection, an effective dosage amount of DNA or RNA will be in the range of from about 0.05 g/kg body weight to about 50 mg/kg body weight. Preferably the dosage will be from about 0.005 mg/kg to about 20 mg/kg and more preferably from about 0.05 mg/kg to about 5 mg/kg. Of course, as 30 the artisan of ordinary skill will appreciate, this dosage will vary according to the tissue site of injection. The appropriate and effective dosage of nucleic acid sequence

can readily be determined by those of ordinary skill in the art and may depend on the condition being treated and the route of administration. The preferred route of administration is by the parenteral route of injection into the interstitial space of tissues. However, other parenteral routes may also be used, such as, inhalation of an 5 aerosol formulation particularly for delivery to lungs or bronchial tissues, throat or mucous membranes of the nose. In addition, naked polynucleotide constructs can be delivered to arteries during angioplasty by the catheter used in the procedure.

The dose response effects of injected polynucleotide in muscle *in vivo* is determined as follows. Suitable template DNA for production of mRNA coding for 10 polypeptide of the present invention is prepared in accordance with a standard recombinant DNA methodology. The template DNA, which may be either circular or linear, is either used as naked DNA or complexed with liposomes. The quadriceps muscles of mice are then injected with various amounts of the template DNA.

Five to six week old female and male Balb/C mice are anesthetized by 15 intraperitoneal injection with 0.3 ml of 2.5% Avertin. A 1.5 cm incision is made on the anterior thigh, and the quadriceps muscle is directly visualized. The template DNA is injected in 0.1 ml of carrier in a 1 cc syringe through a 27 gauge needle over one minute, approximately 0.5 cm from the distal insertion site of the muscle into the knee and about 0.2 cm deep. A suture is placed over the injection site for future 20 localization, and the skin is closed with stainless steel clips.

After an appropriate incubation time (e.g., 7 days) muscle extracts are prepared by excising the entire quadriceps. Every fifth 15 um cross-section of the individual quadriceps muscles is histochemically stained for protein expression. A time course for protein expression may be done in a similar fashion except that 25 quadriceps from different mice are harvested at different times. Persistence of DNA in muscle following injection may be determined by Southern blot analysis after preparing total cellular DNA and HIRT supernatants from injected and control mice. The results of the above experimentation in mice can be used to extrapolate proper dosages and other treatment parameters in humans and other animals using naked 30 DNA.

Example 29: Transgenic Animals.

- The polypeptides of the invention can also be expressed in transgenic animals. Animals of any species, including, but not limited to, mice, rats, rabbits, hamsters, guinea pigs, pigs, micro-pigs, goats, sheep, cows and non-human primates, *e.g.*,
- 5 baboons, monkeys, and chimpanzees may be used to generate transgenic animals. In a specific embodiment, techniques described herein or otherwise known in the art, are used to express polypeptides of the invention in humans, as part of a gene therapy protocol.
- Any technique known in the art may be used to introduce the transgene (*i.e.*,
- 10 polynucleotides of the invention) into animals to produce the founder lines of transgenic animals. Such techniques include, but are not limited to, pronuclear microinjection (Paterson et al., *Appl. Microbiol. Biotechnol.* 40:691-698 (1994); Carver et al., *Biotechnology (NY)* 11:1263-1270 (1993); Wright et al., *Biotechnology (NY)* 9:830-834 (1991); and Hoppe et al., U.S. Pat. No. 4,873,191 (1989)); retrovirus
- 15 mediated gene transfer into germ lines (Van der Putten et al., *Proc. Natl. Acad. Sci., USA* 82:6148-6152 (1985)), blastocysts or embryos; gene targeting in embryonic stem cells (Thompson et al., *Cell* 56:313-321 (1989)); electroporation of cells or embryos (Lo, 1983, *Mol Cell. Biol.* 3:1803-1814 (1983)); introduction of the polynucleotides of the invention using a gene gun (*see, e.g.*, Ulmer et al., *Science*
- 20 259:1745 (1993); introducing nucleic acid constructs into embryonic pluripotent stem cells and transferring the stem cells back into the blastocyst; and sperm-mediated gene transfer (Lavitrano et al., *Cell* 57:717-723 (1989); etc. For a review of such techniques, see Gordon, "Transgenic Animals," *Intl. Rev. Cytol.* 115:171-229 (1989), which is incorporated by reference herein in its entirety.
- 25 Any technique known in the art may be used to produce transgenic clones containing polynucleotides of the invention, for example, nuclear transfer into enucleated oocytes of nuclei from cultured embryonic, fetal, or adult cells induced to quiescence (Campell et al., *Nature* 380:64-66 (1996); Wilmut et al., *Nature* 385:810-813 (1997)).
- 30 The present invention provides for transgenic animals that carry the transgene in all their cells, as well as animals which carry the transgene in some, but not all their

cells, *i.e.*, mosaic animals or chimeric. The transgene may be integrated as a single transgene or as multiple copies such as in concatamers, *e.g.*, head-to-head tandems or head-to-tail tandems. The transgene may also be selectively introduced into and activated in a particular cell type by following, for example, the teaching of Lasko et al. (Lasko et al., Proc. Natl. Acad. Sci. USA 89:6232-6236 (1992)). The regulatory sequences required for such a cell-type specific activation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art. When it is desired that the polynucleotide transgene be integrated into the chromosomal site of the endogenous gene, gene targeting is preferred. Briefly, when such a technique is to be utilized, vectors containing some nucleotide sequences homologous to the endogenous gene are designed for the purpose of integrating, via homologous recombination with chromosomal sequences, into and disrupting the function of the nucleotide sequence of the endogenous gene. The transgene may also be selectively introduced into a particular cell type, thus inactivating the endogenous gene in only that cell type, by following, for example, the teaching of Gu et al. (Gu et al., Science 265:103-106 (1994)). The regulatory sequences required for such a cell-type specific inactivation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art.

Once transgenic animals have been generated, the expression of the recombinant gene may be assayed utilizing standard techniques. Initial screening may be accomplished by Southern blot analysis or PCR techniques to analyze animal tissues to verify that integration of the transgene has taken place. The level of mRNA expression of the transgene in the tissues of the transgenic animals may also be assessed using techniques which include, but are not limited to, Northern blot analysis of tissue samples obtained from the animal, *in situ* hybridization analysis, and reverse transcriptase-PCR (rt-PCR). Samples of transgenic gene-expressing tissue may also be evaluated immunocytochemically or immunohistochemically using antibodies specific for the transgene product.

Once the founder animals are produced, they may be bred, inbred, outbred, or crossbred to produce colonies of the particular animal. Examples of such breeding strategies include, but are not limited to: outbreeding of founder animals with more

- than one integration site in order to establish separate lines; inbreeding of separate lines in order to produce compound transgenics that express the transgene at higher levels because of the effects of additive expression of each transgene; crossing of heterozygous transgenic animals to produce animals homozygous for a given
- 5 integration site in order to both augment expression and eliminate the need for screening of animals by DNA analysis; crossing of separate homozygous lines to produce compound heterozygous or homozygous lines; and breeding to place the transgene on a distinct background that is appropriate for an experimental model of interest.
- 10 Transgenic animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying diseases, disorders, and/or conditions associated with aberrant expression, and in screening for compounds effective in ameliorating such diseases, disorders, and/or conditions.
- 15
- Example 30: Knock-Out Animals.**
- Endogenous gene expression can also be reduced by inactivating or "knocking out" the gene and/or its promoter using targeted homologous recombination. (E.g., see Smithies et al., *Nature* 317:230-234 (1985); Thomas & Capecchi, *Cell* 51:503-512 (1987); Thompson et al., *Cell* 5:313-321 (1989); each of which is incorporated by reference herein in its entirety). For example, a mutant, non-functional polynucleotide of the invention (or a completely unrelated DNA sequence) flanked by DNA homologous to the endogenous polynucleotide sequence (either the coding regions or regulatory regions of the gene) can be used, with or without a selectable marker and/or a negative selectable marker, to transfet cells that express polypeptides of the invention *in vivo*. In another embodiment, techniques known in the art are used to generate knockouts in cells that contain, but do not express the gene of interest. Insertion of the DNA construct, via targeted homologous recombination, results in inactivation of the targeted gene. Such approaches are particularly suited in research and agricultural fields where modifications to embryonic stem cells can be used to generate animal offspring with an inactive targeted gene (e.g., see Thomas &

Capecci 1987 and Thompson 1989, *supra*). However this approach can be routinely adapted for use in humans provided the recombinant DNA constructs are directly administered or targeted to the required site *in vivo* using appropriate viral vectors that will be apparent to those of skill in the art.

- 5        In further embodiments of the invention, cells that are genetically engineered to express the polypeptides of the invention, or alternatively, that are genetically engineered not to express the polypeptides of the invention (e.g., knockouts) are administered to a patient *in vivo*. Such cells may be obtained from the patient (i.e., animal, including human) or an MHC compatible donor and can include, but are not  
10      limited to fibroblasts, bone marrow cells, blood cells (e.g., lymphocytes), adipocytes, muscle cells, endothelial cells etc. The cells are genetically engineered *in vitro* using recombinant DNA techniques to introduce the coding sequence of polypeptides of the invention into the cells, or alternatively, to disrupt the coding sequence and/or endogenous regulatory sequence associated with the polypeptides of the invention,  
15      e.g., by transduction (using viral vectors, and preferably vectors that integrate the transgene into the cell genome) or transfection procedures, including, but not limited to, the use of plasmids, cosmids, YACs, naked DNA, electroporation, liposomes, etc. The coding sequence of the polypeptides of the invention can be placed under the control of a strong constitutive or inducible promoter or promoter/enhancer to achieve  
20      expression, and preferably secretion, of the polypeptides of the invention. The engineered cells which express and preferably secrete the polypeptides of the invention can be introduced into the patient systemically, e.g., in the circulation, or intraperitoneally.

Alternatively, the cells can be incorporated into a matrix and implanted in the body, e.g., genetically engineered fibroblasts can be implanted as part of a skin graft; genetically engineered endothelial cells can be implanted as part of a lymphatic or vascular graft. (See, for example, Anderson et al. U.S. Patent No. 5,399,349; and Mulligan & Wilson, U.S. Patent No. 5,460,959 each of which is incorporated by reference herein in its entirety).

- 30      When the cells to be administered are non-autologous or non-MHC compatible cells, they can be administered using well known techniques which

prevent the development of a host immune response against the introduced cells. For example, the cells may be introduced in an encapsulated form which, while allowing for an exchange of components with the immediate extracellular environment, does not allow the introduced cells to be recognized by the host immune system.

5 Transgenic and "knock-out" animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying diseases, disorders, and/or conditions associated with aberrant expression, and in screening for compounds effective in ameliorating such diseases, disorders, and/or conditions.

10

**Example 31: Production of an Antibody**

a) Hybridoma Technology

The antibodies of the present invention can be prepared by a variety of methods. (See, Current Protocols, Chapter 2.) As one example of such methods, cells 15 expressing polypeptide(s) of the invention are administered to an animal to induce the production of sera containing polyclonal antibodies. In a preferred method, a preparation of polypeptide(s) of the invention is prepared and purified to render it substantially free of natural contaminants. Such a preparation is then introduced into an animal in order to produce polyclonal antisera of greater specific activity.

20 Monoclonal antibodies specific for polypeptide(s) of the invention are prepared using hybridoma technology. (Kohler et al., Nature 256:495 (1975); Kohler et al., Eur. J. Immunol. 6:511 (1976); Kohler et al., Eur. J. Immunol. 6:292 (1976); Hammerling et al., in: Monoclonal Antibodies and T-Cell Hybridomas, Elsevier, N.Y., pp. 563-681 (1981)). In general, an animal (preferably a mouse) is immunized 25 with polypeptide(s) of the invention or, more preferably, with a secreted polypeptide-expressing cell. Such polypeptide-expressing cells are cultured in any suitable tissue culture medium, preferably in Earle's modified Eagle's medium supplemented with 10% fetal bovine serum (inactivated at about 56°C), and supplemented with about 10 g/l of nonessential amino acids, about 1,000 U/ml of penicillin, and about 100 µg/ml 30 of streptomycin.

The splenocytes of such mice are extracted and fused with a suitable myeloma cell line. Any suitable myeloma cell line may be employed in accordance with the present invention; however, it is preferable to employ the parent myeloma cell line (SP2O), available from the ATCC. After fusion, the resulting hybridoma cells are 5 selectively maintained in HAT medium, and then cloned by limiting dilution as described by Wands et al. (*Gastroenterology* 80:225-232 (1981)). The hybridoma cells obtained through such a selection are then assayed to identify clones which secrete antibodies capable of binding the polypeptide(s) of the invention.

Alternatively, additional antibodies capable of binding to polypeptide(s) of the 10 invention can be produced in a two-step procedure using anti-idiotypic antibodies. Such a method makes use of the fact that antibodies are themselves antigens, and therefore, it is possible to obtain an antibody which binds to a second antibody. In accordance with this method, protein specific antibodies are used to immunize an animal, preferably a mouse. The splenocytes of such an animal are then used to 15 produce hybridoma cells, and the hybridoma cells are screened to identify clones which produce an antibody whose ability to bind to the protein-specific antibody can be blocked by polypeptide(s) of the invention. Such antibodies comprise anti-idiotypic antibodies to the protein-specific antibody and are used to immunize an animal to induce formation of further protein-specific antibodies.

20 For in vivo use of antibodies in humans, an antibody is "humanized". Such antibodies can be produced using genetic constructs derived from hybridoma cells producing the monoclonal antibodies described above. Methods for producing chimeric and humanized antibodies are known in the art and are discussed herein. (See, for review, Morrison, *Science* 229:1202 (1985); Oi et al., *BioTechniques* 4:214 (1986); Cabilly et al., U.S. Patent No. 4,816,567; Taniguchi et al., EP 171496; 25 Morrison et al., EP 173494; Neuberger et al., WO 8601533; Robinson et al., WO 8702671; Boulianne et al., *Nature* 312:643 (1984); Neuberger et al., *Nature* 314:268 (1985).)

30 b) Isolation Of Antibody Fragments Directed Against  
Polypeptide(s) From A Library Of scFvs

Naturally occurring V-genes isolated from human PBLs are constructed into a library of antibody fragments which contain reactivities against polypeptide(s) of the invention to which the donor may or may not have been exposed (see e.g., U.S. Patent 5,885,793 incorporated herein by reference in its entirety).

5       Rescue of the Library.

A library of scFvs is constructed from the RNA of human PBLs as described in PCT publication WO 92/01047. To rescue phage displaying antibody fragments, approximately 10<sup>9</sup> E. coli harboring the phagemid are used to inoculate 50 ml of 2xTY containing 1% glucose and 100 µg/ml of ampicillin (2xTY-AMP-GLU) and 10 grown to an O.D. of 0.8 with shaking. Five ml of this culture is used to inoculate 50 ml of 2xTY-AMP-GLU, 2 x 10<sup>8</sup> TU of delta gene 3 helper (M13 delta gene III, see PCT publication WO 92/01047) are added and the culture incubated at 37°C for 45 minutes without shaking and then at 37°C for 45 minutes with shaking. The culture is centrifuged at 4000 r.p.m. for 10 min. and the pellet resuspended in 2 liters of 2xTY 15 containing 100 µg/ml ampicillin and 50 µg/ml kanamycin and grown overnight. Phage are prepared as described in PCT publication WO 92/01047.

M13 delta gene III is prepared as follows: M13 delta gene III helper phage does not encode gene III protein, hence the phage(mid) displaying antibody fragments have a greater avidity of binding to antigen. Infectious M13 delta gene III 20 particles are made by growing the helper phage in cells harboring a pUC19 derivative supplying the wild type gene III protein during phage morphogenesis. The culture is incubated for 1 hour at 37° C without shaking and then for a further hour at 37°C with shaking. Cells are spun down (IEC-Centra 8,400 r.p.m. for 10 min), resuspended in 300 ml 2xTY broth containing 100 µg ampicillin/ml and 25 µg kanamycin/ml (2xTY- 25 AMP-KAN) and grown overnight, shaking at 37°C. Phage particles are purified and concentrated from the culture medium by two PEG-precipitations (Sambrook et al., 1990), resuspended in 2 ml PBS and passed through a 0.45 µm filter (Minisart NML; Sartorius) to give a final concentration of approximately 10<sup>13</sup> transducing units/ml (ampicillin-resistant clones).

30       Panning of the Library.

Immunotubes (Nunc) are coated overnight in PBS with 4 ml of either 100 µg/ml or 10 µg/ml of a polypeptide of the present invention. Tubes are blocked with 2% Marvel-PBS for 2 hours at 37°C and then washed 3 times in PBS. Approximately 10<sup>13</sup> TU of phage is applied to the tube and incubated for 30 minutes at room temperature tumbling on an over and under turntable and then left to stand for another 1.5 hours. Tubes are washed 10 times with PBS 0.1% Tween-20 and 10 times with PBS. Phage are eluted by adding 1 ml of 100 mM triethylamine and rotating 15 minutes on an under and over turntable after which the solution is immediately neutralized with 0.5 ml of 1.0M Tris-HCl, pH 7.4. Phage are then used to infect 10 ml of mid-log E. coli TG1 by incubating eluted phage with bacteria for 30 minutes at 37°C. The E. coli are then plated on TYE plates containing 1% glucose and 100 µg/ml ampicillin. The resulting bacterial library is then rescued with delta gene 3 helper phage as described above to prepare phage for a subsequent round of selection. This process is then repeated for a total of 4 rounds of affinity purification with tube-washing increased to 20 times with PBS, 0.1% Tween-20 and 20 times with PBS for rounds 3 and 4.

Characterization of Binders.

Eluted phage from the 3rd and 4th rounds of selection are used to infect E. coli HB 2151 and soluble scFv is produced (Marks, et al., 1991) from single colonies for assay. ELISAs are performed with microtitre plates coated with either 10 pg/ml of the polypeptide of the present invention in 50 mM bicarbonate pH 9.6. Clones positive in ELISA are further characterized by PCR fingerprinting (see, e.g., PCT publication WO 92/01047) and then by sequencing. These ELISA positive clones may also be further characterized by techniques known in the art, such as, for example, epitope mapping, binding affinity, receptor signal transduction, ability to block or competitively inhibit antibody/antigen binding, and competitive agonistic or antagonistic activity.

**Example 32: Assays Detecting Stimulation or Inhibition of B cell Proliferation and Differentiation**

Generation of functional humoral immune responses requires both soluble and cognate signaling between B-lineage cells and their microenvironment. Signals may 5 impart a positive stimulus that allows a B-lineage cell to continue its programmed development, or a negative stimulus that instructs the cell to arrest its current developmental pathway. To date, numerous stimulatory and inhibitory signals have been found to influence B cell responsiveness including IL-2, IL-4, IL-5, IL-6, IL-7, IL10, IL-13, IL-14 and IL-15. Interestingly, these signals are by themselves weak effectors but can, 10 in combination with various co-stimulatory proteins, induce activation, proliferation, differentiation, homing, tolerance and death among B cell populations.

One of the best studied classes of B-cell co-stimulatory proteins is the TNF-superfamily. Within this family CD40, CD27, and CD30 along with their respective ligands CD154, CD70, and CD153 have been found to regulate a variety of immune 15 responses. Assays which allow for the detection and/or observation of the proliferation and differentiation of these B-cell populations and their precursors are valuable tools in determining the effects various proteins may have on these B-cell populations in terms of proliferation and differentiation. Listed below are two assays designed to allow for the detection of the differentiation, proliferation, or inhibition of B-cell populations and their 20 precursors.

**In Vitro Assay-** Purified polypeptides of the invention, or truncated forms thereof, is assessed for its ability to induce activation, proliferation, differentiation or inhibition and/or death in B-cell populations and their precursors. The activity of the polypeptides of the invention on purified human tonsillar B cells, measured qualitatively over the dose 25 range from 0.1 to 10,000 ng/mL, is assessed in a standard B-lymphocyte co-stimulation assay in which purified tonsillar B cells are cultured in the presence of either formalin-fixed *Staphylococcus aureus* Cowan I (SAC) or immobilized anti-human IgM antibody as the priming agent. Second signals such as IL-2 and IL-15 synergize with SAC and IgM crosslinking to elicit B cell proliferation as measured by tritiated-thymidine incorporation. 30 Novel synergizing agents can be readily identified using this assay. The assay involves isolating human tonsillar B cells by magnetic bead (MACS) depletion of CD3-positive

cells. The resulting cell population is greater than 95% B cells as assessed by expression of CD45R(B220).

Various dilutions of each sample are placed into individual wells of a 96-well plate to which are added  $10^5$  B-cells suspended in culture medium (RPMI 1640 containing 10%  
5 FBS,  $5 \times 10^{-5}$ M 2ME, 100U/ml penicillin, 10ug/ml streptomycin, and  $10^{-5}$  dilution of SAC) in a total volume of 150ul. Proliferation or inhibition is quantitated by a 20h pulse (1uCi/well) with 3H-thymidine (6.7 Ci/mM) beginning 72h post factor addition. The positive and negative controls are IL2 and medium respectively.

In Vivo Assay- BALB/c mice are injected (i.p.) twice per day with buffer only, or  
10 2 mg/Kg of a polypeptide of the invention, or truncated forms thereof. Mice receive this treatment for 4 consecutive days, at which time they are sacrificed and various tissues and serum collected for analyses. Comparison of H&E sections from normal spleens and spleens treated with polypeptides of the invention identify the results of the activity of the polypeptides on spleen cells, such as the diffusion of peri-arterial lymphatic sheaths,  
15 and/or significant increases in the nucleated cellularity of the red pulp regions, which may indicate the activation of the differentiation and proliferation of B-cell populations. Immunohistochemical studies using a B cell marker, anti-CD45R(B220), are used to determine whether any physiological changes to splenic cells, such as splenic disorganization, are due to increased B-cell representation within loosely defined B-cell  
20 zones that infiltrate established T-cell regions.

Flow cytometric analyses of the spleens from mice treated with polypeptide is used to indicate whether the polypeptide specifically increases the proportion of ThB+, CD45R(B220)dull B cells over that which is observed in control mice.

Likewise, a predicted consequence of increased mature B-cell representation in  
25 vivo is a relative increase in serum Ig titers. Accordingly, serum IgM and IgA levels are compared between buffer and polypeptide-treated mice.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides of the invention (e.g., gene therapy), agonists, and/or  
30 antagonists of polynucleotides or polypeptides of the invention.

**Example 33: T Cell Proliferation Assay**

- A CD3-induced proliferation assay is performed on PBMCs and is measured by the uptake of  $^3\text{H}$ -thymidine. The assay is performed as follows. Ninety-six well plates are
- 5 coated with 100  $\mu\text{l}$ /well of mAb to CD3 (HIT3a, Pharmingen) or isotype-matched control mAb (B33.1) overnight at 4 degrees C (1  $\mu\text{g}/\text{ml}$  in .05M bicarbonate buffer, pH 9.5), then washed three times with PBS. PBMC are isolated by F/H gradient centrifugation from human peripheral blood and added to quadruplicate wells ( $5 \times 10^4/\text{well}$ ) of mAb coated plates in RPMI containing 10% FCS and P/S in the presence of varying concentrations of
- 10 polypeptides of the invention (total volume 200  $\mu\text{l}$ ). Relevant protein buffer and medium alone are controls. After 48 hr. culture at 37 degrees C, plates are spun for 2 min. at 1000 rpm and 100  $\mu\text{l}$  of supernatant is removed and stored -20 degrees C for measurement of IL-2 (or other cytokines) if effect on proliferation is observed. Wells are supplemented with 100  $\mu\text{l}$  of medium containing 0.5 uCi of  $^3\text{H}$ -thymidine and cultured at 37 degrees C
- 15 for 18-24 hr. Wells are harvested and incorporation of  $^3\text{H}$ -thymidine used as a measure of proliferation. Anti-CD3 alone is the positive control for proliferation. IL-2 (100 U/ml) is also used as a control which enhances proliferation. Control antibody which does not induce proliferation of T cells is used as the negative controls for the effects of polypeptides of the invention.
- 20 The studies described in this example tested activity of polypeptides of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides of the invention (e.g., gene therapy), agonists, and/or antagonists of polynucleotides or polypeptides of the invention.

- 25 **Example 34: Effect of Polypeptides of the Invention on the Expression of MHC Class II, Costimulatory and Adhesion Molecules and Cell Differentiation of Monocytes and Monocyte-Derived Human Dendritic Cells**

Dendritic cells are generated by the expansion of proliferating precursors found in the peripheral blood: adherent PBMC or elutriated monocytic fractions are cultured for 7-

30 10 days with GM-CSF (50 ng/ml) and IL-4 (20 ng/ml). These dendritic cells have the characteristic phenotype of immature cells (expression of CD1, CD80, CD86, CD40 and

MHC class II antigens). Treatment with activating factors, such as TNF- $\alpha$ , causes a rapid change in surface phenotype (increased expression of MHC class I and II, costimulatory and adhesion molecules, downregulation of FCyRII, upregulation of CD83). These changes correlate with increased antigen-presenting capacity and with functional 5 maturation of the dendritic cells.

FACS analysis of surface antigens is performed as follows. Cells are treated 1-3 days with increasing concentrations of polypeptides of the invention or LPS (positive control), washed with PBS containing 1% BSA and 0.02 mM sodium azide, and then incubated with 1:20 dilution of appropriate FITC- or PE-labeled monoclonal antibodies 10 for 30 minutes at 4 degrees C. After an additional wash, the labeled cells are analyzed by flow cytometry on a FACScan (Becton Dickinson).

Effect on the production of cytokines. Cytokines generated by dendritic cells, in particular IL-12, are important in the initiation of T-cell dependent immune responses. IL-15 12 strongly influences the development of Th1 helper T-cell immune response, and induces cytotoxic T and NK cell function. An ELISA is used to measure the IL-12 release as follows. Dendritic cells ( $10^6$ /ml) are treated with increasing concentrations of polypeptides of the invention for 24 hours. LPS (100 ng/ml) is added to the cell culture as positive control. Supernatants from the cell cultures are then collected and analyzed for 20 IL-12 content using commercial ELISA kit (e.g., R & D Systems (Minneapolis, MN)). The standard protocols provided with the kits are used.

Effect on the expression of MHC Class II, costimulatory and adhesion molecules. Three major families of cell surface antigens can be identified on monocytes: adhesion 25 molecules, molecules involved in antigen presentation, and Fc receptor. Modulation of the expression of MHC class II antigens and other costimulatory molecules, such as B7 and ICAM-1, may result in changes in the antigen presenting capacity of monocytes and ability to induce T cell activation. Increase expression of Fc receptors may correlate with improved monocyte cytotoxic activity, cytokine release and phagocytosis.

30 FACS analysis is used to examine the surface antigens as follows. Monocytes are treated 1-5 days with increasing concentrations of polypeptides of the invention or LPS

(positive control), washed with PBS containing 1% BSA and 0.02 mM sodium azide, and then incubated with 1:20 dilution of appropriate FITC- or PE-labeled monoclonal antibodies for 30 minutes at 4 degreesC. After an additional wash, the labeled cells are analyzed by flow cytometry on a FACScan (Becton Dickinson).

5

- Monocyte activation and/or increased survival. Assays for molecules that activate (or alternatively, inactivate) monocytes and/or increase monocyte survival (or alternatively, decrease monocyte survival) are known in the art and may routinely be applied to determine whether a molecule of the invention functions as an inhibitor or 10 activator of monocytes. Polypeptides, agonists, or antagonists of the invention can be screened using the three assays described below. For each of these assays, Peripheral blood mononuclear cells (PBMC) are purified from single donor leukopacks (American Red Cross, Baltimore, MD) by centrifugation through a Histopaque gradient (Sigma). Monocytes are isolated from PBMC by counterflow centrifugal elutriation.

15

- Monocyte Survival Assay. Human peripheral blood monocytes progressively lose viability when cultured in absence of serum or other stimuli. Their death results from internally regulated process (apoptosis). Addition to the culture of activating factors, such as TNF-alpha dramatically improves cell survival and prevents DNA fragmentation.
- 20 Propidium iodide (PI) staining is used to measure apoptosis as follows. Monocytes are cultured for 48 hours in polypropylene tubes in serum-free medium (positive control), in the presence of 100 ng/ml TNF-alpha (negative control), and in the presence of varying concentrations of the compound to be tested. Cells are suspended at a concentration of  $2 \times 10^6$ /ml in PBS containing PI at a final concentration of 5  $\mu$ g/ml, and then incubated at room 25 temperature for 5 minutes before FACScan analysis. PI uptake has been demonstrated to correlate with DNA fragmentation in this experimental paradigm.

- Effect on cytokine release. An important function of monocytes/macrophages is their regulatory activity on other cellular populations of the immune system through the 30 release of cytokines after stimulation. An ELISA to measure cytokine release is performed as follows. Human monocytes are incubated at a density of  $5 \times 10^5$  cells/ml with

increasing concentrations of the a polypeptide of the invention and under the same conditions, but in the absence of the polypeptide. For IL-12 production, the cells are primed overnight with IFN (100 U/ml) in presence of a polypeptide of the invention. LPS (10 ng/ml) is then added. Conditioned media are collected after 24h and kept frozen until 5 use. Measurement of TNF-alpha, IL-10, MCP-1 and IL-8 is then performed using a commercially available ELISA kit (e.g., R & D Systems (Minneapolis, MN)) and applying the standard protocols provided with the kit.

- Oxidative burst. Purified monocytes are plated in 96-w plate at  $2\text{-}1\times10^5$  cell/well.
- 10 Increasing concentrations of polypeptides of the invention are added to the wells in a total volume of 0.2 ml culture medium (RPMI 1640 + 10% FCS, glutamine and antibiotics). After 3 days incubation, the plates are centrifuged and the medium is removed from the wells. To the macrophage monolayers, 0.2 ml per well of phenol red solution (140 mM NaCl, 10 mM potassium phosphate buffer pH 7.0, 5.5 mM dextrose, 0.56 mM phenol red 15 and 19 U/ml of HRPO) is added, together with the stimulant (200 nM PMA). The plates are incubated at 37°C for 2 hours and the reaction is stopped by adding 20 µl 1N NaOH per well. The absorbance is read at 610 nm. To calculate the amount of  $\text{H}_2\text{O}_2$  produced by the macrophages, a standard curve of a  $\text{H}_2\text{O}_2$  solution of known molarity is performed for each experiment.
- 20 The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polypeptides, polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.
- 25 **Example 35: Biological Effects of Polypeptides of the Invention**
- Astrocyte and Neuronal Assays
- Recombinant polypeptides of the invention, expressed in *Escherichia coli* and purified as described above, can be tested for activity in promoting the survival, neurite outgrowth, or phenotypic differentiation of cortical neuronal cells and for inducing the 30 proliferation of glial fibrillary acidic protein immunopositive cells, astrocytes. The selection of cortical cells for the bioassay is based on the prevalent expression of FGF-1

and FGF-2 in cortical structures and on the previously reported enhancement of cortical neuronal survival resulting from FGF-2 treatment. A thymidine incorporation assay, for example, can be used to elucidate a polypeptide of the invention's activity on these cells.

Moreover, previous reports describing the biological effects of FGF-2 (basic FGF) 5 on cortical or hippocampal neurons *in vitro* have demonstrated increases in both neuron survival and neurite outgrowth (Walicke et al., "Fibroblast growth factor promotes survival of dissociated hippocampal neurons and enhances neurite extension." *Proc. Natl. Acad. Sci. USA* 83:3012-3016. (1986), assay herein incorporated by reference in its entirety). However, reports from experiments done on PC-12 cells suggest that these two 10 responses are not necessarily synonymous and may depend on not only which FGF is being tested but also on which receptor(s) are expressed on the target cells. Using the primary cortical neuronal culture paradigm, the ability of a polypeptide of the invention to induce neurite outgrowth can be compared to the response achieved with FGF-2 using, for example, a thymidine incorporation assay.

15

Fibroblast and endothelial cell assays:

Human lung fibroblasts are obtained from Clonetics (San Diego, CA) and maintained in growth media from Clonetics. Dermal microvascular endothelial cells are obtained from Cell Applications (San Diego, CA). For proliferation assays, the human 20 lung fibroblasts and dermal microvascular endothelial cells can be cultured at 5,000 cells/well in a 96-well plate for one day in growth medium. The cells are then incubated for one day in 0.1% BSA basal medium. After replacing the medium with fresh 0.1% BSA medium, the cells are incubated with the test proteins for 3 days. Alamar Blue (Alamar Biosciences, Sacramento, CA) is added to each well to a final concentration of 10%. The 25 cells are incubated for 4 hr. Cell viability is measured by reading in a CytoFluor fluorescence reader. For the PGE<sub>2</sub> assays, the human lung fibroblasts are cultured at 5,000 cells/well in a 96-well plate for one day. After a medium change to 0.1% BSA basal medium, the cells are incubated with FGF-2 or polypeptides of the invention with or without IL-1 $\alpha$  for 24 hours. The supernatants are collected and assayed for PGE<sub>2</sub> by EIA

kit (Cayman, Ann Arbor, MI). For the IL-6 assays, the human lung fibroblasts are cultured at 5,000 cells/well in a 96-well plate for one day. After a medium change to 0.1% BSA basal medium, the cells are incubated with FGF-2 or with or without polypeptides of the invention IL-1 $\alpha$  for 24 hours. The supernatants are collected and 5 assayed for IL-6 by ELISA kit (Endogen, Cambridge, MA).

Human lung fibroblasts are cultured with FGF-2 or polypeptides of the invention for 3 days in basal medium before the addition of Alamar Blue to assess effects on growth of the fibroblasts. FGF-2 should show a stimulation at 10 - 2500 ng/ml which can be used to compare stimulation with polypeptides of the invention.

10

Parkinson Models.

The loss of motor function in Parkinson's disease is attributed to a deficiency of striatal dopamine resulting from the degeneration of the nigrostriatal dopaminergic projection neurons. An animal model for Parkinson's that has been extensively 15 characterized involves the systemic administration of 1-methyl-4 phenyl 1,2,3,6-tetrahydropyridine (MPTP). In the CNS, MPTP is taken-up by astrocytes and catabolized by monoamine oxidase B to 1-methyl-4-phenyl pyridine (MPP $^{+}$ ) and released. Subsequently, MPP $^{+}$  is actively accumulated in dopaminergic neurons by the high-affinity 20 reuptake transporter for dopamine. MPP $^{+}$  is then concentrated in mitochondria by the electrochemical gradient and selectively inhibits nicotinamide adenine disphosphate: ubiquinone oxidoreductionase (complex I), thereby interfering with electron transport and eventually generating oxygen radicals.

It has been demonstrated in tissue culture paradigms that FGF-2 (basic FGF) has trophic activity towards nigral dopaminergic neurons (Ferrari et al., Dev. Biol. 1989). 25 Recently, Dr. Unsicker's group has demonstrated that administering FGF-2 in gel foam implants in the striatum results in the near complete protection of nigral dopaminergic neurons from the toxicity associated with MPTP exposure (Otto and Unsicker, J. Neuroscience, 1990).

Based on the data with FGF-2, polypeptides of the invention can be evaluated to 30 determine whether it has an action similar to that of FGF-2 in enhancing dopaminergic

neuronal survival *in vitro* and it can also be tested *in vivo* for protection of dopaminergic neurons in the striatum from the damage associated with MPTP treatment. The potential effect of a polypeptide of the invention is first examined *in vitro* in a dopaminergic neuronal cell culture paradigm. The cultures are prepared by dissecting the midbrain floor plate from gestation day 14 Wistar rat embryos. The tissue is dissociated with trypsin and seeded at a density of 200,000 cells/cm<sup>2</sup> on polyorthinine-laminin coated glass coverslips. The cells are maintained in Dulbecco's Modified Eagle's medium and F12 medium containing hormonal supplements (N1). The cultures are fixed with paraformaldehyde after 8 days *in vitro* and are processed for tyrosine hydroxylase, a specific marker for dopaminergic neurons, immunohistochemical staining. Dissociated cell cultures are prepared from embryonic rats. The culture medium is changed every third day and the factors are also added at that time.

Since the dopaminergic neurons are isolated from animals at gestation day 14, a developmental time which is past the stage when the dopaminergic precursor cells are proliferating, an increase in the number of tyrosine hydroxylase immunopositive neurons would represent an increase in the number of dopaminergic neurons surviving *in vitro*. Therefore, if a polypeptide of the invention acts to prolong the survival of dopaminergic neurons, it would suggest that the polypeptide may be involved in Parkinson's Disease.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

**Example 36: The Effect of Polypeptides of the Invention on the Growth of  
Vascular Endothelial Cells**

On day 1, human umbilical vein endothelial cells (HUVEC) are seeded at 2-5x10<sup>4</sup> cells/35 mm dish density in M199 medium containing 4% fetal bovine serum (FBS), 16 units/ml heparin, and 50 units/ml endothelial cell growth supplements (ECGS, Biotechnique, Inc.). On day 2, the medium is replaced with M199 containing 10% FBS, 8 units/ml heparin. A polypeptide having the amino acid sequence of SEQ ID NO:Y, and positive controls, such as VEGF and basic FGF (bFGF) are added, at varying

concentrations. On days 4 and 6, the medium is replaced. On day 8, cell number is determined with a Coulter Counter.

An increase in the number of HUVEC cells indicates that the polypeptide of the invention may proliferate vascular endothelial cells.

5 The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

10 **Example 37: Stimulatory Effect of Polypeptides of the Invention on the Proliferation of Vascular Endothelial Cells**

For evaluation of mitogenic activity of growth factors, the colorimetric MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)2H-tetrazolium) assay with the electron coupling reagent PMS (phenazine methosulfate) was 15 performed (CellTiter 96 AQ, Promega). Cells are seeded in a 96-well plate (5,000 cells/well) in 0.1 mL serum-supplemented medium and are allowed to attach overnight. After serum-starvation for 12 hours in 0.5% FBS, conditions (bFGF, VEGF<sub>165</sub> or a polypeptide of the invention in 0.5% FBS) with or without Heparin (8 U/ml) are added to wells for 48 hours. 20 mg of MTS/PMS mixture (1:0.05) are added per well and allowed 20 to incubate for 1 hour at 37°C before measuring the absorbance at 490 nm in an ELISA plate reader. Background absorbance from control wells (some media, no cells) is subtracted, and seven wells are performed in parallel for each condition. See, Leak *et al.* *In Vitro Cell. Dev. Biol.* 30A:512-518 (1994).

The studies described in this example tested activity of a polypeptide of the 25 invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

**Example 38: Inhibition of PDGF-induced Vascular Smooth Muscle Cell Proliferation Stimulatory Effect**

HAoSMC proliferation can be measured, for example, by BrdUrd incorporation.

- 5 Briefly, subconfluent, quiescent cells grown on the 4-chamber slides are transfected with CRP or FITC-labeled AT2-3LP. Then, the cells are pulsed with 10% calf serum and 6 mg/ml BrdUrd. After 24 h, immunocytochemistry is performed by using BrdUrd Staining Kit (Zymed Laboratories). In brief, the cells are incubated with the biotinylated mouse anti-BrdUrd antibody at 4 degrees C for 2 h after being exposed to denaturing solution and
- 10 then incubated with the streptavidin-peroxidase and diaminobenzidine. After counterstaining with hematoxylin, the cells are mounted for microscopic examination, and the BrdUrd-positive cells are counted. The BrdUrd index is calculated as a percent of the BrdUrd-positive cells to the total cell number. In addition, the simultaneous detection of the BrdUrd staining (nucleus) and the FITC uptake (cytoplasm) is performed for
- 15 individual cells by the concomitant use of bright field illumination and dark field-UV fluorescent illumination. See, Hayashida et al., J. Biol. Chem. 6:271(36):21985-21992 (1996).

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

**Example 39: Stimulation of Endothelial Migration**

- 25 This example will be used to explore the possibility that a polypeptide of the invention may stimulate lymphatic endothelial cell migration.

Endothelial cell migration assays are performed using a 48 well microchemotaxis chamber (Neuroprobe Inc., Cabin John, MD; Falk, W., et al., J. Immunological Methods 1980;33:239-247). Polyvinylpyrrolidone-free polycarbonate filters with a pore size of 8 um (Nucleopore Corp. Cambridge, MA) are coated with 0.1% gelatin for at least 6 hours

30 at room temperature and dried under sterile air. Test substances are diluted to appropriate concentrations in M199 supplemented with 0.25% bovine serum albumin (BSA), and 25

ul of the final dilution is placed in the lower chamber of the modified Boyden apparatus. Subconfluent, early passage (2-6) HUVEC or BMEC cultures are washed and trypsinized for the minimum time required to achieve cell detachment. After placing the filter between lower and upper chamber,  $2.5 \times 10^5$  cells suspended in 50 ul M199 containing 1% FBS are seeded in the upper compartment. The apparatus is then incubated for 5 hours at 37°C in a humidified chamber with 5% CO<sub>2</sub> to allow cell migration. After the incubation period, the filter is removed and the upper side of the filter with the non-migrated cells is scraped with a rubber policeman. The filters are fixed with methanol and stained with a Giemsa solution (Diff-Quick, Baxter, McGraw Park, IL). Migration is quantified by counting cells of three random high-power fields (40x) in each well, and all groups are performed in quadruplicate.


The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

#### Example 40: Stimulation of Nitric Oxide Production by Endothelial Cells

Nitric oxide released by the vascular endothelium is believed to be a mediator of vascular endothelium relaxation. Thus, activity of a polypeptide of the invention can be assayed by determining nitric oxide production by endothelial cells in response to the polypeptide.

Nitric oxide is measured in 96-well plates of confluent microvascular endothelial cells after 24 hours starvation and a subsequent 4 hr exposure to various levels of a positive control (such as VEGF-1) and the polypeptide of the invention. Nitric oxide in the medium is determined by use of the Griess reagent to measure total nitrite after reduction of nitric oxide-derived nitrate by nitrate reductase. The effect of the polypeptide of the invention on nitric oxide release is examined on HUVEC.

Briefly, NO release from cultured HUVEC monolayer is measured with a NO-specific polarographic electrode connected to a NO meter (Iso-NO, World Precision Instruments Inc.) (1049). Calibration of the NO elements is performed according to the following equation:



The standard calibration curve is obtained by adding graded concentrations of  $\text{KNO}_2$  (0, 5, 10, 25, 50, 100, 250, and 500 nmol/L) into the calibration solution containing KI and  $\text{H}_2\text{SO}_4$ . The specificity of the Iso-NO electrode to NO is previously determined by 5 measurement of NO from authentic NO gas (1050). The culture medium is removed and HUVECs are washed twice with Dulbecco's phosphate buffered saline. The cells are then bathed in 5 ml of filtered Krebs-Henseleit solution in 6-well plates, and the cell plates are kept on a slide warmer (Lab Line Instruments Inc.) To maintain the temperature at 37°C. The NO sensor probe is inserted vertically into the wells, keeping the tip of the electrode 2 10 mm under the surface of the solution, before addition of the different conditions.

S-nitroso acetyl penicillamin (SNAP) is used as a positive control. The amount of released NO is expressed as picomoles per  $1 \times 10^6$  endothelial cells. All values reported are means of four to six measurements in each group (number of cell culture wells). See, Leak *et al. Biochem. and Biophys. Res. Comm.* 217:96-105 (1995).

15 The studies described in this example tested activity of polypeptides of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

20 **Example 41: Effect of Polypeptides of the Invention on Cord Formation in Angiogenesis**

Another step in angiogenesis is cord formation, marked by differentiation of 25 endothelial cells. This bioassay measures the ability of microvascular endothelial cells to form capillary-like structures (hollow structures) when cultured *in vitro*.

CADMEC (microvascular endothelial cells) are purchased from Cell Applications, Inc. as proliferating (passage 2) cells and are cultured in Cell Applications' CADMEC Growth Medium and used at passage 5. For the *in vitro* angiogenesis assay, the wells of a 48-well cell culture plate are coated with Cell Applications' Attachment Factor Medium 30 (200 ml/well) for 30 min. at 37°C. CADMEC are seeded onto the coated wells at 7,500 cells/well and cultured overnight in Growth Medium. The Growth Medium is then replaced with 300 mg Cell Applications' Chord Formation Medium containing control

buffer or a polypeptide of the invention (0.1 to 100 ng/ml) and the cells are cultured for an additional 48 hr. The numbers and lengths of the capillary-like chords are quantitated through use of the Boeckeler VIA-170 video image analyzer. All assays are done in triplicate.

5        Commercial (R&D) VEGF (50 ng/ml) is used as a positive control. b-esteradiol (1 ng/ml) is used as a negative control. The appropriate buffer (without protein) is also utilized as a control.

10      The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

**Example 42: Angiogenic Effect on Chick Chorioallantoic Membrane**

15      Chick chorioallantoic membrane (CAM) is a well-established system to examine angiogenesis. Blood vessel formation on CAM is easily visible and quantifiable. The ability of polypeptides of the invention to stimulate angiogenesis in CAM can be examined.

20      Fertilized eggs of the White Leghorn chick (*Gallus gallus*) and the Japanese quail (*Coturnix coturnix*) are incubated at 37.8°C and 80% humidity. Differentiated CAM of 16-day-old chick and 13-day-old quail embryos is studied with the following methods.

25      On Day 4 of development, a window is made into the egg shell of chick eggs. The embryos are checked for normal development and the eggs sealed with cello tape. They are further incubated until Day 13. Thermanox coverslips (Nunc, Naperville, IL) are cut into disks of about 5 mm in diameter. Sterile and salt-free growth factors are dissolved in distilled water and about 3.3 mg/ 5 ml are pipetted on the disks. After air-drying, the inverted disks are applied on CAM. After 3 days, the specimens are fixed in 3% glutaraldehyde and 2% formaldehyde and rinsed in 0.12 M sodium cacodylate buffer. They are photographed with a stereo microscope [Wild M8] and embedded for semi- and ultrathin sectioning as described above. Controls are performed with carrier disks alone.

30      The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to

test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

**Example 43: Angiogenesis Assay Using a Matrigel Implant in Mouse**

5       *In vivo* angiogenesis assay of a polypeptide of the invention measures the ability of an existing capillary network to form new vessels in an implanted capsule of murine extracellular matrix material (Matrigel). The protein is mixed with the liquid Matrigel at 4 degree C and the mixture is then injected subcutaneously in mice where it solidifies. After 7 days, the solid "plug" of Matrigel is removed and examined for the presence of new  
10 blood vessels. Matrigel is purchased from Becton Dickinson Labware/Collaborative Biomedical Products.

When thawed at 4 degree C the Matrigel material is a liquid. The Matrigel is mixed with a polypeptide of the invention at 150 ng/ml at 4 degrees C and drawn into cold 3 ml syringes. Female C57Bl/6 mice approximately 8 weeks old are injected with the  
15 mixture of Matrigel and experimental protein at 2 sites at the midventral aspect of the abdomen (0.5 ml/site). After 7 days, the mice are sacrificed by cervical dislocation, the Matrigel plugs are removed and cleaned (i.e., all clinging membranes and fibrous tissue is removed). Replicate whole plugs are fixed in neutral buffered 10% formaldehyde, embedded in paraffin and used to produce sections for histological examination after  
20 staining with Masson's Trichrome. Cross sections from 3 different regions of each plug are processed. Selected sections are stained for the presence of vWF. The positive control for this assay is bovine basic FGF (150 ng/ml). Matrigel alone is used to determine basal levels of angiogenesis.

The studies described in this example tested activity of a polypeptide of the  
25 invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

**Example 44: Rescue of Ischemia in Rabbit Lower Limb Model**

To study the *in vivo* effects of polynucleotides and polypeptides of the invention on ischemia, a rabbit hindlimb ischemia model is created by surgical removal of one femoral arteries as described previously (Takeshita *et al.*, *Am J. Pathol* 147:1649-1660 5 (1995)). The excision of the femoral artery results in retrograde propagation of thrombus and occlusion of the external iliac artery. Consequently, blood flow to the ischemic limb is dependent upon collateral vessels originating from the internal iliac artery (Takeshita *et al.*, *Am J. Pathol* 147:1649-1660 (1995)). An interval of 10 days is allowed for post-operative recovery of rabbits and development of endogenous collateral vessels. At 10 10 day post-operatively (day 0), after performing a baseline angiogram, the internal iliac artery of the ischemic limb is transfected with 500 mg naked expression plasmid containing a polynucleotide of the invention by arterial gene transfer technology using a hydrogel-coated balloon catheter as described (Riessen *et al.* *Hum Gene Ther.* 4:749-758 (1993); Leclerc *et al.* *J. Clin. Invest.* 90: 936-944 (1992)). When a polypeptide of the 15 invention is used in the treatment, a single bolus of 500 mg polypeptide of the invention or control is delivered into the internal iliac artery of the ischemic limb over a period of 1 min. through an infusion catheter. On day 30, various parameters are measured in these rabbits: (a) BP ratio - The blood pressure ratio of systolic pressure of the ischemic limb to that of normal limb; (b) Blood Flow and Flow Reserve - Resting FL: the blood flow 20 during undilated condition and Max FL: the blood flow during fully dilated condition (also an indirect measure of the blood vessel amount) and Flow Reserve is reflected by the ratio of max FL: resting FL; (c) Angiographic Score - This is measured by the angiogram of collateral vessels. A score is determined by the percentage of circles in an overlaying grid that with crossing opacified arteries divided by the total number in the rabbit thigh; (d) 25 Capillary density - The number of collateral capillaries determined in light microscopic sections taken from hindlimbs.

The studies described in this example tested activity of polynucleotides and polypeptides of the invention. However, one skilled in the art could easily modify the exemplified studies to test the agonists, and/or antagonists of the invention.

**Example 45: Effect of Polypeptides of the Invention on Vasodilation**

Since dilation of vascular endothelium is important in reducing blood pressure, the ability of polypeptides of the invention to affect the blood pressure in spontaneously hypertensive rats (SHR) is examined. Increasing doses (0, 10, 30, 100, 300, and 900 mg/kg) of the polypeptides of the invention are administered to 13-14 week old spontaneously hypertensive rats (SHR). Data are expressed as the mean +/- SEM. Statistical analysis are performed with a paired t-test and statistical significance is defined as p<0.05 vs. the response to buffer alone.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

**Example 46: Rat Ischemic Skin Flap Model**

The evaluation parameters include skin blood flow, skin temperature, and factor VIII immunohistochemistry or endothelial alkaline phosphatase reaction. Expression of polypeptides of the invention, during the skin ischemia, is studied using in situ hybridization.

The study in this model is divided into three parts as follows:

- 20      a) Ischemic skin
- b) Ischemic skin wounds
- c) Normal wounds

The experimental protocol includes:

- 25      a) Raising a 3x4 cm, single pedicle full-thickness random skin flap (myocutaneous flap over the lower back of the animal).
- b) An excisional wounding (4-6 mm in diameter) in the ischemic skin (skin-flap).
- c) Topical treatment with a polypeptide of the invention of the excisional wounds (day 0, 1, 2, 3, 4 post-wounding) at the following various dosage ranges: 1mg to 100 mg.
- d) Harvesting the wound tissues at day 3, 5, 7, 10, 14 and 21 post-wounding for histological, immunohistochemical, and in situ studies.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

5

**Example 47: Peripheral Arterial Disease Model**

Angiogenic therapy using a polypeptide of the invention is a novel therapeutic strategy to obtain restoration of blood flow around the ischemia in case of peripheral 10 arterial diseases. The experimental protocol includes:

- a) One side of the femoral artery is ligated to create ischemic muscle of the hindlimb, the other side of hindlimb serves as a control.
  - b) a polypeptide of the invention, in a dosage range of 20 mg - 500 mg, is delivered intravenously and/or intramuscularly 3 times (perhaps more) per week for 2-3 15 weeks.
  - c) The ischemic muscle tissue is collected after ligation of the femoral artery at 1, 2, and 3 weeks for the analysis of expression of a polypeptide of the invention and histology. Biopsy is also performed on the other side of normal muscle of the contralateral hindlimb.
- 20 The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

25 **Example 48: Ischemic Myocardial Disease Model**

A polypeptide of the invention is evaluated as a potent mitogen capable of stimulating the development of collateral vessels, and restructuring new vessels after coronary artery occlusion. Alteration of expression of the polypeptide is investigated in 30 situ. The experimental protocol includes:

- a) The heart is exposed through a left-side thoracotomy in the rat. Immediately, the left coronary artery is occluded with a thin suture (6-0) and the thorax is closed.
- b) a polypeptide of the invention, in a dosage range of 20 mg - 500 mg, is delivered intravenously and/or intramuscularly 3 times (perhaps more) per week for 2-4 weeks.
- c) Thirty days after the surgery, the heart is removed and cross-sectioned for morphometric and *in situ* analyzes.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

#### Example 49: Rat Corneal Wound Healing Model

- This animal model shows the effect of a polypeptide of the invention on neovascularization. The experimental protocol includes:
- a) Making a 1-1.5 mm long incision from the center of cornea into the stromal layer.
  - b) Inserting a spatula below the lip of the incision facing the outer corner of the eye.
  - c) Making a pocket (its base is 1-1.5 mm from the edge of the eye).
  - d) Positioning a pellet, containing 50ng- 5ug of a polypeptide of the invention, within the pocket.
  - e) Treatment with a polypeptide of the invention can also be applied topically to the corneal wounds in a dosage range of 20mg - 500mg (daily treatment for five days).

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

**Example 50: Diabetic Mouse and Glucocorticoid-Impaired Wound Healing Models**

**A. Diabetic db+/db+ Mouse Model.**

5 To demonstrate that a polypeptide of the invention accelerates the healing process, the genetically diabetic mouse model of wound healing is used. The full thickness wound healing model in the db+/db+ mouse is a well characterized, clinically relevant and reproducible model of impaired wound healing. Healing of the diabetic wound is dependent on formation of granulation tissue and re-epithelialization rather than  
10 contraction (Gartner, M.H. *et al.*, *J. Surg. Res.* 52:389 (1992); Greenhalgh, D.G. *et al.*, *Am. J. Pathol.* 136:1235 (1990)).

The diabetic animals have many of the characteristic features observed in Type II diabetes mellitus. Homozygous (db+/db+) mice are obese in comparison to their normal heterozygous (db+/+m) littermates. Mutant diabetic (db+/db+) mice have a single  
15 autosomal recessive mutation on chromosome 4 (db+) (Coleman *et al.* *Proc. Natl. Acad. Sci. USA* 77:283-293 (1982)). Animals show polyphagia, polydipsia and polyuria. Mutant diabetic mice (db+/db+) have elevated blood glucose, increased or normal insulin levels, and suppressed cell-mediated immunity (Mandel *et al.*, *J. Immunol.* 120:1375  
1978); Debray-Sachs, M. *et al.*, *Clin. Exp. Immunol.* 51(1):1-7 (1983); Leiter *et al.*, *Am. 20 J. of Pathol.* 114:46-55 (1985)). Peripheral neuropathy, myocardial complications, and microvascular lesions, basement membrane thickening and glomerular filtration abnormalities have been described in these animals (Norido, F. *et al.*, *Exp. Neurol.* 83(2):221-232 (1984); Robertson *et al.*, *Diabetes* 29(1):60-67 (1980); Giacomelli *et al.*, *Lab Invest.* 40(4):460-473 (1979); Coleman, D.L., *Diabetes* 31 (Suppl):1-6 (1982)). These  
25 homozygous diabetic mice develop hyperglycemia that is resistant to insulin analogous to human type II diabetes (Mandel *et al.*, *J. Immunol.* 120:1375-1377 (1978)).

The characteristics observed in these animals suggests that healing in this model may be similar to the healing observed in human diabetes (Greenhalgh, *et al.*, *Am. J. of Pathol.* 136:1235-1246 (1990)).

30 Genetically diabetic female C57BL/KsJ (db+/db+) mice and their non-diabetic (db+/+m) heterozygous littermates are used in this study (Jackson Laboratories). The

animals are purchased at 6 weeks of age and are 8 weeks old at the beginning of the study.

Animals are individually housed and received food and water ad libitum. All manipulations are performed using aseptic techniques. The experiments are conducted according to the rules and guidelines of Human Genome Sciences, Inc. Institutional

- 5 Animal Care and Use Committee and the Guidelines for the Care and Use of Laboratory Animals.

Wounding protocol is performed according to previously reported methods (Tsuboi, R. and Rifkin, D.B., *J. Exp. Med.* 172:245-251 (1990)). Briefly, on the day of wounding, animals are anesthetized with an intraperitoneal injection of Avertin (0.01 10 mg/mL), 2,2,2-tribromoethanol and 2-methyl-2-butanol dissolved in deionized water. The dorsal region of the animal is shaved and the skin washed with 70% ethanol solution and iodine. The surgical area is dried with sterile gauze prior to wounding. An 8 mm full-thickness wound is then created using a Keyes tissue punch. Immediately following wounding, the surrounding skin is gently stretched to eliminate wound expansion. The 15 wounds are left open for the duration of the experiment. Application of the treatment is given topically for 5 consecutive days commencing on the day of wounding. Prior to treatment, wounds are gently cleansed with sterile saline and gauze sponges.

Wounds are visually examined and photographed at a fixed distance at the day of surgery and at two day intervals thereafter. Wound closure is determined by daily 20 measurement on days 1-5 and on day 8. Wounds are measured horizontally and vertically using a calibrated Jameson caliper. Wounds are considered healed if granulation tissue is no longer visible and the wound is covered by a continuous epithelium.

A polypeptide of the invention is administered using at a range different doses, from 4mg to 500mg per wound per day for 8 days in vehicle. Vehicle control groups 25 received 50mL of vehicle solution.

Animals are euthanized on day 8 with an intraperitoneal injection of sodium pentobarbital (300mg/kg). The wounds and surrounding skin are then harvested for histology and immunohistochemistry. Tissue specimens are placed in 10% neutral buffered formalin in tissue cassettes between biopsy sponges for further processing.

30 Three groups of 10 animals each (5 diabetic and 5 non-diabetic controls) are evaluated: 1) Vehicle placebo control, 2) untreated group, and 3) treated group.

Wound closure is analyzed by measuring the area in the vertical and horizontal axis and obtaining the total square area of the wound. Contraction is then estimated by establishing the differences between the initial wound area (day 0) and that of post treatment (day 8). The wound area on day 1 is 64mm<sup>2</sup>, the corresponding size of the  
5 dermal punch. Calculations are made using the following formula:

$$[\text{Open area on day 8}] - [\text{Open area on day 1}] / [\text{Open area on day 1}]$$

Specimens are fixed in 10% buffered formalin and paraffin embedded blocks are  
10 sectioned perpendicular to the wound surface (5mm) and cut using a Reichert-Jung  
microtome. Routine hematoxylin-eosin (H&E) staining is performed on cross-sections of  
bisected wounds. Histologic examination of the wounds are used to assess whether the  
healing process and the morphologic appearance of the repaired skin is altered by  
treatment with a polypeptide of the invention. This assessment included verification of  
15 the presence of cell accumulation, inflammatory cells, capillaries, fibroblasts, re-  
epithelialization and epidermal maturity (Greenhalgh, D.G. *et al.*, *Am. J. Pathol.* 136:1235  
(1990)). A calibrated lens micrometer is used by a blinded observer.

Tissue sections are also stained immunohistochemically with a polyclonal rabbit  
anti-human keratin antibody using ABC Elite detection system. Human skin is used as a  
20 positive tissue control while non-immune IgG is used as a negative control. Keratinocyte  
growth is determined by evaluating the extent of reepithelialization of the wound using a  
calibrated lens micrometer.

Proliferating cell nuclear antigen/cyclin (PCNA) in skin specimens is demonstrated  
by using anti-PCNA antibody (1:50) with an ABC Elite detection system. Human colon  
25 cancer can serve as a positive tissue control and human brain tissue can be used as a  
negative tissue control. Each specimen includes a section with omission of the primary  
antibody and substitution with non-immune mouse IgG. Ranking of these sections is  
based on the extent of proliferation on a scale of 0-8, the lower side of the scale reflecting  
slight proliferation to the higher side reflecting intense proliferation.

30 Experimental data are analyzed using an unpaired t test. A p value of < 0.05 is  
considered significant.

**B. Steroid Impaired Rat Model**

The inhibition of wound healing by steroids has been well documented in various *in vitro* and *in vivo* systems (Wahl, Glucocorticoids and Wound healing. In: Anti-

- 5      Inflammatory Steroid Action: Basic and Clinical Aspects. 280-302 (1989); Wahlet *et al.*, *J. Immunol.* 115: 476-481 (1975); Werb *et al.*, *J. Exp. Med.* 147:1684-1694 (1978)).  
Glucocorticoids retard wound healing by inhibiting angiogenesis, decreasing vascular permeability (Ebert *et al.*, *An. Intern. Med.* 37:701-705 (1952)), fibroblast proliferation, and collagen synthesis (Beck *et al.*, *Growth Factors.* 5: 295-304 (1991); Haynes *et al.*,  
10     *J. Clin. Invest.* 61: 703-797 (1978)) and producing a transient reduction of circulating monocytes (Haynes *et al.*, *J. Clin. Invest.* 61: 703-797 (1978); Wahl, "Glucocorticoids and wound healing", In: Antiinflammatory Steroid Action: Basic and Clinical Aspects, Academic Press, New York, pp. 280-302 (1989)). The systemic administration of steroids to impaired wound healing is a well establish phenomenon in rats (Beck *et al.*, *Growth  
15     Factors.* 5: 295-304 (1991); Haynes *et al.*, *J. Clin. Invest.* 61: 703-797 (1978); Wahl, "Glucocorticoids and wound healing", In: Antiinflammatory Steroid Action: Basic and Clinical Aspects, Academic Press, New York, pp. 280-302 (1989); Pierce *et al.*, *Proc. Natl. Acad. Sci. USA* 86: 2229-2233 (1989)).

- To demonstrate that a polypeptide of the invention can accelerate the healing process, the effects of multiple topical applications of the polypeptide on full thickness excisional skin wounds in rats in which healing has been impaired by the systemic administration of methylprednisolone is assessed.

- Young adult male Sprague Dawley rats weighing 250-300 g (Charles River Laboratories) are used in this example. The animals are purchased at 8 weeks of age and  
25     are 9 weeks old at the beginning of the study. The healing response of rats is impaired by the systemic administration of methylprednisolone (17mg/kg/rat intramuscularly) at the time of wounding. Animals are individually housed and received food and water *ad libitum*. All manipulations are performed using aseptic techniques. This study is conducted according to the rules and guidelines of Human Genome Sciences, Inc.  
30     Institutional Animal Care and Use Committee and the Guidelines for the Care and Use of Laboratory Animals.

- The wounding protocol is followed according to section A, above. On the day of wounding, animals are anesthetized with an intramuscular injection of ketamine (50 mg/kg) and xylazine (5 mg/kg). The dorsal region of the animal is shaved and the skin washed with 70% ethanol and iodine solutions. The surgical area is dried with sterile gauze prior to wounding. An 8 mm full-thickness wound is created using a Keyes tissue punch. The wounds are left open for the duration of the experiment. Applications of the testing materials are given topically once a day for 7 consecutive days commencing on the day of wounding and subsequent to methylprednisolone administration. Prior to treatment, wounds are gently cleansed with sterile saline and gauze sponges.
- 10 Wounds are visually examined and photographed at a fixed distance at the day of wounding and at the end of treatment. Wound closure is determined by daily measurement on days 1-5 and on day 8. Wounds are measured horizontally and vertically using a calibrated Jameson caliper. Wounds are considered healed if granulation tissue is no longer visible and the wound is covered by a continuous epithelium.
- 15 The polypeptide of the invention is administered using at a range different doses, from 4mg to 500mg per wound per day for 8 days in vehicle. Vehicle control groups received 50mL of vehicle solution.
- 20 Animals are euthanized on day 8 with an intraperitoneal injection of sodium pentobarbital (300mg/kg). The wounds and surrounding skin are then harvested for histology. Tissue specimens are placed in 10% neutral buffered formalin in tissue cassettes between biopsy sponges for further processing.
- 25 Four groups of 10 animals each (5 with methylprednisolone and 5 without glucocorticoid) are evaluated: 1) Untreated group 2) Vehicle placebo control 3) treated groups.
- Wound closure is analyzed by measuring the area in the vertical and horizontal axis and obtaining the total area of the wound. Closure is then estimated by establishing the differences between the initial wound area (day 0) and that of post treatment (day 8). The wound area on day 1 is 64mm<sup>2</sup>, the corresponding size of the dermal punch. Calculations are made using the following formula:

30

$$[\text{Open area on day 8}] - [\text{Open area on day 1}] / [\text{Open area on day 1}]$$

Specimens are fixed in 10% buffered formalin and paraffin embedded blocks are sectioned perpendicular to the wound surface (5mm) and cut using an Olympus microtome. Routine hematoxylin-eosin (H&E) staining is performed on cross-sections of 5 bisected wounds. Histologic examination of the wounds allows assessment of whether the healing process and the morphologic appearance of the repaired skin is improved by treatment with a polypeptide of the invention. A calibrated lens micrometer is used by a blinded observer to determine the distance of the wound gap.

Experimental data are analyzed using an unpaired t test. A p value of < 0.05 is 10 considered significant.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

15

#### Example 51: Lymphadema Animal Model

The purpose of this experimental approach is to create an appropriate and consistent lymphedema model for testing the therapeutic effects of a polypeptide of the invention in lymphangiogenesis and re-establishment of the lymphatic circulatory system 20 in the rat hind limb. Effectiveness is measured by swelling volume of the affected limb, quantification of the amount of lymphatic vasculature, total blood plasma protein, and histopathology. Acute lymphedema is observed for 7-10 days. Perhaps more importantly, the chronic progress of the edema is followed for up to 3-4 weeks.

Prior to beginning surgery, blood sample is drawn for protein concentration 25 analysis. Male rats weighing approximately ~350g are dosed with Pentobarbital. Subsequently, the right legs are shaved from knee to hip. The shaved area is swabbed with gauze soaked in 70% EtOH. Blood is drawn for serum total protein testing. Circumference and volumetric measurements are made prior to injecting dye into paws after marking 2 measurement levels (0.5 cm above heel, at mid-pt of dorsal paw). The 30 intradermal dorsum of both right and left paws are injected with 0.05 ml of 1% Evan's

Blue. Circumference and volumetric measurements are then made following injection of dye into paws.

Using the knee joint as a landmark, a mid-leg inguinal incision is made circumferentially allowing the femoral vessels to be located. Forceps and hemostats are 5 used to dissect and separate the skin flaps. After locating the femoral vessels, the lymphatic vessel that runs along side and underneath the vessel(s) is located. The main lymphatic vessels in this area are then electrically coagulated suture ligated.

Using a microscope, muscles in back of the leg (near the semitendinosus and adductors) are bluntly dissected. The popliteal lymph node is then located. The 2 proximal and 2 distal lymphatic vessels and distal blood supply of the popliteal node are then and ligated by suturing. The popliteal lymph node, and any accompanying adipose tissue, is then removed by cutting connective tissues.

Care is taken to control any mild bleeding resulting from this procedure. After lymphatics are occluded, the skin flaps are sealed by using liquid skin (Vetbond) (AJ Buck). The separated skin edges are sealed to the underlying muscle tissue while leaving a gap of ~0.5 cm around the leg. Skin also may be anchored by suturing to underlying muscle when necessary.

To avoid infection, animals are housed individually with mesh (no bedding). Recovering animals are checked daily through the optimal edematous peak, which 20 typically occurred by day 5-7. The plateau edematous peak are then observed. To evaluate the intensity of the lymphedema, the circumference and volumes of 2 designated places on each paw before operation and daily for 7 days are measured. The effect plasma proteins on lymphedema is determined and whether protein analysis is a useful testing perimeter is also investigated. The weights of both control and edematous limbs are 25 evaluated at 2 places. Analysis is performed in a blind manner.

Circumference Measurements: Under brief gas anesthetic to prevent limb movement, a cloth tape is used to measure limb circumference. Measurements are done at the ankle bone and dorsal paw by 2 different people then those 2 readings are averaged. Readings are taken from both control and edematous limbs.

30 Volumetric Measurements: On the day of surgery, animals are anesthetized with Pentobarbital and are tested prior to surgery. For daily volumetrics animals are under

brief halothane anesthetic (rapid immobilization and quick recovery), both legs are shaved and equally marked using waterproof marker on legs. Legs are first dipped in water, then dipped into instrument to each marked level then measured by Buxco edema software(Chen/Victor). Data is recorded by one person, while the other is dipping the  
5 limb to marked area.

Blood-plasma protein measurements: Blood is drawn, spun, and serum separated prior to surgery and then at conclusion for total protein and Ca<sup>2+</sup> comparison.

Limb Weight Comparison: After drawing blood, the animal is prepared for tissue collection. The limbs are amputated using a quillotine, then both experimental and control  
10 legs are cut at the ligature and weighed. A second weighing is done as the tibio-cacaneal joint is disarticulated and the foot is weighed.

Histological Preparations: The transverse muscle located behind the knee (popliteal) area is dissected and arranged in a metal mold, filled with freezeGel, dipped into cold methylbutane, placed into labeled sample bags at - 80EC until sectioning. Upon  
15 sectioning, the muscle is observed under fluorescent microscopy for lymphatics..

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

20

**Example 52: Suppression of TNF alpha-induced adhesion molecule expression by a Polypeptide of the Invention**

The recruitment of lymphocytes to areas of inflammation and angiogenesis involves specific receptor-ligand interactions between cell surface adhesion molecules  
25 (CAMs) on lymphocytes and the vascular endothelium. The adhesion process, in both normal and pathological settings, follows a multi-step cascade that involves intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and endothelial leukocyte adhesion molecule-1 (E-selectin) expression on endothelial cells (EC). The expression of these molecules and others on the vascular endothelium  
30 determines the efficiency with which leukocytes may adhere to the local vasculature and extravasate into the local tissue during the development of an inflammatory response. The

local concentration of cytokines and growth factor participate in the modulation of the expression of these CAMs.

Tumor necrosis factor alpha (TNF-a), a potent proinflammatory cytokine, is a stimulator of all three CAMs on endothelial cells and may be involved in a wide variety of 5 inflammatory responses, often resulting in a pathological outcome.

The potential of a polypeptide of the invention to mediate a suppression of TNF-a induced CAM expression can be examined. A modified ELISA assay which uses ECs as a solid phase absorbent is employed to measure the amount of CAM expression on TNF-a treated ECs when co-stimulated with a member of the FGF family of proteins.

10 To perform the experiment, human umbilical vein endothelial cell (HUVEC) cultures are obtained from pooled cord harvests and maintained in growth medium (EGM-2; Clonetics, San Diego, CA) supplemented with 10% FCS and 1% penicillin/streptomycin in a 37 degree C humidified incubator containing 5% CO<sub>2</sub>. HUVECs are seeded in 96-well plates at concentrations of 1 x 10<sup>4</sup> cells/well in EGM 15 medium at 37 degree C for 18-24 hrs or until confluent. The monolayers are subsequently washed 3 times with a serum-free solution of RPMI-1640 supplemented with 100 U/ml penicillin and 100 mg/ml streptomycin, and treated with a given cytokine and/or growth factor(s) for 24 h at 37 degree C. Following incubation, the cells are then evaluated for CAM expression.

20 Human Umbilical Vein Endothelial cells (HUVECs) are grown in a standard 96 well plate to confluence. Growth medium is removed from the cells and replaced with 90 ul of 199 Medium (10% FBS). Samples for testing and positive or negative controls are added to the plate in triplicate (in 10 ul volumes). Plates are incubated at 37 degree C for either 5 h (selectin and integrin expression) or 24 h (integrin expression only). Plates are 25 aspirated to remove medium and 100 µl of 0.1% paraformaldehyde-PBS (with Ca++ and Mg++) is added to each well. Plates are held at 4°C for 30 min.

Fixative is then removed from the wells and wells are washed 1X with PBS(+Ca,Mg)+0.5% BSA and drained. Do not allow the wells to dry. Add 10 µl of diluted primary antibody to the test and control wells. Anti-ICAM-1-Biotin, Anti-VCAM-30 1-Biotin and Anti-E-selectin-Biotin are used at a concentration of 10 µg/ml (1:10 dilution

of 0.1 mg/ml stock antibody). Cells are incubated at 37°C for 30 min. in a humidified environment. Wells are washed X3 with PBS(+Ca,Mg)+0.5% BSA.

Then add 20 µl of diluted ExtrAvidin-Alkaline Phosphotase (1:5,000 dilution) to each well and incubated at 37°C for 30 min. Wells are washed X3 with

- 5 PBS(+Ca,Mg)+0.5% BSA. 1 tablet of p-Nitrophenol Phosphate pNPP is dissolved in 5 ml of glycine buffer (pH 10.4). 100 µl of pNPP substrate in glycine buffer is added to each test well. Standard wells in triplicate are prepared from the working dilution of the ExtrAvidin-Alkaline Phosphotase in glycine buffer: 1:5,000 ( $10^0$ ) >  $10^{-0.5}$  >  $10^{-1}$  >  $10^{-1.5}$ . 5 µl of each dilution is added to triplicate wells and the resulting AP content in each well is
- 10 5.50 ng, 1.74 ng, 0.55 ng, 0.18 ng. 100 µl of pNNP reagent must then be added to each of the standard wells. The plate must be incubated at 37°C for 4h. A volume of 50 µl of 3M NaOH is added to all wells. The results are quantified on a plate reader at 405 nm. The background subtraction option is used on blank wells filled with glycine buffer only. The template is set up to indicate the concentration of AP-conjugate in each standard well [
- 15 5.50 ng; 1.74 ng; 0.55 ng; 0.18 ng]. Results are indicated as amount of bound AP-conjugate in each sample.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

It will be clear that the invention may be practiced otherwise than as particularly described in the foregoing description and examples. Numerous modifications and variations of the present invention are possible in light of the above teachings and, therefore, are within the scope of the appended claims.

- 25 The entire disclosure of each document cited (including patents, patent applications, journal articles, abstracts, laboratory manuals, books, or other disclosures) in the Background of the Invention, Detailed Description, and Examples is hereby incorporated herein by reference. Further, the hard copy of the sequence listing submitted herewith and the corresponding computer readable form are both
- 30 incorporated herein by reference in their entireties.

323

Applicant's or agent's file reference number	PS528PCT	International application No.	unassigned
--	----------	-------------------------------	------------

## INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

<p><b>A. The indications made below relate to the microorganism referred to in the description</b></p> <p>on page <u>65</u> line <u>N/A</u></p>			
<b>B. IDENTIFICATION OF DEPOSIT</b>		Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution American Type Culture Collection			
Address of depositary institution ( <i>including postal code and country</i> ) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America			
Date of deposit	26 April 1999	Accession Number	203957
<b>C. ADDITIONAL INDICATIONS</b> ( <i>leave blank if not applicable</i> )		This information is continued on an additional sheet <input type="checkbox"/>	
<b>D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE</b> ( <i>if the indications are not for all designated States</i> )			
Europe In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC).			
<b>E. SEPARATE FURNISHING OF INDICATIONS</b> ( <i>leave blank if not applicable</i> )			
The indications listed below will be submitted to the International Bureau later ( <i>specify the general nature of the indications e.g. "Accession Number of Deposit"</i> )			
For receiving Office use only		For International Bureau use only	
<input type="checkbox"/> This sheet was received with the international application		<input type="checkbox"/> This sheet was received by the International Bureau on:	
Authorized officer		Authorized officer	

**ATCC Deposit No.: 203957**

#### **CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

#### **NORWAY**

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

#### **AUSTRALIA**

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

#### **FINLAND**

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

#### **UNITED KINGDOM**

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

ATCC Deposit No.: 203957

#### DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

#### SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

#### NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

***What Is Claimed Is:***

1. An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of:
  - (a) a polynucleotide fragment of SEQ ID NO:X or a polynucleotide fragment of the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
  - (b) a polynucleotide encoding a polypeptide fragment of SEQ ID NO:Y or a polypeptide fragment encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
  - (c) a polynucleotide encoding a polypeptide domain of SEQ ID NO:Y or a polypeptide domain encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
  - (d) a polynucleotide encoding a polypeptide epitope of SEQ ID NO:Y or a polypeptide epitope encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
  - (e) a polynucleotide encoding a polypeptide of SEQ ID NO:Y or the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X, having biological activity;
  - (f) a polynucleotide which is a variant of SEQ ID NO:X;
  - (g) a polynucleotide which is an allelic variant of SEQ ID NO:X;
  - (h) a polynucleotide which encodes a species homologue of the SEQ ID NO:Y;
  - (i) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h), wherein said polynucleotide does not hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence of only A residues or of only T residues.

2. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding a secreted protein.

5 3. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding the sequence identified as SEQ ID NO:Y or the polypeptide encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X.

10 4. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises the entire nucleotide sequence of SEQ ID NO:X or the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X.

15 5. The isolated nucleic acid molecule of claim 2, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.

20 6. The isolated nucleic acid molecule of claim 3, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.

25 7. A recombinant vector comprising the isolated nucleic acid molecule of claim 1.

8. A method of making a recombinant host cell comprising the isolated nucleic acid molecule of claim 1.

9. A recombinant host cell produced by the method of claim 8.

30 10. The recombinant host cell of claim 9 comprising vector sequences.

11. An isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence selected from the group consisting of:
  - (a) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;
  - (b) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z, having biological activity;
  - (c) a polypeptide domain of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;
  - (d) a polypeptide epitope of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;
  - (e) a secreted form of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;
  - (f) a full length protein of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;
  - (g) a variant of SEQ ID NO:Y;
  - (h) an allelic variant of SEQ ID NO:Y; or
  - (i) a species homologue of the SEQ ID NO:Y.
12. The isolated polypeptide of claim 11, wherein the secreted form or the full length protein comprises sequential amino acid deletions from either the C-terminus or the N-terminus.
13. An isolated antibody that binds specifically to the isolated polypeptide of claim 11.
14. A recombinant host cell that expresses the isolated polypeptide of claim 11.
15. A method of making an isolated polypeptide comprising:
  - (a) culturing the recombinant host cell of claim 14 under conditions such that said polypeptide is expressed; and

(b) recovering said polypeptide.

16. The polypeptide produced by claim 15.

5 17. A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of the polypeptide of claim 11 or the polynucleotide of claim 1.

10 18. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:

- (a) determining the presence or absence of a mutation in the polynucleotide of claim 1; and  
(b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or absence of said mutation.

15

19. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:

- (a) determining the presence or amount of expression of the polypeptide of claim 11 in a biological sample; and  
20 (b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of the polypeptide.

20. A method for identifying a binding partner to the polypeptide of claim 11 comprising:

- 25 (a) contacting the polypeptide of claim 11 with a binding partner; and  
(b) determining whether the binding partner effects an activity of the polypeptide.

21. The gene corresponding to the cDNA sequence of SEQ ID NO:Y.

30

22. A method of identifying an activity in a biological assay, wherein the method comprises:

- (a) expressing SEQ ID NO:X in a cell;
- (b) isolating the supernatant;
- 5 (c) detecting an activity in a biological assay; and
- (d) identifying the protein in the supernatant having the activity.

23. The product produced by the method of claim 20.

1

&lt;110&gt; Human Genome Sciences, Inc.

&lt;120&gt; 49 Human Secreted Proteins

&lt;130&gt; PS528PCT

&lt;140&gt; Unassigned

&lt;141&gt; 2000-03-22

&lt;150&gt; 60/126,596

&lt;151&gt; 1999-03-26

&lt;150&gt; 60/171,552

&lt;151&gt; 1999-12-22

&lt;160&gt; 176

&lt;170&gt; PatentIn Ver. 2.0

&lt;210&gt; 1

&lt;211&gt; 733

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 1

gggatccgga	gccccaaatct	tctgacaaaaa	ctcacacatg	cccaccgtgc	ccagcacctg	60
aattcgaggg	tgcacccgtca	gttttcctct	tcccccccaa	acccaaggac	accctcatga	120
tctcccgac	tcctgaggc	acatgcgtgg	tgggtggacgt	aagccacgaa	gaccctgagg	180
tcaagttaa	ctggtaacgtg	gacggcgtgg	agggtgcataa	tgccaaagaca	aaggccgcggg	240
aggagcagta	caacagcacg	taccgtgtgg	ttagcgtccct	caccgtcctg	caccaggact	300
ggctgaatgg	caaggagtagc	aagtgcagg	tctccaacaa	agccctccca	acccccattcg	360
agaaaaacca	ctccaaagcc	aaagggcagc	cccgagaacc	acagggttac	accctggccc	420
catcccgaaa	tgagctgacc	aagaaccagg	ttagcctgac	ctggctggtc	aaaggcttct	480
atccaagcga	catgcgcgtg	gagtggaga	gcaatggca	gccggagaac	aactacaaga	540
ccacgcctcc	cgtgctggac	tccgacggct	ccttcttccct	ctacagcaag	ctcaccgtgg	600
acaagagcag	gtggcagcag	gggaacgtct	tctcatgctc	cgtgatgcat	gaggctctgc	660
acaaccacta	cacgcagaag	agcctctccc	tgtctccggg	taaatgagtg	cgacggccgc	720
gactctagag	gat					733

&lt;210&gt; 2

&lt;211&gt; 5

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; Site

&lt;222&gt; (3)

&lt;223&gt; Xaa equals any of the twenty naturally occurring L-amino acids

&lt;400&gt; 2

Trp Ser Xaa Trp Ser

<210> 3  
<211> 86  
<212> DNA  
<213> Homo sapiens

<400> 3  
gcccctcgag atttccccga aatcttagatt tcccccgaat gatttccccg aaatgattc 60  
cccgaaatat ctgccatctc aattag 86

<210> 4  
<211> 27  
<212> DNA  
<213> Homo sapiens

<400> 4  
gcggcaagct ttttgcaaag cctaggc 27

<210> 5  
<211> 271  
<212> DNA  
<213> Homo sapiens

<400> 5  
ctcgagattt cccccaaatc tagatttccc cgaaatgatt tcccccgaat gatttccccg 60  
aaatatatctgc catctcaatt agtcagcaac catagtcccc cccctaactc cgcccatccc 120  
gccccctaact ccgccccagtt ccgccccatc tccgccccat ggctgactaa ttttttttat 180  
ttatgcagag gccgaggccg cctcggccctc tgagctattc cagaagtagt gaggaggctt 240  
ttttggaggc ctaggctttt gaaaaagct t 271

<210> 6  
<211> 32  
<212> DNA  
<213> Homo sapiens

<400> 6  
gcgcctcgagg gatgacagcg atagaacccc gg 32

<210> 7  
<211> 31  
<212> DNA  
<213> Homo sapiens

<400> 7  
gcgaagcttc gcgactcccc ggatccgcct c 31

<210> 8  
<211> 12  
<212> DNA  
<213> Homo sapiens

<400> 8	
ggggacttcc	12
<210> 9	
<211> 73	
<212> DNA	
<213> Homo sapiens	
<400> 9	
gcggcctcgaa ggggacttcc cccgggactt tccgggact ttccggact ttccatcctg	60
ccatctcaat tag	73
<210> 10	
<211> 256	
<212> DNA	
<213> Homo sapiens	
<400> 10	
ctcgaggggaa ctttcccggg gactttccgg ggactttccgg ggactttcca tctgccatct	60
caatttagtca gcaaccatag tccccccct aactccgccc atccccccc taactccgccc	120
cagttccgccc catttccgc cccatggctg actaattttt tttattttatg cagaggccgaa	180
ggccgcctcg gcctctgagc tattccagaa gtatgtgagga ggcttttttg gaggcctagg	240
cttttgc当地 aagctt	256
<210> 11	
<211> 2556	
<212> DNA	
<213> Homo sapiens	
<220>	
<221> SITE	
<222> (1663)	
<223> n equals a,t,g, or c	
<220>	
<221> SITE	
<222> (2553)	
<223> n equals a,t,g, or c	
<400> 11	
tgcacccacg cgtccggccgg gctgcagccg ggcgcgttct ccgggttaca gccggcgccg	60
ccggccgtta gtccggccgg cggcgccatg gccggctcg cgccgcgrgc tccggccggc	120
tctgaggcgc gtctcagect cggcaccttc ctgctggcg cctcggtgt ctgcgtggcc	180
ctgctcagcg ggcggccct gcaggggccgc accgggctgg cgctctacgt ggccgggctc	240
aacgcgtgc tgctgtgt ctatcgccg cctcgctacc agatagccat ccgagcttgt	300
ttccctgggt ttgtgttgg ctgcggcaccg ctgctaagg tttagccagtc ttcttgaggt	360
cactttggct ggtacatgt ctccctgtca ttgttccact attctgaata ctgggtgaca	420
gcagtcaata atccaaaaag tctgtccttg gattccttcc tcctgaatca cagcctggag	480
tatacgttag ctgcttcc ttcttggta gagttcacac ttgaaaatat cttttggcca	540
gaactgaagc agattacgt gctcgtgtc acagggctgc tgatgttggctt cttcgagaa	600
tgtctgagga aggccggcat gttacagct ggctccaatt tcaaccacgt ggtacagaat	660

gaaaaatcacatac tctggtgacc agtggagtgt acgctggtt tcggcatcct	720
tcttacgtcg ggtggttta ctggagttt ggaactcagg tgatgtgtg taaccccatc	780
tgcggcgtca ytatgcctg acagtgtggc gattcttccg cgatcgaaca gaagaagaag	840
aatctcaactt aattcaacttt ttggagagg agtacctgaa gtataagaag agggtgccc	900
cgggctgcc tttcataaaag ggggtcaagg tggacctgtg acggcagtgc gccccgggtga	960
ccttggggcc tccgaccctg tgcagcctgg gacaaaactg ttccgggtg gccgctgcca	1020
catggatttt cttaatcggtt ttatgtcatt agtcaactt ctggaatgtc actcaagacc	1080
aaggcgttag aaggcctgrg gaccaaggc cccactggag cagtctgtcc ttatgccaa	1140
tcaaggcggg acatgggtga aagacgagta aggggcaaat cacagcaata ttccacagcg	1200
ccctccagag ttacctgggg aggaccgagg ccacacgcca ctgccccgaa gggcagagtg	1260
taagtaaagg ataaccagga ctcgctgggaa gagatggact ctktccctcg caaacactcca	1320
cagcagaaag ggtagcagg tacccttct tatcagcggt aaaaatgcat ttacaacctt	1380
tcatttaacc gaaaaacaca gaccgctta acctctttat ttctgtcccc cactgcatga	1440
acatctatac aattttaaaa atacttcctc ataggatgtt ttggcccttc atctatttaa	1500
tcatacgctac atacctattt ttataagta gcagttacaca ttcaaaagggg tattcctagc	1560
tcaatgtttt gtgttcttagt tcaacttttta tcctgcagca agtaaggccta gataactcta	1620
cacgatttgg ctgagttggct ttgtgtgacc gtggcccccag gcnaaggggaa tcatggccct	1680
ggctggcttt cccgggggtc tcagctcctg ttgtcagtgaa taggcggctc aaaggagcat	1740
cagtttctt ttagccaaaga agtgcctact gaatgcctgc cctgtgcgtg gccttaaaca	1800
ttgagaagtg ctgctctccg ttatggggg atttattttt cattttacca tagtttatat	1860
tctcaatttc aatgcctagtc tcagaactct tttttctgt gttctgttct caaaattaca	1920
ttgtccctca tgtcatttca aactgttttc caaaggggatt tgagcatata caactacaaa	1980
tccaagcaga ttgactctca aaaataatct taaatactgc aaatagtccc aactaagatt	2040
cagtcaagtat gtttggggg caagttttttt agagtaagtt ggctttgggtt cacacatcga	2100
agctttaaga ggtgagacgc tggcttcatt ctggactaga caggaacttg gcctcagcgt	2160
gagatcctgc catgcagtgt tgccgtggca ctgaagaagt gtgaatgtga agggggcgctc	2220
ggcgcggggc cagagcacca ctctgcgtcc ccaccacgcg gcctgtgggg agccactaaa	2280
cctttccgtg cctagacctc cccatctgtt gaatgggggtc aataccaccc acctcacagg	2340
gtgttgggtga ggactgagaa gaacaatgtc aaatgtttt aatactcaga tggggagcg	2400
acatcaatga aatctgtact gtatgaaagc tacacaaaaaa tggggagaca ttgggttaat	2460
tgtgccagat acctaaaaatg tatgttccaga aaagcattttt atcaactcag aaatatgact	2520
tatttctaga aaaaaaaaaaaaaaaa aaaaaaaaaat ttnctc	2556

<210> 12  
<211> 1149  
<212> DNA  
<213> Homo sapiens

<400> 12	
tcgaccacg cgtccgggtg acagagcaag actccgtctc aaaaaacaaa caaaaaaaaaa	60
ttgaagtaat gaattttatt tcagtggtat ggggaacctt gtttctgaca gtaggggaag	120
ctatcatgtt cctggtagga ggttgcattt tatttcaaggc ggtggggaaaaa caggacctgg	180
ctttgcatta gtaactgaag ccaggtgggtg aactctcagc atgtgttaagg agccggctga	240
gaaggagctt tgctcccatg atattaaattt atctgattat tggaaacttt tgtaaatgggt	300
cattagttagt cttttttttt tctattatgtt aagagttttt aacttaacag	360
aaaataggca agaacatgtc caagaactcc tgcacactcc tttgcccaga gactattctt	420
tttagagcaaa ggctacagcc cagaatcagc cgcttcaccc cattcatcac agctctcctt	480
tctgtccatc tgggtccact cctcagttt cctgaacttc cgcgattttt gctttgtgg	540
agggttatagg ctgatcattt tggtaatgtt ctttcaatgtt ggattcggtt atgtttctgc	600
atgatttagac cccacctgtg tggacttgaa ggctgaatgtt cacagactctt gtttttttta	660
tccttattctgt tggatcttttccatgtt ggtgggttta ctgctgtcgc ctggaaagcac	720
agggttatgtt ggggtttgtt tggatctttca tgaccctgtt actggccaca tttcaagga	780
ggcgctgttc catatgttgg aggggggtgt tggaaatgtt gatctgggtt ctgggtgtcc	840
tatttccactt agggatattgtc agctcccaga ctttcataa ggatagagctt agggacttg	900

tacatttata gttatttctg tatctgcgtc atatatcatg ttcacacaaa tgcacatcta 960  
tccaaatctaa catcacagag ttgtcttta aaaatatgac aagctggcca tgcgtgatgc 1020  
tcacgcctgt catcccgca ctttgggagg ccaaggcagg cgatcacct gaggttggga 1080  
gttaaagacc agcctggcca acatggagaa acctcgtctc tactaaaaaa aaaaaaaaaag 1140  
ggcgccccgc 1149

<210> 13  
<211> 1281  
<212> DNA  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (29)  
<223> n equals a,t,g, or c

<220>  
<221> SITE  
<222> (47)  
<223> n equals a,t,g, or c

<220>  
<221> SITE  
<222> (83)  
<223> n equals a,t,g, or c

<220>  
<221> SITE  
<222> (121)  
<223> n equals a,t,g, or c

<220>  
<221> SITE  
<222> (133)  
<223> n equals a,t,g, or c

<220>  
<221> SITE  
<222> (154)  
<223> n equals a,t,g, or c

<220>  
<221> SITE  
<222> (1166)  
<223> n equals a,t,g, or c

<220>  
<221> SITE  
<222> (1262)  
<223> n equals a,t,g, or c

<400> 13  
cacgacaggt ttcccgactg aaaagcggncc agtgagcgca accccantta atgtgagttt 60  
gctcaactcat taggcacccccc agnctttaca ctttatgctt cccggctcgt atgttgttg 120

<210> 14  
<211> 712  
<212> DNA  
<213> *Homo sapiens*

```

<400> 14
ccccgggct gcaggaattc ggacgagtt cgcctcaccc tccccagtgc actgaagaag   60
gtAACCGGGT ccagaccac gcccggccag ttctccggcg ggaaggaaaa cccgcgcagag 120
aggcagcaat gaatgtggat cacgaggta acctcttagt ggagggaaatt catcggttgg 180
gttcaaaaaaa tgctgtatggaa aagtttaagcg tggaaatttgg ggtctcttc cgtgtatgata 240
aatgtgc当地 cctctttgaa gcattggtag gaactctttaa agctgc当地 cgaaggaaaga 300
tttgtaacata tccaggagag ctgtttctgc aagggttca tgatgtatgtt gacattatat 360
tactgcaaga ttaatgtggt ttacatatatct ttatgtactg ccatttttg tttctggtaa 420
actggaaatat aaagtgaaag aacaaacatt tgaacataact taatgtatTT ttatagaact 480
tttgtaaacga aaggagattc atgttttaga agtctgttct tttttatatc ttgaaagaaa 540
atctatgtat gatgtatataa aataatttaga cattttctat agatatttga cattctgc当地 600
aagcaacaag caaactgtaa accaactcct atgagaaaata ttatgtatgtt tatgtatataa 660
agacatgtaa ctgtctttaaa tttaaaaaaaaaaaaaaaaactc ga 712

```

<210> 15  
<211> 486  
<212> DNA  
<213> *Homo sapiens*

```
<400> 15
gaattcggca cgagctccag agtgttccca tgatcaccac gtcctttgat cagtgccatc 60
tggaaagagca gatgagtgc a gccctcctct catcctctct gtgcgtggctc cgaacgcgtt 120
cttacagacc caccaacaac caagaagctg cactggttgg tacacactgc agcaaacaag 180
aaaaacaagt atgataaaaaa gtccaaacatc aaaaagaaaa aaaaaaccat agaaaacaatt 240
gaagagagaa tggctaaagg acatgaaaag acagttcata caaaggaaaa ttcaatgctg 300
ttctcgctga ggctggagtc caatgatgct atctcagctc actgcaactt ccgtctcctg 360
ggttcaggag aatggcgtga acccggggagg cggagctgc aqtqagctqa qattqcqcca 420
```

ctgcactcca gcctggcgaa cagagcgaga ctccatctca aaaaaaaaaaaa aaaaaaaaaaaa	480
ctcgag	486

&lt;210&gt; 16

&lt;211&gt; 654

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 16

aaaagccgccc cttagcccccc tcctccctt tcctgcttct gcgagaactc cctccctccc	60
tccagctccg ccagcccagg cgcccccttc ctggaagccg agcggcttcg ctcgcatttc	120
accgcccccg cctctcgcaa tattgcaata tagggaaat gactaatgaa gctaattaaa	180
agaagcattc aaatctgctt tctaccctca ttaacaatata gcagggcact gcccagatgtt	240
tgtaccctgt gtttacattt aacaacattt tatttgctct ttgtatattt aagtgttgtt	300
agggaaacgtt tttcaatcaa aactgaccat gagataaagg aaagagatgt ggcttttgtt	360
atattctatc acaaacactt attgtatctc tgtaaaatatac aatgtatgtt tgcatgtttag	420
tgtttttgtt ctaatgttgc tactccatg gcaaagaaaa aaaaaagaat gaaaaaaaaa	480
aaaaaaatttggaaaaaaa tcaggctcat agcagctact gtgttagaaaa ttccccctac	540
ttctaaatttgc tgaatgtttaggaaaaaaa atcttttattt tggtatattt tcagagacat	600
ttgctcttagt atgggttattt taaataataa aaacttaaaa gaaaaaaaaaaa aaaa	654

&lt;210&gt; 17

&lt;211&gt; 974

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 17

ggcacgagcc agggcgcacc cgtcgccggaaaagctgag gggctggcgc gggggatttgg	60
tggcgacac ttttacgtct acacgtgcct acccgctctgc acgtttctga gtccgcacgg	120
ttgtcttc ttcgtgaatg gacatagggtt ttttgggggg tcccaagaga tacaggcaag	180
cagtacaggg gtgatggagt gctccttgc cttagcgaaa ctgaccctgg cactccctgt	240
aggtctcccc gctgcgaaga ctgagttcttc tcaactgcgtt ttctctccat ttacccggcc	300
tgtctacggc ccaaaccggcc atgctgttgc aaacctgc tggccgctaa gcaaggcttag	360
cccaggctgtt aaccatgtt tctagggtt gtttctctt gcagtcataat cagagattcg	420
gagttgttgc gatcttagag gtcaacatgc ccaaccttta agcccgagtg agtgaatgtt	480
cgcttttac ctgcacaccc cgaaaatcgc ccgtttctgtt gaaacaacgt tgattatgtt	540
gtccttggaaac tttccttgcat gcacattttta ttcccttgcac aatattttt gctacctact	600
gtgtgcagggc attgttagggcc ccggggatac gattttttttt aatgttgcataat gaaacgcaca	660
agatttttttttgc ttcgtggccgg ggcgggtggc tcacgcctgtt agtcccagca ctttggggagg	720
cgagggtgggg tggattgtttt gagggtcaggaa gttcgagacc agcctggccca accttagcga	780
accccccacccctc tactaaaaat aaaaaatttgc gccgggctt gttttttttt gctgttagtcc	840
cagctactcg ggaagctgag gcaggaaaat cacttgcacc ttggaaatgttgg aggttgcgtt	900
gagccaaatgc tccgccttgc ttcttagcctt ggcaacaaaaa tgagactctt ttcgtttttttt	960
aaaaaaaaaaa aaaa	974

&lt;210&gt; 18

&lt;211&gt; 472

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 18

ggcacgaggc gagggtcagt cggctctccg cacgtgtccg cggcctcgcc gaggcgttcc	60
---	----

ccccctggctg	gtttctgctt	ccacctgctg	atctcacaga	gcactgcaag	ctatggca	120
tatgaagtc	ttgacactgag	aaaaccatct	tggataactg	cagcaaggaa	aggaaaaat	180
gcaacaccta	ggagattca	gtaaacagta	gaatcatgcc	aacctaattct	gtgttaaat	240
gcttggaaatg	tgggagccgc	tgatgatgcc	tcttgcgtgt	gtgtctgact	gaatcccttc	300
ttttctcaga	gcagcaaagc	aaaggctggg	aaccaggcca	aatgcctgcc	acttacctta	360
aattgatcag	ccacttttag	attaaaaccc	ctgaaagctg	ccacaccgtg	aaaacaaggc	420
ctccttcaca	ttaaaggcaa	attgcgactt	tgaaaaaaaaa	aaaaaaaaaa	aa	472

<210> 19  
<211> 2596  
<212> DNA  
<213> Homo sapiens

<400> 19

aaaccctgga	gctccaccgc	ggtggcgccc	gctctagaac	tagtggattc	cccggtctgc	60
aggaaattcgg	cacgaggacc	gcccggctgc	tccgcctcc	ccgctccaag	cgccgatctg	120
ggcacccgccc	accagcatgg	acgctcgccg	cgtccgcag	aaagatctca	gagtaaagaa	180
gaacttaaag	aaattcagat	atgtgaagtt	gatttccatg	gaaacctctgt	catcctctga	240
tgacagttgt	gacagctttg	cttctgataa	ttttgcaaac	acgaggctgc	agtcaagttcg	300
ggaaggctgt	aggaccgcg	gcacagtgcag	gcactctgga	cctctcagggg	tggcgatgaa	360
gtttccagcg	cgagactacca	ggggagcaac	caacaaaaaa	gcagagtccc	gccagccctc	420
agagaattct	gtgactgatt	ccaaactccga	tccagaagat	gaaagtggaa	tgaatttttt	480
ggagaaaaagg	gctttaataa	taaagcaaaa	caaagcaatg	cttgcacaaac	tcatgtctga	540
attagaaaagc	ttccctggct	cgttccgtgg	aagacatccc	ctcccaggct	ccgactcaca	600
atcaaggaga	ccgcgaaggc	gtacattccc	gggtgttgc	tccaggagaa	accctgaacg	660
gagagcttgt	cctcttacca	ggtcaagggtc	ccggatccctc	gggtcccttg	acgctctacc	720
catggaggag	gaggaggaag	aggataagta	catgttggtg	agaaagagga	agaccgtgga	780
tggctacatg	aatgaagatg	acctgcccag	aagccgtcgc	tccagatcat	ccgtgaccct	840
tccgcataata	attcgcaggc	tgaagaaaat	tacagaggag	gagttggaga	acgtctgcag	900
caattctcga	gagaagatata	ataaccgttc	actggctct	acttgcatac	aatgcctgca	960
gaagactatt	gataccaaa	caaactgcag	aaaccagac	tgctgggccc	ttcgaggcca	1020
gttctgtgca	ccctgccttc	gaaaccgtta	tggtaagag	gtcaggatgc	ctctgctgga	1080
tccgaactgg	cattggccgc	cttgcgagg	aatctgcac	tgcaggttct	gccggcagcg	1140
agatggacgg	tgtgcactg	gggtcccttg	gtatggatcc	aaatatctatg	gctttggaa	1200
tgtgcatgcc	tacttggaaa	gctgaaacag	gaatttggaa	tgcaagcata	atatctggaa	1260
aatttgcgtc	ctgccttcta	cttctcaaat	ctttttgtt	aaagtttcca	atttttcac	1320
tgaaacactg	gttaaaaatc	tttatgtatca	gcctgtttca	taagaaactc	caatcaagtt	1380
aatcttagca	gacatgttt	tctggagcat	cacagaagtt	atattgttag	ttacactttg	1440
ccctcctgca	gtttcttctc	tgctcccaac	ccccatctca	tagcatcccc	ctctattttcc	1500
aatgctcc	tccaaaccgc	tagttctga	atttcttta	aattacagtt	ttatgaaagc	1560
atattttatt	tacttgggt	tggaaatagcc	ctcataaaac	ctaagactt	ggaaaacacaa	1620
taatagtatt	aactaactag	atctattggaa	tttcagagaa	gagccttcta	acttggttac	1680
acaaaaacga	gtatgattt	gcactcatac	tagttgaat	ttttatata	atcaaggcac	1740
aaaagtctta	aaaccatgt	gaaaaattag	gtattttat	cagattgtat	tctctcaatc	1800
ccatgtattg	cgcttatgtt	acaagttgtt	gtcacagtt	agacttaatt	cctcctaatt	1860
tcttctgc	gaagggttaag	tggtcgtcc	agcttacacg	atcataattc	aaaggttgg	1920
gggcaatgt	atacttaatt	aaaataatga	tggaaagat	atctggagat	tatgagtaag	1980
ctgattttgaa	ttttcagtt	aaaactttag	tataattgtt	gtttgcaaaag	tttattttcg	2040
ttcacatgt	aggatttgca	aataaattct	tggacaattt	tgtatggaaa	cttgatattt	2100
aaaactatgtc	tgtgggttctt	tgcaagttct	tgtaaatttt	taaaccaggc	acaaggttca	2160
agtttagatt	ttaagactt	ttataacaat	gataagtgc	tttttgagaa	tgtactttt	2220
agcagtttgt	taacctgaca	tctctgccag	tctagttct	gggcagggtt	cctgtgtcag	2280
tattccccc	cctctttgca	ttaatcaagg	tattttggtag	aggtggaaatc	taagtgtttt	2340
tatgtccaaat	ttacttgc	atgtaaacca	ttgctgtgcc	attcaatgtt	tatgtcataa	2400

ttggaccttg aatcgataag tgtaaataca gcttttgc tggatgttctt ttatataaaaa	2460
gtttatTTTA ataataaaaat gtttgttcta acttgtctgc tttttaaaaa ataatcttac	2520
tgtacttaat tctaattttt tcctcatatt taaataaaag gccatttcca cctttctaa	2580
aaaaaaaaaaa aaaaaaa .	2596

<210> 20  
<211> 924  
<212> DNA  
<213> *Homo sapiens*

<400> 20  
ggatttctat gcatttgtta atattcagtg atgttgagat ttgcattgtt gttacagggt 60  
ctctttcata tgggtgttt tggtgttat gtggaaattgt taaccactgc tgctatca 120  
tattgttagtt aaactgaaaaa actgtgttaa aaggctgtc cagtcacat ttctatgtt 180  
gacttaagta actgtgtact tcattgtta atatttttag ccagcaccta gtggcctcta 240  
cagaaggaaa tattgttagtt gtccaaagtgg tgccaaactt gaaaatctt gtcattgttt 300  
ataattccag gccaggctcg ctttcttca acactttccg agctttga aagcaaaaaa 360  
catttgcaaa aagagaaaaga aagcaagaat tctgaactt tctaatactc tctccctctag 420  
aattttaaat attttttct tttgtatgtt gagtatctt cagaaaaatc caatcaaatg 480  
actagcggta gaatttccct tgatctggat atttttaggc tgaacagtgt aatagcagag 540  
gactatgagg tgcatacatt atttttgtt gctatcatgg cttattgtt gaatttcatt 600  
taataacaat attcaggctg gaggtgtta ctcacacctg cattcccgac actttggag 660  
actgaggccg gcggtatcacc tgagatcagg agttcgaggc cagcctggcc aacatgacga 720  
agccccagtct ctactaaaaa tactaaattt gctgggtgtt gtggctcaca cctgtaatcc 780  
cagctacttg ggaggctgag gcaggagcat tgcttgagcc tgggaggtgg aggttgtagt 840  
gatctgagat cacactactg cactcccgac tgggtgagg agcaaggctc caacccccc 900  
aaaaaaaaaaa aaaaaaaaaact cgag 924

<210> 21  
<211> 807  
<212> DNA  
<213> *Homo sapiens*

```

<400> 21
ttttttttt ttttttttt ttttttttc acaaagattg aaaaaacttt aataaaagtt      60
aaatttacag acatcttaag ataacttggg aaatatgtag taaaaaagaa tcgagtccac 120
aaattaagaa tatttgcta atatgccaa caccatttc agcaaatcca atctacttaa 180
ctcatatatt taatgtggta attttctaa caaaatttaa tgggggtatg aatgatataat 240
ttatgccctt gacaaggatg acatgtgtga ttttgggtatg actaagaaag gagagttatg 300
tttctgggg ttatgatatc actctggctc atcgaagctc acagaatatg taagggtctg 360
ccacgtccaa agatgttagg caaatgtaat agaaggcgca ccgggctgac acacgttttc 420
atcatacaaa tcttctggca gttctcttc atctccatca gaaaaatatg taggaatgg 480
tagattttta ccgagatct tatatgcagg cagtttagaa tctttgacct ttactaagca 540
atttttatgt ccaggtacag agccatttc atagattatg ttgtgccttgc tgtttattct 600
ccacactttc ccattttcc aggcattttgc gttccaggcc agactctgcc aatatcacca 660
gttgcaacag ctccaggctc cctgtgggtt ttgcgttgc catgcgttagc aggctggct 720
ttaaatcccc atctttcat gacaccttgc aaacctttac caatagttt ggctgtgaca 780
tccacatact gtccctgtatc tcgtgcc 807

```

<210> 22  
<211> 2037  
<212> DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (22)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (28)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (68)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1974)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 22

gttcccgggt	caagaatggc	cnaaccttt	tacccagagg	agaty tacgg	taactgragt	60
ctgccccn	ga acac	ctytca	tatttggcac	ccacggatac	grraggtggg	120
cagggtgc	aa	tc atgg	tgtc	cagcgtgg	raggtggta	180
ggggcc	ctgc	tcaact	acat	tggccttc	acagtca	240
ctttctgt	tc	ccaag	ctgc	tggcgacc	gctggctccc	300
tgagcagg	ca	ccagg	ctgt	actggg	actgggcat	360
ggtc	ttct	ccgg	cttc	ccccc	ccac	420
ctgcccc	ccag	cttc	atcc	tccact	ctt	480
tcct	gt	ctgt	accgc	tggg	actct	540
aaatgtt	cc	tatc	atgt	caagg	ctccgc	600
tgacagac	gt	cat	cat	ccct	cat	660
gtgg	gtac	atgg	cttgc	tcc	ctacc	720
tggccac	gg	act	cttgc	gtac	ctgt	780
gact	ccgt	tc	ctgt	ccgt	actct	840
gat	cc	tc	ccgt	gtgg	tc	900
tttag	cc	cc	tc	gtgg	cc	960
cctcg	tc	tt	tc	cc	cc	1020
at	aa	ac	cc	cc	cc	1080
tctag	tt	cc	cc	cc	cc	1140
ccg	tc	tc	cc	cc	cc	1200
ggc	tc	tc	cc	cc	cc	1260
ggg	tc	tc	cc	cc	cc	1320
agg	gg	gg	cc	cc	cc	1380
cat	gt	tc	cc	cc	cc	1440
tac	tt	tc	cc	cc	cc	1500
agat	tc	tc	cc	cc	cc	1560
caagg	tc	tc	cc	cc	cc	1620
acat	gg	gg	cc	cc	cc	1680
gtaa	aa	at	cc	cc	cc	1740
tttct	tt	tc	cc	cc	cc	1800
tttct	tc	tc	cc	cc	cc	1860
ttccagg	cc	tc	cc	cc	cc	1920

acttcaagac taatgcataa tattaaacat catgttgaag aaataattt agtntcgtaa	1980
tttatacata gcagttctt tggacaggat atattctccc ttcccccaag gcaaata	2037

<210> 23  
<211> 1417  
<212> DNA  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (510)  
<223> n equals a,t,g, or c

<220>  
<221> SITE  
<222> (696)  
<223> n equals a,t,g, or c

<220>  
<221> SITE  
<222> (1363)  
<223> n equals a,t,g, or c

<220>  
<221> SITE  
<222> (1389)  
<223> n equals a,t,g, or c

<220>  
<221> SITE  
<222> (1394)  
<223> n equals a,t,g, or c

<220>  
<221> SITE  
<222> (1417)  
<223> n equals a,t,g, or c

<400> 23	
gggcacgagc ggctgtggtg gttcccgtag agtggataaa gaactggag aaatcaggaa	60
gaggcgaatt tttgcattt tgcggatcc tcagtaaaaaaa taaaaggccat gatagttcaa	120
catacagaga tttccagcaa gctctctatg agttgtcata tcattgtattt aaaggaaatc	180
taaaggcatga acaggcatct aatgttctta gtgacattag tgaatttcgtt gaggatatgc	240
cctccatttc tgctgtatgtt ttctgcataat tagacatttg gacaaattgtt tttagaagaaaa	300
aaaggcaagag agactatttt acacagttgg tattagcatg tttgtatttt gtttcagaca	360
cagttctaaa ggaacgcctg gatccagaaa cactggaaatc attagggtttt atcaaacaat	420
cacagcaattt caatcaaaaatg tcagttaaaa tcaagaaaaacttctttt aagcagcaaa	480
aattcaattt gttaaagagaa gagaatgaan gttatgccaa gctgattgtt gaaattggggc	540
aagattttatc tggaaagtattt actagtgtttaatctttaga aaatatcaaa tctttatag	600
gatgttttaa tctggatcc caataggatgtt gttggatgtt catttttagaa gtgtttgaat	660
gcagaccagt aatgtactttt ctgtctctgtt gattingccctt gttttggaca ttcatttttt	720
atggaaattttt gcaataattt gtggcctttt gtgtttggctt ttcactttagc atcatgttct	780
caaggctcat ccatgttggc gcatgttatca gtactgcattt cctttttatg gctaaatgtt	840
gtttcattttt atgagttgtt accacattttt atttatccat tcagcaattt atggacaggaa	900

acaatggc tttaagtatta aattgttaagt tcaacattaa atgtatycac agttatttgat	960
aatatcaaga ttatacatgg ttgtgaacaga atgctgtgc gaaatggtat gttaaatttatt	1020
tgtcaggcatt tcatgttaagt gattatttc taaggaccct tctagccctg gttttaagaa	1080
atatgtgaat gtatgtttt catcaataaaa gtttaatgca ttaagcatttta gctttaaaatt	1140
tgaatgaagg cagatgtgaa gatatttgcc acatgttgcataatcatgt tttgaaatatta	1200
tttcaatatg aagtatttga aaaatgtcaa tacataaagg aaaggaaatg agtataatttta	1260
agtcaatata tttttaaagc aatttttata atttagcaga cactgcattttaaatataagt	1320
tactattaaa attgtgtccct tggaaaaaaa aaaaaaaaaa aantcgaggg gggggcccggt	1380
acccaatnng ccgnataggg agtcgttattttcan	1417

<210> 24  
<211> 1837  
<212> DNA  
<213> *Homo sapiens*

<220>  
<221> SITE  
<222> (1697)  
<223> n equals a,t,g, or c

<400> 24  
aattgccata tacttctcac ccagtttctc ctaatgtta tatTTTatat aaccatggca 60  
catttatcaa aactagaagt gaatattagt aatgttacta ttaactatgg gctttattca 120  
gatttacca gtTTTCTgc tagtgtactt ttTcttatcc agggTccaat ctaaaatccc 180  
acattgcatt tagTTTGTgt gtTTTCTtT tctttatTTT tttttttt ttggtaatta 240  
agTTTTaa aaaggcata gactatAGGG atttcatTTT caagaataat atTTTcagca 300  
tatggccCTT tcctgatATG tctgactaat ggTTTCTaa aatgtatTTG cagagattGc 360  
cttgcaacAG gTTTCCatGT tttccgatC agaaccaAG tgggaggTgg tggAACCTT 420  
gaaagacata ggtgagacat tggcacgCTC attctgtta aaagacagat cacagaACTG 480  
gatcCTTtagt catgCTTCT gatacgTatC ccaggaacat gCTTAAATGC aggtgactTC 540  
tttttCTTT tgcatatcaa ctgCTTgagg atacagCTG taactTTaa tacttaatGA 600  
accttggta aagccccatC aaagcatTTG gatggtaata acTTTcagaa acaccattCC 660  
tttCTcatCT atCTTTCTa ctaaaatCTaa actgaaAGTGC tacttTCTG cTTTTCCTG 720  
gaataattTC ttCAtttAC gTTTCTTTT aagtataGCC ttTactatGC caacGTTatC 780  
aaatggTTCT ttTacttGtG CCTATGTAGC tgcgaataat attGCCaaAC ttaattttC 840  
ttgattacCT agtcaGtGAA acatATCaGT tggcaaaa attgtgcAGC tctaAGcaca 900  
tttttgcTTT tatggcaggT tgGagaataa ggaagaaata ttTCTTgatG aagattaaaa 960  
atcagccaaa ggaacCGGCTA gtgttaAGCT gggCTGacCT tggcccAGAC aagtattGTC 1020  
agataaaAGAT ttTCAGtGtC taatCAAact tctgcCTTCT tggTTGcACC ttCATACatCTA 1080  
tcgggTTacc ttTCCACAG CTAATGAACT ctcAGCGTTG ctaattAGGA tggTTAACGA 1140  
aaaggGAACA ttGAAGGATC tgatCTacAA ggcaAAACCA aaAGACCCAT ttCTAAAGAA 1200  
gtactgcaac CCTAAGAAGA ttCAGGGCCT ggaACTCCAG CAAATAAAA CATATGGACG 1260  
gcaaataTTA gaggtactGA agtttCTTCA tgacaAGGGA ttCCCTTATG ggcATCTCA 1320  
cgcCTCCAAT gtGATGCTG atGGGGACAC ttggcggCTG ctggacCTG agaattCCtt 1380  
atTgggCCTG CCTTCCttCT accgatCTTA ttTTTcacaA ttCAGGAAAA tcaataCATT 1440  
ggaaAGTGTG gatgtccact gCTTGGCCA CTTACTGTat gaaATGACTT atggacgacc 1500  
gccagactCG gtgcCTGTGG acTCCttCCC tccTgCCCCG tccatGGCTG tggTggCCGt 1560  
gttggagTCT acgCTGTCTT gtGAAGGCTG taaaATGGC atgcCTACCA tctCCCGGCT 1620  
cttacAGatG ccattattCA gCGatGTTT actaaccACT tctGAAAAC cAcAGTTaa 1680  
gatCCCTACA aagtanaAG aggCATTGAG aattGCCAAA gaatgtatAG agaAGAGACT 1740  
aatttgaggAA cagAAACAGA ttCACCAgCA tcgaAGACTG acaAGAGCTC agtcccacca 1800  
tggatCTGAG gaggAAAGAA aaaaaaaaaa aaaaaaaaaa 1837

<210> 25  
<211> 493  
<212> DNA  
<213> Homo sapiens

<400> 25  
ggcacgagct gaccctttt cctcatctgt ctaatcccc aacttaggga aataaatggt 60  
tcctggccctc ttgatctcag ttcagactgc aaactcttag gggcaagggt agctacatat 120  
caggctatgg gtttgggtgt agaatgggt tgataactgtg gtgttctctg aggatgggga 180  
tcccagccaa tgccatctgg catagtgtg tacacaggtg agtttggtaa ggaagatttg 240  
gggaagatgc ctggagtc ttgaatggca actcctgtg atggagtaat ctatctgtct 300  
ctcttccag gtggatggga agagagtccc aaggatgca gggcatcctc tgtacccctt 360  
taatgaccgg tactgagacc acagcttctt ggccctccctt ccagctctgc agctaattgag 420  
gtcctgcccc aacggaaaga gggaggttaat aaagccattt gggatccaa aaaaaaaaaaaa 480  
aaaaaaaaaaa aaa 493

<210> 26  
<211> 460  
<212> DNA  
<213> Homo sapiens

<400> 26  
ggcacgagcc agccttcagt ccctggggcc cgagggctg gccagggctg tgccgggcac 60  
tgggagccac tcacttgagg tggccagca tcatgcagct ggccagcagg gtggccgtgg 120  
ggttggcgat gttcttattt gcgatactct tgccgggttt cctcgtagcc tggggaggca 180  
agacgaagga gagtgggtgg agggcagaag gatgccgggc agtgaactctg ctccctgtgac 240  
acgtccagaa gaagccactc cacagggaca aaagcccaacc agccgggtgc aggggttggg 300  
ggaaggtgtg gggacagata gtttatggg acaggcttc ctctgggtt ggtaaaaatg 360  
ttctggaatg acctgggtgt gacggcagta caaccctgga tatccaaaaa actactaaat 420  
catgcattt gaacgggcta aaaaaaaaaa aaaaaaaaaa 460

<210> 27  
<211> 1369  
<212> DNA  
<213> Homo sapiens

<400> 27  
ggcacgaggt ttttgtaac aaagtagcca tcattataga atattaataa atggattatt 60  
aatatgatgt tttcaaaagg acttgatata aaaattaagg gtaataact tggaaaaaaa 120  
ttttttta aattatagca gtatctata tatccaaata tctattggtt gagccatcca 180  
atagatgagt gacgcttagc tttttatgt aaatggctt cctaacaatg agaatactct 240  
ttttgctta ttcatattgt aaaaaacatt tttatgaa aatatctgag catggtcatt 300  
aacgtggcca ctgcaacaca tattgggtgg agtataaatt aatccagtgt ttctacaagg 360  
caatgtgaca gtatcatgt ttaattcagt catttcattt ctaggaatta tccataaggaa 420  
atagttataa aagacacaca atgatttatg ggcattggctt tgcatttcag tgacattttgt 480  
ataataaaaa agttagaaac aaacgaaata ggtttttttt ttaggtatg cccaaatgaa 540  
gacatattct cctatcagt gtaattaata cttttttttt attgtccaaa ctttttgcaa 600  
tggaaattcc tgctttata cccaaagaatg atgtattttt tttttactcg ggaggctgag 660  
gcaggagaat ggcgtgaacc tgggaggtgg agcttgcagt gagccgagat cgtgccactg 720  
cactccagcc tggcgaaag agcaagactc catctcaaaa aagaagaat aaaaaaagaat 780  
atgtattttt ttcaaaagca ctactgaaac ttactaaatc aaccctcaac aagtcatcaa 840  
ctttgaatat tttaatgaaat tgcccacaac aggcttgcaa atagttctt ggcaggtag 900  
gtataataa tggtaattaa gacgattgtt ttagcctggc ttagtggcat gcacctgttag 960

tcctagctac tcaggaggct gaggcaagaa aaaaaaattt gctggctgca ctgtat	1020
ttatgttct ttcttacta ccgattctaa catcaaaaaca gatgcacca gctgggcaca	1080
gtggctcaca cctgtatcc cagcactttg ggaagctaag gcaggtggat cacctgaggt	1140
caggagttt aaaccagcct ggctaaacttg gtgaaacccc atctctacta aaaatacaca	1200
aattagtca ggcgtggc aggccctgt aatttcagct acttaggagg ctgaggcagg	1260
agaatcactt gaacctggga gggaaagggtt cagtaagcc agatcgctc actgcctcc	1320
agcctaggca acaagagcaa cactccatct caaaaaaaaaa aaaaaaaaaa	1369

&lt;210&gt; 28

&lt;211&gt; 1556

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 28

ggcacgagtg aagctccgcg gtgcctgatg gggccgttgg gggcccggt a gctgttgctg	60
ttgggggacc cccttcatcc tgcgcgtgcc gtcctgtctg cctcatggcg gccatcgagg	120
ttcacctggg ctgcacccctea gcctgtgtgg ccgtctataa ggtatggccgg gctgggtgtgg	180
ttgcaaatga tgccgggtgac cgagttactc cagctgttgt tgcttactca gaaaatgaag	240
agattgttgg attggcagca aaacaaagta gaataagaaa tatttcaaat acagtaatga	300
aagtaaagca gatccctggc agaagctcca gtgatccaca agtcagaaaa tacatcgccg	360
aaagtaaatg ttttagtcatt gaaaaaatg gggaaattaag atatgaaata gataactggag	420
aagaaacaaa atttgttaac ccagaagatg ttgcagact gatatttagt aaaatgaaag	480
aaacggcaca ttctgtattt ggctcagatg caaatgatgt agttattact gtcccgttt	540
attttggaga aaagaaaaaa aatgctctt gatccctcaaa acatgatgtg agagggaaatg	600
cgcgagccat gatgaaatta acgaacagtgc tgaagtagc gaaacattct ttgtcaacct	660
tgggaagtgc caactgtttt cttagctcat tatatgaaagg tcaagatttt gattgcaatg	720
tgtccagagc aagatttgaa ctctttgtt ctccactttt taataagtgt atagaagcaa	780
tcagaggact cttagatcaa aatggattt cagcagatga tatcaacaag gttgtcctt	840
gtggaggggtc ttctcgaaatc ccaaagctac agcaactgtat taaagatctt ttcccagctg	900
ttgagcttct caattctatc cctcctgtatc aagtgtatccc tatttggtgc gctatagaag	960
caggaattct tatttggaaa gaaaaacctgt tgggtggaga ctctcttatg atagagtgtt	1020
cagccagaga tatttttagtt aagggtgtgg acgaatcagg agcccagtag attcacagtg	1080
ctgtttccat cagggactcc ttgcagct cgaagacaac acacattgca agcccgttgg	1140
agcatatctt cagtgtgcct tgaactctat gaggctgtatc ggaagaactc tgccaaagag	1200
gaaaccaagt ttgcacaggt tggactccag gatttagata aaaaagaaaa tggattacgt	1260
gatataatttgc tggatcttac tatgaaaagg gatggatctt tacatgtgac atgcacagat	1320
caagaaactg gaaaatgtga agcaatctt attgagatag catcttagt ttttagagaa	1380
atcaagaatt tttaaaaaca agaatatcaa catttggttt tggatataag tggatgttt	1440
attaaaatac ttttcaatg aactgtataa actatgtttt attaaactac aatataatcag	1500
aaaaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaa	1556

&lt;210&gt; 29

&lt;211&gt; 1259

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 29

aggattcggc cgagcttct tggatattgtt catttgtata tctctccgtt gaattgccta	60
tatataatttc atggccattt tctcatttggg atttctttttt ttcttaccag tttcttagaaa	120
tgcattgtttt attcctcttc ccaactggc atcaagtgtt tcttcttgc tttttctca	180
taaatttagaa tggatctt tcaattttat taatttccct tttttcttaa gtacattaaa	240
aaaggtacaa cagtggaaattt ctcatttgc tttgtcactc tggatgtttt tggatgtgt	300
atcaggattt tggggaaat aactggatat ttcatacagc aagcaataaa ttcaagcat	360

gggaagttaa catagagggtg gtatgtggga tgcataaaat cgttagtcgt aagttaacaa	420
tgagggaaat aattaaattt cactcagygt ttacaaaacat tggaaaacat tctgacctga	480
tgggtctgtat ttctttgtt ggaatttgtt tgcgttta aggataatgt gaattactgt	540
gtgtgttagta taattagaat ataccacagt atctaaaaat tgtttagcat atactttaat	600
cagttggatc tgcttcaccc tcttctcccc atgaagaaaa ttatatgtta agtgctata	660
ccatatctac ttatcttcag taactatatt tagccttagc attacaccag ccttacagcc	720
ttatttcattc atttagttc taaacattaa aatcttaaat actttttgtt taaatttagtt	780
attattttgt ttttattttt ttttaatttc atttttttt tttatcttc tggttaccaa	840
gttttagtga gttaaatggc tgtagagata ttggaaagggg gtctgttga ggatgaatgg	900
taggaatttt acatttgatg ttgtcttatt ttaatgagtc aatacagaaaa gtacttcaga	960
gtatTTATGA aaagtgtaaa tctaattgtt catgagaatg tggctaggac ttatgggtt	1020
taaatttc ttcattctaaa ttatgaagat caatttatgtt gtaatctta ccattaagaa	1080
catgcttatt gataaatcta aatctctatt ttagagcaat atactttgt gcttattcaa	1140
actgcaagga aaagtgtaaat gatgttattt atcctgatc tacccaagta catatgat	1200
cagctgcaat ggcaggatg aatgtataat attaaaaaaaaaaa aaactcgag	1259

&lt;210&gt; 30

&lt;211&gt; 1603

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 30

ggcacgagcg gcacgagcg ctttctccc ccagccttag tgactactct attccttgg	60
ccctgtatt gtcggggacg attgcatgg ctacgccagg aaagttaggct gggtgaccgc	120
aggcctgggtt attggggctg gcccctgcta ttgcatttat agactgacta gggaaagaaa	180
acagaacaag gaaaaatgg ctgagggtgg atctggggat gtggatgatg ctggggactg	240
ttctggggcc aggtataatg actggctctga tgatgatgat gacagcaatg agagcaagag	300
tatagatgg tacccacctt gggctcgat tggactgaa gctggAACCA gagctaggc	360
cagggcaagg gcccaggctt cccgggcacg tcgggctgtc cagaaacggg ctccccccaa	420
ttcagatgat accgtttgtt cccctcaaga gctacaaaag gttctttgtc tggtttagat	480
gtctgaaaaag ctttatattt ttgaagcagc tttattgtc ctggtaaca atgctctta	540
tgcatttaac agagatatta ttctgtatct ggggttctc ccaattgtcg caaagattct	600
caatactcg gatcccatag ttaaggaaaa ggcttaattt gtcctgaata acttgagtgt	660
gaatgtctgaa aatcagcgca ggcttaaagt atacatgat caagtgtgt atgacacaat	720
cacttctcgc ttgaactcat ctgtcagct tgctggactg agattgttca caaatatgac	780
tgttactaat gagtacccgc acatgttgc taattccatt tctgactttt ttctgttatt	840
ttcagcggga aatgaagaaa ccaaacttca ggttctgaaa ctccctttga atttggctga	900
aaatccaggc atgacttaggg aactgcttag ggcggcaatg ccatcttcac tggctccct	960
ctttaataag aaggagaaca aagaagttat tcttaaaactt ctggctatatt ttgagaacat	1020
aaatgataat ttcaaatggg aaaaaatga acctactca aatcaattcg .gtgaagggttc	1080
actttttttt tttttaaaag aatttcaagt gtgtgtat gaaatgttgg gaatagaaaag	1140
tcaccatgt tttttgttga aagttaaagt tggaaaattt atggccaaac ttgttgaaca	1200
tatgttccca aagagccagg aataaacacct tgatttgttta atttagaagc aacacacatt	1260
gtaaaactatt cattttctcc accttggta tatggtaaag gaatccttc agctgccagt	1320
tttgaataat gaatattcata ttgttcatc aatgttgcata tttaactgag ttgttcttta	1380
ggtttaagat ggataaatga atacactac ttgttctgaa aacatgtttt tgctttta	1440
tctcgctgcc tagattgaaa tttttgttca ttcttctgc ataagtgcata gtgaaccaat	1500
tcatcatgag taagctccct tctgtcattt tcattgttta aatttggatg tcatcaataa	1560
aatttggatgta taatgttggaa aaaaaaaaaaaa aaa	1603

&lt;210&gt; 31

&lt;211&gt; 1359

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (808)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 31

ggcacgagcc	gaggctggca	ctggcacaac	tacctgagga	tggctcgca	ggcagtccc	60
agctgctgt	ggctctgtcc	tggcttgg	cccgaggacc	tgtccccgag	cagatgctgg	120
cccaggcccc	agtgcctctg	ggtgacgaga	tgactgtgt	ccagtgtgag	gcctggcca	180
gccctggccc	acctgcaccc	cacatgaaag	cagagggtcc	tgtggatgtc	cgccatgtgc	240
agtggctgt	gggaaagctg	cggttccgg	ggcgcacgt	gtgtccagt	cagcaggagc	300
agtgcgcctt	cctgagcaag	atccacctgt	acacacgccc	ctgcccacage	gaccagagcc	360
ttagccatct	gtctgtca	gaagcagaga	tgctcagggg	accagagg	aggccagcag	420
ctgctgcggg	actctggagc	gtgagaacca	gegcctggag	gtgtcttgg	cgtggcggcg	480
ctctgagct	gtcttcggc	ggtggatgga	cacggtccct	ggcacctgt	ccccggaggt	540
gcctgctgca	gcctcacage	ccacccccc	gcctgggtc	cccgagcgc	gggtggcga	600
gttggacctg	gtatgcggg	agctgcagc	actggaggag	gagctgcgg	aggctgcgg	660
gcmcaggcgg	gccccctggg	aggccaaggc	tggaggctgt	ggacgggggc	cagagtggag	720
tgcgcggcgg	cgggcctctc	gggaggctgt	ggaaaaggag	ctggagact	tacagcagt	780
ctgggagcga	gacggtgccc	cggcccancc	ccatggggca	cacggctgg	tgagacgaaa	840
ggatggggca	gcaggggacc	gggacctg	ggcagctgt	gtatcagga	cgctgaggag	900
ccaggaggcc	tgcctggagg	cggtgtac	tgcactacag	ggacagtgtc	ggcaggaaact	960
ggccaggctg	gtgggagccc	gcctggct	catctggatc	ccgcccac	gacgctgagg	1020
gcctgtcgac	ggggccctcg	gtgggaagcc	tgcctggcc	cagcctgg	gggtcttgg	1080
ggagcagatt	ccaaggccag	gtggcccg	gacgatgca	gatgcagagc	ccacgtcaca	1140
tgctcgctcc	aggggtgggg	ctggctgac	tctggccgga	tcccaggc	gtggctagca	1200
gcactgggg	caggaatggc	tggccctt	aggaggtcg	gacaggtca	gcctgggtgg	1260
ctggaggggg	ctcgaaata	aattgttagca	gttttctgc	aaaaaaaaaa	aaaaaaaaaa	1320
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	1359

&lt;210&gt; 32

&lt;211&gt; 1490

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 32

ggcacgagtg	gactcgagca	aagatgac	cactggag	ggactttctt	ctcttgctc	60
ctggcagtgt	tcccactgt	gccggtt	gtcgaa	cagacatctc	tctagtgtat	120
ggtgcaggct	tgctgttct	tctgttatcc	ctgtgtgtt	taacatctt	cataaaaaga	180
aaagatagct	ttataaagga	agagctatt	gtacatct	tacaggtgt	gagcacagt	240
ctctccatgt	atgttgtgt	tagcact	agtagtct	tcaagaa	aggactgcct	300
ctcatgaatc	aaatttatt	ctggcaaca	ttagcctt	ccttgg	gttgcact	360
atgtctccag	ttctcttca	gcgattgtt	agcatact	tttatt	gtcaac	420
ctacttctaa	gcacagg	tgaagct	tttccact	tgttgtt	tttgcattt	480
gtctggataa	acatagaaca	agaaact	cta	caacaat	gtgttgt	540
ctcacca	tccagg	ttataaact	gatataact	atgttgc	ata	600
tgccctgtc	tattgtt	tgactgt	cagtcc	tttgcattt	atgtgg	660
gtggaa	ttatccc	tttgtt	tatgtgt	tttgc	ttcagtt	720
tactcag	tgtcaaaaa	gcctttt	cattgtt	gtcata	atattat	780
tttgcattt	ttcttctt	tcaagg	tggcag	tttgcattt	ggacaag	840
cagccactat	gtgattgtca	tgtccat	catttttt	gtgttct	atgggt	900
cccagctgt	cacaacgaa	aaactcag	tatgtgg	caa	acccaaa	960

gaggttgctg aagcaccatt cagcatctgg atccctgatc tcctttaag ctaaaatctc	1020
atcaaggcgtt caataagaag atggatatgg atatatagta tattctactc ctgttaaggaa	1080
aatggtatcc ggaattccga attgacaggt tatctggaa acaggagctt cttttttttt	1140
ctagggtttt caggcatgaa atagtgatta tatctgtggaa aagcataagg aaggcattct	1200
cctttttcat ttttttcctt tgctggcag ctcttcccag tgatgttag agcacctgca	1260
gcaatctgtt ccccaagtgc acaacttccc acatacccg aggagagcat atgcctgtgg	1320
gggcagtgtt gatggcatcc agagtcatgg ctgtggctga gctggaaagg aatcaccagg	1380
tgcaccgcgtt aatattttatc agctttcagc actgggtttt ttagacagtc agggtgttatt	1440
atttcaagag cttcaataaaa aaaagtgtttt gcaaaaaaaaaaaaaaaa	1490

<210> 33  
<211> 522  
<212> DNA  
<213> Homo sapiens.

<400> 33	
aaaatataaaa aataaaaatgc acgtcttcca ttcttccccca ctgcctgtgt atagtggagg	60
ttgggtgctca ctcttggtcc ttctgagctt agcagaaaaga actatggcgtt gttctacctg	120
aaaaggggaga actcacatgg gcaggaaaaga gcattgtggc aacaaggag aggtcctcac	180
tctgctcgcc tcttagaagc cacagggggc ttgatatcag ctcagtcac aagaagtctt	240
tccttccact gcttggtt gatTTTaaat ttttaatgtt aaagcatatt gcttgagcca	300
gggaatttga gaccagcctg ggcaacatgg tgagactcag tctccacaaa aaatacaca	360
aattagccgg gcgttttggc atctgcctgtt agtcccaact acttaaggcgtt ctgagggtggg	420
aggatcgctt gagcccccagg aggtcgaggc agctgtgagc tgagctgaga tcacaccact	480
gcactccagc ctgggagtgc aaaaaaaaaaaaaaaa aa	522

<210> 34  
<211> 930  
<212> DNA  
<213> Homo sapiens

<400> 34	
ggcacgagct ctatctggaa tagatgtt gagggtgc aaaaatagcat ctcatggaa	60
aaacaggggac aaatttgtgg atgcaagattt ccagccctta gaagtcttgc gcatatgtaaa	120
tgttttaactt aataaattttt ctatgcctta gtaatggat ttctgtctt ttggaaata	180
tatgcattta ttatttctgc ttctgtgtt cacatgcaaa taatacagaa aggagcaaga	240
tggacaaaga tcttgcgttc ctacaattt catctaattt gaggagacat cccacatata	300
acctaagttt taaaacaaa tgatgtt taaatgtttaatgtttaatgtt cgattgcact	360
gctttttgtt gcaccgcgtt agattcaata ttgcattttt tggttgcatt tggttgcatt	420
agacaggcat ttgaggagt aaatgtatgtt ggttgcatt aaggatgtt cacagaattt	480
cccttctttt taaaattttt cttttgcgtt gatTTTgcata ttctgtctt ctgactggca	540
tgtacagatc gggagccctt tctatTTTctt ctgattgcatt tagatttttctt gtatcaaaac	600
ttgaacagat ttgcgttgc gtttagtact ttatgtaca acctactgtt ctggagatc	660
tctgtatgtt aaattggact aagtttagatt atgttaatct aggcctttt gagttgtct	720
atctttttttt ttgcgttgcatt cacagcgtca aatgtttatc acctcttgcata aagaaggatt	780
agtgcatttcaaa ttaatccaga agatgtact ttccctggta agtataataa actctctttt	840
tctctggcactt agcatttgcata ctggaaattt acttaattttt tttggaccctt aaggagtaca	900
aggaaataact tcaaaaaaaaaaaaaaaa	930

<210> 35  
<211> 1448  
<212> DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 35

gaattcggca cgagttcagt aagaataatg	ttttggctt tcacatatac tcagtttaag	60
tgcttagtat taataacaag ccatgaaggg	aataaattcc tcttcactga gacatagact	120
tkgaaataaa agacattta actgtatgtc	acaattatca atcttagtggta taagatggat	180
ttaaaaaggaa gaacaaaatg ttcccagtag	ttttactgt ctgtgtttt attactatct	240
atgggcatacg tgggaagcat cattgagact	tttagggaaac tataaaagtt ggaagggtgg	300
tggcatcagg ggttggatgc tgggtctcaa	gttcctagct ctgcccccttg tttagtcattt	360
gagtttaata attaatggga atatctactt	cacaggatttg tgaggaatcc taaggggtgt	420
aatccatatac aaacttttag aaaccagttg	tttttattacc tgggaaaggt aakraaggc	480
cagactttt atactactgt tagtatttaa	atttgggata gtctggatgc cacctaatac	540
agttactatg aaattaacaa ggttaactaag	gaagttgata gtaccaggat tatcttattgc	600
tatgtcctaa attaccatag atttagtggc	ttaaaacaaa tgcgtctcag tttctgtctg	660
arcatggtt arataggc tttagaaagc	tcatggtctc atctgcattc tcacctgggt	720
atttgggaag aactcatttc agcctcaactc	ggctggcaga attcagttct tgccactgca	780
ggactgarty tccagaccc tcactgggt	tcagytggag gccccccctt agttcccttgc	840
cagctgggtg ctccctgcattt ggctctggctg	ctgactggac cactgacatg attactgtca	900
ctaccagcaa gtgtcgagag ccaagctgcc	agcaagagggt gtctttcag gtccctgccc	960
tatccaaggg gagaggtctca tacgaaggat	tggataccaa gargetgggg tggggctaat	1020
gggaaggcac ctaragtttgc acagcttt	tttttttaa ctgaatctct ttaaattgggt	1080
cgtctcsccc tacaatgcaaa atgtttgtt	tacaagtaaa aagaaaaatg gctctcacaa	1140
tatgaaaaac cctggctggg cactgtggct	tatataaacc tptaatccca gcactttggg	1200
argcccargc gggtggatcc cttagggtca	ggagttcaag tccaaccagg ccaacatgg	1260
gaaacaccgt ctttactaaa aaaaaaaaaa	ttagccaggc atggtggcat gcccctgtgk	1320
tcccagccac tcgagagatt gaggcaggag	aattgcttga acctgggagg tagaggttgc	1380
agttagtgc gttggccac tgcactccag	tctgggtgac agagtaagac tccacccatcca	1440
aaaaaaaaaa		1448

&lt;210&gt; 36

&lt;211&gt; 2191

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 36

ggggtccgac cccacgcgg	ccgcgtgact ttccatttcc cccgaattga agagcaatta	60
gaagttgtcc aacaggttgt	actttatgtc agaaccgcgc gcaaggatcaa attgaaagaa	120
tcaacttgatt ctggaaacca	aaatggagga aatgtatgtata agactaagaa tgctgagagg	180
aactatttaa atgttttacc	tgggaaattt tatattacac ggcattctaa tctctcagaa	240
atccatgttt cttccatct	ctgtgtggat gaccatgtga aatcgggaaa catcaactgt	300
cgtgtcctg ccattatggg	actccgaaat atactcaaaat tttgctgtac ccatgacatc	360
acaacaataa gcattccctt	cttgctggta catgatatgt cagagggaaat gactataccc	420
tggtgcttaa ggagagccga	acttgtgttc aagtgtgtca aaggtttcat gatggaaatg	480
gtttcatggg atggagaaat	ttctaggaca gtgcaatttc tagtaccaca gagtatttct	540
gaagaaatgt ttatcaact	tagtaacatg cttcccccaga tcttccgagt atcatcaaca	600
ctcaactctg	catccaagca ctaaacccctt atagattgac atgctggcag aagatgattg	660
ttaaaactctc	caggaacctt tgctatgtc ggaatctgtc aagcaaaaaga tgcccagaaa	720
gagaacttgc	agctcaatcc acaaatacag atacatgtgt gtgaaaccat tccaaaaatt	780
tatatactgc	acaaaacttgtt gatcaacccc taacttaaac acttaaaatgc tctttatgaa	840
tttctctttt	tttctctct gtgttacgtg tgaatattag taatctaaaa ctttttat	900
atcacacatg	gacacttggg aaaggaaact tgattatatt tacatggagg catttgactt	960
tttcaagagg	cttgacttgt ctcaagggtca atcctaattt aaacatacaa acaaaatttt	1020
ccttttactt	tctttgccaa acaaaatgt aaaagactg aaatatacat tgcaagtaca	1080
aatttcctgt	gaaaatcttt ttatagaaac acmaatgtat aagacmaatg tgctkgtyct	1140

tttaaattct cctgkttcag aatcttttt taatctactc ctaaggatgt acaagttaga	1200
gtcagaagac gtttggatt tttccctct ctctcatct cccgctgtgc ccttcactt	1260
gcatattaat aacatttcat ggactggaa atagtgttct ttttgcag cttgatgtca	1320
agttagtcta aaccaggacc tggcagttt ttagtgctca tcaacattgt gacaatcaca	1380
caaggaagat catttttaca ttctgtctt ccctcggttc tcagcttgc taaccattcc	1440
tctacctttt gcattttttt gcccataat gtatccccat ttctgttct ctgtttcccc	1500
tcctttcca ttgttttcc ttatggact actttctcag gtgcatacata tcataatattt	1560
gtcccatcta taacatattt aaatgtctaa agtagtaact ccattaaaca aaggcattta	1620
caaaggcaca cagggttttta gaaaagcaat agtttcatca attccaaatgtt atgtggat	1680
tgttaactggc cacaagaatg aaatggggg cattttgggt cataagatgg catgtcttga	1740
tgacaagaaa caaaacgccc ttcatataa tgcctcagtg taataactat tatagaaaact	1800
gttggcaagc agagtgtttt cctataacag aatgtgttctt aattttctac tcgagggaaa	1860
ggtttgcctca ggtaacaaca ctaaagacaa ccctaagaac acccactcca gcagtatgtc	1920
cattagacac taaaactctc caaattttt gtcagggagc ctggcgattc tgccaagaag	1980
gcaggtgtt tgcccttaga gcctatacag ttcttttggaa gaaattgttct ttccaggcacc	2040
actgttaatc actgagactg attctaatgc aaagcaggaa agacagaggt gacaaaggaa	2100
gagttggcga gcagcattca acaaacatcc gtgaatgaaa ctttgcctt ccattccgat	2160
atctgggctg cactgatctc gtgccgattt c	2191

<210> 37  
<211> 1589  
<212> DNA  
<213> Homo sapiens

<400> 37	
ggcacgagaa gaccttgtat ttatagacc cgttataacta gtatttttat cttacttgat	60
gaaatctttt aggccctcta aatttccatc attaaattaa aaactggat tacaggcgtg	120
aaccaccgcg cccggccgc acgttattttt catabaggtt ttccctttgt tctgggattt	180
ttagccttca tacatttttta ctgttaggc tttccctttt cagatgtgg tgataatagt	240
aaaaaaaaattt ttatttgat tattaaggaa gtccactacc ttgtgtcaga ttccctgttt	300
cttttgaag cccttggaaat gaagttttagg gaccactgtat cttagaattctt cttatgtctc	360
ctccactacc cattaacccc actctatagt ctgcctttc gctttttctt ctctccctt	420
ctaamcaccc cgtagamcac tttttttctt gttcatgatt gacccatcaaa ttgccaatac	480
cttggycctt ataamccgtm ttttttttttcaac caacactctg ttgttaacaa atccctcaaa	540
actgttttttctt ttgcctccg ctctgtttt cctgtcatcc acttatactt ttcttcata	600
tgtttttctt cttttttcc cagtttttat tatgtgggg tctgggtctt tttttatgtt	660
tcactgtata ttcaaatca gattttttagc taccatgtac catcttaata atacctagca	720
tttattttact ctttccataat ttttttttca gtttttttttca gtttttttttca gtttttttttca	780
cattcgtat tcatttaattt ctcaaaaacaa ctcaatgttggg ttgatatacagg tataattttt	840
gtttttttttt ttttttttttca gtttttttttca gtttttttttca gtttttttttca gtttttttttca	900
caacttaggg gcaatgttggg ttttttttttca gtttttttttca gtttttttttca gtttttttttca	960
aaccactact agattttttgg ctttttttttca gtttttttttca gtttttttttca gtttttttttca	1020
ttctacccatcc aattcaataac atccatttccatcc ttttttttttca gtttttttttca gtttttttttca	1080
aaaaacacac ttgctcatcc ttatttttttca gtttttttttca gtttttttttca gtttttttttca	1140
tgcgtatcatcc ttttttttttca gtttttttttca gtttttttttca gtttttttttca gtttttttttca	1200
attccatccatcc ttttttttttca gtttttttttca gtttttttttca gtttttttttca gtttttttttca	1260
aatgtatgtat gagacacaga ctttttttttca gtttttttttca gtttttttttca gtttttttttca	1320
tttttttttca gtttttttttca gtttttttttca gtttttttttca gtttttttttca gtttttttttca	1380
ttactgttagc ctttttttttca gtttttttttca gtttttttttca gtttttttttca gtttttttttca	1440
tgggactaca gacatggact atccatccatcc ttttttttttca gtttttttttca gtttttttttca	1500
tcagtttttttca gtttttttttca gtttttttttca gtttttttttca gtttttttttca gtttttttttca	1560
aaagaaaaaaa aaaaaaaaaaa aaactcgag	1589

<210> 38  
 <211> 831  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (53)  
 <223> n equals a,t,g, or c

<400> 38

gggaaaccaa aagcttggag gttccaaccg ggggtggcgg ccggttctag aantagtgga	60
tccccccggg gttgcaggaa ttccgcacrr tgagggtag caagaagaag actggaaatg	120
ccatccctct gtcaccaatc cacagtgggt ttggggagga ggcattggca acatccactg	180
ggctgcacag acagtttat tactacccc cctggctcc gccttctggg gcctgcagc	240
ccatgaatta atcccttcc aggctagcct ggggtacate catccccctt ggctcctaac	300
ccatggagtc aagcctcggg cacatttctc ctaccagcct ggtttggcc atatctatgt	360
aatgcttttg ctttcattta ctttagttgc tcccttaaac aggctcacat tttaaacata	420
acctctgcct cctaagcaaa tacttatatt cataaattac tcccacctga accaccacca	480
ctgccaccac ccacaggatt cctgggcttc cttgcagcat agataaaagc tttttggc	540
atccacttac caggcactgg gtgggagcag gcagcaggc acatccccc tccttggaaag	600
caatatttac tcagcaattc tccactcagc agtgtaaatc actgtggctt cccagcaggc	660
atatgatctc tgcctggtcg ggtttctctc cttttccat gactgaatct gaagctcaag	720
cccccttccc cacagcctct cccacatag cctggaaact gaggtctggc tcattttca	780
gggagctcca tgctccctg gtaaggtaaa aaaaaaaaaa aaaaaactcga g	831

<210> 39  
 <211> 784  
 <212> DNA  
 <213> Homo sapiens

<400> 39

ggcacagcag aagtattaac ttgttcaaat cgtacaaccca aggctcaagt ccatgattgc	60
ccaactccaa agcccatgtt ctttctacct tattatgttg gcattttttt caatgtcagt	120
ttggacccat ataaaaacgc ccagctgtac cctatgagga ggatataaaa atgtgagatg	180
gtagttgaca ctcggaggac attcatatct ccaaacccaa ctttatgaag ttggccacag	240
caagcatgtt ggaaactaga accaggggtt tcatatcaag ccatttgc tt aggtctgtat	300
ctcaaaagct taaaatacaa cttttttgg tgcccttgg ataaggagtc ttatactgag	360
ctcttcttcy ctttwatagc tggccaycr gaaagattaa attaaacgtt tggccacatg	420
gacagttaat ccttagatca cccagttgg tggttcattc ctgetatgtt tggttgatt	480
ttyatttt ggaaaacaaa tagtgagtca gtctgcttc cttcccttc tctgcctcac	540
cactccttcy ggattctctt agatgtctg gtcatactag gtaaaacagta tttttcttaa	600
aattttcctt gaggccatgac agaatcatga gagagctccc ctggctctga tacttaatgc	660
ccccctctaa aaagaaggt ctatttgagg ctattcactt ttgtcatctt gaaagagtct	720
ctgagtctta cctagcagga atattttgtt tctttcccta aaaaaaaaaa aaaaaaaaaact	780
cgag	784

<210> 40  
 <211> 1178  
 <212> DNA  
 <213> Homo sapiens

<400> 40

ggcacgagcg	gtggattcct	gaggcattcaa	tacacatgag	gactccaaag	ttcaaaactgg	60
cccacttagg	attctgggtc	tcacagtcca	cacagtggc	gttcccacgc	atgttttggaa	120
tcgactgcag	ggccatggcc	tcgctctggc	tggtcagctg	ggacttgctt	ttactgctct	180
cgcatgactg	caggctggcc	aggatctggc	tctggatggc	ttggaccagg	gcatcccgt	240
cctcatacgt	cgtggctca	aagtgcacatg	tttggccagt	ggcagacaca	atcataaaagt	300
tgtttgtgtc	tttcttcttt	aggtgtttct	ttttattggc	atgaggagag	ggggccgggt	360
tgagcttggg	gctgggtgt	ctggagatac	tggggctgaa	gcatatggag	tcacccagcc	420
cggtgtccat	gtccttggat	aggcattgc	tttttagact	ggagatgggt	gcacaggccg	480
atgtggctag	ggatggccac	tttctggga	cttgcattgtt	agatgtccga	aggtaatct	540
ctttttatg	aatattcttc	ataataatcac	ctaagcttga	ataataggtt	agcacgcccc	600
tggaacacacag	ggtgacgtat	ttctttttcc	atgttttcag	ccatccccca	cttcgcttta	660
agagcatgcc	ctgtttatgt	gggatggctc	tgccgctccc	gatgggtgtca	gcatgattct	720
ccggggctt	cctcttttttgc	tctgggtcac	tccctttctc	agatgtaaac	aggttgacc	780
agcgcacatgg	ccgcttgcac	acgggggtgg	gtgtgttggc	agtggagga	acactgaact	840
gagggttccctc	ctggcttggc	ctgggagtcg	atggaatggg	ggaggaatag	ttattnaaac	900
tcccacactcc	atttctgttc	ttcgtaatgt	gcacgggtgg	aacctgtgt	gaacagaagg	960
aggaatggct	tcaaaaatttgc	ggtagtggct	tgcagggtcc	tatagacagc	ttacaattac	1020
ctttttaaaaaa	gatacattttt	ctggccagg	catggtggct	cacacctgt	atcacagcac	1080
tttgggagggc	caagggtgggt	ggatcacgag	gtcaggagtt	caagaccatc	ctggccaaca	1140
ttgtgaaacc	ctgtttttac	aaaaaaaaaa	aaaaaaaaaa			1178

<210> 41  
<211> 1579  
<212> DNA  
<213> Homo sapiens

<400> 41						
tgattgtatc	tgaagatcct	gagctgccgt	acatgcgacc	tcctctttca	aaagaactgt	60
gttttcaga	tgacccaaat	gtcacaaga	cactgcgatt	caaacagtgg	aatggaaaag	120
agagaagcat	atatttccag	ccaccttctt	tctatgtctc	tgctcaggac	ctgcctcata	180
ttgagaatgg	tggtgtggct	gtcctcactg	ggaagaaggt	agtacagctg	gatgtgagag	240
acaacatgg	gaaacttaat	gatggcttc	aaataaacata	tgaaaagtgc	ttgattgca	300
caggaggtac	tccaagaagt	ctgtctgca	ttgatagggc	tggagcagag	gtgaagagta	360
gaacaacgc	tttcagaaag	attggagact	ttagaagctt	gcgagaagat	ttcacggaa	420
gtcaaatcaa	ttacgattat	cggtggggc	ttccttggta	gcaactggc	ctgtgcttt	480
gcaaaaaagg	ctcgaggcctt	gggcacagaa	gtgattcaac	tcttccccga	gaaaggaaat	540
atgggaaaga	tcctcccgaa	atacctcgc	aactggacca	tggaaaaagt	cagacgagag	600
ggggtaaagg	tgatgccaa	tgttattgt	caatccgtt	gagtcagcag	tggcaagtt	660
cttatcaagc	tgaaagacgg	caggaaggta	gaaactgacc	acatgtggc	agctgtggc	720
ctggagccca	atgtttagtt	ggccaagact	ggtggccttg	aaatagactc	agattttgg	780
ggcttccggg	taaatgcaga	gctacaagca	cgctctaaca	tctgggtggc	aggagatgt	840
gcatgcttct	acgatataaa	gttggaaagg	aggcgggtag	agcaccatga	tcacgcttt	900
gtgagtggaa	gattggctgg	agaaaaatatg	actggagct	ctaagccgt	ctggcatcag	960
tcaatgttct	ggagtgattt	ggccccgat	gttggctatg	aagctattgg	tcttggac	1020
agtatgttgc	ccacagggtgg	tttttttgc	aaagcaactg	cacaagacaa	ccccaaatct	1080
gccacagacg	agtccggaaac	tggatccga	tccggagatg	agacagagtc	cgaggcctca	1140
gaaattacta	ttcctccag	cacccggca	gttccacagg	ctcccggtca	gggggaggac	1200
tacggcaaaag	gtgtcatctt	ctacctcagg	gacaaagtgg	tcgtgggtat	tgtctatgg	1260
aacatcttta	accgaatgcc	aatagcaagg	agatcatta	aggacgggt	gcagcatgaa	1320
gatctcaatg	aagtggccaa	actattcaac	attcatgaag	actgaagccc	cacagtggaa	1380
ttggcaaaacc	cactgcagcc	cctgagagga	gtcgaatgg	gtaaaggagc	attttttat	1440
tcagcagact	ttctctgtgt	atgagtgt	atgatcaatg	cctttgtgaa	tattncaac	1500
tatgttagta	aattcttaat	gttcacatag	tgaaataat	tctgattctt	ctaaattaaa	1560
aaaaaaaaaa	aaactcgag					1579

<210> 42  
<211> 2288  
<212> DNA  
<213> Homo sapiens

<400> 42

gcaaaggta	ccagaagtca	gcagcttccc	agaagcccc	aagccggggc	atcctccact	60
cactttctg	ctgtgtctgc	cggatgatg	gggaggccct	gcctgctcac	agcggggcg	120
ccctgcttgt	ggaggagaat	ggccatccatcc	ctacagaccc	cagtccaata	cctgctccct	180
gaggccaagg	cccaggactc	agacaagatc	tgcgtgtca	tcgacctgga	cgagaccctg	240
gtgcacagct	ccttcaagcc	agtgaacaac	gcggacttca	tcatccctgt	ggagattgat	300
ggggtgttcc	accaggtcta	cgtgttgaag	cgtcctcatg	tggatgagtt	cctgcagcga	360
atgggcgagc	tcttgaatg	tgtgtgttcc	actgctagcc	tcgccaagta	cgcagaccca	420
gtagctgacc	tgctggacaa	atggggggcc	ttccggggcc	ggctgtttcg	agagtccctgc	480
gtcttccacc	gggggaaacta	cgtgaaggac	ctgagccgt	tgggtcgaga	cctgcggcg	540
gtgctcatcc	tggacaattc	acctgcctcc	tatgtctcc	atccagacaa	tgtgttaccg	600
gtggcctcgt	gttttacaa	catgagtgac	acagagctcc	acgacccct	ccccccttctc	660
gagcaactca	gccgtgtgga	cgacgtgtac	tcagtgc	ggcagccacg	gcacgggagc	720
tagtggggt	gatggggcca	ggacctgccc	ctgaccaatg	atacccacac	cctctccac	780
gaagactgcc	caggcctttg	ttagaaaaac	ccatggggcg	ccgcacact	cagtgcacat	840
gggaagcggg	cgtctccccc	accagcccca	ccaggcgggt	tagggcagc	aggctgeact	900
gaggaccgtg	agctccaggc	cccggtgtcag	tgccttcaaa	cctccctcccc	tattctcagg	960
ggacctgggg	ggccctgcct	gtctgttccct	ttttctgtct	ctgtccatgc	tggcatgttt	1020
ctctgctgcc	aaattggggc	ccttggccccc	ttccggttct	gttccttggg	ggcagggttc	1080
ctgccttgg	cccccagtct	gggaacgggt	gacatcaat	gccttgcata	gagccccctc	1140
ttcccccggcc	agcttccca	ggggcacagc	tctaggctgg	gaggggagaa	ccagccccctc	1200
ccccctggccc	acctctcccc	ttgggactga	gagggccct	accaaccttt	gcctctgcct	1260
tggagggagg	ggaggtctgt	taccactggg	gaaggcagca	ggattctgtc	cttcaggccc	1320
cacagtgcag	cttctccagg	gccgacagct	gagggctgtct	ccctgcata	tccaagcaat	1380
gacctcagac	ttctgcctta	accagccccc	gggcttggt	cccccaagctc	tgagcgtgg	1440
ggcataggca	ggacccccc	tgtggtgc	tataaatatg	tacatgtgt	tatagat	1500
taggggaaagg	agagagggaa	gggtcagggt	agagacaccc	ctcccttgc	ccccccttgc	1560
gcccagaagt	tggggggagg	gagggaaagg	attttacat	ttttttaact	gtat	1620
aatggaaaca	agctggccca	agggggccag	gccctgtcct	ctgtccctca	caccccttgc	1680
ctccgttcat	tcatttcaaa	aaacatttct	tgagcacctt	ctgtgc	ccag catatgttag	1740
gcccaccagc	taagtgtgt	tgggggtct	ctacgccc	tcatcgtgc	ctcccttgc	1800
atcccttcc	gtgccttgc	ggggatctgt	aggaggtgg	accttctgt	gggtttgggg	1860
atctccagga	agcccggcca	agctgtcccc	ttcccccgt	ccaacccatc	tcctacagcc	1920
ccctgcctga	tcccccgt	gctggggca	gtcccaggaa	tatcctgcct	tccaactgtt	1980
tctgaagccc	ctccctctaa	catggcgatt	ccggaggtca	aggccttggg	ctctcccccag	2040
ggtctaacgg	ttaagggac	ccacatacca	gtgccaagg	ggatgtcaag	tgtgtatgtc	2100
gttgtgttcc	ctccccccag	agcgggtggg	cgggggggtga	atatgttgg	cctgcata	2160
gtggccttcc	catttaagt	ccttctctgt	gactgagac	cctagtgt	tgagaactaa	2220
agagaaagcc	agaccctaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	2280
aaaaattt						2288

<210> 43  
<211> 954  
<212> DNA  
<213> Homo sapiens

<400> 43

caggaattcg gcacgagaaa aatgtgggaa aatgctttaa aaaaatagca aaatgtcaa	60
cttcttacaa aaattgttaa cgttaggtac ttctatatat tttatatgac cataatgtcc	120
gtgtgtgtt tgtacccca gtccttgcgtt attgttccgt atattacctg taagcagata	180
ctgtatTTTA ttttagccta tttgacagaa cacatcac tc agaaaaagt aagtttcaga	240
gcaaacagtg aagaatcatg tggtgattgt a gacaaaaagt cggttcacag aacggagcag	300
cggggagagg aaggaaaaag ctccatagtt tggtgcctt cacatcaaga gattggtaaa	360
tttctgagga aagacaggct aatggggcac tgaatggaa caactcctt aaacgtgcag	420
ccttttgaat tttctccaa aaccaagaag ttgacctctg agctgtcagg tgaccactgt	480
gtgcaaagg gatggattct ctgtcagta gacggcttc tccatgaagc gagagtagga	540
agtgtactgg aatggccaag tggactgct tcagctgacc aggttcttt aaaccgtagt	600
catgctttcc cactaactct taaatccta tgcttagaaa attgaggata aggctggca	660
cagtggctca ggcctgtaat cccagcactt tgggagacca aggccgggtt atacaagg	720
caggagatcg agaccatctt ggtaacatg gcaaaaaaccctt gtctctacta aaaatacaaa	780
aaaatagctg ggcgtgttgg cgggcgcctg tagtcccacg tactcaggag gctgaggcag	840
gaggatcaat tgaacatggg aggcggaggt tgcaagtgc caagatggcg ccactgcact	900
ccagcctggg tgatggcgtg agactccatg tcaaaaaaaaaa aaaaaaaaaa ctgc	954

&lt;210&gt; 44

&lt;211&gt; 1563

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 44

ggcacgagaa gatggcagcc cccataccctc aagggttctc ttgtttatcg aggtttttgg	60
gctgggtgtt tcggcagcca gttctggta ctcagtcgc agctatacggtt ccagtaagaa	120
ctaaaaaaacg tttcacacct cctatttac aaccttaatt taaaacagaa aaggagtttta	180
tgcaacatgc ccggaaagca ggattggta ttccctccaga aaaatcggac cggtccatac	240
atctggctt tacagctggt atatgtatg cctatgttcc tcctgagggt gatgcacgca	300
tatcatctt ttc当地aggag ggactgatag agagaactga acgaatgaag aagactatgg	360
catcacaagt gtc当地ccgg aggataaaag actatgtatgc caactttaaa ataaaggact	420
tccctgaaaaa agctaaggat atctttattt aagctcacct ttgtctaaat aactcagacc	480
atgaccgact tcataccctt gtaactgaac actgtttcc agacatgact tggacatca	540
aatataagac cgtccgctgg agctttgtgg aatctttaga gcccctctcat gttgttcaag	600
ttcgctgtt aagtatgtatg aaccaggggca acgtgtacgg ccagatcacc gtacgc当地	660
acaccggca gactctggcc atctatgacc ggttggccg gttgtatgtat ggacaggaag	720
atgtacccaa ggtatgttgg gagtatgtt tattcgaaaa gcaagtgc aaccctatg	780
gaagctggag aatgcatacc aagatgttcc ccccatgggc acccccataag cagcccatcc	840
ttaagacgggt gatgatccct ggcctc当地 tgaaccaga agaagaatat gaagaggcag	900
aaggagagggc ccagaaggct cagctagct gatgacaaaa atgacttcta gggtaagcc	960
tgggtatgtatca ggtctgttgg agctttgttcc cccatgtatcataatggaa	1020
ctaccccttgc tctctccat cctgtctcagg tctttcagc agtctcatca tcagcaacca	1080
tgactgtatgc ctggccctt gcaagggtggca ggtataacat ggc当地atggac actcttctt	1140
ttttaaatTTT atgtctatgtatc tctgtatgtatca gatgacaaaaa cagtatgtt cagagaacat	1200
tgggtatgtatca gtttttcccc acagcaggga ctgtgagaga caaccagcag catccctttt	1260
gtaatcacaag ggcaggatc agagtttggaa atgaaatgtt gtcagggtgt tggaaaaatt	1320
ttgggtatgtatca ctgcacattt cccctgggttcc aggctggcc tggaccagcc ttcaatggc	1380
agaagttggaa gatgacccatc tttgtgagcg atgtgacttt aagggaaatgt aagactgggaa	1440
agaataatggaaatgttataa gacatggaa agggcccttt tcataactg actcactgtat	1500
gaatcacaat ttcatTTTA tggaaaaata taaatccaa gaaataaaaa aaaaaaaaaa	1560
aaa	1563

&lt;210&gt; 45

&lt;211&gt; 1847

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 45

cccacgcgtc	cgcaggatgg	agtgcagtgg	cacggctcg	gctcaactgta	atctccacct	60
ctcaggttca	agtgattctg	ctgcttcagc	cgcacgaga	gctgagatta	ctggcatgtg	120
ccaccatacc	cagctaagct	ctttctatt	aaatttttt	tctgagttt	caactcttt	180
ggtttaact	gccatttcta	tgttctgttt	ctctctgtta	acctacgcct	agacctccctg	240
aaaaacagta	aatgggcccac	acaagaataa	ctactactgt	gatatactga	aaacctgtat	300
gcagccattt	agcacacttg	aacatacaat	tttactcyta	tttcttattt	gtccattttc	360
attctcaact	aagtggaaag	ctgccttaggg	ataggagcga	tgtataattc	ccctcaactga	420
gtcccagccc	aatgtgtgacc	tcatactagg	tattcaatag	ggtactacaa	acaagattt	480
tcatccagca	agcatggaa	atgtttaaa	aacatgatac	cctcaacttt	acaaaagcct	540
tcaaaaattac	cagaagataa	tattgttact	gccaaaaagc	aattcatgtt	tacttagagc	600
ttactaaatg	tcaaactttt	agctctaccc	tttacagaga	gtctccctt	taatcctcac	660
agcaacccca	tgaggtttgg	agaggctaa	taactca	acatagttac	agtcaagtgg	720
cgtagctgat	tcagtttaca	ctcgatcagc	ccatgaattt	aaaaattttaa	gatcccccaa	780
atatttttta	acagtatagg	taagaagtat	agtgatttga	aagaactgtat	ttaaagtaac	840
tcctcaccc	tcagccctta	cctatgcagt	ttcccttgtt	ggaacaccac	cttcgtcccc	900
cctctctact	ggcaaatttgc	tacacatcct	taaagtca	gcaagca	cccaactccc	960
ctcagcagea	ctcccaactgc	acccggcact	cactgcccatt	ctatctaccc	cctgctctag	1020
tccatgtgtc	tgtttattat	ttaccaggag	aatctgagct	ccatggggtt	gagaaccttg	1080
ccttttccacc	ccatcccca	ggtttcttagc	acagtacca	ccacacacac	aagtgtacag	1140
taaatatctg	ttcttggaaat	cattattgtt	gtacatcaa	gagacttagt	ttgcaacatc	1200
tatcttccac	agcagatctg	tatcacaatc	tacaccataa	cttcaacaa	ttcatattttg	1260
tttccatagc	aacttagggaa	agtgcctt	ataatactag	gaaaggcaag	ctctacctta	1320
aggttcaacc	cactgaaata	cttcacaatc	acttgctttt	tgttcttagt	gtgaagagac	1380
agaatgacag	cattttaaact	ttacgtt	aagaacaccc	taactttaat	aatgacagat	1440
aagtttattt	tttcataatgt	actagatgtt	tcattgacaa	aaggacagca	tcttatttaat	1500
tcacaaatct	aaaataccct	taaggttcca	ggtgctgtgg	ctcacacctg	taatccca	1560
actttgggag	gctgagggtga	gaggatca	taaggccagg	agtttgagac	cagcctgggc	1620
aacacagtga	gaccatatct	ttacaaaaaa	ttttaaaaat	tagtgggtt	cggtagcacg	1680
tgcctatagt	tccagtaact	cgggaggctg	aggcaggagg	attacttgg	cacaggagtt	1740
taaggctgca	gtgagccatg	gttatgccac	cgcactgtat	cctgggcaac	agagcgagac	1800
tctgtctcaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	1847

&lt;210&gt; 46

&lt;211&gt; 1391

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (782)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (788)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (789)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (791)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (1019)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (1021)

<223> n equals a,t,g, or c

<400> 46

ggtcgaccca	cgcgtccgcc	cacgcgtccg	gtatgacata	aattttcctt	ccttttactt	60
tcagccttca	aatatttgaa	ttcagtttct	tgttgacatt	tgggtcatgt	ttgttgctgt	120
wtttttgttt	tgctttgttt	ttttaaaattt	tcactctgcc	atctctgttt	ttaatttagta	180
tattttagagt	gcttatatttt	aatgtatattt	ttgatatctt	agggtttata	tttgcatttt	240
tatttttctt	ttcttttttt	acctctgttt	cttatttctc	tttttataat	cctgctttcc	300
tgtggattac	ttgaatatac	ttttaaatttcc	cattataattt	tatctatagt	gttttatatg	360
tatttctttt	taggcktttt	tttagtagttt	ttcttcataat	tacattatag	ataacttattt	420
gccatctattt	ggcatctgtat	cataccattt	tctgtgaagt	aaaaaacact	taccttctkg	480
cagattctttt	tggctttttt	tattttagaaag	ataattatct	taaataatttcc	atctttatata	540
atkttagttat	ataatcttttgc	cttcaaccat	taggtatgtat	ttagaaatct	caaaaagaaga	600
agaaaacctac	tgtgtkcccc	atagttaaac	tcactctgtat	ttttttttct	tcctgatctt	660
ccgagatatac	cttttttattt	gtkttcttgc	tgttttagaga	tgtttcttta	actgttctct	720
taggataagt	gtttttttttt	caaatttcag	aactctttagg	gtttttttttt	cttttttttt	780
tnttttttttttt	nagtttttttgc	ttaaacgtga	agatttttttgc	atttccctt	cattcttaaa	840
ggatatttttgc	atgatagaat	tctgaatggg	actggccccc	tgcctactttt	tttttttttttgc	900
ctataacttgc	acaatattat	gccacttattt	ctggaaactcm	cagattttta	tgagaaatct	960
actctcattt	gaattcccat	ttttctatca	ttgcctctaa	gattttttttta	atccaatana	1020
naatacaaaag	tttttagcaaa	aacatggtaa	attccagcaa	gaaatagaag	atacaatattt	1080
gttttttatttgc	ggagtttatttgc	tatattttag	gcatgttcat	cctgacttagg	gaaatcgcaa	1140
atcctcatttgc	aatatccatc	agccatcaaa	attatttaat	atataaaaca	aaatttatttgc	1200
agatataaaa	gacaatcaca	tggatattttgc	caaattataa	atatgataac	tgaataaaaa	1260
aatctaaagg	agggctcaaa	agcaaaaatgt	aggtgatagt	gagaagttagc	aaagaacttg	1320
aaaacataaa	aattaccagg	tatgatcaac	agagagaaaa	taaaccagaa	aaaaaaaaaa	1380
aaaggcggc	c					1391

<210> 47

<211> 2008

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (1936)

<223> n equals a,t,g, or c

<220>

<221> SITE  
 <222> (1977)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (1978)  
 <223> n equals a,t,g, or c

&lt;400&gt; 47

cccacgcgtc cgccgagttc agcatctgga	ccccggaggc tggcgctggg ggcctgtcca	60
ttgctgtgga gggtcctagc aaagcggcag	attgcatttgc aggatcgcaa agatggctcc	120
tgcggcgctc cctatgtcgt ccaggaacca	ggtgactatg aggtctccat caagttcaat	180
gatgagcaca tcccagacag cccctttgtg	gtgcctgtgg cctccctctc ggatgacgct	240
cggcgtctca ctgtcaccag cttccaggag	acggggctca aggtgaacca gccagcgtcc	300
tttgcgtgc agctgaacgg tgcccgggc	gtgattgtatc cccgggtgca cacaccctcg	360
ggggctgtgg aggagtgtcta	cgctctgttagt ctggacagt acaaggcacac	420
atccccccacg agaatggcgt	ccactccatc gatgtcaagt tcaacgggtgc	480
ggaagtccct tcaagatccg	ccatccatc acatccatccct	540
tcagcctacg gtcctggct	cgaggargt actaccgtt gtcatcaga gtcatcgtg	600
aacaccctga atgcccgtc	ggggcccttg tctgtcacca ttgatggccc	660
cagctggact gtcggagtg	cttgcgggtc catgtggtca	720
ggcaactacc tcattgccc	cttatactcc catggccct	780
aaggccaagg tcactggtcc	caagtacgtt ggcccccacg acatcggtt	840
gttctgggtt agactgttac	ggaggccaca gccttcacga aacatccacg	900
cccaagtctt cctcagatgc	actaccgtt gtcactccatc	960
ttcgtgggcc agaagaactc	cgcaagggtt gtactcggtt gcccctgggt	1020
atggtggggc tgacacggcc	catgtggtca aagcaggcac	1080
aaccgggtt acaatgtcac	aaatcgatgtc aaggagaag gggactacat	1140
aagtggggc acgaaagtgt	cccttggaaagc cccttcaaaag tcaagggtccc	1200
aaagtgcctc cccagctca	ttgaatccca ccagccacac	1260
cacacacaca aatgtgccac	acacattaca cacacacaca	1320
ttgggggtt agtgaaggcc	accacgttcc accccacccg	1380
ttgtctgtt caggacagtgt	gacccatccgtt ggaatgttac	1440
ggctcagggg cagaggctgg	atgaggggccg actggggcca	1500
ctgagtttctt ggcgggctt	tgtaatgttac gtcgttgcggc	1560
ggtcaccctc aaactgcacc	ttgtgggtgtt ctgtgtgtt	1620
tctctctgtt ggctacaacc	ggccggccaga taccctccgtt	1680
aagaaaacag cccccaacc	accccgaggtt aaggacttgg	1740
gcactccacc caagccaggc	aaaggaaagc acaatcgatgt	1800
aaaatgggtt cacggctctg	cccttgcgtt acacactgcg	1860
ttctagggc cttttgcaca	tttgcgtt acggccagct	1920
ccaaataaag tgcggnntgc	ttttttttt acatccatcc	1980
aaaaaaaaaa	ttttttttt acatccatcc	2008
aaaaaaaaaa	aaaaaaaannaa	
agggccggccg ctcttagag		

<210> 48  
 <211> 822  
 <212> DNA  
 <213> Homo sapiens

&lt;400&gt; 48

ggcacgaggt aaggcaaaac	tgagactcat gggtgtggc	60
gctttgcac	tttgacagtggat	120
atgtactgg	aaatcttttta	180
gacctttggg	tttaaccagt	
ttttttttt	gagattgtct	
ttttttttt	tgtttatcct	
ttttttttt	gttgcattta	

gccttccagc ttatggaaaa atacaattc aaattctaac actgctggat ttatgatatt	240
taaggtttct attatatcg ctgcctggat ggagcacaga aacagcgtag tacaatatgc	300
tatgggtata ttcatgacca aagtttacaa tgtggagga gaatagaaa gcaagaggc	360
agttgggaa ttagctgctt gtgttatata actccttaaa agtgaaaaat gatcacaagt	420
aatatgtgagt agtgacagtt ctcttccatt tccttcttc aggttaaggaa aacacactta	480
atattttga gtgtcttaa agatcttcc aaccatccaa aagagaagat gtcttattta	540
tgtgtatatg tcgtgttgtt gactgatttt ttgcctttt actcctgatg tgttttgtgg	600
gtgagaaggc aagcatgtaa ctaagataca gaaaagacca agatgtatg gggcacagtg	660
gcttgcaccc tataatctca actactcaga aggctgaggt ggaaggattt cttgaggcga	720
ggagtccagg ctgcagtggg ctatgattgc accgcacac ttgctgcact ctacccttgg	780
gggacagagt gaagctctgt ctcaaaaaaaaaaaaaaa aa	822

&lt;210&gt; 49

&lt;211&gt; 1383

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 49

ggcacgagct ttgtcgac atctttaaag cattttctt ttatagaat ttcaacttaat	60
gtccaataact gatTTAATGA GCTTGGTTT acacattatc tcttgaagaa aacaatgaa	120
cctttgtgtt ccaaAGCAAT CCATGTTAA agggaaaaaa ttatgcataa ctctgcccag	180
cttcacagta acctttggca ggtgccttag gtcctctggg actctttcc ttatctgaaa	240
aatgaaggac ttggatcagg tgaatggtc ccagctctgc aacttatgtg gctccctcaga	300
ggcacacaag ctctttcca ttatTTGCCA aataatggag gcccgtctt taactgcagt	360
acaactacac aaaatacttg aaactacagt ctTCCTGGTT ttgggttggg actgaatcag	420
tgcaCTCTAG caacacttat ttcttgcgt tctgtggctt cattatgtt ttgtttaatt	480
ttttaaaacm acawtwacwt atyccataat attwcmgctt aattggmara ctgtttcagt	540
ctataggatc tgcaGGAGG aggAGTAATA agggatTTT gactgagctc ttatggaca	600
gagtctctc aggccccctg tcataCTGC cttctgggc cctggggaaa agtggcAtc	660
cccagttgtg gtgcTCTCCA ggtgcctca ggctgtggg gagggagctt cccattctct	720
ccttcagccc actcaattca gaggttaggg gctgaaagaaa gcttctctac aactggctgt	780
tcactggagat gttaaGGGAT gaccatccag ccaggccttc ctcaggacat gggaggcTT	840
atgcttaac atgtgtaaat ccactgcaat aatgactggg tctttaccc cataaggTTG	900
agaatttacc tgtaaacatt ttgtctgaa gaatttggat gtaagtgggg gctgggcTc	960
tatcttatct cacttggctt ctctcagcac agcacTTGC cttgttggc ttacacatcc	1020
tagatgcaca gtaactattt cctaattatt agaaatctat tagaatcaat tgatttcagc	1080
tgggcttgggt ggctccTCC tgtaatcccA gcacTTGGG aggccaaggc tggaggatca	1140
cctgagtcca ggagTTAAG accagcctgg gcaacatagg gagaccatgt ctctacaaaa	1200
aataaaaaat tagccaggca tgggtgggtg cacctgttagt cccagctact caggaggctg	1260
aggcaggagg atctcttgag cctggaggt cagactacag tgagcaatga ttgtgccact	1320
gcactccagc ctgggtgaca gagaagact ctgtcttta aaaaaaaaaaaaaaaactc	1380
gag	1383

&lt;210&gt; 50

&lt;211&gt; 748

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 50

ggcacgagga aggaacgagg caaggagct aaggcagcgt cgttcagccc tggggcattt	60
tattaatgtc ttacgagtt agaagagtgg ggataatttgc catctggag ttctctgccc	120
ttgctgatct gagctcagac ctgcctattt accagagata attgataaca ccctgtaaaca	180
gctgagtaag tagatttttc tgTTTACTG ctttaaaaa aagttaaag tttaaaaata	240

gtataaaactt taattgggtt ctttaaattt tgggttgaa taatgcaatt attatgatat	300
tttgtgaata tttgtaaata atgggattct ggaataaaatt aatccccat gatagaaaag	360
agttaatgaa cactttctcc atacataaca cttagcatt caagaaacat aggactaaa	420
tacatatatt aaaaatttag gccagggtca gtggctcacg cctgtaatcc cagcacttg	480
ggaggctgaa gcggggcagat caccgtgggt caggagttt agaccagcct agccaacatg	540
gtgaaatccc atctcgctta aaaatgc当地 aattagccag gcatgggtgc aggtgcctgt	600
aatcccagct actctggagg ctgaggcagg agaatcactt gaacctggga ggcagaggtt	660
gcagtgagct gagactgtgc cactgcactc cagtctggc gacagagagg ctctgtctca	720
aaaaaaaaaaaa aaaaaaaaaa aaaaaaaaaa	748

<210> 51  
<211> 1224  
<212> DNA  
<213> Homo sapiens

<400> 51	
ggcacgagta tacatccata cacacactt aatattttgt caaaaagaatg aaaaacttctt	60
ataaccatgt tttgaagatc ttttatacct catagaatct cccctggct cttgtttca	120
acaaatgcct gtggatttgtt taaggttcta ctgaatctta agtattattt acagcagaga	180
tggggccagg agtagaatat tcactggaca gatcccaagt ctgttagata aaacagctt	240
ttcatttatcc tctgaatttc ctttgc当地 agagttgttag ggaagaaatg ggggtgtcct	300
cccatggc当地 taacttctt agtgttaaggc ttgggttctc aactttggct atatgtt当地	360
gccactctt attcctaagt ctaatccccaa gggtttctga ttaatttggt gtaggggtgt	420
gccaggacca aataatttta atgttagcc agattgaga accactgc当地 taggagatga	480
caacccccc当地 tctcaggtaa gaaatttagca ggcttattttt gcttaactct agttaatata	540
cgtactgaga aggtctgggaa accatcccaa tagtaatgag gatccatagc tccctgatct	600
ttgtttcaaa ggtctattct atacgaaaag ataccagaga tccctc当地 aatagctgtt	660
tttaggactg gagcaggaa agacaagat gtgcctggat atttctgtc agaaagcaaa	720
gaaataatca gagattattt tcagaagaac ataaaagtct gagggagtt tgactggtca	780
aatctggat tttttttt tccccccgag acagagcctg gctctgtccc tcaggctgg	840
gtgcagtgcc acaatctc当地 ctcaactgc当地 cttggacctc ctgggctcaa gtgacccttc	900
cacctc当地 tcccaatag ctgggactac aggtgc当地 catccccctg gcta当地 aaaaattttt tttttttt gagagatgag gtctcattat gttgcc当地 ctgatctgg	960
actcttggc当地 tcaagcaatc ctaccatgtt gccc当地 cccaa agtgc当地 ttacagggtgt	1020
gagctaccac gccaaatctg gggaaatctg agaatcaaaa taaggaatta tagtcatgg	1080
ttataactca ttgaacaaag taggaatcct ttaatctgtt ctc当地 acagg taaataaaatg	1140
aaaaaaaaaaaa aaaaaaaaaa aaaa	1200
	1224

<210> 52  
<211> 1265  
<212> DNA  
<213> Homo sapiens

<400> 52	
gcaacattat ctgc当地 ttga aacaccacct ccgtggatta ccattggcc caatgggagg	60
gtctggataa tggccattat attatcctaa tccctgctt cctcagagggt tggtaagggg	120
cacttctgct gttccctctt gagtggaccc tggctgccc当地 tctcttgag atgtccctt	180
tcctctcagg gatgagtc当地 agtggggact gggaaaggca gccc当地 ttgtt当地 cttca	240
gttggccagg aatgccc当地 aatgatgatt ctgtttgccc agcttcttgc cgtgagctgg	300
gttggctgtt ttacagcac accaaccctt aagtc当地 ctgcaatttactg tggatttatt	360
gaggcacctgc tagtatgtgc gtgttggg ggtggatata gaaaatgatg gaggcagct	420
ctgc当地 taaa tgagggaggg tggcaaca gctccc当地 cggc当地 gttt当地 aaccagg	480
tatttcttctt cataggaagt gtccataaac attgttctgtt ctc当地 atttgca tgggtt当地	540

gagggttgaa	tgttagtgta	atgaatttag	agtgccttca	aaggattttaa	gctcttgatt	600
tatgtaaaaac	tttcttcagt	attactagc	aggctgataa	taaaagctaa	catatattga	660
atgccttcta	tttgcagggc	actgccttaa	gtgccttcta	tatattagct	tatttaatct	720
ttatagcaac	tttgaagtag	attgcctgt	tacccactta	aaagaggatt	aaaaaaaactt	780
gccgaggatg	gcacagcagg	taatgtcg	agccaggcag	tctgaacgtt	tggccaaaca	840
ctggccactg	taaagatctt	gtggaagtca	gggagtagag	gtggctctc	tcccccaagt	900
gaaggcagca	gccaggacct	accgtcagag	accagcaagg	agcagagaaa	ggtcaggctg	960
gtgcctcaga	aagcatcagc	attctgcac	aacttaatta	aattactgaa	acctttctg	1020
agcttggagc	cattttctt	ggagagtaat	acaattgaaa	cagataattt	aagccaaggaa	1080
ggaaggacag	aatttgtgag	ctcacatatg	tagatggaca	tgtaatgacg	tctgactaaa	1140
acacagagga	aaaaccttaa	agtgaatcat	gtttattcaa	tttccaaaca	agtgcaaaga	1200
cccaggcagc	gtgcctcatg	tttggactct	tgaagaacac	acatgaaaaa	aaaaaaaaaaa	1260
aaaaaa						1265

<210> 53  
<211> 2710  
<212> DNA  
<213> Homo sapiens

<400> 53						
ggggagaaat	cagtgacaga	gggtttttgg	ttttattgtt	atgtgggtt	tctttgtat	60
ttttttgtt	tgttttgtt	ttaaacattc	aaaagcaatt	aaagatcaga	cataggagaa	120
accctgaata	gaaacaaaac	tttgaatgc	tggattcaaa	aaaaaaaaaa	agttatctgg	180
acagcttctt	tgagactatt	aaaaaaactgg	tacaacagt	ctctacaacg	ccaagatcta	240
actaagctt	aaaagtca	gaagttttat	ggctgacaaa	ggactcgcgc	aacgcagaag	300
gcctttccca	ccttaagctt	ccggggatct	gggaatttta	cccccattct	cttctgttg	360
tctgagtctc	atctctctgc	aagcaaggcc	tgaaatcatt	ttgtttgggt	tttttgaggg	420
agagaggccg	ggtggggggg	tgcaaattctg	ccagcagctc	ttacgtaagg	catgttttat	480
tggggagggc	tgagctttta	ttttctctc	tccagtgggg	ttggctttta	ttgtttcttg	540
tttgggtttg	gaatggaaat	atggatagca	gcataaagta	cttttatttt	gacaaaattc	600
attttttca	acaatggaga	catagattt	acccacaata	acttctcccc	ctctcttttt	660
actctgctca	aaaagcatct	ctcccccatt	tacccaaacct	ttgtcataag	tgtgcctggc	720
tggtttgcag	atatttttc	tgctttgtaa	aaattggcca	ttagtgcatt	tattgagatg	780
atctctaaag	agctatgccc	tgacccatccc	ctgattctat	gacattgggg	cccttctttt	840
gctgaaactg	ccttacgtaa	tggtttact	ccttggaaaga	gatttgcgg	aatccatttt	900
atgccaagtg	ctgcccgc	ctgtttctgc	aatatgtgt	gtatgcgtg	gtgatcttgc	960
tggaaatgat	tataagtgt	tgtgtgttgg	gggagtggtt	attacatgca	ttgctgaaga	1020
gtcattctgg	tgttccat	tcctccacc	ttccctgtt	cattttaaatt	acggggcagt	1080
gtcaccgc	agggaggaaa	ctcaaagccg	aaagaaaaat	tccaggcctg	attctggctt	1140
ttgaggttcc	tggttcttga	agccaggcct	gacccgactc	ttagatgggg	tcagtcgggt	1200
cgctttgcag	actgaccctg	gaaatctaca	aaatgcagat	tttcctgtt	tcctcttctc	1260
ttgcccagg	ttttttttt	ttttttttt	taaagcctgg	attgttaacca	gattttcttt	1320
tttccccctt	ctcagctgt	gatatgat	ctcctttcag	ggccccagct	taagggcaaa	1380
gtgagttat	gtgttagacaa	aggcgaggga	caagagagag	ttaacatcta	gacagtggaa	1440
aaagccatgg	tgtgtgttt	ctgggaacca	ccaacacttgc	caggtttgc	tttttccctt	1500
ggttgactac	aagaagaaa	accatgtttt	tgcaagatta	aatgtgggtt	gagtgtgcct	1560
aaattaacca	tccccatttt	tatcatat	ccaccatcac	ttcagggttt	taagagtcag	1620
tgctcacctg	ggcggagctg	gtgtacatt	ttgccttcta	gaaagctaa	tccctgggtt	1680
cgtctgattt	taggttccag	gaacttctg	agaacacccg	atcgccagg	gtaattttct	1740
ggagtttgg	ttgcagggt	agctggggagt	atggccaccc	tgctccacga	tgcggtaatg	1800
aatccagcag	aaatgtgtgaa	gcagcgccttgc	cagatgtaca	actcgccagca	ccggcagc	1860
atcagctgca	tccggacgg	gtggaggacc	gaggggttgg	gggccttcta	ccggagctac	1920
accacgc	tgaccatgaa	catccccctt	cagtccatcc	acttcatcac	ctatgatgtt	1980
ctgcaggagc	aggtaacccc	ccacccggacc	tacaacccat	catctcagggc		2040

gggctggccg	gggcctcgc	cgcggccgcc	acgacccccc	tggacgtctg	taagaccctt	2100
ctgaacactc	aggagaacgt	ggccctctcg	ctggccaaca	tcagcggccg	gctgtcggg	2160
atggccaatg	ccttcggac	ggtgtaccag	ctcaacggcc	tggccggcta	cttcaaaggc	2220
atccaggcgc	gtgtcatcta	ccagatgccc	tccaccegcca	tttcttggtc	tgtctatgag	2280
ttcttcaagt	actttctcac	caagcgcag	ctggaaaatc	gagctccata	ctaaaggaaag	2340
ggatcataga	atcttttctt	aaagtcattc	tctgcctgca	tccagcccc	tgcctctcc	2400
tcacacgtag	atcatttttt	ttttgcagg	gtgctgccta	tgggcctct	gctccccaat	2460
gccttagaga	gaggagggga	cggcacggcc	gctcaccgga	aggctgtgt	cggggacatc	2520
cgaggtgggt	gtggacagga	aggacttggg	aaggggagcg	agaaattgct	ttttctcttc	2580
ctccctgggc	agaatgtac	ttttctgtctt	cactgtggca	gcctccccc	tggatcctta	2640
gatcccagag	gagggaaagaa	aatttgcagt	gactgaaaac	agtaaaaaaa	aaaaaaaaaa	2700
aaaaaaaaaa						2710

```

<210> 54
<211> 3332
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (16)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (28)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (30)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (32)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (44)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (625)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (3138)
<223> n equals a,t,g, or c

<220>

```

<221> SITE  
 <222> (3315)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (3332)  
 <223> n equals a,t,g, or c

<400> 54

actattcagt	gcacangaca	caagtcan	n	gncagtcac	gtcn	gattcc	cgg	gtcgacc	60
cacgcgtccg	gttattaacc	tctctaa	att	tcagggggaa	aat	gtataaa	ta	tgtcatgt	120
at	ttgtataaa	tagtttccc	ttttttaat	gaaaagat	tct	gattgga	tt	gacctgcc	180
actaattt	tgctattaac	ttttcatt	c	taggcaata	agcaaca	aag	acc	acatag	240
catatcatat	actttrtctc	ggcccagac	tgtgggtt	gaatata	actc	atgacagcaa	300		
cacmgatatg	tttcagattt	gccggtcgac	tgaaagcccc	attgat	ttt	tagtaactg	360		
cacggttct	ggaagtcaaa	gtaattctga	tacacagtca	gtaca	aaagca	ctata	caag	420	
at	ttgcctgc	agaatcatat	gtgaacggaa	tcctcc	ttt	acagcacg	ttt	atgc	480
aggatttgc	tcatcaaaaa	acatcttct	tggggagaag	gctgc	aaat	ggaagacatc	540		
agatggacag	atggatggct	tgaccactaa	tggtgtt	gtgatgc	atc	cacgcaatgg	600		
gttcacagaa	gactcca	actc	ctggnat	atcggtgt	gt	ggaaatgttat	660		
ttagcctac	tgaaaccaga	tcggctc	agagag	aaatgg	ttt	gaaacc	720		
atcagttaca	agatgc	ttaattgacc	tctgtgg	ttt	atgtt	tggctact	780		
cagaaggc	ttcccacact	cctaccgt	tgac	ttt	taaga	caggaaatca	840		
atgcagc	acctc	actgc	cctgt	ttt	ttt	atgtgaaga	900		
ggaaagac	gtt	atgatgaa	aaacaaccat	gggtat	ttt	actgc	960		
getatcataa	ctgggaaac	aaagaagaac	gtgatgg	ttt	ttt	atgttatgt	1020		
gttaggtct	ttgtcc	ctgt	ttt	gg	ttt	ttt	1080		
acgc	ccat	gctt	ttt	gg	ttt	ttt	1140		
ctgc	catt	gtcc	ttt	gg	ttt	ttt	1200		
ccttt	ttt	acat	ttt	gg	ttt	ttt	1260		
ctct	ttt	ttt	ttt	gg	ttt	ttt	1320		
ttgg	ttt	ttt	ttt	gg	ttt	ttt	1380		
at	ttt	ttt	ttt	gg	ttt	ttt	1440		
aaact	caac	aaag	ttt	gg	ttt	ttt	1500		
tat	ttt	ttt	ttt	gg	ttt	ttt	1560		
ac	ttt	ttt	ttt	gg	ttt	ttt	1620		
tt	ttt	ttt	ttt	gg	ttt	ttt	1680		
tat	ttt	ttt	ttt	gg	ttt	ttt	1740		
tg	ttt	ttt	ttt	gg	ttt	ttt	1800		
aa	ttt	ttt	ttt	gg	ttt	ttt	1860		
taa	ttt	ttt	ttt	gg	ttt	ttt	1920		
tgt	ttt	ttt	ttt	gg	ttt	ttt	1980		
agc	ttt	ttt	ttt	gg	ttt	ttt	2040		
ca	ttt	ttt	ttt	gg	ttt	ttt	2100		
gca	ttt	ttt	ttt	gg	ttt	ttt	2160		
cc	ttt	ttt	ttt	gg	ttt	ttt	2220		
gaaa	ttt	ttt	ttt	gg	ttt	ttt	2280		
ttt	ttt	ttt	ttt	gg	ttt	ttt	2340		
ttt	ttt	ttt	ttt	gg	ttt	ttt	2400		
ttt	ttt	ttt	ttt	gg	ttt	ttt	2460		
ttt	ttt	ttt	ttt	gg	ttt	ttt	2520		
ttt	ttt	ttt	ttt	gg	ttt	ttt	2580		
ttt	ttt	ttt	ttt	gg	ttt	ttt	2640		
ttt	ttt	ttt	ttt	gg	ttt	ttt	2700		

atgtggtagc ataccttaa tttaycctat tacaaaactg ttctgaattt tctttggtt	2760
ttaaaaaaac aaaactgtt gcttagaagc catgaattat ttatatttac ttcaactgtc	2820
gaaactccct tgtttaaaa aatgatcatt tgggttcaact cagggaaatgc atgtcaggaa	2880
acttgtatta taagtttatt agttgtatg tatcagtaac tgctgttacc ccttttcaa	2940
agaaaatgtaa ttgatttga agtttctag attgtcacat gcttttgac taatgcaaga	3000
aagcaagtcc tgggttatg ttgttctagt cattttattt caggctatat atttagctt	3060
aatttttatt tgcaattaat ttattnaac taagttaaaata cttttcaaaa tacataattg	3120
aattcgtctc tggagtnca ttttgcata atcgagaatg agaaaccaga agtggaaact	3180
gtgaacaact ctattccaca ctccaaaaat actcattga aatagatgaa gagtttgcat	3240
ttaatgtaac acattaaagt atctgggtct tttttaaaag catctttac taataaaagga	3300
actttgttag tggtnaaata aaaaaaaaaa an	3332

<210> 55  
<211> 489  
<212> DNA  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (477)  
<223> n equals a,t,g, or c

<400> 55	
cggcacgagc ttccctaaaa gtatataaaa tttgaaaaga cctagaagtg atcttagtgaa	60
atgaagacgc tgagatacca ttgaggttgg ggaaactact gggacgtgct tacaggataa	120
actgcaaaaac aaaagcacaac gttttaatc atggaatgac atgccttatt ctgaaaactt	180
aacgtttgtt gctgtaccta taattcataa gacattttaa aatggtattt aatcccaata	240
acctatgcgt agggttggat ctgttggta tccctgtttt ttaatggaaa atctggggcc	300
tgaagatggt aggccatgtatgcctgccc ccggcgttga gcctggctcc tgctgttggaa	360
gaaactttcc cagtctgtt agagaggatg tggctctggc aagcctggct cctgcctgtat	420
tctgtatctt ctggtaacac acagccgtca tttaaaaaaa aaaagacaag gtctttnccc	480
tcggacaga	489

<210> 56  
<211> 1314  
<212> DNA  
<213> Homo sapiens

<400> 56	
ggcacgagga gatcttgagt cacagtgaag caacccactg gagtggcat tgctgcattt	60
ggagagtcaatgatgscattttt gggccgcgat gggccttgg gaacatttggt gtgttcatct	120
gcatttcgtatg tgctggaaatc cacaggaatc tgggggtgca catatccagg gtaaaatgtcag	180
ttaacctcgcc caagtggact caagaacaga ttcagtgcattt gcaagagatg gggaaatggaa	240
aggcaaaacccg actttatgaa gcctatcttc ctgagacattt tcggcgcacct cagatagacc	300
cagctgttga aggatttattt cgagacaaat atgagaagaa gaaatacatg gaccgaagtc	360
tggacatcaa tgcctttagg aaagaaaaag atgacaagtg gaaaagaggg agcgaaccag	420
ttccagaaaaaaa aaaattggaa cctgttggttt tgagaaggt gaaaatgcca cagaaaaaaag	480
aagacccaca gctacctcgaaaagctccc cgaaatccac agcgcctgtc atggatttgc	540
tgggccttgc tgctcctgtg gcctgttcaatgcataatggc aataaccctag	600
agaaggattt agatctgttg gcctgttccatcccccttc ttcttcsggt tccagaaaaagg	660
ttgttaggttc catgccaact gcaggagtg ccggctctgt tcctgaaaat ctgaaacctgt	720
ttccggagcc agggagcaaa tcagaagaaa taggcaagaa acagctctt aaagactcca	780
ttctttcact gatggatcc cagacgcctc aaatgcctac tcaagcaatg ttcatggctc	840

ccgctcagat ggcataatccc acagcctacc ccagcttccc cggggttaca ccttcataaca	900
gcataatggg gagcatgatg cttccaccag taggcattgt tgctcagcca ggagcttctg	960
ggatgggtgc cccccatggcc atgcctgcag gctatatggg tggcatgcag gcatcaatga	1020
tgggtgtgcc gaatggaaatg atgaccaccc agcaggctgg ctacatggca ggcattggcag	1080
ctatggccca gactgtgtat ggggtccagc cagctcagca gctgcaatgg aaccttactc	1140
agatgaccca gcagatggct gggatgaact tctatggagc caatggcatg atgaactatg	1200
gacagtcaat gagtggcgga aatggacagg cagcaaatac aactctcagt cctcagatgt	1260
ggaaataaaaa acaaaaacacc tgtaaaaaaaaaaaaaaaaaaaaaac tcga	1314

<210> 57  
<211> 1564  
<212> DNA  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (50)  
<223> n equals a,t,g, or c

<400> 57

aaactgcagt ttaaaagtgt ttatatcctg gatacactaa cagcatttn tccaacttgt	60
ggagtggagg gagtagggaa ggggaggata gtgctaattga actgtgacag gggctagcaa	120
gaaagaaaaga aaaagagttc cctaagtaag ctcctactgg gtgtccttcca ctcacatgg	180
gacaggggccc tgcttttagg cacttactct tccagtgtct attgyataat atgttcagga	240
aggatcccg attcaaagat ttatagaatt agrgttaaaa gggatagata tcttgcgttga	300
ccctgaaaaa attaaggaaat atgcttgaga tattcaatgg cagaggctgg aatagatttt	360
cccaaatttc ctgatgtgaa gttctgttgc tgcattttttt gactgtgtaa aaagattaat	420
ttaaacttaa tgacatgttgc tattcataga agttctttgg gtttctgtgg aaaccttcctc	480
ttgctagctt aagcagaaat gggggattta ttggaaaggaa gctgagatat tgcaccaaac	540
tgcacaaaat tgaatgaaga gctgactaag caaggctgc ctgagaagga accagggtgg	600
tctgggctgt ggtagcggca gcagcagctt gcagatctcc cagcgctgt gctggctcga	660
ctcagacagg tctccactct ctgcgtctg tctctggc agacaggaca ctttgcgtgg	720
ctgtttccctt ccacaaggcc tcagtggtgg caagccagcc tcccacaggc ctctgagaca	780
gaccacccca ttccctccctc tcctgttaac ctgcctttat ttcccttattt gcacttatca	840
ccatgcagaa gcctatgtgt ttgttccctt gtggagatgt aaaaacactg atgcccaggc	900
ctaactccca gagaactctga ttgaactggc ctgggctatg gagccggac atttgcattt	960
ttcttacaag ctctaattgt cagcaggat taagaatcat tgccttcgc atcaacagga	1020
caaataaaaaa atgtgcagca aaatatatgt ttaagtgaat caagaagaca gatctagaaa	1080
cgattgttaa ggaataataa tgcattttgt ccatcaccac acataagtga tggaccag	1140
agccctccca gattgagtgg tgccagggtgt tcgggggtgt ctgcgttaat ctttactatg	1200
gccttgcggg gtagggggca gtgtcctcat tggccaaatg agtcactgag gctgaggat	1260
tcaggctcg tggatggccca cagtttttgc gcaaaccggcc ccactggcc agccaactac	1320
acggggatttc tgatcggtc ctgatgggtg cccatgtatgg gctgtgcggaaa agtgggtgt	1380
agatttctcc accttcacgg aggtggtacc cagggggaggt ggacttcagc agcggaaatg	1440
ggctgggtgc agtggctcac agctgttaatc ccagtgcattt gggagttcga ggcaggagaa	1500
ttgcattgac tcagttttc gagaccatgg gagaccatgt ctctacaaaa aaaaaaaaaaa	1560
aaaa	1564

<210> 58  
<211> 2073  
<212> DNA  
<213> Homo sapiens

&lt;400&gt; 58

ggcacgaggt	gtgtctgtgt	atatgtatat	gtgtgtgtcc	ttgcacatgt	catgtggctg	60
tgcaagtgc	tgtgtgtgt	catgcatgtg	tgtgtgttt	gtgtgtggg	ggaggcagcc	120
tggggctgtc	agaagaggc	agaaggtggg	atcaggccta	gctggacctg	aaccctgtt	180
gtgccagctg	ggtaaacttt	aggcaagtca	tttaagttt	ttctgcctgt	ttccccattc	240
aaagaatgga	ccaaatatta	cttacgttgt	gaagatgaca	aatatgtgtg	taaaatccag	300
gcacacacga	tgtgcttagg	acacagcagt	tatgatttat	ttgtgtgtt	tcttgggata	360
gtggggggag	gatttgcagc	ctttaagga	cttgggaaatt	tcaggcttgc	acagagccag	420
tcttgggagc	ccatcttgg	tggctgtct	gaggggactgg	ggacatgtcg	ccccgtgttta	480
cagagaccca	tagtcagaca	ccatggggcc	aggcagacag	gcaacacacgc	agtccctgccc	540
gcagggcccc	cagtggacag	gcagaggcgc	agataataca	gtggctgtcc	cagggtccac	600
agctgggtgt	ggggggcttg	agggttagaa	ttggccgggc	cctatgcggg	gcatttgatt	660
ctagtgttgt	ctatttttat	ctttttcatac	agatcagggc	accgtccct	ctgggctcgc	720
tgctgtttcc	tgcttcccag	ccccaaatttc	ctcccccttc	ctacctccag	cgcacatcttgc	780
gtgagacgca	tggggacagg	tgtgtgtaca	ccctggggaa	tgtgtgtgtt	gttttcattt	840
atctgtgtcc	atgtcgatca	agagcatacg	ctcatgtgc	ctgtcttagt	ctgttcaggt	900
tgtgataaca	aataacaaca	atcggggat	ttagaacaac	acacatctt	ttttcacagt	960
tcaggagggt	ggtaactcca	agatgagagt	ggcagcagg	gcggggctctg	cagagggtgt	1020
tcttccggga	tgcagcctgc	cggtgtccct	actgtgtctt	cgccaggcaga	agttggcgtg	1080
ccgagccagt	gctctgtat	cagggttgg	agccaaatta	tgagcactcc	tccttcatgg	1140
cctagtcacc	ccccaaaaggc	cccacatct	gataccatca	ctatggaaatt	aggacatcaa	1200
caggtacatt	ttggggggat	aaatgcattc	agaccatggc	actggtttca	gttgtcatgt	1260
aagtccaccac	tcgtatatac	aggctaactc	atgaccctag	atctacatgg	ggctctgcct	1320
ctacctcaca	gcagagatgg	acacccacac	caccatctt	cccgtgtctc	accacctgca	1380
ccccaaattac	ggacacctat	gcctctgtct	tccctgcgtc	tctcagcaact	ctacagcgg	1440
tgacacacac	accttcatct	ttcttccatg	ttcatgttt	cagtggagag	gctggggatt	1500
gggaggagggt	gctgtgggg	tatggggagt	gagatctgtg	ccgcagtg	gtgggattca	1560
ggagaaaaacc	aggcagtgtc	ccaccagg	acttgcttgc	aacacagaaa	cctcttcaat	1620
gaaatggaa	ccctgtctag	aatgccagac	tctctgtca	ccattctctc	tggtcagaac	1680
tggatcaactt	tatgtatgt	aaattgtatt	tgatttattt	ttttcttttt	taagagatga	1740
agtctcaact	tgctgtccag	gctgtgtctca	aactcctggg	ctcgagtg	ccttccgcct	1800
cagcgatccc	aagtgttgg	attacacgt	tgagccacag	caactggccat	aaattgtatt	1860
tgatttttac	agctacctgt	attagccat	gtgaaagtga	ttttccactt	atgtcagaat	1920
acaaagtttc	gtttagggat	aaattgtaaa	aaagaatata	ggcctgggt	gtggctcatg	1980
ctttaatttcc	ccatactcag	cttgcgttacc	ggaaccaaga	ctagtcgagg	caacatagtg	2040
aacctcattt	ctttaaaaaa	aaaaaaaaaa	aaa			2073

&lt;210&gt; 59

&lt;211&gt; 914

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 59

ggcacgagaa	gctatccatg	aaaacacttt	gtgatgtgt	gttttatatc	acagaatgg	60
acctgtgttt	tgattcaaca	agttcaaaac	actcttttca	taaaatctaa	gaagttatgt	120
ttctgaacct	attgaggcctt	tataggaaca	tatgaatatc	cagtcctaaa	aactagaaaat	180
gagcgatctg	tgaaaacact	ttgtgtatgt	ctgtttcata	tcacagaatg	ggacacctgt	240
tttgaagaaa	ccaaacctac	tgacacccctg	atcttggact	tctagtcata	gaactatctt	300
gggacatttc	ctataaatacg	atgcatgca	tacgtggctt	tggaaagatgg	attttaacca	360
actctactga	cgagtctgt	ttaggactct	ttgtccagac	tgacttcata	gagagtgtt	420
gggggtgtgg	gagaggccaa	gcctacaacgc	tgtgggaacgc	tggtggatgg	aaggctgggtt	480
agaattcttc	aggatctggg	gaacctcaga	gagtgtgtaa	acctgttggg	acgttggatg	540
agccaataact	tggcaaacgc	aagaatacaa	agtttctttt	ctttttccat	ttttttccat	600
atactcaaaa	gctggggcca	tgttacatgt	gcccaactgt	ttcattttttt	aatatctttt	660

ggttgcaggc catggcaacc aaatctaaag taacttaac aagaaaaagga atgtttggc	720
tcatgaaaata aaaaagttt gggatggcca ggcattgggg ctccccacctg taatctcagc	780
acttttaggag gctgagacag gagaattgct tgaacctggg aggtggaggt tgcaagtggc	840
taagatggca ccattgcaact ccagcctggc ggacaaaatg agactccatc cccctcaaaa	900
aaaaaaaaaaa aaaa	914

<210> 60  
<211> 41  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (41)  
<223> Xaa equals stop translation

<400> 60  
Met Asn Ile Tyr Thr Ile Leu Lys Ile Leu Pro His Arg Met Leu Trp  
1 5 10 15

Pro Phe Ile Tyr Leu Ile Ile Ala Thr Tyr Leu Phe Phe Ile Ser Ser  
20 25 30

Ser Thr His Ser Lys Gly Tyr Ser Xaa  
35 40

<210> 61  
<211> 41  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (41)  
<223> Xaa equals stop translation

<400> 61  
Met Asn Phe Ile Ser Val Val Trp Gly Thr Leu Phe Leu Thr Val Gly  
1 5 10 15

Glu Ala Ile Met Phe Leu Val Gly Gly Cys Ile Leu Phe Gln Ala Val  
20 25 30

Gly Lys Gln Asp Leu Ala Leu His Xaa  
35 40

<210> 62  
<211> 23  
<212> PRT  
<213> Homo sapiens

<220>

<221> SITE  
<222> (23)  
<223> Xaa equals stop translation

<400> 62  
Met Leu Leu Ser Pro Phe Ile Phe Cys Phe Phe Leu Ile Thr Val Gly  
1 5 10 15  
  
Leu Ile Glu Asn Trp Ser Xaa  
20

<210> 63  
<211> 27  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (27)  
<223> Xaa equals stop translation

<400> 63  
Met Met Met Leu Thr Leu Tyr Tyr Cys Lys Ile Asn Val Val Tyr Ile  
1 5 10 15  
  
Ser Leu Cys Thr Ala Ile Phe Cys Phe Trp Xaa  
20 25

<210> 64  
<211> 41  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (41)  
<223> Xaa equals stop translation

<400> 64  
Met Ser Ala Ala Leu Leu Ser Ser Ser Leu Cys Trp Leu Arg Thr Leu  
1 5 10 15  
  
Ala Tyr Arg Pro Thr Asn Asn Gln Glu Ala Ala Leu Val Gly Thr His  
20 25 30  
  
Cys Ser Lys Gln Gly Lys Gln Val Xaa  
35 40

<210> 65  
<211> 21  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (21)  
<223> Xaa equals stop translation

<400> 65  
Met His Val Ser Val Phe Val Leu Met Leu Leu Leu Pro Trp Gln Arg  
1 5 10 15

Lys Lys Lys Glu Xaa  
20

<210> 66  
<211> 64  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (64)  
<223> Xaa equals stop translation

<400> 66  
Met Glu Cys Ser Leu Thr Leu Ala Gly Leu Thr Leu Ala Leu Pro Val  
1 5 10 15

Gly Leu Pro Ala Ala Lys Thr Glu Ser Leu His Cys Ser Phe Ser Pro  
20 25 30

Val Thr Arg Pro Val Tyr Gly Pro Asn Gly His Ala Ser Glu Asn Leu  
35 40 45

Pro Trp Pro Leu Ser Lys Pro Ser Pro Gly Cys Asn Pro Cys Phe Xaa  
50 55 60

<210> 67  
<211> 7  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (7)  
<223> Xaa equals stop translation

<400> 67  
Ala Ser Cys Leu Cys Val Xaa  
1 5

<210> 68  
<211> 40  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (40)  
<223> Xaa equals stop translation

<400> 68  
Met Thr Val Val Thr Ala Leu Leu Leu Ile Ile Leu Gln Thr Arg Gly  
1 5 10 15

Cys Ser Gln Phe Gly Lys Ala Val Gly Pro Ala Ala Ser Ala Gly Thr  
20 25 30

Leu Asp Leu Ser Gly Trp Arg Xaa  
35 40

<210> 69  
<211> 34  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (34)  
<223> Xaa equals stop translation

<400> 69  
Met Leu Arg Phe Cys Met Leu Leu Gln Val Leu Phe His Met Cys Val  
1 5 10 15

Cys Gly Val Asp Val Glu Leu Leu Thr Thr Ala Ala Ile Thr Tyr Cys  
20 25 30

Ser Xaa

<210> 70  
<211> 14  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (14)  
<223> Xaa equals stop translation

<400> 70  
Phe Phe Phe Phe Phe Ser Gln Arg Leu Thr Lys Leu Xaa

1                   5                   10

<210> 71  
<211> 15  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (12)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (15)  
<223> Xaa equals stop translation

<400> 71  
Met Ser Arg Val Gln Ser Trp Cys Pro Ala Trp Xaa Arg Trp Xaa  
1                   5                   10                   15

<210> 72  
<211> 29  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (29)  
<223> Xaa equals stop translation

<400> 72  
Met Asn Arg His Leu Met Phe Leu Val Thr Leu Val Asn Phe Val Arg  
1                   5                   10                   15

Ile Cys Pro Pro Phe Leu Leu Met Tyr Ser Ala Tyr Xaa  
20                   25

<210> 73  
<211> 34  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (34)  
<223> Xaa equals stop translation

<400> 73  
Met Leu Leu Leu Thr Met Gly Phe Ile Gln Ile Leu Pro Val Phe Leu  
1                   5                   10                   15

40

Leu Val Tyr Phe Phe Tyr Ser Arg Val Gln Ser Lys Ile Pro His Cys  
20 25 30

Ile Xaa

<210> 74  
<211> 9  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (9)  
<223> Xaa equals stop translation

<400> 74  
Met Gly Leu Val Leu Glu Trp Cys Xaa  
1 5

<210> 75  
<211> 37  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (37)  
<223> Xaa equals stop translation

<400> 75  
Met Phe Leu Leu Ala Ile Leu Leu Pro Val Phe Leu Val Ala Trp Gly  
1 5 10 15

Gly Lys Thr Lys Glu Ser Gly Trp Arg Ala Glu Gly Cys Arg Ala Val  
20 25 30

Thr Leu Leu Leu Xaa  
35

<210> 76  
<211> 30  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (30)  
<223> Xaa equals stop translation

<400> 76  
Met Ala Phe Leu Thr Met Arg Ile Leu Phe Phe Ala Tyr Ser Phe Ser

41

1               5               10               15

Lys Lys His Phe Leu Met Glu Ile Ser Glu His Gly His Xaa  
20               25               30

<210> 77  
<211> 29  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (29)  
<223> Xaa equals stop translation

<400> 77  
Met Pro Val Thr Glu Leu Leu Gln Leu Leu Leu Thr Gln Lys Met  
1               5               10               15

Lys Arg Leu Leu Asp Trp Gln Gln Asn Lys Val Glu Xaa  
20               25

<210> 78  
<211> 62  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (62)  
<223> Xaa equals stop translation

<400> 78  
Met Ala Ile Phe Ser Leu Gly Phe Leu Phe Phe Leu Pro Val Ser Arg  
1               5               10               15

Asn Ala Leu Phe Ile Pro Leu Pro Asn Leu Ala Ser Ser Val Ser Tyr  
20               25               30

Val Phe Leu Ser His Lys Leu Glu Cys Phe Ile Phe Ser Tyr Ile Asn  
35               40               45

Phe Pro Phe Phe Leu Ser Thr Leu Lys Lys Val Gln Gln Xaa  
50               55               60

<210> 79  
<211> 29  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE

&lt;222&gt; (29)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 79

Met Trp Met Met Leu Gly Thr Val Leu Gly Pro Gly Ile Met Thr Gly  
1 5 10 15

Leu Met Met Met Met Thr Ala Met Arg Ala Arg Val Xaa  
20 25

&lt;210&gt; 80

&lt;211&gt; 189

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (189)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 80

Gln Gly Ser Arg Glu Leu Leu Leu Ala Leu Ser Trp Leu Leu Ala Arg  
1 5 10 15

Gly Pro Val Pro Glu Gln Met Leu Ala Gln Ala Arg Val Pro Leu Gly  
20 25 30

Asp Glu Met Thr Val Cys Gln Cys Glu Ala Leu Ala Ser Pro Gly Pro  
35 40 45

Pro Ala Pro His Met Glu Ala Glu Gly Pro Val Asp Val Arg His Val  
50 55 60

Gln Trp Leu Met Gly Lys Leu Arg Phe Arg Trp Arg Gln Leu Val Ser  
65 70 75 80

Ser Gln Gln Glu Gln Cys Ala Leu Leu Ser Lys Ile His Leu Tyr Thr  
85 90 95

Arg Gly Cys His Ser Asp Gln Ser Leu Ser His Leu Ser Val Thr Glu  
100 105 110

Ala Glu Met Leu Arg Gly Pro Arg Gly Arg Pro Ala Ala Ala Gly  
115 120 125

Leu Trp Ser Val Arg Thr Ser Ala Trp Arg Leu Ser Trp Arg Gly Gly  
130 135 140

Ala Leu Ser Trp Ser Ser Gly Gly Trp Thr Arg Ser Trp Ala Pro  
145 150 155 160

Val Pro Arg Arg Cys Leu Leu Gln Pro His Ser Pro Pro Pro Cys Pro  
165 170 175

Gly Ser Pro Ser Ala Gly Val Ala Ser Trp Thr Trp Xaa  
180   185

<210> 81  
<211> 17  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (17)  
<223> Xaa equals stop translation

<400> 81  
Leu Thr Gly Val Gly Leu Ser Ser Leu Cys Ser Trp Gln Cys Ser His  
1                         5   10                           15

Xaa

<210> 82  
<211> 35  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (35)  
<223> Xaa equals stop translation

<400> 82  
Met His Val Phe His Ser Ser Pro Leu Pro Val Tyr Ser Gly Gly Trp  
1                         5   10                           15

Cys Ser Leu Leu Val Leu Leu Ser Leu Ala Glu Arg Thr Met Gly Ser  
20   25   30

Ser Thr Xaa  
35

<210> 83  
<211> 13  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (13)  
<223> Xaa equals stop translation

<400> 83  
His Leu Leu Phe Leu Leu Cys Phe Thr Cys Lys Xaa

44

1 5 10

<210> 84  
<211> 37  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (37)  
<223> Xaa equals stop translation

&lt;400&gt;. 84

Met Asp Leu Lys Gly Arg Thr Lys Cys Ser Gln Tyr Phe Leu Leu Ser  
1 5 10 15

Val Val Leu Leu Leu Ser Met Gly Ile Val Gly Ser Ile Ile Glu Thr  
20 25 30

Leu Gly Lys Leu Xaa  
35

<210> 85  
<211> 103  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (103)  
<223> Xaa equals stop translation

&lt;400&gt; 85

Met Gly Leu Arg Asn Ile Leu Lys Val Cys Cys Thr His Asp Ile Thr  
1 5 10 15

Thr Ile Ser Ile Pro Leu Leu Val His Asp Met Ser Glu Glu Met  
20 25 30

Thr Ile Pro Trp Cys Leu Arg Arg Ala Glu Leu Val Phe Lys Cys Val  
35 40 45

Lys Gly Phe Met Met Glu Met Ala Ser Trp Asp Gly Gly Ile Ser Arg  
50 55 60

Thr Val Gln Phe Leu Val Pro Gln Ser Ile Ser Glu Glu Met Phe Tyr  
65 70 75 80

Gln Leu Ser Asn Met Leu Pro Gln Ile Phe Arg Val Ser Ser Thr Leu  
85 90 95

Thr Leu Thr Ser Lys His Xaa  
100

<210> 86  
<211> 33  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (33)  
<223> Xaa equals stop translation

<400> 86  
Met Met Val Ile Ile Val Lys Lys Ile Leu Leu Ile Val Leu Arg Glu  
1 5 10 15

Ser Thr Thr Leu Cys Gln Ile Pro Cys Phe Phe Leu Lys Pro Leu Lys  
20 25 30

Xaa

<210> 87  
<211> 74  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (74)  
<223> Xaa equals stop translation

<400> 87  
Met Ala Asn Ile His Trp Ala Ala Gln Thr Val Leu Leu Leu Pro His  
1 5 10 15

Leu Ala Pro Ala Phe Trp Gly Pro Ala Ala His Glu Leu Ile Pro Phe  
20 25 30

Gln Ala Ser Leu Gly Tyr Ile His Pro Leu Trp Leu Leu Thr His Gly  
35 40 45

Val Lys Pro Arg Ala His Phe Ser Tyr Gln Pro Gly Leu Gly His Ile  
50 55 60

Tyr Val Met Leu Leu Pro Ser Phe Thr Xaa  
65 70

<210> 88  
<211> 35  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (35)  
<223> Xaa equals stop translation

<400> 88  
Met Ile Ala Gln Leu Gln Ser Pro Cys Ser Phe Tyr Leu Ile Met Leu  
1 5 10 15  
  
Ala Leu Phe Ser Met Ser Val Trp Thr His Ile Lys Thr Pro Ser Cys  
20 25 30  
  
Thr Leu Xaa  
35

<210> 89  
<211> 70  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (70)  
<223> Xaa equals stop translation

<400> 89  
Met Ala Ser Leu Trp Leu Val Ser Trp Asp Leu Leu Leu Leu Ser  
1 5 10 15  
  
His Asp Cys Arg Leu Ala Arg Ile Trp Leu Trp Met Ala Trp Thr Gln  
20 25 30  
  
Ala Ser Arg Ser Ser Tyr Val Val Ala Ser Lys Cys His Val Trp Pro  
35 40 45  
  
Val Ala Asp Thr Ile Ile Lys Leu Leu Val Leu Phe Phe Phe Arg Cys  
50 55 60  
  
Phe Phe Leu Leu Ala Xaa  
65 70

<210> 90  
<211> 99  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (99)  
<223> Xaa equals stop translation

<400> 90  
Met Leu Ala Met Lys Leu Leu Val Leu Trp Thr Val Val Cys Pro Gln

47

1	5	10	15
Leu Val Phe Leu Gln Lys Gln Leu His Lys Thr Thr Pro Asn Leu Pro			
20	25	30	
Gln Ser Ser Gln Glu Leu Val Ser Asp Gln Arg Val Arg Gln Ser Pro			
35	40	45	
Arg Pro Gln Lys Leu Leu Phe Leu Pro Ala Pro Arg Gln Phe His Arg			
50	55	60	
Leu Pro Ser Arg Gly Arg Thr Thr Ala Lys Val Ser Ser Ser Thr Ser			
65	70	75	80
Gly Thr Lys Trp Ser Trp Gly Leu Cys Tyr Gly Thr Ser Leu Thr Glu			
85	90	95	

Cys Gln Xaa

<210> 91  
<211> 39  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (39)  
<223> Xaa equals stop translation

<400> 91  
Met Phe Leu Cys Cys Gln Ile Gly Pro Leu Gly Pro Phe Arg Phe Cys  
1               5               10               15  
  
Phe Leu Gly Ala Gly Phe Leu Pro Trp Thr Pro Ser Leu Gly Thr Val  
20               25               30  
  
Asp Ile Lys Cys Leu Ala Xaa  
35

<210> 92  
<211> 39  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (39)  
<223> Xaa equals stop translation

<400> 92  
Met Ser Val Cys Val Leu Tyr Leu Gln Ser Leu Val Ile Val Pro Tyr  
1               5               10               15

Ile Thr Cys Lys Gln Ile Leu Tyr Phe Ile Leu Ala Tyr Leu Thr Glu  
20   25   30

His Ile Thr Gln Lys Lys Xaa  
35

<210> 93  
<211> 47  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (47)  
<223> Xaa equals stop translation

<400> 93  
Met Pro Gly Lys Gln Asp Trp Leu Phe Leu Gln Lys Asn Arg Thr Val  
1   5   10   15

Pro Tyr Ile Trp Pro Val Gln Leu Val Tyr Leu Met Pro Met Phe Leu  
20   25   30

Leu Arg Val Met His Ala Tyr His Leu Phe Gln Arg Arg Asp Xaa  
35   40   45

<210> 94  
<211> 39  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (39)  
<223> Xaa equals stop translation

<400> 94  
Met Cys His His Thr Gln Leu Ser Ser Phe Leu Leu Asn Phe Phe Ser  
1   5   10   15

Glu Phe Ser Thr Leu Leu Val Leu Thr Ala Ile Ser Met Phe Cys Phe  
20   25   30

Ser Leu Val Thr Tyr Ala Xaa  
35

<210> 95  
<211> 24  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (24)  
<223> Xaa equals stop translation

<400> 95  
Met Phe Val Ala Val Phe Leu Phe Cys Phe Val Phe Cys Lys Phe His  
1 5 10 15

Ser Ala Ile Ser Val Phe Asn Xaa  
20

<210> 96  
<211> 36  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (36)  
<223> Xaa equals stop translation

<400> 96  
Met Met Ser Thr Ser Gln Thr Ala Pro Leu Trp Cys Leu Trp Pro Pro  
1 5 10 15

Ser Arg Met Thr Leu Ala Val Ser Leu Ser Pro Ala Ser Arg Arg Arg  
20 25 30

Gly Ser Arg Xaa  
35

<210> 97  
<211> 36  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (36)  
<223> Xaa equals stop translation

<400> 97  
Met Glu Asn Met Tyr Trp Gly Pro Leu Gly Leu Thr Ser Glu Ile Val  
1 5 10 15

Leu Phe Ile Leu Leu His Leu Ala Phe Gln Leu Met Glu Lys Tyr Lys  
20 25 30

Phe Lys Phe Xaa  
35

<210> 98  
<211> 45  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (45)  
<223> Xaa equals stop translation

<400> 98  
Gly Leu Gly Ser Gly Glu Trp Phe Pro Ala Leu Gln Leu Met Trp Leu  
1 5 10 15

Leu Arg Gly Thr Gln Ala Leu Phe His Tyr Leu Pro Asn Asn Gly Gly  
20 25 30

Pro Val Phe Asn Cys Ser Thr Thr Gln Asn Thr Xaa  
35 40 45

<210> 99  
<211> 32  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (32)  
<223> Xaa equals stop translation

<400> 99  
Met Leu Leu Arg Val Arg Arg Val Gly Ile Ile Cys His Leu Glu Phe  
1 5 10 15

Leu Cys Leu Ala Asp Leu Ser Ser Asp Leu Pro Ile Tyr Gln Arg Xaa  
20 25 30

<210> 100  
<211> 24  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (24)  
<223> Xaa equals stop translation

<400> 100  
Met Gly Trp Ser Ser His Trp Ser Asn Phe Leu Ser Val Arg Leu Trp  
1 5 10 15

Phe Ser Thr Leu Ala Ile Cys Xaa  
20

<210> 101  
<211> 47  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (47)  
<223> Xaa equals stop translation

<400> 101  
Met Met Ile Leu Phe Cys Gln Leu Leu Ala Val Ser Trp Gly Cys Cys  
1 5 10 15

Val Tyr Ser Thr Thr Asn Pro Lys Val Ser Ala Ile His Cys Gly Phe  
20 25 30

Ile Glu His Leu Leu Val Cys Ala Cys Val Gly Gly Ile Xaa  
35 40 45

<210> 102  
<211> 35  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (35)  
<223> Xaa equals stop translation

<400> 102  
Met Phe Tyr Trp Gly Gly Leu Ser Phe Tyr Phe Leu Leu Ser Ser Gly  
1 5 10 15

Val Gly Phe Tyr Cys Phe Leu Phe Gly Phe Gly Met Glu Ile Trp Ile  
20 25 30

Ala Ala Xaa  
35

<210> 103  
<211> 49  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (49)

<223> Xaa equals stop translation

<400> 103

Met Cys Val Gln Lys Arg Gln Leu Pro Ile Gly Pro Arg Ser His Phe  
1 5 10 15

Leu Met Val Leu Ile Leu Phe Met Gln Pro Val Pro Phe Val His Ile  
20 25 30

Ser Trp Leu Val Asn Lys Ala Thr Ser Asp Leu Phe Phe Lys Asp Leu  
35 40 45

Xaa

<210> 104

<211> 58

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (54)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 104

Met Tyr Met Pro Ala Pro Pro Leu Ser Leu Ala Pro Ala Val Gly Glu  
1 5 10 15

Thr Phe Pro Val Cys Arg Glu Arg Met Trp Ser Trp Gln Ala Trp Leu  
20 25 30

Leu Pro Asp Ser Val Ser Ser Gly Asn Thr Gln Pro Ser Phe Lys Lys  
35 40 45

Lys Lys Thr Arg Ser Xaa Pro Ser Asp Arg  
50 55

<210> 105

<211> 38

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (2)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (38)

<223> Xaa equals stop translation

<400> 105  
Met Xaa Phe Trp Ala Ala Met Gly Leu Leu Glu His Trp Cys Val His  
1 5 10 15  
Leu His Ser Met Cys Trp Asn Pro Gln Glu Ser Gly Gly Ala His Ile  
20 25 30  
Gln Gly Lys Val Ser Xaa  
35

<210> 106  
<211> 60  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (60)  
<223> Xaa equals stop translation

<400> 106  
Met Leu Ala Arg Leu Arg Gln Val Ser Thr Leu Cys Cys Leu Ser Leu  
1 5 10 15  
Ala Gln Thr Gly His Phe Val Trp Leu Phe Pro Ser Thr Arg Pro Gln  
20 25 30  
Trp Glu Gln Ala Ser Leu Pro Gln Ala Ser Glu Thr Asp His Pro Ile  
35 40 45  
Pro Pro Ser Pro Val Asn Leu Pro Leu Phe Pro Xaa  
50 55 60

<210> 107  
<211> 34  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (34)  
<223> Xaa equals stop translation

<400> 107  
Met Cys Val Cys Met His Val Cys Val Cys Cys Val Trp Trp Glu Ala  
1 5 10 15  
Ala Trp Gly Cys Gln Lys Arg Ala Glu Gly Gly Ile Arg Pro Ser Trp  
20 25 30  
Thr Xaa

<210> 108  
<211> 25  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (25)  
<223> Xaa equals stop translation

<400> 108  
Leu Phe His Ile Thr Glu Trp Asp Leu Cys Phe Glu Glu Thr Asn Pro  
1 5 10 15

Thr Asp Thr Leu Ile Leu Asp Phe Xaa  
20 25

<210> 109  
<211> 223  
<212> PRT  
<213> Homo sapiens

<400> 109  
Ser Glu Ala Arg Leu Ser Leu Ala Thr Phe Leu Leu Gly Ala Ser Val  
1 5 10 15

Leu Ala Leu Pro Leu Leu Thr Arg Ala Gly Leu Gln Gly Arg Thr Gly  
20 25 30

Leu Ala Leu Tyr Val Ala Gly Leu Asn Ala Leu Leu Leu Leu Tyr  
35 40 45

Arg Pro Pro Arg Tyr Gln Ile Ala Ile Arg Ala Cys Phe Leu Gly Phe  
50 55 60

Val Phe Gly Cys Gly Thr Leu Leu Ser Phe Ser Gln Ser Ser Trp Ser  
65 70 75 80

His Phe Gly Trp Tyr Met Cys Ser Leu Ser Leu Phe His Tyr Ser Glu  
85 90 95

Tyr Leu Val Thr Ala Val Asn Asn Pro Lys Ser Leu Ser Leu Asp Ser  
100 105 110

Phe Leu Leu Asn His Ser Leu Glu Tyr Thr Val Ala Ala Leu Ser Ser  
115 120 125

Trp Leu Glu Phe Thr Leu Glu Asn Ile Phe Trp Pro Glu Leu Lys Gln  
130 135 140

Ile Thr Trp Leu Ser Val Thr Gly Leu Leu Met Val Val Phe Gly Glu  
145 150 155 160

Cys Leu Arg Lys Ala Ala Met Phe Thr Ala Gly Ser Asn Phe Asn His  
165 170 175

Val Val Gln Asn Glu Lys Ser Asp Thr His Thr Leu Val Thr Ser Gly  
180 185 190

Val Tyr Ala Trp Phe Arg His Pro Ser Tyr Val Gly Trp Phe Tyr Trp  
195 200 205

Ser Ile Gly Thr Gln Val Met Leu Cys Asn Pro Ile Cys Gly Val  
210 215 220

<210> 110

<211> 223

<212> PRT

<213> Homo sapiens

<400> 110

Ser Glu Ala Arg Leu Ser Leu Ala Thr Phe Leu Leu Gly Ala Ser Val  
1 5 10 15

Leu Ala Leu Pro Leu Leu Thr Arg Ala Gly Leu Gln Gly Arg Thr Gly  
20 25 30

Leu Ala Leu Tyr Val Ala Gly Leu Asn Ala Leu Leu Leu Leu Tyr  
35 40 45

Arg Pro Pro Arg Tyr Gln Ile Ala Ile Arg Ala Cys Phe Leu Gly Phe  
50 55 60

Val Phe Gly Cys Gly Thr Leu Leu Ser Phe Ser Gln Ser Ser Trp Ser  
65 70 75 80

His Phe Gly Trp Tyr Met Cys Ser Leu Ser Leu Phe His Tyr Ser Glu  
85 90 95

Tyr Leu Val Thr Ala Val Asn Asn Pro Lys Ser Leu Ser Leu Asp Ser  
100 105 110

Phe Leu Leu Asn His Ser Leu Glu Tyr Thr Val Ala Ala Leu Ser Ser  
115 120 125

Trp Leu Glu Phe Thr Leu Glu Asn Ile Phe Trp Pro Glu Leu Lys Gln  
130 135 140

Ile Thr Trp Leu Ser Val Thr Gly Leu Leu Met Val Val Phe Gly Glu  
145 150 155 160

Cys Leu Arg Lys Ala Ala Met Phe Thr Ala Gly Ser Asn Phe Asn His  
165 170 175

Val Val Gln Asn Glu Lys Ser Asp Thr His Thr Leu Val Thr Ser Gly  
180 185 190

Val Tyr Ala Trp Phe Arg His Pro Ser Tyr Val Gly Trp Phe Tyr Trp  
195                   200                   205

Ser Ile Gly Thr Gln Val Met Leu Cys Asn Pro Ile Cys Gly Val  
210                   215                   220

<210> 111  
<211> 67  
<212> PRT  
<213> Homo sapiens

<400> 111  
Tyr Trp Ser Ile Gly Thr Gln Val Met Leu Cys Asn Pro Ile Cys Gly  
1                   5                   10                   15

Val Ser Tyr Ala Leu Thr Val Trp Arg Phe Phe Arg Asp Arg Thr Glu  
20                   25                   30

Glu Glu Glu Ile Ser Leu Ile His Phe Phe Gly Glu Glu Tyr Leu Glu  
35                   40                   45

Tyr Lys Lys Arg Val Pro Thr Gly Leu Pro Phe Ile Lys Gly Val Lys  
50                   55                   60

Val Asp Leu  
65

<210> 112  
<211> 64  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (9)  
<223> Xaa equals stop translation

<400> 112  
Tyr Trp Asn Ser Gly Asp Ala Val Xaa Pro His Leu Arg Arg His Tyr  
1                   5                   10                   15

Ala Leu Thr Val Trp Arg Phe Phe Arg Asp Arg Thr Glu Glu Glu  
20                   25                   30

Ile Ser Leu Ile His Phe Phe Gly Glu Glu Tyr Leu Glu Tyr Lys Lys  
35                   40                   45

Arg Val Pro Thr Gly Leu Pro Phe Ile Lys Gly Val Lys Val Asp Leu  
50                   55                   60

<210> 113  
<211> 83  
<212> PRT  
<213> Homo sapiens

<400> 113  
Lys Glu Glu Glu Arg Met Asn Val Asp Glu Glu Ile Gln Lys Leu Glu  
1 5 10 15

Glu Glu Ile His Arg Leu Gly Ser Arg Gln Thr Asp Gly Ser Tyr Lys  
20 25 30

Val Thr Phe Gly Val Leu Phe Asn Asp Asp Arg Cys Ala Asn Ile Phe  
35 40 45

Glu Ala Leu Val Gly Thr Leu Arg Ala Ala Lys Lys Arg Lys Ile Val  
50 55 60

Ala Phe Glu Gly Glu Leu Leu Leu Gln Gly Val His Asp Lys Val Glu  
65 70 75 80

Ile Thr Leu

<210> 114  
<211> 83  
<212> PRT  
<213> Homo sapiens

<400> 114  
Arg Arg Glu Ala Ala Met Asn Val Asp His Glu Val Asn Leu Leu Val  
1 5 10 15

Glu Glu Ile His Arg Leu Gly Ser Lys Asn Ala Asp Gly Lys Leu Ser  
20 25 30

Val Lys Phe Gly Val Leu Phe Arg Asp Asp Lys Cys Ala Asn Leu Phe  
35 40 45

Glu Ala Leu Val Gly Thr Leu Lys Ala Ala Lys Arg Arg Lys Ile Val  
50 55 60

Thr Tyr Pro Gly Glu Leu Leu Leu Gln Gly Val His Asp Asp Val Asp  
65 70 75 80

Ile Ile Leu

<210> 115  
<211> 60  
<212> PRT  
<213> Homo sapiens

&lt;400&gt; 115

Leu Arg Ser Gly Val Gln Asp Tyr Pro Gly Gln His Gly Lys Ile Pro  
1 5 10 15

Ser Leu Leu Lys Ile Gln Glu Leu Ala Gly His Gly Arg Cys Leu  
20 25 30

Gln Ser Gln Leu Leu Arg Arg Leu Arg Gln Glu Asn His Leu Asn Ser  
35 40 45

Gly Gly Arg Gly Cys Ser Glu Pro Lys Ser His Leu  
50 55 60

&lt;210&gt; 116

&lt;211&gt; 60

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (33)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 116

Leu Arg Ser Gly Val Arg Asp Gln Pro Gly Gln Pro Ser Glu Thr Pro  
1 5 10 15

Pro Leu Leu Lys Ile Gln Lys Leu Ala Gly Leu Gly Val Arg Leu  
20 25 30

Xaa Ser Gln Leu Leu Gly Lys Leu Arg Gln Glu Asn His Leu Asn Leu  
35 40 45

Gly Ser Gly Gly Cys Ser Glu Pro Arg Phe Arg Leu  
50 55 60

&lt;210&gt; 117

&lt;211&gt; 14

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 117

Cys Ile Pro Ala Trp Val Thr Glu Gly Asp Ser Val Ser Lys  
1 5 10

&lt;210&gt; 118

&lt;211&gt; 14

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

<221> SITE  
<222> (9)  
<223> Xaa equals stop translation

<400> 118  
Cys Ile Leu Ala Trp Ala Thr Lys Xaa Asp Ser Val Ser Glu  
1 5 10

<210> 119  
<211> 102  
<212> PRT  
<213> Homo sapiens

<400> 119  
Cys Asp Lys Asn Gly Lys Arg Ile Tyr Asp Pro Val Arg Gly Lys Cys  
1 5 10 15

Cys His Gln Cys Arg Ile Glu Ala Asn Val Phe Asn Gly Tyr Cys Gly  
20 25 30

Phe Tyr Arg Gln Lys Thr Leu Gly Tyr His Thr Gln Cys Ser Gln Cys  
35 40 45

Asn His Ser Val Arg Gly Gln Phe Cys Gly Asp Cys Leu Tyr Met Arg  
50 55 60

Tyr Gly Glu His Val Leu Glu Ala Leu Glu Asn Pro Asp Trp Ile Cys  
65 70 75 80

Pro Val Cys Arg Asp Ile Cys Asn Cys Ser Phe Cys Arg Thr Lys Lys  
85 90 95

Gly Trp Leu Pro Thr Gly  
100

<210> 120  
<211> 89  
<212> PRT  
<213> Homo sapiens

<400> 120  
Cys Ser Asn Ser Arg Glu Lys Ile Tyr Asn Arg Ser Leu Gly Ser Thr  
1 5 10 15

Cys His Gln Cys Arg Gln Lys Thr Ile Asp Thr Lys Thr Asn Cys Arg  
20 25 30

Asn Pro Asp Cys Trp Gly Val Arg Gly Gln Phe Cys Gly Pro Cys Leu  
35 40 45

Arg Asn Arg Tyr Gly Glu Glu Val Arg Asp Ala Leu Leu Asp Pro Asn  
50 55 60

60

Trp His Cys Pro Pro Cys Arg Gly Ile Cys Asn Cys Ser Phe Cys Arg  
65                   70                   75                   80

Gln Arg Asp Gly Arg Cys Ala Thr Gly  
85

<210> 121  
<211> 62  
<212> PRT  
<213> Homo sapiens

<400> 121  
Gly Gln Tyr Val Asp Val Thr Ala Lys Thr Ile Gly Lys Gly Phe Gln  
1               5                   10                   15

Gly Val Met Lys Arg Trp Gly Phe Lys Gly Gln Pro Ala Thr His Gly  
20               25                   30

Gln Thr Lys Thr His Arg Arg Pro Gly Ala Val Ala Thr Gly Asp Ile  
35               40                   45

Gly Arg Val Trp Pro Gly Thr Lys Met Pro Gly Lys Met Gly  
50               55                   60

<210> 122  
<211> 62  
<212> PRT  
<213> Homo sapiens

<400> 122  
Gly Gln Tyr Val Asp Val Thr Ala Lys Thr Ile Gly Lys Gly Phe Gln  
1               5                   10                   15

Gly Val Met Lys Arg Trp Gly Phe Lys Gly Gln Pro Ala Thr His Gly  
20               25                   30

Gln Thr Lys Thr His Arg Arg Pro Gly Ala Val Ala Thr Gly Asp Ile  
35               40                   45

Gly Arg Val Trp Pro Gly Thr Lys Met Pro Gly Lys Met Gly  
50               55                   60

<210> 123  
<211> 77  
<212> PRT  
<213> Homo sapiens

<400> 123  
Lys Val Trp Arg Ile Asn Thr Lys His Asn Ile Ile Tyr Val Asn Gly  
1               5                   10                   15

Ser Val Pro Gly His Lys Asn Cys Leu Val Lys Val Lys Asp Ser Lys

61

20 25 30

Leu Pro Ala Tyr Lys Asp Leu Gly Lys Asn Leu Pro Phe Pro Thr Tyr  
35 40 45

Phe Pro Asp Gly Asp Glu Glu Leu Pro Glu Asp Leu Tyr Asp Glu  
50 55 60

Asn Val Cys Gln Pro Gly Ala Pro Ser Ile Thr Phe Ala  
65 70 75

&lt;210&gt; 124

&lt;211&gt; 77

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 124

Lys Val Trp Arg Ile Asn Thr Lys His Asn Ile Ile Tyr Val Asn Gly  
1 5 10 15

Ser Val Pro Gly His Lys Asn Cys Leu Val Lys Val Lys Asp Ser Lys  
20 25 30

Leu Pro Ala Tyr Lys Asp Leu Gly Lys Asn Leu Pro Phe Pro Thr Tyr  
35 40 45

Phe Pro Asp Gly Asp Glu Glu Leu Pro Glu Asp Leu Tyr Asp Glu  
50 55 60

Asn Val Cys Gln Pro Gly Ala Pro Ser Ile Thr Phe Ala  
65 70 75

&lt;210&gt; 125

&lt;211&gt; 87

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 125

Lys Val Gly Ser Arg Arg Val Ile Gln Cys Gly Ala Ala Leu Met Leu  
1 5 10 15

Ala Leu Gly Met Ile Gly Lys Phe Ser Ala Leu Phe Ala Ser Leu Pro  
20 25 30

Asp Pro Val Leu Gly Ala Leu Phe Cys Thr Leu Phe Gly Met Ile Thr  
35 40 45

Ala Val Gly Leu Ser Asn Leu Gln Phe Ile Asp Leu Asn Ser Ser Arg  
50 55 60

Asn Leu Phe Val Leu Gly Phe Ser Ile Phe Phe Gly Leu Val Leu Pro  
65 70 75 80

Ser Tyr Leu Arg Gln Asn Pro  
85

<210> 126

<211> 87

<212> PRT

<213> Homo sapiens

<400> 126

Gln Val Gly Ser Arg Arg Val Val Gln Tyr Gly Ala Ala Ile Met Leu  
1 5 10 15

Val Leu Gly Thr Ile Gly Lys Phe Thr Ala Leu Phe Ala Ser Leu Pro  
20 25 30

Asp Pro Ile Leu Gly Gly Met Phe Cys Thr Leu Phe Gly Met Ile Thr  
35 40 45

Ala Val Gly Leu Ser Asn Leu Gln Phe Val Asp Met Asn Ser Ser Arg  
50 55 60

Asn Leu Phe Val Leu Gly Phe Ser Met Phe Phe Gly Leu Thr Leu Pro  
65 70 75 80

Asn Tyr Leu Glu Ser Asn Pro  
85

<210> 127

<211> 54

<212> PRT

<213> Homo sapiens

<400> 127

Trp Leu Leu Cys Phe Ile Phe Thr Val Thr Asp Val Phe Pro Pro Asp  
1 5 10 15

Ser Thr Lys Tyr Gly Phe Tyr Ala Arg Thr Asp Ala Arg Gln Gly Val  
20 25 30

Leu Leu Val Ala Pro Trp Phe Lys Val Pro Tyr Pro Phe Gln Trp Gly  
35 40 45

Leu Pro Thr Val Ser Ala  
50

<210> 128

<211> 54

<212> PRT

<213> Homo sapiens

<400> 128

Trp Leu Leu Cys Tyr Val Leu Thr Asp Val Leu Pro Thr Asp

1 5 10 15

Pro Lys Ala Tyr Gly Phe Gln Ala Arg Thr Asp Ala Arg Gly Asp Ile  
20 25 30

Met Ala Ile Ala Pro Trp Ile Arg Ile Pro Tyr Pro Cys Gln Trp Gly  
35 40 45

Leu Pro Thr Val Thr Ala  
50

<210> 129

<211> 56

<212> PRT

<213> Homo sapiens

<400> 129

Gly Thr Pro Glu Glu Arg Gly Ile Arg Lys Trp Lys Lys Gly Val Gly  
1 5 10 15

Lys Gly Asn Lys Ser Leu Asp Gly Met Glu Ser Tyr Asn Leu Pro Phe  
20 25 30

Gly Met Asn Ile Ile Lys Lys Tyr Arg Cys Phe Ser Tyr Leu Pro Ile  
35 40 45

Ser Pro Thr Phe Val Gly Tyr Thr  
50 55

<210> 130

<211> 56

<212> PRT

<213> Homo sapiens

<400> 130

Gly Ser Pro Glu Glu Arg Gly Leu Ile Gln Trp Lys Ala Gly Ala His  
1 5 10 15

Ala Asn Ser Asp Met Ser Ser Leu Lys Ser Tyr Asp Phe Pro Ile  
20 25 30

Gly Met Gly Ile Val Lys Arg Ile Thr Phe Leu Lys Tyr Ile Pro Ile  
35 40 45

Cys Pro Val Phe Lys Gly Phe Ser  
50 55

<210> 131

<211> 22

<212> PRT

<213> Homo sapiens

<400> 131  
Ala Ser Ile Ile Glu Ser Ile Gly Asp Tyr Tyr Ala Cys Ala Arg Leu  
1 5 10 15  
Ser Cys Ala Pro Pro Pro  
20

<210> 132  
<211> 22  
<212> PRT  
<213> Homo sapiens

<400> 132  
Ala Gly Ile Ile Glu Ser Ile Gly Asp Tyr Tyr Ala Cys Ala Arg Leu  
1 5 10 15  
Ala Gly Ala Pro Pro Pro  
20

<210> 133  
<211> 27  
<212> PRT  
<213> Homo sapiens

<400> 133  
Gln Trp Gly Leu Pro Thr Val Ser Ala Ala Gly Val Ile Gly Met Leu  
1 5 10 15  
Ser Ala Val Val Ala Ser Ile Ile Glu Ser Ile  
20 25

<210> 134  
<211> 27  
<212> PRT  
<213> Homo sapiens

<400> 134  
Gln Tyr Gly Ala Ala Ile Met Leu Val Leu Gly Thr Ile Gly Lys Phe  
1 5 10 15  
Thr Ala Leu Phe Ala Ser Leu Pro Asp Pro Ile  
20 25

<210> 135  
<211> 157  
<212> PRT  
<213> Homo sapiens

<400> 135  
Glu Ile Leu Met Glu Leu Leu Gly Ser Leu His His Pro Tyr Ile Tyr  
1 5 10 15

Pro Val Leu Asp Leu Gly Phe Leu Arg Asn Ser Ser Tyr Asn Tyr Ala  
 20                    25                    30

Cys Leu Val Thr Pro Phe Asn Ser Arg Gly Ser Leu Lys Asp Leu Ile  
 35                    40                    45

Tyr Lys Ala Gln Trp Asn Glu Pro Trp Ala Arg Lys Tyr Thr Arg Lys  
 50                    55                    60

Pro Asn Gly Leu Pro Val Ser Gln Val Gln Arg Leu Gly Arg Gln Ile  
 65                    70                    75                    80

Leu Glu Ala Leu Leu Phe Leu Lys Glu Arg Gly Phe Pro Leu His Gly  
 85                    90                    95

His Leu His Ser Gly Asn Val Ile Leu Gln Asn Gly Ala Ala Arg Leu  
 100                  105                  110

Ser Gly Leu Glu Asn Gly Leu Leu Gly Leu Ser Ser Arg Ile Asn Ala  
 115                  120                  125

Val Met Trp Ser Arg Ser Val Thr Glu Ile Glu Asn Val Asp Ile Val  
 130                  135                  140

Cys Phe Gly His Leu Leu Tyr Glu Met Cys Thr Gly Gln  
 145                  150                  155

<210> 136

<211> 155

<212> PRT

<213> Homo sapiens

<400> 136

Gln Cys Leu Ile Lys Leu Leu Pro Ser Cys Leu His Pro Tyr Ile Tyr  
 1                    5                    10                    15

Arg Val Thr Phe Ala Thr Ala Asn Glu Ser Ser Ala Leu Leu Ile Arg  
 20                  25                  30

Met Phe Asn Glu Lys Gly Thr Leu Lys Asp Leu Ile Tyr Lys Ala Lys  
 35                  40                  45

Pro Lys Asp Pro Phe Leu Lys Lys Tyr Cys Asn Pro Lys Lys Ile Gln  
 50                  55                  60

Gly Leu Glu Leu Gln Gln Ile Lys Thr Tyr Gly Arg Gln Ile Leu Glu  
 65                  70                  75                  80

Val Leu Lys Phe Leu His Asp Lys Gly Phe Pro Tyr Gly His Leu His  
 85                  90                  95

Ala Ser Asn Val Met Leu Asp Gly Asp Thr Cys Arg Leu Leu Asp Leu  
 100                105                110

Glu Asn Ser Leu Leu Gly Leu Pro Ser Phe Tyr Arg Ser Tyr Phe Ser  
115 120 125

Gln Phe Arg Lys Ile Asn Thr Leu Glu Ser Val Asp Val His Cys Phe  
130 135 140

Gly His Leu Leu Tyr Glu Met Thr Tyr Gly Arg  
145 150 155

<210> 137

<211> 32

<212> PRT

<213> Homo sapiens

<400> 137

Ala Thr Arg Asn Thr Gly Lys Ser Ile Ala Asn Lys Asn Ile Ala Asn  
1 5 10 15

Pro Thr Ala Thr Leu Leu Ala Ser Cys Met Met Leu Asp His Leu Lys  
20 25 30

<210> 138

<211> 32

<212> PRT

<213> Homo sapiens

<400> 138

Ala Thr Arg Asn Thr Gly Lys Ser Ile Ala Asn Lys Asn Ile Ala Asn  
1 5 10 15

Pro Thr Ala Thr Leu Leu Ala Ser Cys Met Met Leu Asp His Leu Lys  
20 25 30

<210> 139

<211> 30

<212> PRT

<213> Homo sapiens

<400> 139

Pro Ala Leu Leu Cys Arg Pro Trp Glu Val Leu Ala Ala His Glu Ala  
1 5 10 15

Pro Arg Arg Ser Ile Ser Ser Gln Gln Thr Ile Pro Pro Ser  
20 25 30

<210> 140  
<211> 33  
<212> PRT  
<213> Homo sapiens

<400> 140  
Pro Gly Leu Tyr Cys Arg His His Gln Val Ile Pro Glu His Phe His  
1 5 10 15

His Pro Thr Arg Lys Ala Cys Pro His Lys Leu Ser Val Pro Thr Pro  
20 25 30

Ser

<210> 141  
<211> 156  
<212> PRT  
<213> Homo sapiens

<400> 141  
Met Ala Ala Ile Gly Val His Leu Gly Cys Thr Ser Ala Cys Val Ala  
1 5 10 15

Val Tyr Lys Asp Gly Arg Ala Asp Val Val Ala Asn Asp Ala Gly Asp  
20 25 30

Arg Val Thr Pro Ala Ile Val Ala Tyr Ser Glu Arg Glu Gln Val Val  
35 40 45

Gly Leu Ala Ala Lys Gln Ser Arg Ile Arg His Val Ser Ser Thr Val  
50 55 60

Val Lys Val Lys Gln Ile Leu Gly Arg Ser Ser Ala Asp Pro Gln Ala  
65 70 75 80

Gln Lys Tyr Ile Ser Glu Ser Lys Cys Leu Val Ile Glu Lys Asn Gly  
85 90 95

Lys Leu Arg Tyr Glu Ile Asp Thr Gly Glu Glu Thr Lys Leu Val Asn  
100 105 110

Pro Glu Asp Val Ala Arg Leu Ile Phe Ser Lys Met Lys Glu Thr Ala  
115 120 125

His Ser Val Leu Gly Ser Asp Ala Asn Asp Val Val Val Thr Val Pro  
130 135 140

Phe Asp Phe Gly Glu Lys Gln Lys Ser Ala Leu Gly  
145 150 155

<210> 142

<211> 156  
<212> PRT  
<213> Homo sapiens

<400> 142

Met	Ala	Ala	Ile	Gly	Val	His	Leu	Gly	Cys	Thr	Ser	Ala	Cys	Val	Ala
1				5					10					15	
Val	Tyr	Lys	Asp	Gly	Arg	Ala	Gly	Val	Val	Ala	Asn	Asp	Ala	Gly	Asp
	20							25					30		
Arg	Val	Thr	Pro	Ala	Val	Val	Ala	Tyr	Ser	Glu	Asn	Glu	Glu	Ile	Val
	35							40				45			
Gly	Leu	Ala	Ala	Lys	Gln	Ser	Arg	Ile	Arg	Asn	Ile	Ser	Asn	Thr	Val
	50					55				60					
Met	Lys	Val	Lys	Gln	Ile	Leu	Gly	Arg	Ser	Ser	Ser	Asp	Pro	Gln	Ala
	65					70				75			80		
Gln	Lys	Tyr	Ile	Ala	Glu	Ser	Lys	Cys	Leu	Val	Ile	Glu	Lys	Asn	Gly
		85							90				95		
Lys	Leu	Arg	Tyr	Glu	Ile	Asp	Thr	Gly	Glu	Glu	Thr	Lys	Phe	Val	Asn
		100						105				110			
Pro	Glu	Asp	Val	Ala	Arg	Leu	Ile	Phe	Ser	Lys	Met	Lys	Glu	Thr	Ala
	115						120					125			
His	Ser	Val	Leu	Gly	Ser	Asp	Ala	Asn	Asp	Val	Val	Ile	Thr	Val	Pro
	130						135				140				
Phe	Asp	Phe	Gly	Glu	Lys	Gln	Lys	Asn	Ala	Leu	Gly				
	145						150				155				

<210> 143  
<211> 165  
<212> PRT  
<213> Homo sapiens

<400> 143

Phe	Lys	His	Asp	Val	Arg	Gly	Asn	Ala	Arg	Ala	Met	Met	Lys	Leu	Met
1				5					10				15		
Asn	Ser	Ala	Glu	Val	Ala	Lys	His	Ser	Leu	Ser	Thr	Leu	Gly	Ser	Ala
		20						25				30			
Asn	Cys	Phe	Val	Asp	Ser	Leu	Tyr	Glu	Gly	Gln	Asp	Phe	Asp	Cys	Asn
		35						40				45			
Val	Ser	Arg	Ala	Arg	Phe	Glu	Leu	Leu	Cys	Ser	Pro	Leu	Phe	Asn	Lys
		50						55				60			
Cys	Thr	Glu	Ala	Ile	Arg	Glu	Leu	Leu	Arg	Gln	Thr	Gly	Phe	Thr	Ala

69

65	70	75	80
Asp Asp Ile Asn Lys Val Val Leu Trp His Glu Gly Gly Ser Ser Arg			
85		90	95
Ile Pro Lys Leu Gln Gln Leu Ile Lys Asp Leu Phe Pro Ala Val Asp			
100		105	110
Leu Leu Asn Ser Ile Pro Pro Asp Glu Val Ile Pro Ile Gly Ala Ala			
115		120	125
Ile Glu Ala Gly Ile Leu Val Gly Lys Glu Ser Thr Ser Gly Asp Asp			
130		135	140
Ser Val Met Ile Glu Cys Ser Ala Lys Asp Ile Leu Val Lys Gly Val			
145		150	155
Asp Glu Ser Gly Ala			
	165		
<210> 144			
<211> 163			
<212> PRT			
<213> Homo sapiens			
<400> 144			
Phe Lys His Asp Val Arg Gly Asn Ala Arg Ala Met Met Lys Leu Thr			
1	5	10	15
Asn Ser Ala Glu Val Ala Lys His Ser Leu Ser Thr Leu Gly Ser Ala			
20		25	30
Asn Cys Phe Leu Asp Ser Leu Tyr Glu Gly Gln Asp Phe Asp Cys Asn			
35		40	45
Val Ser Arg Ala Arg Phe Glu Leu Leu Cys Ser Pro Leu Phe Asn Lys			
50		55	60
Cys Ile Glu Ala Ile Arg Gly Leu Leu Asp Gln Asn Gly Phe Thr Ala			
65		70	75
Asp Asp Ile Asn Lys Val Val Leu Cys Gly Gly Ser Ser Arg Ile Pro			
85		90	95
Lys Leu Gln Gln Leu Ile Lys Asp Leu Phe Pro Ala Val Glu Leu Leu			
100		105	110
Asn Ser Ile Pro Pro Asp Glu Val Ile Pro Ile Gly Ala Ala Ile Glu			
115		120	125
Ala Gly Ile Leu Ile Gly Lys Glu Asn Leu Leu Val Glu Asp Ser Leu			
130		135	140
Met Ile Glu Cys Ser Ala Arg Asp Ile Leu Val Lys Gly Val Asp Glu			

70

145

150

155

160

Ser Gly Ala

&lt;210&gt; 145

&lt;211&gt; 262

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 145

Met Gln Lys Arg Pro Phe Pro Tyr Glu Ile Asp Glu Ile Leu Gly Val  
1 5 10 15Arg Asp Leu Arg Lys Val Leu Ala Leu Leu Gln Lys Ser Asp Asp Pro  
20 25 30Phe Ile Gln Gln Val Ala Leu Leu Thr Leu Ser Asn Asn Ala Asn Tyr  
35 40 45Ser Cys Asn Gln Glu Thr Ile Arg Lys Leu Gly Gly Leu Pro Ile Ile  
50 55 60Ala Asn Met Ile Asn Lys Thr Asp Pro His Ile Lys Glu Lys Ala Leu  
65 70 75 80Met Ala Met Asn Asn Leu Ser Glu Asn Tyr Glu Asn Gln Gly Arg Leu  
85 90 95Gln Val Tyr Met Asn Lys Val Met Asp Asp Ile Met Ala Ser Asn Leu  
100 105 110Asn Ser Ala Val Gln Val Val Gly Leu Lys Phe Leu Thr Asn Met Thr  
115 120 125Ile Thr Asn Asp Tyr Gln His Leu Leu Val Asn Ser Ile Ala Asn Phe  
130 135 140Phe Arg Leu Leu Ser Gln Gly Gly Lys Ile Lys Val Glu Ile Leu  
145 150 155 160Lys Ile Leu Ser Asn Phe Ala Glu Asn Pro Asp Met Leu Lys Lys Leu  
165 170 175Leu Ser Thr Gln Val Pro Ala Ser Phe Ser Ser Leu Tyr Asn Ser Tyr  
180 185 190Val Glu Ser Glu Ile Leu Ile Asn Ala Leu Thr Leu Phe Glu Ile Ile  
195 200 205Tyr Asp Asn Leu Arg Ala Glu Val Phe Asn Tyr Arg Glu Phe Asn Lys  
210 215 220

Gly Ser Leu Phe Tyr Leu Cys Thr Thr Ser Gly Val Cys Val Lys Lys

225

230

235

240

Ile Arg Ala Leu Ala Asn His His Asp Leu Leu Val Lys Val Lys Val  
245 250 255

Ile Lys Leu Val Asn Lys  
260

<210> 146  
<211> 264  
<212> PRT  
<213> Homo sapiens

<400> 146  
Val Gln Lys Arg Ala Ser Pro Asn Ser Asp Asp Thr Val Leu Ser Pro  
1 5 10 15

Gln Glu Leu Gln Lys Val Leu Cys Leu Val Glu Met Ser Glu Lys Pro  
20 25 30

Tyr Ile Leu Glu Ala Ala Leu Ile Ala Leu Gly Asn Asn Ala Ala Tyr  
35 40 45

Ala Phe Asn Arg Asp Ile Ile Arg Asp Leu Gly Gly Leu Pro Ile Val  
50 55 60

Ala Lys Ile Leu Asn Thr Arg Asp Pro Ile Val Lys Glu Lys Ala Leu  
65 70 75 80

Ile Val Leu Asn Asn Leu Ser Val Asn Ala Glu Asn Gln Arg Arg Leu  
85 90 95

Lys Val Tyr Met Asn Gln Val Cys Asp Asp Thr Ile Thr Ser Arg Leu  
100 105 110

Asn Ser Ser Val Gln Leu Ala Gly Leu Arg Leu Leu Thr Asn Met Thr  
115 120 125

Val Thr Asn Glu Tyr Gln His Met Leu Ala Asn Ser Ile Ser Asp Phe  
130 135 140

Phe Arg Leu Phe Ser Ala Gly Asn Glu Glu Thr Lys Leu Gln Val Leu  
145 150 155 160

Lys Leu Leu Leu Asn Leu Ala Glu Asn Pro Ala Met Thr Arg Glu Leu  
165 170 175

Leu Arg Ala Gln Val Pro Ser Ser Leu Gly Ser Leu Phe Asn Lys Lys  
180 185 190

Glu Asn Lys Glu Val Ile Leu Lys Leu Leu Val Ile Phe Glu Asn Ile  
195 200 205

Asn Asp Asn Phe Lys Trp Glu Glu Asn Glu Pro Thr Gln Asn Gln Phe

210                    215                    220

Gly Glu Gly Ser Leu Phe Phe Leu Lys Glu Phe Gln Val Cys Ala  
225                    230                    235                    240

Asp Lys Val Leu Gly Ile Glu Ser His His Asp Phe Leu Val Lys Val  
245                    250                    255

Lys Val Gly Lys Phe Met Ala Lys  
260

<210> 147

<211> 94

<212> PRT

<213> Homo sapiens

<400> 147

Leu Pro Ile Phe Asp Pro Phe Leu Met Gly Ala Leu Leu Met Leu Lys  
1                    5                    10                    15

Leu Ile Ile Pro Tyr Gly Leu Leu Ser Thr Cys Leu Gly Ile Leu Asn  
20                    25                    30

Leu Lys Leu Asn Phe Lys Asp Tyr Thr Ile Ser Ser Leu Ile Ile Ser  
35                    40                    45

Met Ser Asp Ile Leu Ser Leu Asn Phe Phe Tyr Leu Leu Arg Thr Glu  
50                    55                    60

Gly Ser Trp Leu Asp Ile Gly Ile Thr Ile Ser Asn Tyr Cys Leu Ala  
65                    70                    75                    80

Ile Leu Ser Ser Leu Phe Met Leu Ile Leu Glu Val Leu Gly  
85                    90

<210> 148

<211> 94

<212> PRT

<213> Homo sapiens

<400> 148

Leu Thr Val Phe Ser Pro Phe Met Met Gly Ala Leu Met Met Trp Lys  
1                    5                    10                    15

Ile Leu Ile Pro Phe Val Leu Val Met Cys Ala Phe Glu Ala Val Gln  
20                    25                    30

Leu Thr Thr Gln Leu Ser Ser Lys Ser Leu Phe Leu Ile Val Leu Val  
35                    40                    45

Ile Ser Asp Ile Met Ala Leu His Phe Phe Phe Leu Val Lys Asp Tyr  
50                    55                    60

Gly Ser Trp Leu Asp Ile Gly Thr Ser Ile Ser His Tyr Val Ile Val  
 65                    70                    75                    80

Met Ser Met Thr Ile Phe Leu Val Phe Leu Asn Gly Leu Gly  
 85                    90

<210> 149  
<211> 91  
<212> PRT  
<213> Homo sapiens

<400> 149  
Trp Ile Ile Thr Ser Val Leu Leu Ser Thr Phe Thr Leu Phe Asp Ala  
 1                    5                    10                    15

Val Lys Ile Glu Asp Leu Asn Gln Ile His Leu Ala Gly Leu Leu Ile  
 20                    25                    30

Ile Leu Ser Ala Phe Tyr Ala Leu Tyr Lys Ile His Ser Arg Ile Asn  
 35                    40                    45

Ser Tyr Thr Arg Ala Ile Phe Ala Ile Gln Ile Ser Leu Val Ala Ala  
 50                    55                    60

Met Leu Ala Val Thr His Arg Ser Val Ile Ser Leu Gln Leu Arg Gln  
 65                    70                    75                    80

Gly Leu Pro Arg Glu Ser Gln Val Ala Gly Trp  
 85                    90

<210> 150  
<211> 95  
<212> PRT  
<213> Homo sapiens

<400> 150  
Trp Thr Phe Phe Ser Leu Leu Ala Val Phe Pro Leu Met Pro Val  
 1                    5                    10                    15

Val Gly Arg Lys Pro Asp Ile Ser Leu Val Met Gly Ala Gly Leu Leu  
 20                    25                    30

Val Leu Leu Leu Ser Leu Cys Val Val Thr Ser Leu Met Lys Arg Lys  
 35                    40                    45

Asp Ser Phe Ile Lys Glu Glu Leu Leu Val His Leu Leu Gln Val Leu  
 50                    55                    60

Ser Thr Val Leu Ser Met Tyr Val Val Tyr Ser Thr Gln Ser Ser Leu  
 65                    70                    75                    80

Leu Arg Lys Gln Gly Leu Pro Leu Met Asn Gln Ile Ile Ser Trp  
 85                    90                    95

<210> 151  
<211> 55  
<212> PRT  
<213> Homo sapiens

<400> 151  
Leu Arg Ser Gly Val Gln Asp Tyr Pro Gly Gln His Gly Lys Ile Pro  
1 5 10 15

Ser Leu Leu Lys Ile Gln Glu Leu Ala Gly His Gly Gly Arg Cys Leu  
20 25 30

Gln Ser Gln Leu Leu Arg Arg Leu Arg Gln Glu Asn His Leu Asn Ser  
35 40 45

Gly Gly Arg Gly Cys Ser Glu  
50 55

<210> 152  
<211> 55  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (33)  
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 152  
Leu Arg Ser Gly Val Gln Val Gln Pro Gly Gln His Gly Glu Thr Pro  
1 5 10 15

Ser Leu Leu Lys Ile Lys Lys Leu Ala Arg His Gly Gly Met Arg Leu  
20 25 30

Xaa Ser Gln Pro Leu Glu Arg Leu Arg Gln Glu Asn Cys Leu Asn Leu  
35 40 45

Gly Gly Arg Gly Cys Ser Glu  
50 55

<210> 153  
<211> 15  
<212> PRT  
<213> Homo sapiens

<400> 153  
Cys Ile Pro Ala Trp Val Thr Glu Gly Asp Ser Val Ser Lys Gln  
1 5 10 15

<210> 154  
<211> 15  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (9)  
<223> Xaa equals stop translation

<400> 154  
Cys Thr Pro Val Trp Val Thr Glu Xaa Asp Ser Thr Ser Lys Lys  
1 5 10 15

<210> 155  
<211> 69  
<212> PRT  
<213> Homo sapiens

<400> 155  
Ile Val Tyr His Leu Val Val Asp Glu Thr Leu Gln Ser Leu Glu Ile  
1 5 10 15

Asn Ser Arg His Pro Cys Leu Ala Gly Val Arg Asn Ile Ile Arg Thr  
20 25 30

Ala Ala Arg Tyr Asn Thr Ser Thr Ile His Ile Pro Leu Leu Ile  
35 40 45

Asp Arg Pro Asp Glu Ser Thr Thr Ile Ala Trp Cys Leu Lys Arg Ala  
50 55 60

Glu Met Leu Phe Lys  
65

<210> 156  
<211> 69  
<212> PRT  
<213> Homo sapiens

<400> 156  
Val Ala Phe His Leu Cys Val Asp Asp His Val Lys Ser Gly Asn Ile  
1 5 10 15

Thr Ala Arg Asp Pro Ala Ile Met Gly Leu Arg Asn Ile Leu Lys Val  
20 25 30

Cys Cys Thr His Asp Ile Thr Thr Ile Ser Ile Pro Leu Leu Val  
35 40 45

His Asp Met Ser Glu Glu Met Thr Ile Pro Trp Cys Leu Arg Arg Ala  
50 55 60

Glu Leu Val Phe Lys  
65

<210> 157  
<211> 75  
<212> PRT  
<213> *Homo sapiens*

<400> 157  
Phe Phe Phe Phe Glu Thr Gln Ser His Ser Val Thr Arg Leu Glu Cys  
1 5 10 15

Ser Gly Thr Ile Ser Ala His Cys Asn Leu Cys Leu Pro Gly Ser Ser  
20 25 30

Asn	Ser	Pro	Ala	Ser	Ala	Ser	Arg	Val	Ala	Gly	Thr	Ala	Gly	Thr	Cys
			35				40					45			

Arg Arg Ala Gln Leu Ile Phe Val Phe Leu Ala Glu Met Gly Phe His  
50 55 60

His Val Gly Arg Asp Gly Leu Asp Leu Asn Leu  
65 70 75

<210> 158  
<211> 73  
<212> PRT  
<213> *Homo sapiens*

<400> 158  
Phe Phe Phe Ser Arg Glu Arg Pro Thr Leu Leu Pro Arg Leu Glu Cys  
1 5 10 15

Ser Gly Ala Asn Met Ala Tyr Cys Ser Leu Arg Leu Pro Ser Ser Thr  
20 25 30

Asp Pro Pro Ala Ala Ala Ser Arg Val Gly Gly Thr Thr Asp Met Asp  
35 40 45

Tyr His Thr Lys Leu Phe Leu Phe Leu Val Gln Val Gly Ser Gln Phe  
50 55 60

Val Ala Gln Glu Leu Glu Thr Ser Leu  
65 70

<210> 159  
<211> 226  
<212> PRT  
<213> *Homo sapiens*

<400> 159  
Gln Lys Val Val Thr Leu Arg Lys Gln Gln Gln Leu Leu Ala Ala Cys

1	5	10	15
Lys Ser Leu Pro Ser Ser Pro Ser His Ser Ala Ala Ser Thr Pro Val			
20	25	30	
Ala Gly Gln Ala Ser Asn Gly Gly His Thr Ser Asp Tyr Ser Ser Ser			
35	40	45	
Leu Pro Ser Ser Pro Asn Val Gly His Arg Glu Leu Arg Ala Glu Ala			
50	55	60	
Ala Ala Val Ala Gly Leu Ser Thr Pro Gly Ser Leu His Arg Ala Ala			
65	70	75	80
Lys Arg Arg Thr Ser Leu Phe Ala Asn Arg Arg Gly Ser Asp Ser Glu			
85	90	95	
Lys Arg Ser Leu Asp Ser Arg Gly Glu Thr Thr Gly Ser Gly Arg Ala			
100	105	110	
Ile Pro Ile Lys Gln Ser Phe Leu Leu Lys Arg Ser Gly Asn Ser Leu			
115	120	125	
Asn Lys Glu Trp Lys Lys Tyr Val Thr Leu Ser Ser Asn Gly Phe			
130	135	140	
Leu Leu Tyr His Pro Ser Ile Asn Asp Tyr Ile His Ser Thr His Gly			
145	150	155	160
Lys Glu Met Asp Leu Leu Arg Thr Thr Val Lys Val Pro Gly Lys Arg			
165	170	175	
Pro Pro Arg Ala Ile Ser Ala Phe Gly Pro Ser Ala Ser Ile Asn Gly			
180	185	190	
Leu Val Lys Asp Met Ser Thr Val Gln Met Gly Glu Gly Leu Glu Ala			
195	200	205	
Thr Thr Pro Met Pro Ser Pro Ser Pro Ser Pro Ser Ser Leu Gln Pro			
210	215	220	
Pro Pro			
225			

<210> 160  
<211> 231  
<212> PRT  
<213> Homo sapiens  
  
<220>  
<221> SITE  
<222> (24)  
<223> Xaa equals stop translation

<400> 160  
 Arg Lys Cys Ile Phe Leu Lys Gly Asn Cys Lys Leu Ser Ile Gly Pro  
 1 5 10 15

Cys Lys Pro Leu Pro Asn Phe Xaa Ser His Ser Ser Phe Cys Ser Thr  
 20 25 30

Gln Val Ser Thr Val His Ile Thr Lys Asn Arg Asn Gly Gly Ser  
 35 40 45

Leu Asn Asn Tyr Ser Ser Ser Ile Pro Ser Thr Pro Ser Thr Ser Gln  
 50 55 60

Glu Asp Pro Gln Phe Ser Val Pro Pro Thr Ala Asn Thr Pro Thr Pro  
 65 70 75 80

Val Cys Lys Arg Ser Met Arg Trp Ser Asn Leu Phe Thr Ser Glu Lys  
 85 90 95

Gly Ser Asp Pro Asp Lys Glu Arg Lys Ala Pro Glu Asn His Ala Asp  
 100 105 110

Thr Ile Gly Ser Gly Arg Ala Ile Pro Ile Lys Gln Gly Met Leu Leu  
 115 120 125

Lys Arg Ser Gly Lys Trp Leu Lys Thr Trp Lys Lys Tyr Val Thr  
 130 135 140

Leu Cys Ser Asn Gly Val Leu Thr Tyr Tyr Ser Ser Leu Gly Asp Tyr  
 145 150 155 160

Met Lys Asn Ile His Lys Lys Glu Ile Asp Leu Arg Thr Ser Thr Ile  
 165 170 175

Lys Val Pro Gly Lys Trp Pro Ser Leu Ala Thr Ser Ala Cys Ala Pro  
 180 185 190

Ile Ser Ser Ser Lys Ser Asn Gly Leu Ser Lys Asp Met Asp Thr Gly  
 195 200 205

Leu Gly Asp Ser Ile Cys Phe Ser Pro Ser Ile Ser Ser Thr Thr Ser  
 210 215 220

Pro Lys Leu Asn Pro Pro Pro  
 225 230

<210> 161  
 <211> 200  
 <212> PRT  
 <213> Homo sapiens

<400> 161  
 Lys Ser Leu Ala Val Val Gly Gly Phe Ile Gly Leu Glu Ile Ala  
 1 5 10 15

Ala Thr Ala Arg Lys Leu Gly Ala Glu Val Leu Leu Ile Glu Ser Ser  
           20                     25                     30

Pro Arg Val Leu Ser Arg Gly Val Pro Ala Glu Ile Ala Lys Val Val  
           35                     40                     45

Thr Glu Arg His Arg Gln Glu Gly Val Asn Ile Leu Cys Gly Glu Gln  
           50                     55                     60

Ile Thr Ser Ile Ala Thr Glu Asn Asp Lys Val Gln Ile Leu Phe Ala  
           65                     70                     75                     80

Asn Gly Thr Thr Arg Leu Ala Asp Ile Val Val Val Gly Ile Gly Val  
           85                     90                     95

Ile Pro Asn Val Glu Leu Ala Glu Ala Ala Gly Leu Leu Ile Asp Asn  
           100                    105                    110

Gly Ile Ala Val Asp Ala Thr Leu Arg Thr Ser Asp Pro Asp Ile Phe  
           115                    120                    125

Ala Ala Gly Asp Cys Cys Ser Phe Pro Leu Ser His Tyr Arg Glu Arg  
           130                    135                    140

Arg Val Arg Leu Glu Ala Trp Arg Asn Ala Gln Asp Gln Gly Met Leu  
           145                    150                    155                    160

Val Ala Ala Asn Leu Leu Gly Arg Gly Leu Ala Ile Ala Ser Val Pro  
           165                    170                    175

Trp Phe Trp Ser Asp Gln Tyr Glu Leu Thr Leu Gln Ile Ala Gly Leu  
           180                    185                    190

Ser Asp Gly Ala Ala Thr Thr Val  
           195                    200

<210> 162  
 <211> 205  
 <212> PRT  
 <213> Homo sapiens

<400> 162  
 Lys Ser Ile Thr Ile Ile Gly Gly Phe Leu Gly Ser Glu Leu Ala  
     1              5                     10                    15

Cys Ala Leu Gly Arg Lys Ala Arg Ala Leu Gly Thr Glu Val Ile Gln  
     20                     25                     30

Leu Phe Pro Glu Lys Gly Asn Met Gly Lys Ile Leu Pro Glu Tyr Leu  
     35                     40                     45

Ser Asn Trp Thr Met Glu Lys Val Arg Arg Glu Gly Val Lys Val Met  
     50                     55                     60

80

Pro Asn Ala Ile Val Gln Ser Val Gly Val Ser Ser Gly Lys Leu Leu  
 65                   70                   75                   80

Ile Lys Leu Lys Asp Gly Arg Lys Val Glu Thr Asp His Ile Val Ala  
 85                   90                   95

Ala Val Gly Leu Glu Pro Asn Val Glu Leu Ala Lys Thr Gly Gly Leu  
 100                 105                 110

Glu Ile Asp Ser Asp Phe Gly Gly Phe Arg Val Asn Ala Glu Leu Gln  
 115                 120                 125

Ala Arg Ser Asn Ile Trp Val Ala Gly Asp Ala Ala Cys Phe Tyr Asp  
 130                 135                 140

Ile Lys Leu Gly Arg Arg Arg Val Glu His His Asp His Ala Val Val  
 145                 150                 155                 160

Ser Gly Arg Leu Ala Gly Glu Asn Met Thr Gly Ala Ala Lys Pro Tyr  
 165                 170                 175

Trp His Gln Ser Met Phe Trp Ser Asp Leu Gly Pro Asp Val Gly Tyr  
 180                 185                 190

Glu Ala Ile Gly Leu Val Asp Ser Ser Leu Pro Thr Val  
 195                 200                 205

<210> 163

<211> 182

<212> PRT

<213> Homo sapiens

<400> 163

Pro Ala Lys Tyr Leu Leu Pro Glu Val Thr Val Leu Asp Tyr Gly Lys  
 1                 5                     10                   15

Lys Cys Val Val Ile Asp Leu Asp Glu Thr Leu Val His Ser Ser Phe  
 20                 25                     30

Lys Pro Ile Ser Asn Ala Asp Phe Ile Val Pro Val Glu Ile Asp Gly  
 35                 40                     45

Thr Ile His Gln Val Tyr Val Leu Lys Arg Pro His Val Asp Glu Phe  
 50                 55                     60

Leu Gln Arg Met Gly Gln Leu Phe Glu Cys Val Leu Phe Thr Ala Ser  
 65                 70                     75                   80

Leu Ala Lys Tyr Ala Asp Pro Val Ala Asp Leu Leu Asp Arg Trp Gly  
 85                 90                     95

Val Phe Arg Ala Arg Leu Phe Arg Glu Ser Cys Val Phe His Arg Gly  
 100                 105                     110

Asn Tyr Val Lys Asp Leu Ser Arg Leu Gly Arg Glu Leu Ser Lys Val  
115 120 125

Ile Ile Val Asp Asn Ser Pro Ala Ser Tyr Ile Phe His Pro Glu Asn  
130 135 140

Ala Val Pro Val Gln Ser Trp Phe Asp Asp Met Thr Asp Thr Glu Leu  
145 150 155 160

Leu Asp Leu Ile Pro Phe Phe Glu Gly Leu Ser Arg Glu Asp Asp Val  
165 170 175

Tyr Ser Met Leu His Arg  
180

<210> 164

<211> 182

<212> PRT

<213> Homo sapiens

<400> 164

Pro Val Gln Tyr Leu Leu Pro Glu Ala Lys Ala Gln Asp Ser Asp Lys  
1 5 10 15

Ile Cys Val Val Ile Asp Leu Asp Glu Thr Leu Val His Ser Ser Phe  
20 25 30

Lys Pro Val Asn Asn Ala Asp Phe Ile Ile Pro Val Glu Ile Asp Gly  
35 40 45

Val Val His Gln Val Tyr Val Leu Lys Arg Pro His Val Asp Glu Phe  
50 55 60

Leu Gln Arg Met Gly Glu Leu Phe Glu Cys Val Leu Phe Thr Ala Ser  
65 70 75 80

Leu Ala Lys Tyr Ala Asp Pro Val Ala Asp Leu Leu Asp Lys Trp Gly  
85 90 95

Ala Phe Arg Ala Arg Leu Phe Arg Glu Ser Cys Val Phe His Arg Gly  
100 105 110

Asn Tyr Val Lys Asp Leu Ser Arg Leu Gly Arg Asp Leu Arg Arg Val  
115 120 125

Leu Ile Leu Asp Asn Ser Pro Ala Ser Tyr Val Phe His Pro Asp Asn  
130 135 140

Ala Val Pro Val Ala Ser Trp Phe Asp Asn Met Ser Asp Thr Glu Leu  
145 150 155 160

His Asp Leu Leu Pro Phe Phe Glu Gln Leu Ser Arg Val Asp Asp Val  
165 170 175

Tyr Ser Val Leu Arg Gln  
180

<210> 165  
<211> 61  
<212> PRT  
<213> Homo sapiens

<400> 165  
Lys Ala Ser Gln Cys Asn Val Ser Leu Lys Lys Gln Arg Ser Arg Ser  
1 5 10 15

Ile Leu Ser Ser Phe Phe Cys Cys Phe Arg Asp Tyr Asn Val Glu Ala  
20 25 30

Pro Pro Pro Ser Ser Pro Ser Val Leu Pro Pro Leu Val Glu Glu Asn  
35 40 45

Gly Gly Leu Gln Lys Pro Pro Ala Lys Tyr Leu Leu Pro  
50 55 60

<210> 166  
<211> 59  
<212> PRT  
<213> Homo sapiens

<400> 166  
Lys Gly Asp Gln Lys Ser Ala Ala Ser Gln Lys Pro Arg Ser Arg Gly  
1 5 10 15

Ile Leu His Ser Leu Phe Cys Cys Val Cys Arg Asp Asp Gly Glu Ala  
20 25 30

Leu Pro Ala His Ser Gly Ala Pro Leu Leu Val Glu Glu Asn Gly Ala  
35 40 45

Ile Pro Thr Asp Pro Ser Pro Ile Pro Ala Pro  
50 55

<210> 167  
<211> 362  
<212> PRT  
<213> Homo sapiens

<400> 167  
Ser Lys Ala Glu Ile Ser Phe Glu Asp Arg Lys Asp Gly Ser Cys Gly  
1 5 10 15

Val Ala Tyr Val Val Gln Glu Pro Gly Asp Tyr Glu Val Ser Val Lys  
20 25 30

Phe Asn Glu Glu His Ile Pro Asp Ser Pro Phe Val Val Pro Val Ala  
35 40 45

Ser Pro Ser Gly Asp Ala Arg Arg Leu Thr Val Ser Ser Leu Gln Glu  
50 55 60

Ser Gly Leu Lys Val Asn Gln Pro Ala Ser Phe Ala Val Ser Leu Asn  
65 70 75 80

Gly Ala Lys Gly Ala Ile Asp Ala Lys Val His Ser Pro Ser Gly Ala  
85 90 95

Leu Glu Glu Cys Tyr Val Thr Glu Ile Asp Gln Asp Lys Tyr Ala Val  
100 105 110

Arg Phe Ile Pro Arg Glu Asn Gly Val Tyr Leu Ile Asp Val Lys Phe  
115 120 125

Asn Gly Thr His Ile Pro Gly Ser Pro Phe Lys Ile Arg Val Gly Glu  
130 135 140

Pro Gly His Gly Gly Asp Pro Gly Leu Val Ser Ala Tyr Gly Ala Gly  
145 150 155 160

Leu Glu Gly Gly Val Thr Gly Asn Pro Ala Glu Phe Val Val Asn Thr  
165 170 175

Ser Asn Ala Gly Ala Gly Ala Leu Ser Val Thr Ile Asp Gly Pro Ser  
180 185 190

Lys Val Lys Met Asp Cys Gln Glu Cys Pro Glu Gly Tyr Arg Val Thr  
195 200 205

Tyr Thr Pro Met Ala Pro Gly Ser Tyr Leu Ile Ser Ile Lys Tyr Gly  
210 215 220

Gly Pro Tyr His Ile Gly Gly Ser Pro Phe Lys Ala Lys Val Thr Gly  
225 230 235 240

Pro Arg Leu Val Ser Asn His Ser Leu His Glu Thr Ser Ser Val Phe  
245 250 255

Val Asp Ser Leu Thr Lys Ala Thr Cys Ala Pro Gln His Gly Ala Pro  
260 265 270

Gly Pro Gly Pro Ala Asp Ala Ser Lys Val Val Ala Lys Gly Leu Gly  
275 280 285

Leu Ser Lys Ala Tyr Val Gly Gln Lys Ser Ser Phe Thr Val Asp Cys  
290 295 300

Ser Lys Ala Gly Asn Asn Met Leu Leu Val Gly Val His Gly Pro Arg  
305 310 315 320

Thr Pro Cys Glu Glu Ile Leu Val Lys His Val Gly Ser Arg Leu Tyr

325	330	335
-----	-----	-----

Ser Val Ser Tyr Leu Leu Lys Asp Lys Gly Glu Tyr Thr Leu Val Val	340	345
---	-----	-----

Lys Trp Gly Asp Glu His Ile Pro Gly Ser	355	360
---	-----	-----

<210> 168

<211> 364

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (164)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 168

Ala Lys Arg Gln Ile Ala Phe Glu Asp Arg Lys Asp Gly Ser Cys Gly	1	5	10	15
---	---	---	----	----

Val Ser Tyr Val Val Gln Glu Pro Gly Asp Tyr Glu Val Ser Ile Lys	20	25	30
---	----	----	----

Phe Asn Asp Glu His Ile Pro Asp Ser Pro Phe Val Val Pro Val Ala	35	40	45
---	----	----	----

Ser Leu Ser Asp Asp Ala Arg Arg Leu Thr Val Thr Ser Leu Gln Glu	50	55	60
---	----	----	----

Thr Gly Leu Lys Val Asn Gln Pro Ala Ser Phe Ala Val Gln Leu Asn	65	70	75	80
---	----	----	----	----

Gly Ala Arg Gly Val Ile Asp Ala Arg Val His Thr Pro Ser Gly Ala	85	90	95
---	----	----	----

Val Glu Glu Cys Tyr Val Ser Glu Leu Asp Ser Asp Lys His Thr Ile	100	105	110
---	-----	-----	-----

Arg Phe Ile Pro His Glu Asn Gly Val His Ser Ile Asp Val Lys Phe	115	120	125
---	-----	-----	-----

Asn Gly Ala His Ile Pro Gly Ser Pro Phe Lys Ile Arg Val Gly Glu	130	135	140
---	-----	-----	-----

Gln Ser Gln Ala Gly Asp Pro Gly Leu Val Ser Ala Tyr Gly Pro Gly	145	150	155	160
---	-----	-----	-----	-----

Leu Glu Gly Xaa Thr Thr Gly Val Ser Ser Glu Phe Ile Val Asn Thr	165	170	175
---	-----	-----	-----

Leu Asn Ala Gly Ser Gly Ala Leu Ser Val Thr Ile Asp Gly Pro Ser	180	185	190
---	-----	-----	-----

Lys Val Gln Leu Asp Cys Arg Glu Cys Pro Glu Gly His Val Val Thr  
 195                    200                    205

Tyr Thr Pro Met Ala Pro Gly Asn Tyr Leu Ile Ala Ile Lys Tyr Gly  
 210                    215                    220

Gly Pro Gln His Ile Val Gly Ser Pro Phe Lys Ala Lys Val Thr Gly  
 225                    230                    240

Pro Arg Leu Ser Gly Gly His Ser Leu His Glu Thr Ser Thr Val Leu  
 245                    250                    255

Val Glu Thr Val Thr Lys Ser Ser Ser Arg Gly Ser Ser Tyr Ser  
 260                    265                    270

Ser Ile Pro Lys Phe Ser Ser Asp Ala Ser Lys Val Val Thr Arg Gly  
 275                    280                    285

Pro Gly Leu Ser Gln Ala Phe Val Gly Gln Lys Asn Ser Phe Thr Val  
 290                    295                    300

Asp Cys Ser Lys Ala Gly Thr Asn Met Met Val Gly Val His Gly  
 305                    310                    320

Pro Lys Thr Pro Cys Glu Glu Val Tyr Val Lys His Met Gly Asn Arg  
 325                    330                    335

Val Tyr Asn Val Thr Tyr Thr Val Lys Glu Lys Gly Asp Tyr Ile Leu  
 340                    345                    350

Ile Val Lys Trp Gly Asp Glu Ser Val Pro Gly Ser  
 355                    360

<210> 169  
<211> 194  
<212> PRT  
<213> Homo sapiens

<400> 169  
Asn Ser Val Ser Tyr Ala Ile Ser Gly Ala Leu Ala Thr Val Ile His  
 1                    5                    10                    15

Asp Ala Val Met Asn Pro Ala Glu Val Val Lys Gln Arg Met Gln Met  
 20                    25                    30

Ile Phe Ser Pro Tyr Gly Asn Ser Leu Glu Cys Ile Arg Cys Ile Tyr  
 35                    40                    45

Ile Arg Glu Gly Leu Arg Ala Phe Tyr Arg Ser Tyr Ile Thr Gln Leu  
 50                    55                    60

Thr Leu Asn Val Pro Tyr Gln Cys Thr His Phe Met Ile Tyr Glu Tyr  
 65                    70                    75                    80

Met Gln Asn Leu Leu Asn Pro His His Asp Tyr Asn Pro Ser Ser His  
 85 90 95

Leu Val Ser Gly Gly Ile Ala Gly Gly Ile Ala Ala Ala Ile Thr Thr  
 100 105 110

Pro Leu Asp Cys Val Lys Thr Val Leu Asn Thr Gln Gln Thr Pro Arg  
 115 120 125

Phe Asn Thr Thr Tyr Arg Leu Leu Thr Gln Ser Glu His Thr Ala Tyr  
 130 135 140

Tyr Lys Gly Leu Ala Asp Gly Ile Lys Thr Ile Tyr Tyr Leu Arg Gly  
 145 150 155 160

Thr Gly Gly Phe Phe Arg Gly Leu Gln Ala Arg Ile Ile Phe Gln Ile  
 165 170 175

Pro Ser Thr Ala Leu Ser Trp Ser Ala Tyr Glu Leu Cys Lys Tyr Met  
 180 185 190

Leu Ser

<210> 170

<211> 188

<212> PRT

<213> Homo sapiens

<400> 170

Ser Gly Val Cys Phe Ala Gly Ile Ala Gly Ser Met Ala Thr Leu Leu  
 1 5 10 15

His Asp Ala Val Met Asn Pro Ala Glu Val Val Lys Gln Arg Leu Gln  
 20 25 30

Met Tyr Asn Ser Gln His Arg Ser Ala Ile Ser Cys Ile Arg Thr Val  
 35 40 45

Trp Arg Thr Glu Gly Leu Gly Ala Phe Tyr Arg Ser Tyr Thr Thr Gln  
 50 55 60

Leu Thr Met Asn Ile Pro Phe Gln Ser Ile His Phe Ile Thr Tyr Glu  
 65 70 75 80

Phe Leu Gln Glu Gln Val Asn Pro His Arg Thr Tyr Asn Pro Gln Ser  
 85 90 95

His Ile Ile Ser Gly Gly Leu Ala Gly Ala Leu Ala Ala Ala Thr  
 100 105 110

Thr Pro Leu Asp Val Cys Lys Thr Leu Leu Asn Thr Gln Glu Asn Val  
 115 120 125

Ala Leu Ser Leu Ala Asn Ile Ser Gly Arg Leu Ser Gly Met Ala Asn  
 130                    135                    140

Ala Phe Arg Thr Val Tyr Gln Leu Asn Gly Leu Ala Gly Tyr Phe Lys  
 145                    150                    155                    160

Gly Ile Gln Ala Arg Val Ile Tyr Gln Met Pro Ser Thr Ala Ile Ser  
 165                    170                    175

Trp Ser Val Tyr Glu Phe Phe Lys Tyr Phe Leu Thr  
 180                    185

<210> 171

<211> 206

<212> PRT

<213> Homo sapiens

<400> 171

Trp Arg Glu Val Ser Ile Asn Gly Asp Val Tyr Glu Pro Arg Val Thr  
 1                    5                    10                    15

Arg Ser Ser Ser Ala Lys Gly Val Phe Val Pro Glu Trp Thr Asn Met  
 20                    25                    30

Leu Gln Asp Gly Thr Leu Ile Asp Leu Cys Gly Ala Thr Ile Leu Trp  
 35                    40                    45

Arg Thr Ala Asp Gly Leu Glu Arg Ser Pro Lys Met Arg Glu Leu Glu  
 50                    55                    60

Met Ala Leu Asp Arg Leu Asn Ala Gly Arg Pro Gln Cys Pro Val Asn  
 65                    70                    75                    80

Leu Asn Thr Leu Val Ile Pro Lys Lys Arg Asn Gly Arg Gln Ile Asn  
 85                    90                    95

Arg Arg Gln Pro Tyr Val Tyr Leu Gln Cys Gly His Val Gln Gly Arg  
 100                    105                    110

His Glu Trp Gly Val Gln Glu Asn Ser Gly Gln Arg Ser Gly Lys Cys  
 115                    120                    125

Pro Ile Cys Leu Val Glu Ser Glu Arg Ile Val Gln Leu Ser Met Gly  
 130                    135                    140

Met Glu Pro Ser Phe His Leu Asp Ser Gly Val Leu Asp His Thr Phe  
 145                    150                    155                    160

Asn Pro Cys Gly His Met Ala Ser Lys Gln Thr Val Leu Tyr Trp Ser  
 165                    170                    175

Arg Ile Pro Leu Pro Gln Gly Thr Cys Arg Tyr Asp Pro Val Cys Pro  
 180                    185                    190

Phe Cys Tyr Gln Leu Leu Ala Thr Glu Arg Pro Phe Tyr Lys  
195                   200                   205

<210> 172  
<211> 205  
<212> PRT  
<213> Homo sapiens

<400> 172  
Trp Arg Glu Ile Ser Val Cys Gly Asn Val Phe Ser Leu Arg Glu Thr  
1               5                   10                   15

Arg Ser Ala Gln Gln Arg Gly Lys Met Val Glu Ile Glu Thr Asn Gln  
20               25                   30

Leu Gln Asp Gly Ser Leu Ile Asp Leu Cys Gly Ala Thr Leu Leu Trp  
35               40                   45

Arg Thr Ala Glu Gly Leu Ser His Thr Pro Thr Val Lys His Leu Glu  
50               55                   60

Ala Leu Arg Gln Glu Ile Asn Ala Ala Arg Pro Gln Cys Pro Val Gly  
65               70                   75                   80

Phe Asn Thr Leu Ala Phe Pro Ser Met Lys Arg Lys Asp Val Val Asp  
85               90                   95

Glu Lys Gln Pro Trp Val Tyr Leu Asn Cys Gly His Val His Gly Tyr  
100               105                   110

His Asn Trp Gly Asn Lys Glu Glu Arg Asp Gly Lys Asp Arg Glu Cys  
115               120                   125

Pro Met Cys Arg Ser Val Gly Pro Tyr Val Pro Leu Trp Leu Gly Cys  
130               135                   140

Glu Ala Gly Phe Tyr Val Asp Ala Gly Pro Pro Thr His Ala Phe Ser  
145               150                   155                   160

Pro Cys Gly His Val Cys Ser Glu Lys Thr Thr Ala Tyr Trp Ser Gln  
165               170                   175

Ile Pro Leu Pro His Gly Thr His Thr Phe His Ala Ala Cys Pro Phe  
180               185                   190

Cys Ala His Gln Leu Ala Gly Glu Gln Gly Tyr Ile Arg  
195               200                   205

<210> 173  
<211> 118  
<212> PRT  
<213> Homo sapiens

&lt;400&gt; 173

Pro	Arg	Trp	Ala	Ala	Trp	Asn	Leu	Gly	Val	Phe	Ile	Cys	Ile	Arg	Cys
1															15

Ala	Gly	Ile	His	Arg	Asn	Leu	Gly	Val	His	Ile	Ser	Lys	Val	Arg	Ser

Val	Asn	Leu	Asp	Ser	Trp	Thr	Pro	Glu	Gln	Val	Gln	Thr	Met	Arg	Val

Met	Gly	Asn	Glu	Lys	Ala	Arg	Gln	Val	Tyr	Glu	His	Asp	Leu	Pro	Ala

Gln	Phe	Arg	Arg	Pro	Thr	Asn	Asp	Gln	Gln	Met	Glu	Gln	Phe	Ile	Arg

Ser	Lys	Tyr	Glu	Gln	Lys	Arg	Tyr	Ile	Leu	Arg	Asp	Phe	Val	Tyr	Pro

Arg	Val	Asp	Ala	Ser	Gln	Leu	Pro	Lys	Ser	Leu	Ser	Gln	Ala	Gln	Lys

Lys	Val	Gly	Thr	Pro	Val

&lt;210&gt; 174

&lt;211&gt; 113

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 174

Pro	Arg	Trp	Ala	Ser	Trp	Asn	Ile	Gly	Val	Phe	Ile	Cys	Ile	Arg	Cys
1															15

Ala	Gly	Ile	His	Arg	Asn	Leu	Gly	Val	His	Ile	Ser	Arg	Val	Lys	Ser

Val	Asn	Leu	Asp	Gln	Trp	Thr	Gln	Glu	Gln	Ile	Gln	Cys	Met	Gln	Glu

Met	Gly	Asn	Gly	Lys	Ala	Asn	Arg	Leu	Tyr	Glu	Ala	Tyr	Leu	Pro	Glu

Thr	Phe	Arg	Arg	Pro	Gln	Ile	Asp	Pro	Ala	Val	Glu	Gly	Phe	Ile	Arg
65															80

Asp	Lys	Tyr	Glu	Lys	Lys	Tyr	Met	Asp	Arg	Ser	Leu	Asp	Ile	Asn	
85															95

Ala	Phe	Arg	Lys	Glu	Lys	Asp	Asp	Lys	Trp	Lys	Arg	Gly	Ser	Glu	Pro
100															110

Val

<210> 175  
<211> 49  
<212> PRT  
<213> Homo sapiens

<400> 175  
Leu Ala Gly His Gly Gly Arg Cys Leu Gln Ser Gln Leu Leu Arg Arg  
1 5 10 15  
  
Leu Arg Gln Glu Asn His Leu Asn Ser Gly Gly Arg Gly Cys Ser Glu  
20 25 30  
  
Pro Lys Ser His Leu Cys Ile Pro Ala Trp Val Thr Glu Gly Asp Ser  
35 40 45  
  
Val

<210> 176  
<211> 49  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (10)  
<223> Xaa equals stop translation  
  
<220>  
<221> SITE  
<222> (46)  
<223> Xaa equals stop translation

<400> 176  
Met Ala Arg His Gly Gly Ser His Leu Xaa Ser Gln His Phe Arg Arg  
1 5 10 15  
  
Leu Arg Gln Glu Asn Cys Leu Asn Leu Gly Gly Gly Cys Ser Glu  
20 25 30  
  
Leu Arg Trp His His Cys Thr Pro Ala Trp Arg Thr Lys Xaa Asp Ser  
35 40 45

Ile

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US00/07483

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) :C07K 14/00; C12N 15/11, 15/63, 15/64, 1/21  
US CL :435/320.1, 471, 252.3, 69.1; 530/350; 536/23.1

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/320.1, 471, 252.3, 69.1; 530/350; 536/23.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Commercial Sequence Databases:Genbank, Swissprot  
search terms:SEQ ID NOS:11 and 60

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Database Genbank, Accession No. AF064084, DAI et al., 'Mammalian prenylcysteine carboxyl methyltransferase is in the endoplasmic reticulum'. J. Biol. Chem., 18 May 1998.	1, 3, 5, 6
---		-----
Y	WATSON et al. 'Methods of creating recombinant DNA molecules'. In: Recombinant DNA Second Edition. New York W.H.Freeman and Co. 1994, Chapter 5, pages 63-77, especially pages 73-76.	7-10, 14, 15
Y		7-10, 14, 15

Further documents are listed in the continuation of Box C.  See patent family annex.

* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*B* earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means		
*P* document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

28 JUNE 2000

Date of mailing of the international search report

28 JUL 2000

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Faximile No. (703) 305-3230

Authorized officer

JOHN S. BRUSCA

Telephone No. (703) 308-0196

## INTERNATIONAL SEARCH REPORT

International application No. PCT/US00/07483
---

**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
  
  
  
2.  Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
  
  
  
3.  Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1.  As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
  
  
  
4.  No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-12, 14-16, and SEQ ID NOS: 11 and 60

**Remark on Protest**

- The additional search fees were accompanied by the applicant's protest.  
 No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US00/07483

**BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING**  
This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1.

Group I, claims 1-12, 14-16, drawn to nucleic acids, vectors comprising the nucleic acids, polypeptides encoded by the nucleic acids, host cells comprising the nucleic acids, and methods of making and using host cells comprising the nucleic acids.

Group II, claim(s) 13, drawn to antibodies.

Group III, claim(s) 17, drawn to a therapeutic method of using the nucleic acid or the protein of Group I.

Group IV, claim(s) 18 and 19, drawn to a diagnostic method of using the nucleic acid or protein of Group I.

Group V, claim(s) 20, drawn to a method of identifying a binding partner to the protein of Group I.

Group VI, claim(s) 21, drawn to a gene comprising the nucleic acid of Group I.

Group VII, claim(s) 22, drawn to a method of identifying an activity of a protein of Group I.

Group VIII, claim(s) 23, drawn to a binding partner of the protein of Group I.

The inventions listed as Groups I-VIII do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: PCT Rule 13.1 and Annex B do not provide for unity of invention between two or more different products or methods of use that share a special technical feature.

In addition, each Group detailed above reads on distinct Groups drawn to multiple sequences. The sequences are distinct because they are unrelated sequences, and a further lack of unity is applied to each Group. The lack of unity is partially waived and the Applicants must further elect 10 sequences for examination in the elected Group detailed above.